

Introduction

Adverse Event Reporting System (AERS) Report

The Adverse Event Reporting System (AERS) is a computerized database maintained by the U.S. Food and Drug Administration (FDA) to support post-marketing safety surveillance of pharmaceutical and therapeutic biological products. It plays a critical role in identifying new adverse events and medication errors that may not have been detected during clinical trials.

This report presents comprehensive Graphical summaries, summary tables and patient-level listings derived from the AERS database to support ongoing pharmacovigilance activities. The analyses include adverse event frequencies, drug-event relationships, outcomes, and demographic trends. Data used in this report were sourced from AERS 2023Q4 updates, which are released by the FDA approximately 4 to 6 weeks after the end of each calendar quarter.

The AERS database includes the following core datasets:

- DEMO: Patient demographic and administrative information
- DRUG: Reported drug data (suspect, concomitant, interacting)
- REAC: Coded adverse event terms using MedDRA
- OUTC: Patient outcomes such as death, hospitalization, or disability
- RPSR: Sources of the report (healthcare professional, consumer, etc.)
- THER: Therapy dates (start/end) for reported drugs
- INDI: Indications for drug administration

Patient-Level Listings

The Patient-Level Listings section provides detailed, case-level adverse event data as reported to the AERS system. Each listing includes information on patient demographics, suspect and concomitant drugs, therapy dates, adverse event terms, outcomes, indications, and source of report.

These listings allow for case traceability and support in-depth clinical and regulatory review of individual adverse event reports.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
100144838	.	.	20231123	20231205	Expedited	8	Week	0	GROUP1	
1001678124	.	20120330	20231130	20231211	Expedited	56	Year	56	GROUP3	Female
100293662	.	.	20231108	20231115	Expedited	32	Year	32	GROUP2	Male
100356167	.	20140321	20230928	20231002	Expedited	84	Year	84	GROUP4	Female
1006401878	.	20121201	20231010	20231012	Expedited	71	Year	71	GROUP3	Female
1007468610	.	20090714	20231204	20231215	Expedited	52	Year	52	GROUP3	Male
1008408132	.	20140121	20231227	20231231	Expedited	70	Year	70	GROUP3	Male
1009418019	.	20130222	20231207	20231211	Expedited	28	Year	28	GROUP2	Female
1014222251	.	20131201	20231220	20231227	Expedited	52	Year	52	GROUP3	Male
101451672	.	20140201	20231121	20231128	Periodic	52	Year	52	GROUP3	Female
1015212331	.	20131205	20231011	20231023	Expedited	38	Year	38	GROUP2	Female
101621574	.	20140325	20180423	20231107	Expedited	40	Year	40	GROUP2	Female
1016611037	.	20140430	20231011	20231023	Expedited	34	Year	34	GROUP2	Female
1017130214	.	.	20231212	20231219	Expedited	63	Year	63	GROUP3	Female
1017572232	.	20121201	20231108	20231115	Expedited	65	Year	65	GROUP3	Female
101780773	.	20140401	20231128	20231201	Expedited	59	Year	59	GROUP3	Female
101916392	.	20110101	20231023	20231103	Expedited	75	Year	75	GROUP3	Female
1020642923	.	20111201	20231129	20231211	Expedited	46	Year	46	GROUP2	Female
102371704	.	20130101	20231023	20231101	Expedited	50	Year	50	GROUP2	Female
1027487983	.	20151125	20231013	20231016	Expedited	46	Year	46	GROUP2	Male
1028518546	.	20140703	20231205	20231211	Expedited	49	Year	49	GROUP2	Female
1030948614	.	.	20231212	20231220	Expedited	72	Year	72	GROUP3	Male
103443973	.	20140701	20231122	20231128	Expedited	81	Year	81	GROUP4	Female
1035913611	.	20190901	20231208	20231219	Expedited	70	Year	70	GROUP3	Female
103687216	.	20140506	20231031	20231105	Expedited	68	Year	68	GROUP3	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231205	Health Professional	.	CA
.		.	20231211	Health Professional	.	CA
.		.	20231115	Health Professional	.	AU
50	Kilograms	50	20231002	Physician	.	JP
77	Kilograms	77	20231012	Health Professional	.	
.		.	20231215	Health Professional	.	CA
.		.	20231231	Consumer	.	CA
54.4	Kilograms	54.4	20231211	Consumer	.	
89.5	Kilograms	89.5	20231227	Consumer	.	
.		.	20231127	Consumer	.	US
101	Kilograms	101	20231023	Consumer	.	CA
.		.	20231107	Physician	.	US
.		.	20231023	Consumer	.	CA
.		.	20231219	Consumer	.	US
57	Kilograms	57	20231115	Health Professional	.	
.		.	20231202	Physician	.	
.		.	20231103	Physician	.	LK
.		.	20231211	Consumer	.	CA
.		.	20231101	Health Professional	.	TN
100	Kilograms	100	20231016	Health Professional	.	
79	Kilograms	79	20231211	Consumer	.	
.		.	20231220	Physician	.	CA
56	Kilograms	56	20231128	Pharmacist	.	NL
.		.	20231219	Physician	.	CA
77	Kilograms	77	20231106	Physician	.	IT

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
103749689	.	20140714	20180424	20231107	Expedited	68	Year	68	GROUP3	Female
103892335	.	20080401	20231205	20231213	Expedited	42	Year	42	GROUP2	Male
103985405	.	20170101	20231108	20231114	Expedited	50	Year	50	GROUP2	Female
104003092	.	20110814	20231124	20231201	Expedited	76	Year	76	GROUP4	Male
1040513313	.	20110815	20231211	20231221	Expedited	56	Year	56	GROUP3	Female
104490482	.	.	20231213	20231221	Expedited	51	Year	51	GROUP3	Male
104580772	.	.	20231213	20231221	Expedited	34	Year	34	GROUP2	Male
104580883	.	.	20231213	20231221	Expedited	42	Year	42	GROUP2	Female
104635823	.	20020830	20231011	20231018	Periodic	4	Year	4	GROUP1	Male
104665748	.	20040101	20231113	20231120	Expedited	13	Year	13	GROUP1	Male
104825157	.	20000101	20231027	20231031	Expedited	67	Year	67	GROUP3	Female
105144244	.	20141002	20231101	20231107	Expedited	37	Year	37	GROUP2	Female
1051596718	.	20131024	20231208	20231215	Expedited	70	Year	70	GROUP3	Male
1052690058	.	20140701	20231003	20231005	Expedited	75	Year	75	GROUP3	Male
1054038738	.	20140723	20231106	20231114	Expedited	56	Year	56	GROUP3	Male
105741013	.	.	20231016	20231019	Expedited	56	Year	56	GROUP3	Male
1058928657	.	20141101	20231101	20231113	Expedited	61	Year	61	GROUP3	Female
105947013	.	.	20231101	20231113	Expedited	23	Year	23	GROUP1	Female
106091663	.	.	20231122	20231204	Expedited	64	Year	64	GROUP3	Male
106336646	.	20060310	20231115	20231123	Expedited	14	Year	14	GROUP1	Male
106352232	.	.	20231127	20231130	Expedited	64	Year	64	GROUP3	Male
106520463	.	20140301	20231127	20231206	Periodic	60	Year	60	GROUP3	Female
1069198853	.	20130404	20231207	20231218	Expedited	74	Year	74	GROUP3	Male
1070483325	.	.	20231120	20231205	Expedited	64	Year	64	GROUP3	Female
107314353	.	.	20231122	20231202	Expedited	8	Year	8	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
89	Kilograms	89	20231107	Physician	.	ES
.		.	20231213	Health Professional	.	CZ
.		.	20231114	Physician	.	CA
.		.	20231201	Health Professional	.	GB
.		.	20231221	Consumer	.	CA
.		.	20231221	Health Professional	.	FR
.		.	20231221	Health Professional	.	FR
.		.	20231221	Health Professional	.	FR
.		.	20231018	Lawyer	.	US
.		.	20231120	Health Professional	.	US
.		.	20231031	Consumer	.	US
62	Kilograms	62	20231107	Health Professional	.	CA
110.2	Kilograms	110.2	20231215	Health Professional	.	CA
73	Kilograms	73	20231005	Consumer	.	
.		.	20231114	Health Professional	.	CA
.		.	20231019	Health Professional	.	FR
.		.	20231113	Consumer	.	CA
.		.	20231113	Health Professional	.	US
.		.	20231204	Physician	.	IT
.		.	20231123	Health Professional	.	US
.		.	20231130	Physician	.	IT
59	Kilograms	59	20231206	Consumer	.	US
.		.	20231218	Consumer	.	CA
68	Kilograms	68	20231205	Health Professional	.	CA
.		.	20231202	Physician	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Unique number for identifying a FAERS re</i>	<i>i_f_cod</i>	<i>Date the adverse event occurred or began</i>	<i>Date manufacturer first received initial</i>	<i>Date FDA received Case(YYYYMMDD format).</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event.</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age in years.</i>	<i>Derived age group.</i>	<i>Code for patient's sex</i>
1074008517	.	20131126	20231201	20231206	Expedited	68	Year	68	GROUP3	Female
107408544	.	.	20231218	20231228	Periodic	66	Year	66	GROUP3	Female
1074197911	.	.	20231201	20231207	Expedited	62	Year	62	GROUP3	Female
1075880717	.	20150101	20231003	20231013	Expedited	72	Year	72	GROUP3	Female
1078729218	.	20150116	20231130	20231207	Expedited	51	Year	51	GROUP3	Female
108390175	.	20090101	20231118	20231129	Expedited	58	Year	58	GROUP3	Male
1088288812	.	.	20231017	20231020	Periodic	77	Year	77	GROUP4	Male
109031962	.	.	20230930	20231008	Expedited	91	Year	91	GROUP4	Female
109174139	.	.	20231016	20231021	Expedited	47	Year	47	GROUP2	Female
1092018038	.	20150101	20231103	20231108	Expedited	2	Year	2	GROUP1	Female
109448672	.	20131101	20231113	20231122	Periodic	14	Year	14	GROUP1	Male
109893399	.	20190114	20231127	20231204	Expedited	57	Year	57	GROUP3	Female
1099047564	.	20150312	20231107	20231108	Expedited	57	Year	57	GROUP3	Male
109916134	.	20130101	20231217	20231221	Periodic	64	Year	64	GROUP3	Female
109922307	.	.	20231102	20231105	Expedited	58	Year	58	GROUP3	Male
109971003	.	20131201	20231210	20231221	Expedited	58	Year	58	GROUP3	Female
1102019552	.	20120807	20231116	20231123	Expedited	46	Year	46	GROUP2	Female
1102109863	.	20141110	20231204	20231215	Expedited	59	Year	59	GROUP3	Male
110215902	.	.	20231019	20231030	Expedited	58	Year	58	GROUP3	Male
1102411313	.	20140101	20231017	20231024	Expedited	68	Year	68	GROUP3	Male
110462235	.	.	20231026	20231109	Expedited	58	Year	58	GROUP3	Male
110471852	.	20150101	20231109	20231118	Periodic	54	Year	54	GROUP3	Female
110577006	.	20141017	20231011	20231016	Expedited	41	Year	41	GROUP2	Female
110734563	.	20150413	20231124	20231128	Expedited	33	Year	33	GROUP2	Female
110755913	.	20150101	20160119	20231025	Expedited	54	Year	54	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
136.1	Kilograms	136.1	20231206	Consumer	.	.
.	.	.	20231228	Consumer	.	US
83.91	Kilograms	83.91	20231207	Health Professional	.	US
59	Kilograms	59	20231013	Consumer	.	US
.	.	.	20231208	Physician	.	CA
100	Kilograms	100	20231129	Physician	.	GB
78.84	Kilograms	78.84	20231020	Consumer	.	US
.	.	.	20231008	Health Professional	.	US
.	.	.	20231021	Health Professional	.	ES
.	.	.	20231108	Health Professional	.	CA
.	.	.	20231122	Lawyer	.	US
113.4	Kilograms	113.4	20231204	Consumer	.	US
83.5	Kilograms	83.5	20231108	Health Professional	.	.
69.388	Kilograms	69.388	20231221	Consumer	.	US
.	.	.	20231105	Health Professional	.	FR
96.599	Kilograms	96.599	20231221	Health Professional	.	US
97	Kilograms	97	20231123	Health Professional	.	.
95	Kilograms	95	20231215	Consumer	.	CA
.	.	.	20231030	Health Professional	.	FR
.	.	.	20231024	Health Professional	.	CA
.	.	.	20231109	Health Professional	.	FR
.	.	.	20231117	Consumer	.	US
78.542	Kilograms	78.542	20231016	Health Professional	.	.
.	.	.	20231128	Health Professional	.	US
.	.	.	20231025	Physician	.	JP

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1107567522	.	20110317	20231212	20231219	Expedited	48	Year	48	GROUP2	Male
110781863	.	19990516	20231009	20231016	Periodic	14	Year	14	GROUP1	Male
1109083723	.	.	20201209	20231202	Expedited	64	Year	64	GROUP3	Female
110972475	.	.	20231204	20231214	Expedited	78	Year	78	GROUP4	Female
110995353	.	.	20230821	20231104	Expedited	28	Year	28	GROUP2	Male
111186103	.	19980101	20231013	20231017	Periodic	1	Decade	10	GROUP1	Male
111191394	.	20060801	20231206	20231213	Periodic	8	Year	8	GROUP1	Male
1112193211	.	20130423	20231215	20231222	Expedited	50	Year	50	GROUP2	Female
111403192	.	20081101	20231025	20231102	Periodic	18	Year	18	GROUP1	Male
111430143	.	.	20150511	20231116	Expedited	27	Year	27	GROUP2	Female
111513767	.	20141101	20231221	20231228	Expedited	40	Year	40	GROUP2	Female
111755239	.	20150421	20231218	20231229	Expedited	17	Year	17	GROUP1	Female
111772814	.	.	20231113	20231122	Expedited	30	Year	30	GROUP2	Female
1118598419	.	20150101	20230901	20231128	Expedited	57	Year	57	GROUP3	Female
111984347	.	20131220	20231122	20231204	Expedited	25	Year	25	GROUP1	Male
1119850317	.	.	20231205	20231208	Expedited	67	Year	67	GROUP3	Female
112024568	.	20150316	20231018	20231030	Expedited	56	Year	56	GROUP3	Female
1121274917	.	20150605	20231115	20231129	Expedited	55	Year	55	GROUP3	Male
1121749411	.	20140717	20231221	20231228	Expedited	59	Year	59	GROUP3	Female
112237713	.	20120601	20231215	20231222	Periodic	52	Year	52	GROUP3	Female
112281423	.	.	20231101	20231110	Expedited	67	Year	67	GROUP3	Female
112305158	.	20140612	20231220	20231226	Expedited	58	Year	58	GROUP3	Female
112534824	.	20150624	20231012	20231020	Expedited	74	Year	74	GROUP3	Female
1126655518	.	20150501	20231006	20231013	Expedited	69	Year	69	GROUP3	Male
112845693	.	20141212	20150109	20231001	Periodic	37	Year	37	GROUP2	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231219	Health Professional	.	CA
.		.	20231016	Health Professional	.	US
69	Kilograms	69	20231202	Consumer	.	CA
.		.	20231214	Physician	.	US
.		.	20231104	Health Professional	.	DE
.		.	20231017	Lawyer	.	US
.		.	20231213	Health Professional	.	US
80.726	Kilograms	80.726	20231222	Physician	.	US
.		.	20231102	Lawyer	.	US
.		.	20231116	Health Professional	.	US
.		.	20231228	Health Professional	.	FR
69	Kilograms	69	20231229	Physician	.	CZ
.		.	20231122	Physician	.	FR
.		.	20231127	Health Professional	.	CA
.		.	20231204	Consumer	.	CA
73	Kilograms	73	20231207	Physician	.	CA
.		.	20231030	Consumer	.	CA
63.492	Kilograms	63.492	20231129	Pharmacist	.	CA
126.4	Kilograms	126.4	20231228	Physician	.	CA
.		.	20231222	Consumer	.	US
.		.	20231110	Health Professional	.	US
.		.	20231226	Physician	.	CA
40	Kilograms	40	20231020	Physician	.	JP
.		.	20231013	Health Professional	.	CA
73.16	Kilograms	73.16	20231001	Consumer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
112877752	.	20130612	20231121	20231201	Expedited	71	Year	71	GROUP3	Female
112904962	.	20130612	20231121	20231202	Expedited	71	Year	71	GROUP3	Female
1129109810	.	20150112	20231123	20231130	Expedited	55	Year	55	GROUP3	Male
113024092	.	20130612	20231113	20231120	Expedited	71	Year	71	GROUP3	Female
1131105412	.	20160512	20231221	20231227	Expedited	64	Year	64	GROUP3	Male
113145098	.	.	20231207	20231220	Periodic	55	Year	55	GROUP3	Female
113155356	.	20150617	20231210	20231221	Expedited	71	Year	71	GROUP3	Male
113222892	.	20150101	20231212	20231218	Periodic	38	Year	38	GROUP2	Female
113257456	.	20140822	20231102	20231107	Expedited	36	Year	36	GROUP2	Female
1134491610	.	20150723	20231130	20231203	Expedited	19	Year	19	GROUP1	Female
113625366	.	.	20231218	20231229	Expedited	77	Year	77	GROUP4	Female
113625446	.	.	20231124	20231226	Expedited	77	Year	77	GROUP4	Female
113659802	.	20150722	20150803	20231001	Periodic	88	Year	88	GROUP4	Male
113662138	.	20150510	20231127	20231129	Expedited	34	Year	34	GROUP2	Female
113685715	.	.	20231026	20231102	Expedited	77	Year	77	GROUP4	Female
113755943	.	20080101	20231002	20231005	Periodic	54	Year	54	GROUP3	Female
1138286731	.	.	20231017	20231024	Expedited	60	Year	60	GROUP3	Female
113868659	.	20140201	20231031	20231114	Periodic	60	Year	60	GROUP3	Female
1140884841	.	20150624	20231220	20231227	Expedited	55	Year	55	GROUP3	Female
1142723210	.	20061010	20231031	20231109	Expedited	56	Year	56	GROUP3	Female
1144435333	.	20141001	20231122	20231204	Expedited	64	Year	64	GROUP3	Male
1144476723	.	20150818	20231205	20231208	Expedited	40	Year	40	GROUP2	Female
114473694	.	.	20231109	20231115	Expedited	72	Year	72	GROUP3	Female
1145016915	.	20170201	20231206	20231213	Expedited	41	Year	41	GROUP2	Female
1145717522	.	.	20231017	20231020	Expedited	60	Year	60	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
59.42	Kilograms	59.42	20231201	Consumer	.	GB
59.42	Kilograms	59.42	20231202	Consumer	.	GB
101	Kilograms	101	20231130	Consumer	.	CO
59.42	Kilograms	59.42	20231121	Consumer	.	GB
.		.	20231227	Consumer	.	CA
91	Kilograms	91	20231220	Consumer	.	US
78.912	Kilograms	78.912	20231221	Health Professional	.	US
.		.	20231217	Consumer	.	US
.		.	20231107	Health Professional	.	
.		.	20231203	Physician	.	US
.		.	20231229	Health Professional	.	DE
.		.	20231226	Health Professional	.	CA
.		.	20231001	Physician	.	US
.		.	20231129	Physician	.	BE
.		.	20231102	Health Professional	.	CA
.		.	20231005	Physician	.	
.		.	20231024	Consumer	.	CA
67	Kilograms	67	20231114	Consumer	.	US
48	Kilograms	48	20231227	Health Professional	.	
83.9	Kilograms	83.9	20231109	Physician	.	US
76.5	Kilograms	76.5	20231204	Consumer	.	CA
73	Kilograms	73	20231208	Physician	.	CA
.		.	20231115	Physician	.	IT
.		.	20231213	Health Professional	.	
.		.	20231020	Health Professional	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
114734765	.	20150311	20230713	20231219	Periodic	42	Year	42	GROUP2	Female
1147514547	.	20130603	20231108	20231110	Expedited	29	Year	29	GROUP2	Female
1148683512	.	.	20231129	20231212	Periodic	52	Year	52	GROUP3	Female
1149087937	.	20140101	20231205	20231208	Expedited	3	Year	3	GROUP1	Female
115140276	.	20130101	20231019	20231027	Periodic	57	Year	57	GROUP3	Female
1151574948	.	20050101	20231205	20231215	Expedited	1	Year	1	GROUP1	Female
1151945678	.	20150901	20231218	20231225	Expedited	43	Year	43	GROUP2	Female
115203716	.	20150115	20231010	20231017	Expedited	5	Year	5	GROUP1	Female
1156227656	.	20150817	20231012	20231020	Expedited	36	Year	36	GROUP2	Female
115668012	.	.	20231104	20231109	Expedited	82	Year	82	GROUP4	Female
1157787013	.	20150918	20231116	20231116	Expedited	17	Year	17	GROUP1	Male
115900453	.	20150923	20231127	20231129	Expedited	32	Year	32	GROUP2	Female
115921113	.	.	20231201	20231212	Periodic	68	Year	68	GROUP3	Female
115925813	.	.	20231214	20231225	Expedited	50	Year	50	GROUP2	Female
1161812071	.	20150416	20231218	20231225	Expedited	62	Year	62	GROUP3	Female
116289952	.	.	20231214	20231222	Expedited	47	Year	47	GROUP2	Male
116313907	.	20180829	20231213	20231220	Expedited	50	Year	50	GROUP2	Female
1163175032	.	20140501	20231206	20231211	Expedited	50	Year	50	GROUP2	Female
116502727	.	20150601	20231108	20231115	Expedited	57	Year	57	GROUP3	Female
116530282	.	20150701	20151008	20231001	Expedited	71	Year	71	GROUP3	Female
116545458	.	20150924	20231018	20231023	Expedited	17	Year	17	GROUP1	Female
1166352379	.	20151001	20231114	20231115	Expedited	41	Year	41	GROUP2	Female
1168672145	.	20050101	20231212	20231222	Expedited	53	Year	53	GROUP3	Female
1168789257	.	20150101	20231023	20231029	Expedited	44	Year	44	GROUP2	Female
1169217617	.	20120416	20231030	20231107	Expedited	37	Year	37	GROUP2	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231219	Consumer	.	US
68	Kilograms	68	20231110	Health Professional	.	
.		.	20231212	Health Professional	.	US
64	Kilograms	64	20231208	Health Professional	.	CA
.		.	20231027	Consumer	.	US
64	Kilograms	64	20231215	Physician	.	CA
97	Kilograms	97	20231225	Physician	.	CA
41.7	Kilograms	41.7	20231017	Physician	.	
81.5	Kilograms	81.5	20231020	Health Professional	.	AU
.		.	20231109	Physician	.	IT
78	Kilograms	78	20231116	Consumer	.	US
69	Kilograms	69	20231129	Physician	.	US
.		.	20231212	Health Professional	.	US
.		.	20231226	Health Professional	.	US
.		.	20231225	Health Professional	.	CA
.		.	20231222	Physician	.	IR
.		.	20231220	Physician	.	CA
85	Kilograms	85	20231211	Consumer	.	
.		.	20231115	Consumer	.	US
.		.	20231001	Health Professional	.	FR
.		.	20231023	Physician	.	US
95	Kilograms	95	20231115	Health Professional	.	
50	Kilograms	50	20231222	Consumer	.	US
.		.	20231029	Consumer	.	CA
.		.	20231107	Consumer	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
117037909	.	20110101	20231018	20231026	Expedited	65	Year	65	GROUP3	Female
117194573	.	.	20231005	20231011	Expedited	66	Year	66	GROUP3	Female
1174511318	.	20150203	20170213	20231202	Expedited	71	Year	71	GROUP3	Female
117720064	.	20150601	20181002	20231129	Expedited	58	Year	58	GROUP3	Female
117760955	.	20070101	20231113	20231120	Periodic	14	Year	14	GROUP1	Male
1178230313	.	.	20231124	20231128	Expedited	64	Year	64	GROUP3	Female
1178453618	.	20120201	20231212	20231219	Expedited	22	Year	22	GROUP1	Female
1178812814	.	20141201	20231205	20231212	Expedited	61	Year	61	GROUP3	Male
1179178614	.	20220101	20231011	20231020	Expedited	56	Year	56	GROUP3	Female
118087772	.	.	20150323	20231127	Expedited	5	Decade	50	GROUP2	Female
118134552	.	20151024	20231019	20231023	Expedited	36	Year	36	GROUP2	Female
118172344	.	20140101	20231009	20231012	Periodic	20	Year	20	GROUP1	Male
118173123	.	20050601	20231127	20231205	Periodic	13	Year	13	GROUP1	
118191622	.	20131016	20231213	20231224	Periodic	12	Year	12	GROUP1	Male
118278119	.	20150101	20231003	20231013	Expedited	58	Year	58	GROUP3	Male
118406256	.	20150201	20231003	20231013	Expedited	48	Year	48	GROUP2	Male
118406345	.	20151101	20231003	20231013	Expedited	45	Year	45	GROUP2	Female
118490297	.	.	20231208	20231220	Expedited	80	Year	80	GROUP4	Male
1185945712	.	20150301	20190719	20231026	Expedited	56	Year	56	GROUP3	Male
118666423	.	20151208	20231005	20231011	Expedited	41	Year	41	GROUP2	Male
118689222	.	.	20231108	20231116	Periodic	8	Decade	80	GROUP4	Male
118712772	.	.	20231125	20231205	Expedited	9	Year	9	GROUP1	Male
118713032	.	20140201	20231125	20231204	Expedited	62	Year	62	GROUP3	Female
118745404	.	20150201	20231124	20231206	Expedited	89	Year	89	GROUP4	Male
1189796319	.	20141029	20231102	20231114	Expedited	66	Year	66	GROUP3	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231026	Health Professional	.	CA
.		.	20231011	Health Professional	.	CA
78.005	Kilograms	78.005	20231202	Consumer	.	US
.		.	20231129	Physician	.	CA
.		.	20231120	Lawyer	.	US
69	Kilograms	69	20231128	Health Professional	.	
.		.	20231219	Physician	.	CA
83.9	Kilograms	83.9	20231212	Consumer	.	
.		.	20231020	Consumer	.	US
.		.	20231127	Consumer	.	
.		.	20231023	Consumer	.	US
77.18	Kilograms	77.18	20231012	Lawyer	.	US
.		.	20231206	Lawyer	.	US
.		.	20231224	Health Professional	.	US
.		.	20231013	Physician	.	AT
84	Kilograms	84	20231013	Physician	.	AT
.		.	20231013	Physician	.	AT
.		.	20231220	Health Professional	.	FR
.		.	20231026	Consumer	.	US
.		.	20231011	Consumer	.	US
.		.	20231116	Physician	.	US
.		.	20231205	Health Professional	.	IN
.		.	20231204	Health Professional	.	IN
69	Kilograms	69	20231207	Health Professional	.	FR
.		.	20231114	Health Professional	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
119104223	.	20151228	20160203	20231102	Expedited	50	Year	50	GROUP2	Female
119219533	.	.	20231219	20231229	Expedited	23	Year	23	GROUP1	Male
119270783	.	20100514	20231114	20231120	Expedited	39	Year	39	GROUP2	Female
1192728610	.	20170811	20231213	20231220	Expedited	82	Year	82	GROUP4	Female
119326774	.	20160101	20231003	20231012	Expedited	26	Year	26	GROUP2	Male
1193375735	.	20140806	20231005	20231009	Expedited	73	Year	73	GROUP3	Female
1193535523	.	20150401	20231102	20231109	Expedited	74	Year	74	GROUP3	Male
1193793115	.	20160217	20231127	20231204	Expedited	42	Year	42	GROUP2	Male
119478563	.	20160109	20231010	20231012	Expedited	82	Year	82	GROUP4	Male
1196876534	.	20141208	20231102	20231109	Expedited	40	Year	40	GROUP2	Male
119875983	.	20160118	20231214	20231226	Expedited	41	Year	41	GROUP2	Female
119911782	.	20080101	20231113	20231122	Periodic	33	Year	33	GROUP2	Male
120093639	.	20151101	20231018	20231026	Expedited	81	Year	81	GROUP4	Female
120604794	.	.	20231018	20231024	Periodic	64	Year	64	GROUP3	Female
120740156	.	20151219	20160301	20231120	Expedited	72	Year	72	GROUP3	Male
120779963	.	20121002	20160325	20231001	Expedited	71	Year	71	GROUP3	Female
1207853043	.	20150101	20230926	20231006	Expedited	46	Year	46	GROUP2	Female
120813973	.	20160203	20170227	20231001	Expedited	57	Year	57	GROUP3	Male
1208222832	.	20160101	20231031	20231107	Expedited	71	Year	71	GROUP3	Male
1209904323	.	20140731	20230922	20231002	Expedited	44	Year	44	GROUP2	Female
121031125	.	20150201	20231003	20231013	Expedited	50	Year	50	GROUP2	Male
121083429	.	20160124	20231130	20231212	Expedited	5	Year	5	GROUP1	Male
121090126	.	20170331	20231031	20231110	Expedited	43	Year	43	GROUP2	Female
1211671714	.	20160201	20231204	20231208	Expedited	39	Year	39	GROUP2	Female
121178303	.	.	20231213	20231222	Expedited	30	Year	30	GROUP2	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231101	Physician	.	CN
.		.	20231229	Health Professional	.	IR
87.168	Kilograms	87.168	20231120	Consumer	.	US
85	Kilograms	85	20231220	Consumer	.	US
.		.	20231012	Consumer	.	US
87	Kilograms	87	20231009	Health Professional	.	
124	Kilograms	124	20231109	Consumer	.	US
.		.	20231204	Health Professional	.	CA
73.923	Kilograms	73.923	20231012	Health Professional	.	US
67	Kilograms	67	20231109	Physician	.	
.		.	20231226	Physician	.	CA
.		.	20231122	Health Professional	.	US
88	Kilograms	88	20231026	Physician	.	
.		.	20231024	Physician	.	US
86	Kilograms	86	20231120	Physician	.	IT
74	Kilograms	74	20231001	Physician	.	DE
.		.	20231006	Physician	.	CA
72.2	Kilograms	72.2	20231001	Physician	.	JP
.		.	20231107	Consumer	.	CA
26.786	Kilograms	26.786	20231002	Physician	.	CA
108	Kilograms	108	20231013	Physician	.	AT
21	Kilograms	21	20231212	Physician	.	DE
66	Kilograms	66	20231110	Physician	.	CA
.		.	20231208	Physician	.	SE
.		.	20231222	Physician	.	GB

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
121210477	.	.	20231205	20231218	Periodic	39	Year	39	GROUP2	Female
1212230540	.	20151219	20231215	20231221	Expedited	61	Year	61	GROUP3	Female
1213390067	.	20141010	20231010	20231012	Expedited	49	Year	49	GROUP2	Male
121344112	.	.	20231019	20231122	Expedited	44	Year	44	GROUP2	Male
121344172	.	.	20231019	20231122	Expedited	19	Year	19	GROUP1	Female
121344383	.	.	20231130	20231208	Expedited	19	Year	19	GROUP1	Female
121345362	.	.	20231019	20231122	Expedited	44	Year	44	GROUP2	Male
121345672	.	.	20231019	20231122	Expedited	41	Year	41	GROUP2	Female
121349972	.	.	20231019	20231122	Expedited	49	Year	49	GROUP2	Male
121350152	.	.	20231130	20231208	Expedited	54	Year	54	GROUP3	Female
121350502	.	.	20231019	20231121	Expedited	44	Year	44	GROUP2	Female
121351362	.	.	20231130	20231208	Expedited	39	Year	39	GROUP2	Female
121351453	.	.	20231130	20231208	Expedited	32	Year	32	GROUP2	Female
121351482	.	.	20231019	20231122	Expedited	24	Year	24	GROUP1	Female
121351512	.	.	20231019	20231122	Expedited	19	Year	19	GROUP1	Female
1213893320	.	.	20231128	20231205	Expedited	68	Year	68	GROUP3	Female
121389514	.	20130101	20231005	20231009	Expedited	33	Year	33	GROUP2	Female
1213946925	.	20121119	20231202	20231208	Expedited	43	Year	43	GROUP2	Female
121400216	.	.	20231011	20231013	Expedited	63	Year	63	GROUP3	Female
121614898	.	20150616	20231009	20231012	Expedited	75	Year	75	GROUP3	Female
121684513	.	20100701	20231003	20231013	Expedited	37	Year	37	GROUP2	Female
121851406	.	20160201	20231114	20231120	Periodic	76	Year	76	GROUP4	Female
1218588315	.	20160307	20231003	20231012	Expedited	63	Year	63	GROUP3	Female
1219006311	.	20151123	20231003	20231006	Expedited	76	Year	76	GROUP4	Female
1219366031	.	20160101	20231127	20231211	Expedited	43	Year	43	GROUP2	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231218	Consumer	.	US
.		.	20231221	Consumer	.	CA
70	Kilograms	70	20231012	Health Professional	.	
.		.	20231122	Consumer	.	US
64.55	Kilograms	64.55	20231122	Health Professional	.	US
.		.	20231208	Consumer	.	US
.		.	20231123	Consumer	.	US
.		.	20231122	Consumer	.	US
101	Kilograms	101	20231122	Consumer	.	US
.		.	20231208	Consumer	.	US
.		.	20231121	Consumer	.	US
.		.	20231208	Consumer	.	US
.		.	20231208	Consumer	.	US
.		.	20231122	Consumer	.	US
.		.	20231122	Consumer	.	US
48	Kilograms	48	20231205	Consumer	.	US
.		.	20231009	Health Professional	.	US
64	Kilograms	64	20231209	Health Professional	.	
.		.	20231013	Pharmacist	.	NO
62	Kilograms	62	20231012	Physician	.	DE
.		.	20231013	Physician	.	AT
49.887	Kilograms	49.887	20231120	Consumer	.	US
44	Kilograms	44	20231012	Health Professional	.	JP
72	Kilograms	72	20231006	Health Professional	.	
.		.	20231211	Consumer	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
121944728	.	20160311	20180108	20231121	Expedited	45	Year	45	GROUP2	Male
122095957	.	20150401	20231129	20231201	Expedited	40	Year	40	GROUP2	Male
122104123	.	.	20231207	20231220	Expedited	63	Year	63	GROUP3	Female
122200518	.	20160323	20231206	20231218	Expedited	70	Year	70	GROUP3	Male
1223166310	.	20150512	20231106	20231110	Expedited	66	Year	66	GROUP3	Female
1224068929	.	20120801	20231124	20231129	Expedited	53	Year	53	GROUP3	Female
122443472	.	.	20231019	20231028	Periodic	56	Year	56	GROUP3	Female
1224849317	.	20160308	20231116	20231128	Expedited	75	Year	75	GROUP3	Male
122550212	.	.	20231101	20231109	Expedited	34	Year	34	GROUP2	Male
122656474	.	20150918	20231005	20231010	Expedited	78	Year	78	GROUP4	Male
122657802	.	20160214	20231026	20231030	Expedited	52	Year	52	GROUP3	Male
1226963211	.	20160410	20231102	20231108	Expedited	17	Year	17	GROUP1	Male
122815454	.	.	20231204	20231211	Expedited	78	Year	78	GROUP4	Female
122844006	.	.	20231108	20231117	Expedited	48	Year	48	GROUP2	Female
1229068117	.	.	20231022	20231101	Expedited	60	Year	60	GROUP3	Female
1229378940	.	20150608	20231106	20231109	Expedited	66	Year	66	GROUP3	Female
123033744	.	20091001	20231213	20231224	Periodic	12	Year	12	GROUP1	Male
123036974	.	20070813	20231025	20231030	Periodic	7	Year	7	GROUP1	Male
123040872	.	20111014	20230929	20231005	Periodic	8	Year	8	GROUP1	Male
1230456626	.	20150701	20231207	20231215	Expedited	55	Year	55	GROUP3	Female
1230619217	.	20160701	20231116	20231128	Expedited	57	Year	57	GROUP3	Male
123066303	.	.	20230927	20231103	Expedited	63	Year	63	GROUP3	Female
123066314	.	.	20231003	20231103	Expedited	64	Year	64	GROUP3	Female
123090303	.	.	20230927	20231103	Expedited	21	Year	21	GROUP1	Female
123090423	.	.	20230927	20231103	Expedited	29	Year	29	GROUP2	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
77	Kilograms	77	20231121	Physician	.	TH
.		.	20231201	Health Professional	.	
.		.	20231220	Health Professional	.	US
63	Kilograms	63	20231218	Consumer	.	CA
106.1	Kilograms	106.1	20231110	Consumer	.	US
100.2	Kilograms	100.2	20231129	Consumer	.	
.		.	20231028	Consumer	.	US
.		.	20231128	Physician	.	CA
.		.	20231109	Physician	.	US
47.9	Kilograms	47.9	20231010	Physician	.	JP
.		.	20231030	Physician	.	ES
54	Kilograms	54	20231108	Consumer	.	CO
.		.	20231211	Physician	.	US
.		.	20231118	Health Professional	.	US
.		.	20231101	Consumer	.	US
130	Kilograms	130	20231109	Consumer	.	
.		.	20231224	Lawyer	.	US
.		.	20231030	Lawyer	.	US
.		.	20231006	Health Professional	.	US
.		.	20231215	Physician	.	CA
113	Kilograms	113	20231127	Consumer	.	US
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
123097115	.	20140401	20231003	20231013	Expedited	33	Year	33	GROUP2	Female
123119083	.	.	20230927	20231103	Expedited	40	Year	40	GROUP2	Male
123119133	.	.	20230927	20231103	Expedited	50	Year	50	GROUP2	Female
123119193	.	.	20230927	20231103	Expedited	40	Year	40	GROUP2	Male
123119243	.	.	20230927	20231103	Expedited	54	Year	54	GROUP3	Male
123119253	.	.	20230927	20231103	Expedited	50	Year	50	GROUP2	Male
123119263	.	.	20230927	20231103	Expedited	47	Year	47	GROUP2	Female
123119286	.	.	20230927	20231103	Expedited	66	Year	66	GROUP3	Female
123119353	.	.	20230927	20231103	Expedited	59	Year	59	GROUP3	Male
123119363	.	.	20230927	20231103	Expedited	32	Year	32	GROUP2	Male
123119443	.	.	20230927	20231102	Expedited	48	Year	48	GROUP2	Male
123120013	.	.	20230927	20231103	Expedited	51	Year	51	GROUP3	Female
123121313	.	.	20230927	20231103	Expedited	56	Year	56	GROUP3	Male
123333823	.	20130101	20230913	20231019	Periodic	48	Year	48	GROUP2	Female
1233895913	.	20160502	20231206	20231218	Periodic	59	Year	59	GROUP3	Female
123430863	.	.	20231204	20231208	Expedited	31	Year	31	GROUP2	Male
1234722916	.	20160101	20230921	20231003	Expedited	32	Year	32	GROUP2	Female
123507647	.	20160101	20231213	20231219	Expedited	49	Year	49	GROUP2	Female
123563352	.	20130801	20231019	20231025	Expedited	47	Year	47	GROUP2	Male
1235836630	.	20131029	20231130	20231212	Expedited	51	Year	51	GROUP3	Female
123602163	.	.	20231019	20231222	Expedited	35	Year	35	GROUP2	Female
123673573	.	20040101	20231120	20231128	Expedited	3	Decade	30	GROUP2	Male
123712795	.	20150909	20231218	20231221	Expedited	75	Year	75	GROUP3	Female
1237277237	.	20160101	20230926	20231005	Expedited	82	Year	82	GROUP4	Male
123828053	.	20160401	20231107	20231112	Expedited	43	Year	43	GROUP2	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
50	Kilograms	50	20231013	Physician	.	AT
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231102	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231103	Health Professional	.	NO
.		.	20231019	Physician	.	US
71.67	Kilograms	71.67	20231218	Health Professional	.	US
.		.	20231208	Physician	.	US
.		.	20231003	Physician	.	CA
67	Kilograms	67	20231220	Physician	.	FR
.		.	20231025	Physician	.	PT
.		.	20231212	Consumer	.	CA
.		.	20231222	Consumer	.	US
.		.	20231129	Health Professional	.	US
85.714	Kilograms	85.714	20231221	Physician	.	US
.		.	20231005	Consumer	.	CA
.		.	20231112	Consumer	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1238769515	.	20141201	20231219	20231230	Expedited	46	Year	46	GROUP2	Female
123877733	.	20160311	20231120	20231123	Periodic	49	Year	49	GROUP2	Male
123883414	.	20160430	20160531	20231122	Expedited	30	Year	30	GROUP2	Female
1239199829	.	20150311	20231211	20231221	Expedited	53	Year	53	GROUP3	Female
123928902	.	20151001	20230818	20231019	Periodic	32	Year	32	GROUP2	Female
124058976	.	.	20231222	20231230	Expedited	57	Year	57	GROUP3	Male
1241683811	.	.	20230926	20231006	Expedited	76	Year	76	GROUP4	Female
1241759015	.	20160412	20231017	20231026	Expedited	62	Year	62	GROUP3	Female
1242381216	.	20160401	20231017	20231027	Expedited	62	Year	62	GROUP3	Female
124267893	.	20130501	20230731	20231019	Periodic	42	Year	42	GROUP2	Female
1243188715	.	20160506	20231115	20231118	Expedited	48	Year	48	GROUP2	Male
1244105814	.	20160316	20231003	20231013	Expedited	48	Year	48	GROUP2	Female
1244109913	.	20170108	20231003	20231016	Expedited	43	Year	43	GROUP2	Female
124454965	.	20040714	20231106	20231115	Periodic	8	Year	8	GROUP1	Male
124455942	.	20090101	20231016	20231018	Periodic	3	Decade	30	GROUP2	Male
124557465	.	20160101	20231211	20231229	Expedited	49	Year	49	GROUP2	Female
124576196	.	20160301	20231220	20231228	Expedited	38	Year	38	GROUP2	Female
124647052	.	.	20231204	20231208	Expedited	31	Year	31	GROUP2	Male
124656152	.	.	20231205	20231214	Expedited	31	Year	31	GROUP2	Male
124658184	.	.	20231204	20231213	Expedited	31	Year	31	GROUP2	Male
1246649231	.	20120801	20231012	20231023	Expedited	71	Year	71	GROUP3	Female
124697266	.	20200526	20231213	20231218	Expedited	76	Year	76	GROUP4	Female
124729263	.	.	20231019	20231031	Expedited	69	Year	69	GROUP3	Female
1248414317	.	20150519	20231215	20231226	Expedited	38	Year	38	GROUP2	Female
1248745116	.	20140605	20231214	20231226	Expedited	56	Year	56	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231230	Consumer	.	CA
.		.	20231123	Consumer	.	US
53	Kilograms	53	20231122	Physician	.	
.		.	20231221	Consumer	.	CA
.		.	20231019	Consumer	.	US
.		.	20231230	Health Professional	.	GB
.		.	20231006	Consumer	.	US
.		.	20231026	Physician	.	CA
.		.	20231027	Health Professional	.	CA
.		.	20231019	Physician	.	US
70	Kilograms	70	20231118	Consumer	.	CO
110	Kilograms	110	20231013	Consumer	.	CA
.		.	20231016	Consumer	.	CA
.		.	20231115	Health Professional	.	US
.		.	20231018	Lawyer	.	US
67	Kilograms	67	20231214	Physician	.	FR
.		.	20231228	Consumer	.	CA
.		.	20231208	Physician	.	US
.		.	20231214	Physician	.	US
.		.	20231213	Physician	.	US
.		.	20231023	Consumer	.	CA
.		.	20231218	Consumer	.	US
.		.	20231031	Physician	.	US
.		.	20231226	Consumer	.	CA
.		.	20231226	Physician	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1248777719	.	20160531	20231109	20231120	Expedited	56	Year	56	GROUP3	Male
124879704	.	.	20231218	20231229	Expedited	48	Year	48	GROUP2	Male
125035915	.	20160515	20231002	20231005	Expedited	42	Year	42	GROUP2	Male
1251723528	.	20160101	20231122	20231130	Expedited	68	Year	68	GROUP3	Female
1251759434	.	20160205	20231106	20231113	Expedited	59	Year	59	GROUP3	Female
125236397	.	20140304	20231107	20231114	Expedited	55	Year	55	GROUP3	Male
1252758731	.	20121001	20231108	20231117	Expedited	70	Year	70	GROUP3	Male
125285222	.	.	20231031	20231109	Expedited	26	Year	26	GROUP2	Female
125316252	.	20130801	20231019	20231030	Expedited	47	Year	47	GROUP2	Male
1253212410	.	20160304	20231220	20231226	Expedited	61	Year	61	GROUP3	Female
1253507817	.	20120101	20231212	20231222	Expedited	59	Year	59	GROUP3	Female
125419252	.	20160621	20231130	20231206	Expedited	75	Year	75	GROUP3	Male
1254806012	.	20160626	20220618	20231004	Expedited	41	Year	41	GROUP2	Male
1254818510	.	.	20231101	20231115	Periodic	70	Year	70	GROUP3	Female
125511353	.	.	20231004	20231011	Expedited	25	Year	25	GROUP1	Female
125520368	.	20190901	20231208	20231218	Expedited	70	Year	70	GROUP3	Female
125529493	.	20160101	20231019	20231130	Expedited	41	Year	41	GROUP2	Female
125595734	.	20150720	20231213	20231218	Expedited	50	Year	50	GROUP2	Female
125609252	.	20150101	20231127	20231209	Expedited	75	Year	75	GROUP3	Male
1256504624	.	20151001	20231211	20231218	Expedited	62	Year	62	GROUP3	Male
1258205211	.	20140921	20231024	20231106	Expedited	37	Year	37	GROUP2	Male
1258253825	.	20160601	20231222	20231227	Expedited	51	Year	51	GROUP3	Male
1258700623	.	20160401	20231115	20231122	Expedited	60	Year	60	GROUP3	Female
1259605217	.	20200201	20231201	20231214	Expedited	46	Year	46	GROUP2	Female
125972513	.	.	20231201	20231214	Expedited	61	Year	61	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231120	Consumer	.	CA
.		.	20231229	Physician	.	US
.		.	20231005	Physician	.	US
.		.	20231201	Consumer	.	CA
69.5	Kilograms	69.5	20231113	Physician	.	CL
68	Kilograms	68	20231114	Consumer	.	CA
.		.	20231118	Consumer	.	CA
.		.	20231109	Physician	.	TR
.		.	20231030	Health Professional	.	PT
.		.	20231226	Health Professional	.	CA
.		.	20231222	Consumer	.	CA
105	Kilograms	105	20231206	Physician	.	GB
.		.	20231004	Consumer	.	IN
61	Kilograms	61	20231115	Consumer	.	US
.		.	20231011	Physician	.	US
.		.	20231216	Physician	.	CA
.		.	20231130	Consumer	.	US
.		.	20231218	Physician	.	CA
.		.	20231209	Physician	.	JP
69	Kilograms	69	20231218	Consumer	.	CA
.		.	20231106	Physician	.	CA
.		.	20231227	Consumer	.	CA
.		.	20231122	Consumer	.	CA
.		.	20231214	Consumer	.	CA
.		.	20231214	Physician	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
125974976	.	20230201	20231128	20231207	Periodic	58	Year	58	GROUP3	Female
126018092	.	.	20231213	20231221	Expedited	57	Year	57	GROUP3	Male
126027722	.	20160701	20231211	20231219	Expedited	63	Year	63	GROUP3	Male
126052728	.	20160701	20231031	20231102	Expedited	76	Year	76	GROUP4	Female
126079123	.	.	20231113	20231116	Periodic	80	Year	80	GROUP4	Male
126083683	.	.	20231113	20231121	Periodic	85	Year	85	GROUP4	Male
126083763	.	.	20231113	20231120	Periodic	80	Year	80	GROUP4	Male
126102746	.	20160706	20231108	20231117	Expedited	62	Year	62	GROUP3	Male
1261220638	.	20150510	20231115	20231122	Expedited	40	Year	40	GROUP2	Female
126144642	.	.	20231130	20231208	Expedited	53	Year	53	GROUP3	Female
1261461519	.	20160101	20231201	20231208	Expedited	66	Year	66	GROUP3	Female
126146323	.	20150101	20230918	20231019	Periodic	60	Year	60	GROUP3	Male
1262188810	.	20160701	20231107	20231115	Expedited	76	Year	76	GROUP4	Female
1262194015	.	20160701	20231026	20231031	Expedited	41	Year	41	GROUP2	Female
1262399912	.	20160701	20231009	20231011	Expedited	58	Year	58	GROUP3	Male
126300813	.	.	20231013	20231020	Expedited	85	Year	85	GROUP4	Female
126446453	.	20160727	20231208	20231214	Expedited	54	Year	54	GROUP3	Female
1264583518	.	20151218	20231016	20231022	Expedited	45	Year	45	GROUP2	Male
1264877314	.	20180801	20231031	20231106	Periodic	63	Year	63	GROUP3	Male
1265259319	.	20160805	20231124	20231204	Expedited	72	Year	72	GROUP3	Male
126525949	.	.	20231109	20231115	Periodic	66	Year	66	GROUP3	Male
1265982714	.	20220310	20231205	20231207	Expedited	17	Year	17	GROUP1	Female
1266158617	.	20160819	20231113	20231120	Periodic	62	Year	62	GROUP3	Female
126629514	.	20160801	20231011	20231016	Expedited	26	Year	26	GROUP2	Female
126636233	.	20160628	20231117	20231130	Expedited	61	Year	61	GROUP3	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231207	Health Professional	.	US
.		.	20231221	Health Professional	.	GB
.		.	20231219	Health Professional	.	KR
.		.	20231103	Physician	.	FR
.		.	20231116	Health Professional	.	US
.		.	20231121	Health Professional	.	US
.		.	20231120	Health Professional	.	US
.		.	20231117	Health Professional	.	CA
88	Kilograms	88	20231122	Physician	.	CA
.		.	20231208	Consumer	.	US
86	Kilograms	86	20231208	Consumer	.	US
.		.	20231019	Health Professional	.	US
.		.	20231115	Physician	.	FR
59	Kilograms	59	20231031	Consumer	.	CA
.		.	20231011	Consumer	.	US
.		.	20231020	Health Professional	.	US
.		.	20231215	Physician	.	US
.		.	20231022	Physician	.	CA
.		.	20231106	Consumer	.	US
95.5	Kilograms	95.5	20231204	Consumer	.	US
.		.	20231115	Physician	.	US
60.781	Kilograms	60.781	20231207	Health Professional	.	US
70	Kilograms	70	20231120	Physician	.	US
88.5	Kilograms	88.5	20231016	Health Professional	.	
90.703	Kilograms	90.703	20231130	Consumer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
126661713	.	20160201	20230724	20231019	Periodic	45	Year	45	GROUP2	Female
1266682834	.	.	20231218	20231227	Expedited	77	Year	77	GROUP4	Female
126694216	.	20160101	20231127	20231205	Expedited	43	Year	43	GROUP2	Female
1267143810	.	20160810	20231130	20231208	Expedited	56	Year	56	GROUP3	Male
1267308830	.	20160301	20231102	20231108	Expedited	52	Year	52	GROUP3	Female
1267604333	.	.	20231127	20231129	Expedited	43	Year	43	GROUP2	Female
126784766	.	20160101	20231107	20231113	Expedited	48	Year	48	GROUP2	Male
1267970510	.	20160802	20231116	20231129	Expedited	66	Year	66	GROUP3	Male
1268469220	.	20150515	20231106	20231112	Expedited	55	Year	55	GROUP3	Male
126849622	.	20160803	20231214	20231221	Expedited	60	Year	60	GROUP3	Male
126865539	.	20160701	20231208	20231214	Expedited	76	Year	76	GROUP4	Female
126946204	.	20150412	20170407	20231202	Expedited	62	Year	62	GROUP3	Male
1269688715	.	.	20231020	20231025	Expedited	60	Year	60	GROUP3	Female
126982523	.	20030101	20231113	20231121	Periodic	1	Decade	10	GROUP1	Male
1270466920	.	20160623	20231128	20231201	Expedited	37	Year	37	GROUP2	Male
127133207	.	.	20231017	20231024	Expedited	58	Year	58	GROUP3	Female
1271617516	.	20160101	20231205	20231212	Expedited	62	Year	62	GROUP3	Male
1271619614	.	20140701	20221108	20231206	Expedited	70	Year	70	GROUP3	Female
1272747538	.	20160609	20230922	20231003	Expedited	62	Year	62	GROUP3	Female
127335812	.	.	20231012	20231020	Expedited	64	Year	64	GROUP3	Female
1273672134	.	20160101	20220325	20231129	Expedited	78	Year	78	GROUP4	Male
127442575	.	20060801	20231117	20231124	Expedited	46	Year	46	GROUP2	Male
127476922	.	20160501	20230724	20231019	Periodic	51	Year	51	GROUP3	Female
1276662113	.	.	20231120	20231130	Expedited	63	Year	63	GROUP3	Male
1276746115	.	.	20231119	20231120	Expedited	74	Year	74	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231019	Health Professional	.	US
.		.	20231227	Physician	.	CA
.		.	20231205	Physician	.	CA
.		.	20231208	Consumer	.	CA
.		.	20231108	Health Professional	.	CA
68	Kilograms	68	20231129	Physician	.	CA
.		.	20231113	Consumer	.	CA
.		.	20231129	Physician	.	CA
.		.	20231113	Physician	.	JP
104	Kilograms	104	20231221	Physician	.	FR
.		.	20231214	Health Professional	.	FR
101.4	Kilograms	101.4	20231202	Lawyer	.	US
.		.	20231025	Physician	.	
.		.	20231121	Lawyer	.	US
.		.	20231201	Consumer	.	CA
.		.	20231024	Consumer	.	CA
.		.	20231212	Consumer	.	CA
68	Kilograms	68	20231206	Health Professional	.	CA
74	Kilograms	74	20231003	Physician	.	CA
.		.	20231020	Consumer	.	NO
.		.	20231129	Physician	.	CA
.		.	20231124	Physician	.	US
.		.	20231019	Physician	.	US
.		.	20231130	Physician	.	CA
59.864	Kilograms	59.864	20231120	Physician	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
127688913	.	20130601	20230724	20231019	Periodic	48	Year	48	GROUP2	Female
127739882	.	20131001	20231211	20231222	Expedited	60	Year	60	GROUP3	Male
127795064	.	20160101	20230811	20231025	Expedited	93	Year	93	GROUP4	Male
1278946016	.	20160919	20231017	20231019	Expedited	68	Year	68	GROUP3	Female
1279005821	.	20160101	20231017	20231023	Expedited	68	Year	68	GROUP3	Male
127908472	.	.	20230925	20231002	Expedited	35	Year	35	GROUP2	Male
127919063	.	20131001	20231211	20231220	Expedited	60	Year	60	GROUP3	Male
127923264	.	20030101	20231006	20231013	Periodic	7	Year	7	GROUP1	Male
127928484	.	19950101	20231025	20231031	Periodic	11	Year	11	GROUP1	Male
127932064	.	20020801	20231006	20231012	Periodic	10	Year	10	GROUP1	Male
127932964	.	20021201	20231122	20231129	Periodic	15	Year	15	GROUP1	Male
127934284	.	20000201	20230929	20231005	Periodic	11	Year	11	GROUP1	Male
128111456	.	20160801	20231206	20231208	Expedited	58	Year	58	GROUP3	Male
128125275	.	20150904	20231117	20231122	Expedited	62	Year	62	GROUP3	Female
1281285321	.	20150101	20231123	20231204	Expedited	60	Year	60	GROUP3	Female
1282456425	.	20110101	20231122	20231130	Expedited	68	Year	68	GROUP3	Female
128337604	.	20161004	20231215	20231226	Expedited	56	Year	56	GROUP3	Male
1283816224	.	20130501	20230926	20231004	Expedited	68	Year	68	GROUP3	Female
1284001415	.	20140101	20231127	20231204	Expedited	83	Year	83	GROUP4	Female
1284111422	.	20160926	20231129	20231204	Expedited	26	Year	26	GROUP2	Male
128418645	.	20160516	20231221	20231228	Expedited	28	Year	28	GROUP2	Male
128428173	.	.	20231214	20231219	Expedited	71	Year	71	GROUP3	Male
128607137	.	20160801	20231005	20231011	Expedited	78	Year	78	GROUP4	Male
128713873	.	.	20231122	20231201	Expedited	45	Year	45	GROUP2	Male
128796683	.	20160501	20231025	20231031	Expedited	61	Year	61	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231019	Health Professional	.	US
.		.	20231222	Health Professional	.	IT
.		.	20231025	Physician	.	GB
.		.	20231019	Health Professional	.	CA
.		.	20231023	Consumer	.	CA
.		.	20231002	Health Professional	.	TR
.		.	20231220	Health Professional	.	IT
.		.	20231013	Lawyer	.	US
.		.	20231031	Health Professional	.	US
.		.	20231012	Health Professional	.	US
.		.	20231130	Lawyer	.	US
.		.	20231006	Lawyer	.	US
.		.	20231208	Consumer	.	US
45	Kilograms	45	20231122	Physician	.	JP
64	Kilograms	64	20231204	Health Professional	.	CA
.		.	20231130	Health Professional	.	CA
72	Kilograms	72	20231226	Health Professional	.	CA
.		.	20231004	Consumer	.	CA
54.43	Kilograms	54.43	20231204	Consumer	.	US
.		.	20231204	Health Professional	.	CA
.		.	20231228	Consumer	.	CA
.		.	20231219	Physician	.	US
.		.	20231011	Physician	.	JP
81	Kilograms	81	20231201	Consumer	.	
.		.	20231031	Physician	.	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
128813963	.	20050101	20231009	20231018	Periodic	1	Decade	10	GROUP1	Male
128814004	.	20060109	20230927	20231004	Periodic	4	Year	4	GROUP1	Male
128814102	.	20040330	20231213	20231224	Periodic	10	Year	10	GROUP1	Male
128830863	.	20161001	20231017	20231023	Expedited	31	Year	31	GROUP2	Male
1288783427	.	20150204	20231201	20231213	Expedited	31	Year	31	GROUP2	Male
128896804	.	20160927	20231114	20231117	Expedited	11	Year	11	GROUP1	Male
128906342	.	20160801	20230818	20231019	Periodic	33	Year	33	GROUP2	Female
129175148	.	20150701	20231127	20231203	Expedited	41	Year	41	GROUP2	Female
1292916520	.	20161030	20231205	20231215	Expedited	80	Year	80	GROUP4	Female
129382472	.	20160901	20231030	20231124	Periodic	78	Year	78	GROUP4	Female
129392585	.	20161001	20230927	20231025	Periodic	56	Year	56	GROUP3	Female
129401283	.	20160101	20231217	20231224	Periodic	3	Decade	30	GROUP2	Male
129407123	.	20050831	20231120	20231124	Periodic	8	Year	8	GROUP1	Male
129411963	.	20000401	20231120	20231126	Periodic	8	Year	8	GROUP1	Male
1294339813	.	20160727	20231115	20231122	Expedited	60	Year	60	GROUP3	Male
1294445310	.	20110101	20231211	20231213	Expedited	33	Year	33	GROUP2	Female
1294587413	.	20150527	20231030	20231101	Expedited	60	Year	60	GROUP3	Female
129482007	.	20110101	20231010	20231017	Expedited	24	Year	24	GROUP1	Female
129534697	.	20160403	20230712	20231123	Expedited	57	Year	57	GROUP3	Female
1295393127	.	20170101	20231023	20231101	Expedited	46	Year	46	GROUP2	Female
1295753119	.	20111201	20231109	20231114	Expedited	1	Year	1	GROUP1	Male
1295809811	.	20150901	20231019	20231027	Expedited	52	Year	52	GROUP3	Female
129640184	.	20151016	20231207	20231215	Expedited	54	Year	54	GROUP3	Female
129702073	.	.	20230927	20231020	Periodic	78	Year	78	GROUP4	Female
129710933	.	20120901	20231115	20231121	Expedited	22	Year	22	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231018	Health Professional	.	US
.		.	20231004	Health Professional	.	US
.		.	20231224	Health Professional	.	US
.		.	20231023	Health Professional	.	CA
.		.	20231213	Physician	.	CA
.		.	20231116	Physician	.	GB
.		.	20231019	Consumer	.	US
.		.	20231204	Consumer	.	CA
51	Kilograms	51	20231215	Physician	.	US
.		.	20231124	Consumer	.	US
70	Kilograms	70	20231025	Consumer	.	US
.		.	20231224	Lawyer	.	US
.		.	20231125	Lawyer	.	US
.		.	20231126	Lawyer	.	US
113.4	Kilograms	113.4	20231122	Physician	.	US
113.4	Kilograms	113.4	20231213	Physician	.	US
97	Kilograms	97	20231101	Consumer	.	CA
65	Kilograms	65	20231017	Physician	.	
73	Kilograms	73	20231123	Physician	.	ES
.		.	20231101	Health Professional	.	CA
24	Kilograms	24	20231114	Health Professional	.	US
.		.	20231027	Physician	.	CA
.		.	20231215	Physician	.	CA
.		.	20231020	Physician	.	US
79.83	Kilograms	79.83	20231121	Physician	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
129756816	.	20161001	20231019	20231026	Expedited	22	Year	22	GROUP1	Male
129758429	.	20160719	20230929	20231002	Expedited	74	Year	74	GROUP3	Male
1298165819	.	20160927	20231128	20231207	Expedited	52	Year	52	GROUP3	Female
1298245917	.	20161111	20231116	20231124	Expedited	43	Year	43	GROUP2	Male
129887515	.	20120101	20231006	20231010	Expedited	60	Year	60	GROUP3	Female
129895932	.	20160921	20231009	20231016	Expedited	57	Year	57	GROUP3	Male
129913302	.	.	20231016	20231019	Expedited	52	Year	52	GROUP3	Female
129929712	.	20160901	20231107	20231117	Expedited	84	Year	84	GROUP4	Male
129936304	.	20090101	20231106	20231112	Periodic	22	Year	22	GROUP1	Male
1299455329	.	20160101	20231207	20231214	Expedited	72	Year	72	GROUP3	Male
129969329	.	20160902	20231031	20231107	Expedited	69	Year	69	GROUP3	Female
1300378736	.	20161001	20231120	20231128	Expedited	61	Year	61	GROUP3	Male
130099107	.	20140720	20231108	20231114	Expedited	34	Year	34	GROUP2	Female
1301226125	.	20170823	20231025	20231030	Expedited	57	Year	57	GROUP3	Female
130167094	.	20151231	20231031	20231109	Expedited	8	Month	0	GROUP1	Male
1302401118	.	20161101	20231010	20231020	Expedited	40	Year	40	GROUP2	Female
130260364	.	20050101	20231113	20231123	Periodic	6	Decade	60	GROUP3	Male
130297032	.	20161015	20231108	20231118	Expedited	70	Year	70	GROUP3	Female
130314855	.	20160628	20231106	20231114	Expedited	59	Year	59	GROUP3	Female
130357263	.	20150729	20231207	20231220	Periodic	70	Year	70	GROUP3	Female
1305805713	.	.	20231207	20231222	Expedited	65	Year	65	GROUP3	Female
1306707611	.	20161101	20231226	20231229	Expedited	45	Year	45	GROUP2	Female
1306917111	.	20210101	20231010	20231019	Expedited	67	Year	67	GROUP3	Female
130719762	.	20161221	20231218	20231227	Expedited	38	Year	38	GROUP2	Female
1307598415	.	20161101	20231205	20231211	Expedited	40	Year	40	GROUP2	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231026	Physician	.	BE
85	Kilograms	85	20231002	Physician	.	
.		.	20231207	Consumer	.	CA
.		.	20231124	Consumer	.	CA
.		.	20231010	Consumer	.	US
.		.	20231016	Physician	.	
.		.	20231019	Health Professional	.	CA
.		.	20231117	Consumer	.	GB
76.726	Kilograms	76.726	20231112	Lawyer	.	US
.		.	20231214	Consumer	.	CA
.		.	20231107	Physician	.	CA
91	Kilograms	91	20231128	Consumer	.	CA
.		.	20231114	Consumer	.	IN
114	Kilograms	114	20231030	Consumer	.	US
3.41	Kilograms	3.41	20231109	Physician	.	DE
.		.	20231020	Consumer	.	US
.		.	20231123	Health Professional	.	US
.		.	20231118	Physician	.	IT
.		.	20231114	Consumer	.	CA
64.23	Kilograms	64.23	20231220	Physician	.	US
.		.	20231222	Physician	.	CA
.		.	20231229	Health Professional	.	US
97.5	Kilograms	97.5	20231019	Consumer	.	US
.		.	20231227	Health Professional	.	CA
.		.	20231211	Consumer	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
130799412	.	.	20231225	20231227	Periodic	66	Year	66	GROUP3	Male
1308956011	.	20201123	20231129	20231211	Periodic	66	Year	66	GROUP3	Male
130896044	.	.	20231012	20231020	Expedited	38	Year	38	GROUP2	Female
130913686	.	20161223	20230927	20231004	Expedited	41	Year	41	GROUP2	Female
130951602	.	.	20231221	20231226	Periodic	81	Year	81	GROUP4	Female
1309831715	.	.	20231127	20231204	Expedited	17	Year	17	GROUP1	Male
1310972321	.	.	20231106	20231110	Expedited	43	Year	43	GROUP2	Female
131179953	.	20080528	20231211	20231218	Expedited	15	Year	15	GROUP1	Male
131181313	.	19990101	20230927	20231005	Periodic	9	Year	9	GROUP1	Male
131181364	.	20061017	20230927	20231005	Periodic	16	Year	16	GROUP1	Male
131181465	.	20130501	20231009	20231016	Periodic	22	Year	22	GROUP1	Male
131181983	.	20070101	20231013	20231019	Periodic	11	Year	11	GROUP1	Male
131182343	.	20061001	20231013	20231016	Periodic	15	Year	15	GROUP1	Male
1312065018	.	20060301	20231130	20231212	Periodic	57	Year	57	GROUP3	Female
1312448414	.	20180201	20231004	20231010	Expedited	36	Year	36	GROUP2	Female
131271632	.	.	20230508	20231220	Expedited	58	Year	58	GROUP3	Male
131300352	.	20160303	20231211	20231220	Expedited	17	Year	17	GROUP1	Male
1313174010	.	20160701	20231116	20231128	Expedited	69	Year	69	GROUP3	Male
131346387	.	20170107	20231114	20231121	Expedited	49	Year	49	GROUP2	Female
131396835	.	20161223	20231113	20231120	Periodic	59	Year	59	GROUP3	Female
131408182	.	20161001	20161014	20231118	Periodic	49	Year	49	GROUP2	Female
1315318823	.	20160707	20231006	20231016	Expedited	67	Year	67	GROUP3	Female
131584896	.	20161101	20231204	20231208	Expedited	30	Year	30	GROUP2	Male
131614126	.	.	20231207	20231212	Expedited	36	Year	36	GROUP2	Male
131674923	.	.	20231128	20231206	Periodic	73	Year	73	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231227	Physician	.	US
71	Kilograms	71	20231211	Consumer	.	US
.		.	20231020	Physician	.	US
.		.	20231004	Physician	.	US
.		.	20231226	Consumer	.	US
.		.	20231204	Consumer	.	US
84	Kilograms	84	20231110	Consumer	.	US
.		.	20231218	Health Professional	.	US
.		.	20231005	Lawyer	.	US
.		.	20231005	Health Professional	.	US
.		.	20231016	Health Professional	.	US
.		.	20231019	Health Professional	.	US
.		.	20231017	Lawyer	.	US
.		.	20231212	Physician	.	US
.		.	20231010	Consumer	.	CA
.		.	20231221	Physician	.	
60	Kilograms	60	20231220	Physician	.	DE
.		.	20231127	Consumer	.	US
.		.	20231121	Consumer	.	CA
66	Kilograms	66	20231120	Consumer	.	US
102.95	Kilograms	102.95	20231118	Health Professional	.	US
73	Kilograms	73	20231016	Consumer	.	CA
.		.	20231208	Physician	.	CA
.		.	20231212	Health Professional	.	
.		.	20231206	Physician	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
131675473	.	.	20231129	20231211	Periodic	73	Year	73	GROUP3	Female
131717653	.	.	20231115	20231128	Periodic	68	Year	68	GROUP3	Female
131717783	.	20170112	20231108	20231115	Periodic	84	Year	84	GROUP4	Female
131720564	.	20160101	20231006	20231009	Expedited	70	Year	70	GROUP3	Male
131836203	.	.	20231115	20231128	Periodic	68	Year	68	GROUP3	Female
131884112	.	20160401	20170127	20231220	Expedited	54	Year	54	GROUP3	Female
131948255	.	20120501	20231110	20231117	Expedited	42	Year	42	GROUP2	Male
132256512	.	20170208	20231107	20231114	30 Day	58	Year	58	GROUP3	Female
1322723239	.	.	20231213	20231222	Expedited	77	Year	77	GROUP4	Female
1323008512	.	20200421	20231107	20231110	Expedited	74	Year	74	GROUP3	Female
132357762	.	.	20231106	20231109	Periodic	29	Year	29	GROUP2	Male
132446642	.	20160801	20230823	20231019	Periodic	29	Year	29	GROUP2	Female
132535658	.	20161201	20230925	20231005	Expedited	63	Year	63	GROUP3	Male
132573907	.	.	20231225	20231228	Expedited	78	Year	78	GROUP4	Male
132594262	.	.	20231213	20231227	Periodic	63	Year	63	GROUP3	Female
1326573916	.	20160707	20231208	20231215	Expedited	77	Year	77	GROUP4	Female
132667138	.	20160809	20231204	20231213	Expedited	3	Week	0	GROUP1	Male
1326925316	.	20170207	20231003	20231016	Expedited	40	Year	40	GROUP2	Female
1327001616	.	20131201	20231101	20231103	Expedited	65	Year	65	GROUP3	Male
1327789813	.	20170202	20231017	20231019	Expedited	63	Year	63	GROUP3	Female
132807613	.	.	20231031	20231108	Expedited	36	Year	36	GROUP2	Male
132818014	.	20160901	20231011	20231020	Expedited	69	Year	69	GROUP3	Female
132846696	.	20161201	20231218	20231220	Expedited	32	Year	32	GROUP2	Female
1328785317	.	20170220	20231218	20231219	Periodic	17	Year	17	GROUP1	Male
1329621913	.	20161227	20230930	20231220	Expedited	71	Year	71	GROUP3	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231211	Consumer	.	US
.		.	20231128	Consumer	.	US
59	Kilograms	59	20231115	Physician	.	US
.		.	20231009	Physician	.	PT
.		.	20231127	Consumer	.	US
.		.	20231220	Consumer	.	US
.		.	20231117	Physician	.	US
.		.	20231114	Consumer	.	US
.		.	20231222	Health Professional	.	CA
87	Kilograms	87	20231110	Consumer	.	US
.		.	20231109	Physician	.	US
.		.	20231019	Consumer	.	US
108	Kilograms	108	20231005	Consumer	.	US
.		.	20231228	Health Professional	.	IT
.		.	20231227	Consumer	.	US
.		.	20231215	Health Professional	.	CA
3.18	Kilograms	3.18	20231213	Physician	.	DE
57	Kilograms	57	20231016	Physician	.	GR
94.785	Kilograms	94.785	20231103	Physician	.	US
.		.	20231019	Consumer	.	CA
.		.	20231108	Consumer	.	CA
.		.	20231020	Consumer	.	US
.		.	20231220	Physician	.	US
59	Kilograms	59	20231219	Physician	.	US
113.4	Kilograms	113.4	20231220	Physician	.	FR

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1330128110	.	.	20231206	20231218	Periodic	78	Year	78	GROUP4	Female
133030383	.	20061001	20231020	20231025	Expedited	0	Year	0	GROUP1	Male
1330367811	.	20170217	20231006	20231011	Expedited	18	Year	18	GROUP1	Female
1330513013	.	20230228	20231227	20231230	Expedited	40	Year	40	GROUP2	Female
133104092	.	20061201	20231122	20231130	Periodic	10	Year	10	GROUP1	Male
133104383	.	20160601	20230927	20231006	Periodic	15	Year	15	GROUP1	Male
133108794	.	20040726	20231023	20231026	Periodic	5	Year	5	GROUP1	Male
133116253	.	20160601	20230925	20231003	Periodic	21	Year	21	GROUP1	Male
133116604	.	20070201	20231210	20231215	Periodic	17	Year	17	GROUP1	Male
1335105016	.	20150101	20231013	20231020	Expedited	78	Year	78	GROUP4	Female
133523655	.	20110101	20231208	20231213	Expedited	52	Year	52	GROUP3	Male
1335799321	.	20180101	20231020	20231026	Periodic	65	Year	65	GROUP3	Male
133583395	.	20170301	20231020	20231027	Expedited	48	Year	48	GROUP2	Male
133599388	.	20160423	20231220	20231228	Expedited	51	Year	51	GROUP3	Male
1336515012	.	20120701	20231207	20231214	Expedited	33	Year	33	GROUP2	Male
133701598	.	20160601	20231002	20231004	Expedited	41	Year	41	GROUP2	Male
133748923	.	.	20231103	20231110	Expedited	62	Year	62	GROUP3	Male
133761803	.	20150401	20231115	20231122	Expedited	14	Year	14	GROUP1	Female
133829345	.	20161001	20231107	20231114	Expedited	47	Year	47	GROUP2	Female
133931897	.	20161006	20231128	20231204	Expedited	51	Year	51	GROUP3	Female
1339532714	.	20170310	20231205	20231212	Periodic	59	Year	59	GROUP3	Male
133959212	.	.	20231208	20231220	Expedited	25	Year	25	GROUP1	Male
1339710411	.	20170322	20231205	20231206	Expedited	59	Year	59	GROUP3	Female
134010312	.	20130219	20231003	20231016	Expedited	43	Year	43	GROUP2	Male
134018982	.	20141101	20231003	20231013	Expedited	38	Year	38	GROUP2	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
75	Kilograms	75	20231218	Consumer	.	US
36.281	Kilograms	36.281	20231025	Health Professional	.	US
48	Kilograms	48	20231011	Consumer	.	CO
.		.	20231230	Consumer	.	CA
.		.	20231201	Lawyer	.	US
.		.	20231006	Lawyer	.	US
.		.	20231027	Lawyer	.	US
.		.	20231003	Lawyer	.	US
116.8	Kilograms	116.8	20231215	Health Professional	.	US
73	Kilograms	73	20231020	Consumer	.	US
.		.	20231213	Health Professional	.	IT
99.79	Kilograms	99.79	20231026	Physician	.	US
.		.	20231027	Consumer	.	CA
89	Kilograms	89	20231228	Pharmacist	.	FR
35.9	Kilograms	35.9	20231214	Physician	.	JP
.		.	20231004	Consumer	.	US
.		.	20231110	Health Professional	.	KR
.		.	20231122	Physician	.	US
.		.	20231115	Consumer	.	US
114	Kilograms	114	20231204	Consumer	.	US
125	Kilograms	125	20231212	Pharmacist	.	US
.		.	20231220	Health Professional	.	US
.		.	20231206	Consumer	.	CA
72	Kilograms	72	20231016	Physician	.	AT
.		.	20231013	Physician	.	AT

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Unique number for identifying a FAERS re</i>	<i>i_f_cod</i>	<i>Date the adverse event occurred or began</i>	<i>Date manufacturer first received initial</i>	<i>Date FDA received Case(YYYYMMDD format).</i>	<i>Code for the type of report submitted</i>	<i>Numeric value of patient's age at event.</i>	<i>Unit abbreviation for patient's age</i>	<i>Derived age in years.</i>	<i>Derived age group.</i>	<i>Code for patient's sex</i>
134019173	.	20100108	20231003	20231013	Expedited	41	Year	41	GROUP2	Female
134040983	.	20110601	20231003	20231017	Expedited	26	Year	26	GROUP2	Female
134065693	.	20130801	20231003	20231017	Expedited	34	Year	34	GROUP2	Female
134066473	.	20130301	20231003	20231017	Expedited	39	Year	39	GROUP2	Male
134083414	.	20070309	20231006	20231012	Expedited	9	Year	9	GROUP1	Male
134083585	.	20060421	20231115	20231201	Periodic	10	Year	10	GROUP1	Male
134083883	.	20160812	20231213	20231218	Periodic	19	Year	19	GROUP1	Male
134084944	.	20020506	20231009	20231013	Periodic	9	Year	9	GROUP1	Male
134085124	.	20011206	20230929	20231005	Periodic	9	Year	9	GROUP1	Male
134085334	.	20000525	20231213	20231219	Periodic	9	Year	9	GROUP1	Male
134085342	.	20021211	20231206	20231215	Expedited	3	Year	3	GROUP1	Male
134085894	.	20011205	20231128	20231201	Periodic	12	Year	12	GROUP1	Male
134085953	.	20050301	20231122	20231130	Periodic	8	Year	8	GROUP1	Male
134088083	.	20011203	20230927	20231006	Expedited	5	Year	5	GROUP1	Male
134088094	.	20070801	20231115	20231121	Expedited	16	Year	16	GROUP1	Male
134088254	.	20010601	20231101	20231107	Periodic	8	Year	8	GROUP1	Male
134088884	.	20031213	20231115	20231123	Periodic	16	Year	16	GROUP1	Male
134089644	.	20130624	20231009	20231014	Periodic	12	Year	12	GROUP1	Male
134090483	.	20130801	20231115	20231123	Expedited	10	Year	10	GROUP1	Male
134091664	.	20130625	20230929	20231005	Periodic	14	Year	14	GROUP1	Male
134091734	.	20050101	20230927	20231005	Expedited	1	Decade	10	GROUP1	Male
134091874	.	20080101	20231011	20231020	Periodic	7	Year	7	GROUP1	Male
134091934	.	20120502	20231006	20231010	Periodic	15	Year	15	GROUP1	Male
134092324	.	20140609	20231013	20231017	Periodic	24	Year	24	GROUP1	Male
134092425	.	20051028	20231121	20231129	Periodic	6	Year	6	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231013	Physician	.	AT
70	Kilograms	70	20231017	Physician	.	AT
58	Kilograms	58	20231017	Physician	.	AT
90	Kilograms	90	20231017	Physician	.	AT
.		.	20231012	Health Professional	.	US
.		.	20231201	Health Professional	.	US
.		.	20231218	Lawyer	.	US
.		.	20231013	Health Professional	.	US
.		.	20231005	Lawyer	.	US
.		.	20231219	Lawyer	.	US
.		.	20231215	Health Professional	.	US
.		.	20231201	Health Professional	.	US
.		.	20231130	Lawyer	.	US
.		.	20231006	Health Professional	.	US
.		.	20231121	Lawyer	.	US
.		.	20231108	Lawyer	.	US
.		.	20231123	Lawyer	.	US
.		.	20231014	Lawyer	.	US
.		.	20231124	Health Professional	.	US
.		.	20231006	Lawyer	.	US
.		.	20231005	Health Professional	.	US
.		.	20231020	Health Professional	.	US
.		.	20231010	Health Professional	.	US
.		.	20231017	Lawyer	.	US
.		.	20231129	Health Professional	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
134092954	.	20020314	20231206	20231213	Periodic	3	Year	3	GROUP1	Male
134092974	.	20080403	20231011	20231016	Expedited	13	Year	13	GROUP1	Male
134093924	.	20070817	20231213	20231218	Periodic	8	Year	8	GROUP1	Male
134094144	.	20040806	20231217	20231227	Periodic	4	Year	4	GROUP1	Male
134094673	.	20030307	20231122	20231130	Periodic	6	Year	6	GROUP1	Male
134095584	.	20070115	20231113	20231121	Periodic	9	Year	9	GROUP1	Male
134095753	.	20111001	20231213	20231219	Periodic	14	Year	14	GROUP1	Male
134096323	.	20030121	20231211	20231215	Periodic	7	Year	7	GROUP1	Male
134097154	.	20031216	20231106	20231111	Periodic	14	Year	14	GROUP1	Male
1340999011	.	20201216	20231127	20231129	Expedited	69	Year	69	GROUP3	Female
134103104	.	20040401	20231211	20231218	Periodic	10	Year	10	GROUP1	Male
134103174	.	20081017	20231106	20231112	Periodic	11	Year	11	GROUP1	Male
134103552	.	20120601	20231106	20231113	Periodic	12	Year	12	GROUP1	Male
134103722	.	20131011	20231009	20231013	Periodic	19	Year	19	GROUP1	Male
134104485	.	20040301	20231115	20231123	Periodic	12	Year	12	GROUP1	Male
134104624	.	20020101	20231006	20231011	Periodic	4	Year	4	GROUP1	Male
134106743	.	20080118	20231025	20231103	Periodic	3	Year	3	GROUP1	Male
134108014	.	20110601	20231113	20231120	Expedited	19	Year	19	GROUP1	Male
134108254	.	20030716	20231006	20231009	Periodic	5	Year	5	GROUP1	Male
134108264	.	20070606	20231030	20231105	Periodic	12	Year	12	GROUP1	Male
134108573	.	20151221	20231213	20231221	Expedited	21	Year	21	GROUP1	Male
134109433	.	20080604	20231211	20231218	Periodic	14	Year	14	GROUP1	Male
134109483	.	20120926	20231211	20231218	Periodic	19	Year	19	GROUP1	Male
134110303	.	20080211	20231101	20231108	Periodic	17	Year	17	GROUP1	Male
134110902	.	20110131	20231106	20231113	Periodic	11	Year	11	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231214	Health Professional	.	US
.		.	20231017	Health Professional	.	US
.		.	20231218	Lawyer	.	US
.		.	20231227	Lawyer	.	US
.		.	20231201	Lawyer	.	US
.		.	20231121	Lawyer	.	US
.		.	20231219	Lawyer	.	US
.		.	20231214	Lawyer	.	US
.		.	20231111	Health Professional	.	US
96	Kilograms	96	20231129	Consumer	.	US
.		.	20231218	Lawyer	.	US
.		.	20231112	Lawyer	.	US
.		.	20231113	Lawyer	.	US
.		.	20231013	Lawyer	.	US
.		.	20231123	Lawyer	.	US
.		.	20231011	Lawyer	.	US
.		.	20231103	Health Professional	.	US
.		.	20231120	Health Professional	.	US
.		.	20231009	Health Professional	.	US
.		.	20231105	Lawyer	.	US
.		.	20231222	Lawyer	.	US
.		.	20231216	Lawyer	.	US
.		.	20231218	Health Professional	.	US
.		.	20231108	Lawyer	.	US
.		.	20231113	Lawyer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
134111692	.	19961001	20231129	20231206	Periodic	12	Year	12	GROUP1	Male
134112042	.	20090101	20230927	20231006	Periodic	20	Year	20	GROUP1	Male
134112052	.	20010101	20230929	20231007	Periodic	14	Year	14	GROUP1	Male
134112122	.	20071004	20231115	20231123	Periodic	14	Year	14	GROUP1	Male
134112272	.	20130101	20231013	20231020	Periodic	18	Year	18	GROUP1	Male
134112282	.	20010301	20231213	20231221	Periodic	12	Year	12	GROUP1	Male
134112744	.	20080101	20231101	20231108	Expedited	17	Year	17	GROUP1	Male
134113004	.	20130411	20231030	20231031	Periodic	19	Year	19	GROUP1	Male
134113124	.	20060101	20231011	20231017	Periodic	17	Year	17	GROUP1	Male
134113163	.	20070101	20231101	20231108	Periodic	14	Year	14	GROUP1	Male
134113423	.	20070402	20231025	20231031	Periodic	11	Year	11	GROUP1	Male
134113942	.	20150101	20231106	20231112	Periodic	23	Year	23	GROUP1	Male
134116013	.	20020608	20231213	20231224	Periodic	8	Year	8	GROUP1	Male
134116323	.	20110405	20231030	20231105	Periodic	17	Year	17	GROUP1	Male
134116633	.	20061010	20231101	20231110	Periodic	16	Year	16	GROUP1	Male
134117702	.	20071201	20231129	20231207	Periodic	13	Year	13	GROUP1	Male
134118434	.	20010907	20231206	20231213	Periodic	4	Year	4	GROUP1	Male
134118773	.	20080901	20231009	20231017	Periodic	10	Year	10	GROUP1	Male
134120823	.	20131202	20231025	20231103	Periodic	27	Year	27	GROUP2	Male
134121494	.	20061201	20231013	20231020	Expedited	22	Year	22	GROUP1	Male
134121804	.	20110101	20230927	20231006	Periodic	3	Decade	30	GROUP2	Male
134121844	.	20131009	20230929	20231005	Periodic	15	Year	15	GROUP1	Male
134123292	.	20050901	20231011	20231019	Periodic	20	Year	20	GROUP1	Male
134123484	.	20130805	20230927	20231004	Periodic	22	Year	22	GROUP1	Male
134123494	.	20121116	20231011	20231015	Periodic	24	Year	24	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.	.	.	20231206	Lawyer	.	US
.	.	.	20231006	Lawyer	.	US
.	.	.	20231007	Lawyer	.	US
.	.	.	20231123	Lawyer	.	US
.	.	.	20231020	Lawyer	.	US
.	.	.	20231222	Lawyer	.	US
.	.	.	20231108	Health Professional	.	US
.	.	.	20231031	Health Professional	.	US
.	.	.	20231017	Health Professional	.	US
.	.	.	20231108	Health Professional	.	US
.	.	.	20231031	Health Professional	.	US
.	.	.	20231112	Lawyer	.	US
.	.	.	20231224	Lawyer	.	US
.	.	.	20231105	Lawyer	.	US
.	.	.	20231110	Lawyer	.	US
.	.	.	20231207	Lawyer	.	US
.	.	.	20231213	Lawyer	.	US
.	.	.	20231017	Health Professional	.	US
.	.	.	20231103	Lawyer	.	US
.	.	.	20231020	Lawyer	.	US
.	.	.	20231006	Lawyer	.	US
.	.	.	20231005	Lawyer	.	US
.	.	.	20231019	Lawyer	.	US
.	.	.	20231004	Health Professional	.	US
.	.	.	20231015	Lawyer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
134124233	.	20130101	20231030	20231102	Periodic	18	Year	18	GROUP1	Male
134124934	.	20130124	20231013	20231018	Periodic	22	Year	22	GROUP1	Male
134125224	.	20140403	20231129	20231206	Periodic	17	Year	17	GROUP1	Male
134125873	.	20060401	20231101	20231107	Periodic	5	Year	5	GROUP1	Male
134127613	.	20021028	20231211	20231218	Periodic	15	Year	15	GROUP1	Male
134128594	.	20090615	20231211	20231218	Periodic	9	Year	9	GROUP1	Male
134128773	.	20110901	20231115	20231121	Expedited	21	Year	21	GROUP1	Male
134130324	.	20030911	20231211	20231213	Periodic	16	Year	16	GROUP1	Male
134130353	.	20120101	20231030	20231107	Periodic	3	Decade	30	GROUP2	Male
134132583	.	20061109	20231115	20231123	Periodic	2	Year	2	GROUP1	Male
134132774	.	20151222	20231122	20231129	Periodic	31	Year	31	GROUP2	Male
134132973	.	20120228	20231206	20231213	Periodic	10	Year	10	GROUP1	Male
134132993	.	20050829	20231211	20231218	Periodic	19	Year	19	GROUP1	Male
134133329	.	20100916	20231116	20231124	Periodic	18	Year	18	GROUP1	Male
134136225	.	20150511	20231030	20231106	Periodic	26	Year	26	GROUP2	Male
134136262	.	20131202	20230927	20231004	Periodic	24	Year	24	GROUP1	Male
134136362	.	20061216	20231013	20231019	Periodic	20	Year	20	GROUP1	Male
134136665	.	20080714	20231117	20231124	Periodic	18	Year	18	GROUP1	Male
134137264	.	20130429	20231006	20231016	Expedited	19	Year	19	GROUP1	Male
134138514	.	20100201	20231211	20231218	Periodic	22	Year	22	GROUP1	Male
134141165	.	.	20231222	20231229	Expedited	49	Year	49	GROUP2	Male
134148654	.	20070406	20231211	20231223	Periodic	21	Year	21	GROUP1	Male
134190143	.	20060809	20231106	20231112	Periodic	12	Year	12	GROUP1	Male
134190213	.	20141112	20231106	20231111	Periodic	18	Year	18	GROUP1	Male
134191844	.	20131112	20231106	20231112	Periodic	25	Year	25	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231102	Health Professional	.	US
.		.	20231018	Lawyer	.	US
.		.	20231206	Health Professional	.	US
.		.	20231108	Lawyer	.	US
.		.	20231216	Lawyer	.	US
.		.	20231216	Lawyer	.	US
.		.	20231121	Health Professional	.	US
.		.	20231213	Lawyer	.	US
.		.	20231107	Health Professional	.	US
.		.	20231124	Health Professional	.	US
.		.	20231129	Lawyer	.	US
.		.	20231213	Health Professional	.	US
.		.	20231216	Lawyer	.	US
.		.	20231124	Lawyer	.	US
.		.	20231106	Lawyer	.	US
.		.	20231004	Lawyer	.	US
.		.	20231019	Lawyer	.	US
.		.	20231124	Health Professional	.	US
83.99	Kilograms	83.99	20231016	Health Professional	.	US
.		.	20231216	Lawyer	.	US
.		.	20231229	Health Professional	.	CA
.		.	20231224	Lawyer	.	US
.		.	20231112	Lawyer	.	US
.		.	20231111	Lawyer	.	US
.		.	20231112	Lawyer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
134194003	.	20081212	20231106	20231114	Periodic	31	Year	31	GROUP2	Male
134194094	.	20060101	20230929	20231007	Periodic	3	Decade	30	GROUP2	Male
1341979423	.	20170201	20231207	20231218	Expedited	57	Year	57	GROUP3	Female
134281817	.	20170331	20231214	20231220	Expedited	66	Year	66	GROUP3	Female
134333438	.	.	20231019	20231026	Expedited	50	Year	50	GROUP2	Female
1344289218	.	20170202	20231017	20231023	Expedited	45	Year	45	GROUP2	Male
1345284711	.	20161206	20231201	20231208	Expedited	54	Year	54	GROUP3	Female
134551344	.	20130618	20231219	20231229	Expedited	53	Year	53	GROUP3	Male
134631473	.	20170411	20231110	20231115	Expedited	67	Year	67	GROUP3	Male
134678273	.	20141201	20200730	20231017	Periodic	26	Year	26	GROUP2	Male
134844377	.	20140101	20231027	20231103	Expedited	60	Year	60	GROUP3	Female
1348445812	.	20160927	20231017	20231025	Expedited	65	Year	65	GROUP3	Female
134851012	.	20120611	20231108	20231116	Periodic	9	Year	9	GROUP1	Male
134860119	.	20150101	20231101	20231107	Expedited	18	Year	18	GROUP1	Female
1348660214	.	20170201	20231101	20231103	Expedited	75	Year	75	GROUP3	Male
134896563	.	20020201	20231217	20231225	Periodic	6	Year	6	GROUP1	Male
134947526	.	20211013	20230929	20231007	Expedited	72	Year	72	GROUP3	Female
135068785	.	20231118	20231122	20231124	Expedited	73	Year	73	GROUP3	Female
135213614	.	.	20231024	20231106	Periodic	68	Year	68	GROUP3	Female
135289153	.	20161204	20170630	20231017	Periodic	68	Year	68	GROUP3	Female
135316108	.	20170201	20231003	20231009	Expedited	49	Year	49	GROUP2	Female
135360507	.	20170415	20170627	20231227	Expedited	27	Year	27	GROUP2	Female
135388083	.	20131001	20231101	20231108	Periodic	23	Year	23	GROUP1	Male
135388403	.	20110101	20231129	20231203	Periodic	3	Decade	30	GROUP2	Male
135403142	.	20150520	20231212	20231214	Expedited	34	Year	34	GROUP2	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231114	Lawyer	.	US
.		.	20231007	Health Professional	.	US
47	Kilograms	47	20231218	Consumer	.	US
94.3	Kilograms	94.3	20231220	Health Professional	.	US
.		.	20231026	Pharmacist	.	CA
.		.	20231023	Consumer	.	CA
65	Kilograms	65	20231208	Physician	.	FR
.		.	20231229	Physician	.	IT
.		.	20231115	Physician	.	AU
.		.	20231018	Consumer	.	US
.		.	20231103	Health Professional	.	CA
.		.	20231025	Consumer	.	CA
.		.	20231116	Health Professional	.	US
.		.	20231107	Health Professional	.	CA
46	Kilograms	46	20231103	Physician	.	JP
.		.	20231225	Lawyer	.	US
.		.	20231007	Consumer	.	US
.		.	20231124	Consumer	.	US
.		.	20231106	Consumer	.	US
63	Kilograms	63	20231017	Physician	.	US
.		.	20231009	Physician	.	CA
51.701	Kilograms	51.701	20231227	Physician	.	US
.		.	20231108	Health Professional	.	US
.		.	20231204	Lawyer	.	US
.		.	20231214	Health Professional	.	AR

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
135404313	.	20170503	20180908	20231222	Expedited	34	Year	34	GROUP2	Female
1354156015	.	20110612	20231120	20231128	Expedited	76	Year	76	GROUP4	Male
135456789	.	20211201	20231110	20231120	Expedited	74	Year	74	GROUP3	Female
135501352	.	20150523	20180905	20231214	Expedited	33	Year	33	GROUP2	Female
135512305	.	20110612	20231121	20231129	Expedited	76	Year	76	GROUP4	Male
135557787	.	20170201	20231201	20231218	Expedited	57	Year	57	GROUP3	Female
135557947	.	20170216	20231024	20231121	Periodic	56	Year	56	GROUP3	Female
135581292	.	20231101	20231128	20231210	Expedited	93	Year	93	GROUP4	Female
135598512	.	20160101	20230928	20231002	Periodic	57	Year	57	GROUP3	Female
1356075629	.	20170310	20231031	20231115	Expedited	70	Year	70	GROUP3	Female
1356231521	.	20150821	20231129	20231212	Expedited	55	Year	55	GROUP3	Female
135653454	.	20170504	20231114	20231124	Expedited	48	Year	48	GROUP2	Male
135684412	.	20170401	20231206	20231215	Expedited	65	Year	65	GROUP3	Female
135688168	.	.	20231205	20231218	Periodic	55	Year	55	GROUP3	Female
135704317	.	20180201	20231003	20231015	Expedited	75	Year	75	GROUP3	Male
135737695	.	20170515	20231109	20231117	Expedited	14	Year	14	GROUP1	Female
135983634	.	20170501	20231127	20231204	Periodic	72	Year	72	GROUP3	Female
1360172115	.	20170517	20231025	20231031	Expedited	18	Year	18	GROUP1	Female
136030473	.	20170516	20231113	20231123	Expedited	43	Year	43	GROUP2	Female
1360873920	.	20170101	20231102	20231110	Expedited	60	Year	60	GROUP3	Female
136144782	.	.	20231127	20231210	Expedited	86	Year	86	GROUP4	Male
136145633	.	.	20231003	20231011	Expedited	7	Year	7	GROUP1	Female
136226523	.	.	20231117	20231127	Expedited	79	Year	79	GROUP4	Male
136250703	.	20110801	20231213	20231224	Periodic	9	Year	9	GROUP1	Male
136256883	.	20011220	20231115	20231123	Periodic	9	Year	9	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231222	Health Professional	.	AR
.		.	20231127	Health Professional	.	HR
72.12	Kilograms	72.12	20231120	Physician	.	US
.		.	20231214	Physician	.	AR
.		.	20231129	Physician	.	HR
.		.	20231214	Consumer	.	US
62	Kilograms	62	20231121	Consumer	.	US
.		.	20231210	Consumer	.	US
.		.	20231002	Consumer	.	US
49	Kilograms	49	20231115	Physician	.	JP
.		.	20231212	Consumer	.	CA
.		.	20231124	Consumer	.	CA
.		.	20231215	Health Professional	.	US
72.562	Kilograms	72.562	20231218	Physician	.	US
90	Kilograms	90	20231015	Consumer	.	GB
41.4	Kilograms	41.4	20231117	Physician	.	DE
86	Kilograms	86	20231204	Health Professional	.	US
.		.	20231031	Physician	.	CA
.		.	20231123	Physician	.	DE
91	Kilograms	91	20231110	Consumer	.	US
.		.	20231210	Health Professional	.	IT
.		.	20231011	Health Professional	.	US
.		.	20231127	Physician	.	US
.		.	20231224	Lawyer	.	US
.		.	20231123	Lawyer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
136257352	.	20130301	20231108	20231115	Periodic	10	Year	10	GROUP1	
136263763	.	20071203	20231113	20231121	Periodic	13	Year	13	GROUP1	Male
136264304	.	20100319	20231115	20231123	Periodic	12	Year	12	GROUP1	Male
1364104913	.	20170101	20231213	20231225	Expedited	72	Year	72	GROUP3	Female
136425604	.	.	20231020	20231030	Expedited	4	Year	4	GROUP1	Female
1364544612	.	20211201	20231211	20231218	Expedited	32	Year	32	GROUP2	Female
136492084	.	20170501	20231019	20231222	Expedited	52	Year	52	GROUP3	Female
136509072	.	20160423	20231204	20231205	Expedited	51	Year	51	GROUP3	Male
136553689	.	20170522	20230925	20231005	Expedited	10	Year	10	GROUP1	Male
136574623	.	20160501	20221221	20231030	30 Day	58	Year	58	GROUP3	Female
136603483	.	20170615	20230831	20231019	Periodic	20	Year	20	GROUP1	Male
136641333	.	19990521	20231205	20231208	Expedited	55	Year	55	GROUP3	Female
136695112	.	.	20231106	20231113	Expedited	17	Year	17	GROUP1	Female
136720014	.	20150601	20231122	20231128	Expedited	58	Year	58	GROUP3	Female
136720135	.	20170601	20231115	20231121	Periodic	47	Year	47	GROUP2	Female
136748363	.	.	20231206	20231218	Periodic	55	Year	55	GROUP3	Female
136754955	.	.	20230927	20231004	Expedited	58	Year	58	GROUP3	Female
1367789622	.	20170206	20231130	20231205	Expedited	46	Year	46	GROUP2	Female
1368793837	.	20121226	20231219	20231221	Expedited	45	Year	45	GROUP2	Female
136971772	.	20170608	20231129	20231206	Expedited	86	Year	86	GROUP4	Male
136999614	.	.	20231206	20231215	Expedited	52	Year	52	GROUP3	Female
137009446	.	20170101	20231031	20231108	Expedited	57	Year	57	GROUP3	Male
1370558410	.	20180101	20231207	20231219	Expedited	55	Year	55	GROUP3	Female
137068223	.	20131101	20231030	20231108	Periodic	19	Year	19	GROUP1	Male
1370783914	.	.	20231114	20231123	Expedited	71	Year	71	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231115	Lawyer	.	US
.		.	20231121	Lawyer	.	US
.		.	20231124	Lawyer	.	US
.		.	20231225	Physician	.	CA
.		.	20231030	Physician	.	US
.		.	20231218	Consumer	.	US
79.3	Kilograms	79.3	20231222	Consumer	.	US
89	Kilograms	89	20231205	Health Professional	.	FR
.		.	20231005	Physician	.	IT
98.865	Kilograms	98.865	20231030	Consumer	.	US
.		.	20231019	Physician	.	US
71	Kilograms	71	20231208	Health Professional	.	DE
.		.	20231113	Pharmacist	.	US
.		.	20231128	Consumer	.	US
.		.	20231121	Physician	.	US
65.77	Kilograms	65.77	20231218	Consumer	.	US
52	Kilograms	52	20231004	Consumer	.	CA
102.5	Kilograms	102.5	20231205	Health Professional	.	AU
75	Kilograms	75	20231221	Health Professional	.	
75	Kilograms	75	20231206	Physician	.	FR
.		.	20231215	Health Professional	.	CA
.		.	20231108	Consumer	.	US
63.56	Kilograms	63.56	20231219	Consumer	.	
.		.	20231108	Lawyer	.	US
.		.	20231123	Consumer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1370841319	.	20170601	20231215	20231225	Expedited	63	Year	63	GROUP3	Male
137101862	.	.	20231003	20231011	Expedited	57	Year	57	GROUP3	Male
137109882	.	20170601	20231201	20231206	Expedited	80	Year	80	GROUP4	Female
1371451212	.	20170601	20231115	20231120	Expedited	44	Year	44	GROUP2	Male
1372081420	.	20170628	20231208	20231220	Expedited	45	Year	45	GROUP2	Female
137211834	.	.	20230921	20231003	Expedited	36	Year	36	GROUP2	Male
137218048	.	20170401	20231206	20231213	Periodic	41	Year	41	GROUP2	Female
1372180710	.	20150601	20231211	20231220	Expedited	73	Year	73	GROUP3	Male
137279573	.	20070101	20231106	20231112	Periodic	1	Decade	10	GROUP1	Male
137290084	.	.	20231207	20231220	Periodic	79	Year	79	GROUP4	Female
137386173	.	20090123	20230926	20231005	Expedited	19	Year	19	GROUP1	Female
137386794	.	20140505	20171026	20231109	Expedited	63	Year	63	GROUP3	Female
137409038	.	20170423	20231031	20231106	Expedited	50	Year	50	GROUP2	Male
1374176710	.	20170601	20231110	20231120	Periodic	74	Year	74	GROUP3	Male
1374265414	.	20170508	20231113	20231123	Expedited	93	Year	93	GROUP4	Female
137487108	.	20170512	20231003	20231013	Expedited	34	Year	34	GROUP2	Female
137522382	.	20170511	20230802	20231019	Periodic	25	Year	25	GROUP1	Female
137554609	.	.	20231108	20231115	Periodic	69	Year	69	GROUP3	Female
137584676	.	20180212	20231224	20231228	Periodic	70	Year	70	GROUP3	Female
137602843	.	20170307	20180214	20231222	Expedited	43	Year	43	GROUP2	
1376235317	.	20170703	20231030	20231107	Expedited	59	Year	59	GROUP3	Male
1376332113	.	20170116	20231124	20231129	Expedited	41	Year	41	GROUP2	Female
137660858	.	20170630	20230925	20231005	Expedited	80	Year	80	GROUP4	Male
137705952	.	20170601	20170710	20231017	Expedited	32	Year	32	GROUP2	Female
137758354	.	20170320	20231010	20231025	Expedited	78	Year	78	GROUP4	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
80	Kilograms	80	20231225	Health Professional	.	NL
.		.	20231011	Physician	.	US
.		.	20231206	Consumer	.	US
.		.	20231120	Consumer	.	CA
86	Kilograms	86	20231220	Consumer	.	CA
.		.	20231003	Physician	.	IT
52.6	Kilograms	52.6	20231213	Consumer	.	US
.		.	20231220	Physician	.	US
.		.	20231112	Health Professional	.	US
.		.	20231220	Health Professional	.	US
56.236	Kilograms	56.236	20231005	Health Professional	.	US
72.562	Kilograms	72.562	20231109	Physician	.	US
67	Kilograms	67	20231106	Physician	.	JP
.		.	20231120	Consumer	.	US
.		.	20231123	Physician	.	IT
.		.	20231013	Physician	.	AT
.		.	20231019	Physician	.	US
.		.	20231115	Physician	.	US
.		.	20231228	Consumer	.	US
.		.	20231222	Pharmacist	.	IT
61	Kilograms	61	20231107	Consumer	.	US
.		.	20231129	Health Professional	.	GB
.		.	20231005	Consumer	.	US
52	Kilograms	52	20231017	Physician	.	FR
.		.	20231025	Consumer	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
137759762	.	20170601	20231218	20231222	Periodic	58	Year	58	GROUP3	Female
137766663	.	20170701	20230728	20231019	Periodic	58	Year	58	GROUP3	Female
137772209	.	.	20231115	20231121	Periodic	65	Year	65	GROUP3	Female
1377890014	.	20170714	20231030	20231108	Expedited	59	Year	59	GROUP3	Female
137797418	.	20170508	20231116	20231122	Expedited	93	Year	93	GROUP4	Female
137939098	.	.	20231115	20231124	Periodic	65	Year	65	GROUP3	Female
137946867	.	20090901	20231108	20231120	Periodic	58	Year	58	GROUP3	Female
137950625	.	20120301	20231212	20231220	Expedited	27	Year	27	GROUP2	Female
137953569	.	20190320	20231012	20231020	Expedited	65	Year	65	GROUP3	Female
1379794013	.	20170411	20231201	20231206	Expedited	65	Year	65	GROUP3	Male
138034264	.	.	20231006	20231018	Expedited	26	Year	26	GROUP2	Female
138034274	.	.	20231006	20231018	Expedited	32	Year	32	GROUP2	Female
138047364	.	20190301	20231106	20231115	Periodic	70	Year	70	GROUP3	Female
138061715	.	.	20231007	20231018	Expedited	63	Year	63	GROUP3	Female
138063465	.	.	20231023	20231026	Expedited	4	Year	4	GROUP1	Female
1381361621	.	20170716	20231115	20231120	Expedited	22	Year	22	GROUP1	Female
138144548	.	.	20231211	20231214	Expedited	42	Year	42	GROUP2	Female
1381458414	.	20161201	20231026	20231102	Expedited	47	Year	47	GROUP2	Female
138190892	.	.	20231020	20231027	Expedited	4	Year	4	GROUP1	Female
1382073610	.	20170101	20231207	20231214	Expedited	46	Year	46	GROUP2	Female
138220764	.	.	20231218	20231228	Periodic	53	Year	53	GROUP3	Female
138221163	.	.	20231011	20231027	Periodic	48	Year	48	GROUP2	Female
1382387616	.	20170717	20231023	20231026	Expedited	78	Year	78	GROUP4	Female
138240195	.	20180201	20231017	20231027	Expedited	75	Year	75	GROUP3	Male
138243255	.	20180201	20230921	20231215	Expedited	75	Year	75	GROUP3	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231222	Consumer	.	US
.		.	20231019	Consumer	.	US
.		.	20231121	Physician	.	US
.		.	20231108	Consumer	.	US
.		.	20231122	Physician	.	IT
.		.	20231124	Physician	.	US
.		.	20231120	Physician	.	US
57	Kilograms	57	20231220	Consumer	.	FR
84	Kilograms	84	20231020	Health Professional	.	US
73.84	Kilograms	73.84	20231206	Physician	.	
.		.	20231018	Physician	.	DK
.		.	20231018	Physician	.	DK
67	Kilograms	67	20231115	Physician	.	US
.		.	20231018	Physician	.	US
.		.	20231026	Physician	.	US
.		.	20231120	Physician	.	CA
.		.	20231214	Physician	.	PL
.		.	20231102	Physician	.	CA
.		.	20231027	Physician	.	US
.		.	20231214	Consumer	.	CA
.		.	20231228	Consumer	.	US
.		.	20231027	Physician	.	US
82	Kilograms	82	20231026	Consumer	.	US
90	Kilograms	90	20231027	Consumer	.	GB
90	Kilograms	90	20231215	Physician	.	GB

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
138249634	.	20170701	20231026	20231107	Expedited	79	Year	79	GROUP4	Female
138280514	.	20170502	20231025	20231101	Expedited	56	Year	56	GROUP3	Female
138438642	.	.	20231020	20231103	Expedited	4	Year	4	GROUP1	Female
138495567	.	.	20231206	20231212	Periodic	65	Year	65	GROUP3	Male
138496985	.	20170701	20231128	20231204	Expedited	60	Year	60	GROUP3	Female
1384976425	.	20170101	20231204	20231218	Expedited	45	Year	45	GROUP2	Female
138595578	.	20170801	20231112	20231113	Periodic	22	Year	22	GROUP1	Male
138596048	.	20170731	20231205	20231212	Expedited	68	Year	68	GROUP3	Female
138616765	.	20120101	20230718	20231019	Periodic	53	Year	53	GROUP3	Female
1386495825	.	20150818	20231205	20231215	Expedited	40	Year	40	GROUP2	Female
138649637	.	.	20231017	20231020	Expedited	74	Year	74	GROUP3	Male
138673334	.	20181113	20231026	20231106	Expedited	74	Year	74	GROUP3	Female
138679475	.	20170508	20231020	20231031	Expedited	84	Year	84	GROUP4	Male
138685115	.	20170530	20231025	20231027	Expedited	55	Year	55	GROUP3	Female
138725076	.	.	20231114	20231121	Expedited	64	Year	64	GROUP3	Male
138788178	.	.	20231114	20231123	Expedited	75	Year	75	GROUP3	Female
138805649	.	20160316	20231102	20231113	Expedited	52	Year	52	GROUP3	Female
138808379	.	20210101	20231031	20231108	Expedited	69	Year	69	GROUP3	Female
138831273	.	.	20231108	20231116	Expedited	83	Year	83	GROUP4	Male
1388544823	.	20170801	20231128	20231206	Periodic	70	Year	70	GROUP3	Female
138859793	.	20170729	20231208	20231218	Periodic	55	Year	55	GROUP3	Female
1388612812	.	20140330	20231201	20231211	Expedited	65	Year	65	GROUP3	Female
1388815623	.	20170703	20231220	20231227	Expedited	32	Year	32	GROUP2	Female
138899054	.	20170815	20231103	20231110	Expedited	38	Year	38	GROUP2	Male
138899924	.	20170815	20231103	20231110	Expedited	38	Year	38	GROUP2	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231107	Consumer	.	US
.		.	20231101	Physician	.	DE
.		.	20231103	Physician	.	US
.		.	20231212	Physician	.	US
.		.	20231204	Physician	.	CA
85	Kilograms	85	20231216	Physician	.	CA
72.8	Kilograms	72.8	20231113	Physician	.	US
83.2	Kilograms	83.2	20231212	Health Professional	.	US
.		.	20231019	Physician	.	US
73	Kilograms	73	20231215	Physician	.	CA
.		.	20231020	Physician	.	CA
.		.	20231107	Consumer	.	US
.		.	20231031	Consumer	.	US
.		.	20231027	Consumer	.	US
.		.	20231121	Health Professional	.	US
.		.	20231123	Health Professional	.	US
.		.	20231113	Consumer	.	CA
57.15	Kilograms	57.15	20231108	Consumer	.	US
.		.	20231114	Physician	.	US
59	Kilograms	59	20231206	Consumer	.	US
.		.	20231216	Physician	.	US
.		.	20231211	Health Professional	.	CA
52	Kilograms	52	20231227	Health Professional	.	MX
53.2	Kilograms	53.2	20231110	Physician	.	TH
53.2	Kilograms	53.2	20231110	Physician	.	TH

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
138968022	.	.	20231006	20231017	Expedited	66	Year	66	GROUP3	Male
139014062	.	.	20231122	20231128	Periodic	66	Year	66	GROUP3	Male
1390640853	.	.	20231204	20231215	Expedited	54	Year	54	GROUP3	Male
139095848	.	20171128	20231128	20231205	Periodic	57	Year	57	GROUP3	Female
139096632	.	.	20231011	20231023	Periodic	48	Year	48	GROUP2	Female
139098684	.	20170813	20230712	20231123	Expedited	41	Year	41	GROUP2	Female
1391241510	.	.	20231026	20231106	Periodic	55	Year	55	GROUP3	Female
139164899	.	20170801	20231120	20231128	Expedited	64	Year	64	GROUP3	Female
139220472	.	20170824	20231218	20231229	Expedited	64	Year	64	GROUP3	Male
139270592	.	.	20231113	20231121	Periodic	64	Year	64	GROUP3	Female
139322146	.	.	20230926	20231018	Periodic	62	Year	62	GROUP3	Female
139396629	.	20170819	20231205	20231211	Expedited	56	Year	56	GROUP3	Male
139422144	.	20160101	20231101	20231103	Expedited	71	Year	71	GROUP3	Female
139451095	.	20170714	20231215	20231222	Expedited	50	Year	50	GROUP2	Male
139531276	.	.	20231113	20231122	Expedited	46	Year	46	GROUP2	Female
139558402	.	20170321	20231207	20231218	Periodic	34	Year	34	GROUP2	Female
139616948	.	20170101	20231114	20231120	Periodic	52	Year	52	GROUP3	Male
139663359	.	20230901	20231218	20231220	Expedited	62	Year	62	GROUP3	Male
1397569911	.	20171009	20231006	20231020	Periodic	71	Year	71	GROUP3	Female
139787556	.	20160801	20231215	20231219	Expedited	45	Year	45	GROUP2	Female
139818419	.	.	20231115	20231122	Expedited	74	Year	74	GROUP3	Female
139821246	.	20160101	20231124	20231130	Expedited	43	Year	43	GROUP2	Female
1398440115	.	20170801	20231019	20231023	Expedited	78	Year	78	GROUP4	Female
1398623521	.	20161001	20231128	20231211	Expedited	44	Year	44	GROUP2	Female
139915564	.	20001107	20231009	20231015	Periodic	10	Year	10	GROUP1	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231017	Physician	.	US
.		.	20231127	Physician	.	US
.		.	20231215	Health Professional	.	CA
52.16	Kilograms	52.16	20231205	Consumer	.	US
.		.	20231023	Physician	.	US
86	Kilograms	86	20231123	Physician	.	BE
99.79	Kilograms	99.79	20231106	Consumer	.	US
.		.	20231127	Consumer	.	CA
83.9	Kilograms	83.9	20231229	Consumer	.	US
.		.	20231121	Physician	.	US
.		.	20231018	Physician	.	US
59.41	Kilograms	59.41	20231211	Consumer	.	CA
.		.	20231103	Physician	.	US
.		.	20231222	Physician	.	JP
120	Kilograms	120	20231122	Physician	.	DE
.		.	20231218	Physician	.	AR
173	Kilograms	173	20231120	Consumer	.	US
.		.	20231220	Health Professional	.	US
60	Kilograms	60	20231020	Consumer	.	US
81.633	Kilograms	81.633	20231219	Physician	.	US
.		.	20231122	Consumer	.	US
.		.	20231130	Consumer	.	CA
68	Kilograms	68	20231023	Health Professional	.	FR
.		.	20231211	Health Professional	.	GB
.		.	20231015	Lawyer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
139915794	.	20050209	20231106	20231111	Periodic	7	Year	7	GROUP1	Male
139935215	.	20170801	20231020	20231026	Expedited	78	Year	78	GROUP4	Female
1400296014	.	20171212	20231116	20231122	Expedited	52	Year	52	GROUP3	Male
140047764	.	.	20231126	20231129	Periodic	72	Year	72	GROUP3	Female
140133603	.	.	20231025	20231103	Expedited	73	Year	73	GROUP3	Female
1401551726	.	20161101	20231204	20231212	Expedited	81	Year	81	GROUP4	Female
140166944	.	.	20231031	20231115	Periodic	51	Year	51	GROUP3	Female
1401872018	.	20171004	20231024	20231024	Periodic	60	Year	60	GROUP3	Female
140197882	.	20161018	20231010	20231018	Expedited	4	Decade	40	GROUP2	Female
140201353	.	.	20231017	20231026	Expedited	19	Year	19	GROUP1	Male
140224902	.	.	20231213	20231222	Expedited	30	Year	30	GROUP2	Male
140263542	.	20160701	20231025	20231101	Periodic	53	Year	53	GROUP3	Female
140276465	.	.	20231019	20231025	Periodic	55	Year	55	GROUP3	Female
140321947	.	20161015	20231128	20231205	Expedited	61	Year	61	GROUP3	Female
140322799	.	20150101	20231128	20231204	Expedited	68	Year	68	GROUP3	Female
140352985	.	20051010	20231120	20231128	Expedited	46	Year	46	GROUP2	Male
140582737	.	20170801	20231215	20231221	Expedited	48	Year	48	GROUP2	Female
140618962	.	20220401	20231004	20231016	Expedited	1	Day	0	GROUP1	Male
140674133	.	20191104	20231020	20231027	Expedited	57	Year	57	GROUP3	Male
1406854813	.	20170901	20231121	20231129	Periodic	75	Year	75	GROUP3	Female
140685794	.	20171005	20231107	20231115	Expedited	63	Year	63	GROUP3	Female
1406863810	.	20171003	20231108	20231120	Expedited	50	Year	50	GROUP2	Female
140741412	.	.	20231019	20231222	Expedited	33	Year	33	GROUP2	Female
140741433	.	20170917	20231019	20231222	Expedited	70	Year	70	GROUP3	Male
140741793	.	20170816	20231019	20231222	Expedited	56	Year	56	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231111	Lawyer	.	US
68	Kilograms	68	20231026	Health Professional	.	FR
.		.	20231122	Health Professional	.	CA
.		.	20231129	Physician	.	US
.		.	20231103	Consumer	.	AU
56	Kilograms	56	20231212	Consumer	.	US
.		.	20231115	Physician	.	US
84	Kilograms	84	20231024	Consumer	.	US
.		.	20231018	Physician	.	DE
.		.	20231026	Physician	.	JP
.		.	20231222	Physician	.	GB
.		.	20231101	Physician	.	US
.		.	20231025	Health Professional	.	US
81.19	Kilograms	81.19	20231205	Consumer	.	US
75	Kilograms	75	20231204	Consumer	.	US
115.67	Kilograms	115.67	20231128	Consumer	.	US
.		.	20231221	Physician	.	US
3.6	Kilograms	3.6	20231016	Physician	.	DE
94	Kilograms	94	20231027	Consumer	.	CO
75	Kilograms	75	20231129	Consumer	.	US
.		.	20231115	Pharmacist	.	US
94	Kilograms	94	20231120	Consumer	.	US
.		.	20231222	Consumer	.	US
.		.	20231222	Consumer	.	US
24.489	Kilograms	24.489	20231222	Consumer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
140767853	.	.	20231019	20231222	Expedited	45	Year	45	GROUP2	Male
1407855417	.	20161201	20220413	20231129	Expedited	82	Year	82	GROUP4	Male
140873515	.	20170501	20171107	20231027	Expedited	65	Year	65	GROUP3	Male
140889657	.	.	20231215	20231222	Expedited	39	Year	39	GROUP2	Male
140889883	.	.	20231211	20231224	Expedited	62	Year	62	GROUP3	Female
140937954	.	20170915	20231215	20231226	Expedited	74	Year	74	GROUP3	Female
141055037	.	.	20231207	20231218	Expedited	76	Year	76	GROUP4	Female
1410933811	.	20150101	20231205	20231208	Expedited	67	Year	67	GROUP3	Female
141117332	.	20140101	20231012	20231018	Expedited	62	Year	62	GROUP3	Male
141126973	.	20150301	20231202	20231212	Expedited	61	Year	61	GROUP3	Female
1411302434	.	20160505	20230925	20231211	Expedited	27	Year	27	GROUP2	Female
141183804	.	.	20231004	20231011	Periodic	49	Year	49	GROUP2	Female
141193053	.	.	20231219	20231228	Periodic	79	Year	79	GROUP4	Female
141339415	.	.	20231115	20231129	Periodic	58	Year	58	GROUP3	Female
141339594	.	20171001	20231206	20231212	Periodic	71	Year	71	GROUP3	Male
141385172	.	20170306	20230316	20231127	Expedited	2	Year	2	GROUP1	Male
141385362	.	.	20230316	20231127	Expedited	6	Year	6	GROUP1	Male
1413969813	.	20170811	20231004	20231010	Expedited	29	Year	29	GROUP2	Male
1414225213	.	20170101	20231030	20231103	Expedited	69	Year	69	GROUP3	Male
1414377319	.	20170811	20231213	20231221	Expedited	29	Year	29	GROUP2	Male
1414484410	.	20140514	20231214	20231220	Expedited	61	Year	61	GROUP3	Female
141487334	.	20150923	20231009	20231012	Expedited	70	Year	70	GROUP3	Female
141780049	.	20170701	20231129	20231212	Expedited	80	Year	80	GROUP4	Female
141793048	.	20171001	20231012	20231024	Expedited	84	Year	84	GROUP4	Male
1418135815	.	20170101	20231006	20231015	Expedited	36	Year	36	GROUP2	Male

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231222	Consumer	.	US
.		.	20231129	Consumer	.	CA
.		.	20231027	Consumer	.	CA
.		.	20231222	Health Professional	.	IT
.		.	20231224	Physician	.	US
51.26	Kilograms	51.26	20231226	Consumer	.	US
.		.	20231218	Physician	.	US
.		.	20231208	Physician	.	AR
.		.	20231018	Physician	.	CZ
.		.	20231212	Health Professional	.	US
.		.	20231211	Consumer	.	CA
.		.	20231010	Physician	.	US
.		.	20231228	Health Professional	.	US
61	Kilograms	61	20231129	Consumer	.	US
73	Kilograms	73	20231212	Health Professional	.	US
.		.	20231127	Consumer	.	
.		.	20231127	Consumer	.	
.		.	20231010	Health Professional	.	GB
54.5	Kilograms	54.5	20231103	Physician	.	JP
.		.	20231221	Health Professional	.	GB
.		.	20231220	Consumer	.	US
67	Kilograms	67	20231012	Physician	.	DE
.		.	20231212	Consumer	.	US
.		.	20231024	Consumer	.	US
.		.	20231015	Consumer	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1418151821	.	20170706	20231205	20231207	Expedited	68	Year	68	GROUP3	Male
141822732	.	20171108	20231030	20231106	Expedited	49	Year	49	GROUP2	Female
141849162	.	.	20231019	20231130	Expedited	36	Year	36	GROUP2	Female
141854317	.	20170925	20231012	20231018	Expedited	67	Year	67	GROUP3	Male
1418670210	.	20150401	20231124	20231201	Expedited	51	Year	51	GROUP3	Male
141910407	.	.	20231220	20231229	Expedited	66	Year	66	GROUP3	Female
141970065	.	20170102	20210121	20231019	Expedited	54	Year	54	GROUP3	Female
1420640823	.	20150101	20231030	20231107	Expedited	80	Year	80	GROUP4	Female
142102925	.	.	20231019	20231025	Periodic	69	Year	69	GROUP3	Female
1421105519	.	20160101	20231218	20231229	Expedited	74	Year	74	GROUP3	Female
142115326	.	20180101	20231218	20231222	Expedited	69	Year	69	GROUP3	Male
1421450714	.	20190301	20231024	20231030	Expedited	54	Year	54	GROUP3	Female
142159437	.	20180227	20231026	20231101	Expedited	74	Year	74	GROUP3	Female
142189696	.	20110126	20231211	20231219	Periodic	12	Year	12	GROUP1	Male
142200433	.	20161128	20231013	20231018	Periodic	21	Year	21	GROUP1	Male
142200542	.	20071211	20231009	20231014	Periodic	15	Year	15	GROUP1	Male
142200983	.	20081201	20231115	20231121	Expedited	10	Year	10	GROUP1	Male
142203133	.	20080505	20231025	20231030	Periodic	5	Year	5	GROUP1	Male
142210402	.	19980320	20231013	20231018	Periodic	8	Year	8	GROUP1	Male
142215293	.	20060513	20231006	20231011	Periodic	20	Year	20	GROUP1	Male
142254786	.	.	20231009	20231019	Periodic	76	Year	76	GROUP4	Female
142303596	.	20170701	20180517	20231030	Expedited	84	Year	84	GROUP4	Female
142364779	.	.	20231102	20231115	Periodic	72	Year	72	GROUP3	Female
142383367	.	20170801	20231025	20231106	Periodic	89	Year	89	GROUP4	Female
142403725	.	20170728	20231006	20231017	Expedited	62	Year	62	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
52	Kilograms	52	20231207	Physician	.	JP
.		.	20231105	Consumer	.	US
.		.	20231130	Consumer	.	US
57	Kilograms	57	20231018	Health Professional	.	CO
.		.	20231201	Physician	.	DE
61	Kilograms	61	20231229	Physician	.	US
73	Kilograms	73	20231019	Physician	.	PL
72.109	Kilograms	72.109	20231107	Consumer	.	US
.		.	20231025	Health Professional	.	US
68	Kilograms	68	20231229	Consumer	.	US
.		.	20231222	Consumer	.	CA
83	Kilograms	83	20231030	Consumer	.	US
78	Kilograms	78	20231101	Consumer	.	US
.		.	20231219	Lawyer	.	US
.		.	20231018	Lawyer	.	US
.		.	20231014	Lawyer	.	US
.		.	20231121	Lawyer	.	US
.		.	20231030	Lawyer	.	US
.		.	20231018	Lawyer	.	US
.		.	20231011	Lawyer	.	US
.		.	20231019	Physician	.	US
.		.	20231030	Consumer	.	US
100	Kilograms	100	20231115	Health Professional	.	US
.		.	20231106	Consumer	.	US
125.7	Kilograms	125.7	20231017	Physician	.	DE

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
142412133	.	20171113	20171204	20231102	Periodic	48	Year	48	GROUP2	Male
1424139818	.	20160711	20230927	20231006	Expedited	62	Year	62	GROUP3	Female
142422628	.	.	20231211	20231218	Periodic	72	Year	72	GROUP3	Female
1424238317	.	20230101	20231119	20231121	Expedited	64	Year	64	GROUP3	Female
1424281711	.	20171201	20231019	20231025	Expedited	76	Year	76	GROUP4	Male
142460537	.	20131209	20231011	20231025	Expedited	81	Year	81	GROUP4	Female
142469435	.	20231017	20231204	20231213	Expedited	86	Year	86	GROUP4	Female
142470504	.	.	20231208	20231219	Expedited	49	Year	49	GROUP2	Female
1424799217	.	20171101	20231023	20231026	Expedited	77	Year	77	GROUP4	Female
142508296	.	20210101	20231020	20231026	Expedited	65	Year	65	GROUP3	Female
1425263112	.	20170101	20231002	20231012	Expedited	67	Year	67	GROUP3	Female
142533919	.	20150401	20231208	20231211	Expedited	51	Year	51	GROUP3	Male
142565245	.	20180912	20231116	20231128	Periodic	71	Year	71	GROUP3	Female
142601998	.	20170101	20231205	20231215	Expedited	66	Year	66	GROUP3	Female
142608883	.	.	20231019	20231222	Expedited	24	Year	24	GROUP1	Male
1426169513	.	.	20231212	20231222	Expedited	34	Year	34	GROUP2	Female
142637714	.	20140117	20231010	20231025	Expedited	81	Year	81	GROUP4	Female
142647993	.	.	20221003	20231117	Expedited	54	Year	54	GROUP3	Male
1426532218	.	.	20231010	20231016	Expedited	33	Week	0	GROUP1	Female
1426712212	.	20180301	20231009	20231018	Expedited	57	Year	57	GROUP3	Female
1426832112	.	20170511	20231212	20231218	Expedited	76	Year	76	GROUP4	Female
1427193628	.	20160912	20231026	20231106	Expedited	55	Year	55	GROUP3	Female
142737888	.	.	20231016	20231023	Expedited	47	Year	47	GROUP2	Female
142783569	.	.	20231213	20231219	Expedited	61	Year	61	GROUP3	Female
142783792	.	.	20231205	20231214	Expedited	77	Year	77	GROUP4	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231101	Physician	.	CN
53.5	Kilograms	53.5	20231006	Consumer	.	CA
.		.	20231218	Health Professional	.	US
113	Kilograms	113	20231121	Consumer	.	US
66	Kilograms	66	20231025	Consumer	.	JP
59	Kilograms	59	20231025	Health Professional	.	DE
.		.	20231213	Consumer	.	US
.		.	20231219	Health Professional	.	ES
91	Kilograms	91	20231026	Consumer	.	US
.		.	20231026	Consumer	.	US
72	Kilograms	72	20231012	Consumer	.	US
.		.	20231211	Physician	.	DE
.		.	20231128	Pharmacist	.	US
.		.	20231215	Health Professional	.	US
.		.	20231222	Health Professional	.	US
.		.	20231222	Physician	.	FR
59	Kilograms	59	20231025	Health Professional	.	DE
.		.	20231117	Health Professional	.	DE
1.97	Kilograms	1.97	20231016	Physician	.	IT
79	Kilograms	79	20231018	Consumer	.	US
.		.	20231218	Consumer	.	CA
68	Kilograms	68	20231106	Consumer	.	CA
.		.	20231023	Health Professional	.	ES
70	Kilograms	70	20231219	Consumer	.	CA
.		.	20231214	Health Professional	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
1427871915	.	20171101	20231124	20231130	Expedited	25	Year	25	GROUP1	Male
1428050112	.	20171202	20231111	20231128	Expedited	57	Year	57	GROUP3	Male
142811692	.	20170613	20230922	20231004	Expedited	73	Year	73	GROUP3	Female
142814146	.	.	20231102	20231105	Expedited	33	Week	0	GROUP1	Female
142833057	.	.	20231114	20231128	Periodic	60	Year	60	GROUP3	Female
1428496428	.	20171201	20231106	20231110	Expedited	11	Year	11	GROUP1	Male
1428599911	.	20171124	20231116	20231124	Expedited	64	Year	64	GROUP3	Male
142911993	.	20171206	20180102	20231031	Expedited	62	Year	62	GROUP3	Female
142942216	.	20171201	20231130	20231208	Expedited	59	Year	59	GROUP3	Female
1429422710	.	20171001	20231020	20231026	Expedited	46	Year	46	GROUP2	Female
1429500911	.	.	20231110	20231120	Periodic	70	Year	70	GROUP3	Female
142955987	.	20170601	20231219	20231228	Periodic	64	Year	64	GROUP3	Female
142983667	.	20170101	20231102	20231105	Expedited	70	Year	70	GROUP3	Male
1430029613	.	.	20231017	20231024	Periodic	64	Year	64	GROUP3	Female
1430176611	.	20170623	20231113	20231123	Expedited	71	Year	71	GROUP3	Male
143057083	.	20170818	20231120	20231123	Expedited	57	Year	57	GROUP3	Female
1430640525	.	20171101	20231107	20231108	Expedited	70	Year	70	GROUP3	Female
1430697314	.	20070601	20231213	20231228	Expedited	54	Year	54	GROUP3	Male
143071374	.	20180401	20231023	20231123	Expedited	66	Year	66	GROUP3	Female
143082005	.	.	20231121	20231130	Expedited	44	Year	44	GROUP2	Female
143085747	.	20231005	20231205	20231211	Expedited	78	Year	78	GROUP4	Female
143140669	.	.	20231020	20231025	Periodic	53	Year	53	GROUP3	Female
1431616619	.	20171129	20231003	20231016	Expedited	29	Year	29	GROUP2	Female
143174024	.	.	20231206	20231218	Expedited	60	Year	60	GROUP3	Male
143177233	.	20171027	20231017	20231025	Expedited	58	Year	58	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231130	Health Professional	.	CA
.		.	20231127	Consumer	.	CA
.		.	20231001	Physician	.	FR
1.97	Kilograms	1.97	20231105	Health Professional	.	IT
.		.	20231128	Consumer	.	US
60	Kilograms	60	20231110	Physician	.	DE
90	Kilograms	90	20231124	Physician	.	US
.		.	20231031	Physician	.	CN
.		.	20231208	Consumer	.	CA
.		.	20231026	Physician	.	CA
.		.	20231120	Health Professional	.	US
68.8	Kilograms	68.8	20231228	Physician	.	US
.		.	20231105	Consumer	.	CA
.		.	20231024	Physician	.	US
62	Kilograms	62	20231123	Physician	.	JP
.		.	20231123	Physician	.	IT
58	Kilograms	58	20231108	Consumer	.	CO
.		.	20231228	Health Professional	.	CA
81.179	Kilograms	81.179	20231123	Health Professional	.	US
70	Kilograms	70	20231130	Consumer	.	CA
.		.	20231211	Health Professional	.	US
.		.	20231025	Physician	.	US
98	Kilograms	98	20231016	Consumer	.	CA
.		.	20231217	Health Professional	.	ES
73.5	Kilograms	73.5	20231025	Physician	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
143194534	.	.	20231110	20231113	Expedited	23	Year	23	GROUP1	Male
1432006827	.	20170901	20231129	20231206	Expedited	68	Year	68	GROUP3	Female
143203668	.	20160401	20231204	20231212	Expedited	49	Year	49	GROUP2	Female
143219769	.	20171020	20231004	20231009	Expedited	79	Year	79	GROUP4	Male
143257937	.	20161229	20231018	20231025	Expedited	58	Year	58	GROUP3	Female
143266924	.	20111001	20231108	20231117	Expedited	682	Month	56	GROUP3	Male
143267206	.	20170323	20231121	20231123	Expedited	41	Year	41	GROUP2	Female
143289407	.	.	20231206	20231212	Periodic	66	Year	66	GROUP3	Female
143300738	.	.	20231113	20231117	Expedited	59	Year	59	GROUP3	Female
143315568	.	20171101	20231122	20231129	Expedited	61	Year	61	GROUP3	Female
143328739	.	20171101	20231122	20231207	Expedited	61	Year	61	GROUP3	Female
143330282	.	20170101	20231020	20231025	Expedited	55	Year	55	GROUP3	Male
143334972	.	.	20231119	20231122	Expedited	19	Year	19	GROUP1	Male
1433358713	.	20171130	20231016	20231018	Expedited	71	Year	71	GROUP3	Female
143367803	.	20170818	20180410	20231222	Expedited	57	Year	57	GROUP3	
1433816211	.	20150401	20231213	20231218	Expedited	51	Year	51	GROUP3	Male
143391815	.	20160423	20231121	20231202	Expedited	51	Year	51	GROUP3	Male
143401328	.	20131209	20231016	20231026	Expedited	81	Year	81	GROUP4	Female
143411503	.	20171226	20231103	20231108	Expedited	50	Year	50	GROUP2	Male
143417927	.	20170122	20231213	20231227	Expedited	29	Year	29	GROUP2	Female
1434359325	.	20171214	20231026	20231103	Expedited	77	Year	77	GROUP4	Female
1434974915	.	20171201	20231212	20231218	Expedited	69	Year	69	GROUP3	Male
143513307	.	20120601	20231010	20231023	Periodic	48	Year	48	GROUP2	Female
143528054	.	20171201	20231221	20231228	Periodic	69	Year	69	GROUP3	Female
1435354013	.	20160401	20231221	20231228	Expedited	32	Year	32	GROUP2	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231113	Physician	.	SE
75	Kilograms	75	20231206	Health Professional	.	US
84	Kilograms	84	20231212	Consumer	.	CA
.		.	20231009	Physician	.	DE
.		.	20231025	Physician	.	PT
90.3	Kilograms	90.3	20231116	Lawyer	.	
64	Kilograms	64	20231123	Physician	.	BE
.		.	20231212	Health Professional	.	US
.		.	20231117	Health Professional	.	BE
.		.	20231129	Consumer	.	US
.		.	20231207	Physician	.	US
.		.	20231025	Physician	.	FR
.		.	20231122	Health Professional	.	FR
.		.	20231018	Physician	.	JP
.		.	20231222	Physician	.	IT
.		.	20231218	Physician	.	DE
89	Kilograms	89	20231202	Pharmacist	.	FR
59	Kilograms	59	20231026	Health Professional	.	DE
.		.	20231108	Physician	.	
54.8	Kilograms	54.8	20231227	Physician	.	CA
88	Kilograms	88	20231103	Health Professional	.	US
.		.	20231218	Consumer	.	CA
.		.	20231023	Lawyer	.	US
47.63	Kilograms	47.63	20231228	Consumer	.	US
.		.	20231228	Health Professional	.	CA

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	<i>i_f_cod</i>	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
143541296	.	20180516	20231018	20231020	Expedited	34	Year	34	GROUP2	Female
143548763	.	20171115	20231113	20231120	Expedited	79	Year	79	GROUP4	Male
143554104	.	20180101	20231117	20231130	Periodic	47	Year	47	GROUP2	Female
143571063	.	.	20231122	20231129	Expedited	51	Year	51	GROUP3	Female
143601572	.	20171113	20230930	20231005	Expedited	92	Year	92	GROUP4	Male
1436028512	.	.	20231123	20231205	Expedited	51	Year	51	GROUP3	Female
143603143	.	20170412	20231115	20231124	Expedited	91	Year	91	GROUP4	Male
1436032414	.	.	20231129	20231210	Expedited	85	Year	85	GROUP4	Female
143604073	.	20171230	20180112	20231031	Expedited	58	Year	58	GROUP3	Male
143615107	.	20180104	20231012	20231018	Expedited	68	Year	68	GROUP3	Male
143637083	.	20170412	20231124	20231130	Expedited	91	Year	91	GROUP4	Male
1436614116	.	20150811	20231120	20231129	Expedited	69	Year	69	GROUP3	Female
1436642628	.	20121122	20210726	20231130	Expedited	84	Year	84	GROUP4	Female
143676595	.	20121016	20231002	20231011	Expedited	3	Year	3	GROUP1	Female
143681994	.	20180101	20230929	20231005	Periodic	62	Year	62	GROUP3	Male
143687149	.	20171201	20231110	20231115	Periodic	76	Year	76	GROUP4	Female
143695845	.	20180101	20231103	20231108	Expedited	64	Year	64	GROUP3	
1437062820	.	20150811	20231120	20231128	Expedited	69	Year	69	GROUP3	Female
143707489	.	.	20231009	20231018	Expedited	65	Year	65	GROUP3	Male
1437094910	.	20180102	20231219	20231229	Expedited	31	Year	31	GROUP2	Female
1437426811	.	.	20231009	20231018	Periodic	62	Year	62	GROUP3	Female
143744162	.	20180201	20231009	20231017	Periodic	69	Year	69	GROUP3	Female
143744817	.	20160101	20231016	20231102	Expedited	81	Year	81	GROUP4	Female
1437469315	.	20140301	20231117	20231124	Expedited	65	Year	65	GROUP3	Female
1437586416	.	.	20231020	20231025	Expedited	70	Year	70	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231020	Consumer	.	CA
102	Kilograms	102	20231121	Physician	.	FR
.		.	20231130	Health Professional	.	US
.		.	20231127	Physician	.	CZ
65	Kilograms	65	20231005	Physician	.	ES
.		.	20231205	Physician	.	CZ
.		.	20231124	Physician	.	ES
.		.	20231210	Physician	.	PL
.		.	20231031	Physician	.	CN
62	Kilograms	62	20231018	Consumer	.	CA
.		.	20231130	Physician	.	ES
70	Kilograms	70	20231128	Physician	.	US
.		.	20231130	Physician	.	CA
29.4	Kilograms	29.4	20231011	Physician	.	JP
90.72	Kilograms	90.72	20231005	Consumer	.	US
64	Kilograms	64	20231115	Consumer	.	US
.		.	20231108	Physician	.	
70	Kilograms	70	20231128	Physician	.	US
77.11	Kilograms	77.11	20231018	Health Professional	.	US
.		.	20231229	Physician	.	CA
64.853	Kilograms	64.853	20231018	Physician	.	US
.		.	20231016	Consumer	.	US
.		.	20231102	Physician	.	PL
55	Kilograms	55	20231124	Health Professional	.	
.		.	20231025	Consumer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

Unique number for identifying a FAERS re	i_f_cod	Date the adverse event occurred or began	Date manufacturer first received initial	Date FDA received Case(YYYYMMDD format).	Code for the type of report submitted	Numeric value of patient's age at event.	Unit abbreviation for patient's age	Derived age in years.	Derived age group.	Code for patient's sex
143775425	.	.	20231009	20231019	Periodic	62	Year	62	GROUP3	Female
143790744	.	.	20231219	20231228	Expedited	35	Year	35	GROUP2	Female
143796002	.	.	20231104	20231114	Expedited	19	Year	19	GROUP1	Male
1437978110	.	.	20231122	20231129	Expedited	51	Year	51	GROUP3	Female
143818984	.	.	20231003	20231006	Expedited	44	Year	44	GROUP2	Female
143820222	.	.	20231124	20231201	Expedited	19	Year	19	GROUP1	Male
1438459414	.	.	20231221	20231228	Expedited	85	Year	85	GROUP4	Female
1438980031	.	20171008	20231020	20231027	Expedited	59	Year	59	GROUP3	Male
143907633	.	.	20231101	20231113	Expedited	51	Year	51	GROUP3	Female
143910355	.	20220718	20231208	20231220	Periodic	71	Year	71	GROUP3	Female
1439105412	.	20190801	20231213	20231220	Periodic	68	Year	68	GROUP3	Male
143915137	.	.	20231120	20231124	Expedited	48	Year	48	GROUP2	Female
143926136	.	20180105	20231120	20231124	Expedited	68	Year	68	GROUP3	Female
1439446731	.	20171225	20231128	20231206	Expedited	48	Year	48	GROUP2	Male
1440101011	.	20171209	20231004	20231005	Expedited	81	Year	81	GROUP4	Female
1440127223	.	20171114	20231115	20231120	Expedited	71	Year	71	GROUP3	Male
1440251012	.	.	20231122	20231130	Periodic	74	Year	74	GROUP3	Male
144030058	.	20171201	20231103	20231110	Expedited	65	Year	65	GROUP3	Female
1440413413	.	20180101	20231109	20231115	Periodic	67	Year	67	GROUP3	Female
144041844	.	.	20231102	20231109	Expedited	34	Year	34	GROUP2	Female
144094247	.	20120101	20231106	20231110	Expedited	47	Year	47	GROUP2	Male
144101502	.	.	20231116	20231129	Periodic	60	Year	60	GROUP3	Female
144113282	.	20171103	20171113	20231118	Expedited	69	Year	69	GROUP3	Male
144123922	.	20170412	20231117	20231128	Expedited	91	Year	91	GROUP4	Male
1441261414	.	20180129	20231026	20231101	Expedited	69	Year	69	GROUP3	Female

ADVERSE EVENT REPORTING SYSTEM (AERS)

Demographic Listings

<i>Numeric value of patient's weight.</i>	<i>Unit abbreviation for patient's weight.</i>	<i>Derived weight in kilograms.</i>	<i>Date report was sent (YYYYMMDD format).</i>	<i>Reporter's type of occupation.</i>	<i>death_dt</i>	<i>The country where the event occurred.</i>
.		.	20231019	Physician	.	US
.		.	20231228	Physician	.	CA
.		.	20231115	Health Professional	.	FR
.		.	20231129	Physician	.	CZ
.		.	20231006	Health Professional	.	NL
.		.	20231201	Health Professional	.	FR
.		.	20231228	Health Professional	.	PL
.		.	20231027	Consumer	.	CA
.		.	20231113	Physician	.	CZ
68.95	Kilograms	68.95	20231220	Consumer	.	US
79.365	Kilograms	79.365	20231220	Consumer	.	US
.		.	20231124	Consumer	.	CA
.		.	20231124	Physician	.	
.		.	20231206	Physician	.	DE
.		.	20231005	Physician	.	CA
.		.	20231120	Consumer	.	CA
106	Kilograms	106	20231130	Consumer	.	US
104	Kilograms	104	20231110	Consumer	.	US
46	Kilograms	46	20231115	Consumer	.	US
.		.	20231109	Health Professional	.	RO
.		.	20231109	Consumer	.	US
.		.	20231129	Consumer	.	US
122.45	Kilograms	122.45	20231118	Consumer	.	US
.		.	20231127	Physician	.	ES
82	Kilograms	82	20231101	Consumer	.	US

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
100144838	1	Primary Suspect Drug	ISENTRESS	Validated trade name used	Transplacental	400 mg, bid	Does not apply				22145
100144838	2	Secondary Suspect Drug	ISENTRESS	Validated trade name used	Transplacental	400 mg	Does not apply				22145
100144838	3	Secondary Suspect Drug	ISENTRESS	Validated trade name used	Transplacental	UNK	Does not apply				22145
100144838	4	Secondary Suspect Drug	ABACAVIR	Validated trade name used	Transplacental	300 mg, bid	Does not apply				.
100144838	5	Secondary Suspect Drug	ABACAVIR	Validated trade name used	Transplacental	300 mg	Does not apply				.
100144838	6	Secondary Suspect Drug	ABACAVIR	Validated trade name used	Transplacental	300.0 Milligram 1 every 1 Days	Does not apply				.
100144838	7	Secondary Suspect Drug	ACYCLOVIR	Validated trade name used	Transplacental	UNK	Does not apply				.
100144838	8	Secondary Suspect Drug	ACYCLOVIR	Validated trade name used			Does not apply				.
100144838	9	Secondary Suspect Drug	AZITHROMYCIN	Validated trade name used	Transplacental	2 every 1 days	Does not apply				.
100144838	10	Secondary Suspect Drug	AZITHROMYCIN	Validated trade name used	Transplacental	UNK	Does not apply				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
100144838	11	Secondary Suspect Drug	BACTRIM	Validated trade name used	Transplacental	400 mg, bid	Does not apply				.
100144838	12	Secondary Suspect Drug	BACTRIM	Validated trade name used	Transplacental	UNK	Does not apply				.
100144838	13	Secondary Suspect Drug	INTELENCE	Validated trade name used	Transplacental	200 mg, bid	Does not apply				.
100144838	14	Secondary Suspect Drug	INTELENCE	Validated trade name used	Transplacental	200 mg	Does not apply				.
100144838	15	Secondary Suspect Drug	INTELENCE	Validated trade name used	Transplacental	200 mg, 1 every 1 Days	Does not apply				.
100144838	16	Secondary Suspect Drug	LAMIVUDINE	Validated trade name used	Transplacental	150 mg, bid	Does not apply				.
100144838	17	Secondary Suspect Drug	LAMIVUDINE	Validated trade name used	Transplacental	150 mg	Does not apply				.
100144838	18	Secondary Suspect Drug	PREZISTA	Validated trade name used	Transplacental	600 mg, bid	Does not apply				.
100144838	19	Secondary Suspect Drug	PREZISTA	Validated trade name used	Transplacental	600 mg, qd	Does not apply				.
100144838	20	Secondary Suspect Drug	PREZISTA	Validated trade name used	Transplacental	600 mg	Does not apply				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
100144838	21	Secondary Suspect Drug	RITONAVIR	Validated trade name used	Transplacental	100 mg, bid	Does not apply				.
100144838	22	Secondary Suspect Drug	RITONAVIR	Validated trade name used	Transplacental	100 mg	Does not apply				.
100144838	23	Secondary Suspect Drug	VIREAD	Validated trade name used	Transplacental	300 mg, qd	Does not apply				.
100144838	24	Secondary Suspect Drug	VIREAD	Validated trade name used	Transplacental	300 mg	Does not apply				.
100144838	25	Secondary Suspect Drug	VIREAD	Validated trade name used	Transdermal	300 mg, qd	Does not apply				.
100144838	26	Secondary Suspect Drug	VIREAD	Validated trade name used	Transdermal	300 mg	Does not apply				.
100144838	27	Secondary Suspect Drug	ZIDOVUDINE	Validated trade name used	Transplacental	300 mg, bid	Does not apply				.
100144838	28	Secondary Suspect Drug	ZIDOVUDINE	Validated trade name used	Transplacental	300 mg	Does not apply				.
100144838	29	Concomitant	FOLIC ACID	Validated trade name used	Transplacental						.
100144838	30	Concomitant	IRON	Validated trade name used	Transplacental	UNK					.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
100144838	31	Concomitant	MAGNESIUM GLUCONATE	Validated trade name used	Transplacental			
100144838	32	Concomitant	IRON;MINERALS NOS;VITAMINS NOS	Validated trade name used	Transplacental			Unknown
100144838	33	Concomitant	CALCIUM CARBONATE	Validated trade name used	Unknown			
100144838	34	Concomitant	CALCIUM PANTOTHENATE	Validated trade name used	Unknown			
100144838	35	Concomitant	ERGOCALCIFEROL	Validated trade name used	Unknown			
100144838	36	Concomitant	FERROUS FUMARATE	Validated trade name used	Unknown			
100144838	37	Concomitant	NICOTINAMIDE	Validated trade name used	Unknown			
100144838	38	Concomitant	PYRIDOXINE HYDROCHLORIDE	Validated trade name used	Unknown			
100144838	39	Concomitant	VITAMIN A PALMITATE	Validated trade name used	Unknown			
100144838	40	Concomitant	RIBOFLAVIN	Validated trade name used	Unknown			
100144838	41	Concomitant	THIAMINE MONONITRATE	Validated trade name used	Unknown			
100144838	42	Concomitant	VITAMIN B12	Validated trade name used	Unknown			
100144838	43	Concomitant	VITAMIN C	Validated trade name used	Unknown			
1001678124	1	Primary Suspect Drug	SANDOSTATIN	Validated trade name used	Subcutaneous	UNK, TID (cont 02 weeks post 01st LAR)	Positive dechallenge	Unknown
1001678124	2	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used	Intramuscular	20 mg, QMO	Positive dechallenge	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1001678124	3	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used			Positive dechallenge	Unknown
1001678124	4	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO (once a month)	Unknown	
1001678124	5	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (once a month)	Unknown	
1001678124	6	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO (every 4 weeks)	Unknown	
1001678124	7	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO (once a month)	Unknown	
1001678124	8	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Unknown	UNK	Unknown	
1001678124	9	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO	Unknown	
1001678124	10	Concomitant	SANDOSTATIN	Validated trade name used	Subcutaneous	UNK, TID	Positive dechallenge	
1001678124	11	Concomitant	AFINITOR	Validated trade name used	Oral	10 mg, QD	Positive dechallenge	
1001678124	12	Concomitant	AFINITOR	Validated trade name used	Oral	UNK	Positive dechallenge	
1001678124	13	Concomitant	DEXILANT	Validated trade name used	Oral	UNK	Unknown	
1001678124	14	Concomitant	INSULIN NOS	Validated trade name used	Unknown	UNK	Positive dechallenge	
1001678124	15	Concomitant	VITAMIN D	Validated trade name used	Oral	UNK (10000 units)	Unknown	
1001678124	16	Concomitant	CRESTOR	Validated trade name used	Oral		Unknown	
1001678124	17	Concomitant	ASPIRIN	Validated trade name used	Oral	UNK	Unknown	

16SEP2015

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1001678124	18	Concomitant	BUPROPION	Validated trade name used	Oral	UNK	Unknown	
1001678124	19	Concomitant	FERROUS SULFATE	Validated trade name used	Oral	UNK	Unknown	
1001678124	20	Concomitant	CALCIUM	Validated trade name used	Oral	UNK	Unknown	
1001678124	21	Concomitant	ABILIFY	Validated trade name used	Unknown	UNK	Unknown	
1002130539	1	Primary Suspect Drug	SANDOSTATIN	Validated trade name used	Subcutaneous	50 ug (test dose)	Does not apply	
1002130539	2	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used			Does not apply	
1002130539	3	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used			Does not apply	
1002130539	4	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (every 4 weeks)		
1002130539	5	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (every 4 weeks)		
1002130539	6	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q4W		
1002130539	7	Concomitant	FRAGMIN	Validated trade name used	Subcutaneous	1 ml, QD		
100293662	1	Primary Suspect Drug	CYCLOSPORINE	Validated trade name used	Unknown	UNK	Positive dechallenge	
100293662	2	Secondary Suspect Drug	CYCLOSPORINE	Validated trade name used			Positive dechallenge	
100293662	3	Secondary Suspect Drug	BASILIXIMAB	Validated trade name used	Unknown	UNK	Unknown	
100293662	4	Secondary Suspect Drug	BASILIXIMAB	Validated trade name used			Unknown	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		.
		19667
		19667
		19667
		19667
		19667
		19667
		.
		50574
		50574
		.
		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
100293662	5	Secondary Suspect Drug	PREDNISOLONE	Validated trade name used	Oral	UNK	Unknown	
100293662	6	Secondary Suspect Drug	PREDNISOLONE	Validated trade name used			Unknown	
100293662	7	Secondary Suspect Drug	MYCOPHENOLATE MOFETIL	Validated trade name used	Unknown	UNK	Unknown	
100293662	8	Secondary Suspect Drug	MYCOPHENOLATE MOFETIL	Validated trade name used			Unknown	
100356167	1	Primary Suspect Drug	DABIGATRAN ETEXILATE MESYLATE	Validated trade name used	Oral		Does not apply	
100356167	2	Concomitant	CARVEDILOL	Validated trade name used	Oral		Does not apply	
100356167	3	Concomitant	ENALAPRIL	Validated trade name used	Oral		Positive dechallenge	
100356167	4	Concomitant	PILSICAINIDE HYDROCHLORIDE	Validated trade name used	Oral		Positive dechallenge	
100356167	5	Concomitant	ADALAT	Validated trade name used	Oral		Positive dechallenge	
100356167	6	Concomitant	SPIRONOLACTONE	Validated trade name used	Oral		Positive dechallenge	
100356167	7	Concomitant	AMMONIUM GLYCYRRHIZATE	Validated trade name used	Oral		Positive dechallenge	
100356167	8	Concomitant	URSO	Validated trade name used	Oral		Positive dechallenge	
1006401878	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	Unknown dose?Received outside RPAP, clinical research. No details provided, batch/lot not included	Unknown	
1006401878	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	1st RPAP dose	Unknown	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f		Lot number of the drug (as reported).	NDA number.
			.
			.
			.
			.
Unknown			22512
			.
			.
			.
			.
			.
			.
			.
B20282,B20172,B20343,B20162,B20213,			125276
B20282,B20172,B20343,B20162,B20213,			125276

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1006401878	3	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	Though PIRs were received, batch/lot numbers were not provided.	Unknown	
1006401878	4	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	5	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	Received outside RPAP, dosing and frequency not available	Unknown	
1006401878	6	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	Though PIRs were received	Unknown	
1006401878	7	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	8	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	9	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	10	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	11	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	Though PIRs were received, batch/lot numbers were not provided.	Unknown	
1006401878	12	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	13	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1006401878	14	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	15	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	16	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	17	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	18	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1006401878	19	Secondary Suspect Drug	METHOTREXATE	Validated trade name used	Unknown		Does not apply	
1006401878	20	Secondary Suspect Drug	CELEBREX	Validated trade name used	Unknown		Unknown	
1006401878	21	Concomitant	FOLIC ACID	Validated trade name used				
1006401878	22	Concomitant	HYDROCHLOROTHIAZIDE	Validated trade name used				
1006401878	23	Concomitant	DICLOFENAC	Validated trade name used				
1006401878	24	Concomitant	CRESTOR	Validated trade name used				
1006401878	25	Concomitant	PLAVIX	Validated trade name used				
1006401878	26	Concomitant	ASPIRIN	Validated trade name used				

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
B20282,B20172,B20343,B20162,B20213,		125276
B20282,B20172,B20343,B20162,B20213,		125276
B20282,B20172,B20343,B20162,B20213,		125276
B20282,B20172,B20343,B20162,B20213,		125276
B20282,B20172,B20343,B20162,B20213,		125276
UNKNOWN		.
UNKNOWN		.
		.
		.
		.
		.
		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1006401878	27	Concomitant	NITROGLYCERIN	Validated trade name used				
1006401878	28	Concomitant	LOPRESSOR	Validated trade name used				
1006401878	29	Concomitant	METAMUCIL	Validated trade name used				
1006401878	30	Concomitant	METOPROLOL	Validated trade name used				
1006401878	31	Concomitant	CLONAZEPAM	Validated trade name used				
1006401878	32	Concomitant	FOLIC ACID	Validated trade name used				
1007468610	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1007468610	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1007468610	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1007468610	4	Concomitant	ALVESCO	Validated trade name used	Respiratory (inhalation)	2 dosage form, BID		
1007468610	5	Concomitant	SPIRIVA	Validated trade name used	Respiratory (inhalation)	1 dosage form, QD	Unknown	
1007468610	6	Concomitant	SYMBICORT	Validated trade name used	Respiratory (inhalation)	2 dosage form, BID (200 ug, budesonide, 6 ug, formoterol fumarate	Unknown	
1007468610	7	Concomitant	ALBUTEROL	Validated trade name used		(4 puffs)	Unknown	
1007468610	8	Concomitant	VENTOLIN	Validated trade name used		2 dosage form, PRN	Unknown	
1007468610	9	Concomitant	VENTOLIN	Validated trade name used		(2 puffs at 6 a3) }24 hours prior to testing	Unknown	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		.
		.
		.
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
		.
		.
		.
UNKNOWN		.
UNKNOWN,UNKNOWN,UNKNOWN		.
UNKNOWN,UNKNOWN,UNKNOWN		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1007468610	10	Concomitant	VENTOLIN	Validated trade name used		(2 puffs at 6 a3) greater than 24 hours prior to testing	Unknown	
100764782	1	Primary Suspect Drug	LEVETIRACETAM	Validated trade name used		500 milligram, Once Daily (qd)	Unknown	Unknown
1008408132	1	Primary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (every 4 weeks)	Positive dechallenge	
1008408132	2	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	60 mg, QMO (every 4 weeks)	Positive dechallenge	
1008408132	3	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (every 4 weeks)	Positive dechallenge	
1008408132	4	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Unknown	UNK	Positive dechallenge	
1008408132	5	Concomitant	JARDIANCE	Validated trade name used	Oral	25 mg, QD	Unknown	
1008408132	6	Concomitant	PERINDOPRIL	Validated trade name used	Oral	8 mg	Unknown	
1008408132	7	Concomitant	ROSUVASTATIN	Validated trade name used	Oral	20 mg	Unknown	
100941024	1	Primary Suspect Drug	LEVETIRACETAM	Validated trade name used		500 milligram, qd (IN THE FIRST TRIMESTER)	Unknown	
1009418019	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	8 mg/kg	Positive dechallenge	
1009418019	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1009418019	3	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1009418019	4	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1009418019	5	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
UNKNOWN,UNKNOWN,UNKNOWN	.	.
		.
		21008
		21008
S0091, 350475		21008
		21008
		.
		.
		.
		90843
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125276
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125276
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125276
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125276
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125276

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1009418019	6	Secondary Suspect Drug	RITUXAN	Validated trade name used	Intravenous (not otherwise specified)	Most recent dose of infusion was received on 02/May/2013	Unknown
1009418019	7	Secondary Suspect Drug	METHOTREXATE	Validated trade name used	Unknown		Unknown
1009418019	8	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Subcutaneous		Unknown
1009418019	9	Concomitant	NAPROXEN	Validated trade name used			
1009418019	10	Concomitant	TYLENOL	Validated trade name used			
1009418019	11	Concomitant	FOSAMAX	Validated trade name used			
1009418019	12	Concomitant	ANAKINRA	Validated trade name used			
1009418019	13	Concomitant	OMEPRAZOLE	Validated trade name used			
1009418019	14	Concomitant	VALACYCLOVIR	Validated trade name used		2 week course	
1009418019	15	Concomitant	PERCOCET	Validated trade name used			
1009418019	16	Concomitant	CYCLOSPORINE	Validated trade name used			
1009418019	17	Concomitant	FOLIC ACID	Validated trade name used			
1009418019	18	Concomitant	PREDNISONE	Validated trade name used			
1014222251	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		
1014222251	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
ASKED BUT UNKNOWN			103705
UNKNOWN			.
ASKED BUT UNKNOWN			125472
			.
			.
			.
			.
			.
			.
			.
			.
B2052,B2035,B2059,B2039,B2041,B206,			125276
B2052,B2035,B2059,B2039,B2041,B206,			125276

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction	Rechallenge code, indicating if reaction
1014222251	3	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			
1014222251	4	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			
1014222251	5	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			
1014222251	6	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			
1014222251	7	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	On hold		
1014222251	8	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			
1014222251	9	Concomitant	ZOPICLONE	Validated trade name used		AT BED TIME		
1014222251	10	Concomitant	MELOXICAM	Validated trade name used				
1014222251	11	Concomitant	LYRICA	Validated trade name used				
1014222251	12	Concomitant	TEGRETOL	Validated trade name used				
1014222251	13	Concomitant	ROSUVASTATIN	Validated trade name used				
1014222251	14	Concomitant	PREGABALIN	Validated trade name used				
1014222251	15	Concomitant	HYDROXYCHLOROQUINE	Validated trade name used				
1014222251	16	Concomitant	CYMBALTA	Validated trade name used		Uncertain if it is twice a day as per physician		
1014222251	17	Concomitant	PANTOPRAZOLE SODIUM	Validated trade name used				

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1014222251	18	Concomitant	ADVAIR HFA	Validated trade name used				
1014222251	19	Concomitant	ATROVENT	Validated trade name used				
1014222251	20	Concomitant	PREDNISONE	Validated trade name used				
1014222251	21	Concomitant	PREDNISONE	Validated trade name used				
1014222251	22	Concomitant	ATROVENT	Validated trade name used				
1014222251	23	Concomitant	CRESTOR	Validated trade name used				
1014222251	24	Concomitant	LEVETIRACETAM	Validated trade name used				
1014222251	25	Concomitant	PLAQUENIL	Validated trade name used				
1014222251	26	Concomitant	SULFASALAZINE	Validated trade name used				
1014222251	27	Concomitant	MELOXICAM	Validated trade name used				
1014222251	28	Concomitant	XARELTO	Validated trade name used				
101451672	1	Primary Suspect Drug	ENBREL	Validated trade name used	Unknown	50 milligram, qwk		
1015212331	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		.
		.
		.
		.
		.
		.
1044814		103795
SUR62,S0004,SE068,SAD52,SEJ08,SJY86		103976
SUR62,S0004,SE068,SAD52,SEJ08,SJY86		103976
SUR62,S0004,SE068,SAD52,SEJ08,SJY86		103976

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1015212331	4	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	5	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	6	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	7	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	8	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	9	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	10	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	11	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	12	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	13	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	14	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	15	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	16	Secondary Suspect Drug	XOLAIR	Validated trade name used	Unknown		Unknown	
1015212331	17	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1015212331	18	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1015212331	19	Secondary Suspect Drug	COSENTYX	Validated trade name used	Unknown		Unknown	
1015212331	20	Concomitant	ADVAIR HFA	Validated trade name used	Unknown	1 DF (500/50)		
1015212331	21	Concomitant	ADVAIR HFA	Validated trade name used	Unknown	1 DF, QD		
1015212331	22	Concomitant	ADVAIR HFA	Validated trade name used	Unknown	1 DF, BID		
1015212331	23	Concomitant	OMNARIS	Validated trade name used	Nasal	2 DF, each nostril		
1015212331	24	Concomitant	ALVESCO	Validated trade name used	Unknown	puff		
1015212331	25	Concomitant	RABEPRAZOLE	Validated trade name used	Oral			
1015212331	26	Concomitant	RANITIDINE	Validated trade name used				
1015212331	27	Concomitant	CETIRIZINE HYDROCHLORIDE	Validated trade name used	Oral	20 mg, UNK		
1015212331	28	Concomitant	SINGULAIR	Validated trade name used	Oral	10 mg, daily		
1015212331	29	Concomitant	ZOLOFT	Validated trade name used	Oral	50 mg, QHS		
1015212331	30	Concomitant	BENADRYL	Validated trade name used	Oral	2 DF, OTHER		
101621574	1	Primary Suspect Drug	AFLIBERCEPT	Validated trade name used	Intravenous drip	234 mg,QCY		
101621574	2	Secondary Suspect Drug	FLUOROURACIL	Validated trade name used	Intravenous bolus	660 mg,QCY		
101621574	3	Secondary Suspect Drug	FLUOROURACIL	Validated trade name used	Intravenous drip	3960 mg,QCY		

<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
		.
		.
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
		125418
		.
		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
101621574	4	Secondary Suspect Drug	IRINOTECAN	Validated trade name used	Intravenous drip	300 mg,QCY		
101621574	5	Secondary Suspect Drug	LEUCOVORIN	Validated trade name used	Intravenous drip	660 mg,QCY		
101621574	6	Concomitant	TYLENOL	Validated trade name used		UNK	Unknown	
101621574	7	Concomitant	CALCIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM CHLORIDE	Validated trade name used		UNK	Unknown	
1016611037	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1016611037	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1016611037	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1016611037	4	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1016611037	5	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous	UNK	Unknown	
1016611037	6	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous	UNK	Unknown	
1016611037	7	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous	UNK	Unknown	
1016611037	8	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous	UNK	Unknown	
1016611037	9	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1016611037	10	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	
1016611037	11	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1016611037	12	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1016611037	13	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1016611037	14	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1016611037	15	Secondary Suspect Drug	PREDNISONE	Validated trade name used	Unknown		Positive dechallenge
1016611037	16	Secondary Suspect Drug	PREDNISONE	Validated trade name used	Unknown		Positive dechallenge
1016611037	17	Secondary Suspect Drug	PREDNISONE	Validated trade name used	Unknown	UNK	Positive dechallenge
1016611037	18	Secondary Suspect Drug	PREDNISONE	Validated trade name used	Unknown	(1 course for 3 weeks)	Positive dechallenge
1016611037	19	Concomitant	ADVAIR HFA	Validated trade name used	Unknown	250 OT, UNK	
1016611037	20	Concomitant	LOSEC	Validated trade name used	Unknown		
1016611037	21	Concomitant	ALVESCO	Validated trade name used	Unknown		
1016611037	22	Concomitant	ALVESCO	Validated trade name used			
1016611037	23	Concomitant	VENTOLIN	Validated trade name used	Unknown	200 ug	Unknown
1016611037	24	Concomitant	METERGOLINE	Validated trade name used	Unknown	UNK	Unknown
1016611037	25	Concomitant	CLINDAMYCIN	Validated trade name used		UNK	Unknown
1016611037	26	Concomitant	ATROVENT	Validated trade name used	Unknown		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
	ASKED BUT UNKNOWN,SN262,SAD52,SLL42		103976
	ASKED BUT UNKNOWN,SN262,SAD52,SLL42		103976
	ASKED BUT UNKNOWN,SN262,SAD52,SLL42		103976
	UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN		.
	UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN		.
	UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN		.
	UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN		.
			.
			.
			.
			.
			.
	UNKNOWN		.
	UNKNOWN		.
	UNKNOWN		.
			.

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
101676303	1	Primary Suspect Drug	EFAVIRENZ	Validated trade name used	Oral	600 mg, qd	Unknown
101676303	2	Concomitant	STAVUDINE	Validated trade name used		30 mg, UNK	Unknown
101676303	3	Concomitant	RIFAMPIN	Validated trade name used			Unknown
101676303	4	Concomitant	RIFAMPIN	Validated trade name used			Unknown
101676303	5	Concomitant	ETHAMBUTOL HYDROCHLORIDE	Validated trade name used			Unknown
101676303	6	Concomitant	PYRAZINAMIDE	Validated trade name used			Unknown
101676303	7	Concomitant	LAMIVUDINE	Validated trade name used		150 mg, UNK	Unknown
101676313	1	Primary Suspect Drug	EFAVIRENZ	Validated trade name used	Oral		Unknown
101676313	2	Concomitant	STAVUDINE	Validated trade name used		30 mg, bid	Unknown
101676313	3	Concomitant	RIFAMPIN	Validated trade name used		1DF:8-10 mg/kg/day	Unknown
101676313	4	Concomitant	ISONIAZID	Validated trade name used		1DF:4-5 mg/kg/day	Unknown
101676313	5	Concomitant	ETHAMBUTOL HYDROCHLORIDE	Validated trade name used		1Df:15-20 mg/kg/day	Unknown
101676313	6	Concomitant	PYRAZINAMIDE	Validated trade name used		1DF:20-30 mg/kg/day	Unknown
101676313	7	Concomitant	LAMIVUDINE	Validated trade name used		150 mg, UNK	Unknown
101678657	1	Primary Suspect Drug	BELIMUMAB	Validated trade name used	Intravenous (not otherwise specified)	10 mg/kg, CYC	Does not apply

16SEP2015

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
101678657	2	Concomitant	PREDNISONE	Validated trade name used	Oral	5 mg, qd	Unknown
101678657	3	Concomitant	NEUPOGEN	Validated trade name used	Subcutaneous	300 ug, qd	Unknown
101678657	4	Concomitant	NEUPOGEN	Validated trade name used	Subcutaneous	300 ug, qd	Unknown
101678657	5	Concomitant	NEUPOGEN	Validated trade name used	Subcutaneous	480 ug, qd	Unknown
101678657	6	Concomitant	NEUPOGEN	Validated trade name used	Subcutaneous	300 ug, bid	Unknown
101678657	7	Concomitant	NEUPOGEN	Validated trade name used	Subcutaneous	480 ug, qd	Unknown
101678657	8	Concomitant	VANCOMYCIN	Validated trade name used	Intravenous (not otherwise specified)	1 g, bid	Unknown
101678657	9	Concomitant	VANCOMYCIN	Validated trade name used	Intravenous (not otherwise specified)	1 g, bid	Unknown
101678657	10	Concomitant	VANCOMYCIN	Validated trade name used	Intravenous (not otherwise specified)	750 mg, bid	Unknown
101678657	11	Concomitant	VANCOMYCIN	Validated trade name used	Intravenous (not otherwise specified)	125 mg, qid	Unknown
101678657	12	Concomitant	FLAGYL	Validated trade name used	Intravenous (not otherwise specified)	500 mg, tid	Unknown
101678657	13	Concomitant	FLAGYL	Validated trade name used	Intravenous (not otherwise specified)	500 UNK	Unknown
101678657	14	Concomitant	FLAGYL	Validated trade name used	Intravenous (not otherwise specified)	500 mg, tid	Unknown
101678657	15	Concomitant	VORICONAZOLE	Validated trade name used	Intravenous (not otherwise specified)	250 mg, bid	Unknown
1017130214	1	Primary Suspect Drug	XELJANZ	Validated trade name used		5 mg, 2x/day	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction
1017130214	2	Secondary Suspect Drug	XELJANZ	Validated trade name used		5 mg, 1x/day	
1017572232	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	3	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	4	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	5	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	6	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	7	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	8	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	9	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	10	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	11	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge
1017572232	12	Concomitant	FOLIC ACID	Validated trade name used			
1017572232	13	Concomitant	RAMIPRIL	Validated trade name used			
1017572232	14	Concomitant	CRESTOR	Validated trade name used			

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
			203214
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
	B20141,B20071,B20262,B20152,B20071,		125276
			.
			.
			.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1017572232	15	Concomitant	METHOTREXATE	Validated trade name used			
1017572232	16	Concomitant	HYDROXYCHLOROQUINE	Validated trade name used			
1017572232	17	Concomitant	CALCIUM	Validated trade name used			
1017572232	18	Concomitant	METFORMIN	Validated trade name used			
101780773	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Unknown
101780773	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Subcutaneous		Unknown
101780773	3	Concomitant	AMITRIPTYLINE	Validated trade name used			
101780773	4	Concomitant	ESTROGENS	Validated trade name used			
101780773	5	Concomitant	PLAQUENIL	Validated trade name used			
101780773	6	Concomitant	PROGESTERONE	Validated trade name used			
101780773	7	Concomitant	ERGOCALCIFEROL	Validated trade name used			
101916392	1	Primary Suspect Drug	VALPROATE SODIUM	Validated trade name used	Unknown		Does not apply
101916392	2	Secondary Suspect Drug	VALPROATE SODIUM	Validated trade name used	Unknown		Does not apply
101916392	3	Secondary Suspect Drug	VALPROATE SODIUM	Validated trade name used	Unknown		Does not apply
101916392	4	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Unknown		Positive dechallenge

ADVERSE EVENT REPORTING SYSTEM (AERS)

Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
			.
			.
			.
			.
ASKED BUT UNKNOWN			125276
ASKED BUT UNKNOWN			125472
			.
			.
			.
			.
			.
Not Available			18723
Not Available			18723
Not Available			18723
Not Available			.

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction
101916392	5	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Unknown		Positive dechallenge
101916392	6	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Unknown		Positive dechallenge
101916392	7	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Unknown	take at bedtime	Positive dechallenge
101916392	8	Secondary Suspect Drug	LORAZEPAM	Validated trade name used	Oral		Does not apply
101916392	9	Concomitant	HALOPERIDOL	Validated trade name used	Unknown		
1020642923	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	4	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	5	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	6	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	7	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	8	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	9	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		
1020642923	10	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1020642923	11	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	12	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	13	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	14	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	15	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	16	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	17	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous	UNK		
1020642923	18	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	19	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	20	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	21	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	22	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous			
1020642923	23	Concomitant	PULMICORT TURBUHALER	Validated trade name used	Unknown	UNK		
1020642923	24	Concomitant	IBUPROFEN	Validated trade name used	Unknown	UNK, QD		
1020642923	25	Concomitant	BRICANYL	Validated trade name used	Unknown	UNK		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
S0072F,S0004,SD875,SL043,ASKED BUT		103976
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1020642923	26	Concomitant	FORMOTEROL FUMARATE	Validated trade name used	Unknown	2 dosage form, BID		
1020642923	27	Concomitant	ZADITOR	Validated trade name used	Unknown	1 dosage form, BID	Unknown	
1020642923	28	Concomitant	MONTELUKAST SODIUM	Validated trade name used		1 dosage form, QD	Unknown	
1020642923	29	Concomitant	ALVESCO	Validated trade name used	Unknown			
1020642923	30	Concomitant	ALVESCO	Validated trade name used	Unknown			
1020642923	31	Concomitant	CROMOLYN SODIUM	Validated trade name used				
102371704	1	Primary Suspect Drug	VALPROATE SODIUM	Validated trade name used	Unknown	2000 mg	Positive dechallenge	
102371704	2	Secondary Suspect Drug	CLARITHROMYCIN	Validated trade name used	Other		Positive dechallenge	
102371704	3	Secondary Suspect Drug	LEVETIRACETAM	Validated trade name used	Unknown		Positive dechallenge	
102371704	4	Secondary Suspect Drug	CELECOXIB	Validated trade name used	Unknown		Positive dechallenge	
102371704	5	Secondary Suspect Drug	PHENOBARBITAL	Validated trade name used	Unknown	100 mg QD	Unknown	
102371704	6	Secondary Suspect Drug	AMOXICILLIN\CLAVULANIC ACID	Validated trade name used	Unknown		Positive dechallenge	
1027487983	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			Unknown
1027487983	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			Unknown
1027487983	3	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)	Clinical trial		Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.
		.
		.
		.
Not available		18723
Not available		50662
Not available		.
Not available		.
Not available		.
Not available		.
B2055,B2058,B2059,B2060,B2062,B2063		125276
B2055,B2058,B2059,B2060,B2062,B2063		125276
B2055,B2058,B2059,B2060,B2062,B2063		125276

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1027487983	4	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			Unknown
1027487983	5	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			Unknown
1027487983	6	Concomitant	METHOTREXATE	Validated trade name used				
1027487983	7	Concomitant	FOLIC ACID	Validated trade name used				
1027487983	8	Concomitant	NEXIUM	Validated trade name used				
1027487983	9	Concomitant	PROCHLORPERAZINE	Validated trade name used				
1027487983	10	Concomitant	NAPROXEN	Validated trade name used				
1028518546	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1028518546	2	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1028518546	3	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1028518546	4	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1028518546	5	Secondary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)		Positive dechallenge	
1028518546	6	Secondary Suspect Drug	RITUXAN	Validated trade name used	Intravenous drip	Day 1; 15		
1028518546	7	Concomitant	PREVACID	Validated trade name used				
1028518546	8	Concomitant	NAPROXEN	Validated trade name used				

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
B2055,B2058,B2059,B2060,B2062,B2063		125276
B2055,B2058,B2059,B2060,B2062,B2063		125276
		.
		.
		.
		.
		.
B20262,B20142,B20152,B20303,B20383,		125276
B20262,B20142,B20152,B20303,B20383,		125276
B20262,B20142,B20152,B20303,B20383,		125276
B20262,B20142,B20152,B20303,B20383,		125276
B20262,B20142,B20152,B20303,B20383,		125276
N7220,N7258,N7294,H0971,H0992,H0994		103705
		.
		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1028518546	9	Concomitant	SULFASALAZINE	Validated trade name used				
1028518546	10	Concomitant	DIPHENHYDRAMINE	Validated trade name used	Oral			
1028518546	11	Concomitant	ACETAMINOPHEN	Validated trade name used	Oral			
1028518546	12	Concomitant	METHYLPREDNISOLONE	Validated trade name used	Intravenous (not otherwise specified)			
1028518546	13	Concomitant	LEUCOVORIN	Validated trade name used				
1028518546	14	Concomitant	TYLENOL	Validated trade name used	Oral			
1028518546	15	Concomitant	BENADRYL	Validated trade name used	Oral			
1028518546	16	Concomitant	SOLU-MEDROL	Validated trade name used	Intravenous (not otherwise specified)			
1028518546	17	Concomitant	METHOTREXATE	Validated trade name used				
1028518546	18	Concomitant	PANTOPRAZOLE SODIUM	Validated trade name used				
1030948614	1	Primary Suspect Drug	LUCENTIS	Validated trade name used	Intraocular		Unknown	
1030948614	2	Secondary Suspect Drug	LUCENTIS	Validated trade name used	Other		Unknown	
1030948614	3	Secondary Suspect Drug	LUCENTIS	Validated trade name used	Unknown		Unknown	
1030948614	4	Secondary Suspect Drug	LUCENTIS	Validated trade name used	Intraocular	UNK (solution intravitreal)	Unknown	
1030948614	5	Secondary Suspect Drug	LUCENTIS	Validated trade name used	Intraocular	UNK (solution injection)	Unknown	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		.
		.
		.
		.
		.
		.
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125156
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125156
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125156
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125156
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125156

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1030948614	6	Secondary Suspect Drug	AVASTIN	Validated trade name used	Intraocular		Unknown	
1030948614	7	Secondary Suspect Drug	AVASTIN	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
1030948614	8	Secondary Suspect Drug	BEVACIZUMAB	Validated trade name used	Intraocular		Unknown	
1030948614	9	Secondary Suspect Drug	BEVACIZUMAB	Validated trade name used	Intravenous (not otherwise specified)		Unknown	
103443973	1	Primary Suspect Drug	XGEVA	Validated trade name used	Subcutaneous	1.7 milliliter, q2wk (1.7 ml (70 mg/ml))		
103443973	2	Concomitant	ANASTROZOLE	Validated trade name used	Oral	1 mg, qd (1 piece (s) once a day)		
103443973	3	Concomitant	OMEPRAZOLE	Validated trade name used	Oral	20 mg, qd (1 piece once a day)		
103443973	4	Concomitant	NAPROXEN	Validated trade name used	Oral	500 mg, bid (1 piece (s) twice a day)		
1035913611	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	
1035913611	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	
1035913611	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	
1035913611	4	Secondary Suspect Drug	VALSARTAN	Validated trade name used	Oral		Unknown	
1035913611	5	Secondary Suspect Drug	CORTISONE	Validated trade name used	Unknown		Unknown	
1035913611	6	Secondary Suspect Drug	LANOLIN	Validated trade name used	Unknown		Unknown	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125085
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125085
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125085
ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		125085
1045804A		125320
		.
		.
		.
UNKNOWN,UNKNOWN,UNKNOWN		103976
UNKNOWN,UNKNOWN,UNKNOWN		103976
UNKNOWN,UNKNOWN,UNKNOWN		103976
UNKNOWN		.
UNKNOWN		.
UNKNOWN		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>
1035913611	7	Secondary Suspect Drug	NEOMYCIN	Validated trade name used	Unknown		Unknown	Unknown	UNKNOWN
1035913611	8	Concomitant	ALVESCO	Validated trade name used	Unknown		Unknown		
1035913611	9	Concomitant	PREDNISONE	Validated trade name used	Unknown		Unknown		
1035913611	10	Concomitant	SPIRIVA	Validated trade name used	Unknown		Unknown		
1035913611	11	Concomitant	SYMBICORT	Validated trade name used	Unknown		Unknown		
1035913611	12	Concomitant	VENTOLIN	Validated trade name used	Unknown	PRN	Unknown		
1035913611	13	Concomitant	FLOVENT	Validated trade name used	Unknown		Unknown		
103687216	1	Primary Suspect Drug	ZYKADIA	Validated trade name used	Oral	750 mg, QD			
103687216	2	Secondary Suspect Drug	ZYKADIA	Validated trade name used	Oral	600 mg, QD			
103687216	3	Concomitant	DEXTROSE	Validated trade name used	Unknown	5 %, 500 cc bid ev			
103749689	1	Primary Suspect Drug	AFLIBERCEPT	Validated trade name used	Intravenous drip	324 mg,QCY	Positive dechallenge		

<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
	.
	.
	.
	.
	.
	.
	.
	205755
	205755
	.
	125418

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>
103749689	2	Secondary Suspect Drug	AFLIBERCEPT	Validated trade name used	Intravenous drip	324 mg,QCY	Positive dechallenge		
103749689	3	Secondary Suspect Drug	FLUOROURACIL	Validated trade name used	Intravenous drip	2232 mg,QCY	Positive dechallenge		
103749689	4	Secondary Suspect Drug	FLUOROURACIL	Validated trade name used	Intravenous bolus	1488 mg,QCY	Positive dechallenge		
103749689	5	Secondary Suspect Drug	FLUOROURACIL	Validated trade name used	Intravenous bolus	1488 mg,UNK	Positive dechallenge		
103749689	6	Secondary Suspect Drug	FLUOROURACIL	Validated trade name used	Intravenous drip	2232 mg,QCY	Positive dechallenge		
103749689	7	Secondary Suspect Drug	IRINOTECAN	Validated trade name used	Intravenous drip	334.8 mg,QCY	Positive dechallenge		UNKNOWN
103749689	8	Secondary Suspect Drug	IRINOTECAN	Validated trade name used	Intravenous drip	334.8 mg,QCY	Positive dechallenge		UNKNOWN
103749689	9	Secondary Suspect Drug	LEUCOVORIN	Validated trade name used	Intravenous drip	744 mg,QCY	Positive dechallenge		UNKNOWN
103749689	10	Secondary Suspect Drug	LEUCOVORIN	Validated trade name used	Intravenous drip	744 mg,QCY	Positive dechallenge		UNKNOWN
103749689	11	Concomitant	GRANISETRON	Validated trade name used		UNK	Unknown		
103749689	12	Concomitant	ATROPINE	Validated trade name used	Unknown	UNK	Unknown		

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction	Rechalleng e code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f
103749689	13	Concomitant	METOCLOPRAMIDE	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	14	Concomitant	METOCLOPRAMIDE	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	15	Concomitant	MEGESTROL ACETATE	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	16	Concomitant	LOPERAMIDE	Validated trade name used		UNK	Unknown		
103749689	17	Concomitant	OCTREOTIDE	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	18	Concomitant	MEGESTROL ACETATE	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	19	Concomitant	PRIMPERAN	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	20	Concomitant	GRANULOCYTE COLONY-STIMULATING FACTOR NOS	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	21	Concomitant	DOPAMINE	Validated trade name used	Unknown	UNK	Unknown		
103749689	22	Concomitant	HALOPERIDOL	Validated trade name used	Unknown	UNK UNK,UNK	Unknown		
103749689	23	Concomitant	MIDAZOLAM	Validated trade name used		UNK	Unknown		

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS) **Drug Listings**

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
103749689	24	Concomitant	OMEPRAZOLE	Validated trade name used	Unknown	UNK	Unknown	
103892335	1	Secondary Suspect Drug	DOXORUBICIN	Validated trade name used	Unknown	liposome injection, Cyclic	Unknown	
103892335	2	Secondary Suspect Drug	VINCRIStINE	Validated trade name used	Unknown	UNK, Cyclic	Unknown	
103892335	3	Primary Suspect Drug	PREDNISOLONE	Validated trade name used	Unknown	UNK, Cyclic	Unknown	
103892335	4	Secondary Suspect Drug	CYCLOPHOSPHAMIDE	Validated trade name used	Unknown	UNK, Cyclic	Unknown	
103892335	5	Secondary Suspect Drug	RITUXIMAB	Validated trade name used	Unknown	UNK, Cyclic	Unknown	
103892335	6	Concomitant	TENOFOVIR	Validated trade name used	Unknown	UNK	Unknown	
103892335	7	Concomitant	TENOFOVIR	Validated trade name used	Unknown	UNK	Unknown	
103892335	8	Concomitant	HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN	Validated trade name used	Unknown	UNK	Unknown	
103892335	9	Concomitant	HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN	Validated trade name used	Unknown	UNK	Unknown	
103928076	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral			Unknown
103928076	2	Secondary Suspect Drug	RISPERDAL	Validated trade name used	Oral	0.5 to 1 mg		Unknown
103928076	3	Secondary Suspect Drug	RISPERDAL	Validated trade name used	Oral			Unknown
103928375	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral	varying doses of 0.25 mg and 0.5 mg three times a day		Unknown
103928375	2	Secondary Suspect Drug	RISPERDAL	Validated trade name used	Oral	therapy start date: //2009; varying doses of 0.5 mg three times a day and 5 mg daily		Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		17469
		.
		.
		.
		.
		.
		.
		20272
		20272
		20272
		20272
		20272

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction	Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
103928375	3	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Oral		Unknown	Unknown			20272
103928375	4	Secondary Suspect Drug	RISPERDAL M-TAB	Validated trade name used	Oral		Unknown	Unknown			21444
103928375	5	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Oral		Unknown				.
103985405	1	Primary Suspect Drug	GILENYA	Validated trade name used	Oral	0.5 mg, QD	Positive dechallenge				22527
103985405	2	Secondary Suspect Drug	GILENYA	Validated trade name used	Unknown	UNK	Positive dechallenge				22527
104003092	1	Secondary Suspect Drug	ENALAPRIL MALEATE	Validated trade name used		UNK					.
104003092	2	Primary Suspect Drug	CLOPIDOGREL BISULFATE	Validated trade name used	Oral	75 mg,QD	Negative dechallenge				20839
104003092	3	Secondary Suspect Drug	ASPIRIN	Validated trade name used	Oral	75 mg,QD	Negative dechallenge				.
104003092	4	Concomitant	DOXAZOSIN	Validated trade name used	Oral	2 mg,QD	Unknown				.
104003092	5	Concomitant	FUROSEMIDE	Validated trade name used	Oral	40 mg,QD	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechalleng e code, indicating if reaction	Rechalleng e code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
104003092	6	Concomitant	ISOSORBIDE MONONITRATE	Validated trade name used	Oral	20 mg,QD	Unknown				.
104003092	7	Concomitant	NEBIVOLOL	Validated trade name used	Oral	10 mg,QD	Unknown				.
104003092	8	Concomitant	RAMIPRIL	Validated trade name used	Oral	10 mg,QD	Unknown				.
1040513313	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown		ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1040513313	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown		ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1040513313	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown		ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1040513313	4	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown		ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1040513313	5	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown		ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1040513313	6	Concomitant	SYMBICORT	Validated trade name used	Unknown						.

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction	Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
1040513313	7	Concomitant	BRICANYL	Validated trade name used	Unknown						.
1040513313	8	Concomitant	ADVAIR HFA	Validated trade name used	Unknown						.
1040513313	9	Concomitant	VENTOLIN	Validated trade name used	Unknown	4 puffs daily					.
1040513313	10	Concomitant	SPIRIVA	Validated trade name used			Unknown		UNKNOWN		.
1040513313	11	Concomitant	ZENHALE	Validated trade name used		strength: 200 mcg	Unknown		UNKNOWN		.
1041491125	1	Primary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, Q4W (every 4 weeks)					21008
1041491125	2	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q4W (every 4 weeks)			368833		21008
1041491125	3	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (once a month)					21008
1041491125	4	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q4W (every 4 weeks)					21008
1041491125	5	Secondary Suspect Drug	SYNTHROID	Validated trade name used	Unknown	UNK	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1041491125	6	Concomitant	CRESTOR	Validated trade name used	Unknown	UNK	Unknown	
1041491125	7	Concomitant	VITAMINS	Validated trade name used	Unknown	UNK	Unknown	
1041491125	8	Concomitant	VITAMIN D	Validated trade name used	Unknown	UNK	Unknown	
1041491125	9	Concomitant	CALCIUM	Validated trade name used	Unknown	UNK	Unknown	
1041491125	10	Concomitant	METOPROLOL	Validated trade name used	Unknown	UNK UNK, PRN	Unknown	
104232052	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown	Unknown
104232052	2	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown	Unknown
104232195	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown	Unknown
104232195	2	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Does not apply	Unknown
104232195	3	Secondary Suspect Drug	RISPERDAL CONSTA	Validated trade name used	Intramuscular		Unknown	Unknown
104232195	4	Secondary Suspect Drug	RISPERDAL CONSTA	Validated trade name used			Unknown	Unknown
104232195	5	Secondary Suspect Drug	RISPERDAL CONSTA	Validated trade name used			Unknown	Unknown
104232195	6	Secondary Suspect Drug	RISPERDAL CONSTA	Validated trade name used			Unknown	Unknown
104232195	7	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Oral		Unknown	
104232203	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		.
		.
		20272
		21999
		20272
		21999
		21346
		21346
		21346
		21346
		.
		20272

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
104232203	2	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown	Unknown
104266473	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown	Unknown
104266473	2	Secondary Suspect Drug	RISPERDAL	Validated trade name used			Unknown	Unknown
104266473	3	Secondary Suspect Drug	RISPERDAL	Validated trade name used			Unknown	Unknown
104266473	4	Secondary Suspect Drug	RISPERDAL	Validated trade name used			Unknown	Unknown
104266473	5	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown	Unknown
104266473	6	Secondary Suspect Drug	INVEGA	Validated trade name used			Unknown	Unknown
104266473	7	Secondary Suspect Drug	RISPERDAL M-TAB	Validated trade name used	Oral		Unknown	Unknown
104266473	8	Secondary Suspect Drug	RISPERIDONE	Validated trade name used	Unknown		Unknown	
104490482	1	Primary Suspect Drug	TRAMADOL	Validated trade name used	Unknown	UNK	Does not apply	
104490482	2	Secondary Suspect Drug	CODEINE	Validated trade name used	Unknown	UNK	Does not apply	
104490482	3	Secondary Suspect Drug	LYRICA	Validated trade name used	Unknown	UNK	Does not apply	
104490482	4	Concomitant	MORPHINE	Validated trade name used	Unknown	UNK	Does not apply	
104490482	5	Concomitant	ALCOHOL	Validated trade name used	Unknown	UNK	Does not apply	
104580772	1	Primary Suspect Drug	TRAMADOL	Validated trade name used	Unknown	UNK	Does not apply	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		21999
		20272
		20272
		20272
		20272
		21999
		21999
		21444
		.
		203494
		.
		.
		.
		.
		203494

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
104580772	2	Secondary Suspect Drug	LYRICA	Validated trade name used	Unknown	UNK	Does not apply	
104580772	3	Secondary Suspect Drug	OXYCODONE	Validated trade name used	Unknown	UNK	Does not apply	
104580772	4	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Unknown	UNK	Does not apply	
104580883	1	Primary Suspect Drug	ACETAMINOPHEN	Validated trade name used	Unknown	UNK	Does not apply	
104580883	2	Secondary Suspect Drug	TRAMADOL	Validated trade name used	Unknown	UNK	Does not apply	
104580883	3	Secondary Suspect Drug	LYRICA	Validated trade name used	Unknown	UNK	Does not apply	
104580883	4	Secondary Suspect Drug	AMITRIPTYLINE	Validated trade name used	Unknown	UNK	Does not apply	
104580883	5	Secondary Suspect Drug	NORTRIPTYLINE	Validated trade name used	Unknown	UNK	Does not apply	
104580883	6	Secondary Suspect Drug	ALCOHOL	Validated trade name used	Unknown	UNK	Does not apply	
104635823	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown	Unknown
104635823	2	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown	Unknown
104665748	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral	varying doses of 0.5 mg, 1 mg and 2 mg	Unknown	Unknown
104665748	2	Secondary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown	Unknown
104665748	3	Secondary Suspect Drug	RISPERDAL	Validated trade name used			Unknown	Unknown
104665748	4	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		.
		.
		.
		207229
		203494
		.
		.
		.
		.
		20588
		21999
		20272
		20272
		20272
		21999

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
104665748	5	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown	Unknown
104825157	1	Primary Suspect Drug	LIPITOR	Validated trade name used	Unknown	10 mg, 1x/day	Unknown	Unknown
104825157	2	Secondary Suspect Drug	LIPITOR	Validated trade name used	Unknown	20 milligram	Unknown	Unknown
104825157	3	Concomitant	ATENOLOL	Validated trade name used	Unknown	50 milligram, qd		
104825157	4	Concomitant	QUINAPRIL	Validated trade name used	Unknown	UNK		
105144244	1	Primary Suspect Drug	STELARA	Validated trade name used	Subcutaneous			
105144244	2	Secondary Suspect Drug	STELARA	Validated trade name used				
1051596718	1	Primary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO (every 4 weeks)	Unknown	
1051596718	2	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q4W	Unknown	
1051596718	3	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q3W	Unknown	
1051596718	4	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q3W	Unknown	
1051596718	5	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, Q4W	Unknown	
1052690058	1	Primary Suspect Drug	ACTEMRA	Validated trade name used	Intravenous (not otherwise specified)			
1052690058	2	Concomitant	FOSINOPRIL	Validated trade name used				
1052690058	3	Concomitant	NORVASC	Validated trade name used				

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
		21999
		20702
		20702
		.
		.
		125261
		125261
		21008
369477		21008
		21008
		21008
		21008
B20343,B20283,B2043,B2038,B2048,B20		125276
		.
		.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1052690058	4	Concomitant	OXYCODONE	Validated trade name used			
1052690058	5	Concomitant	FOLIC ACID	Validated trade name used			
1052690058	6	Concomitant	PANTOPRAZOLE	Validated trade name used			
1052690058	7	Concomitant	AMLODIPINE	Validated trade name used			
1052690058	8	Concomitant	ROSUVASTATIN	Validated trade name used			
1052690058	9	Concomitant	DICLOFENAC	Validated trade name used			
1052690058	10	Concomitant	ASPIRIN	Validated trade name used			
1052690058	11	Concomitant	CEPHALEXIN	Validated trade name used		for 7 day.	
1054038738	1	Primary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO (every 4 week)	
1054038738	2	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	30 mg, QMO	
1054038738	3	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	40 mg, QMO	
1054038738	4	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO	
1054038738	5	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO (every 4 weeks)	
1054038738	6	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO	
1054038738	7	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, Q4W	

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1054038738	8	Secondary Suspect Drug	SANDOSTATIN LAR DEPOT	Validated trade name used	Intramuscular	20 mg, QMO	
1054038738	9	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used	Subcutaneous	UNK UNK, ONCE/SINGLE (Test dose)	Unknown
1054038738	10	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used			Unknown
1054038738	11	Secondary Suspect Drug	SANDOSTATIN	Validated trade name used			Unknown
1054038738	12	Concomitant	CRESTOR	Validated trade name used	Unknown	UNK	Unknown
1054038738	13	Concomitant	ASPIRIN	Validated trade name used	Unknown		Unknown
1054038738	14	Concomitant	XARELTO	Validated trade name used	Unknown	UNK	Unknown
1054038738	15	Concomitant	FLOMAX	Validated trade name used	Unknown	UNK	Unknown
105481232	1	Primary Suspect Drug	LEVETIRACETAM	Validated trade name used	Unknown	daily dose: 3250 (units unspecified)	
105481232	2	Secondary Suspect Drug	LEVETIRACETAM	Validated trade name used	Unknown	unk	
105524185	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown
105524185	2	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown
105524185	3	Secondary Suspect Drug	ZYPREXA	Validated trade name used	Oral		Unknown
105524185	4	Secondary Suspect Drug	SEROQUEL	Validated trade name used	Unknown		Unknown
105741013	1	Primary Suspect Drug	CYCLOSPORINE	Validated trade name used	Unknown	UNK, target blood level: 280-320 ng/ml	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
			21008
			21008
			21008
			21008
			.
			.
			.
			.
Unknown	Unk		203059
Unknown	Unk		203059
			20272
			21999
			.
			.
			50574

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechalleng e code, indicating if reaction	Rechalleng e code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
105741013	2	Secondary Suspect Drug	CYCLOSPORINE	Validated trade name used			Unknown				50574
105741013	3	Secondary Suspect Drug	MYCOPHENOLATE MOFETIL	Validated trade name used	Unknown	2 g, QD	Unknown				.
105741013	4	Secondary Suspect Drug	MYCOPHENOLATE MOFETIL	Validated trade name used			Unknown				.
105741013	5	Secondary Suspect Drug	PREDNISOLONE	Validated trade name used	Unknown	20 mg, QD	Unknown				.
105741013	6	Secondary Suspect Drug	PREDNISOLONE	Validated trade name used			Unknown				.
1058928657	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1058928657	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1058928657	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976
1058928657	4	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN, ASKED BUT UNKNOWN		103976

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

Unique number for identifying a FAERS re	Unique number for identifying a drug for	Code for drug's reported role in event.	Name of medicinal product.	Code for source of DRUGNAME.	The route of drug administration	Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction	Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
1058928657	5	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	6	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	7	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	8	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	9	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	10	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	11	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	12	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	13	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous	UNK	Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976
1058928657	14	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown	ASKED BUT UNKNOWN,ASKED BUT UNKNOWN		103976

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1058928657	15	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	16	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	17	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	18	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	19	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	20	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	21	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	22	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	23	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	24	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	25	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	26	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	27	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	28	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	29	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>
1058928657	30	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	31	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	32	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	33	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	34	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	35	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	36	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	37	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	38	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	39	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	40	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	41	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	42	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown
1058928657	43	Secondary Suspect Drug	XOLAIR	Validated trade name used	Unknown	UNK	Positive dechallenge	Unknown
1058928657	44	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Positive dechallenge	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1058928657	45	Secondary Suspect Drug	PNEUMOVAX 23	Validated trade name used	Unknown		Does not apply
1058928657	46	Concomitant	SPIRIVA	Validated trade name used	Unknown	UNK	Unknown
1058928657	47	Concomitant	ADVAIR HFA	Validated trade name used	Unknown	UNK	Unknown
1058928657	48	Concomitant	SINGULAIR	Validated trade name used	Unknown	UNK	Unknown
1058928657	49	Concomitant	NASONEX	Validated trade name used	Unknown	UNK	Unknown
1058928657	50	Concomitant	VENTOLIN	Validated trade name used	Unknown	UNK UNK, BID	Unknown
1058928657	51	Concomitant	SYMBICORT	Validated trade name used	Unknown	UNK	Unknown
1058928657	52	Concomitant	PREDNISONE	Validated trade name used			
105947013	1	Primary Suspect Drug	TRAMADOL HYDROCHLORIDE	Validated trade name used	Oral	1.5 g, UNK	Does not apply
105947013	2	Secondary Suspect Drug	NAPROXEN	Validated trade name used	Oral	UNK	Does not apply
105947013	3	Secondary Suspect Drug	METAXALONE	Validated trade name used	Oral	12 g, UNK	Does not apply
1060157312	1	Primary Suspect Drug	RUXOLITINIB	Validated trade name used	Oral	10 mg, BID (twice daily)	Does not apply
1060157312	2	Secondary Suspect Drug	RUXOLITINIB	Validated trade name used	Oral	10 mg, QD	Does not apply
1060157312	3	Secondary Suspect Drug	RUXOLITINIB	Validated trade name used	Oral	10 mg, BID	Does not apply
1060157312	4	Secondary Suspect Drug	RUXOLITINIB	Validated trade name used	Oral	5 mg, BID	Does not apply

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
	ASKED BUT UNKNOWN		.
	unknown		.
	UNKNOWN		.
	UNKNOWN		.
	UNKNOWN		.
	UNKNOWN		.
	UNKNOWN		.
	UNKNOWN		.
			.
Unknown			203494
Unknown			200629
Unknown			.
			202192
			202192
			202192
			202192

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1060157312	5	Concomitant	EPREX	Validated trade name used	Unknown	UNK	Does not apply
1060157312	6	Concomitant	RAMIPRIL	Validated trade name used	Unknown	UNK	Does not apply
106091663	1	Primary Suspect Drug	LEVETIRACETAM	Validated trade name used	Unknown	3000 mg, Daily	Does not apply
106091663	2	Secondary Suspect Drug	LEVETIRACETAM	Validated trade name used			Does not apply
106091663	3	Secondary Suspect Drug	LACOSAMIDE	Validated trade name used	Oral	200 mg, single loading dose	Does not apply
106091663	4	Secondary Suspect Drug	LACOSAMIDE	Validated trade name used	Oral	100 mg, Two Times a Day	Does not apply
106091663	5	Secondary Suspect Drug	LACOSAMIDE	Validated trade name used	Oral	200 mg, Two Times a Day	Does not apply
106091663	6	Secondary Suspect Drug	PREGABALIN	Validated trade name used	Unknown	300 milligram, Once a Day	Does not apply
106091663	7	Secondary Suspect Drug	PHENOBARBITAL	Validated trade name used	Unknown	50 mg, Once a Day	Does not apply
106091663	8	Secondary Suspect Drug	PHENOBARBITAL	Validated trade name used			Does not apply
106336646	1	Primary Suspect Drug	RISPERDAL	Validated trade name used	Oral		Unknown
106336646	2	Secondary Suspect Drug	RISPERDAL	Validated trade name used	Oral	at varying doses of 0.5 mg to 1 mg	Unknown
106336646	3	Secondary Suspect Drug	RISPERDAL	Validated trade name used	Oral	At varying doses of 1 mg to 2 mg	Unknown
106336646	4	Secondary Suspect Drug	INVEGA	Validated trade name used	Oral		Unknown
106352232	1	Primary Suspect Drug	LACOSAMIDE	Validated trade name used	Oral	200 mg, One time Dose, loading dose	Does not apply

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
			.
			.
Unknown			78993
Unknown			78993
Unknown			204994
Unknown			204994
Unknown			204994
			205321
Unknown			.
Unknown			.
Unknown			20272
Unknown			20272
Unknown			20272
Unknown			21999
			.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
106352232	2	Secondary Suspect Drug	LACOSAMIDE	Validated trade name used	Oral	100 mg twice daily upto 200 mg twice a day maintenance dose	Does not apply
106352232	3	Secondary Suspect Drug	LEVETIRACETAM	Validated trade name used		Up to 3000 mg per day	Does not apply
106352232	4	Concomitant	PREGABALIN	Validated trade name used		upto 150 mg twice daily	Does not apply
106352232	5	Concomitant	PHENOBARBITAL	Validated trade name used		50 milligram	Does not apply
106520463	1	Primary Suspect Drug	PRISTIQ EXTENDED-RELEASE	Validated trade name used		UNK	Unknown
1069198853	1	Primary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	2	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	3	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	4	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	5	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	6	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	7	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	8	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	9	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown
1069198853	10	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous		Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1069198853	11	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	12	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	13	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	14	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	15	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	16	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	17	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	18	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	19	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	20	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	21	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	22	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	23	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	24	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	25	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	26	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	27	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	28	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	29	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	30	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	31	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	32	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	33	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	34	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	35	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	36	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1069198853	37	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	38	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	39	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	40	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	41	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	42	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	43	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	44	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	45	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	46	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	47	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	48	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	49	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	50	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	51	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	52	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	53	Secondary Suspect Drug	XOLAIR	Validated trade name used	Subcutaneous
1069198853	54	Concomitant	PREDNISONE	Validated trade name used	
1069198853	55	Concomitant	SINGULAIR	Validated trade name used	Unknown
1069198853	56	Concomitant	VENTOLIN	Validated trade name used	Unknown
1069198853	57	Concomitant	ADVAIR HFA	Validated trade name used	Unknown
1069198853	58	Concomitant	ZENHALE	Validated trade name used	Unknown
1069198853	59	Concomitant	SPIRIVA	Validated trade name used	Unknown
1069198853	60	Concomitant	ALVESCO	Validated trade name used	Unknown
1069198853	61	Concomitant	INSULIN NOS	Validated trade name used	Unknown
1070483325	1	Secondary Suspect Drug	SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used	Oral

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Verbatim text for dose, frequency, and r	Dechallenge code, indicating if reaction	Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
	Unknown		S0053A,S0060A,S0061D,S0062,S0065E,S		103976
30 mg, QD	Unknown		UNKNOWN		.
	Unknown				.
	Unknown				.
1 DF, TID	Positive dechallenge				.
	Unknown				.
	Unknown				.
	Unknown				.
					.
60 milligram	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	2	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Oral
1070483325	3	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Oral
1070483325	4	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Oral
1070483325	5	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Oral
1070483325	6	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Unknown
1070483325	7	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Unknown
1070483325	8	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Oral
1070483325	9	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Unknown
1070483325	10	Secondary Suspect Drug	BACLOFEN	Validated trade name used	Oral
1070483325	11	Secondary Suspect Drug	HYDROMORPHONE	Validated trade name used	Unknown
1070483325	12	Secondary Suspect Drug	CALCIUM CARBONATE	Validated trade name used	Unknown
1070483325	13	Primary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown
1070483325	14	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown
1070483325	15	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown
1070483325	16	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown
1070483325	17	Secondary Suspect Drug	FUROSEMIDE	Validated trade name used	Unknown
1070483325	18	Secondary Suspect Drug	ZOPICLONE	Validated trade name used	Oral
1070483325	19	Secondary Suspect Drug	ZOPICLONE	Validated trade name used	Unknown
1070483325	20	Secondary Suspect Drug	CALCIUM CARBONATE	Validated trade name used	Unknown
1070483325	21	Secondary Suspect Drug	ALENDRONATE SODIUM	Validated trade name used	Unknown
1070483325	22	Secondary Suspect Drug	ALENDRONATE	Validated trade name used	Oral
1070483325	23	Secondary Suspect Drug	ALENDRONATE	Validated trade name used	Buccal
1070483325	24	Secondary Suspect Drug	NORTRIPTYLINE	Validated trade name used	Unknown
1070483325	25	Secondary Suspect Drug	MYCOPHENOLIC ACID	Validated trade name used	Unknown
1070483325	26	Secondary Suspect Drug	NORTRIPTYLINE	Validated trade name used	Oral

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
3 milligram, qd	Unknown				.
1 dosage form, qd	Unknown				.
60 milligram	Unknown				.
UNK	Unknown				.
3 milligram, qd	Unknown				.
60 milligram	Unknown				.
1 milligram, qd	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
600 milligram	Unknown				211067
60 milligram, UNK	Unknown				211067
600 milligram	Unknown				211067
UNK	Unknown				211067
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				77982
UNK	Unknown				77982
UNK	Unknown				77982
UNK	Unknown				.
UNK	Unknown				91558
UNK	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	27	Secondary Suspect Drug	WARFARIN SODIUM	Validated trade name used	Unknown
1070483325	28	Secondary Suspect Drug	TIZANIDINE HYDROCHLORIDE	Validated trade name used	Oral
1070483325	29	Secondary Suspect Drug	PREDNISONE	Validated trade name used	Unknown
1070483325	30	Secondary Suspect Drug	TIZANIDINE	Validated trade name used	Oral
1070483325	31	Secondary Suspect Drug	TIZANIDINE	Validated trade name used	Unknown
1070483325	32	Secondary Suspect Drug	MOMETASONE	Validated trade name used	Unknown
1070483325	33	Secondary Suspect Drug	NAPROXEN SODIUM	Validated trade name used	Unknown
1070483325	34	Secondary Suspect Drug	BACLOFEN	Validated trade name used	Unknown
1070483325	35	Secondary Suspect Drug	BACLOFEN	Validated trade name used	Oral
1070483325	36	Secondary Suspect Drug	CALCIUM CARBONATE	Validated trade name used	Unknown
1070483325	37	Secondary Suspect Drug	FOLIC ACID	Validated trade name used	Oral
1070483325	38	Secondary Suspect Drug	FOLIC ACID	Validated trade name used	Unknown
1070483325	39	Secondary Suspect Drug	GLICLAZIDE	Validated trade name used	Unknown
1070483325	40	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Oral
1070483325	41	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Oral
1070483325	42	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Oral
1070483325	43	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Oral
1070483325	44	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Unknown
1070483325	45	Secondary Suspect Drug	DULOXETINE	Validated trade name used	Unknown
1070483325	46	Secondary Suspect Drug	LORATADINE	Validated trade name used	Oral
1070483325	47	Secondary Suspect Drug	LORATADINE	Validated trade name used	Oral
1070483325	48	Secondary Suspect Drug	LORATADINE	Validated trade name used	Unknown
1070483325	49	Secondary Suspect Drug	MYCOPHENOLATE MOFETIL	Validated trade name used	Unknown
1070483325	50	Secondary Suspect Drug	TRIMIPRAMINE	Validated trade name used	Unknown
1070483325	51	Secondary Suspect Drug	ALENDRONATE SODIUM\CHOLECALCIFEROL	Validated trade name used	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
UNK	Unknown				91386
UNK	Unknown				76533
UNK	Unknown				.
UNK	Unknown				76533
UNK	Unknown				76533
UNK	Unknown				91161
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
10 milligram	Unknown				.
UNK	Unknown				202045
3 milligram, qd	Unknown				202045
1 dosage form, qd	Unknown				202045
1 milligram, qd	Unknown				202045
1 milligram	Unknown				202045
1 dosage form, qd	Unknown				202045
10 milligram	Unknown				999999
UNK	Unknown				999999
UNK	Unknown				999999
UNK	Unknown				91558
UNK	Unknown				.
UNK	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>
1070483325	52	Secondary Suspect Drug	DOCUSATE SODIUM	Validated trade name used	Unknown	UNK
1070483325	53	Secondary Suspect Drug	DOCUSATE SODIUM	Validated trade name used	Unknown	3 milliliter, qd
1070483325	54	Secondary Suspect Drug	LORATADINE	Validated trade name used	Unknown	10 mg, UNK
1070483325	55	Secondary Suspect Drug	HYDROCHLOROTHIAZIDE	Validated trade name used	Oral	UNK
1070483325	56	Secondary Suspect Drug	CLARITHROMYCIN	Validated trade name used	Unknown	10 milligram
1070483325	57	Secondary Suspect Drug	RANITIDINE	Validated trade name used	Unknown	UNK
1070483325	58	Secondary Suspect Drug	SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used	Oral	UNK
1070483325	59	Secondary Suspect Drug	ASPIRIN	Validated trade name used	Unknown	UNK
1070483325	60	Secondary Suspect Drug	TRIMETHOPRIM	Validated trade name used	Unknown	UNK
1070483325	61	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Intravenous (not otherwise specified)	600 milligram
1070483325	62	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Intravenous (not otherwise specified)	600 milliequivalent
1070483325	63	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Intravenous (not otherwise specified)	UNK
1070483325	64	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown	600 milligram
1070483325	65	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown	60 milligram
1070483325	66	Secondary Suspect Drug	POTASSIUM CHLORIDE	Validated trade name used	Unknown	600 milliequivalent

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1070483325	67	Secondary Suspect Drug	ACIDOPHILUS	Validated trade name used	Oral	UNK	Unknown
1070483325	68	Secondary Suspect Drug	LORATADINE	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	69	Secondary Suspect Drug	LORATADINE	Validated trade name used	Intravenous (not otherwise specified)	600 milligram	Unknown
1070483325	70	Secondary Suspect Drug	LORATADINE	Validated trade name used	Intravenous (not otherwise specified)	10 milligram	Unknown
1070483325	71	Secondary Suspect Drug	THYMOCYTE IMMUNE GLOBULIN NOS	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	72	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	73	Secondary Suspect Drug	ATIVAN	Validated trade name used	Unknown	UNK	Unknown
1070483325	74	Secondary Suspect Drug	CELLCEPT	Validated trade name used	Unknown	UNK	Unknown
1070483325	75	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	3 milligram, qd	Unknown
1070483325	76	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	3 milligram, qd	Unknown
1070483325	77	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	UNK, qd	Unknown
1070483325	78	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	1 dosage form, qd	Unknown
1070483325	79	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	1 dosage form, qd	Unknown
1070483325	80	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	UNK UNK, qd	Unknown
1070483325	81	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Unknown	3 milligram, qd	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1070483325	82	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	1 milligram, qd	Unknown
1070483325	83	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Unknown	1 dosage form, qd	Unknown
1070483325	84	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	UNK	Unknown
1070483325	85	Secondary Suspect Drug	IMODIUM	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	86	Secondary Suspect Drug	IMODIUM	Validated trade name used	Unknown	UNK	Unknown
1070483325	87	Secondary Suspect Drug	B100	Validated trade name used	Unknown	UNK	Unknown
1070483325	88	Secondary Suspect Drug	LYRICA	Validated trade name used	Oral	UNK	Unknown
1070483325	89	Secondary Suspect Drug	MELATONIN	Validated trade name used	Unknown	5 milligram	Unknown
1070483325	90	Secondary Suspect Drug	NASONEX	Validated trade name used	Unknown	UNK	Unknown
1070483325	91	Secondary Suspect Drug	HYDROCHLOROTHIAZIDE	Validated trade name used	Oral	UNK	Unknown
1070483325	92	Secondary Suspect Drug	HYDROCHLOROTHIAZIDE	Validated trade name used	Unknown	UNK	Unknown
1070483325	93	Secondary Suspect Drug	FISH OIL	Validated trade name used	Oral	UNK	Unknown
1070483325	94	Secondary Suspect Drug	FISH OIL	Validated trade name used	Unknown	UNK	Unknown
1070483325	95	Secondary Suspect Drug	SENNOSIDES A AND B	Validated trade name used	Unknown	UNK	Unknown
1070483325	96	Secondary Suspect Drug	SENOKOT	Validated trade name used	Unknown	UNK	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1070483325	97	Secondary Suspect Drug	VITAMIN B12	Validated trade name used	Unknown	UNK	Unknown
1070483325	98	Secondary Suspect Drug	VITAMIN C	Validated trade name used	Unknown	UNK	Unknown
1070483325	99	Secondary Suspect Drug	VITAMIN D	Validated trade name used	Unknown	UNK	Unknown
1070483325	100	Secondary Suspect Drug	ZANTAC	Validated trade name used	Oral	UNK	Unknown
1070483325	101	Secondary Suspect Drug	VITAMIN B12	Validated trade name used	Unknown	UNK	Unknown
1070483325	102	Secondary Suspect Drug	NIACINAMIDE\PYRIDOXINE HYDROCHLORIDE\RIBOFLAVIN\THIAMINE HYDROCHLORIDE	Validated trade name used	Unknown	UNK, Unknown	Unknown
1070483325	103	Secondary Suspect Drug	DOCONEXENT\ICOSAPENT	Validated trade name used	Unknown	1000 mg, UNK	Unknown
1070483325	104	Secondary Suspect Drug	BIFIDOBACTERIUM ANIMALIS LACTIS	Validated trade name used	Unknown	UNK	Unknown
1070483325	105	Secondary Suspect Drug	VITAMINS	Validated trade name used	Unknown		Unknown
1070483325	106	Secondary Suspect Drug	NIACINAMIDE\PYRIDOXINE HYDROCHLORIDE\RIBOFLAVIN\THIAMINE HYDROCHLORIDE	Validated trade name used	Unknown	UNK	Unknown
1070483325	107	Secondary Suspect Drug	SENNA LEAF	Validated trade name used	Oral		Unknown
1070483325	108	Secondary Suspect Drug	DEXPANTHENOL	Validated trade name used	Unknown	UNK	Unknown
1070483325	109	Secondary Suspect Drug	ERGOCALCIFEROL	Validated trade name used	Unknown	UNK	Unknown
1070483325	110	Secondary Suspect Drug	PYRIDOXINE HYDROCHLORIDE	Validated trade name used	Unknown	UNK	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	111	Secondary Suspect Drug	RIBOFLAVIN	Validated trade name used	Unknown
1070483325	112	Secondary Suspect Drug	THIAMINE HYDROCHLORIDE	Validated trade name used	Oral
1070483325	113	Secondary Suspect Drug	RETINOL	Validated trade name used	Oral
1070483325	114	Secondary Suspect Drug	RETINOL	Validated trade name used	Oral
1070483325	115	Secondary Suspect Drug	RETINOL	Validated trade name used	Unknown
1070483325	116	Secondary Suspect Drug	RETINOL	Validated trade name used	Oral
1070483325	117	Secondary Suspect Drug	RETINOL	Validated trade name used	Unknown
1070483325	118	Secondary Suspect Drug	RETINOL	Validated trade name used	Unknown
1070483325	119	Secondary Suspect Drug	RETINOL	Validated trade name used	Unknown
1070483325	120	Secondary Suspect Drug	RETINOL	Validated trade name used	Unknown
1070483325	121	Secondary Suspect Drug	RETINOL	Validated trade name used	Unknown
1070483325	122	Secondary Suspect Drug	NICOTINAMIDE	Validated trade name used	Unknown
1070483325	123	Secondary Suspect Drug	CALCIUM	Validated trade name used	Unknown
1070483325	124	Secondary Suspect Drug	CYANOCOBALAMIN	Validated trade name used	Unknown
1070483325	125	Secondary Suspect Drug	SENNA LEAF	Validated trade name used	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
UNK	Unknown				.
UNK	Unknown				.
3 mg, qd	Unknown				.
1 DF, qd	Unknown				.
600 mEq, UNK	Unknown				.
UNK	Unknown				.
1 DF, qd	Unknown				.
3 mg, qd	Unknown				.
UNK, 600 MU	Unknown				.
600 milligram	Unknown				.
UNK	Unknown				.
	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	126	Secondary Suspect Drug	LOPERAMIDE	Validated trade name used	Intravenous (not otherwise specified)
1070483325	127	Secondary Suspect Drug	CLARITIN	Validated trade name used	Unknown
1070483325	128	Secondary Suspect Drug	CLARITIN	Validated trade name used	Intravenous (not otherwise specified)
1070483325	129	Secondary Suspect Drug	BIFIDOBACTERIUM ANIMALIS LACTIS	Validated trade name used	Unknown
1070483325	130	Secondary Suspect Drug	FISH OIL	Validated trade name used	Unknown
1070483325	131	Secondary Suspect Drug	HUMAN IMMUNOGLOBULIN G	Validated trade name used	Intravenous (not otherwise specified)
1070483325	132	Secondary Suspect Drug	HORSE CHESTNUT	Validated trade name used	Unknown
1070483325	133	Secondary Suspect Drug	FOSAMAX	Validated trade name used	Unknown
1070483325	134	Secondary Suspect Drug	FISH OIL\TOCOPHEROL	Validated trade name used	Unknown
1070483325	135	Secondary Suspect Drug	FISH OIL\TOCOPHEROL	Validated trade name used	Oral
1070483325	136	Secondary Suspect Drug	BACLOFEN	Validated trade name used	Unknown
1070483325	137	Secondary Suspect Drug	ASCORBIC ACID	Validated trade name used	Unknown
1070483325	138	Secondary Suspect Drug	CALCIUM CARBONATE	Validated trade name used	Unknown
1070483325	139	Secondary Suspect Drug	FISH OIL	Validated trade name used	Oral
1070483325	140	Secondary Suspect Drug	FISH OIL	Validated trade name used	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	141	Secondary Suspect Drug	SULFATRIM	Validated trade name used	Intravenous (not otherwise specified)
1070483325	142	Secondary Suspect Drug	BIOTIN	Validated trade name used	Unknown
1070483325	143	Secondary Suspect Drug	COD LIVER OIL	Validated trade name used	Oral
1070483325	144	Secondary Suspect Drug	INSULIN NOS	Validated trade name used	Unknown
1070483325	145	Secondary Suspect Drug	LACTOBACILLUS CASEI	Validated trade name used	Unknown
1070483325	146	Secondary Suspect Drug	OMEGA-3-ACID ETHYL ESTERS	Validated trade name used	Unknown
1070483325	147	Secondary Suspect Drug	VITAMIN D3	Validated trade name used	Unknown
1070483325	148	Secondary Suspect Drug	TRIAMTERENE	Validated trade name used	Unknown
1070483325	149	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Oral
1070483325	150	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Oral
1070483325	151	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Oral
1070483325	152	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Oral
1070483325	153	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Oral
1070483325	154	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Unknown
1070483325	155	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used	Oral

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
400 IU, UNK	Unknown				.
UNK	Unknown				.
60 milligram	Unknown				.
1 dosage form, qd	Unknown				.
3 milligram, qd	Unknown				.
UNK	Unknown				.
3 dosage form	Unknown				.
UNK	Unknown				.
1 milligram, qd	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	156	Secondary Suspect Drug	DOCONEXENT	Validated trade name used	Unknown
1070483325	157	Secondary Suspect Drug	SULFAMETHOXAZOLE	Validated trade name used	Intravenous (not otherwise specified)
1070483325	158	Secondary Suspect Drug	BIFIDOBACTERIUM LONGUM\LACTOBACILLUS ACIDOPHILUS	Validated trade name used	Oral
1070483325	159	Secondary Suspect Drug	LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN	Validated trade name used	Unknown
1070483325	160	Secondary Suspect Drug	AMINOBENZOIC ACID	Validated trade name used	Unknown
1070483325	161	Secondary Suspect Drug	EQUINE THYMOCYTE IMMUNE GLOBULIN	Validated trade name used	Intravenous (not otherwise specified)
1070483325	162	Secondary Suspect Drug	BIFIDOBACTERIUM BIFIDUM	Validated trade name used	Unknown
1070483325	163	Secondary Suspect Drug	CHOLINE BITARTRATE	Validated trade name used	Unknown
1070483325	164	Secondary Suspect Drug	GAMASTAN	Validated trade name used	Intravenous (not otherwise specified)
1070483325	165	Secondary Suspect Drug	INOSITOL	Validated trade name used	Unknown
1070483325	166	Secondary Suspect Drug	LACTOBACILLUS ACIDOPHILUS	Validated trade name used	Oral
1070483325	167	Secondary Suspect Drug	LECITHIN	Validated trade name used	Unknown
1070483325	168	Secondary Suspect Drug	NASONEX	Validated trade name used	Intravenous (not otherwise specified)
1070483325	169	Secondary Suspect Drug	SENNOSIDES A AND B	Validated trade name used	Unknown
1070483325	170	Secondary Suspect Drug	DOCUSATE SODIUM\SENNOSIDES A AND B	Validated trade name used	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>
1070483325	171	Secondary Suspect Drug	.ALPHA.-TOCOPHEROL, D-	Validated trade name used	Oral
1070483325	172	Secondary Suspect Drug	GUAIFENESIN\SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used	Unknown
1070483325	173	Secondary Suspect Drug	BIFIDOBACTERIUM LONGUM	Validated trade name used	Unknown
1070483325	174	Secondary Suspect Drug	CHOLECALCIFEROL	Validated trade name used	Unknown
1070483325	175	Secondary Suspect Drug	CHOLECALCIFEROL	Validated trade name used	Unknown
1070483325	176	Secondary Suspect Drug	CREATINE	Validated trade name used	Unknown
1070483325	177	Secondary Suspect Drug	FRUCTOSE	Validated trade name used	Unknown
1070483325	178	Secondary Suspect Drug	.ALPHA.-TOCOPHEROL ACETATE, D-EVENING PRIMROSE OIL\FISH OIL	Validated trade name used	Unknown
1070483325	179	Secondary Suspect Drug	VITAMINS	Validated trade name used	Unknown
1070483325	180	Secondary Suspect Drug	MYCOPHENOLATE MOFETIL HYDROCHLORIDE	Validated trade name used	Unknown
1070483325	181	Secondary Suspect Drug	BIFIDOBACTERIUM BIFIDUM\LYSOZYME	Validated trade name used	Unknown
1070483325	182	Secondary Suspect Drug	INULIN	Validated trade name used	Unknown
1070483325	183	Secondary Suspect Drug	VITAMIN B1	Validated trade name used	Unknown
1070483325	184	Secondary Suspect Drug	HORSE CHESTNUT	Validated trade name used	Unknown
1070483325	185	Secondary Suspect Drug	LORATADINE\PSEUDOEPHEDRINE SULFATE	Validated trade name used	Unknown

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
400 international unit	Unknown				.
1000 international unit	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
UNK	Unknown				.
10 mg, UNK	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>
1070483325	186	Secondary Suspect Drug	VITAMIN B12	Validated trade name used
1070483325	187	Secondary Suspect Drug	SULFADIAZINE\TRIMETHOPRIM	Validated trade name used
1070483325	188	Secondary Suspect Drug	HYDROXOCOBALAMIN	Validated trade name used
1070483325	189	Secondary Suspect Drug	VACCINIA IMMUNE GLOBULIN HUMAN	Validated trade name used
1070483325	190	Secondary Suspect Drug	VITAMIN B1	Validated trade name used
1070483325	191	Secondary Suspect Drug	CYANOCOBALAMIN	Validated trade name used
1070483325	192	Secondary Suspect Drug	LACTOBACILLUS REUTERI	Validated trade name used
1070483325	193	Secondary Suspect Drug	LACTOBACILLUS REUTERI	Validated trade name used
1070483325	194	Secondary Suspect Drug	DOCUSATE SODIUM\SENNA LEAF	Validated trade name used
1070483325	195	Secondary Suspect Drug	CREATININE	Validated trade name used
1070483325	196	Secondary Suspect Drug	SODIUM CHLORIDE	Validated trade name used
1070483325	197	Secondary Suspect Drug	MAGNESIUM CARBONATE	Validated trade name used
1070483325	198	Secondary Suspect Drug	CALCIUM GLUCONATE	Validated trade name used
1070483325	199	Secondary Suspect Drug	DOCUSATE CALCIUM	Validated trade name used
1070483325	200	Secondary Suspect Drug	CALCIUM PANTOTHENATE	Validated trade name used
1070483325	201	Secondary Suspect Drug	SENNOSIDES A AND B	Validated trade name used
1070483325	202	Secondary Suspect Drug	LACTOBACILLUS CASEI	Validated trade name used
1070483325	203	Secondary Suspect Drug	DOCUSATE SODIUM\SENNOSIDES A AND B	Validated trade name used
1070483325	204	Secondary Suspect Drug	GAMMAGARD	Validated trade name used
1070483325	205	Secondary Suspect Drug	GAMMAGARD	Validated trade name used
1070483325	206	Secondary Suspect Drug	TETANUS IMMUNE GLOBULIN (HUMAN)	Validated trade name used
1070483325	207	Secondary Suspect Drug	SULFADIAZINE	Validated trade name used
1070483325	208	Secondary Suspect Drug	SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used
1070483325	209	Secondary Suspect Drug	SULFADIAZINE	Validated trade name used
1070483325	210	Secondary Suspect Drug	SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used
1070483325	211	Secondary Suspect Drug	SULFADIAZINE	Validated trade name used

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>	<i>Rechallenge code, indicating if reaction</i>	<i>Expiration date of the drug. (YYYYMMDD f</i>	<i>Lot number of the drug (as reported).</i>	<i>NDA number.</i>
Unknown	UNK	Unknown				.
Intravenous (not otherwise specified)	UNK	Unknown				.
Unknown	UNK	Unknown				.
Intravenous (not otherwise specified)	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	3 milliliter	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Unknown	UNK	Unknown				.
Intravenous (not otherwise specified)	UNK	Unknown				.
Unknown	UNK	Unknown				.
Oral	1 dosage form, qd	Unknown				.
Oral	60 milligram	Unknown				.
Oral	3 milligram, qd	Unknown				.
Oral	UNK	Unknown				.
Intravenous (not otherwise specified)	UNK	Unknown				.

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>
1070483325	212	Secondary Suspect Drug	CLOPRENALINE HYDROCHLORIDE	Validated trade name used
1070483325	213	Secondary Suspect Drug	BROMHEXINE\SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used
1070483325	214	Secondary Suspect Drug	POTASSIUM CHLORIDE\SODIUM CHLORIDE	Validated trade name used
1070483325	215	Secondary Suspect Drug	SULFADIAZINE\TETROXOPRIM	Validated trade name used
1070483325	216	Secondary Suspect Drug	SULFADIAZINE\TETROXOPRIM	Validated trade name used
1070483325	217	Secondary Suspect Drug	SULFADIAZINE\TETROXOPRIM	Validated trade name used
1070483325	218	Secondary Suspect Drug	SULFADIAZINE\TETROXOPRIM	Validated trade name used
1070483325	219	Secondary Suspect Drug	CREATINE	Validated trade name used
1070483325	220	Secondary Suspect Drug	ALENDRONIC ACID	Validated trade name used
1070483325	221	Secondary Suspect Drug	DULOXETINE HYDROCHLORIDE	Validated trade name used
1070483325	222	Secondary Suspect Drug	DULOXETINE HYDROCHLORIDE	Validated trade name used
1070483325	223	Secondary Suspect Drug	DULOXETINE HYDROCHLORIDE	Validated trade name used
1070483325	224	Secondary Suspect Drug	DULOXETINE HYDROCHLORIDE	Validated trade name used
1070483325	225	Secondary Suspect Drug	NORTRIPTYLINE	Validated trade name used
1070483325	226	Secondary Suspect Drug	HYDROMORPHONE HYDROCHLORIDE	Validated trade name used
1070483325	227	Secondary Suspect Drug	ASCORBIC ACID	Validated trade name used
1070483325	228	Secondary Suspect Drug	SULFAMETHOXAZOLE	Validated trade name used
1070483325	229	Secondary Suspect Drug	SENNOSIDES	Validated trade name used
1070483325	230	Secondary Suspect Drug	DOCUSATE SODIUM\SENNOSIDES A AND B	Validated trade name used
1070483325	231	Secondary Suspect Drug	IMODIUM	Validated trade name used
1070483325	232	Secondary Suspect Drug	MOMETASONE FUROATE	Validated trade name used
1070483325	233	Secondary Suspect Drug	HORSE CHESTNUT	Validated trade name used
1070483325	234	Secondary Suspect Drug	TETANUS IMMUNE GLOBULIN (HUMAN)	Validated trade name used
1070483325	235	Secondary Suspect Drug	NIACINAMIDE	Validated trade name used
1070483325	236	Secondary Suspect Drug	SULFADIAZINE	Validated trade name used
1070483325	237	Secondary Suspect Drug	VITAMIN E	Validated trade name used

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1070483325	238	Secondary Suspect Drug	ATLANTIC SALMON OIL	Validated trade name used	Unknown	UNK	Unknown
1070483325	239	Secondary Suspect Drug	ATLANTIC SALMON OIL	Validated trade name used	Oral	UNK	Unknown
1070483325	240	Secondary Suspect Drug	LACTOBACILLUS REUTERI	Validated trade name used	Unknown	UNK	Unknown
1070483325	241	Secondary Suspect Drug	CYMBALTA	Validated trade name used	Oral	3 milliliter, qd	Unknown
1070483325	242	Secondary Suspect Drug	CYMBALTA	Validated trade name used			Unknown
1070483325	243	Secondary Suspect Drug	PREDNISOLONE	Validated trade name used	Unknown	UNK	Unknown
1070483325	244	Secondary Suspect Drug	VITAMIN C	Validated trade name used	Oral	3 milliliter, qd	Unknown
1070483325	245	Secondary Suspect Drug	SULFAMETHOXAZOLE\TRIMETHOPRIM	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	246	Secondary Suspect Drug	BROMHEXINE HYDROCHLORIDE	Validated trade name used	Unknown	UNK	Unknown
1070483325	247	Secondary Suspect Drug	RETINOL	Validated trade name used	Intravenous (not otherwise specified)	600 milliequivalent	Unknown
1070483325	248	Secondary Suspect Drug	3-DEHYDRORETINOL	Validated trade name used	Oral	UNK	Unknown
1070483325	249	Secondary Suspect Drug	3-DEHYDRORETINOL	Validated trade name used	Unknown	UNK	Unknown
1070483325	250	Secondary Suspect Drug	3-DEHYDRORETINOL	Validated trade name used	Oral	1 dosage form, qd	Unknown
1070483325	251	Secondary Suspect Drug	3-DEHYDRORETINOL	Validated trade name used	Unknown	600 international unit	Unknown
1070483325	252	Secondary Suspect Drug	3-DEHYDRORETINOL	Validated trade name used	Oral	3 milligram	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1070483325	253	Secondary Suspect Drug	PROBIOTICS NOS	Validated trade name used	Unknown	UNK	Unknown
1070483325	254	Secondary Suspect Drug	PROBIOTICS NOS	Validated trade name used	Unknown	UNK	Unknown
1070483325	255	Secondary Suspect Drug	HUMAN IMMUNOGLOBULIN G	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	256	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Oral	3 dosage form, qd	Unknown
1070483325	257	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Oral	1 dosage form	Unknown
1070483325	258	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Oral	UNK	Unknown
1070483325	259	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Unknown	600 international unit	Unknown
1070483325	260	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Unknown	UNK	Unknown
1070483325	261	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Oral	1 dosage form, qd	Unknown
1070483325	262	Secondary Suspect Drug	VITAMIN A	Validated trade name used	Oral	3 milligram, qd	Unknown
1070483325	263	Secondary Suspect Drug	CHOLECALCIFEROL	Validated trade name used	Unknown	UNK	Unknown
1070483325	264	Secondary Suspect Drug	.ALPHA.-TOCOPHEROL	Validated trade name used	Unknown	UNK	Unknown
1070483325	265	Secondary Suspect Drug	BIFIDOBACTERIUM LONGUM	Validated trade name used	Unknown	UNK	Unknown
1070483325	266	Secondary Suspect Drug	DIETARY SUPPLEMENT\PROBIOTICS	Validated trade name used	Unknown	UNK	Unknown
1070483325	267	Secondary Suspect Drug	COBAMAMIDE	Validated trade name used	Unknown	UNK	Unknown

[illegible]

ADVERSE EVENT REPORTING SYSTEM (AERS)

Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1070483325	268	Secondary Suspect Drug	POTASSIUM CHLORIDE\SODIUM CHLORIDE	Validated trade name used	Intravenous (not otherwise specified)	UNK	Unknown
1070483325	269	Secondary Suspect Drug	NASONEX	Validated trade name used	Unknown	UNK	Unknown
1070483325	270	Concomitant	RANITIDINE	Validated trade name used	Unknown	UNK	Does not apply
1070483325	271	Concomitant	MAGNESIUM CITRATE	Validated trade name used	Unknown	UNK	Does not apply
107314353	1	Primary Suspect Drug	DEXMETHYLPHENIDATE HYDROCHLORIDE	Validated trade name used	Unknown	20 mg, in the morning	Does not apply
107314353	2	Interacting	DEXMETHYLPHENIDATE HYDROCHLORIDE	Validated trade name used	Unknown	5 mg, at noon	Does not apply
107314353	3	Interacting	GUANFACINE HYDROCHLORIDE	Validated trade name used	Unknown	3 mg, Every morning	Does not apply
107314353	4	Interacting	GUANFACINE HYDROCHLORIDE	Validated trade name used	Oral	5 mg at noon	Does not apply
107314353	5	Interacting	RISPERIDONE	Validated trade name used	Unknown	0.25 mg, in the evening	Does not apply
107316442	1	Primary Suspect Drug	FLUCONAZOLE	Validated trade name used	Unknown	3 DF, 1/week	Unknown
107316442	2	Interacting	FISH OIL	Validated trade name used	Unknown	8000 mg, Daily	Unknown
1074008517	1	Primary Suspect Drug	RITUXAN	Validated trade name used	Intravenous (not otherwise specified)	Day 1 and Day 15, 24/Jun/2016 (previous rituximab infusion)	
1074008517	2	Secondary Suspect Drug	RITUXAN	Validated trade name used	Intravenous (not otherwise specified)		
1074008517	3	Secondary Suspect Drug	RITUXAN	Validated trade name used	Intravenous (not otherwise specified)	500 mg once	
1074008517	4	Secondary Suspect Drug	RITUXAN	Validated trade name used	Intravenous (not otherwise specified)	500 mg once	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
			.
			.
			.
			.
		204266	
		204266	
		74796	
		74796	
		78269	
		.	.
		.	.
H06553,H0985,H0768,N3728,H0882,UNKN			103705
H06553,H0985,H0768,N3728,H0882,UNKN			103705
H06553,H0985,H0768,N3728,H0882,UNKN			103705
H06553,H0985,H0768,N3728,H0882,UNKN			103705

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

<i>Unique number for identifying a FAERS re</i>	<i>Unique number for identifying a drug for</i>	<i>Code for drug's reported role in event.</i>	<i>Name of medicinal product.</i>	<i>Code for source of DRUGNAME.</i>	<i>The route of drug administration</i>	<i>Verbatim text for dose, frequency, and r</i>	<i>Dechallenge code, indicating if reaction</i>
1074008517	5	Secondary Suspect Drug	RITUXAN	Validated trade name used	Intravenous (not otherwise specified)	day 1 and 15	
1074008517	6	Secondary Suspect Drug	BRICANYL	Validated trade name used	Unknown	As required	Unknown
1074008517	7	Concomitant	SYMBICORT	Validated trade name used	Unknown		
1074008517	8	Concomitant	ALBUTEROL	Validated trade name used	Unknown		
1074008517	9	Concomitant	ACETAMINOPHEN	Validated trade name used	Oral		
1074008517	10	Concomitant	ACETAMINOPHEN	Validated trade name used	Oral		
1074008517	11	Concomitant	SOLU-MEDROL	Validated trade name used	Intravenous (not otherwise specified)		
1074008517	12	Concomitant	SOLU-MEDROL	Validated trade name used	Intravenous (not otherwise specified)		
1074008517	13	Concomitant	METHOTREXATE	Validated trade name used	Oral		

ADVERSE EVENT REPORTING SYSTEM (AERS)
Drug Listings

Rechallenge code, indicating if reaction	Expiration date of the drug. (YYYYMMDD f	Lot number of the drug (as reported).	NDA number.
	H06553,H0985,H0768,N3728,H0882,UNKN		103705
UNKNOWN			.
UNKNOWN			.
UNKNOWN			.
			.
			.
			.
			.

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
100144838	Foetal exposure during pregnancy
100144838	Toxicity to various agents
100144838	Anaemia
1001678124	Dizziness
1001678124	Rash
1001678124	Anaemia
1001678124	Oedema peripheral
1001678124	Swelling
1001678124	Proctalgia
1001678124	Dyspepsia
1001678124	Weight decreased
1001678124	Haemorrhoidal haemorrhage
1001678124	Erythema
1001678124	Skin irritation
1001678124	Eye pruritus
1001678124	Pruritus
1001678124	Sensitisation
1001678124	Needle issue
1001678124	Paronychia
1001678124	Disturbance in attention
1001678124	Blood creatine increased
1001678124	Illness
1001678124	Nasopharyngitis
1001678124	Nausea
1001678124	Pain in extremity
1001678124	Nasal congestion
1001678124	Haemorrhoids
1001678124	Metastasis

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1001678124	Hypertension
1001678124	Scab
1001678124	Periorbital oedema
1001678124	Tendonitis
1001678124	Skin sensitisation
1001678124	Mass
1001678124	Cyst
1001678124	Acne
1001678124	Miliaria
1001678124	Fall
1001678124	Secretion discharge
1001678124	COVID-19
1001678124	Hypersensitivity
1001678124	Cellulitis
1001678124	Fatigue
1001678124	Tremor
1001678124	Oedema
1001678124	Cough
1001678124	Crying
1001678124	Induration
1001678124	Product use issue
1001678124	Anxiety
1001678124	Balance disorder
1001678124	Dry skin
1001678124	Rectal fissure
1001678124	Injection site haematoma
1001678124	Rosacea
1001678124	Vitamin B12 deficiency

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1001678124	Abdominal pain
1001678124	Pain
1001678124	Bone pain
1001678124	Urinary tract infection
1001678124	Injection site mass
1001678124	Hypoglycaemia
1001678124	Pneumonia
1001678124	Sputum discoloured
1001678124	Injection site pain
1001678124	Injection site pain
1001678124	Metastases to liver
1001678124	Ovarian cyst
1001678124	Rash
1001678124	Bronchitis
1001678124	Peripheral swelling
1001678124	Sinusitis
1001678124	Injection site hypersensitivity
1001678124	Arthralgia
1001678124	Headache
1001678124	Protein urine
1001678124	Localised infection
1001678124	Musculoskeletal pain
1001678124	Mobility decreased
1001678124	Blood pressure systolic increased
1001678124	Hypersomnia
1002130539	Infection
1002130539	Blood pressure increased
1002130539	Diarrhoea

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1002130539	Heart rate increased
1002130539	Blood glucose increased
1002130539	Product availability issue
1002130539	Dyspnoea
1002130539	Injection site haemorrhage
1002130539	Wrist fracture
1002130539	Nephrolithiasis
1002130539	Haemorrhage
1002130539	White blood cell count increased
1002130539	White blood cell count decreased
1002130539	Hypopituitarism
1002130539	Pulmonary embolism
1002130539	Injection site pain
1002130539	Pain
1002130539	Post procedural complication
100293662	Staphylococcal infection
100293662	Wound infection staphylococcal
100293662	Mycobacterium haemophilum infection
100293662	Toxicity to various agents
100356167	Cardiac arrest
100356167	Aortic dissection
100356167	Haemorrhage
100356167	Disseminated intravascular coagulation
100356167	Shock haemorrhagic
1006401878	Hyperhidrosis
1006401878	Loss of consciousness
1006401878	Haemorrhage
1006401878	Sinusitis

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1006401878	Blood pressure systolic increased
1006401878	Breast pain
1006401878	Pain in extremity
1006401878	Arthritis
1006401878	Abdominal discomfort
1006401878	Swelling
1006401878	Weight increased
1006401878	Musculoskeletal stiffness
1006401878	Blister
1006401878	Depression
1006401878	Heart rate decreased
1006401878	Blood pressure diastolic abnormal
1006401878	Chest discomfort
1006401878	Infusion related reaction
1006401878	Blood pressure diastolic increased
1006401878	Hypotension
1006401878	Abdominal pain upper
1006401878	Body temperature decreased
1006401878	Mobility decreased
1006401878	Malaise
1006401878	Blood pressure increased
1006401878	Gastroenteritis
1006401878	Product dispensing error
1006401878	Blood pressure systolic abnormal
1006401878	Nervousness
1006401878	Fatigue
1006401878	Hypertension
1006401878	Arthralgia

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

*Unique number for identifying a FAERS
re*

Preferred term to describe the event

1006401878	Back pain
1006401878	Weight decreased
1006401878	Respiratory rate increased
1006401878	Hypersomnia
1006401878	Oxygen saturation decreased
1006401878	Haematoma
1006401878	Osteoarthritis
1006401878	Dehydration
1006401878	Heart rate increased
1006401878	Neck pain
1006401878	Feeling hot
1006401878	Infection
1006401878	Nasopharyngitis
1006401878	Influenza
1007468610	Expiratory reserve volume decreased
1007468610	Weight decreased
1007468610	Wheezing
1007468610	Asthma
1007468610	Heart rate increased
1007468610	Total lung capacity decreased
1007468610	Middle insomnia
1007468610	Allergy test positive
1007468610	Forced expiratory volume decreased
1007468610	Dyspnoea
1007468610	Restrictive pulmonary disease
1007468610	Obstructive airways disorder
1007468610	Productive cough

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

*Unique number for identifying a FAERS
re*

Preferred term to describe the event

100764782	Maternal exposure during pregnancy
100764782	Abortion spontaneous
1008408132	Body temperature decreased
1008408132	White blood cell count increased
1008408132	Malaise
1008408132	Headache
1008408132	Fatigue
1008408132	Injection site haemorrhage
1008408132	Abdominal pain upper
1008408132	Abdominal pain
1008408132	Needle issue
1008408132	Limb injury
1008408132	Cough
1008408132	Arthralgia
1008408132	Blood pressure increased
1008408132	Nausea
1008408132	Blood glucose increased
1008408132	Malignant neoplasm progression
1008408132	Diarrhoea
1008408132	Nasal congestion
1008408132	Underdose
1008408132	Injection site pain
1008408132	Vomiting
1008408132	Weight increased
1008408132	Pruritus
1008408132	Hepatic enzyme increased
1008408132	Wrong technique in product usage process

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1008408132	Small intestine carcinoma
100941024	Maternal exposure during pregnancy
100941024	Abortion spontaneous
1009418019	Organ failure
1009418019	Knee arthroplasty
1009418019	Heart rate increased
1009418019	Drug ineffective
1009418019	Arthropathy
1009418019	Sepsis syndrome
1009418019	Weight decreased
1009418019	Musculoskeletal disorder
1009418019	Infection
1009418019	Nasopharyngitis
1009418019	Hypotension
1009418019	Herpes zoster
1009418019	Weight increased
1009418019	Haemophagocytic lymphohistiocytosis
1009418019	Drug hypersensitivity
1009418019	COVID-19
1009418019	Fall
1009418019	Arthritis infective
1014222251	Blood pressure systolic abnormal
1014222251	Weight increased
1014222251	Contusion
1014222251	Blood pressure increased
1014222251	Joint swelling
1014222251	Synovial cyst
1014222251	Pain

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1014222251	Blood pressure diastolic abnormal
1014222251	Dizziness
1014222251	Rheumatoid arthritis
1014222251	Asthenia
1014222251	Paraesthesia oral
1014222251	Headache
1014222251	Malaise
1014222251	Abdominal pain
1014222251	Loss of consciousness
1014222251	Seizure
1014222251	Arthralgia
1014222251	Peripheral swelling
1014222251	Fall
1014222251	Nystagmus
1014222251	Limb injury
1014222251	Head injury
1014222251	Infection
1014222251	Nausea
1014222251	Infusion related reaction
1014222251	Cerebrovascular accident
1014222251	Ill-defined disorder
1014222251	Loss of consciousness
1014222251	Blood pressure fluctuation
1014222251	Pneumonia
1014222251	Arthropathy
1014222251	Pulse absent
1014222251	Blood pressure diastolic decreased
1014222251	Oxygen saturation decreased

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1014222251	Road traffic accident
1014222251	Body temperature decreased
1014222251	Visual impairment
1014222251	Myalgia
1014222251	Dry mouth
1014222251	Fatigue
1014222251	Wound infection
1014222251	Blood pressure systolic increased
1014222251	Blood creatine phosphokinase increased
1014222251	Hypoaesthesia oral
1014222251	Somnolence
1014222251	Resuscitation
1014222251	Hypoaesthesia oral
1014222251	Pulmonary artery aneurysm
1014222251	Blood pressure diastolic increased
1014222251	Erythema
1014222251	Skin laceration
101451672	Diabetes mellitus
1015212331	Anaphylactic reaction
1015212331	Diarrhoea
1015212331	Middle insomnia
1015212331	Blood pressure increased
1015212331	Forced expiratory volume decreased
1015212331	Influenza
1015212331	Pneumonia
1015212331	Total lung capacity decreased
1015212331	Weight decreased
1015212331	Sensitivity to weather change

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1015212331	Malaise
1015212331	Nasopharyngitis
1015212331	Psoriatic arthropathy
1015212331	Anaphylactic reaction
1015212331	Oropharyngeal pain
1015212331	Cardiac failure congestive
1015212331	Weight increased
1015212331	Sinusitis
1015212331	Asthma
1015212331	Swelling
1015212331	Asthma
1015212331	Glomerular filtration rate decreased
1015212331	Pruritus
1015212331	Pain
1015212331	Product dose omission issue
1015212331	Obstructive airways disorder
1015212331	Swelling face
1015212331	Body mass index increased
1015212331	Pyrexia
1015212331	Blood urea decreased
1015212331	Body temperature decreased
1015212331	Respiratory disorder
1015212331	Arthralgia
1015212331	Drug hypersensitivity
1015212331	Obesity
1015212331	Reversible airways obstruction
101621574	Pneumonia
101621574	Gastrointestinal perforation

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1016611037	Weight increased
1016611037	Lymphadenitis
1016611037	Nasopharyngitis
1016611037	Cough
1016611037	Blood glucose decreased
1016611037	Anaphylactic shock
1016611037	Vocal cord dysfunction
1016611037	Lower respiratory tract infection
1016611037	Presyncope
1016611037	Dizziness
1016611037	Headache
1016611037	Concomitant disease aggravated
1016611037	Abdominal pain
1016611037	Dyspnoea
1016611037	Anaphylactic reaction
1016611037	Endometriosis
1016611037	Hypersensitivity
1016611037	Nausea
1016611037	Palpitations
1016611037	Malaise
1016611037	Blood immunoglobulin E increased
1016611037	Asthma
1016611037	Somnolence
1016611037	Abdominal pain upper
101676303	Delirium
101676313	Insomnia
101678657	Klebsiella sepsis

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1017130214	Arthropathy
1017130214	Influenza
1017130214	COVID-19
1017130214	Product dose omission in error
1017130214	Hip surgery
1017130214	Ear infection
1017130214	Infection
1017130214	Memory impairment
1017130214	Sinusitis
1017130214	Nasopharyngitis
1017130214	Illness
1017130214	Dysphonia
1017130214	Bronchitis
1017130214	Immune system disorder
1017572232	Pyrexia
1017572232	Blood pressure fluctuation
1017572232	Lung disorder
1017572232	Illness
1017572232	Pyrexia
1017572232	Body temperature increased
1017572232	Pain
1017572232	Blood pressure diastolic increased
1017572232	Ill-defined disorder
1017572232	Hepatic enzyme increased
1017572232	Neutrophil count increased
1017572232	Influenza
1017572232	Nasopharyngitis

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1017572232	Drug ineffective
1017572232	Malaise
1017572232	Hypertension
1017572232	Cough
1017572232	Fatigue
1017572232	Weight decreased
1017572232	Blood pressure increased
101780773	Retinal detachment
101916392	Extrapyramidal disorder
101916392	Inappropriate schedule of product administration
101916392	Somnolence
101916392	Hypothermia
1020642923	Upper respiratory tract congestion
1020642923	Pain in extremity
1020642923	Breath sounds abnormal
1020642923	Injection site swelling
1020642923	Wheezing
1020642923	Muscle injury
1020642923	Bronchitis
1020642923	Nasopharyngitis
1020642923	Skeletal injury
1020642923	Pain
1020642923	Oedema
1020642923	Food allergy
1020642923	Progesterone decreased
1020642923	Skin abrasion
1020642923	Gastrointestinal disorder

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1020642923	Erythema
1020642923	Wrong technique in product usage process
1020642923	Chest discomfort
1020642923	Gait disturbance
1020642923	Candida infection
1020642923	Oesophageal candidiasis
1020642923	Hypotension
1020642923	Urinary tract infection
1020642923	Body temperature decreased
1020642923	Limb injury
1020642923	Anxiety
1020642923	Scratch
1020642923	Upper respiratory tract infection
1020642923	Road traffic accident
1020642923	Rhonchi
1020642923	Gastroenteritis viral
1020642923	Mouth injury
102371704	Oedema peripheral
102371704	Face oedema
102371704	Cardio-respiratory arrest
102371704	Drug intolerance
102371704	Drug reaction with eosinophilia and systemic symptoms
102371704	Generalised tonic-clonic seizure
102371704	Lymphadenopathy
102371704	Status epilepticus
102371704	Aspartate aminotransferase increased
102371704	Pyrexia

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
102371704	Oedema peripheral
102371704	Alanine aminotransferase increased
102371704	Erythema
1027487983	Cough
1027487983	Rheumatoid lung
1027487983	Heart rate increased
1027487983	Haemoptysis
1027487983	Dyspnoea
1027487983	Arthralgia
1027487983	Influenza
1027487983	Umbilical hernia
1027487983	Gait disturbance
1027487983	Drug ineffective
1027487983	Road traffic accident
1027487983	Weight increased
1027487983	Blood pressure systolic increased
1027487983	Testicular mass
1027487983	Grip strength decreased
1027487983	Panic disorder
1027487983	Blood pressure increased
1027487983	Musculoskeletal stiffness
1027487983	Weight decreased
1027487983	Blood pressure diastolic abnormal
1027487983	Cataract
1027487983	Hypertension
1027487983	Oxygen saturation decreased
1027487983	Lower respiratory tract infection
1027487983	Nasopharyngitis

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1027487983	Rheumatoid arthritis
1027487983	Pneumonia
1028518546	Blood pressure increased
1028518546	Heart rate increased
1028518546	Blood pressure systolic increased
1028518546	Oedema peripheral
1028518546	Cough
1028518546	Blood pressure fluctuation
1028518546	Abdominal hernia
1028518546	Oxygen saturation decreased
1028518546	Bronchitis viral
1028518546	Wound
1028518546	Hernia
1028518546	Blood pressure diastolic decreased
1028518546	Blood pressure diastolic abnormal
1028518546	Oxygen saturation decreased
1028518546	Blood pressure increased
1028518546	Rheumatoid nodule
1028518546	Arthritis infective
1028518546	Pain in extremity
1028518546	Asthma
1028518546	Blood pressure systolic abnormal
1028518546	Nasopharyngitis
1028518546	Nodule
1028518546	Bursitis
1028518546	Ovarian fibroma
1028518546	Diverticulitis
1028518546	Pyrexia

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1028518546	Nasopharyngitis
1028518546	Respiratory rate increased
1028518546	Oedema
1028518546	Blood pressure diastolic increased
1030948614	Macular oedema
1030948614	Product use issue
1030948614	Haemorrhage
1030948614	Off label use
103443973	Deformity thorax
103443973	Metastases to bone
103443973	Osteomalacia
1035913611	Cataract
1035913611	Drug hypersensitivity
1035913611	Decreased activity
1035913611	Wheezing
1035913611	Pneumonia
1035913611	General physical health deterioration
1035913611	Fatigue
1035913611	Chest discomfort
1035913611	Dyspnoea
1035913611	Illness
1035913611	Gait disturbance
1035913611	Cough
1035913611	Asthmatic crisis
1035913611	Pain
103687216	General physical health deterioration
103749689	Diarrhoea

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
103749689	Flatulence
103749689	Asthenia
103749689	Diarrhoea
103749689	Dyspnoea
103749689	Sepsis
103749689	Stomatitis
103749689	Abdominal pain
103749689	Pyrexia
103892335	Acute hepatic failure
103892335	Jaundice
103892335	Hepatitis B
103892335	Hepatic encephalopathy
103928076	Depression
103928076	Abnormal weight gain
103928076	Off label use
103928076	Product use in unapproved indication
103928076	Abdominal discomfort
103928076	Gynaecomastia
103928076	Emotional disorder
103928375	Off label use
103928375	Hyperprolactinaemia
103928375	Product use in unapproved indication
103928375	Galactorrhoea
103928375	Abnormal weight gain
103928375	Gynaecomastia
103985405	Visual acuity reduced
103985405	Pain in extremity

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
103985405	Lymphocyte count decreased
103985405	Expanded disability status scale score increased
103985405	Nephrolithiasis
103985405	Visual impairment
103985405	Musculoskeletal stiffness
103985405	Fatigue
103985405	Eye pain
103985405	Drug intolerance
103985405	Headache
104003092	Epistaxis
104003092	Dementia
1040513313	Oropharyngeal pain
1040513313	Forced expiratory volume decreased
1040513313	Asthma
1040513313	Pyrexia
1040513313	Dyspnoea
1040513313	Fatigue
1040513313	Middle insomnia
1040513313	Obstructive airways disorder
1041491125	Anxiety
1041491125	Nausea
1041491125	Malignant neoplasm progression
1041491125	Product use complaint
1041491125	Kidney infection
1041491125	Palpitations
1041491125	Hypertension
1041491125	Herpes zoster

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1041491125	Incorrect dose administered
1041491125	Drug dose omission by device
1041491125	Injection site haemorrhage
1041491125	Carcinoid tumour
1041491125	Blood pressure systolic increased
1041491125	Blood pressure increased
1041491125	Syncope
1041491125	Rubber sensitivity
1041491125	Vertigo
1041491125	Dizziness
1041491125	Stress
1041491125	Hyperparathyroidism
1041491125	Vomiting
1041491125	Cystitis
1041491125	Blood pressure diastolic increased
1041491125	Body temperature decreased
1041491125	Injection site pain
104232052	Hyperprolactinaemia
104232052	Gynaecomastia
104232052	Abnormal weight gain
104232195	Gynaecomastia
104232195	Hyperglycaemia
104232195	Increased appetite
104232195	Hyperprolactinaemia
104232195	Galactorrhoea
104232195	Obesity
104232195	Extrapyrmidal disorder

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
104232203	Abnormal weight gain
104232203	Hyperprolactinaemia
104232203	Hyperglycaemia
104232203	Gynaecomastia
104266473	Obesity
104266473	Hyperprolactinaemia
104266473	Gynaecomastia
104490482	Completed suicide
104490482	Toxicity to various agents
104490482	Overdose
104490482	Death
104580772	Completed suicide
104580772	Overdose
104580883	Overdose
104580883	Completed suicide
104580883	Death
104635823	Appetite disorder
104635823	Gynaecomastia
104635823	Overweight
104635823	Hyperprolactinaemia
104635823	Off label use
104635823	Emotional disorder
104665748	Emotional distress
104665748	Diabetes mellitus
104665748	Weight increased
104665748	Gynaecomastia
104825157	Muscle spasms

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
104825157	Muscular weakness
104825157	Tremor
104825157	Diabetes mellitus
104825157	Limb discomfort
104825157	Myalgia
104825157	Limb discomfort
105144244	Inappropriate schedule of product administration
105144244	Product dose omission issue
105144244	Pituitary tumour benign
1051596718	Groin pain
1051596718	Blood pressure systolic increased
1051596718	Flushing
1051596718	Anxiety
1051596718	Back pain
1051596718	Lower respiratory tract infection
1051596718	Constipation
1051596718	Diarrhoea
1051596718	Blood pressure increased
1051596718	Arthralgia
1051596718	Sinusitis
1051596718	Arthralgia
1051596718	Flank pain
1051596718	Asthenia
1051596718	Abdominal pain lower
1051596718	Needle issue
1051596718	Hyperhidrosis
1051596718	Depression

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1051596718	Weight increased
1051596718	Limb mass
1051596718	Nausea
1051596718	Malaise
1051596718	Renal pain
1051596718	Incorrect dose administered by device
1051596718	Abdominal pain
1051596718	Gait disturbance
1051596718	Inappropriate schedule of product administration
1051596718	Fatigue
1051596718	Nasal polyps
1051596718	Musculoskeletal stiffness
1052690058	Contusion
1052690058	Weight decreased
1052690058	Off label use
1052690058	Neck pain
1052690058	Haemorrhage
1052690058	Blood pressure systolic abnormal
1052690058	Oropharyngeal pain
1052690058	Osteoarthritis
1052690058	Blood pressure diastolic abnormal
1052690058	Body temperature decreased
1052690058	Heart rate decreased
1052690058	Blood pressure increased
1052690058	Rheumatoid arthritis
1052690058	Localised infection
1052690058	Hypotension

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1052690058	Influenza
1052690058	Arthralgia
1052690058	Nasopharyngitis
1052690058	Weight increased
1052690058	Infusion related reaction
1052690058	Oxygen saturation decreased
1052690058	Blood pressure systolic increased
1052690058	Hernia
1052690058	Prostatic mass
1052690058	Prostate cancer
1054038738	Blood urine present
1054038738	Anuria
1054038738	Cardiac failure congestive
1054038738	Cardiomegaly
1054038738	Heart rate increased
1054038738	Blood growth hormone increased
1054038738	Blood pressure increased
1054038738	Muscle spasms
1054038738	Basal cell carcinoma
1054038738	Injection site haemorrhage
1054038738	COVID-19
1054038738	Cystitis
1054038738	Injection site mass
1054038738	Atrial fibrillation
1054038738	Seasonal affective disorder
1054038738	Palpitations
1054038738	Dysuria
1054038738	Insulin-like growth factor increased

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

*Unique number for identifying a FAERS
re*

Preferred term to describe the event

1054038738	Headache
1054038738	Heart rate irregular
1054038738	Cardiac failure acute
1054038738	Pain
1054038738	Constipation
1054038738	Device occlusion
1054038738	Musculoskeletal stiffness
1054038738	Micturition urgency
1054038738	Ventricular extrasystoles
1054038738	Prostatomegaly
1054038738	Tendon rupture
1054038738	Muscle tightness
105481232	Maternal exposure during pregnancy
105481232	Stillbirth
105524185	Weight increased
105741013	Phaeohyphomycosis
105741013	Abiotrophia defectiva endocarditis
105741013	Fungal disease carrier
105741013	Product use in unapproved indication
105741013	Pneumonia bacterial
105741013	Alternaria infection
1058928657	Urinary tract infection
1058928657	Pyrexia
1058928657	Rash
1058928657	Body temperature increased
1058928657	Choking
1058928657	Pruritus

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

*Unique number for identifying a FAERS
re*

Preferred term to describe the event

1058928657	Skin plaque
1058928657	Body temperature decreased
1058928657	Weight decreased
1058928657	Productive cough
1058928657	Osteoporosis
1058928657	Pneumonia
1058928657	Radius fracture
1058928657	Respiratory tract infection
1058928657	Tinnitus
1058928657	Abdominal pain
1058928657	Heart rate increased
1058928657	Swelling face
1058928657	Upper limb fracture
1058928657	Temperature intolerance
1058928657	Anxiety
1058928657	Oedema peripheral
1058928657	Ulna fracture
1058928657	Feeling abnormal
1058928657	Lower respiratory tract infection bacterial
1058928657	Injection site pain
1058928657	Hypoaesthesia
1058928657	Bronchitis
1058928657	Cellulitis
1058928657	Influenza
1058928657	Face oedema
1058928657	Arthralgia
1058928657	Vomiting

ADVERSE EVENT REPORTING SYSTEM (AERS)

Reaction Listings

*Unique number for identifying a FAERS
re*

Preferred term to describe the event

1058928657	Cough
1058928657	Wrong technique in product usage process
1058928657	Sleep disorder
1058928657	Osteoarthritis
1058928657	Vaccination site cellulitis
1058928657	Off label use
1058928657	Peripheral swelling
1058928657	Diverticulitis
1058928657	Throat irritation
1058928657	Dyspnoea
1058928657	Fatigue
1058928657	Myalgia
1058928657	Pneumovirus test positive
1058928657	Skin discolouration
1058928657	Sputum discoloured
1058928657	Haemoptysis
1058928657	Body temperature fluctuation
1058928657	Blood pressure systolic increased
1058928657	Bronchial obstruction
1058928657	Pneumonia
1058928657	Limb mass
1058928657	Asthenia
1058928657	Swelling
1058928657	Viral infection
1058928657	Pain
1058928657	Erythema
1058928657	Pain in extremity

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1058928657	Secretion discharge
105947013	Tachycardia
105947013	Hypotonia
105947013	Serotonin syndrome
105947013	Blood prolactin increased
105947013	Muscle rigidity
105947013	Unresponsive to stimuli
105947013	Suicidal behaviour
105947013	Respiratory depression
105947013	Hyperthermia
105947013	Hypoxia
105947013	Somnolence
105947013	Hyperhidrosis
105947013	Overdose
105947013	Miosis
105947013	Clonus
105947013	Status epilepticus
105947013	Autonomic nervous system imbalance
105947013	Mydriasis
1060157312	Infrequent bowel movements
1060157312	Single functional kidney
1060157312	Blood urine present
1060157312	Pneumonia
1060157312	Infection
1060157312	Urinary tract infection
1060157312	Abdominal pain
1060157312	Spinal pain

ADVERSE EVENT REPORTING SYSTEM (AERS) Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1060157312	Lip erythema
1060157312	Contusion
1060157312	Rash
1060157312	Death
1060157312	Constipation
1060157312	Skin atrophy
1060157312	Platelet count decreased
1060157312	Haemoglobin decreased
1060157312	Renal pain
1060157312	Cystitis
1060157312	Hypotension
1060157312	Nephrolithiasis
1060157312	Oral discomfort
106091663	Seizure
106091663	Metabolic encephalopathy
106091663	Stupor
106091663	Somnolence
106091663	Partial seizures
106091663	Acute hepatic failure
106091663	Disease progression
106091663	Death
106091663	Hepatic encephalopathy
106091663	Partial seizures with secondary generalisation
106091663	Hepatic failure
106091663	Drug intolerance
106091663	Drug ineffective
106091663	Anticonvulsant drug level below therapeutic

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
106091663	Mental status changes
106091663	Ammonia increased
106336646	Hyperprolactinaemia
106336646	Galactorrhoea
106336646	Emotional disorder
106336646	Gynaecomastia
106336646	Obesity
106352232	Hepatic failure
106352232	Partial seizures
106352232	Metabolic encephalopathy
106520463	Burning mouth syndrome
1069198853	Myalgia
1069198853	Chest discomfort
1069198853	Oedema peripheral
1069198853	Cataract
1069198853	Cough
1069198853	Myocardial infarction
1069198853	Productive cough
1069198853	Back pain
1069198853	Dyspnoea
1069198853	Blood pressure increased
1069198853	Pneumonia
1069198853	Influenza like illness
1069198853	Influenza
1069198853	Ear injury
1069198853	Contusion
1069198853	Nerve compression
1069198853	Injection site swelling

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1069198853	Intervertebral disc protrusion
1069198853	Nasal congestion
1069198853	Infection
1069198853	Nasopharyngitis
1069198853	Pulmonary function test decreased
1069198853	Asthma
1069198853	Headache
1069198853	Chills
1069198853	Pyrexia
1069198853	Weight decreased
1069198853	Hypoaesthesia
1069198853	Rhinorrhoea
1070483325	Off label use
1070483325	Somnolence
1070483325	Underdose
1070483325	Pneumonia aspiration
1070483325	Gastrooesophageal reflux disease
1070483325	Coma
1070483325	Incorrect route of product administration
107314353	Feeling cold
107314353	Drug interaction
107314353	Hypotension
107314353	Accidental overdose
107314353	Depressed level of consciousness
107314353	Sinus bradycardia
107314353	Fatigue
107314353	Hyperhidrosis
107316442	Food interaction

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
107316442	Insomnia
107316442	Sleep apnoea syndrome
107316442	Drug ineffective
1074008517	Drug ineffective
1074008517	Heart rate increased
1074008517	Musculoskeletal stiffness
1074008517	Infusion related reaction
1074008517	Tooth abscess
1074008517	Blood pressure increased
1074008517	Atrial fibrillation
1074008517	Emphysema
1074008517	Dyspnoea
1074008517	Smoke sensitivity
1074008517	Hypersensitivity
1074008517	Paraesthesia
1074008517	Diverticulitis
1074008517	Weight decreased
1074008517	Cardiac failure congestive
1074008517	Fungal infection
107408544	Ear discomfort
107408544	Nasopharyngitis
107408544	Product prescribing error
1074197911	Speech disorder
1074197911	Body height decreased
1074197911	Off label use
1074197911	Off label use
1074197911	Pain in extremity
1074197911	Tendon rupture

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1074197911	Drug hypersensitivity
107584123	Galactorrhoea
107584123	Abnormal weight gain
107584123	Gynaecomastia
107584123	Hyperprolactinaemia
1075880717	Feeling abnormal
1075880717	Pain
1075880717	Nasopharyngitis
1075880717	Nausea
1075880717	Feeling jittery
1075880717	Dizziness
1075880717	Vomiting
1075880717	Menopause
1075880717	Pyrexia
1075880717	Arthralgia
1075880717	Headache
1075880717	Therapeutic response unexpected
1075880717	Condition aggravated
1075880717	Palpitations
1075880717	Feeling abnormal
1075880717	Withdrawal syndrome
1075880717	Babesiosis
1075880717	Body height decreased
1075880717	Asthenia
1075880717	Malaise
1075880717	Back pain
1075880717	Anxiety
1075880717	Nervousness

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1075880717	Fall
1075880717	Fall
1075880717	Dizziness
1075880717	Hormone level abnormal
1078729218	Sneezing
1078729218	Malaise
1078729218	Abdominal pain upper
1078729218	Pollakiuria
1078729218	Forced expiratory volume decreased
1078729218	Asthma
1078729218	Blood pressure increased
1078729218	Bronchial hyperreactivity
1078729218	Respiratory rate increased
1078729218	Vital capacity decreased
1078729218	Rhinorrhoea
1078729218	Cough
1078729218	Lung disorder
1078729218	Influenza like illness
1078729218	Total lung capacity decreased
1078729218	Weight decreased
1078729218	Middle insomnia
1078729218	Headache
1078729218	Productive cough
1078729218	Wheezing
1078729218	Nasopharyngitis
1078729218	Obstructive airways disorder
1078729218	Dyspnoea
1078729218	Heart rate increased

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

<i>Unique number for identifying a FAERS re</i>	<i>Preferred term to describe the event</i>
1080136616	Lung disorder
1080136616	COVID-19
1080136616	Drug dependence
1080136616	Depression
1080136616	Decreased activity
1080136616	Oral fungal infection
1080136616	Pain
1080136616	Diplopia
1080136616	Ill-defined disorder
1080136616	Arthritis
1080136616	Viral infection
1080136616	Bone disorder
1080136616	Vomiting
1080136616	Pyrexia
1080136616	Off label use
1080136616	Uterine leiomyoma
1080136616	Hand deformity
1080136616	Bronchitis
1080136616	Ear infection
1080136616	Arthralgia
1080136616	Menopause
1080136616	Fatigue
1080136616	Diarrhoea
1080136616	Anxiety
1080136616	Thymoma
1080136616	Nausea
1080136616	Inflammation
1080136616	Myasthenia gravis

ADVERSE EVENT REPORTING SYSTEM (AERS)
Reaction Listings

Unique number for identifying a FAERS re		Preferred term to describe the event
1080136616	Drug intolerance	
108390175	Hypertensive heart disease	
108390175	Hypokalaemia	
108390175	Confusional state	
108390175	Dysarthria	
108390175	Blood urine present	
108390175	Myocardial ischaemia	
108390175	Gait disturbance	
108390175	Multifocal motor neuropathy	
108390175	Fatigue	

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
100144838	Other Serious (Important Medical Event)
1001678124	Other Serious (Important Medical Event)
1002130539	Hospitalization - Initial or Prolonged
1002130539	Other Serious (Important Medical Event)
100293662	Other Serious (Important Medical Event)
100356167	Life-Threatening
100356167	Hospitalization - Initial or Prolonged
100356167	Death
1006401878	Other Serious (Important Medical Event)
1006401878	Hospitalization - Initial or Prolonged
1007468610	Other Serious (Important Medical Event)
1007468610	Hospitalization - Initial or Prolonged
100764782	Other Serious (Important Medical Event)
1008408132	Hospitalization - Initial or Prolonged
1008408132	Other Serious (Important Medical Event)
100941024	Other Serious (Important Medical Event)
1009418019	Hospitalization - Initial or Prolonged
1009418019	Life-Threatening
1009418019	Other Serious (Important Medical Event)
1014222251	Hospitalization - Initial or Prolonged
1014222251	Other Serious (Important Medical Event)
101451672	Other Serious (Important Medical Event)
1015212331	Hospitalization - Initial or Prolonged
1015212331	Other Serious (Important Medical Event)
101621574	Death
101621574	Hospitalization - Initial or Prolonged
1016611037	Hospitalization - Initial or Prolonged
1016611037	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
101676303	Life-Threatening
101676303	Disability
101676303	Other Serious (Important Medical Event)
101676313	Disability
101676313	Life-Threatening
101678657	Death
101678657	Other Serious (Important Medical Event)
1017130214	Other Serious (Important Medical Event)
1017572232	Other Serious (Important Medical Event)
101780773	Other Serious (Important Medical Event)
101916392	Hospitalization - Initial or Prolonged
101916392	Life-Threatening
101916392	Other Serious (Important Medical Event)
1020642923	Other Serious (Important Medical Event)
102371704	Life-Threatening
102371704	Hospitalization - Initial or Prolonged
102371704	Other Serious (Important Medical Event)
1027487983	Hospitalization - Initial or Prolonged
1027487983	Other Serious (Important Medical Event)
1028518546	Hospitalization - Initial or Prolonged
1028518546	Other Serious (Important Medical Event)
1030948614	Other Serious (Important Medical Event)
103443973	Other Serious (Important Medical Event)
1035913611	Hospitalization - Initial or Prolonged
1035913611	Other Serious (Important Medical Event)
103687216	Death
103687216	Hospitalization - Initial or Prolonged
103749689	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
103749689	Hospitalization - Initial or Prolonged
103892335	Hospitalization - Initial or Prolonged
103985405	Other Serious (Important Medical Event)
104003092	Hospitalization - Initial or Prolonged
1040513313	Other Serious (Important Medical Event)
1041491125	Other Serious (Important Medical Event)
104232195	Other Serious (Important Medical Event)
104490482	Death
104490482	Other Serious (Important Medical Event)
104580772	Death
104580883	Death
104580883	Other Serious (Important Medical Event)
104665748	Other Serious (Important Medical Event)
104825157	Other Serious (Important Medical Event)
105144244	Other Serious (Important Medical Event)
1051596718	Hospitalization - Initial or Prolonged
1051596718	Other Serious (Important Medical Event)
1052690058	Other Serious (Important Medical Event)
1054038738	Hospitalization - Initial or Prolonged
1054038738	Other Serious (Important Medical Event)
105481232	Other Serious (Important Medical Event)
105741013	Other Serious (Important Medical Event)
1058928657	Hospitalization - Initial or Prolonged
1058928657	Other Serious (Important Medical Event)
105947013	Hospitalization - Initial or Prolonged
105947013	Life-Threatening
105947013	Other Serious (Important Medical Event)
1060157312	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1060157312	Death
1060157312	Other Serious (Important Medical Event)
106091663	Hospitalization - Initial or Prolonged
106091663	Death
106091663	Other Serious (Important Medical Event)
106336646	Other Serious (Important Medical Event)
106352232	Death
106352232	Other Serious (Important Medical Event)
1069198853	Hospitalization - Initial or Prolonged
1069198853	Other Serious (Important Medical Event)
1070483325	Hospitalization - Initial or Prolonged
1070483325	Other Serious (Important Medical Event)
107314353	Hospitalization - Initial or Prolonged
107314353	Other Serious (Important Medical Event)
107316442	Other Serious (Important Medical Event)
1074008517	Other Serious (Important Medical Event)
1074197911	Hospitalization - Initial or Prolonged
1074197911	Other Serious (Important Medical Event)
1075880717	Hospitalization - Initial or Prolonged
1078729218	Other Serious (Important Medical Event)
1080136616	Hospitalization - Initial or Prolonged
1080136616	Other Serious (Important Medical Event)
108390175	Death
108390175	Hospitalization - Initial or Prolonged
108390175	Other Serious (Important Medical Event)
108824172	Death
109031962	Hospitalization - Initial or Prolonged
109031962	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
109108923	Hospitalization - Initial or Prolonged
109108923	Other Serious (Important Medical Event)
109174139	Hospitalization - Initial or Prolonged
109174139	Other Serious (Important Medical Event)
1092018038	Other Serious (Important Medical Event)
109651512	Death
109651512	Other Serious (Important Medical Event)
109680288	Hospitalization - Initial or Prolonged
109680288	Other Serious (Important Medical Event)
1097587654	Hospitalization - Initial or Prolonged
1097587654	Other Serious (Important Medical Event)
1098206364	Other Serious (Important Medical Event)
109893399	Other Serious (Important Medical Event)
1099047564	Other Serious (Important Medical Event)
109922307	Death
109922307	Hospitalization - Initial or Prolonged
109922307	Other Serious (Important Medical Event)
109948122	Other Serious (Important Medical Event)
109971003	Other Serious (Important Medical Event)
1102019552	Other Serious (Important Medical Event)
1102109863	Other Serious (Important Medical Event)
1102109863	Hospitalization - Initial or Prolonged
110215902	Hospitalization - Initial or Prolonged
110215902	Death
1102411313	Other Serious (Important Medical Event)
110462235	Hospitalization - Initial or Prolonged
110462235	Other Serious (Important Medical Event)
110462235	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
110471852	Other Serious (Important Medical Event)
110471852	Hospitalization - Initial or Prolonged
110577006	Other Serious (Important Medical Event)
110734563	Hospitalization - Initial or Prolonged
110755913	Hospitalization - Initial or Prolonged
110755913	Death
110755913	Other Serious (Important Medical Event)
1107567522	Other Serious (Important Medical Event)
110781863	Other Serious (Important Medical Event)
1109083723	Hospitalization - Initial or Prolonged
1109083723	Other Serious (Important Medical Event)
110972475	Other Serious (Important Medical Event)
110995353	Death
110995353	Other Serious (Important Medical Event)
111012256	Other Serious (Important Medical Event)
111044465	Other Serious (Important Medical Event)
1112193211	Other Serious (Important Medical Event)
111425004	Hospitalization - Initial or Prolonged
111425004	Other Serious (Important Medical Event)
111430143	Hospitalization - Initial or Prolonged
111500224	Other Serious (Important Medical Event)
111513767	Hospitalization - Initial or Prolonged
111665733	Other Serious (Important Medical Event)
1117182022	Hospitalization - Initial or Prolonged
1117182022	Life-Threatening
1117182022	Other Serious (Important Medical Event)
111731695	Hospitalization - Initial or Prolonged
111731695	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
111755239	Disability
111755239	Hospitalization - Initial or Prolonged
111772814	Hospitalization - Initial or Prolonged
111772814	Life-Threatening
111772814	Other Serious (Important Medical Event)
111787964	Death
111787964	Other Serious (Important Medical Event)
1118598419	Hospitalization - Initial or Prolonged
1118598419	Other Serious (Important Medical Event)
111984347	Other Serious (Important Medical Event)
1119850317	Hospitalization - Initial or Prolonged
1119850317	Other Serious (Important Medical Event)
112024568	Other Serious (Important Medical Event)
1121274917	Hospitalization - Initial or Prolonged
1121274917	Other Serious (Important Medical Event)
1121749411	Hospitalization - Initial or Prolonged
112237713	Other Serious (Important Medical Event)
112281423	Death
112281423	Hospitalization - Initial or Prolonged
112305158	Other Serious (Important Medical Event)
112362434	Other Serious (Important Medical Event)
112534824	Other Serious (Important Medical Event)
1126655518	Hospitalization - Initial or Prolonged
1126655518	Other Serious (Important Medical Event)
112687622	Hospitalization - Initial or Prolonged
112877752	Hospitalization - Initial or Prolonged
112904962	Hospitalization - Initial or Prolonged
1129109810	Disability

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1129109810	Other Serious (Important Medical Event)
113024092	Hospitalization - Initial or Prolonged
113066405	Congenital Anomaly
113066405	Disability
113066405	Hospitalization - Initial or Prolonged
113066405	Other Serious (Important Medical Event)
1131105412	Life-Threatening
1131105412	Other Serious (Important Medical Event)
1131105412	Hospitalization - Initial or Prolonged
113146645	Hospitalization - Initial or Prolonged
113146645	Disability
113146645	Other Serious (Important Medical Event)
113155356	Other Serious (Important Medical Event)
113155356	Hospitalization - Initial or Prolonged
113257456	Other Serious (Important Medical Event)
1134491610	Other Serious (Important Medical Event)
1134491610	Hospitalization - Initial or Prolonged
113600164	Other Serious (Important Medical Event)
113625366	Hospitalization - Initial or Prolonged
113625366	Other Serious (Important Medical Event)
113625446	Hospitalization - Initial or Prolonged
113625446	Life-Threatening
113625446	Other Serious (Important Medical Event)
113662138	Disability
113662138	Hospitalization - Initial or Prolonged
113662138	Life-Threatening
113685715	Hospitalization - Initial or Prolonged
113755943	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1138286731	Congenital Anomaly
1138286731	Other Serious (Important Medical Event)
1138286731	Disability
1138286731	Hospitalization - Initial or Prolonged
113895298	Hospitalization - Initial or Prolonged
113895298	Other Serious (Important Medical Event)
1140884841	Other Serious (Important Medical Event)
114216053	Hospitalization - Initial or Prolonged
114216053	Other Serious (Important Medical Event)
1142723210	Hospitalization - Initial or Prolonged
1142723210	Other Serious (Important Medical Event)
114378733	Other Serious (Important Medical Event)
1144435333	Hospitalization - Initial or Prolonged
1144435333	Other Serious (Important Medical Event)
1144476723	Congenital Anomaly
1144476723	Death
1144476723	Disability
1144476723	Hospitalization - Initial or Prolonged
1144476723	Life-Threatening
1144476723	Other Serious (Important Medical Event)
114473694	Hospitalization - Initial or Prolonged
1145016915	Other Serious (Important Medical Event)
1145717522	Congenital Anomaly
1145717522	Disability
1145717522	Hospitalization - Initial or Prolonged
1145717522	Other Serious (Important Medical Event)
114731322	Other Serious (Important Medical Event)
114734765	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1147514547	Other Serious (Important Medical Event)
114756606	Other Serious (Important Medical Event)
114798209	Other Serious (Important Medical Event)
1148683512	Disability
1148683512	Other Serious (Important Medical Event)
1149087937	Disability
1149087937	Hospitalization - Initial or Prolonged
1149087937	Life-Threatening
1149087937	Other Serious (Important Medical Event)
114958534	Other Serious (Important Medical Event)
115140276	Other Serious (Important Medical Event)
1151574948	Disability
1151574948	Hospitalization - Initial or Prolonged
1151574948	Life-Threatening
1151574948	Other Serious (Important Medical Event)
115173833	Other Serious (Important Medical Event)
1151945678	Congenital Anomaly
1151945678	Death
1151945678	Other Serious (Important Medical Event)
1151945678	Life-Threatening
1151945678	Hospitalization - Initial or Prolonged
1151945678	Disability
115203716	Other Serious (Important Medical Event)
115203716	Hospitalization - Initial or Prolonged
1156227656	Hospitalization - Initial or Prolonged
1156227656	Other Serious (Important Medical Event)
115668012	Hospitalization - Initial or Prolonged
115668012	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
115732526	Other Serious (Important Medical Event)
115732526	Hospitalization - Initial or Prolonged
1157787013	Other Serious (Important Medical Event)
115800019	Other Serious (Important Medical Event)
1158070941	Disability
1158070941	Death
1158070941	Congenital Anomaly
1158070941	Hospitalization - Initial or Prolonged
1158070941	Other Serious (Important Medical Event)
1158070941	Life-Threatening
115863238	Other Serious (Important Medical Event)
115900453	Hospitalization - Initial or Prolonged
115907586	Other Serious (Important Medical Event)
115925813	Hospitalization - Initial or Prolonged
115925813	Death
115925813	Life-Threatening
1161812071	Other Serious (Important Medical Event)
1161812071	Hospitalization - Initial or Prolonged
116289952	Other Serious (Important Medical Event)
116313907	Other Serious (Important Medical Event)
1163175032	Hospitalization - Initial or Prolonged
1163175032	Other Serious (Important Medical Event)
116502727	Other Serious (Important Medical Event)
116530282	Other Serious (Important Medical Event)
116530282	Hospitalization - Initial or Prolonged
116533853	Other Serious (Important Medical Event)
116545458	Other Serious (Important Medical Event)
116545458	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1166352379	Other Serious (Important Medical Event)
116787914	Other Serious (Important Medical Event)
1168672145	Other Serious (Important Medical Event)
1168789257	Other Serious (Important Medical Event)
1168789257	Hospitalization - Initial or Prolonged
1169217617	Other Serious (Important Medical Event)
116951916	Hospitalization - Initial or Prolonged
116951916	Other Serious (Important Medical Event)
1169665434	Other Serious (Important Medical Event)
1169665434	Hospitalization - Initial or Prolonged
117037909	Disability
117037909	Hospitalization - Initial or Prolonged
117037909	Other Serious (Important Medical Event)
117194573	Other Serious (Important Medical Event)
1174511318	Hospitalization - Initial or Prolonged
1174511318	Other Serious (Important Medical Event)
117720064	Other Serious (Important Medical Event)
117760955	Other Serious (Important Medical Event)
117761484	Other Serious (Important Medical Event)
1178230313	Hospitalization - Initial or Prolonged
1178453618	Other Serious (Important Medical Event)
117876845	Other Serious (Important Medical Event)
1178812814	Hospitalization - Initial or Prolonged
1178812814	Other Serious (Important Medical Event)
1179178614	Other Serious (Important Medical Event)
118134552	Hospitalization - Initial or Prolonged
118134552	Other Serious (Important Medical Event)
118168512	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
118171395	Other Serious (Important Medical Event)
118197754	Other Serious (Important Medical Event)
118278119	Other Serious (Important Medical Event)
118278119	Hospitalization - Initial or Prolonged
118406256	Hospitalization - Initial or Prolonged
118406256	Other Serious (Important Medical Event)
118406345	Other Serious (Important Medical Event)
118406345	Hospitalization - Initial or Prolonged
118490297	Other Serious (Important Medical Event)
1185945712	Other Serious (Important Medical Event)
1185945712	Hospitalization - Initial or Prolonged
118666423	Hospitalization - Initial or Prolonged
118666423	Other Serious (Important Medical Event)
118688722	Other Serious (Important Medical Event)
118688732	Other Serious (Important Medical Event)
118689052	Other Serious (Important Medical Event)
118689122	Other Serious (Important Medical Event)
118689132	Other Serious (Important Medical Event)
118689152	Other Serious (Important Medical Event)
118689222	Death
118689222	Other Serious (Important Medical Event)
118689722	Other Serious (Important Medical Event)
118689842	Other Serious (Important Medical Event)
118689852	Other Serious (Important Medical Event)
118689862	Other Serious (Important Medical Event)
118689872	Other Serious (Important Medical Event)
118689952	Other Serious (Important Medical Event)
118712772	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
118713032	Death
118745404	Other Serious (Important Medical Event)
118745404	Hospitalization - Initial or Prolonged
118806382	Other Serious (Important Medical Event)
1189796319	Hospitalization - Initial or Prolonged
1189796319	Other Serious (Important Medical Event)
119104223	Hospitalization - Initial or Prolonged
119219533	Hospitalization - Initial or Prolonged
119219533	Other Serious (Important Medical Event)
119270783	Other Serious (Important Medical Event)
1192728610	Hospitalization - Initial or Prolonged
1192728610	Other Serious (Important Medical Event)
119326774	Hospitalization - Initial or Prolonged
1193375735	Hospitalization - Initial or Prolonged
1193375735	Other Serious (Important Medical Event)
119338255	Hospitalization - Initial or Prolonged
119338255	Other Serious (Important Medical Event)
1193535523	Hospitalization - Initial or Prolonged
1193535523	Other Serious (Important Medical Event)
1193793115	Hospitalization - Initial or Prolonged
1193793115	Other Serious (Important Medical Event)
119478563	Death
119478563	Other Serious (Important Medical Event)
1196876534	Other Serious (Important Medical Event)
119875983	Other Serious (Important Medical Event)
120093639	Hospitalization - Initial or Prolonged
120093639	Other Serious (Important Medical Event)
1204027949	Disability

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1204027949	Hospitalization - Initial or Prolonged
1204027949	Other Serious (Important Medical Event)
120668283	Other Serious (Important Medical Event)
120740156	Hospitalization - Initial or Prolonged
120751903	Hospitalization - Initial or Prolonged
120751903	Other Serious (Important Medical Event)
120779963	Life-Threatening
1207853043	Hospitalization - Initial or Prolonged
1207853043	Other Serious (Important Medical Event)
120813973	Hospitalization - Initial or Prolonged
1208222832	Hospitalization - Initial or Prolonged
1208222832	Other Serious (Important Medical Event)
1209904323	Hospitalization - Initial or Prolonged
1209904323	Other Serious (Important Medical Event)
121031125	Death
121031125	Hospitalization - Initial or Prolonged
121031125	Other Serious (Important Medical Event)
1210599713	Hospitalization - Initial or Prolonged
1210599713	Other Serious (Important Medical Event)
121083429	Hospitalization - Initial or Prolonged
121090126	Other Serious (Important Medical Event)
1211671714	Death
1211671714	Hospitalization - Initial or Prolonged
1211671714	Other Serious (Important Medical Event)
121178303	Other Serious (Important Medical Event)
1212230540	Hospitalization - Initial or Prolonged
1212230540	Other Serious (Important Medical Event)
121225423	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1213390067	Hospitalization - Initial or Prolonged
1213390067	Other Serious (Important Medical Event)
121344112	Hospitalization - Initial or Prolonged
121344172	Hospitalization - Initial or Prolonged
121344383	Hospitalization - Initial or Prolonged
121345362	Hospitalization - Initial or Prolonged
121345362	Other Serious (Important Medical Event)
121345672	Hospitalization - Initial or Prolonged
121349972	Hospitalization - Initial or Prolonged
121349972	Other Serious (Important Medical Event)
121350152	Hospitalization - Initial or Prolonged
121350152	Other Serious (Important Medical Event)
121350502	Hospitalization - Initial or Prolonged
121350502	Other Serious (Important Medical Event)
121351362	Other Serious (Important Medical Event)
121351362	Hospitalization - Initial or Prolonged
121351453	Hospitalization - Initial or Prolonged
121351453	Other Serious (Important Medical Event)
121351482	Hospitalization - Initial or Prolonged
121351482	Other Serious (Important Medical Event)
121351512	Hospitalization - Initial or Prolonged
121351512	Other Serious (Important Medical Event)
1213893320	Other Serious (Important Medical Event)
121389514	Other Serious (Important Medical Event)
1213946925	Other Serious (Important Medical Event)
121400216	Life-Threatening
121400216	Hospitalization - Initial or Prolonged
121400216	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
121614898	Hospitalization - Initial or Prolonged
121684513	Hospitalization - Initial or Prolonged
121684513	Other Serious (Important Medical Event)
121851406	Other Serious (Important Medical Event)
1218588315	Hospitalization - Initial or Prolonged
1218588315	Death
1218588315	Life-Threatening
1218588315	Other Serious (Important Medical Event)
1219006311	Other Serious (Important Medical Event)
1219366031	Other Serious (Important Medical Event)
121944728	Hospitalization - Initial or Prolonged
121944728	Life-Threatening
121944728	Other Serious (Important Medical Event)
122095957	Other Serious (Important Medical Event)
1220965353	Other Serious (Important Medical Event)
122104123	Life-Threatening
122104123	Other Serious (Important Medical Event)
122200518	Other Serious (Important Medical Event)
122200518	Hospitalization - Initial or Prolonged
1223166310	Other Serious (Important Medical Event)
1223166310	Hospitalization - Initial or Prolonged
1224068929	Other Serious (Important Medical Event)
1224068929	Hospitalization - Initial or Prolonged
122443472	Other Serious (Important Medical Event)
1224849317	Other Serious (Important Medical Event)
1224849317	Hospitalization - Initial or Prolonged
122512633	Other Serious (Important Medical Event)
122512633	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
122550212	Other Serious (Important Medical Event)
122656474	Hospitalization - Initial or Prolonged
122657802	Other Serious (Important Medical Event)
122657802	Hospitalization - Initial or Prolonged
1226963211	Other Serious (Important Medical Event)
122815454	Other Serious (Important Medical Event)
122844006	Hospitalization - Initial or Prolonged
122844006	Other Serious (Important Medical Event)
1229068117	Other Serious (Important Medical Event)
1229378940	Hospitalization - Initial or Prolonged
1229378940	Other Serious (Important Medical Event)
122975224	Hospitalization - Initial or Prolonged
122975224	Other Serious (Important Medical Event)
1230227453	Other Serious (Important Medical Event)
1230227453	Hospitalization - Initial or Prolonged
1230456626	Hospitalization - Initial or Prolonged
1230456626	Other Serious (Important Medical Event)
1230619217	Hospitalization - Initial or Prolonged
1230619217	Other Serious (Important Medical Event)
123066303	Life-Threatening
123066314	Other Serious (Important Medical Event)
123066314	Death
123090303	Death
123090423	Death
123097115	Hospitalization - Initial or Prolonged
123098207	Other Serious (Important Medical Event)
123098207	Disability
123098207	Death

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
123098207	Congenital Anomaly
123119083	Death
123119133	Death
123119193	Death
123119243	Life-Threatening
123119253	Death
123119263	Life-Threatening
123119286	Death
123119353	Death
123119363	Life-Threatening
123119443	Death
123120013	Death
123121313	Death
123333823	Other Serious (Important Medical Event)
123430863	Other Serious (Important Medical Event)
123430863	Hospitalization - Initial or Prolonged
123430863	Life-Threatening
1234722916	Other Serious (Important Medical Event)
1234722916	Hospitalization - Initial or Prolonged
123507647	Other Serious (Important Medical Event)
123507647	Hospitalization - Initial or Prolonged
123507647	Life-Threatening
1235162812	Other Serious (Important Medical Event)
1235162812	Disability
1235162812	Death
1235162812	Hospitalization - Initial or Prolonged
123563352	Other Serious (Important Medical Event)
1235836630	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
123602163	Other Serious (Important Medical Event)
123602163	Hospitalization - Initial or Prolonged
123673573	Other Serious (Important Medical Event)
123712795	Hospitalization - Initial or Prolonged
123712795	Other Serious (Important Medical Event)
1237277237	Other Serious (Important Medical Event)
1237277237	Death
123828053	Hospitalization - Initial or Prolonged
123828053	Other Serious (Important Medical Event)
123865169	Other Serious (Important Medical Event)
1238769515	Other Serious (Important Medical Event)
123883414	Hospitalization - Initial or Prolonged
1239199829	Other Serious (Important Medical Event)
1239199829	Hospitalization - Initial or Prolonged
123928902	Other Serious (Important Medical Event)
124058976	Hospitalization - Initial or Prolonged
124058976	Other Serious (Important Medical Event)
1241345017	Life-Threatening
1241345017	Hospitalization - Initial or Prolonged
1241345017	Disability
1241345017	Other Serious (Important Medical Event)
1241683811	Hospitalization - Initial or Prolonged
1241683811	Life-Threatening
1241683811	Other Serious (Important Medical Event)
1241759015	Hospitalization - Initial or Prolonged
1241759015	Other Serious (Important Medical Event)
124193252	Other Serious (Important Medical Event)
1242381216	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1242381216	Other Serious (Important Medical Event)
1242661017	Other Serious (Important Medical Event)
124267893	Other Serious (Important Medical Event)
1243188715	Other Serious (Important Medical Event)
1244105814	Other Serious (Important Medical Event)
1244109913	Hospitalization - Initial or Prolonged
1244109913	Other Serious (Important Medical Event)
124519574	Other Serious (Important Medical Event)
124557465	Hospitalization - Initial or Prolonged
124557465	Life-Threatening
124557465	Other Serious (Important Medical Event)
124576196	Hospitalization - Initial or Prolonged
124576196	Other Serious (Important Medical Event)
124647052	Other Serious (Important Medical Event)
124656152	Hospitalization - Initial or Prolonged
124656152	Other Serious (Important Medical Event)
124658184	Hospitalization - Initial or Prolonged
124658184	Life-Threatening
124658184	Other Serious (Important Medical Event)
1246649231	Hospitalization - Initial or Prolonged
1246649231	Other Serious (Important Medical Event)
124697266	Other Serious (Important Medical Event)
124729263	Other Serious (Important Medical Event)
1248414317	Other Serious (Important Medical Event)
1248745116	Other Serious (Important Medical Event)
1248777719	Other Serious (Important Medical Event)
124879704	Hospitalization - Initial or Prolonged
124879704	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
125035915	Hospitalization - Initial or Prolonged
1251723528	Other Serious (Important Medical Event)
1251723528	Hospitalization - Initial or Prolonged
1251759434	Hospitalization - Initial or Prolonged
1251759434	Other Serious (Important Medical Event)
125236397	Hospitalization - Initial or Prolonged
125236397	Other Serious (Important Medical Event)
1252758731	Hospitalization - Initial or Prolonged
1252758731	Other Serious (Important Medical Event)
125285222	Hospitalization - Initial or Prolonged
125285222	Other Serious (Important Medical Event)
125316252	Other Serious (Important Medical Event)
1253212410	Other Serious (Important Medical Event)
1253212410	Hospitalization - Initial or Prolonged
1253507817	Other Serious (Important Medical Event)
125419252	Other Serious (Important Medical Event)
1254806012	Other Serious (Important Medical Event)
125511353	Other Serious (Important Medical Event)
125511353	Hospitalization - Initial or Prolonged
125511353	Life-Threatening
125520368	Other Serious (Important Medical Event)
125520368	Hospitalization - Initial or Prolonged
125529493	Hospitalization - Initial or Prolonged
125529493	Other Serious (Important Medical Event)
125579484	Other Serious (Important Medical Event)
125595734	Other Serious (Important Medical Event)
125609252	Other Serious (Important Medical Event)
125619276	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1256504624	Other Serious (Important Medical Event)
1258205211	Other Serious (Important Medical Event)
1258205211	Hospitalization - Initial or Prolonged
1258253825	Other Serious (Important Medical Event)
1258700623	Life-Threatening
1258700623	Other Serious (Important Medical Event)
1258700623	Hospitalization - Initial or Prolonged
1259605217	Other Serious (Important Medical Event)
125972513	Hospitalization - Initial or Prolonged
125972513	Other Serious (Important Medical Event)
126018092	Hospitalization - Initial or Prolonged
126018092	Other Serious (Important Medical Event)
126027722	Death
126052728	Hospitalization - Initial or Prolonged
126052728	Other Serious (Important Medical Event)
126083683	Other Serious (Important Medical Event)
126083763	Other Serious (Important Medical Event)
126102746	Other Serious (Important Medical Event)
1261220638	Other Serious (Important Medical Event)
1261220638	Disability
126144642	Hospitalization - Initial or Prolonged
126144642	Other Serious (Important Medical Event)
1261461519	Hospitalization - Initial or Prolonged
1261461519	Other Serious (Important Medical Event)
126146323	Other Serious (Important Medical Event)
1262188810	Hospitalization - Initial or Prolonged
1262194015	Hospitalization - Initial or Prolonged
1262194015	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1262399912	Hospitalization - Initial or Prolonged
126300813	Death
126300813	Other Serious (Important Medical Event)
126446453	Other Serious (Important Medical Event)
1264583518	Hospitalization - Initial or Prolonged
1264583518	Other Serious (Important Medical Event)
1264862010	Other Serious (Important Medical Event)
1264877314	Hospitalization - Initial or Prolonged
1264877314	Other Serious (Important Medical Event)
126510864	Other Serious (Important Medical Event)
1265259319	Hospitalization - Initial or Prolonged
1265259319	Other Serious (Important Medical Event)
126525949	Hospitalization - Initial or Prolonged
126525949	Other Serious (Important Medical Event)
126566772	Death
126566772	Other Serious (Important Medical Event)
1265982714	Hospitalization - Initial or Prolonged
126599422	Other Serious (Important Medical Event)
126629514	Hospitalization - Initial or Prolonged
126629514	Other Serious (Important Medical Event)
126636233	Death
126636233	Other Serious (Important Medical Event)
126661713	Other Serious (Important Medical Event)
126666384	Death
126666384	Other Serious (Important Medical Event)
1266682834	Hospitalization - Initial or Prolonged
1266682834	Life-Threatening
1266682834	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
126694216	Other Serious (Important Medical Event)
1267143810	Other Serious (Important Medical Event)
1267308830	Hospitalization - Initial or Prolonged
1267308830	Other Serious (Important Medical Event)
1267604333	Disability
1267604333	Hospitalization - Initial or Prolonged
1267604333	Life-Threatening
1267604333	Other Serious (Important Medical Event)
126784766	Other Serious (Important Medical Event)
1267970510	Other Serious (Important Medical Event)
1268469220	Other Serious (Important Medical Event)
1268469220	Hospitalization - Initial or Prolonged
126849622	Life-Threatening
126865539	Hospitalization - Initial or Prolonged
126865539	Other Serious (Important Medical Event)
126908303	Hospitalization - Initial or Prolonged
126908303	Other Serious (Important Medical Event)
126915713	Other Serious (Important Medical Event)
126946204	Hospitalization - Initial or Prolonged
126946204	Other Serious (Important Medical Event)
1269688715	Congenital Anomaly
1269688715	Disability
1269688715	Hospitalization - Initial or Prolonged
1269688715	Other Serious (Important Medical Event)
1270466920	Hospitalization - Initial or Prolonged
1270466920	Other Serious (Important Medical Event)
127133207	Hospitalization - Initial or Prolonged
127133207	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)
Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1271450712	Hospitalization - Initial or Prolonged
1271617516	Other Serious (Important Medical Event)
1271619614	Hospitalization - Initial or Prolonged
1271619614	Other Serious (Important Medical Event)
1272747538	Hospitalization - Initial or Prolonged
1272747538	Other Serious (Important Medical Event)
127335812	Death
1273672134	Death
1273672134	Hospitalization - Initial or Prolonged
1273672134	Other Serious (Important Medical Event)
127442575	Hospitalization - Initial or Prolonged
127442575	Other Serious (Important Medical Event)
127476922	Other Serious (Important Medical Event)
1276662113	Other Serious (Important Medical Event)
1276746115	Other Serious (Important Medical Event)
127688913	Other Serious (Important Medical Event)
127739882	Hospitalization - Initial or Prolonged
127739882	Other Serious (Important Medical Event)
127769588	Other Serious (Important Medical Event)
127795064	Death
127795064	Hospitalization - Initial or Prolonged
127795064	Other Serious (Important Medical Event)
1278946016	Hospitalization - Initial or Prolonged
1278946016	Other Serious (Important Medical Event)
1279005821	Other Serious (Important Medical Event)
127908472	Other Serious (Important Medical Event)
127919063	Hospitalization - Initial or Prolonged
127919063	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
127923264	Other Serious (Important Medical Event)
127925774	Other Serious (Important Medical Event)
127928484	Other Serious (Important Medical Event)
127970915	Other Serious (Important Medical Event)
128111456	Other Serious (Important Medical Event)
128125275	Hospitalization - Initial or Prolonged
128125275	Disability
1281285321	Hospitalization - Initial or Prolonged
1281285321	Disability
1281285321	Other Serious (Important Medical Event)
1282456425	Other Serious (Important Medical Event)
1282456425	Disability
128337604	Other Serious (Important Medical Event)
1283816224	Other Serious (Important Medical Event)
1283816224	Hospitalization - Initial or Prolonged
1284001415	Other Serious (Important Medical Event)
1284111422	Hospitalization - Initial or Prolonged
1284111422	Other Serious (Important Medical Event)
128418645	Hospitalization - Initial or Prolonged
128418645	Other Serious (Important Medical Event)
128428173	Death
128428173	Other Serious (Important Medical Event)
128452458	Other Serious (Important Medical Event)
128452458	Hospitalization - Initial or Prolonged
128455702	Other Serious (Important Medical Event)
128533274	Other Serious (Important Medical Event)
1285374010	Other Serious (Important Medical Event)
1285374010	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
128607137	Death
128607137	Hospitalization - Initial or Prolonged
128713873	Other Serious (Important Medical Event)
128759653	Other Serious (Important Medical Event)
128796683	Death
128796683	Hospitalization - Initial or Prolonged
128813852	Other Serious (Important Medical Event)
128815644	Other Serious (Important Medical Event)
128830863	Hospitalization - Initial or Prolonged
128835772	Other Serious (Important Medical Event)
1288783427	Other Serious (Important Medical Event)
1288783427	Hospitalization - Initial or Prolonged
128896804	Hospitalization - Initial or Prolonged
128906342	Other Serious (Important Medical Event)
129175148	Other Serious (Important Medical Event)
1292916520	Hospitalization - Initial or Prolonged
1292916520	Other Serious (Important Medical Event)
129309562	Other Serious (Important Medical Event)
129381218	Death
129381218	Other Serious (Important Medical Event)
1294339813	Hospitalization - Initial or Prolonged
1294339813	Other Serious (Important Medical Event)
1294445310	Other Serious (Important Medical Event)
1294587413	Hospitalization - Initial or Prolonged
1294587413	Disability
1294587413	Other Serious (Important Medical Event)
1294608711	Other Serious (Important Medical Event)
129482007	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
129534697	Hospitalization - Initial or Prolonged
129534697	Other Serious (Important Medical Event)
1295393127	Disability
1295393127	Life-Threatening
1295393127	Other Serious (Important Medical Event)
1295753119	Death
1295753119	Hospitalization - Initial or Prolonged
1295753119	Other Serious (Important Medical Event)
1295809811	Hospitalization - Initial or Prolonged
1295809811	Other Serious (Important Medical Event)
129640184	Other Serious (Important Medical Event)
129661094	Other Serious (Important Medical Event)
129710933	Other Serious (Important Medical Event)
129756816	Hospitalization - Initial or Prolonged
129756816	Other Serious (Important Medical Event)
129758429	Hospitalization - Initial or Prolonged
129797152	Hospitalization - Initial or Prolonged
129797152	Other Serious (Important Medical Event)
1298165819	Other Serious (Important Medical Event)
1298245917	Disability
1298245917	Hospitalization - Initial or Prolonged
1298245917	Other Serious (Important Medical Event)
129832442	Death
129832442	Other Serious (Important Medical Event)
129832442	Hospitalization - Initial or Prolonged
129879489	Hospitalization - Initial or Prolonged
129879489	Other Serious (Important Medical Event)
129887515	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
129895932	Hospitalization - Initial or Prolonged
129913302	Hospitalization - Initial or Prolonged
129913302	Other Serious (Important Medical Event)
129929712	Other Serious (Important Medical Event)
1299455329	Other Serious (Important Medical Event)
129969329	Hospitalization - Initial or Prolonged
129969329	Other Serious (Important Medical Event)
1300378736	Hospitalization - Initial or Prolonged
130099107	Other Serious (Important Medical Event)
130099107	Hospitalization - Initial or Prolonged
1301226125	Other Serious (Important Medical Event)
1301373012	Other Serious (Important Medical Event)
130167094	Other Serious (Important Medical Event)
130167094	Congenital Anomaly
1302401118	Other Serious (Important Medical Event)
1302401118	Hospitalization - Initial or Prolonged
130260364	Other Serious (Important Medical Event)
130297032	Other Serious (Important Medical Event)
130314855	Hospitalization - Initial or Prolonged
130314855	Other Serious (Important Medical Event)
130375084	Other Serious (Important Medical Event)
1305805713	Disability
1305805713	Other Serious (Important Medical Event)
1306707611	Hospitalization - Initial or Prolonged
1306707611	Other Serious (Important Medical Event)
1306917111	Other Serious (Important Medical Event)
130714024	Other Serious (Important Medical Event)
130719762	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
1307598415	Hospitalization - Initial or Prolonged
1307598415	Other Serious (Important Medical Event)
130765083	Hospitalization - Initial or Prolonged
130896044	Other Serious (Important Medical Event)
130896044	Hospitalization - Initial or Prolonged
130913686	Hospitalization - Initial or Prolonged
130951602	Other Serious (Important Medical Event)
1309831715	Disability
1310972321	Disability
131179953	Hospitalization - Initial or Prolonged
131181364	Other Serious (Important Medical Event)
131181465	Other Serious (Important Medical Event)
1312448414	Hospitalization - Initial or Prolonged
131300352	Hospitalization - Initial or Prolonged
131300352	Life-Threatening
1313174010	Other Serious (Important Medical Event)
131346387	Other Serious (Important Medical Event)
1314326413	Hospitalization - Initial or Prolonged
1314326413	Other Serious (Important Medical Event)
131474342	Other Serious (Important Medical Event)
1315318823	Hospitalization - Initial or Prolonged
1315318823	Other Serious (Important Medical Event)
131584896	Hospitalization - Initial or Prolonged
131614126	Life-Threatening
131717783	Other Serious (Important Medical Event)
131720564	Death
131720564	Hospitalization - Initial or Prolonged
131720564	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
131884112	Other Serious (Important Medical Event)
131948255	Other Serious (Important Medical Event)
132256512	Other Serious (Important Medical Event)
1322723239	Hospitalization - Initial or Prolonged
1322723239	Life-Threatening
1322723239	Other Serious (Important Medical Event)
132292854	Hospitalization - Initial or Prolonged
1323008512	Hospitalization - Initial or Prolonged
1323008512	Other Serious (Important Medical Event)
132340655	Hospitalization - Initial or Prolonged
132446642	Other Serious (Important Medical Event)
132535658	Other Serious (Important Medical Event)
132535658	Hospitalization - Initial or Prolonged
132573907	Other Serious (Important Medical Event)
132573907	Hospitalization - Initial or Prolonged
132573907	Life-Threatening
1326573916	Other Serious (Important Medical Event)
132667138	Hospitalization - Initial or Prolonged
132667138	Congenital Anomaly
132667138	Other Serious (Important Medical Event)
1326925316	Hospitalization - Initial or Prolonged
1326925316	Other Serious (Important Medical Event)
1327001616	Other Serious (Important Medical Event)
132718234	Death
132718234	Other Serious (Important Medical Event)
1327789813	Hospitalization - Initial or Prolonged
1327789813	Other Serious (Important Medical Event)
132807613	Life-Threatening

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
132807613	Other Serious (Important Medical Event)
132818014	Other Serious (Important Medical Event)
132846696	Other Serious (Important Medical Event)
1328785317	Other Serious (Important Medical Event)
1329621913	Hospitalization - Initial or Prolonged
1329621913	Death
1329621913	Other Serious (Important Medical Event)
133030383	Other Serious (Important Medical Event)
133030383	Disability
1330367811	Hospitalization - Initial or Prolonged
1330367811	Other Serious (Important Medical Event)
1330513013	Other Serious (Important Medical Event)
133076635	Other Serious (Important Medical Event)
133108513	Other Serious (Important Medical Event)
133116253	Other Serious (Important Medical Event)
1331956117	Other Serious (Important Medical Event)
1331956117	Hospitalization - Initial or Prolonged
1333644913	Other Serious (Important Medical Event)
1333644913	Hospitalization - Initial or Prolonged
133365235	Hospitalization - Initial or Prolonged
133365235	Other Serious (Important Medical Event)
133429876	Hospitalization - Initial or Prolonged
133473682	Hospitalization - Initial or Prolonged
1335105016	Hospitalization - Initial or Prolonged
133523655	Death
133523655	Hospitalization - Initial or Prolonged
133523655	Life-Threatening
133523655	Other Serious (Important Medical Event)

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
133523846	Hospitalization - Initial or Prolonged
133523846	Other Serious (Important Medical Event)
1335529225	Hospitalization - Initial or Prolonged
1335529225	Other Serious (Important Medical Event)
133583395	Other Serious (Important Medical Event)
133599388	Life-Threatening
133599388	Other Serious (Important Medical Event)
1336515012	Other Serious (Important Medical Event)
1336515012	Hospitalization - Initial or Prolonged
133701598	Other Serious (Important Medical Event)
133748923	Other Serious (Important Medical Event)
133748923	Death
133761803	Other Serious (Important Medical Event)
133761803	Hospitalization - Initial or Prolonged
133761803	Life-Threatening
133829345	Other Serious (Important Medical Event)
133931897	Other Serious (Important Medical Event)
133931897	Hospitalization - Initial or Prolonged
133959212	Hospitalization - Initial or Prolonged
1339710411	Hospitalization - Initial or Prolonged
1339710411	Other Serious (Important Medical Event)
134010312	Hospitalization - Initial or Prolonged
134010312	Other Serious (Important Medical Event)
134018982	Other Serious (Important Medical Event)
134019173	Hospitalization - Initial or Prolonged
134019173	Other Serious (Important Medical Event)
134033914	Other Serious (Important Medical Event)
134040983	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
134040983	Life-Threatening
134040983	Other Serious (Important Medical Event)
134065693	Death
134065693	Other Serious (Important Medical Event)
134066473	Disability
134066473	Other Serious (Important Medical Event)
134066473	Hospitalization - Initial or Prolonged
134083414	Other Serious (Important Medical Event)
134085342	Other Serious (Important Medical Event)
134085953	Other Serious (Important Medical Event)
134088083	Other Serious (Important Medical Event)
134088094	Other Serious (Important Medical Event)
134090483	Other Serious (Important Medical Event)
134091734	Other Serious (Important Medical Event)
134092954	Other Serious (Important Medical Event)
134092974	Other Serious (Important Medical Event)
134094214	Other Serious (Important Medical Event)
134095674	Other Serious (Important Medical Event)
1340999011	Other Serious (Important Medical Event)
134105123	Disability
134105123	Other Serious (Important Medical Event)
134107453	Other Serious (Important Medical Event)
134108014	Other Serious (Important Medical Event)
134108573	Other Serious (Important Medical Event)
134109483	Other Serious (Important Medical Event)
134110902	Other Serious (Important Medical Event)
134112744	Other Serious (Important Medical Event)
134112744	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)

Outcome Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for a patient outcome.</i>
134114023	Other Serious (Important Medical Event)
134115182	Other Serious (Important Medical Event)
134121044	Other Serious (Important Medical Event)
134121334	Hospitalization - Initial or Prolonged
134121494	Other Serious (Important Medical Event)
134128773	Other Serious (Important Medical Event)
134130353	Other Serious (Important Medical Event)
134137264	Other Serious (Important Medical Event)
134141165	Life-Threatening
134141165	Other Serious (Important Medical Event)
134141165	Hospitalization - Initial or Prolonged
134145813	Other Serious (Important Medical Event)
134190294	Other Serious (Important Medical Event)
134194003	Other Serious (Important Medical Event)
1341979423	Other Serious (Important Medical Event)
1341979423	Hospitalization - Initial or Prolonged
134281817	Other Serious (Important Medical Event)
1342967213	Other Serious (Important Medical Event)
1342967213	Hospitalization - Initial or Prolonged
134333438	Hospitalization - Initial or Prolonged

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230149591	Consumer	
230150561	Health Professional	
230150731	Health Professional	
230150811	Health Professional	
230150931	Health Professional	
230151421	Health Professional	
230151441	Health Professional	
230151461	Health Professional	
230151481	Health Professional	
230151491	Health Professional	
230151501	Health Professional	
230151511	Health Professional	
230151701	Health Professional	
230151751	Health Professional	
230151771	Health Professional	
230151831	Health Professional	
230151901	Consumer	
230152091	Health Professional	
230152101	Health Professional	
230152111	Health Professional	
230152121	Health Professional	
230152221	Health Professional	
230152451	Health Professional	
230152851	Health Professional	
230152861	Health Professional	
230152881	Health Professional	
230152891	Health Professional	
230152921	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230152931	Health Professional
230153341	Health Professional
230153391	Health Professional
230153411	Health Professional
230153431	Health Professional
230153471	Health Professional
230153491	Health Professional
230153521	Health Professional
230153591	Health Professional
230153821	Health Professional
230154961	Health Professional
230155621	Health Professional
230155661	Health Professional
230155771	Health Professional
230155811	Consumer
230155831	Health Professional
230155841	Health Professional
230155931	Health Professional
230155991	Health Professional
230156001	Health Professional
230156261	Health Professional
230157861	Health Professional
230157931	Health Professional
230157951	Health Professional
230158481	Consumer
230158591	Consumer
230158601	Consumer
230158781	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230158801	Health Professional	
230159641	Consumer	
230159651	Consumer	
230159661	Consumer	
230159681	Consumer	
230159691	Consumer	
230159701	Consumer	
230159711	Consumer	
230159811	Consumer	
230159821	Consumer	
230159871	Consumer	
230160001	Consumer	
230160011	Consumer	
230160061	Consumer	
230160211	Consumer	
230160221	Consumer	
230160231	Consumer	
230197401	Consumer	
230197411	Consumer	
230197431	Health Professional	
230197441	Consumer	
230198071	Consumer	
230198091	Consumer	
230198111	Consumer	
230198121	Consumer	
230198131	Consumer	
230198141	Consumer	
230198781	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230198811	Consumer	
230198821	Consumer	
230199141	Consumer	
230199181	Health Professional	
230199191	Health Professional	
230199201	Health Professional	
230199601	Consumer	
230199611	Consumer	
230199631	Consumer	
230199651	Health Professional	
230199731	Consumer	
230199741	Health Professional	
230199751	Health Professional	
230200111	Consumer	
230200491	Health Professional	
230200501	Consumer	
230200741	Health Professional	
230200751	Health Professional	
230200761	Health Professional	
230200781	Health Professional	
230200791	Health Professional	
230200811	Health Professional	
230200821	Health Professional	
230200831	Health Professional	
230200841	Consumer	
230201081	Consumer	
230201101	Health Professional	
230201191	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230201211	Health Professional	
230201461	Health Professional	
230201471	Health Professional	
230201481	Health Professional	
230201971	Health Professional	
230201981	Consumer	
230201991	Health Professional	
230202011	Consumer	
230202021	Health Professional	
230202031	Health Professional	
230202041	Health Professional	
230202361	Health Professional	
230202561	Health Professional	
230202601	Health Professional	
230202661	Health Professional	
230202671	Health Professional	
230202691	Health Professional	
230202701	Health Professional	
230202711	Health Professional	
230202721	Health Professional	
230202741	Health Professional	
230202751	Health Professional	
230202761	Health Professional	
230202771	Consumer	
230203241	Health Professional	
230203251	Health Professional	
230203261	Consumer	
230203311	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230203331	Health Professional	
230203441	Health Professional	
230203461	Health Professional	
230203511	Consumer	
230203521	Health Professional	
230203821	Consumer	
230203841	Health Professional	
230203851	Consumer	
230203861	Consumer	
230203871	Health Professional	
230203881	Consumer	
230204061	Consumer	
230204861	Consumer	
230204871	Consumer	
230204961	Consumer	
230204971	Health Professional	
230205251	Consumer	
230205261	Health Professional	
230205291	Health Professional	
230205301	Consumer	
230205401	Health Professional	
230205421	Consumer	
230205721	Health Professional	
230205891	Health Professional	
230206921	Health Professional	
230207111	Health Professional	
230207441	Health Professional	
230208151	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230208171	Health Professional	
230208181	Health Professional	
230208221	Health Professional	
230208231	Health Professional	
230209081	Health Professional	
230209171	Health Professional	
230209181	Health Professional	
230209291	Health Professional	
230209381	Health Professional	
230210551	Health Professional	
230210561	Consumer	
230210741	Consumer	
230211181	Health Professional	
230211201	Health Professional	
230211501	Health Professional	
230211641	Health Professional	
230211681	Health Professional	
230212641	Health Professional	
230212661	Health Professional	
230213191	Health Professional	
230213201	Health Professional	
230213211	Health Professional	
230213231	Health Professional	
230213241	Consumer	
230213291	Consumer	
230213801	Health Professional	
230213821	Health Professional	
230213831	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230213841	Consumer
230213851	Consumer
230215161	Health Professional
230215581	Health Professional
230215591	Health Professional
230216671	Consumer
230216701	Consumer
230216721	Consumer
230216731	Health Professional
230216741	Health Professional
230216761	Health Professional
230216771	Consumer
230216781	Consumer
230216791	Health Professional
230216801	Consumer
230216811	Consumer
230217081	Consumer
230217141	Health Professional
230217181	Consumer
230217181	Foreign
230218001	Consumer
230218981	Health Professional
230220921	Health Professional
230221111	Health Professional
230221121	Health Professional
230221151	Health Professional
230221161	Health Professional
230221201	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230221221	Health Professional
230221231	Health Professional
230221611	Health Professional
230221621	Health Professional
230221631	Health Professional
230222141	Health Professional
230222151	Health Professional
230223471	Health Professional
230223521	Health Professional
230223541	Health Professional
230224461	Health Professional
230225671	Health Professional
230225681	Consumer
230225691	Health Professional
230227971	Health Professional
230228021	Health Professional
230228031	Consumer
230228651	Consumer
230228731	Consumer
230228741	Consumer
230228751	Consumer
230228761	Consumer
230228861	Consumer
230228881	Health Professional
230228891	Health Professional
230230021	Consumer
230230031	Consumer
230230111	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230233171	Health Professional	
230233701	Health Professional	
230233731	Health Professional	
230233741	Health Professional	
230233751	Health Professional	
230233791	Health Professional	
230234551	Health Professional	
230266111	Health Professional	
230266701	Health Professional	
230266711	Health Professional	
230267181	Health Professional	
230267371	Health Professional	
230267381	Health Professional	
230267401	Health Professional	
230267601	Health Professional	
230267631	Health Professional	
230267661	Health Professional	
230268181	Health Professional	
230268261	Consumer	
230268391	Health Professional	
230268691	Health Professional	
230268701	Consumer	
230268711	Health Professional	
230268721	Consumer	
230268741	Health Professional	
230268751	Consumer	
230268771	Health Professional	
230268781	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230268801	Health Professional	
230269091	Health Professional	
230269131	Consumer	
230269151	Health Professional	
230269211	Health Professional	
230269711	Consumer	
230269741	Health Professional	
230269751	Consumer	
230270211	Health Professional	
230270331	Health Professional	
230270341	Health Professional	
230270361	Consumer	
230270971	Consumer	
230270981	Consumer	
230271001	Health Professional	
230271021	Health Professional	
230271031	Health Professional	
230271041	Health Professional	
230271051	Consumer	
230271351	Consumer	
230271361	Health Professional	
230271391	Consumer	
230271821	Consumer	
230271921	Consumer	
230272671	Consumer	
230272681	Consumer	
230272691	Health Professional	
230272711	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230273111	Health Professional	
230273121	Consumer	
230273131	Health Professional	
230273221	Health Professional	
230273231	Health Professional	
230273241	Consumer	
230273251	Health Professional	
230273331	Consumer	
230273341	Health Professional	
230275461	Health Professional	
230275521	Consumer	
230275531	Health Professional	
230275541	Health Professional	
230275551	Health Professional	
230275971	Health Professional	
230275991	Health Professional	
230276451	Health Professional	
230276561	Health Professional	
230277301	Consumer	
230277391	Health Professional	
230277451	Health Professional	
230277471	Health Professional	
230277481	Health Professional	
230277671	Consumer	
230277691	Consumer	
230278081	Health Professional	
230278101	Consumer	
230278111	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230278201	Health Professional
230278211	Health Professional
230278221	Consumer
230278231	Consumer
230278971	Health Professional
230278991	Consumer
230279001	Consumer
230279051	Health Professional
230279061	Consumer
230279071	Consumer
230279081	Consumer
230279391	Consumer
230279401	Consumer
230279411	Health Professional
230279421	Health Professional
230279431	Consumer
230279441	Consumer
230279451	Consumer
230279461	Consumer
230279481	Consumer
230279491	Consumer
230279511	Consumer
230280121	Health Professional
230280141	Health Professional
230280161	Health Professional
230280171	Health Professional
230280381	Health Professional
230281151	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230281651	Health Professional	
230281661	Health Professional	
230281671	Consumer	
230281771	Consumer	
230281791	Consumer	
230281821	Consumer	
230282371	Health Professional	
230282401	Health Professional	
230282421	Consumer	
230282471	Consumer	
230282481	Consumer	
230282511	Consumer	
230282521	Consumer	
230282531	Health Professional	
230282541	Consumer	
230282561	Health Professional	
230282571	Consumer	
230282591	Consumer	
230282601	Consumer	
230282621	Health Professional	
230283291	Health Professional	
230283331	Consumer	
230283341	Consumer	
230283351	Consumer	
230283381	Health Professional	
230283611	Consumer	
230283641	Consumer	
230283681	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230283771	Consumer	
230283881	Health Professional	
230284541	Health Professional	
230284551	Health Professional	
230284561	Consumer	
230284571	Health Professional	
230284591	Consumer	
230284611	Health Professional	
230284681	Health Professional	
230284691	Health Professional	
230284711	Health Professional	
230284721	Health Professional	
230284731	Health Professional	
230284771	Health Professional	
230285241	Health Professional	
230285261	Health Professional	
230285271	Health Professional	
230285281	Health Professional	
230285651	Health Professional	
230285661	Health Professional	
230286161	Health Professional	
230286981	Health Professional	
230286991	Health Professional	
230287001	Health Professional	
230287011	Health Professional	
230287021	Health Professional	
230289041	Health Professional	
230289051	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230289451	Health Professional
230289471	Health Professional
230289481	Consumer
230289491	Health Professional
230289501	Health Professional
230289511	Health Professional
230289521	Health Professional
230289901	Health Professional
230289961	Health Professional
230289971	Health Professional
230290111	Consumer
230290231	Health Professional
230290241	Health Professional
230290251	Health Professional
230290281	Health Professional
230290911	Consumer
230290921	Health Professional
230290931	Consumer
230290961	Health Professional
230290971	Health Professional
230291371	Health Professional
230291621	Health Professional
230292491	Health Professional
230320321	Health Professional
230320331	Health Professional
230320351	Health Professional
230320651	Health Professional
230320691	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230320881	Health Professional	
230320891	Health Professional	
230321501	Health Professional	
230321511	Health Professional	
230321571	Health Professional	
230321581	Health Professional	
230322591	Health Professional	
230322601	Health Professional	
230323091	Consumer	
230323131	Consumer	
230323141	Consumer	
230323161	Health Professional	
230323721	Health Professional	
230324311	Consumer	
230324321	Health Professional	
230324331	Health Professional	
230324341	Health Professional	
230324351	Health Professional	
230324361	Health Professional	
230324611	Health Professional	
230324631	Health Professional	
230324641	Health Professional	
230324651	Health Professional	
230324661	Health Professional	
230324721	Health Professional	
230324731	Health Professional	
230324741	Health Professional	
230324751	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230325151	Health Professional	
230326301	Consumer	
230327281	Health Professional	
230327291	Health Professional	
230327661	Health Professional	
230327681	Health Professional	
230327691	Health Professional	
230327701	Health Professional	
230327711	Health Professional	
230327721	Health Professional	
230327731	Health Professional	
230327751	Health Professional	
230327771	Health Professional	
230328151	Health Professional	
230330041	Health Professional	
230330341	Health Professional	
230330401	Health Professional	
230330771	Health Professional	
230330781	Consumer	
230330821	Consumer	
230331151	Health Professional	
230331161	Health Professional	
230331171	Consumer	
230331181	Health Professional	
230331191	Consumer	
230331251	Consumer	
230331271	Health Professional	
230331311	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230331461	Consumer
230331691	Health Professional
230331721	Health Professional
230331751	Health Professional
230332511	Consumer
230333101	Health Professional
230333111	Consumer
230333121	Health Professional
230333131	Health Professional
230333471	Consumer
230333481	Health Professional
230333521	Consumer
230333531	Health Professional
230334131	Consumer
230334141	Consumer
230334151	Consumer
230334291	Health Professional
230334301	Consumer
230334811	Consumer
230334831	Consumer
230334841	Consumer
230335131	Health Professional
230335161	Consumer
230335171	Consumer
230335181	Consumer
230335191	Health Professional
230335201	Consumer
230335211	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230335221	Consumer
230335371	Consumer
230335391	Health Professional
230335401	Consumer
230335431	Health Professional
230335441	Health Professional
230335451	Consumer
230335461	Health Professional
230335911	Health Professional
230335931	Health Professional
230335941	Health Professional
230335951	Health Professional
230336271	Health Professional
230336281	Consumer
230336291	Consumer
230336301	Foreign
230336301	Consumer
230336311	Consumer
230336411	Health Professional
230336451	Health Professional
230336471	Consumer
230337211	Health Professional
230337461	Health Professional
230337491	Health Professional
230337891	Health Professional
230338211	Consumer
230338221	Health Professional
230338381	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230338421	Health Professional	
230338721	Health Professional	
230339191	Health Professional	
230339771	Consumer	
230339781	Health Professional	
230339791	Health Professional	
230339861	Consumer	
230339881	Consumer	
230339891	Health Professional	
230339921	Consumer	
230339931	Consumer	
230339941	Consumer	
230340521	Consumer	
230340551	Consumer	
230340581	Consumer	
230340591	Consumer	
230340601	Consumer	
230340611	Health Professional	
230340631	Consumer	
230340981	Consumer	
230341021	Health Professional	
230341031	Consumer	
230341041	Health Professional	
230341081	Consumer	
230341151	Health Professional	
230341301	Consumer	
230341321	Consumer	
230341331	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230341341	Health Professional	
230341351	Consumer	
230341511	Health Professional	
230341521	Health Professional	
230341541	Consumer	
230341731	Health Professional	
230341741	Consumer	
230341761	Consumer	
230341771	Health Professional	
230341791	Health Professional	
230341801	Health Professional	
230342101	Health Professional	
230342111	Health Professional	
230342291	Health Professional	
230342311	Consumer	
230342331	Health Professional	
230342341	Health Professional	
230342351	Health Professional	
230342761	Health Professional	
230342771	Consumer	
230342801	Health Professional	
230342881	Health Professional	
230342891	Health Professional	
230342921	Health Professional	
230343431	Health Professional	
230343441	Health Professional	
230345131	Health Professional	
230345141	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230345151	Consumer
230345161	Health Professional
230345181	Consumer
230345191	Health Professional
230345201	Health Professional
230345211	Consumer
230345231	Consumer
230345241	Health Professional
230345551	Consumer
230345561	Health Professional
230345571	Health Professional
230345581	Health Professional
230345631	Health Professional
230345701	Health Professional
230345721	Health Professional
230345751	Consumer
230345771	Health Professional
230345781	Health Professional
230345801	Health Professional
230345811	Consumer
230346081	Health Professional
230346091	Health Professional
230346301	Health Professional
230346321	Health Professional
230346371	Health Professional
230346381	Health Professional
230346871	Health Professional
230347261	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230347861	Consumer
230347971	Consumer
230372951	Health Professional
230372961	Health Professional
230372991	Consumer
230373491	Health Professional
230374001	Health Professional
230374011	Health Professional
230374021	Health Professional
230374031	Health Professional
230374391	Health Professional
230374821	Health Professional
230374831	Consumer
230374841	Health Professional
230374851	Health Professional
230374961	Health Professional
230375031	Health Professional
230375041	Consumer
230375061	Consumer
230375651	Consumer
230375731	Health Professional
230375811	Health Professional
230375861	Health Professional
230375871	Health Professional
230376261	Consumer
230376291	Consumer
230376821	Consumer
230376831	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230376861	Health Professional
230376881	Consumer
230376891	Consumer
230376901	Consumer
230377241	Health Professional
230377251	Health Professional
230377311	Consumer
230377321	Health Professional
230378171	Health Professional
230378181	Consumer
230378191	Health Professional
230378241	Consumer
230378251	Health Professional
230378261	Consumer
230378291	Consumer
230378331	Consumer
230378371	Health Professional
230379101	Health Professional
230379111	Consumer
230379391	Consumer
230379401	Consumer
230379411	Consumer
230379421	Health Professional
230379431	Health Professional
230379441	Health Professional
230379451	Consumer
230379461	Consumer
230379881	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230379901	Consumer	
230379951	Health Professional	
230379961	Consumer	
230379971	Consumer	
230380791	Consumer	
230380891	Consumer	
230381011	Consumer	
230381631	Health Professional	
230382081	Consumer	
230382121	Consumer	
230382131	Health Professional	
230382681	Health Professional	
230382691	Consumer	
230382741	Health Professional	
230382771	Consumer	
230382801	Health Professional	
230382821	Health Professional	
230383031	Health Professional	
230383041	Health Professional	
230383051	Consumer	
230383061	Health Professional	
230383131	Health Professional	
230383151	Health Professional	
230383711	Health Professional	
230383741	Health Professional	
230383751	Consumer	
230384011	Consumer	
230384021	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230384031	Health Professional
230384041	Health Professional
230384051	Health Professional
230384261	Health Professional
230384301	Health Professional
230384321	Health Professional
230384341	Health Professional
230385151	Health Professional
230385311	Health Professional
230385851	Health Professional
230385861	Health Professional
230385921	Health Professional
230385931	Health Professional
230386301	Health Professional
230386311	Health Professional
230386321	Health Professional
230390331	Health Professional
230390341	Consumer
230390421	Health Professional
230390431	Health Professional
230391191	Health Professional
230391201	Consumer
230391481	Health Professional
230391491	Health Professional
230391501	Consumer
230391511	Consumer
230391861	Consumer
230391881	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230391891	Consumer
230392371	Health Professional
230392381	Consumer
230392391	Health Professional
230392401	Health Professional
230392411	Consumer
230392421	Consumer
230392431	Consumer
230392441	Consumer
230392461	Health Professional
230392471	Health Professional
230392481	Health Professional
230393551	Health Professional
230393571	Health Professional
230393731	Health Professional
230394991	Health Professional
230396691	Health Professional
230397591	Health Professional
230397641	Health Professional
230397691	Health Professional
230397701	Health Professional
230397711	Consumer
230397751	Health Professional
230397761	Consumer
230398271	Health Professional
230398331	Health Professional
230398341	Health Professional
230398351	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230398371	Health Professional	
230398381	Health Professional	
230398391	Health Professional	
230398951	Health Professional	
230398961	Health Professional	
230398971	Health Professional	
230399061	Health Professional	
230399841	Health Professional	
230401091	Health Professional	
230401101	Health Professional	
230401521	Consumer	
230401541	Consumer	
230401551	Consumer	
230401561	Health Professional	
230401601	Health Professional	
230401611	Consumer	
230401621	Health Professional	
230401751	Consumer	
230402331	Consumer	
230402981	Health Professional	
230403111	Health Professional	
230404001	Consumer	
230404051	Consumer	
230404061	Health Professional	
230404071	Health Professional	
230404121	Health Professional	
230404131	Health Professional	
230404381	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230404421	Consumer
230404431	Health Professional
230404471	Health Professional
230404531	Health Professional
230404541	Health Professional
230404761	Consumer
230404791	Consumer
230404811	Consumer
230404821	Consumer
230488491	Health Professional
230488521	Consumer
230489301	Consumer
230490011	Health Professional
230490021	Health Professional
230490031	Health Professional
230490131	Health Professional
230490141	Consumer
230490151	Health Professional
230490181	Health Professional
230490191	Health Professional
230490201	Health Professional
230490801	Health Professional
230490841	Health Professional
230491351	Health Professional
230491381	Health Professional
230492071	Consumer
230492141	Health Professional
230492151	Consumer

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230492161	Consumer
230492171	Health Professional
230492181	Consumer
230492211	Health Professional
230492261	Health Professional
230492281	Health Professional
230492301	Health Professional
230493181	Consumer
230493391	Health Professional
230493411	Health Professional
230493421	Health Professional
230493431	Health Professional
230493461	Health Professional
230493471	Health Professional
230493481	Health Professional
230493521	Health Professional
230493531	Health Professional
230493541	Health Professional
230494091	Health Professional
230494101	Health Professional
230494111	Health Professional
230494121	Health Professional
230494131	Health Professional
230494141	Health Professional
230494151	Health Professional
230494191	Health Professional
230494221	Health Professional
230494451	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230494471	Health Professional
230494491	Health Professional
230494551	Health Professional
230494561	Health Professional
230494571	Consumer
230494581	Consumer
230494611	Health Professional
230494641	Consumer
230494901	Consumer
230494911	Health Professional
230494961	Health Professional
230494971	Consumer
230495301	Health Professional
230495311	Health Professional
230495331	Consumer
230495341	Health Professional
230495361	Health Professional
230495431	Health Professional
230495441	Health Professional
230495451	Health Professional
230495461	Health Professional
230495481	Consumer
230495501	Consumer
230496161	Consumer
230496751	Consumer
230496761	Health Professional
230496771	Health Professional
230496841	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230496851	Health Professional	
230496881	Health Professional	
230496931	Health Professional	
230496941	Health Professional	
230496961	Health Professional	
230497301	Consumer	
230497331	Health Professional	
230497361	Consumer	
230497371	Consumer	
230497381	Consumer	
230497391	Health Professional	
230497401	Health Professional	
230497751	Health Professional	
230497791	Consumer	
230497801	Health Professional	
230497811	Health Professional	
230497891	Consumer	
230497901	Consumer	
230497921	Health Professional	
230498111	Consumer	
230498121	Consumer	
230498131	Health Professional	
230498141	Consumer	
230498601	Health Professional	
230498611	Consumer	
230498621	Health Professional	
230498631	Foreign	
230498631	Consumer	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>	<i>Code for the source of the report.</i>
230498651	Consumer
230498661	Consumer
230498681	Health Professional
230498721	Consumer
230498731	Consumer
230498781	Consumer
230498791	Consumer
230498841	Consumer
230499421	Consumer
230499471	Consumer
230499501	Consumer
230499511	Health Professional
230499531	Health Professional
230499541	Consumer
230499551	Health Professional
230499581	Consumer
230499661	Consumer
230499681	Consumer
230499691	Consumer
230500131	Health Professional
230500161	Health Professional
230500861	Health Professional
230500871	Health Professional
230500881	Health Professional
230500891	Health Professional
230501341	Health Professional
230501491	Health Professional
230501781	Health Professional

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230502371	Health Professional	
230502431	Consumer	
230502701	Consumer	
230502721	Consumer	
230502801	Consumer	
230502811	Consumer	
230503011	Consumer	
230503041	Health Professional	
230503121	Health Professional	
230503141	Health Professional	
230503461	Consumer	
230503491	Health Professional	
230503501	Health Professional	
230503531	Health Professional	
230504781	Consumer	
230504791	Consumer	
230504811	Health Professional	
230504821	Consumer	
230504831	Health Professional	
230504841	Foreign	
230504841	Consumer	
230504851	Consumer	
230504861	Health Professional	
230504871	Consumer	
230504881	Health Professional	
230504901	Health Professional	
230504911	Health Professional	
230505551	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Report Source Listings

<i>Unique number for identifying a FAERS re</i>		<i>Code for the source of the report.</i>
230505561	Health Professional	
230505571	Health Professional	
230505601	Health Professional	
230505731	Health Professional	
230505741	Health Professional	
230505751	Health Professional	
230505991	Consumer	
230506001	Consumer	
230506011	Consumer	
230506031	Health Professional	
230506541	Health Professional	
230506591	Health Professional	
230506601	Health Professional	
230506611	Health Professional	
230506621	Health Professional	
230506661	Health Professional	
230506741	Consumer	
230506771	Consumer	
230506791	Health Professional	
230507081	Health Professional	

ADVERSE EVENT REPORTING SYSTEM (AERS)
Therapy Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Date the therapy was started (or re-star</i>	<i>A date therapy was stopped for this drug</i>	<i>Derived duration.</i>
678348247096	14137	15414164292	15474714923	302783283

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
100144838	1	HIV infection
100144838	2	Product used for unknown indication
100144838	4	Product used for unknown indication
100144838	7	HIV infection
100144838	8	Product used for unknown indication
100144838	9	HIV infection
100144838	10	Product used for unknown indication
100144838	11	HIV infection
100144838	12	Product used for unknown indication
100144838	13	Product used for unknown indication
100144838	16	Product used for unknown indication
100144838	18	Product used for unknown indication
100144838	21	Product used for unknown indication
100144838	23	Product used for unknown indication
100144838	27	Product used for unknown indication
100144838	29	Product used for unknown indication
100144838	30	Product used for unknown indication
100144838	33	Product used for unknown indication
100144838	34	Product used for unknown indication
100144838	35	Product used for unknown indication
100144838	36	Product used for unknown indication
100144838	37	Product used for unknown indication
100144838	38	Product used for unknown indication
100144838	39	Product used for unknown indication
100144838	40	Product used for unknown indication
100144838	41	Product used for unknown indication
100144838	42	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
100144838	43	Product used for unknown indication
1001678124	1	Neuroendocrine tumour
1001678124	4	Neuroendocrine tumour
1001678124	10	Neuroendocrine tumour
1001678124	11	Neuroendocrine tumour
1001678124	13	Product used for unknown indication
1001678124	14	Product used for unknown indication
1001678124	15	Product used for unknown indication
1001678124	16	Product used for unknown indication
1001678124	17	Product used for unknown indication
1001678124	18	Product used for unknown indication
1001678124	19	Product used for unknown indication
1001678124	20	Product used for unknown indication
1001678124	21	Product used for unknown indication
1002130539	1	Neuroendocrine tumour
1002130539	4	Neuroendocrine tumour
1002130539	7	Product used for unknown indication
100293662	1	Immunosuppressant drug therapy
100293662	2	Renal transplant
100293662	3	Immunosuppressant drug therapy
100293662	4	Renal transplant
100293662	5	Renal transplant
100293662	6	Immunosuppressant drug therapy
100293662	7	Immunosuppressant drug therapy
100293662	8	Renal transplant
100356167	1	Atrial fibrillation
100356167	2	Hypertension

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
100356167	3	Hypertension
100356167	4	Atrial fibrillation
100356167	5	Hypertension
100356167	6	Product used for unknown indication
100356167	7	Viral hepatitis carrier
100356167	8	Viral hepatitis carrier
1006401878	1	Rheumatoid arthritis
1006401878	19	Product used for unknown indication
1006401878	20	Arthralgia
1006401878	21	Product used for unknown indication
1006401878	22	Product used for unknown indication
1006401878	23	Product used for unknown indication
1006401878	24	Product used for unknown indication
1006401878	25	Product used for unknown indication
1006401878	26	Product used for unknown indication
1006401878	27	Product used for unknown indication
1006401878	28	Product used for unknown indication
1006401878	29	Product used for unknown indication
1006401878	30	Product used for unknown indication
1006401878	31	Product used for unknown indication
1007468610	1	Asthma
1007468610	5	Product used for unknown indication
1007468610	6	Product used for unknown indication
1007468610	7	Product used for unknown indication
1007468610	8	Product used for unknown indication
100764782	1	Epilepsy
1008408132	1	Small intestine carcinoma

ADVERSE EVENT REPORTING SYSTEM (AERS) Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1008408132	5	Product used for unknown indication
1008408132	6	Product used for unknown indication
1008408132	7	Product used for unknown indication
100941024	1	Epilepsy
1009418019	1	Juvenile idiopathic arthritis
1009418019	2	Rheumatoid arthritis
1009418019	6	Juvenile idiopathic arthritis
1009418019	7	Product used for unknown indication
1009418019	8	Rheumatoid arthritis
1014222251	1	Rheumatoid arthritis
1014222251	20	Product used for unknown indication
101451672	1	Psoriatic arthropathy
1015212331	1	Asthma
1015212331	19	Product used for unknown indication
1015212331	20	Product used for unknown indication
1015212331	23	Product used for unknown indication
1015212331	24	Product used for unknown indication
1015212331	27	Product used for unknown indication
1015212331	28	Product used for unknown indication
1015212331	29	Product used for unknown indication
1015212331	30	Chronic spontaneous urticaria
101621574	1	Colorectal cancer metastatic
101621574	2	Colorectal cancer metastatic
101621574	4	Colorectal cancer metastatic
101621574	5	Colorectal cancer metastatic
101621574	6	Therapeutic procedure
1016611037	1	Asthma

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1016611037	15	Product used for unknown indication
1016611037	19	Product used for unknown indication
1016611037	20	Product used for unknown indication
1016611037	21	Nasopharyngitis
1016611037	22	Illness
1016611037	23	Product used for unknown indication
1016611037	24	Product used for unknown indication
1016611037	25	Infected cyst
1016611037	26	Product used for unknown indication
101676303	1	HIV infection
101676303	2	Product used for unknown indication
101676303	3	Product used for unknown indication
101676303	4	Product used for unknown indication
101676303	5	Product used for unknown indication
101676303	6	Product used for unknown indication
101676303	7	Product used for unknown indication
101676313	1	HIV infection
101676313	2	Antiretroviral therapy
101676313	3	Tuberculosis
101676313	4	Tuberculosis
101676313	5	Tuberculosis
101676313	6	Tuberculosis
101676313	7	Antiretroviral therapy
101678657	1	Systemic lupus erythematosus
101678657	2	Systemic lupus erythematosus
101678657	3	Autoimmune neutropenia
101678657	8	Infection

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
101678657	9	Clostridium difficile infection
101678657	12	Infection
101678657	13	Clostridium difficile infection
101678657	15	Infection
1017572232	1	Rheumatoid arthritis
101780773	1	Rheumatoid arthritis
101780773	2	Rheumatoid arthritis
101780773	3	Product used for unknown indication
101780773	4	Product used for unknown indication
101780773	5	Product used for unknown indication
101780773	6	Product used for unknown indication
101780773	7	Product used for unknown indication
101916392	1	Bipolar disorder
101916392	2	Bipolar disorder
101916392	3	Bipolar disorder
101916392	4	Bipolar disorder
101916392	5	Bipolar disorder
101916392	6	Bipolar disorder
101916392	7	Bipolar disorder
101916392	8	Agitation
101916392	9	Product used for unknown indication
1020642923	1	Asthma
1020642923	23	Product used for unknown indication
1020642923	24	Product used for unknown indication
1020642923	25	Product used for unknown indication
1020642923	27	Product used for unknown indication
1020642923	28	Asthma

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
102371704	1	Epilepsy
102371704	2	Angina pectoris
102371704	3	Epilepsy
102371704	4	Epilepsy
102371704	5	Epilepsy
102371704	6	Upper respiratory tract infection
1027487983	1	Rheumatoid arthritis
1027487983	6	Product used for unknown indication
1027487983	7	Product used for unknown indication
1027487983	8	Product used for unknown indication
1027487983	9	Product used for unknown indication
1027487983	10	Product used for unknown indication
1028518546	1	Rheumatoid arthritis
1028518546	6	Rheumatoid arthritis
1028518546	10	Premedication
1028518546	11	Premedication
1028518546	12	Premedication
1028518546	14	Premedication
1028518546	15	Premedication
1028518546	16	Premedication
1030948614	1	Product used for unknown indication
1030948614	6	Product used for unknown indication
1030948614	8	Product used for unknown indication
103443973	1	Breast cancer
1035913611	1	Asthma
1035913611	4	Product used for unknown indication
1035913611	5	Pneumonia

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1035913611	6	Product used for unknown indication
1035913611	7	Product used for unknown indication
1035913611	8	Product used for unknown indication
1035913611	9	Product used for unknown indication
1035913611	10	Product used for unknown indication
1035913611	11	Product used for unknown indication
1035913611	12	Product used for unknown indication
1035913611	13	Product used for unknown indication
103687216	1	Non-small cell lung cancer
103687216	3	Dehydration
103749689	1	Colorectal cancer metastatic
103749689	3	Colorectal cancer metastatic
103749689	7	Colorectal cancer metastatic
103749689	9	Colorectal cancer metastatic
103749689	11	Prophylaxis
103749689	12	Prophylaxis
103749689	24	Prophylaxis
103892335	1	Non-Hodgkin's lymphoma
103892335	2	Non-Hodgkin's lymphoma
103892335	3	Non-Hodgkin's lymphoma
103892335	4	Non-Hodgkin's lymphoma
103892335	5	Non-Hodgkin's lymphoma
103892335	6	Prophylaxis
103892335	7	Prophylaxis
103892335	8	Prophylaxis
103892335	9	Prophylaxis
103928076	1	Attention deficit hyperactivity disorder

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
103928375	1	Attention deficit hyperactivity disorder
103928375	3	Product used for unknown indication
103928375	4	Attention deficit hyperactivity disorder
103928375	5	Product used for unknown indication
103985405	1	Relapsing-remitting multiple sclerosis
104003092	1	Cardiac failure chronic
104003092	2	Product used for unknown indication
104003092	3	Myocardial ischaemia
104003092	4	Product used for unknown indication
104003092	5	Product used for unknown indication
104003092	6	Product used for unknown indication
104003092	7	Product used for unknown indication
104003092	8	Product used for unknown indication
1040513313	1	Asthma
1040513313	2	Asthma
1040513313	6	Product used for unknown indication
1040513313	7	Product used for unknown indication
1040513313	8	Product used for unknown indication
1040513313	9	Product used for unknown indication
1040513313	10	Product used for unknown indication
1040513313	11	Product used for unknown indication
1041491125	1	Carcinoid tumour
1041491125	5	Product used for unknown indication
1041491125	6	Product used for unknown indication
1041491125	7	Product used for unknown indication
1041491125	8	Product used for unknown indication
1041491125	9	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1041491125	10	Product used for unknown indication
104232052	1	Product used for unknown indication
104232052	2	Product used for unknown indication
104232195	1	Product used for unknown indication
104232195	2	Product used for unknown indication
104232195	3	Product used for unknown indication
104232195	7	Product used for unknown indication
104232203	1	Product used for unknown indication
104232203	2	Product used for unknown indication
104266473	1	Tourette's disorder
104266473	2	Schizophrenia
104266473	3	Bipolar disorder
104266473	4	Psychotic disorder
104266473	5	Bipolar disorder
104266473	6	Tourette's disorder
104266473	7	Product used for unknown indication
104266473	8	Product used for unknown indication
104490482	1	Product used for unknown indication
104490482	2	Product used for unknown indication
104490482	3	Product used for unknown indication
104490482	4	Product used for unknown indication
104490482	5	Product used for unknown indication
104580772	1	Product used for unknown indication
104580772	2	Product used for unknown indication
104580772	3	Product used for unknown indication
104580772	4	Product used for unknown indication
104580883	1	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
104580883	2	Product used for unknown indication
104580883	3	Product used for unknown indication
104580883	4	Product used for unknown indication
104580883	5	Product used for unknown indication
104580883	6	Product used for unknown indication
104635823	1	Aggression
104635823	2	Product used for unknown indication
104665748	1	Bipolar II disorder
104665748	2	Bipolar disorder
104665748	3	Psychotic disorder
104665748	4	Bipolar II disorder
104665748	5	Psychotic disorder
104825157	1	Blood cholesterol abnormal
104825157	3	Hypertension
104825157	4	Product used for unknown indication
105144244	1	Psoriasis
1051596718	1	Gastroenteropancreatic neuroendocrine tumour disease
1052690058	1	Rheumatoid arthritis
1052690058	11	Localised infection
1054038738	1	Acromegaly
1054038738	9	Acromegaly
1054038738	12	Product used for unknown indication
1054038738	13	Product used for unknown indication
1054038738	14	Anticoagulant therapy
1054038738	15	Product used for unknown indication
105481232	1	Epilepsy
105524185	1	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
105524185	2	Product used for unknown indication
105524185	3	Product used for unknown indication
105524185	4	Product used for unknown indication
105741013	1	Immunosuppression
105741013	2	Heart and lung transplant
105741013	3	Immunosuppression
105741013	4	Heart and lung transplant
105741013	5	Immunosuppression
105741013	6	Heart and lung transplant
1058928657	1	Asthma
1058928657	2	Psoriasis
1058928657	45	Product used for unknown indication
1058928657	46	Product used for unknown indication
1058928657	47	Product used for unknown indication
1058928657	48	Product used for unknown indication
1058928657	49	Product used for unknown indication
1058928657	50	Productive cough
1058928657	51	Product used for unknown indication
105947013	1	Back pain
105947013	2	Back pain
105947013	3	Back pain
1060157312	1	Myelofibrosis
1060157312	5	Product used for unknown indication
1060157312	6	Product used for unknown indication
106091663	1	Partial seizures
106091663	2	Partial seizures with secondary generalisation
106091663	3	Partial seizures

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
106091663	6	Partial seizures
106091663	7	Partial seizures
106091663	8	Partial seizures
106336646	1	Attention deficit hyperactivity disorder
106336646	2	Disturbance in social behaviour
106336646	4	Product used for unknown indication
106352232	1	Partial seizures
106352232	3	Seizure
106352232	4	Seizure
106352232	5	Seizure
1069198853	1	Asthma
1069198853	54	Product used for unknown indication
1069198853	55	Product used for unknown indication
1069198853	56	Product used for unknown indication
1069198853	57	Product used for unknown indication
1069198853	58	Product used for unknown indication
1069198853	59	Product used for unknown indication
1069198853	60	Product used for unknown indication
1069198853	61	Diabetes mellitus
1070483325	1	Product used for unknown indication
1070483325	2	Product used for unknown indication
1070483325	10	Product used for unknown indication
1070483325	11	Product used for unknown indication
1070483325	12	Product used for unknown indication
1070483325	13	Product used for unknown indication
1070483325	14	Product used for unknown indication
1070483325	17	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	18	Product used for unknown indication
1070483325	20	Product used for unknown indication
1070483325	21	Product used for unknown indication
1070483325	22	Product used for unknown indication
1070483325	24	Product used for unknown indication
1070483325	25	Product used for unknown indication
1070483325	26	Product used for unknown indication
1070483325	27	Product used for unknown indication
1070483325	28	Product used for unknown indication
1070483325	29	Product used for unknown indication
1070483325	30	Product used for unknown indication
1070483325	32	Product used for unknown indication
1070483325	33	Product used for unknown indication
1070483325	34	Product used for unknown indication
1070483325	36	Product used for unknown indication
1070483325	37	Product used for unknown indication
1070483325	39	Product used for unknown indication
1070483325	40	Product used for unknown indication
1070483325	46	Product used for unknown indication
1070483325	49	Product used for unknown indication
1070483325	50	Product used for unknown indication
1070483325	51	Product used for unknown indication
1070483325	52	Product used for unknown indication
1070483325	53	Pain
1070483325	54	Product used for unknown indication
1070483325	55	Product used for unknown indication
1070483325	56	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	57	Product used for unknown indication
1070483325	58	Product used for unknown indication
1070483325	59	Product used for unknown indication
1070483325	60	Product used for unknown indication
1070483325	61	Product used for unknown indication
1070483325	67	Product used for unknown indication
1070483325	68	Product used for unknown indication
1070483325	71	Product used for unknown indication
1070483325	72	Product used for unknown indication
1070483325	73	Product used for unknown indication
1070483325	74	Product used for unknown indication
1070483325	75	Pain
1070483325	76	Product used for unknown indication
1070483325	85	Product used for unknown indication
1070483325	87	Product used for unknown indication
1070483325	88	Product used for unknown indication
1070483325	89	Product used for unknown indication
1070483325	90	Product used for unknown indication
1070483325	91	Product used for unknown indication
1070483325	93	Product used for unknown indication
1070483325	95	Product used for unknown indication
1070483325	96	Product used for unknown indication
1070483325	97	Product used for unknown indication
1070483325	98	Product used for unknown indication
1070483325	99	Product used for unknown indication
1070483325	100	Product used for unknown indication
1070483325	101	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	102	Product used for unknown indication
1070483325	103	Product used for unknown indication
1070483325	104	Product used for unknown indication
1070483325	105	Product used for unknown indication
1070483325	106	Product used for unknown indication
1070483325	107	Product used for unknown indication
1070483325	108	Product used for unknown indication
1070483325	109	Product used for unknown indication
1070483325	110	Product used for unknown indication
1070483325	111	Product used for unknown indication
1070483325	112	Product used for unknown indication
1070483325	113	Product used for unknown indication
1070483325	122	Product used for unknown indication
1070483325	123	Product used for unknown indication
1070483325	124	Product used for unknown indication
1070483325	125	Product used for unknown indication
1070483325	126	Product used for unknown indication
1070483325	127	Product used for unknown indication
1070483325	129	Product used for unknown indication
1070483325	130	Product used for unknown indication
1070483325	131	Product used for unknown indication
1070483325	132	Product used for unknown indication
1070483325	133	Product used for unknown indication
1070483325	134	Product used for unknown indication
1070483325	136	Product used for unknown indication
1070483325	137	Product used for unknown indication
1070483325	138	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	139	Product used for unknown indication
1070483325	141	Product used for unknown indication
1070483325	142	Product used for unknown indication
1070483325	143	Product used for unknown indication
1070483325	144	Product used for unknown indication
1070483325	145	Product used for unknown indication
1070483325	146	Product used for unknown indication
1070483325	147	Product used for unknown indication
1070483325	148	Product used for unknown indication
1070483325	149	Product used for unknown indication
1070483325	156	Product used for unknown indication
1070483325	157	Product used for unknown indication
1070483325	158	Product used for unknown indication
1070483325	159	Product used for unknown indication
1070483325	160	Product used for unknown indication
1070483325	161	Product used for unknown indication
1070483325	162	Product used for unknown indication
1070483325	163	Product used for unknown indication
1070483325	164	Product used for unknown indication
1070483325	165	Product used for unknown indication
1070483325	166	Product used for unknown indication
1070483325	167	Product used for unknown indication
1070483325	168	Product used for unknown indication
1070483325	169	Product used for unknown indication
1070483325	170	Product used for unknown indication
1070483325	171	Product used for unknown indication
1070483325	172	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	173	Product used for unknown indication
1070483325	174	Product used for unknown indication
1070483325	176	Product used for unknown indication
1070483325	177	Product used for unknown indication
1070483325	178	Product used for unknown indication
1070483325	179	Product used for unknown indication
1070483325	180	Product used for unknown indication
1070483325	181	Product used for unknown indication
1070483325	182	Product used for unknown indication
1070483325	183	Product used for unknown indication
1070483325	184	Product used for unknown indication
1070483325	185	Product used for unknown indication
1070483325	186	Product used for unknown indication
1070483325	187	Product used for unknown indication
1070483325	188	Product used for unknown indication
1070483325	189	Product used for unknown indication
1070483325	190	Product used for unknown indication
1070483325	191	Product used for unknown indication
1070483325	192	Product used for unknown indication
1070483325	194	Product used for unknown indication
1070483325	195	Product used for unknown indication
1070483325	196	Product used for unknown indication
1070483325	197	Product used for unknown indication
1070483325	198	Product used for unknown indication
1070483325	199	Product used for unknown indication
1070483325	200	Product used for unknown indication
1070483325	201	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	202	Product used for unknown indication
1070483325	203	Product used for unknown indication
1070483325	204	Product used for unknown indication
1070483325	206	Product used for unknown indication
1070483325	207	Product used for unknown indication
1070483325	211	Product used for unknown indication
1070483325	212	Product used for unknown indication
1070483325	213	Product used for unknown indication
1070483325	214	Product used for unknown indication
1070483325	215	Product used for unknown indication
1070483325	218	Product used for unknown indication
1070483325	219	Product used for unknown indication
1070483325	220	Product used for unknown indication
1070483325	221	Product used for unknown indication
1070483325	225	Product used for unknown indication
1070483325	226	Product used for unknown indication
1070483325	227	Product used for unknown indication
1070483325	228	Product used for unknown indication
1070483325	229	Product used for unknown indication
1070483325	230	Product used for unknown indication
1070483325	231	Product used for unknown indication
1070483325	232	Product used for unknown indication
1070483325	233	Product used for unknown indication
1070483325	234	Product used for unknown indication
1070483325	235	Product used for unknown indication
1070483325	236	Product used for unknown indication
1070483325	237	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1070483325	238	Product used for unknown indication
1070483325	240	Product used for unknown indication
1070483325	241	Product used for unknown indication
1070483325	242	Pain
1070483325	243	Product used for unknown indication
1070483325	244	Product used for unknown indication
1070483325	245	Product used for unknown indication
1070483325	246	Product used for unknown indication
1070483325	247	Product used for unknown indication
1070483325	248	Product used for unknown indication
1070483325	253	Product used for unknown indication
1070483325	254	Product used for unknown indication
1070483325	255	Product used for unknown indication
1070483325	256	Product used for unknown indication
1070483325	263	Product used for unknown indication
1070483325	264	Product used for unknown indication
1070483325	265	Product used for unknown indication
1070483325	266	Product used for unknown indication
1070483325	267	Product used for unknown indication
1070483325	268	Product used for unknown indication
1070483325	269	Product used for unknown indication
1070483325	270	Product used for unknown indication
1070483325	271	Product used for unknown indication
107314353	1	Attention deficit hyperactivity disorder
107314353	3	Attention deficit hyperactivity disorder
107314353	5	Attention deficit hyperactivity disorder
107316442	1	Onychomycosis

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
107316442	2	Product used for unknown indication
1074008517	1	Rheumatoid arthritis
1074008517	6	Product used for unknown indication
1074008517	7	Product used for unknown indication
1074008517	8	Fluid imbalance
1074008517	9	Premedication
1074008517	11	Premedication
1074008517	22	Tachycardia
1074008517	23	Product used for unknown indication
1074008517	24	Premedication
1074008517	25	Premedication
1074008517	26	Product used for unknown indication
107408544	1	Rheumatoid arthritis
1074197911	1	Rheumatoid arthritis
107584123	1	Bipolar disorder
107584123	2	Seizure
107584123	3	Product used for unknown indication
1075880717	1	Hormone replacement therapy
1075880717	2	Osteoporosis
1075880717	3	Bone disorder
1075880717	4	Bone density abnormal
1075880717	6	Arthritis
1075880717	7	Back pain
1075880717	8	Panic attack
1078729218	1	Asthma
1078729218	2	Asthma
1080136616	1	Polymyositis

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1080136616	2	Dermatomyositis
1080136616	3	Product used for unknown indication
1080136616	4	Product used for unknown indication
1080136616	5	Product used for unknown indication
1080136616	6	Product used for unknown indication
1080136616	7	Product used for unknown indication
1080136616	8	Product used for unknown indication
1080136616	9	Contrast media allergy
1080136616	10	Premedication
1080136616	11	Premedication
1080136616	12	Premedication
108390175	1	Hypertension
108390175	2	Hypertension
108390175	4	Hypertension
108390175	5	Influenza like illness
108390175	6	Dyspnoea
108390175	7	Catarrh
108824172	1	Testis cancer
108824172	2	Testis cancer
108824172	3	Testis cancer
1088288812	1	Rheumatoid arthritis
1088288812	4	Hypertension
1088288812	5	Diabetes mellitus
1088288812	6	Diabetes mellitus
1088288812	7	Blood cholesterol abnormal
109031962	1	Agitation
109031962	3	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
109031962	4	Product used for unknown indication
109031962	5	Delirium
109031962	7	Product used for unknown indication
109031962	8	Product used for unknown indication
109108923	1	Narcolepsy
109108923	4	Diabetes mellitus
109108923	5	Hypertension
109108923	6	Restless legs syndrome
109108923	7	Narcolepsy
109108923	8	Vitamin D deficiency
109108923	9	Anaemia
109108923	10	Neuropathy peripheral
109108923	11	Intervertebral disc protrusion
109108923	12	Spinal cord compression
109108923	13	Hypertension
109108923	14	Product used for unknown indication
109108923	15	Product used for unknown indication
109108923	16	Product used for unknown indication
109108923	17	Product used for unknown indication
109174139	1	Depression
109174139	2	Product used for unknown indication
109174139	4	Depression
109174139	5	Depression
109174139	6	Depression
109174139	7	Depression
109174139	8	Depression
109174139	10	Depression

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
109174139	11	Depression
109174139	12	Depression
109174139	13	Depression
109174139	14	Depression
109174139	15	Depression
109174139	16	Depression
109174139	17	Depression
109174139	18	Depression
109174139	19	Depression
109174139	20	Depression
109174139	21	Depression
109174139	22	Depression
109174139	23	Depression
1092018038	1	Muckle-Wells syndrome
109448672	1	Aggression
109448672	2	Product used for unknown indication
109651512	1	Central nervous system lymphoma
109651512	2	Central nervous system lymphoma
109651512	3	Central nervous system lymphoma
109651512	4	Central nervous system lymphoma
109680288	1	Cataplexy
109680288	2	Narcolepsy
109680288	3	Somnolence
109680288	4	Product used for unknown indication
109680288	5	Product used for unknown indication
109680288	6	Product used for unknown indication
1097587654	1	Neuroendocrine tumour

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1097587654	12	Product used for unknown indication
1098206364	1	HER2 positive breast cancer
1098206364	8	Product used for unknown indication
1098206364	9	Breast cancer metastatic
1098206364	13	Breast cancer metastatic
1098206364	16	Product used for unknown indication
1098206364	17	Product used for unknown indication
1098206364	18	Pain
1098206364	21	Premedication
1098206364	22	Breast cancer
1098206364	24	Flushing
109893399	1	Rheumatoid arthritis
1099047564	1	Rheumatoid arthritis
1099047564	15	Product used for unknown indication
109916134	1	Smoking cessation therapy
109916134	5	Blood pressure abnormal
109916134	9	Anxiety
109922307	1	Pyrexia
109922307	2	Stem cell transplant
109922307	3	Prophylaxis against graft versus host disease
109922307	4	Proteus test positive
109922307	5	Allogenic stem cell transplantation
109922307	6	Prophylaxis against graft versus host disease
109922307	7	Allogenic stem cell transplantation
109922307	8	Prophylaxis against graft versus host disease
109922307	9	Pyrexia
109922307	10	Pyrexia

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
109922307	11	Allogenic stem cell transplantation
109922307	12	Pyrexia
109948122	1	Mucopolysaccharidosis VI
109948122	3	Product used for unknown indication
109948122	4	Product used for unknown indication
109948122	5	Product used for unknown indication
109948122	6	Product used for unknown indication
109971003	1	Type IIa hyperlipidaemia
109971003	8	Carotid artery disease
109971003	10	Osteoporosis prophylaxis
109971003	11	Supplementation therapy
109971003	12	Insomnia
109971003	13	Supplementation therapy
109971003	14	Supplementation therapy
109971003	16	Chest pain
109971003	17	Product used for unknown indication
109971003	18	Product used for unknown indication
109971003	19	Mental disorder
109971003	20	Product used for unknown indication
109971003	21	Product used for unknown indication
109971003	22	Nausea
109971003	23	Vomiting
109971003	24	Depression
109971003	25	Vitamin D deficiency
1102019552	1	Rheumatoid arthritis
1102019552	10	Hypertension
1102019552	11	Diabetes mellitus

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1102019552	12	Diabetes mellitus
1102019552	17	Product used for unknown indication
1102109863	1	Asthma
1102109863	63	Product used for unknown indication
1102109863	64	Dyspnoea exertional
1102109863	65	Dyspnoea
1102109863	66	Asthma
1102109863	74	Product used for unknown indication
1102109863	75	Asthma
1102109863	80	Product used for unknown indication
1102109863	81	Product used for unknown indication
1102109863	83	Product used for unknown indication
1102109863	84	Product used for unknown indication
1102109863	85	Product used for unknown indication
110215902	1	Proteus test positive
110215902	2	Culture stool positive
110215902	3	Pyrexia
110215902	4	Proteus test positive
110215902	5	Pyrexia
110215902	6	Pyrexia
110215902	7	Bone marrow conditioning regimen
110215902	8	Chemotherapy
110215902	9	Chronic myeloid leukaemia
110215902	10	Chemotherapy
110215902	11	Chronic myeloid leukaemia
110215902	12	Chemotherapy
110215902	13	Chronic myeloid leukaemia

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
110215902	14	Bone marrow conditioning regimen
110215902	15	Bone marrow conditioning regimen
110215902	16	Allogenic stem cell transplantation
110215902	17	Prophylaxis against graft versus host disease
110215902	18	Allogenic stem cell transplantation
110215902	19	Prophylaxis against graft versus host disease
110215902	20	Prophylaxis against graft versus host disease
110215902	21	Stem cell transplant
110215902	22	Pyrexia
1102411313	1	Neuroendocrine carcinoma
1102411313	4	Neuroendocrine carcinoma
1102411313	5	Product used for unknown indication
1102411313	6	Product used for unknown indication
1102411313	7	Product used for unknown indication
1102411313	8	Product used for unknown indication
1102411313	9	Product used for unknown indication
110462235	1	Pyrexia
110462235	2	Proteus test positive
110462235	3	Culture stool positive
110462235	4	Pyrexia
110462235	5	Chronic myeloid leukaemia
110462235	6	Chemotherapy
110462235	7	Pyrexia
110462235	8	Proteus test positive
110462235	9	Prophylaxis
110462235	10	Aspergillus test positive
110462235	11	Stem cell transplant

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
110462235	12	Prophylaxis against graft versus host disease
110462235	13	Chronic myeloid leukaemia
110462235	14	Chemotherapy
110462235	15	Chronic myeloid leukaemia
110462235	16	Prophylaxis against graft versus host disease
110462235	17	Allogenic stem cell transplantation
110462235	18	Bone marrow conditioning regimen
110462235	19	Chronic myeloid leukaemia
110462235	20	Pyrexia
110462235	21	Product used for unknown indication
110462235	22	Prophylaxis
110462235	23	Stem cell transplant
110462235	24	Allogenic stem cell transplantation
110462235	25	Product used for unknown indication
110462235	26	Aspergillus test positive
110462235	27	Allogenic stem cell transplantation
110462235	28	Bone marrow conditioning regimen
110471852	1	Psoriatic arthropathy
110577006	1	Multiple sclerosis
110577006	3	Product used for unknown indication
110577006	4	Product used for unknown indication
110577006	5	Product used for unknown indication
110577006	6	Product used for unknown indication
110577006	7	Product used for unknown indication
110577006	8	Product used for unknown indication
110734563	1	Hereditary angioedema
110734563	2	Hereditary angioedema

ADVERSE EVENT REPORTING SYSTEM (AERS)

Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
110734563	3	Immune system disorder
110734563	4	Immune system disorder
110734563	5	Immune system disorder
110755913	1	Malignant melanoma
1107567522	1	Acromegaly
1107567522	2	Gastroenteropancreatic neuroendocrine tumour disease
1107567522	4	Cardiac disorder
1107567522	5	Cardiac disorder
1107567522	6	Product used for unknown indication
1107567522	7	Product used for unknown indication
1107567522	8	Hypertension
110781863	1	Attention deficit hyperactivity disorder
110781863	2	Obsessive-compulsive disorder
110781863	3	Product used for unknown indication
1109083723	1	Product used for unknown indication
1109083723	2	Product used for unknown indication
1109083723	3	Product used for unknown indication
1109083723	4	Product used for unknown indication
1109083723	5	Product used for unknown indication
1109083723	6	Product used for unknown indication
1109083723	7	Product used for unknown indication
1109083723	8	Product used for unknown indication
1109083723	9	Product used for unknown indication
1109083723	10	Product used for unknown indication
1109083723	11	Product used for unknown indication
1109083723	12	Product used for unknown indication
1109083723	13	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	14	Product used for unknown indication
1109083723	15	Product used for unknown indication
1109083723	16	Product used for unknown indication
1109083723	17	Product used for unknown indication
1109083723	18	Product used for unknown indication
1109083723	19	Product used for unknown indication
1109083723	20	Product used for unknown indication
1109083723	21	Product used for unknown indication
1109083723	22	Product used for unknown indication
1109083723	23	Product used for unknown indication
1109083723	24	Product used for unknown indication
1109083723	25	Product used for unknown indication
1109083723	26	Product used for unknown indication
1109083723	27	Product used for unknown indication
1109083723	28	Pain
1109083723	29	Pain
1109083723	30	Pain
1109083723	31	Product used for unknown indication
1109083723	32	Product used for unknown indication
1109083723	33	Product used for unknown indication
1109083723	34	Product used for unknown indication
1109083723	35	Product used for unknown indication
1109083723	36	Product used for unknown indication
1109083723	37	Product used for unknown indication
1109083723	38	Product used for unknown indication
1109083723	39	Product used for unknown indication
1109083723	40	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	41	Product used for unknown indication
1109083723	42	Product used for unknown indication
1109083723	43	Product used for unknown indication
1109083723	44	Product used for unknown indication
1109083723	45	Product used for unknown indication
1109083723	46	Product used for unknown indication
1109083723	47	Product used for unknown indication
1109083723	48	Product used for unknown indication
1109083723	49	Product used for unknown indication
1109083723	50	Product used for unknown indication
1109083723	51	Product used for unknown indication
1109083723	52	Product used for unknown indication
1109083723	53	Product used for unknown indication
1109083723	54	Product used for unknown indication
1109083723	55	Product used for unknown indication
1109083723	56	Product used for unknown indication
1109083723	57	Product used for unknown indication
1109083723	58	Product used for unknown indication
1109083723	59	Product used for unknown indication
1109083723	60	Product used for unknown indication
1109083723	61	Product used for unknown indication
1109083723	63	Product used for unknown indication
1109083723	64	Product used for unknown indication
1109083723	75	Product used for unknown indication
1109083723	76	Pain
1109083723	77	Product used for unknown indication
1109083723	78	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	79	Product used for unknown indication
1109083723	80	Product used for unknown indication
1109083723	81	Product used for unknown indication
1109083723	82	Product used for unknown indication
1109083723	83	Product used for unknown indication
1109083723	84	Product used for unknown indication
1109083723	85	Product used for unknown indication
1109083723	86	Product used for unknown indication
1109083723	87	Product used for unknown indication
1109083723	88	Product used for unknown indication
1109083723	89	Product used for unknown indication
1109083723	90	Product used for unknown indication
1109083723	91	Product used for unknown indication
1109083723	92	Product used for unknown indication
1109083723	93	Product used for unknown indication
1109083723	95	Product used for unknown indication
1109083723	96	Pain
1109083723	97	Product used for unknown indication
1109083723	98	Product used for unknown indication
1109083723	99	Product used for unknown indication
1109083723	100	Product used for unknown indication
1109083723	101	Product used for unknown indication
1109083723	102	Product used for unknown indication
1109083723	103	Product used for unknown indication
1109083723	104	Product used for unknown indication
1109083723	105	Product used for unknown indication
1109083723	106	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	107	Product used for unknown indication
1109083723	108	Product used for unknown indication
1109083723	109	Product used for unknown indication
1109083723	110	Product used for unknown indication
1109083723	111	Product used for unknown indication
1109083723	112	Product used for unknown indication
1109083723	113	Product used for unknown indication
1109083723	114	Product used for unknown indication
1109083723	115	Product used for unknown indication
1109083723	116	Product used for unknown indication
1109083723	117	Product used for unknown indication
1109083723	118	Product used for unknown indication
1109083723	119	Product used for unknown indication
1109083723	120	Product used for unknown indication
1109083723	121	Product used for unknown indication
1109083723	122	Product used for unknown indication
1109083723	123	Product used for unknown indication
1109083723	124	Product used for unknown indication
1109083723	125	Product used for unknown indication
1109083723	126	Product used for unknown indication
1109083723	127	Product used for unknown indication
1109083723	128	Product used for unknown indication
1109083723	129	Product used for unknown indication
1109083723	130	Product used for unknown indication
1109083723	131	Product used for unknown indication
1109083723	132	Product used for unknown indication
1109083723	133	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	134	Product used for unknown indication
1109083723	135	Product used for unknown indication
1109083723	138	Product used for unknown indication
1109083723	140	Product used for unknown indication
1109083723	141	Product used for unknown indication
1109083723	142	Product used for unknown indication
1109083723	143	Product used for unknown indication
1109083723	146	Product used for unknown indication
1109083723	147	Product used for unknown indication
1109083723	151	Product used for unknown indication
1109083723	155	Product used for unknown indication
1109083723	156	Product used for unknown indication
1109083723	157	Product used for unknown indication
1109083723	158	Product used for unknown indication
1109083723	159	Product used for unknown indication
1109083723	160	Product used for unknown indication
1109083723	161	Product used for unknown indication
1109083723	164	Product used for unknown indication
1109083723	165	Product used for unknown indication
1109083723	166	Product used for unknown indication
1109083723	167	Product used for unknown indication
1109083723	168	Product used for unknown indication
1109083723	169	Product used for unknown indication
1109083723	170	Product used for unknown indication
1109083723	171	Product used for unknown indication
1109083723	172	Product used for unknown indication
1109083723	173	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	174	Product used for unknown indication
1109083723	175	Product used for unknown indication
1109083723	176	Product used for unknown indication
1109083723	177	Product used for unknown indication
1109083723	179	Product used for unknown indication
1109083723	191	Product used for unknown indication
1109083723	200	Product used for unknown indication
1109083723	201	Product used for unknown indication
1109083723	202	Product used for unknown indication
1109083723	204	Product used for unknown indication
1109083723	205	Product used for unknown indication
1109083723	206	Product used for unknown indication
1109083723	207	Product used for unknown indication
1109083723	213	Product used for unknown indication
1109083723	214	Product used for unknown indication
1109083723	215	Product used for unknown indication
1109083723	216	Product used for unknown indication
1109083723	217	Product used for unknown indication
1109083723	218	Product used for unknown indication
1109083723	219	Product used for unknown indication
1109083723	220	Pain
1109083723	221	Product used for unknown indication
1109083723	222	Product used for unknown indication
1109083723	223	Product used for unknown indication
1109083723	224	Product used for unknown indication
1109083723	225	Product used for unknown indication
1109083723	226	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	227	Product used for unknown indication
1109083723	228	Product used for unknown indication
1109083723	229	Product used for unknown indication
1109083723	230	Product used for unknown indication
1109083723	231	Product used for unknown indication
1109083723	232	Product used for unknown indication
1109083723	233	Product used for unknown indication
1109083723	234	Product used for unknown indication
1109083723	235	Product used for unknown indication
1109083723	236	Product used for unknown indication
1109083723	237	Product used for unknown indication
1109083723	238	Product used for unknown indication
1109083723	239	Pain
1109083723	240	Product used for unknown indication
1109083723	241	Product used for unknown indication
1109083723	242	Product used for unknown indication
1109083723	243	Product used for unknown indication
1109083723	244	Product used for unknown indication
1109083723	245	Product used for unknown indication
1109083723	246	Product used for unknown indication
1109083723	247	Product used for unknown indication
1109083723	248	Product used for unknown indication
1109083723	249	Product used for unknown indication
1109083723	250	Product used for unknown indication
1109083723	251	Product used for unknown indication
1109083723	252	Product used for unknown indication

ADVERSE EVENT REPORTING SYSTEM (AERS)
Indication Listings

<i>Unique number for identifying a FAERS re</i>	<i>Drug sequence number for identifying a d</i>	<i>Preferred Term-level medical terminology</i>
1109083723	253	Product used for unknown indication
1109083723	254	Product used for unknown indication

Summary Tables

The Summary Tables section presents aggregated safety data to support pharmacovigilance signal detection and risk evaluation. These tables include analyses of adverse events by System Organ Class (SOC) and Preferred Term (PT), drug-event frequencies, patient outcomes (e.g., death, hospitalization), and demographic trends (e.g., gender, age groups).

The data are summarized to provide a high-level overview of potential safety concerns and reporting patterns across the database.

Demographic Summary Table Derived Age Group

		Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
AGE (YEARS)	N	27299	52972	112E3	39042	232E3
	MEAN	13.60	39.52	63.93	81.73	55.41
	MEDIAN	14.00	40.00	64.00	80.00	60.00
	GM	13.60	39.52	63.93	81.73	55.41
	MIN	0.00	26.00	51.00	76.00	0.00
	MAX	25.00	50.00	75.00	700.0	700.0
	RANGE	0-25	26-50	51-75	76-700	0-700
	STD	7.47	7.10	6.91	6.30	21.54
GENDER	M	13148 (48.2)	18824 (35.5)	45791 (40.8)	17412 (44.6)	95175 (.)
	F	13156 (48.2)	33152 (62.6)	64255 (57.3)	20645 (52.9)	131208 (.)
	U	14 (0.1)	29 (0.1)	54 (0.0)	19 (0.0)	116 (.)
OCCUPATION	HP	7140 (26.2)	13985 (26.4)	24866 (22.2)	7240 (18.5)	53231 (.)
	MD	9987 (36.6)	16735 (31.6)	32657 (29.1)	10399 (26.6)	69778 (.)
	PH	1022 (3.7)	2667 (5.0)	6826 (6.1)	3420 (8.8)	13935 (.)
	LW	362 (1.3)	593 (1.1)	610 (0.5)	48 (0.1)	1613 (.)
	CN	8505 (31.2)	17801 (33.6)	44223 (39.4)	17083 (43.8)	87612 (.)
REPORT	EXP	15003 (55.0)	33251 (62.8)	66923 (59.6)	24270 (62.2)	139447 (.)
	PER	8716 (31.9)	16262 (30.7)	37631 (33.5)	12475 (32.0)	75084 (.)
	DIR	788 (2.9)	2690 (5.1)	6006 (5.4)	1858 (4.8)	11342 (.)
	5DAY	7 (0.0)	48 (0.1)	137 (0.1)	23 (0.1)	215 (.)
	30DAY	2785 (10.2)	721 (1.4)	1502 (1.3)	416 (1.1)	5424 (.)
Weight (KILOGRAMS)	N	6377	12059	28574	9408	56418
	MEAN	45.89	78.97	80.03	70.76	74.40
	MEDIAN	45.60	74.80	73.01	69.00	70.31
	GM	45.89	78.97	80.03	70.76	74.40
	MIN	0.12	0.00	0.00	3.00	0.00
	MAX	291.6	390.0	87075	220.0	87075

Demographic Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
RANGE	0.117-291.6	0-390	0-87075	3-220	0-87075
STD	30.28	25.28	515.2	18.84	367.2

Drug Summary Table
Derived Age Group

		Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
DECHALLENGE	Y	8300 (9.2%)	20084 (22.2%)	46171 (51.0%)	15954 (17.6%)	90509
	N	1242 (7.6%)	3822 (23.3%)	8747 (53.4%)	2558 (15.6%)	16369
	U	35635 (8.2%)	134900 (31.2%)	189151 (43.7%)	72861 (16.8%)	432547
	D	13910 (10.4%)	38574 (28.8%)	57000 (42.6%)	24469 (18.3%)	133953
RECHALLENGE	Y	230 (9.7%)	548 (23.2%)	1259 (53.3%)	324 (13.7%)	2361
	N	355 (6.4%)	1611 (29.0%)	2797 (50.4%)	785 (14.1%)	5548
	U	12934 (15.3%)	23145 (27.3%)	36700 (43.3%)	11914 (14.1%)	84693
	D	405 (6.7%)	1569 (25.8%)	3309 (54.4%)	804 (13.2%)	6087
ROLE	Primary Suspect Drug	27306 (11.8%)	52981 (22.9%)	112170 (48.5%)	39039 (16.9%)	231496
	Secondary Suspect Drug	44835 (9.3%)	157234 (32.6%)	206943 (43.0%)	72795 (15.1%)	481807
	Concomitant	32182 (6.7%)	104405 (21.8%)	256845 (53.7%)	84829 (17.7%)	478261
	Interacting	749 (8.1%)	2071 (22.3%)	2945 (31.7%)	3525 (37.9%)	9290
ROUTE	Un	27750 (7.9%)	101318 (28.7%)	165245 (46.7%)	59181 (16.7%)	353494
	Or	14456 (6.6%)	52120 (23.7%)	107486 (48.8%)	46137 (21.0%)	220199
	Su	12398 (11.8%)	35091 (33.3%)	46580 (44.3%)	11174 (10.6%)	105243
	In	11442 (12.4%)	26790 (29.1%)	42843 (46.6%)	10843 (11.8%)	91918
	In	1312 (6.8%)	3994 (20.8%)	11289 (58.9%)	2575 (13.4%)	19170
	Ot	1091 (8.6%)	3744 (29.3%)	5932 (46.5%)	1993 (15.6%)	12760
	In	923 (12.4%)	2106 (28.2%)	3664 (49.1%)	776 (10.4%)	7469
	To	381 (7.7%)	1928 (38.9%)	1836 (37.0%)	812 (16.4%)	4957
	Re	290 (6.7%)	648 (15.0%)	2051 (47.5%)	1332 (30.8%)	4321
	Tr	2359 (84.3%)	394 (14.1%)	39 (1.4%)	8 (0.3%)	2800
	Op	74 (3.9%)	426 (22.6%)	929 (49.3%)	454 (24.1%)	1883
	In	124 (6.6%)	524 (28.1%)	965 (51.7%)	255 (13.7%)	1868
	In	2 (0.1%)	1403 (86.0%)	222 (13.6%)	5 (0.3%)	1632
	In	393 (27.6%)	485 (34.1%)	481 (33.8%)	63 (4.4%)	1422
	In	328 (23.6%)	1019 (73.4%)	41 (3.0%)	0 (0.0%)	1388

Drug Summary Table Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Na	142 (11.4%)	267 (21.5%)	680 (54.7%)	155 (12.5%)	1244
Tr	106 (8.5%)	213 (17.1%)	600 (48.3%)	324 (26.1%)	1243
Re	78 (7.1%)	338 (30.7%)	163 (14.8%)	521 (47.4%)	1100
In	60 (6.7%)	204 (22.7%)	467 (51.9%)	169 (18.8%)	900
Cu	25 (2.9%)	637 (74.6%)	151 (17.7%)	41 (4.8%)	854
In	7 (0.9%)	657 (85.5%)	83 (10.8%)	21 (2.7%)	768
En	6 (0.9%)	549 (78.1%)	136 (19.3%)	12 (1.7%)	703
Va	13 (2.1%)	173 (28.5%)	321 (53.0%)	99 (16.3%)	606
Su	43 (9.6%)	165 (36.7%)	199 (44.3%)	42 (9.4%)	449
In	23 (5.8%)	144 (36.3%)	209 (52.6%)	21 (5.3%)	397
Pa	34 (8.7%)	93 (23.8%)	211 (54.0%)	53 (13.6%)	391
Bu	9 (2.3%)	278 (72.2%)	70 (18.2%)	28 (7.3%)	385
In	15 (4.0%)	39 (10.4%)	205 (54.7%)	116 (30.9%)	375
Ep	19 (8.4%)	151 (66.8%)	54 (23.9%)	2 (0.9%)	226
In	5 (2.7%)	137 (73.3%)	36 (19.3%)	9 (4.8%)	187
In	3 (1.9%)	31 (19.6%)	29 (18.4%)	95 (60.1%)	158
Ur	2 (1.3%)	122 (81.9%)	24 (16.1%)	1 (0.7%)	149
Su	10 (8.3%)	89 (74.2%)	16 (13.3%)	5 (4.2%)	120
De	20 (22.2%)	36 (40.0%)	30 (33.3%)	4 (4.4%)	90
In	11 (14.9%)	20 (27.0%)	41 (55.4%)	2 (2.7%)	74
Pe	0 (0.0%)	56 (87.5%)	8 (12.5%)	0 (0.0%)	64
Tr	56 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	56
In	2 (3.8%)	25 (48.1%)	25 (48.1%)	0 (0.0%)	52
In	16 (35.6%)	16 (35.6%)	13 (28.9%)	0 (0.0%)	45
Or	1 (2.3%)	17 (38.6%)	22 (50.0%)	4 (9.1%)	44
Au	3 (7.0%)	12 (27.9%)	21 (48.8%)	7 (16.3%)	43
In	2 (5.9%)	2 (5.9%)	30 (88.2%)	0 (0.0%)	34

Drug Summary Table
Derived Age Group

		<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
	In	0 (0.0%)	12 (63.2%)	7 (36.8%)	0 (0.0%)	19
	In	2 (11.1%)	15 (83.3%)	1 (5.6%)	0 (0.0%)	18
	In	3 (18.8%)	5 (31.3%)	5 (31.3%)	3 (18.8%)	16
	In	0 (0.0%)	4 (28.6%)	9 (64.3%)	1 (7.1%)	14
	In	1 (7.7%)	10 (76.9%)	2 (15.4%)	0 (0.0%)	13
	En	0 (0.0%)	1 (7.7%)	7 (53.8%)	5 (38.5%)	13
	Oc	1 (7.7%)	8 (61.5%)	4 (30.8%)	0 (0.0%)	13
	In	0 (0.0%)	6 (50.0%)	4 (33.3%)	2 (16.7%)	12
	He	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
	In	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
	In	1 (12.5%)	1 (12.5%)	4 (50.0%)	2 (25.0%)	8
	In	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
	lo	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
	En	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
	Pe	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
	Re	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
	In	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
	In	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
	In	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
	Ex	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
	In	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
VALUE VERBATIM	Va	104021 (8.8%)	313888 (26.4%)	571404 (48.1%)	197759 (16.7%)	1187072
	Ve	1051 (7.6%)	2803 (20.3%)	7499 (54.4%)	2429 (17.6%)	13782

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Off label use	2900 (14.6%)	4796 (24.2%)	9115 (46.0%)	2997 (15.1%)	19808
Fatigue	636 (5.0%)	3536 (27.8%)	6694 (52.6%)	1863 (14.6%)	12729
Drug ineffective	1612 (12.7%)	3822 (30.2%)	5924 (46.8%)	1312 (10.4%)	12670
Diarrhoea	1297 (12.1%)	2137 (20.0%)	5527 (51.7%)	1732 (16.2%)	10693
Death	234 (2.3%)	894 (8.9%)	4796 (47.9%)	4090 (40.8%)	10014
Nausea	722 (7.5%)	2768 (28.6%)	5059 (52.3%)	1118 (11.6%)	9667
COVID-19	475 (5.4%)	2348 (26.9%)	4830 (55.3%)	1083 (12.4%)	8736
Pain	504 (6.1%)	2577 (31.0%)	4375 (52.6%)	863 (10.4%)	8319
Headache	678 (8.3%)	2865 (35.1%)	3975 (48.7%)	641 (7.9%)	8159
Product dose omission issue	914 (11.5%)	2149 (27.1%)	3814 (48.1%)	1050 (13.2%)	7927
Dyspnoea	461 (6.3%)	1779 (24.3%)	3867 (52.8%)	1219 (16.6%)	7326
Arthralgia	385 (5.3%)	2178 (30.0%)	4029 (55.5%)	663 (9.1%)	7255
Pruritus	987 (14.3%)	1983 (28.8%)	3161 (45.9%)	750 (10.9%)	6881
Rash	826 (13.0%)	1685 (26.6%)	3071 (48.5%)	753 (11.9%)	6335
Vomiting	1030 (16.3%)	1754 (27.8%)	2832 (44.9%)	687 (10.9%)	6303
Pyrexia	1093 (17.6%)	1700 (27.4%)	2847 (45.9%)	569 (9.2%)	6209
Drug dose omission by device	1435 (23.4%)	543 (8.8%)	3056 (49.8%)	1107 (18.0%)	6141
Malaise	334 (5.5%)	1572 (25.9%)	3229 (53.2%)	939 (15.5%)	6074
Dizziness	387 (6.5%)	1676 (28.2%)	2878 (48.5%)	992 (16.7%)	5933
Asthenia	255 (4.6%)	1305 (23.5%)	2877 (51.8%)	1119 (20.1%)	5556
Pneumonia	369 (7.0%)	1005 (19.0%)	2915 (55.2%)	995 (18.8%)	5284
Inappropriate schedule of product administration	728 (14.2%)	1340 (26.1%)	2483 (48.4%)	584 (11.4%)	5135
Fall	259 (5.2%)	674 (13.5%)	2487 (49.9%)	1562 (31.4%)	4982
Cough	498 (10.1%)	1134 (23.0%)	2665 (54.0%)	639 (12.9%)	4936
Condition aggravated	582 (12.3%)	1417 (29.9%)	2202 (46.5%)	535 (11.3%)	4736
Injection site pain	757 (17.4%)	1188 (27.3%)	1960 (45.0%)	449 (10.3%)	4354
Nasopharyngitis	433 (10.1%)	1450 (33.8%)	2026 (47.3%)	376 (8.8%)	4285

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Product use in unapproved indication	621 (14.6%)	1341 (31.5%)	1802 (42.3%)	494 (11.6%)	4258
Weight decreased	351 (8.3%)	955 (22.5%)	2252 (53.0%)	688 (16.2%)	4246
Pain in extremity	229 (5.5%)	1124 (26.8%)	2329 (55.6%)	506 (12.1%)	4188
Decreased appetite	347 (8.9%)	747 (19.2%)	2006 (51.5%)	797 (20.5%)	3897
Device difficult to use	218 (5.9%)	351 (9.4%)	2146 (57.8%)	1000 (26.9%)	3715
Illness	314 (8.6%)	862 (23.7%)	1947 (53.4%)	521 (14.3%)	3644
Abdominal pain	459 (12.8%)	1127 (31.4%)	1649 (46.0%)	350 (9.8%)	3585
Neutropenia	285 (8.0%)	928 (26.0%)	1792 (50.2%)	568 (15.9%)	3573
Anxiety	367 (10.7%)	1330 (38.9%)	1449 (42.4%)	274 (8.0%)	3420
Constipation	199 (5.9%)	596 (17.6%)	1861 (55.0%)	730 (21.6%)	3386
Back pain	137 (4.1%)	872 (25.8%)	1925 (57.1%)	440 (13.0%)	3374
Urinary tract infection	142 (4.2%)	641 (19.2%)	1787 (53.4%)	777 (23.2%)	3347
Hypertension	137 (4.2%)	892 (27.3%)	1679 (51.3%)	563 (17.2%)	3271
Insomnia	235 (7.4%)	1086 (34.3%)	1487 (47.0%)	358 (11.3%)	3166
Gait disturbance	144 (4.7%)	753 (24.8%)	1599 (52.7%)	540 (17.8%)	3036
Incorrect dose administered	574 (19.0%)	824 (27.3%)	1293 (42.9%)	324 (10.7%)	3015
Weight increased	411 (14.1%)	1085 (37.1%)	1227 (42.0%)	201 (6.9%)	2924
Acute kidney injury	256 (8.8%)	510 (17.5%)	1464 (50.4%)	677 (23.3%)	2907
Anaemia	159 (5.6%)	500 (17.8%)	1539 (54.7%)	618 (21.9%)	2816
Abdominal pain upper	260 (9.4%)	841 (30.3%)	1364 (49.1%)	312 (11.2%)	2777
Wrong technique in product usage process	220 (7.9%)	448 (16.1%)	1519 (54.7%)	589 (21.2%)	2776
Drug hypersensitivity	125 (4.5%)	736 (26.6%)	1502 (54.2%)	409 (14.8%)	2772
Peripheral swelling	105 (3.8%)	672 (24.5%)	1449 (52.8%)	520 (18.9%)	2746
Hypotension	238 (8.8%)	607 (22.5%)	1304 (48.3%)	553 (20.5%)	2702
Erythema	359 (13.7%)	760 (29.0%)	1239 (47.3%)	260 (9.9%)	2618
Somnolence	393 (15.1%)	725 (27.9%)	1046 (40.3%)	432 (16.6%)	2596
Accidental exposure to product	238 (9.2%)	598 (23.1%)	1396 (54.0%)	353 (13.7%)	2585

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood pressure increased	94 (3.6%)	533 (20.6%)	1614 (62.5%)	342 (13.2%)	2583
Infection	218 (8.6%)	699 (27.4%)	1288 (50.5%)	343 (13.5%)	2548
Abdominal discomfort	192 (7.6%)	755 (29.8%)	1261 (49.7%)	329 (13.0%)	2537
Dry skin	614 (25.7%)	646 (27.0%)	920 (38.5%)	209 (8.7%)	2389
White blood cell count decreased	72 (3.0%)	390 (16.3%)	1514 (63.4%)	412 (17.3%)	2388
Feeling abnormal	143 (6.1%)	652 (27.6%)	1249 (52.9%)	317 (13.4%)	2361
Toxicity to various agents	535 (22.7%)	746 (31.7%)	863 (36.6%)	211 (9.0%)	2355
Alopecia	126 (5.4%)	699 (29.7%)	1228 (52.2%)	298 (12.7%)	2351
Joint swelling	106 (4.6%)	694 (29.9%)	1289 (55.5%)	234 (10.1%)	2323
Product use issue	367 (15.9%)	657 (28.5%)	998 (43.2%)	286 (12.4%)	2308
Muscle spasms	116 (5.0%)	665 (28.9%)	1219 (53.0%)	301 (13.1%)	2301
Hospitalisation	218 (9.6%)	469 (20.8%)	1093 (48.4%)	480 (21.2%)	2260
Therapy interrupted	92 (4.1%)	503 (22.5%)	1225 (54.8%)	417 (18.6%)	2237
Myalgia	137 (6.1%)	658 (29.5%)	1201 (53.8%)	237 (10.6%)	2233
Influenza	261 (11.7%)	712 (31.9%)	1079 (48.3%)	180 (8.1%)	2232
Hypoaesthesia	130 (5.8%)	872 (39.2%)	1047 (47.1%)	175 (7.9%)	2224
Urticaria	283 (12.8%)	885 (39.9%)	888 (40.1%)	160 (7.2%)	2216
Hypersensitivity	174 (7.9%)	819 (37.2%)	1026 (46.6%)	182 (8.3%)	2201
Depression	207 (9.7%)	843 (39.5%)	923 (43.3%)	161 (7.5%)	2134
Asthma	190 (9.0%)	627 (29.7%)	1107 (52.4%)	189 (8.9%)	2113
Disease recurrence	103 (4.9%)	550 (26.0%)	1281 (60.6%)	179 (8.5%)	2113
Platelet count decreased	116 (5.5%)	305 (14.5%)	1267 (60.4%)	411 (19.6%)	2099
Chest pain	145 (6.9%)	648 (31.0%)	1082 (51.8%)	212 (10.2%)	2087
Sinusitis	126 (6.1%)	703 (34.2%)	1082 (52.7%)	143 (7.0%)	2054
Memory impairment	67 (3.4%)	501 (25.1%)	1063 (53.3%)	363 (18.2%)	1994
Confusional state	91 (4.6%)	498 (25.1%)	895 (45.1%)	502 (25.3%)	1986
Drug interaction	235 (11.9%)	483 (24.5%)	898 (45.5%)	359 (18.2%)	1975

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Seizure	661 (34.0%)	537 (27.6%)	609 (31.3%)	137 (7.0%)	1944
Haemorrhage	577 (29.8%)	631 (32.6%)	539 (27.8%)	191 (9.9%)	1938
Disease progression	123 (6.5%)	458 (24.3%)	1069 (56.7%)	234 (12.4%)	1884
Paraesthesia	121 (6.4%)	770 (41.0%)	842 (44.9%)	144 (7.7%)	1877
Tremor	167 (9.0%)	482 (26.0%)	882 (47.5%)	326 (17.6%)	1857
Chills	150 (8.1%)	574 (31.0%)	941 (50.9%)	184 (10.0%)	1849
Oropharyngeal pain	184 (10.0%)	621 (33.9%)	888 (48.4%)	141 (7.7%)	1834
Thrombocytopenia	171 (9.5%)	343 (19.1%)	977 (54.5%)	303 (16.9%)	1794
Eczema	610 (34.8%)	509 (29.1%)	543 (31.0%)	90 (5.1%)	1752
General physical health deterioration	72 (4.1%)	505 (28.8%)	829 (47.3%)	345 (19.7%)	1751
Therapeutic product effect incomplete	158 (9.2%)	457 (26.6%)	913 (53.1%)	192 (11.2%)	1720
Muscular weakness	75 (4.4%)	543 (32.0%)	814 (48.0%)	265 (15.6%)	1697
Malignant neoplasm progression	33 (2.0%)	251 (14.9%)	1084 (64.3%)	317 (18.8%)	1685
Rheumatoid arthritis	32 (1.9%)	588 (35.2%)	911 (54.5%)	141 (8.4%)	1672
Gastrointestinal disorder	117 (7.0%)	537 (32.2%)	840 (50.4%)	172 (10.3%)	1666
Infusion related reaction	133 (8.3%)	763 (47.5%)	636 (39.6%)	74 (4.6%)	1606
Musculoskeletal stiffness	70 (4.4%)	574 (35.8%)	792 (49.4%)	167 (10.4%)	1603
Sepsis	135 (8.6%)	256 (16.3%)	857 (54.4%)	327 (20.8%)	1575
Haemoglobin decreased	83 (5.3%)	294 (18.8%)	878 (56.3%)	305 (19.6%)	1560
Visual impairment	79 (5.1%)	424 (27.3%)	744 (47.9%)	306 (19.7%)	1553
Hyperhidrosis	111 (7.2%)	521 (33.8%)	766 (49.7%)	144 (9.3%)	1542
Abdominal distension	111 (7.2%)	452 (29.4%)	764 (49.8%)	208 (13.6%)	1535
Dehydration	146 (9.5%)	256 (16.7%)	807 (52.6%)	325 (21.2%)	1534
Neuropathy peripheral	35 (2.3%)	212 (14.0%)	1006 (66.6%)	258 (17.1%)	1511
Loss of consciousness	170 (11.3%)	346 (23.0%)	717 (47.7%)	269 (17.9%)	1502
Drug intolerance	100 (6.7%)	547 (36.5%)	630 (42.0%)	222 (14.8%)	1499
Overdose	318 (21.5%)	517 (35.0%)	463 (31.4%)	178 (12.1%)	1476

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vision blurred	116 (7.9%)	456 (31.0%)	731 (49.7%)	168 (11.4%)	1471
Psoriasis	64 (4.4%)	510 (35.0%)	778 (53.4%)	104 (7.1%)	1456
Hereditary angioedema	254 (17.4%)	823 (56.5%)	364 (25.0%)	15 (1.0%)	1456
Contusion	154 (10.6%)	411 (28.4%)	669 (46.2%)	215 (14.8%)	1449
Cerebrovascular accident	23 (1.6%)	137 (9.5%)	827 (57.3%)	456 (31.6%)	1443
Sleep disorder	239 (16.6%)	515 (35.7%)	551 (38.2%)	137 (9.5%)	1442
Chest discomfort	107 (7.5%)	417 (29.1%)	765 (53.3%)	146 (10.2%)	1435
Myelosuppression	136 (9.7%)	318 (22.7%)	802 (57.2%)	145 (10.3%)	1401
Device leakage	809 (57.8%)	132 (9.4%)	313 (22.4%)	146 (10.4%)	1400
Swelling	96 (6.9%)	538 (38.7%)	604 (43.4%)	153 (11.0%)	1391
Heart rate increased	142 (10.2%)	459 (33.1%)	650 (46.9%)	136 (9.8%)	1387
Blood glucose increased	56 (4.1%)	187 (13.6%)	867 (62.8%)	270 (19.6%)	1380
Renal impairment	56 (4.1%)	221 (16.1%)	753 (54.8%)	344 (25.0%)	1374
Maternal exposure during pregnancy	211 (15.5%)	1104 (81.0%)	47 (3.4%)	1 (0.1%)	1363
Crohn's disease	264 (19.4%)	550 (40.4%)	489 (36.0%)	57 (4.2%)	1360
Migraine	114 (8.4%)	712 (52.4%)	497 (36.6%)	35 (2.6%)	1358
Colitis ulcerative	202 (15.0%)	580 (43.0%)	495 (36.7%)	72 (5.3%)	1349
Intentional product use issue	73 (5.4%)	324 (24.0%)	680 (50.4%)	271 (20.1%)	1348
Febrile neutropenia	283 (21.1%)	220 (16.4%)	644 (48.0%)	194 (14.5%)	1341
Device issue	437 (32.7%)	305 (22.8%)	472 (35.3%)	123 (9.2%)	1337
Arthritis	64 (4.8%)	238 (17.8%)	832 (62.3%)	201 (15.1%)	1335
Rhinorrhoea	157 (11.9%)	344 (26.1%)	678 (51.4%)	140 (10.6%)	1319
Stress	115 (8.7%)	416 (31.6%)	661 (50.2%)	126 (9.6%)	1318
Atrial fibrillation	9 (0.7%)	57 (4.3%)	739 (56.3%)	508 (38.7%)	1313
Bronchitis	80 (6.1%)	314 (24.0%)	775 (59.1%)	142 (10.8%)	1311
Oedema peripheral	51 (3.9%)	290 (22.2%)	669 (51.3%)	295 (22.6%)	1305
Palpitations	67 (5.1%)	476 (36.5%)	623 (47.8%)	137 (10.5%)	1303

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Nasal congestion	170 (13.0%)	413 (31.7%)	636 (48.8%)	84 (6.4%)	1303
Discomfort	151 (11.6%)	537 (41.4%)	520 (40.1%)	89 (6.9%)	1297
Product dose omission in error	221 (17.3%)	331 (25.9%)	612 (47.8%)	115 (9.0%)	1279
Renal failure	85 (6.7%)	292 (22.9%)	668 (52.3%)	232 (18.2%)	1277
Hot flush	21 (1.7%)	240 (19.2%)	721 (57.8%)	265 (21.3%)	1247
Neoplasm progression	27 (2.2%)	167 (13.4%)	792 (63.8%)	256 (20.6%)	1242
Injection site erythema	215 (17.5%)	436 (35.4%)	518 (42.0%)	63 (5.1%)	1232
Balance disorder	51 (4.1%)	228 (18.5%)	631 (51.3%)	321 (26.1%)	1231
No adverse event	199 (16.2%)	410 (33.4%)	484 (39.4%)	136 (11.1%)	1229
Tachycardia	261 (21.3%)	435 (35.5%)	430 (35.1%)	99 (8.1%)	1225
Loss of personal independence in daily activities	75 (6.2%)	319 (26.3%)	664 (54.7%)	157 (12.9%)	1215
Haematochezia	160 (13.2%)	414 (34.1%)	519 (42.8%)	121 (10.0%)	1214
Skin exfoliation	244 (20.1%)	342 (28.2%)	522 (43.1%)	104 (8.6%)	1212
Syncope	155 (12.9%)	320 (26.5%)	494 (41.0%)	237 (19.7%)	1206
Mobility decreased	36 (3.0%)	379 (31.5%)	599 (49.8%)	190 (15.8%)	1204
Neutrophil count decreased	48 (4.1%)	191 (16.3%)	732 (62.5%)	200 (17.1%)	1171
Intentional product misuse	166 (14.2%)	340 (29.2%)	495 (42.5%)	164 (14.1%)	1165
Dermatitis atopic	364 (31.7%)	367 (31.9%)	379 (33.0%)	40 (3.5%)	1150
Dysphagia	93 (8.1%)	265 (23.1%)	566 (49.4%)	221 (19.3%)	1145
Dyspepsia	49 (4.3%)	354 (31.1%)	617 (54.2%)	118 (10.4%)	1138
Wheezing	59 (5.2%)	336 (29.7%)	589 (52.1%)	147 (13.0%)	1131
Treatment failure	238 (21.4%)	490 (44.0%)	330 (29.6%)	56 (5.0%)	1114
Injection site swelling	248 (22.5%)	374 (33.9%)	430 (38.9%)	52 (4.7%)	1104
Dry mouth	26 (2.4%)	396 (36.0%)	524 (47.6%)	155 (14.1%)	1101
Hepatic enzyme increased	94 (8.7%)	429 (39.6%)	482 (44.5%)	79 (7.3%)	1084
Oxygen saturation decreased	139 (12.9%)	188 (17.5%)	586 (54.4%)	164 (15.2%)	1077
Cardiac failure	42 (3.9%)	123 (11.5%)	537 (50.0%)	371 (34.6%)	1073

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Productive cough	72 (6.7%)	207 (19.3%)	630 (58.8%)	162 (15.1%)	1071
Injection site haemorrhage	98 (9.3%)	300 (28.5%)	541 (51.3%)	115 (10.9%)	1054
Hallucination	71 (6.7%)	118 (11.2%)	509 (48.3%)	355 (33.7%)	1053
Stomatitis	54 (5.2%)	316 (30.3%)	546 (52.3%)	127 (12.2%)	1043
Epistaxis	220 (21.2%)	172 (16.5%)	464 (44.6%)	184 (17.7%)	1040
Dry eye	144 (14.0%)	300 (29.2%)	500 (48.6%)	85 (8.3%)	1029
Blood pressure decreased	78 (7.6%)	204 (19.9%)	564 (54.9%)	181 (17.6%)	1027
Product preparation error	60 (5.9%)	168 (16.4%)	637 (62.1%)	160 (15.6%)	1025
Inflammation	103 (10.1%)	411 (40.3%)	455 (44.7%)	50 (4.9%)	1019
Device breakage	778 (76.3%)	127 (12.5%)	94 (9.2%)	20 (2.0%)	1019
Suicidal ideation	184 (18.1%)	466 (45.9%)	327 (32.2%)	38 (3.7%)	1015
Myocardial infarction	10 (1.0%)	146 (14.5%)	605 (60.2%)	244 (24.3%)	1005
Influenza like illness	67 (6.7%)	441 (44.0%)	441 (44.0%)	54 (5.4%)	1003
Blood creatinine increased	41 (4.1%)	206 (20.6%)	539 (54.0%)	212 (21.2%)	998
Intentional overdose	399 (40.0%)	337 (33.8%)	231 (23.1%)	31 (3.1%)	998
Pulmonary embolism	50 (5.1%)	194 (19.8%)	566 (57.6%)	172 (17.5%)	982
Gastroesophageal reflux disease	78 (8.1%)	262 (27.1%)	494 (51.1%)	133 (13.8%)	967
Cardiac disorder	35 (3.6%)	114 (11.9%)	514 (53.4%)	299 (31.1%)	962
Product storage error	109 (11.3%)	185 (19.3%)	501 (52.1%)	166 (17.3%)	961
Herpes zoster	23 (2.4%)	224 (23.3%)	570 (59.3%)	144 (15.0%)	961
Injection site bruising	109 (11.4%)	305 (31.9%)	468 (48.9%)	75 (7.8%)	957
Device malfunction	284 (29.8%)	188 (19.7%)	389 (40.8%)	92 (9.7%)	953
Leukopenia	79 (8.3%)	277 (29.2%)	458 (48.2%)	136 (14.3%)	950
Drug abuse	225 (23.7%)	516 (54.3%)	173 (18.2%)	36 (3.8%)	950
Dysphonia	21 (2.2%)	204 (21.7%)	519 (55.1%)	198 (21.0%)	942
Arthropathy	35 (3.7%)	349 (37.0%)	451 (47.9%)	107 (11.4%)	942
Lower respiratory tract infection	31 (3.3%)	385 (41.2%)	408 (43.7%)	110 (11.8%)	934

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Thrombosis	46 (4.9%)	163 (17.5%)	513 (55.0%)	211 (22.6%)	933
Cardiac arrest	114 (12.3%)	266 (28.7%)	408 (44.0%)	139 (15.0%)	927
Wrong technique in device usage process	494 (53.3%)	104 (11.2%)	254 (27.4%)	74 (8.0%)	926
Device use error	257 (27.8%)	64 (6.9%)	397 (42.9%)	207 (22.4%)	925
Upper respiratory tract infection	89 (9.7%)	281 (30.6%)	459 (50.1%)	88 (9.6%)	917
Respiratory failure	134 (14.6%)	172 (18.8%)	471 (51.4%)	139 (15.2%)	916
Hypoacusis	13 (1.4%)	56 (6.1%)	388 (42.5%)	457 (50.0%)	914
Drug ineffective for unapproved indication	195 (21.3%)	286 (31.3%)	363 (39.7%)	70 (7.7%)	914
Anaphylactic reaction	147 (16.2%)	305 (33.5%)	367 (40.3%)	91 (10.0%)	910
Cytokine release syndrome	64 (7.0%)	152 (16.7%)	594 (65.3%)	99 (10.9%)	909
Interstitial lung disease	23 (2.5%)	90 (9.9%)	518 (57.0%)	277 (30.5%)	908
Psoriatic arthropathy	18 (2.0%)	445 (49.1%)	390 (43.0%)	53 (5.8%)	906
Diabetes mellitus	15 (1.7%)	149 (16.5%)	589 (65.3%)	149 (16.5%)	902
Pancytopenia	85 (9.4%)	152 (16.9%)	485 (53.8%)	180 (20.0%)	902
Pleural effusion	71 (7.9%)	162 (18.0%)	451 (50.1%)	216 (24.0%)	900
Cataract	18 (2.0%)	65 (7.3%)	630 (70.3%)	183 (20.4%)	896
Swelling face	98 (10.9%)	315 (35.2%)	407 (45.4%)	76 (8.5%)	896
Treatment noncompliance	167 (18.7%)	299 (33.4%)	292 (32.6%)	137 (15.3%)	895
Suicide attempt	307 (34.4%)	371 (41.6%)	191 (21.4%)	23 (2.6%)	892
Therapeutic response decreased	181 (20.5%)	268 (30.4%)	365 (41.3%)	69 (7.8%)	883
Neck pain	31 (3.5%)	295 (33.5%)	470 (53.4%)	84 (9.5%)	880
C-reactive protein increased	98 (11.2%)	305 (34.7%)	409 (46.6%)	66 (7.5%)	878
Oedema	63 (7.2%)	277 (31.8%)	398 (45.6%)	134 (15.4%)	872
Therapeutic product effect decreased	72 (8.3%)	383 (44.1%)	332 (38.2%)	81 (9.3%)	868
Rash pruritic	69 (8.0%)	218 (25.4%)	454 (52.9%)	118 (13.7%)	859
Bone pain	31 (3.6%)	242 (28.3%)	498 (58.3%)	83 (9.7%)	854
Adverse drug reaction	127 (15.1%)	251 (29.8%)	356 (42.3%)	108 (12.8%)	842

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Intentional dose omission	104 (12.4%)	257 (30.6%)	363 (43.2%)	116 (13.8%)	840
Hyponatraemia	28 (3.4%)	95 (11.4%)	404 (48.6%)	305 (36.7%)	832
Alanine aminotransferase increased	113 (13.6%)	226 (27.3%)	417 (50.3%)	73 (8.8%)	829
Flushing	68 (8.2%)	267 (32.4%)	414 (50.2%)	76 (9.2%)	825
Blister	47 (5.7%)	351 (42.5%)	339 (41.1%)	88 (10.7%)	825
Therapeutic response shortened	171 (20.8%)	298 (36.2%)	319 (38.7%)	36 (4.4%)	824
Feeling hot	65 (8.0%)	295 (36.3%)	378 (46.6%)	74 (9.1%)	812
Emotional distress	117 (14.5%)	319 (39.4%)	341 (42.2%)	32 (4.0%)	809
Hypokalaemia	75 (9.3%)	141 (17.5%)	426 (52.9%)	164 (20.3%)	806
Depressed mood	83 (10.3%)	225 (28.1%)	416 (51.9%)	78 (9.7%)	802
Adverse event	60 (7.5%)	158 (19.7%)	397 (49.5%)	187 (23.3%)	802
Septic shock	85 (10.7%)	122 (15.4%)	445 (56.0%)	142 (17.9%)	794
Hypothyroidism	28 (3.5%)	189 (23.8%)	470 (59.3%)	106 (13.4%)	793
Underdose	243 (30.7%)	181 (22.9%)	265 (33.5%)	102 (12.9%)	791
Chronic kidney disease	25 (3.2%)	230 (29.1%)	436 (55.2%)	99 (12.5%)	790
Lung disorder	28 (3.5%)	233 (29.5%)	422 (53.5%)	106 (13.4%)	789
Flatulence	82 (10.4%)	172 (21.8%)	432 (54.8%)	102 (12.9%)	788
Therapy non-responder	128 (16.5%)	299 (38.5%)	282 (36.3%)	68 (8.8%)	777
Burning sensation	44 (5.7%)	224 (29.2%)	423 (55.2%)	75 (9.8%)	766
Product prescribing error	171 (22.4%)	140 (18.3%)	300 (39.3%)	153 (20.0%)	764
Dysgeusia	30 (3.9%)	170 (22.3%)	442 (58.0%)	120 (15.7%)	762
Needle issue	144 (18.9%)	216 (28.4%)	333 (43.8%)	68 (8.9%)	761
Exposure via skin contact	161 (21.2%)	163 (21.4%)	357 (46.9%)	80 (10.5%)	761
Vertigo	44 (5.8%)	215 (28.3%)	404 (53.1%)	98 (12.9%)	761
Gait inability	40 (5.3%)	238 (31.3%)	371 (48.8%)	111 (14.6%)	760
Lactic acidosis	63 (8.3%)	131 (17.4%)	438 (58.0%)	123 (16.3%)	755
Cellulitis	61 (8.1%)	199 (26.4%)	404 (53.5%)	91 (12.1%)	755

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Therapy cessation	99 (13.1%)	165 (21.9%)	371 (49.2%)	119 (15.8%)	754
Osteoarthritis	3 (0.4%)	220 (29.6%)	422 (56.8%)	98 (13.2%)	743
Device mechanical issue	647 (87.3%)	28 (3.8%)	52 (7.0%)	14 (1.9%)	741
Hepatic function abnormal	49 (6.6%)	157 (21.3%)	412 (55.8%)	120 (16.3%)	738
Brain fog	41 (5.6%)	222 (30.2%)	388 (52.8%)	84 (11.4%)	735
Neoplasm malignant	9 (1.2%)	127 (17.3%)	450 (61.5%)	146 (19.9%)	732
Exposure during pregnancy	155 (21.2%)	546 (74.7%)	30 (4.1%)	0 (0.0%)	731
Blood cholesterol increased	16 (2.2%)	296 (40.6%)	363 (49.8%)	54 (7.4%)	729
Bradycardia	80 (11.0%)	144 (19.8%)	298 (40.9%)	206 (28.3%)	728
Frequent bowel movements	75 (10.3%)	260 (35.8%)	335 (46.1%)	56 (7.7%)	726
Osteoporosis	15 (2.1%)	214 (30.0%)	406 (56.9%)	79 (11.1%)	714
Agitation	164 (23.1%)	227 (32.0%)	240 (33.9%)	78 (11.0%)	709
Nephrolithiasis	25 (3.6%)	186 (26.4%)	433 (61.5%)	60 (8.5%)	704
Rash erythematous	126 (18.0%)	189 (27.0%)	334 (47.7%)	51 (7.3%)	700
Incorrect dose administered by device	181 (26.0%)	97 (13.9%)	313 (45.0%)	105 (15.1%)	696
Surgery	47 (6.8%)	235 (33.9%)	342 (49.3%)	70 (10.1%)	694
Aspartate aminotransferase increased	103 (14.9%)	166 (24.0%)	341 (49.2%)	83 (12.0%)	693
Speech disorder	41 (5.9%)	160 (23.1%)	364 (52.6%)	127 (18.4%)	692
Liver disorder	35 (5.1%)	234 (34.3%)	324 (47.4%)	90 (13.2%)	683
Viral infection	149 (21.8%)	195 (28.6%)	283 (41.4%)	56 (8.2%)	683
Multiple organ dysfunction syndrome	152 (22.4%)	124 (18.2%)	294 (43.2%)	110 (16.2%)	680
Amnesia	24 (3.6%)	244 (36.1%)	312 (46.2%)	95 (14.1%)	675
Injection site pruritus	104 (15.4%)	247 (36.6%)	286 (42.4%)	37 (5.5%)	674
Extra dose administered	79 (11.8%)	176 (26.3%)	339 (50.7%)	74 (11.1%)	668
Limb injury	103 (15.5%)	148 (22.3%)	316 (47.5%)	98 (14.7%)	665
Plasma cell myeloma	1 (0.2%)	55 (8.3%)	453 (68.3%)	154 (23.2%)	663
Dyspnoea exertional	14 (2.1%)	94 (14.2%)	386 (58.4%)	167 (25.3%)	661

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Eye pruritus	126 (19.1%)	157 (23.8%)	334 (50.7%)	42 (6.4%)	659
Ocular hyperaemia	143 (21.8%)	163 (24.8%)	298 (45.4%)	52 (7.9%)	656
Ear infection	159 (24.6%)	210 (32.5%)	255 (39.5%)	22 (3.4%)	646
Throat irritation	41 (6.4%)	272 (42.3%)	289 (44.9%)	41 (6.4%)	643
Completed suicide	82 (12.8%)	243 (37.9%)	273 (42.6%)	43 (6.7%)	641
Gastrointestinal haemorrhage	57 (8.9%)	91 (14.2%)	304 (47.4%)	189 (29.5%)	641
Angioedema	57 (9.0%)	219 (34.6%)	288 (45.5%)	69 (10.9%)	633
Lethargy	101 (16.0%)	177 (28.1%)	258 (41.0%)	94 (14.9%)	630
Respiratory tract infection	70 (11.1%)	134 (21.3%)	362 (57.5%)	64 (10.2%)	630
Hypoglycaemia	57 (9.1%)	138 (21.9%)	306 (48.6%)	128 (20.3%)	629
Colitis	50 (8.0%)	121 (19.4%)	383 (61.3%)	71 (11.4%)	625
Pulmonary oedema	34 (5.4%)	120 (19.2%)	331 (53.0%)	140 (22.4%)	625
Heart rate decreased	35 (5.7%)	109 (17.7%)	368 (59.7%)	104 (16.9%)	616
Contraindicated product administered	21 (3.4%)	294 (47.7%)	234 (38.0%)	67 (10.9%)	616
Drug-induced liver injury	66 (10.7%)	208 (33.9%)	272 (44.3%)	68 (11.1%)	614
Injection site mass	52 (8.5%)	140 (22.8%)	337 (55.0%)	84 (13.7%)	613
Ill-defined disorder	38 (6.2%)	249 (40.8%)	271 (44.4%)	53 (8.7%)	611
Cognitive disorder	51 (8.3%)	145 (23.7%)	265 (43.4%)	150 (24.5%)	611
Renal disorder	16 (2.6%)	95 (15.6%)	360 (59.1%)	138 (22.7%)	609
SARS-CoV-2 test positive	38 (6.3%)	239 (39.8%)	278 (46.3%)	46 (7.7%)	601
Product availability issue	145 (24.2%)	186 (31.0%)	227 (37.8%)	42 (7.0%)	600
Hypoxia	84 (14.0%)	137 (22.9%)	259 (43.3%)	118 (19.7%)	598
Red blood cell count decreased	15 (2.5%)	95 (15.9%)	358 (59.9%)	130 (21.7%)	598
Multiple sclerosis	26 (4.4%)	338 (56.6%)	224 (37.5%)	9 (1.5%)	597
Limb discomfort	27 (4.5%)	166 (27.9%)	327 (55.0%)	75 (12.6%)	595
Disturbance in attention	72 (12.1%)	192 (32.3%)	281 (47.3%)	49 (8.2%)	594
Blood pressure systolic increased	8 (1.4%)	80 (13.6%)	418 (71.2%)	81 (13.8%)	587

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Eye irritation	102 (17.4%)	168 (28.6%)	249 (42.4%)	68 (11.6%)	587
Rectal haemorrhage	57 (9.8%)	171 (29.3%)	276 (47.3%)	79 (13.6%)	583
Skin disorder	36 (6.2%)	133 (22.9%)	312 (53.6%)	101 (17.4%)	582
Fluid retention	17 (2.9%)	147 (25.3%)	305 (52.6%)	111 (19.1%)	580
Delirium	62 (10.8%)	145 (25.2%)	202 (35.1%)	167 (29.0%)	576
Road traffic accident	51 (8.9%)	273 (47.4%)	205 (35.6%)	47 (8.2%)	576
Taste disorder	9 (1.6%)	143 (25.0%)	309 (53.9%)	112 (19.5%)	573
Skin discolouration	92 (16.2%)	114 (20.0%)	275 (48.3%)	88 (15.5%)	569
Irritability	160 (28.1%)	188 (33.0%)	187 (32.9%)	34 (6.0%)	569
Eye pain	50 (8.8%)	156 (27.6%)	275 (48.7%)	84 (14.9%)	565
Systemic lupus erythematosus	21 (3.7%)	373 (66.0%)	161 (28.5%)	10 (1.8%)	565
Medication error	70 (12.4%)	240 (42.6%)	173 (30.7%)	81 (14.4%)	564
Electrocardiogram QT prolonged	107 (19.1%)	144 (25.7%)	224 (39.9%)	86 (15.3%)	561
Hepatic cytolysis	67 (11.9%)	134 (23.9%)	276 (49.2%)	84 (15.0%)	561
Intestinal obstruction	37 (6.7%)	125 (22.5%)	312 (56.1%)	82 (14.7%)	556
Depressed level of consciousness	91 (16.5%)	118 (21.3%)	224 (40.5%)	120 (21.7%)	553
Cystitis	23 (4.2%)	104 (19.0%)	313 (57.2%)	107 (19.6%)	547
Hyperkalaemia	24 (4.4%)	69 (12.6%)	292 (53.4%)	162 (29.6%)	547
Wound	33 (6.1%)	294 (53.9%)	178 (32.7%)	40 (7.3%)	545
Haemarthrosis	224 (41.2%)	218 (40.1%)	92 (16.9%)	10 (1.8%)	544
Multiple sclerosis relapse	34 (6.3%)	325 (59.9%)	182 (33.5%)	2 (0.4%)	543
Deep vein thrombosis	25 (4.6%)	122 (22.6%)	305 (56.6%)	87 (16.1%)	539
Fungal infection	35 (6.6%)	178 (33.4%)	267 (50.1%)	53 (9.9%)	533
Head injury	106 (20.0%)	65 (12.2%)	221 (41.6%)	139 (26.2%)	531
Injection site reaction	86 (16.3%)	204 (38.6%)	217 (41.0%)	22 (4.2%)	529
Skin lesion	41 (7.8%)	137 (26.0%)	281 (53.3%)	68 (12.9%)	527
Movement disorder	27 (5.1%)	151 (28.7%)	264 (50.1%)	85 (16.1%)	527

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skin fissures	132 (25.2%)	175 (33.4%)	189 (36.1%)	28 (5.3%)	524
Acne	103 (19.7%)	214 (41.0%)	179 (34.3%)	26 (5.0%)	522
Pollakiuria	25 (4.8%)	108 (20.7%)	289 (55.4%)	100 (19.2%)	522
Liver injury	49 (9.4%)	251 (48.2%)	183 (35.1%)	38 (7.3%)	521
Lacrimation increased	37 (7.1%)	103 (19.8%)	320 (61.4%)	61 (11.7%)	521
Rash macular	75 (14.5%)	119 (22.9%)	248 (47.8%)	77 (14.8%)	519
Metabolic acidosis	107 (20.6%)	103 (19.8%)	230 (44.3%)	79 (15.2%)	519
Injury	55 (10.6%)	273 (52.8%)	152 (29.4%)	37 (7.2%)	517
Device expulsion	135 (26.2%)	368 (71.3%)	12 (2.3%)	1 (0.2%)	516
Rhabdomyolysis	61 (11.8%)	147 (28.5%)	212 (41.2%)	95 (18.4%)	515
Lymphadenopathy	72 (14.0%)	144 (28.0%)	251 (48.7%)	48 (9.3%)	515
Epilepsy	115 (22.4%)	186 (36.2%)	150 (29.2%)	63 (12.3%)	514
Oral herpes	50 (9.8%)	194 (38.1%)	242 (47.5%)	23 (4.5%)	509
Product prescribing issue	77 (15.2%)	96 (19.0%)	243 (48.1%)	89 (17.6%)	505
Mental disorder	64 (12.7%)	205 (40.7%)	181 (35.9%)	54 (10.7%)	504
Coma	68 (13.5%)	157 (31.2%)	215 (42.7%)	64 (12.7%)	504
Pancreatitis	53 (10.6%)	159 (31.7%)	240 (47.8%)	50 (10.0%)	502
Chronic obstructive pulmonary disease	2 (0.4%)	36 (7.2%)	326 (65.1%)	137 (27.3%)	501
Impaired healing	14 (2.8%)	280 (56.1%)	172 (34.5%)	33 (6.6%)	499
Fibromyalgia	11 (2.2%)	277 (55.5%)	195 (39.1%)	16 (3.2%)	499
White blood cell count increased	50 (10.0%)	165 (33.1%)	232 (46.6%)	51 (10.2%)	498
Pneumonitis	19 (3.8%)	82 (16.5%)	318 (63.9%)	79 (15.9%)	498
Arrhythmia	29 (5.8%)	129 (26.0%)	245 (49.3%)	94 (18.9%)	497
Drug dependence	76 (15.5%)	242 (49.3%)	143 (29.1%)	30 (6.1%)	491
Nervousness	23 (4.7%)	100 (20.5%)	273 (55.9%)	92 (18.9%)	488
Full blood count abnormal	11 (2.3%)	56 (11.5%)	328 (67.2%)	93 (19.1%)	488
Dysarthria	47 (9.7%)	145 (30.0%)	222 (45.9%)	70 (14.5%)	484

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Drug reaction with eosinophilia and systemic symptoms	113 (23.4%)	127 (26.3%)	168 (34.9%)	74 (15.4%)	482
Product communication issue	41 (8.5%)	75 (15.6%)	277 (57.6%)	88 (18.3%)	481
Knee arthroplasty	3 (0.6%)	101 (21.0%)	327 (68.0%)	50 (10.4%)	481
Neuralgia	15 (3.1%)	177 (36.9%)	229 (47.7%)	59 (12.3%)	480
Bone density decreased	12 (2.5%)	221 (46.2%)	223 (46.7%)	22 (4.6%)	478
Device dislocation	96 (20.1%)	243 (50.9%)	94 (19.7%)	44 (9.2%)	477
Dyskinesia	101 (21.2%)	87 (18.3%)	210 (44.1%)	78 (16.4%)	476
Hyperglycaemia	55 (11.6%)	80 (16.9%)	244 (51.6%)	94 (19.9%)	473
Therapy partial responder	79 (16.7%)	123 (26.0%)	235 (49.7%)	36 (7.6%)	473
Dysuria	26 (5.5%)	120 (25.4%)	238 (50.4%)	88 (18.6%)	472
Type 2 diabetes mellitus	3 (0.6%)	265 (56.1%)	172 (36.4%)	32 (6.8%)	472
Eye swelling	74 (15.7%)	138 (29.3%)	216 (45.9%)	43 (9.1%)	471
Full blood count decreased	6 (1.3%)	42 (8.9%)	268 (56.9%)	155 (32.9%)	471
Anaphylactic shock	39 (8.3%)	139 (29.6%)	247 (52.6%)	45 (9.6%)	470
Conjunctivitis	110 (23.6%)	132 (28.3%)	183 (39.2%)	42 (9.0%)	467
Device information output issue	424 (92.0%)	15 (3.3%)	18 (3.9%)	4 (0.9%)	461
Night sweats	8 (1.8%)	221 (48.7%)	178 (39.2%)	47 (10.4%)	454
Joint injury	93 (20.5%)	91 (20.0%)	208 (45.8%)	62 (13.7%)	454
Device use issue	240 (53.0%)	57 (12.6%)	114 (25.2%)	42 (9.3%)	453
COVID-19 pneumonia	10 (2.2%)	108 (23.9%)	252 (55.8%)	82 (18.1%)	452
Foetal exposure during pregnancy	446 (99.1%)	4 (0.9%)	0 (0.0%)	0 (0.0%)	450
Aggression	141 (31.4%)	138 (30.7%)	97 (21.6%)	73 (16.3%)	449
Unevaluable event	25 (5.6%)	106 (23.8%)	224 (50.2%)	91 (20.4%)	446
Dysstasia	21 (4.7%)	113 (25.3%)	232 (52.0%)	80 (17.9%)	446
Bacterial infection	54 (12.1%)	95 (21.3%)	239 (53.7%)	57 (12.8%)	445
Urinary retention	46 (10.4%)	81 (18.2%)	186 (41.9%)	131 (29.5%)	444
Anhedonia	25 (5.7%)	215 (48.8%)	199 (45.1%)	2 (0.5%)	441

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Synovitis	22 (5.0%)	259 (59.0%)	142 (32.3%)	16 (3.6%)	439
Blindness	22 (5.0%)	101 (23.1%)	221 (50.5%)	94 (21.5%)	438
Syringe issue	46 (10.6%)	60 (13.9%)	202 (46.7%)	125 (28.9%)	433
Ascites	32 (7.4%)	99 (22.9%)	226 (52.3%)	75 (17.4%)	432
Diverticulitis	1 (0.2%)	67 (15.6%)	284 (66.0%)	78 (18.1%)	430
Tinnitus	17 (4.0%)	141 (32.9%)	231 (54.0%)	39 (9.1%)	428
Product administration interrupted	80 (18.7%)	183 (42.9%)	136 (31.9%)	28 (6.6%)	427
Altered state of consciousness	49 (11.5%)	115 (27.0%)	156 (36.6%)	106 (24.9%)	426
Therapeutic response unexpected	35 (8.2%)	82 (19.3%)	223 (52.5%)	85 (20.0%)	425
Pneumonia aspiration	35 (8.3%)	67 (15.8%)	171 (40.3%)	151 (35.6%)	424
Liver function test increased	21 (5.0%)	122 (28.8%)	211 (49.8%)	70 (16.5%)	424
Cardiac failure congestive	6 (1.4%)	50 (11.9%)	205 (48.7%)	160 (38.0%)	421
Hip fracture	1 (0.2%)	17 (4.0%)	212 (50.5%)	190 (45.2%)	420
Body temperature increased	90 (21.5%)	119 (28.5%)	159 (38.0%)	50 (12.0%)	418
Poor quality device used	349 (83.9%)	26 (6.3%)	30 (7.2%)	11 (2.6%)	416
Intercepted product preparation error	18 (4.3%)	22 (5.3%)	221 (53.3%)	154 (37.1%)	415
Sneezing	29 (7.0%)	91 (21.9%)	240 (57.8%)	55 (13.3%)	415
Eye disorder	23 (5.5%)	95 (22.9%)	210 (50.6%)	87 (21.0%)	415
Incorrect route of product administration	54 (13.0%)	131 (31.6%)	157 (37.8%)	73 (17.6%)	415
Cerebral haemorrhage	21 (5.1%)	52 (12.6%)	209 (50.5%)	132 (31.9%)	414
Lymphocyte count decreased	21 (5.1%)	121 (29.2%)	239 (57.7%)	33 (8.0%)	414
Urinary incontinence	25 (6.1%)	102 (24.7%)	208 (50.4%)	78 (18.9%)	413
Laboratory test abnormal	26 (6.3%)	67 (16.3%)	233 (56.6%)	86 (20.9%)	412
Restlessness	63 (15.4%)	137 (33.6%)	165 (40.4%)	43 (10.5%)	408
Respiratory disorder	62 (15.3%)	113 (27.8%)	185 (45.6%)	46 (11.3%)	406
Product dispensing error	49 (12.1%)	59 (14.6%)	215 (53.2%)	81 (20.0%)	404
Skin burning sensation	49 (12.1%)	137 (33.9%)	191 (47.3%)	27 (6.7%)	404

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Disorientation	25 (6.2%)	117 (29.1%)	181 (45.0%)	79 (19.7%)	402
Kidney infection	19 (4.7%)	119 (29.7%)	219 (54.6%)	44 (11.0%)	401
Localised infection	18 (4.5%)	68 (17.2%)	241 (60.9%)	69 (17.4%)	396
Irritable bowel syndrome	7 (1.8%)	267 (67.4%)	103 (26.0%)	19 (4.8%)	396
Hypersomnia	53 (13.4%)	115 (29.1%)	159 (40.3%)	68 (17.2%)	395
Musculoskeletal pain	2 (0.5%)	189 (48.0%)	177 (44.9%)	26 (6.6%)	394
Adrenal insufficiency	36 (9.1%)	101 (25.6%)	203 (51.5%)	54 (13.7%)	394
Gastritis	37 (9.4%)	114 (28.9%)	208 (52.8%)	35 (8.9%)	394
Middle insomnia	43 (10.9%)	132 (33.5%)	191 (48.5%)	28 (7.1%)	394
Crying	117 (29.9%)	124 (31.7%)	127 (32.5%)	23 (5.9%)	391
Cholelithiasis	18 (4.6%)	100 (25.6%)	223 (57.2%)	49 (12.6%)	390
Blood pressure fluctuation	5 (1.3%)	80 (20.5%)	251 (64.4%)	54 (13.8%)	390
Sciatica	4 (1.0%)	172 (44.2%)	171 (44.0%)	42 (10.8%)	389
Blood potassium decreased	18 (4.6%)	53 (13.6%)	262 (67.4%)	56 (14.4%)	389
Lip swelling	59 (15.4%)	101 (26.4%)	161 (42.0%)	62 (16.2%)	383
Sleep disorder due to a general medical condition	72 (18.8%)	73 (19.1%)	201 (52.6%)	36 (9.4%)	382
Product quality issue	57 (15.0%)	123 (32.3%)	150 (39.4%)	51 (13.4%)	381
Generalised tonic-clonic seizure	144 (37.9%)	120 (31.6%)	91 (23.9%)	25 (6.6%)	380
Product administration error	46 (12.1%)	82 (21.6%)	172 (45.3%)	80 (21.1%)	380
Accidental overdose	96 (25.3%)	78 (20.5%)	153 (40.3%)	53 (13.9%)	380
Glossodynia	5 (1.3%)	256 (67.5%)	100 (26.4%)	18 (4.7%)	379
Impaired quality of life	69 (18.4%)	129 (34.3%)	158 (42.0%)	20 (5.3%)	376
Panic attack	66 (17.6%)	172 (45.7%)	125 (33.2%)	13 (3.5%)	376
Procedural pain	50 (13.3%)	127 (33.9%)	171 (45.6%)	27 (7.2%)	375
Pericarditis	10 (2.7%)	265 (71.0%)	91 (24.4%)	7 (1.9%)	373
Blood pressure abnormal	11 (3.0%)	48 (12.9%)	223 (59.9%)	90 (24.2%)	372
Joint stiffness	16 (4.3%)	128 (34.4%)	196 (52.7%)	32 (8.6%)	372

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypocalcaemia	24 (6.5%)	54 (14.6%)	202 (54.4%)	91 (24.5%)	371
Proteinuria	41 (11.1%)	93 (25.1%)	169 (45.7%)	67 (18.1%)	370
Poor quality sleep	27 (7.3%)	104 (28.2%)	183 (49.6%)	55 (14.9%)	369
Hypophagia	44 (11.9%)	59 (16.0%)	174 (47.2%)	92 (24.9%)	369
Emotional disorder	122 (33.1%)	99 (26.8%)	123 (33.3%)	25 (6.8%)	369
Hallucination, visual	39 (10.6%)	43 (11.7%)	159 (43.2%)	127 (34.5%)	368
Nightmare	31 (8.4%)	106 (28.8%)	179 (48.6%)	52 (14.1%)	368
Lower limb fracture	13 (3.6%)	141 (38.5%)	162 (44.3%)	50 (13.7%)	366
Palmar-plantar erythrodysesthesia syndrome	8 (2.2%)	55 (15.1%)	260 (71.2%)	42 (11.5%)	365
Abdominal pain lower	51 (14.0%)	132 (36.2%)	152 (41.6%)	30 (8.2%)	365
Skin haemorrhage	86 (23.6%)	97 (26.6%)	142 (38.9%)	40 (11.0%)	365
Breast cancer	1 (0.3%)	102 (28.0%)	218 (59.9%)	43 (11.8%)	364
Shock	51 (14.0%)	88 (24.2%)	177 (48.6%)	48 (13.2%)	364
Hepatotoxicity	52 (14.4%)	76 (21.0%)	189 (52.2%)	45 (12.4%)	362
Feeling cold	9 (2.5%)	107 (29.6%)	208 (57.6%)	37 (10.2%)	361
Injection site rash	72 (19.9%)	118 (32.7%)	153 (42.4%)	18 (5.0%)	361
Blood glucose decreased	31 (8.6%)	59 (16.3%)	210 (58.2%)	61 (16.9%)	361
Rash maculo-papular	37 (10.2%)	72 (19.9%)	215 (59.6%)	37 (10.2%)	361
Mental status changes	71 (19.7%)	77 (21.4%)	151 (41.9%)	61 (16.9%)	360
Psychotic disorder	52 (14.4%)	147 (40.8%)	138 (38.3%)	23 (6.4%)	360
Ear pain	32 (8.9%)	136 (37.9%)	168 (46.8%)	23 (6.4%)	359
Device delivery system issue	189 (52.6%)	31 (8.6%)	105 (29.2%)	34 (9.5%)	359
Staphylococcal infection	44 (12.3%)	88 (24.6%)	171 (47.8%)	55 (15.4%)	358
Blood bilirubin increased	45 (12.6%)	70 (19.6%)	216 (60.5%)	26 (7.3%)	357
Throat tightness	44 (12.3%)	155 (43.4%)	136 (38.1%)	22 (6.2%)	357
Injection site urticaria	93 (26.1%)	137 (38.4%)	120 (33.6%)	7 (2.0%)	357
Diabetic ketoacidosis	34 (9.5%)	115 (32.2%)	174 (48.7%)	34 (9.5%)	357

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood creatine phosphokinase increased	43 (12.1%)	78 (21.9%)	162 (45.5%)	73 (20.5%)	356
Cardio-respiratory arrest	36 (10.1%)	77 (21.6%)	177 (49.7%)	66 (18.5%)	356
Ankylosing spondylitis	14 (3.9%)	181 (50.8%)	144 (40.4%)	17 (4.8%)	356
Device defective	120 (33.8%)	70 (19.7%)	126 (35.5%)	39 (11.0%)	355
Seasonal allergy	25 (7.1%)	81 (22.9%)	207 (58.5%)	41 (11.6%)	354
Dementia	3 (0.8%)	7 (2.0%)	126 (35.6%)	218 (61.6%)	354
Unresponsive to stimuli	60 (17.0%)	65 (18.4%)	174 (49.3%)	54 (15.3%)	353
Drug eruption	29 (8.2%)	74 (21.0%)	195 (55.4%)	54 (15.3%)	352
Drug effective for unapproved indication	54 (15.3%)	80 (22.7%)	161 (45.7%)	57 (16.2%)	352
Mucosal inflammation	51 (14.6%)	70 (20.0%)	186 (53.1%)	43 (12.3%)	350
Cytopenia	38 (10.9%)	28 (8.0%)	202 (57.9%)	81 (23.2%)	349
Aphasia	23 (6.6%)	96 (27.5%)	174 (49.9%)	56 (16.0%)	349
Skin ulcer	10 (2.9%)	74 (21.2%)	211 (60.5%)	54 (15.5%)	349
Haemoptysis	25 (7.2%)	67 (19.3%)	174 (50.0%)	82 (23.6%)	348
Oral pain	32 (9.2%)	70 (20.2%)	195 (56.4%)	49 (14.2%)	346
Decreased immune responsiveness	13 (3.8%)	109 (31.6%)	202 (58.6%)	21 (6.1%)	345
Gastroenteritis viral	79 (23.0%)	86 (25.1%)	157 (45.8%)	21 (6.1%)	343
Obesity	52 (15.2%)	203 (59.2%)	80 (23.3%)	8 (2.3%)	343
Feeding disorder	36 (10.5%)	63 (18.4%)	182 (53.1%)	62 (18.1%)	343
Drug effect less than expected	47 (13.8%)	113 (33.1%)	139 (40.8%)	42 (12.3%)	341
Mouth ulceration	39 (11.4%)	93 (27.3%)	178 (52.2%)	31 (9.1%)	341
Pallor	89 (26.2%)	91 (26.8%)	119 (35.0%)	41 (12.1%)	340
Clostridium difficile infection	42 (12.4%)	76 (22.4%)	173 (50.9%)	49 (14.4%)	340
Hip arthroplasty	1 (0.3%)	106 (31.3%)	183 (54.0%)	49 (14.5%)	339
Encephalopathy	65 (19.2%)	59 (17.4%)	149 (44.0%)	66 (19.5%)	339
Device adhesion issue	3 (0.9%)	52 (15.3%)	233 (68.7%)	51 (15.0%)	339
Poor venous access	67 (19.8%)	102 (30.2%)	145 (42.9%)	24 (7.1%)	338

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Exposure to toxic agent	37 (10.9%)	107 (31.7%)	159 (47.0%)	35 (10.4%)	338
Haematoma	57 (17.0%)	79 (23.6%)	126 (37.6%)	73 (21.8%)	335
Insurance issue	51 (15.2%)	99 (29.6%)	164 (49.0%)	21 (6.3%)	335
Serotonin syndrome	89 (26.6%)	115 (34.3%)	104 (31.0%)	27 (8.1%)	335
Rib fracture	3 (0.9%)	50 (15.0%)	194 (58.1%)	87 (26.0%)	334
Hand deformity	1 (0.3%)	244 (73.3%)	79 (23.7%)	9 (2.7%)	333
Metastases to bone	2 (0.6%)	75 (22.5%)	216 (64.9%)	40 (12.0%)	333
Prescribed underdose	47 (14.2%)	135 (40.7%)	115 (34.6%)	35 (10.5%)	332
Osteopenia	11 (3.3%)	116 (34.9%)	190 (57.2%)	15 (4.5%)	332
Incorrect product administration duration	24 (7.3%)	62 (18.7%)	143 (43.2%)	102 (30.8%)	331
Haematuria	37 (11.2%)	47 (14.2%)	160 (48.3%)	87 (26.3%)	331
Transient ischaemic attack	3 (0.9%)	50 (15.1%)	167 (50.5%)	111 (33.5%)	331
Abortion spontaneous	59 (17.9%)	266 (80.9%)	4 (1.2%)	0 (0.0%)	329
Ageusia	7 (2.1%)	69 (21.1%)	185 (56.6%)	66 (20.2%)	327
Erectile dysfunction	36 (11.0%)	149 (45.7%)	121 (37.1%)	20 (6.1%)	326
Sedation	52 (16.0%)	91 (27.9%)	132 (40.5%)	51 (15.6%)	326
Osteonecrosis	21 (6.5%)	154 (47.4%)	139 (42.8%)	11 (3.4%)	325
Tooth disorder	18 (5.6%)	79 (24.4%)	181 (55.9%)	46 (14.2%)	324
Hepatic failure	32 (9.9%)	84 (26.1%)	164 (50.9%)	42 (13.0%)	322
Spinal operation	7 (2.2%)	39 (12.1%)	234 (72.9%)	41 (12.8%)	321
Immune effector cell-associated neurotoxicity syndrom	28 (8.8%)	62 (19.4%)	192 (60.2%)	37 (11.6%)	319
Presyncope	23 (7.2%)	78 (24.5%)	153 (48.1%)	64 (20.1%)	318
Respiratory distress	50 (15.7%)	62 (19.5%)	149 (46.9%)	57 (17.9%)	318
Blood test abnormal	18 (5.7%)	59 (18.6%)	174 (54.7%)	67 (21.1%)	318
Transaminases increased	51 (16.1%)	64 (20.2%)	143 (45.1%)	59 (18.6%)	317
Mood altered	90 (28.8%)	103 (32.9%)	88 (28.1%)	32 (10.2%)	313
Scratch	94 (30.0%)	69 (22.0%)	119 (38.0%)	31 (9.9%)	313

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Sinus disorder	11 (3.5%)	61 (19.6%)	186 (59.6%)	54 (17.3%)	312
Cardiogenic shock	41 (13.2%)	111 (35.7%)	102 (32.8%)	57 (18.3%)	311
Pulmonary fibrosis	3 (1.0%)	91 (29.3%)	157 (50.5%)	60 (19.3%)	311
Eating disorder	35 (11.3%)	72 (23.2%)	156 (50.3%)	47 (15.2%)	310
Neurotoxicity	62 (20.1%)	66 (21.4%)	146 (47.4%)	34 (11.0%)	308
Foot fracture	10 (3.2%)	92 (29.9%)	165 (53.6%)	41 (13.3%)	308
Intervertebral disc protrusion	7 (2.3%)	97 (31.6%)	183 (59.6%)	20 (6.5%)	307
Product complaint	20 (6.5%)	69 (22.5%)	167 (54.6%)	50 (16.3%)	306
Lymphopenia	42 (13.7%)	115 (37.6%)	132 (43.1%)	17 (5.6%)	306
Immunodeficiency	17 (5.6%)	103 (33.8%)	161 (52.8%)	24 (7.9%)	305
Hepatic steatosis	21 (6.9%)	106 (34.9%)	153 (50.3%)	24 (7.9%)	304
Agranulocytosis	19 (6.3%)	71 (23.4%)	167 (54.9%)	47 (15.5%)	304
Acute myocardial infarction	13 (4.3%)	69 (22.8%)	159 (52.5%)	62 (20.5%)	303
Cholestasis	20 (6.6%)	60 (19.9%)	147 (48.7%)	75 (24.8%)	302
Pericardial effusion	37 (12.3%)	69 (22.8%)	150 (49.7%)	46 (15.2%)	302
Device physical property issue	191 (63.5%)	32 (10.6%)	54 (17.9%)	24 (8.0%)	301
Hepatitis	30 (10.0%)	97 (32.3%)	142 (47.3%)	31 (10.3%)	300
Helicobacter infection	12 (4.0%)	228 (76.0%)	56 (18.7%)	4 (1.3%)	300
Pemphigus	2 (0.7%)	232 (77.6%)	60 (20.1%)	5 (1.7%)	299
Prescribed overdose	22 (7.4%)	168 (56.4%)	77 (25.8%)	31 (10.4%)	298
Product distribution issue	28 (9.4%)	76 (25.6%)	139 (46.8%)	54 (18.2%)	297
Infusion site pain	39 (13.1%)	75 (25.3%)	148 (49.8%)	35 (11.8%)	297
Tooth loss	21 (7.1%)	134 (45.1%)	126 (42.4%)	16 (5.4%)	297
Musculoskeletal discomfort	18 (6.1%)	72 (24.3%)	170 (57.4%)	36 (12.2%)	296
Acute respiratory distress syndrome	70 (23.7%)	64 (21.7%)	132 (44.7%)	29 (9.8%)	295
Device occlusion	60 (20.3%)	53 (18.0%)	147 (49.8%)	35 (11.9%)	295
Obstructive airways disorder	18 (6.1%)	62 (21.0%)	141 (47.8%)	74 (25.1%)	295

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Toothache	13 (4.4%)	105 (35.6%)	149 (50.5%)	28 (9.5%)	295
Eosinophilia	21 (7.1%)	64 (21.7%)	144 (48.8%)	66 (22.4%)	295
Skin laceration	46 (15.6%)	57 (19.4%)	136 (46.3%)	55 (18.7%)	294
Pancreatitis acute	43 (14.6%)	95 (32.3%)	130 (44.2%)	26 (8.8%)	294
Swollen tongue	11 (3.7%)	110 (37.4%)	134 (45.6%)	39 (13.3%)	294
Acute respiratory failure	23 (7.8%)	63 (21.4%)	151 (51.4%)	57 (19.4%)	294
Candida infection	36 (12.3%)	76 (25.9%)	141 (48.1%)	40 (13.7%)	293
Angina pectoris	11 (3.8%)	61 (20.9%)	162 (55.5%)	58 (19.9%)	292
Folliculitis	4 (1.4%)	243 (83.2%)	42 (14.4%)	3 (1.0%)	292
Hypomagnesaemia	6 (2.1%)	25 (8.6%)	159 (54.5%)	102 (34.9%)	292
Cerebral infarction	6 (2.1%)	31 (10.7%)	143 (49.3%)	110 (37.9%)	290
Drug resistance	42 (14.5%)	77 (26.6%)	136 (47.1%)	34 (11.8%)	289
Pulmonary mass	9 (3.1%)	50 (17.4%)	172 (59.7%)	57 (19.8%)	288
Bursitis	1 (0.3%)	196 (68.1%)	83 (28.8%)	8 (2.8%)	288
Thyroid disorder	7 (2.4%)	52 (18.1%)	195 (67.7%)	34 (11.8%)	288
Deafness	17 (5.9%)	37 (12.9%)	127 (44.3%)	106 (36.9%)	287
Faeces discoloured	31 (10.9%)	43 (15.1%)	145 (50.9%)	66 (23.2%)	285
Tooth infection	14 (4.9%)	85 (29.8%)	158 (55.4%)	28 (9.8%)	285
Musculoskeletal chest pain	10 (3.5%)	66 (23.2%)	178 (62.5%)	31 (10.9%)	285
Respiratory syncytial virus infection	94 (33.1%)	50 (17.6%)	111 (39.1%)	29 (10.2%)	284
Haemophagocytic lymphohistiocytosis	63 (22.3%)	84 (29.7%)	123 (43.5%)	13 (4.6%)	283
Joint range of motion decreased	8 (2.8%)	181 (64.0%)	70 (24.7%)	24 (8.5%)	283
Head discomfort	27 (9.6%)	82 (29.1%)	134 (47.5%)	39 (13.8%)	282
Lung neoplasm malignant	0 (0.0%)	16 (5.7%)	188 (66.9%)	77 (27.4%)	281
Pharyngeal swelling	21 (7.5%)	116 (41.4%)	117 (41.8%)	26 (9.3%)	280
Hyperthyroidism	14 (5.0%)	82 (29.3%)	158 (56.4%)	26 (9.3%)	280
Uveitis	38 (13.6%)	88 (31.5%)	122 (43.7%)	31 (11.1%)	279

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skin irritation	54 (19.4%)	83 (29.7%)	121 (43.4%)	21 (7.5%)	279
Body temperature decreased	24 (8.6%)	59 (21.2%)	172 (61.9%)	23 (8.3%)	278
Haemorrhoids	16 (5.8%)	65 (23.5%)	156 (56.3%)	40 (14.4%)	277
Pain in jaw	11 (4.0%)	78 (28.2%)	154 (55.6%)	34 (12.3%)	277
Drug level increased	46 (16.6%)	96 (34.7%)	115 (41.5%)	20 (7.2%)	277
Femur fracture	15 (5.4%)	22 (7.9%)	144 (52.0%)	96 (34.7%)	277
Spinal pain	10 (3.6%)	102 (36.8%)	151 (54.5%)	14 (5.1%)	277
Product use complaint	75 (27.2%)	44 (15.9%)	100 (36.2%)	57 (20.7%)	276
Pharyngitis streptococcal	93 (33.8%)	100 (36.4%)	71 (25.8%)	11 (4.0%)	275
Metastases to liver	0 (0.0%)	61 (22.3%)	187 (68.2%)	26 (9.5%)	274
Device failure	92 (33.7%)	62 (22.7%)	97 (35.5%)	22 (8.1%)	273
Sleep apnoea syndrome	22 (8.1%)	94 (34.4%)	149 (54.6%)	8 (2.9%)	273
Diplopia	16 (5.9%)	67 (24.5%)	154 (56.4%)	36 (13.2%)	273
Pain of skin	18 (6.6%)	74 (27.2%)	156 (57.4%)	24 (8.8%)	272
Respiratory tract congestion	20 (7.4%)	65 (24.1%)	153 (56.7%)	32 (11.9%)	270
Melaena	12 (4.5%)	36 (13.4%)	108 (40.1%)	113 (42.0%)	269
Gynaecomastia	180 (66.9%)	35 (13.0%)	36 (13.4%)	18 (6.7%)	269
Glomerular filtration rate decreased	6 (2.2%)	43 (16.1%)	165 (61.8%)	53 (19.9%)	267
Anger	50 (18.7%)	113 (42.3%)	85 (31.8%)	19 (7.1%)	267
Retching	57 (21.3%)	74 (27.7%)	109 (40.8%)	27 (10.1%)	267
Vascular device infection	71 (26.6%)	71 (26.6%)	114 (42.7%)	11 (4.1%)	267
Mental impairment	31 (11.7%)	81 (30.5%)	125 (47.0%)	29 (10.9%)	266
Aphonia	8 (3.0%)	63 (23.8%)	156 (58.9%)	38 (14.3%)	265
Pneumothorax	33 (12.5%)	45 (17.0%)	130 (49.1%)	57 (21.5%)	265
Blood alkaline phosphatase increased	14 (5.3%)	50 (18.9%)	162 (61.1%)	39 (14.7%)	265
Dermatitis	40 (15.2%)	75 (28.4%)	126 (47.7%)	23 (8.7%)	264
Duodenal ulcer perforation	1 (0.4%)	240 (90.9%)	20 (7.6%)	3 (1.1%)	264

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Choking	29 (11.0%)	46 (17.5%)	134 (51.0%)	54 (20.5%)	263
Tubulointerstitial nephritis	28 (10.7%)	47 (17.9%)	159 (60.7%)	28 (10.7%)	262
Leukocytosis	35 (13.4%)	59 (22.5%)	141 (53.8%)	27 (10.3%)	262
Nervous system disorder	29 (11.1%)	102 (39.1%)	105 (40.2%)	25 (9.6%)	261
Neutrophil count normal	26 (10.0%)	117 (45.0%)	112 (43.1%)	5 (1.9%)	260
Skin infection	36 (13.9%)	83 (32.0%)	118 (45.6%)	22 (8.5%)	259
Eye infection	19 (7.4%)	59 (22.9%)	149 (57.8%)	31 (12.0%)	258
Polyneuropathy	10 (3.9%)	44 (17.1%)	167 (64.7%)	37 (14.3%)	258
Jaundice	15 (5.8%)	55 (21.4%)	127 (49.4%)	60 (23.3%)	257
Abnormal behaviour	61 (23.9%)	83 (32.5%)	68 (26.7%)	43 (16.9%)	255
Faeces soft	42 (16.5%)	70 (27.6%)	112 (44.1%)	30 (11.8%)	254
Hernia	8 (3.2%)	53 (20.9%)	158 (62.5%)	34 (13.4%)	253
Laryngitis	7 (2.8%)	91 (36.0%)	137 (54.2%)	18 (7.1%)	253
Expired product administered	32 (12.7%)	37 (14.7%)	117 (46.4%)	66 (26.2%)	252
Product supply issue	32 (12.7%)	65 (25.8%)	125 (49.6%)	30 (11.9%)	252
Autoimmune disorder	15 (6.0%)	152 (60.6%)	74 (29.5%)	10 (4.0%)	251
Upper limb fracture	24 (9.6%)	24 (9.6%)	158 (62.9%)	45 (17.9%)	251
Therapeutic reaction time decreased	34 (13.5%)	109 (43.4%)	97 (38.6%)	11 (4.4%)	251
Prostate cancer	0 (0.0%)	6 (2.4%)	183 (73.2%)	61 (24.4%)	250
Hypertransaminaemia	46 (18.5%)	60 (24.1%)	111 (44.6%)	32 (12.9%)	249
Toxic epidermal necrolysis	15 (6.0%)	57 (22.9%)	134 (53.8%)	43 (17.3%)	249
Secretion discharge	42 (16.9%)	73 (29.3%)	112 (45.0%)	22 (8.8%)	249
Gamma-glutamyltransferase increased	29 (11.6%)	52 (20.9%)	138 (55.4%)	30 (12.0%)	249
Parkinson's disease	0 (0.0%)	9 (3.6%)	142 (57.0%)	98 (39.4%)	249
Hepatic cirrhosis	5 (2.0%)	77 (31.0%)	142 (57.3%)	24 (9.7%)	248
Tachypnoea	51 (20.6%)	67 (27.0%)	102 (41.1%)	28 (11.3%)	248
Spinal fracture	5 (2.0%)	27 (10.9%)	140 (56.5%)	76 (30.6%)	248

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Glycosylated haemoglobin increased	3 (1.2%)	38 (15.4%)	164 (66.7%)	41 (16.7%)	246
Ankle fracture	5 (2.0%)	72 (29.4%)	147 (60.0%)	21 (8.6%)	245
Haematocrit decreased	16 (6.6%)	58 (23.9%)	137 (56.4%)	32 (13.2%)	243
Pharyngitis	44 (18.2%)	80 (33.1%)	107 (44.2%)	11 (4.5%)	242
Ligament sprain	42 (17.4%)	53 (22.0%)	126 (52.3%)	20 (8.3%)	241
Anti-cyclic citrullinated peptide antibody positive	1 (0.4%)	206 (85.5%)	34 (14.1%)	0 (0.0%)	241
Myoclonus	37 (15.4%)	75 (31.3%)	98 (40.8%)	30 (12.5%)	240
Sinus congestion	15 (6.3%)	64 (26.7%)	140 (58.3%)	21 (8.8%)	240
Chromaturia	20 (8.3%)	55 (22.9%)	122 (50.8%)	43 (17.9%)	240
Multiple fractures	3 (1.3%)	107 (44.6%)	122 (50.8%)	8 (3.3%)	240
Gastroenteritis	57 (23.8%)	66 (27.5%)	95 (39.6%)	22 (9.2%)	240
Blood iron decreased	17 (7.1%)	61 (25.4%)	122 (50.8%)	40 (16.7%)	240
Temperature intolerance	11 (4.6%)	93 (38.9%)	122 (51.0%)	13 (5.4%)	239
Face oedema	35 (14.6%)	81 (33.9%)	108 (45.2%)	15 (6.3%)	239
Sputum discoloured	12 (5.0%)	32 (13.4%)	142 (59.7%)	52 (21.8%)	238
Gout	0 (0.0%)	36 (15.3%)	139 (58.9%)	61 (25.8%)	236
Nonspecific reaction	3 (1.3%)	12 (5.1%)	129 (54.7%)	92 (39.0%)	236
Immune system disorder	11 (4.7%)	47 (19.9%)	155 (65.7%)	23 (9.7%)	236
Muscle twitching	33 (14.0%)	87 (37.0%)	100 (42.6%)	15 (6.4%)	235
Increased appetite	43 (18.3%)	73 (31.1%)	102 (43.4%)	17 (7.2%)	235
Haematemesis	22 (9.4%)	62 (26.4%)	102 (43.4%)	49 (20.9%)	235
Thrombotic microangiopathy	50 (21.3%)	54 (23.0%)	112 (47.7%)	19 (8.1%)	235
Lip dry	30 (12.8%)	165 (70.2%)	28 (11.9%)	12 (5.1%)	235
Myocarditis	25 (10.7%)	72 (30.8%)	98 (41.9%)	39 (16.7%)	234
Withdrawal syndrome	34 (14.5%)	81 (34.6%)	107 (45.7%)	12 (5.1%)	234
Muscle spasticity	11 (4.7%)	113 (48.7%)	101 (43.5%)	7 (3.0%)	232
Sinus tachycardia	59 (25.4%)	67 (28.9%)	94 (40.5%)	12 (5.2%)	232

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ventricular tachycardia	15 (6.5%)	94 (40.5%)	76 (32.8%)	47 (20.3%)	232
Grip strength decreased	3 (1.3%)	139 (59.9%)	82 (35.3%)	8 (3.4%)	232
Blood urine present	12 (5.2%)	60 (26.0%)	120 (51.9%)	39 (16.9%)	231
Nodule	10 (4.3%)	55 (23.8%)	145 (62.8%)	21 (9.1%)	231
Pneumocystis jirovecii pneumonia	30 (13.0%)	36 (15.6%)	137 (59.3%)	28 (12.1%)	231
Multiple allergies	16 (7.0%)	30 (13.1%)	155 (67.7%)	28 (12.2%)	229
Bone loss	1 (0.4%)	116 (50.9%)	107 (46.9%)	4 (1.8%)	228
Glaucoma	18 (7.9%)	39 (17.1%)	120 (52.6%)	51 (22.4%)	228
Platelet count increased	33 (14.5%)	51 (22.4%)	127 (55.7%)	17 (7.5%)	228
Paraesthesia oral	10 (4.4%)	72 (31.6%)	136 (59.6%)	10 (4.4%)	228
Coronavirus infection	6 (2.6%)	70 (30.8%)	106 (46.7%)	45 (19.8%)	227
Orthostatic hypotension	4 (1.8%)	24 (10.6%)	109 (48.2%)	89 (39.4%)	226
Ischaemic stroke	3 (1.3%)	24 (10.6%)	135 (59.7%)	64 (28.3%)	226
Cytomegalovirus infection	49 (21.7%)	46 (20.4%)	112 (49.6%)	19 (8.4%)	226
Muscle injury	6 (2.7%)	185 (82.2%)	24 (10.7%)	10 (4.4%)	225
Acute myeloid leukaemia	20 (8.9%)	39 (17.3%)	117 (52.0%)	49 (21.8%)	225
Back disorder	3 (1.3%)	30 (13.4%)	141 (62.9%)	50 (22.3%)	224
Bone disorder	4 (1.8%)	33 (14.7%)	150 (67.0%)	37 (16.5%)	224
Delusion	17 (7.6%)	52 (23.2%)	100 (44.6%)	55 (24.6%)	224
Circulatory collapse	35 (15.7%)	48 (21.5%)	96 (43.0%)	44 (19.7%)	223
Osteonecrosis of jaw	1 (0.5%)	17 (7.7%)	150 (67.6%)	54 (24.3%)	222
Eructation	20 (9.0%)	36 (16.3%)	138 (62.4%)	27 (12.2%)	221
Rheumatic fever	0 (0.0%)	197 (89.1%)	24 (10.9%)	0 (0.0%)	221
Stevens-Johnson syndrome	20 (9.0%)	65 (29.4%)	103 (46.6%)	33 (14.9%)	221
Skin cancer	0 (0.0%)	20 (9.0%)	135 (61.1%)	66 (29.9%)	221
Restless legs syndrome	8 (3.6%)	63 (28.6%)	123 (55.9%)	26 (11.8%)	220
Initial insomnia	39 (17.8%)	72 (32.9%)	93 (42.5%)	15 (6.8%)	219

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Sickle cell anaemia with crisis	83 (37.9%)	102 (46.6%)	34 (15.5%)	0 (0.0%)	219
Blood sodium decreased	9 (4.1%)	28 (12.8%)	132 (60.3%)	50 (22.8%)	219
Red blood cell sedimentation rate increased	23 (10.5%)	83 (37.9%)	100 (45.7%)	13 (5.9%)	219
Blood lactate dehydrogenase increased	43 (19.6%)	38 (17.4%)	113 (51.6%)	25 (11.4%)	219
Oropharyngeal discomfort	17 (7.8%)	64 (29.5%)	112 (51.6%)	24 (11.1%)	217
Pneumonia bacterial	15 (6.9%)	31 (14.3%)	118 (54.4%)	53 (24.4%)	217
Blood pressure diastolic decreased	8 (3.7%)	53 (24.4%)	125 (57.6%)	31 (14.3%)	217
Fear	24 (11.1%)	72 (33.3%)	98 (45.4%)	22 (10.2%)	216
Post procedural complication	17 (7.9%)	61 (28.2%)	108 (50.0%)	30 (13.9%)	216
Acute hepatic failure	60 (27.8%)	40 (18.5%)	98 (45.4%)	18 (8.3%)	216
Weight fluctuation	16 (7.4%)	47 (21.9%)	127 (59.1%)	25 (11.6%)	215
Hallucination, auditory	42 (19.5%)	61 (28.4%)	91 (42.3%)	21 (9.8%)	215
Symptom recurrence	19 (8.9%)	81 (37.9%)	102 (47.7%)	12 (5.6%)	214
Cold sweat	29 (13.6%)	58 (27.1%)	104 (48.6%)	23 (10.7%)	214
Basal cell carcinoma	0 (0.0%)	30 (14.0%)	144 (67.3%)	40 (18.7%)	214
Rash papular	23 (10.7%)	54 (25.2%)	110 (51.4%)	27 (12.6%)	214
Accident	28 (13.1%)	38 (17.8%)	108 (50.7%)	39 (18.3%)	213
Bacteraemia	22 (10.4%)	56 (26.4%)	107 (50.5%)	27 (12.7%)	212
Product administered at inappropriate site	30 (14.2%)	53 (25.1%)	95 (45.0%)	33 (15.6%)	211
Device related infection	46 (21.8%)	62 (29.4%)	87 (41.2%)	16 (7.6%)	211
Renal injury	10 (4.7%)	70 (33.2%)	116 (55.0%)	15 (7.1%)	211
Intercepted product administration error	6 (2.8%)	28 (13.3%)	137 (64.9%)	40 (19.0%)	211
Carpal tunnel syndrome	6 (2.9%)	44 (21.0%)	137 (65.2%)	23 (11.0%)	210
Anosmia	7 (3.3%)	81 (38.8%)	105 (50.2%)	16 (7.7%)	209
Oral candidiasis	11 (5.3%)	46 (22.0%)	118 (56.5%)	34 (16.3%)	209
Pulmonary toxicity	9 (4.3%)	21 (10.0%)	120 (57.4%)	59 (28.2%)	209
Nocturia	2 (1.0%)	46 (22.0%)	117 (56.0%)	44 (21.1%)	209

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Heart rate irregular	9 (4.3%)	41 (19.6%)	115 (55.0%)	44 (21.1%)	209
Hypercalcaemia	10 (4.8%)	33 (15.8%)	115 (55.0%)	51 (24.4%)	209
Disseminated intravascular coagulation	33 (15.9%)	42 (20.2%)	109 (52.4%)	24 (11.5%)	208
Premature delivery	44 (21.2%)	164 (78.8%)	0 (0.0%)	0 (0.0%)	208
C-reactive protein abnormal	7 (3.4%)	158 (76.0%)	41 (19.7%)	2 (1.0%)	208
Vasculitis	14 (6.7%)	53 (25.5%)	126 (60.6%)	15 (7.2%)	208
Drug withdrawal syndrome	25 (12.0%)	102 (49.0%)	61 (29.3%)	20 (9.6%)	208
Knee operation	3 (1.4%)	30 (14.5%)	145 (70.0%)	29 (14.0%)	207
Muscle tightness	11 (5.3%)	81 (39.1%)	95 (45.9%)	20 (9.7%)	207
Abscess	26 (12.6%)	66 (31.9%)	91 (44.0%)	24 (11.6%)	207
Rheumatoid factor positive	1 (0.5%)	160 (77.3%)	45 (21.7%)	1 (0.5%)	207
Sensitivity to weather change	13 (6.3%)	43 (20.9%)	128 (62.1%)	22 (10.7%)	206
Photophobia	23 (11.2%)	77 (37.4%)	92 (44.7%)	14 (6.8%)	206
Myasthenia gravis	10 (4.9%)	38 (18.5%)	82 (40.0%)	75 (36.6%)	205
Anal incontinence	10 (4.9%)	54 (26.3%)	112 (54.6%)	29 (14.1%)	205
Neutrophil count increased	13 (6.3%)	61 (29.8%)	116 (56.6%)	15 (7.3%)	205
Poisoning	35 (17.2%)	126 (61.8%)	34 (16.7%)	9 (4.4%)	204
Poisoning deliberate	59 (28.9%)	69 (33.8%)	61 (29.9%)	15 (7.4%)	204
Electrolyte imbalance	27 (13.3%)	47 (23.2%)	105 (51.7%)	24 (11.8%)	203
Immune-mediated enterocolitis	1 (0.5%)	27 (13.3%)	144 (70.9%)	31 (15.3%)	203
Tendonitis	7 (3.5%)	74 (36.6%)	111 (55.0%)	10 (5.0%)	202
Gastric ulcer	15 (7.4%)	38 (18.8%)	115 (56.9%)	34 (16.8%)	202
Fracture	9 (4.5%)	31 (15.3%)	94 (46.5%)	68 (33.7%)	202
Vaginal haemorrhage	30 (14.9%)	108 (53.7%)	54 (26.9%)	9 (4.5%)	201
Dermatitis allergic	31 (15.4%)	64 (31.8%)	95 (47.3%)	11 (5.5%)	201
Respiratory rate increased	35 (17.5%)	39 (19.5%)	102 (51.0%)	24 (12.0%)	200
Skin plaque	13 (6.5%)	68 (34.2%)	110 (55.3%)	8 (4.0%)	199

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Small intestinal obstruction	13 (6.6%)	62 (31.3%)	97 (49.0%)	26 (13.1%)	198
Muscle rigidity	22 (11.1%)	48 (24.2%)	99 (50.0%)	29 (14.6%)	198
Quality of life decreased	23 (11.7%)	77 (39.1%)	85 (43.1%)	12 (6.1%)	197
Complication associated with device	44 (22.3%)	76 (38.6%)	60 (30.5%)	17 (8.6%)	197
Cyst	15 (7.6%)	56 (28.4%)	113 (57.4%)	13 (6.6%)	197
Gastrointestinal infection	15 (7.7%)	72 (36.7%)	90 (45.9%)	19 (9.7%)	196
Product substitution issue	14 (7.1%)	63 (32.1%)	83 (42.3%)	36 (18.4%)	196
Hypervolaemia	12 (6.1%)	37 (18.9%)	110 (56.1%)	37 (18.9%)	196
Mood swings	41 (21.0%)	71 (36.4%)	66 (33.8%)	17 (8.7%)	195
Decreased activity	12 (6.2%)	52 (26.7%)	109 (55.9%)	22 (11.3%)	195
Hypokinesia	9 (4.6%)	68 (34.9%)	107 (54.9%)	11 (5.6%)	195
Gallbladder disorder	5 (2.6%)	46 (23.7%)	125 (64.4%)	18 (9.3%)	194
Tumour marker increased	1 (0.5%)	35 (18.0%)	130 (67.0%)	28 (14.4%)	194
Hemiparesis	14 (7.2%)	57 (29.4%)	98 (50.5%)	25 (12.9%)	194
Muscle atrophy	16 (8.2%)	46 (23.7%)	110 (56.7%)	22 (11.3%)	194
Liver function test abnormal	27 (14.0%)	34 (17.6%)	103 (53.4%)	29 (15.0%)	193
Injury associated with device	15 (7.8%)	42 (21.8%)	94 (48.7%)	42 (21.8%)	193
Wrist fracture	13 (6.7%)	23 (11.9%)	118 (61.1%)	39 (20.2%)	193
Brain oedema	26 (13.5%)	75 (38.9%)	83 (43.0%)	9 (4.7%)	193
Appendicitis	35 (18.2%)	60 (31.3%)	64 (33.3%)	33 (17.2%)	192
Pulmonary hypertension	25 (13.1%)	38 (19.9%)	85 (44.5%)	43 (22.5%)	191
Defaecation urgency	11 (5.8%)	51 (26.7%)	100 (52.4%)	29 (15.2%)	191
Cyanosis	39 (20.5%)	47 (24.7%)	88 (46.3%)	16 (8.4%)	190
Nephropathy toxic	29 (15.3%)	48 (25.3%)	85 (44.7%)	28 (14.7%)	190
Peritonitis	18 (9.5%)	40 (21.1%)	95 (50.0%)	37 (19.5%)	190
Progressive multifocal leukoencephalopathy	5 (2.6%)	67 (35.3%)	92 (48.4%)	26 (13.7%)	190
Back injury	3 (1.6%)	79 (41.8%)	79 (41.8%)	28 (14.8%)	189

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Foot deformity	10 (5.3%)	61 (32.3%)	104 (55.0%)	14 (7.4%)	189
Dermatitis contact	15 (8.0%)	69 (36.7%)	87 (46.3%)	17 (9.0%)	188
Wound infection	1 (0.5%)	108 (57.4%)	66 (35.1%)	13 (6.9%)	188
Tumour lysis syndrome	13 (6.9%)	33 (17.6%)	106 (56.4%)	36 (19.1%)	188
Blood potassium increased	10 (5.3%)	23 (12.2%)	108 (57.4%)	47 (25.0%)	188
Blood glucose abnormal	7 (3.7%)	36 (19.3%)	119 (63.6%)	25 (13.4%)	187
Clostridium difficile colitis	31 (16.6%)	36 (19.3%)	85 (45.5%)	35 (18.7%)	187
Coronary artery disease	1 (0.5%)	15 (8.1%)	119 (64.0%)	51 (27.4%)	186
Upper gastrointestinal haemorrhage	13 (7.0%)	31 (16.7%)	93 (50.0%)	49 (26.3%)	186
Mass	17 (9.2%)	33 (17.8%)	122 (65.9%)	13 (7.0%)	185
Blood triglycerides increased	18 (9.7%)	68 (36.8%)	89 (48.1%)	10 (5.4%)	185
Aspiration	27 (14.7%)	24 (13.0%)	64 (34.8%)	69 (37.5%)	184
Asphyxia	13 (7.1%)	97 (53.0%)	63 (34.4%)	10 (5.5%)	183
Pregnancy	19 (10.4%)	163 (89.1%)	1 (0.5%)	0 (0.0%)	183
Thirst	11 (6.0%)	63 (34.4%)	87 (47.5%)	22 (12.0%)	183
Apathy	19 (10.4%)	60 (32.8%)	75 (41.0%)	29 (15.8%)	183
Autism spectrum disorder	176 (96.2%)	6 (3.3%)	1 (0.5%)	0 (0.0%)	183
Peripheral coldness	21 (11.5%)	38 (20.9%)	94 (51.6%)	29 (15.9%)	182
Second primary malignancy	5 (2.7%)	23 (12.6%)	134 (73.6%)	20 (11.0%)	182
Sleep disorder due to general medical condition, inso	4 (2.2%)	141 (77.5%)	34 (18.7%)	3 (1.6%)	182
Injection site discharge	40 (22.1%)	57 (31.5%)	70 (38.7%)	14 (7.7%)	181
Metastases to lung	2 (1.1%)	34 (18.8%)	121 (66.9%)	24 (13.3%)	181
Immune-mediated hepatic disorder	1 (0.6%)	32 (17.7%)	124 (68.5%)	24 (13.3%)	181
Swollen joint count increased	0 (0.0%)	150 (82.9%)	29 (16.0%)	2 (1.1%)	181
Musculoskeletal disorder	6 (3.3%)	40 (22.1%)	107 (59.1%)	28 (15.5%)	181
Immunosuppression	15 (8.3%)	49 (27.1%)	91 (50.3%)	26 (14.4%)	181
Ileus	26 (14.4%)	44 (24.4%)	81 (45.0%)	29 (16.1%)	180

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Neutrophilia	16 (8.9%)	56 (31.1%)	100 (55.6%)	8 (4.4%)	180
Abnormal dreams	7 (3.9%)	52 (29.1%)	89 (49.7%)	31 (17.3%)	179
Extrapyramidal disorder	41 (22.9%)	52 (29.1%)	69 (38.5%)	17 (9.5%)	179
Impaired work ability	6 (3.4%)	85 (47.5%)	80 (44.7%)	8 (4.5%)	179
Tenderness	21 (11.7%)	60 (33.5%)	91 (50.8%)	7 (3.9%)	179
Heavy menstrual bleeding	33 (18.5%)	141 (79.2%)	4 (2.2%)	0 (0.0%)	178
Bronchopulmonary aspergillosis	19 (10.7%)	16 (9.0%)	123 (69.1%)	20 (11.2%)	178
Haemorrhage intracranial	26 (14.6%)	27 (15.2%)	64 (36.0%)	61 (34.3%)	178
Hyperbilirubinaemia	24 (13.5%)	47 (26.4%)	80 (44.9%)	27 (15.2%)	178
Joint dislocation	19 (10.7%)	59 (33.3%)	81 (45.8%)	18 (10.2%)	177
Bronchiectasis	3 (1.7%)	21 (11.9%)	101 (57.1%)	52 (29.4%)	177
Injection site warmth	24 (13.6%)	58 (32.8%)	87 (49.2%)	8 (4.5%)	177
End stage renal disease	7 (4.0%)	72 (40.7%)	78 (44.1%)	20 (11.3%)	177
Diabetes mellitus inadequate control	11 (6.2%)	30 (16.9%)	101 (57.1%)	35 (19.8%)	177
Ejection fraction decreased	10 (5.7%)	32 (18.2%)	110 (62.5%)	24 (13.6%)	176
Gingival bleeding	25 (14.2%)	53 (30.1%)	78 (44.3%)	20 (11.4%)	176
Skin swelling	30 (17.1%)	45 (25.7%)	87 (49.7%)	13 (7.4%)	175
Affective disorder	49 (28.0%)	56 (32.0%)	59 (33.7%)	11 (6.3%)	175
Akathisia	43 (24.6%)	88 (50.3%)	39 (22.3%)	5 (2.9%)	175
Photosensitivity reaction	28 (16.0%)	47 (26.9%)	77 (44.0%)	23 (13.1%)	175
Drug level decreased	53 (30.3%)	62 (35.4%)	53 (30.3%)	7 (4.0%)	175
Hypoaesthesia oral	17 (9.8%)	66 (37.9%)	81 (46.6%)	10 (5.7%)	174
Ulcer	7 (4.0%)	42 (24.1%)	86 (49.4%)	39 (22.4%)	174
Mydriasis	82 (47.1%)	49 (28.2%)	32 (18.4%)	11 (6.3%)	174
Hypoalbuminaemia	33 (19.0%)	37 (21.3%)	78 (44.8%)	26 (14.9%)	174
Frustration tolerance decreased	16 (9.2%)	35 (20.1%)	89 (51.1%)	34 (19.5%)	174
Metastases to central nervous system	3 (1.7%)	47 (27.0%)	112 (64.4%)	12 (6.9%)	174

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Prostatic specific antigen increased	0 (0.0%)	2 (1.2%)	113 (65.3%)	58 (33.5%)	173
Psychomotor hyperactivity	53 (30.6%)	53 (30.6%)	56 (32.4%)	11 (6.4%)	173
Venooclusive disease	57 (32.9%)	34 (19.7%)	81 (46.8%)	1 (0.6%)	173
Eosinophil count increased	22 (12.7%)	44 (25.4%)	86 (49.7%)	21 (12.1%)	173
Paralysis	8 (4.6%)	57 (32.9%)	91 (52.6%)	17 (9.8%)	173
Incorrect disposal of product	1 (0.6%)	15 (8.7%)	118 (68.6%)	38 (22.1%)	172
Liquid product physical issue	75 (43.6%)	38 (22.1%)	47 (27.3%)	12 (7.0%)	172
Schizophrenia	16 (9.3%)	66 (38.4%)	87 (50.6%)	3 (1.7%)	172
Haematotoxicity	18 (10.5%)	36 (21.1%)	99 (57.9%)	18 (10.5%)	171
Pulmonary congestion	9 (5.3%)	40 (23.4%)	101 (59.1%)	21 (12.3%)	171
Infusion site swelling	23 (13.5%)	42 (24.6%)	88 (51.5%)	18 (10.5%)	171
Respiratory depression	43 (25.3%)	54 (31.8%)	57 (33.5%)	16 (9.4%)	170
Generalised oedema	13 (7.6%)	53 (31.2%)	82 (48.2%)	22 (12.9%)	170
Poor quality product administered	51 (30.2%)	34 (20.1%)	64 (37.9%)	20 (11.8%)	169
Coagulopathy	33 (19.5%)	31 (18.3%)	76 (45.0%)	29 (17.2%)	169
Food allergy	24 (14.2%)	69 (40.8%)	67 (39.6%)	9 (5.3%)	169
Intentional self-injury	63 (37.7%)	78 (46.7%)	25 (15.0%)	1 (0.6%)	167
Blood calcium decreased	8 (4.8%)	26 (15.6%)	84 (50.3%)	49 (29.3%)	167
Nerve injury	3 (1.8%)	54 (32.5%)	88 (53.0%)	21 (12.7%)	166
Tuberculosis	5 (3.0%)	62 (37.3%)	87 (52.4%)	12 (7.2%)	166
Bradykinesia	14 (8.4%)	27 (16.3%)	89 (53.6%)	36 (21.7%)	166
Macular degeneration	3 (1.8%)	13 (7.8%)	89 (53.6%)	61 (36.7%)	166
Gastrointestinal pain	9 (5.5%)	37 (22.4%)	102 (61.8%)	17 (10.3%)	165
Gastrointestinal inflammation	27 (16.4%)	57 (34.5%)	74 (44.8%)	7 (4.2%)	165
Paranoia	25 (15.2%)	58 (35.2%)	66 (40.0%)	16 (9.7%)	165
Nail disorder	4 (2.4%)	56 (33.9%)	84 (50.9%)	21 (12.7%)	165
Live birth	14 (8.5%)	146 (88.5%)	5 (3.0%)	0 (0.0%)	165

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vitamin D deficiency	10 (6.1%)	63 (38.4%)	79 (48.2%)	12 (7.3%)	164
Cholecystitis	9 (5.5%)	24 (14.6%)	98 (59.8%)	33 (20.1%)	164
Economic problem	8 (4.9%)	98 (59.8%)	57 (34.8%)	1 (0.6%)	164
Neoplasm	7 (4.3%)	31 (19.0%)	110 (67.5%)	15 (9.2%)	163
Mucous stools	18 (11.0%)	75 (46.0%)	59 (36.2%)	11 (6.7%)	163
Sopor	31 (19.0%)	38 (23.3%)	64 (39.3%)	30 (18.4%)	163
Hunger	15 (9.3%)	46 (28.4%)	91 (56.2%)	10 (6.2%)	162
Hypercholesterolaemia	3 (1.9%)	88 (54.7%)	46 (28.6%)	24 (14.9%)	161
Blood urea increased	11 (6.8%)	29 (18.0%)	98 (60.9%)	23 (14.3%)	161
Micturition urgency	10 (6.2%)	45 (28.0%)	78 (48.4%)	28 (17.4%)	161
Tooth abscess	10 (6.2%)	45 (28.0%)	92 (57.1%)	14 (8.7%)	161
Infusion site erythema	20 (12.4%)	42 (26.1%)	79 (49.1%)	20 (12.4%)	161
Miosis	18 (11.2%)	67 (41.6%)	54 (33.5%)	22 (13.7%)	161
Eye haemorrhage	14 (8.8%)	21 (13.1%)	105 (65.6%)	20 (12.5%)	160
Osteomyelitis	11 (6.9%)	35 (21.9%)	92 (57.5%)	22 (13.8%)	160
Lupus-like syndrome	40 (25.0%)	81 (50.6%)	36 (22.5%)	3 (1.9%)	160
Blood magnesium decreased	3 (1.9%)	21 (13.2%)	112 (70.4%)	23 (14.5%)	159
Accidental underdose	10 (6.3%)	56 (35.2%)	82 (51.6%)	11 (6.9%)	159
Injection site discomfort	28 (17.6%)	43 (27.0%)	78 (49.1%)	10 (6.3%)	159
Bowel movement irregularity	18 (11.3%)	32 (20.1%)	95 (59.7%)	14 (8.8%)	159
Peripheral venous disease	0 (0.0%)	125 (78.6%)	27 (17.0%)	7 (4.4%)	159
Circumstance or information capable of leading to med	31 (19.5%)	16 (10.1%)	76 (47.8%)	36 (22.6%)	159
Neuroleptic malignant syndrome	10 (6.3%)	58 (36.5%)	81 (50.9%)	10 (6.3%)	159
Eye inflammation	24 (15.1%)	49 (30.8%)	68 (42.8%)	18 (11.3%)	159
Lymphoma	6 (3.8%)	29 (18.4%)	94 (59.5%)	29 (18.4%)	158
Dizziness postural	3 (1.9%)	21 (13.3%)	96 (60.8%)	38 (24.1%)	158
Pulmonary thrombosis	1 (0.6%)	21 (13.3%)	103 (65.2%)	33 (20.9%)	158

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Rotator cuff syndrome	1 (0.6%)	28 (17.8%)	115 (73.2%)	13 (8.3%)	157
Facet joint syndrome	0 (0.0%)	144 (91.7%)	13 (8.3%)	0 (0.0%)	157
Abnormal faeces	28 (17.9%)	33 (21.2%)	73 (46.8%)	22 (14.1%)	156
Swelling of eyelid	19 (12.2%)	44 (28.2%)	78 (50.0%)	15 (9.6%)	156
Pelvic pain	27 (17.3%)	64 (41.0%)	53 (34.0%)	12 (7.7%)	156
Fear of injection	66 (42.3%)	34 (21.8%)	47 (30.1%)	9 (5.8%)	156
Unintentional medical device removal	9 (5.8%)	42 (26.9%)	90 (57.7%)	15 (9.6%)	156
Enteritis	39 (25.0%)	25 (16.0%)	71 (45.5%)	21 (13.5%)	156
Aphthous ulcer	15 (9.6%)	48 (30.8%)	86 (55.1%)	7 (4.5%)	156
Metastasis	2 (1.3%)	49 (31.6%)	84 (54.2%)	20 (12.9%)	155
Cardiovascular disorder	14 (9.0%)	62 (40.0%)	62 (40.0%)	17 (11.0%)	155
Salivary hypersecretion	32 (20.6%)	48 (31.0%)	54 (34.8%)	21 (13.5%)	155
Anal abscess	22 (14.2%)	65 (41.9%)	64 (41.3%)	4 (2.6%)	155
Dystonia	51 (32.9%)	42 (27.1%)	50 (32.3%)	12 (7.7%)	155
Sensory disturbance	9 (5.8%)	73 (47.4%)	54 (35.1%)	18 (11.7%)	154
Motor dysfunction	17 (11.0%)	25 (16.2%)	97 (63.0%)	15 (9.7%)	154
Bronchospasm	25 (16.2%)	29 (18.8%)	85 (55.2%)	15 (9.7%)	154
Renal tubular necrosis	4 (2.6%)	45 (29.4%)	77 (50.3%)	27 (17.6%)	153
Myelodysplastic syndrome	4 (2.6%)	19 (12.4%)	93 (60.8%)	37 (24.2%)	153
Facial paralysis	16 (10.5%)	38 (24.8%)	74 (48.4%)	25 (16.3%)	153
Escherichia infection	18 (11.8%)	25 (16.3%)	85 (55.6%)	25 (16.3%)	153
Bedridden	13 (8.5%)	29 (19.0%)	64 (41.8%)	47 (30.7%)	153
Product physical issue	25 (16.4%)	31 (20.4%)	77 (50.7%)	19 (12.5%)	152
Upper-airway cough syndrome	5 (3.3%)	37 (24.3%)	90 (59.2%)	20 (13.2%)	152
Spinal disorder	2 (1.3%)	40 (26.3%)	95 (62.5%)	15 (9.9%)	152
Petechiae	28 (18.4%)	23 (15.1%)	76 (50.0%)	25 (16.4%)	152
Visual acuity reduced	13 (8.6%)	39 (25.7%)	71 (46.7%)	29 (19.1%)	152

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Body height decreased	9 (6.0%)	14 (9.3%)	70 (46.4%)	58 (38.4%)	151
Scar	14 (9.3%)	44 (29.1%)	85 (56.3%)	8 (5.3%)	151
Device deployment issue	17 (11.3%)	53 (35.1%)	54 (35.8%)	27 (17.9%)	151
Pulmonary arterial hypertension	7 (4.6%)	35 (23.2%)	75 (49.7%)	34 (22.5%)	151
Periorbital swelling	25 (16.7%)	41 (27.3%)	68 (45.3%)	16 (10.7%)	150
Subarachnoid haemorrhage	5 (3.4%)	22 (14.8%)	78 (52.3%)	44 (29.5%)	149
Posterior reversible encephalopathy syndrome	54 (36.2%)	28 (18.8%)	61 (40.9%)	6 (4.0%)	149
Inappropriate antidiuretic hormone secretion	11 (7.4%)	12 (8.1%)	62 (41.6%)	64 (43.0%)	149
Mania	31 (20.8%)	64 (43.0%)	50 (33.6%)	4 (2.7%)	149
Scab	21 (14.2%)	26 (17.6%)	78 (52.7%)	23 (15.5%)	148
Incorrect drug administration rate	29 (19.6%)	32 (21.6%)	67 (45.3%)	20 (13.5%)	148
Ventricular fibrillation	8 (5.4%)	34 (23.0%)	64 (43.2%)	42 (28.4%)	148
Lung opacity	6 (4.1%)	13 (8.8%)	75 (51.0%)	53 (36.1%)	147
Diffuse large B-cell lymphoma	17 (11.6%)	27 (18.5%)	64 (43.8%)	38 (26.0%)	146
Colitis microscopic	0 (0.0%)	29 (19.9%)	82 (56.2%)	35 (24.0%)	146
Bone marrow failure	26 (17.9%)	28 (19.3%)	71 (49.0%)	20 (13.8%)	145
Disability	5 (3.5%)	62 (43.1%)	64 (44.4%)	13 (9.0%)	144
Malnutrition	13 (9.0%)	24 (16.7%)	85 (59.0%)	22 (15.3%)	144
Urosepsis	4 (2.8%)	14 (9.7%)	84 (58.3%)	42 (29.2%)	144
Post procedural infection	5 (3.5%)	28 (19.4%)	96 (66.7%)	15 (10.4%)	144
Non-small cell lung cancer	1 (0.7%)	19 (13.2%)	95 (66.0%)	29 (20.1%)	144
Cerebral disorder	11 (7.6%)	32 (22.2%)	79 (54.9%)	22 (15.3%)	144
On and off phenomenon	0 (0.0%)	9 (6.3%)	85 (59.0%)	50 (34.7%)	144
Lymphoedema	5 (3.5%)	24 (16.8%)	87 (60.8%)	27 (18.9%)	143
Spinal compression fracture	0 (0.0%)	16 (11.2%)	77 (53.8%)	50 (35.0%)	143
Hiatus hernia	3 (2.1%)	22 (15.4%)	96 (67.1%)	22 (15.4%)	143
Ear discomfort	6 (4.2%)	58 (40.6%)	64 (44.8%)	15 (10.5%)	143

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Aspergillus infection	15 (10.5%)	23 (16.1%)	96 (67.1%)	9 (6.3%)	143
Impaired gastric emptying	11 (7.7%)	44 (31.0%)	76 (53.5%)	11 (7.7%)	142
Skin reaction	8 (5.6%)	49 (34.5%)	66 (46.5%)	19 (13.4%)	142
Tooth extraction	9 (6.3%)	27 (19.0%)	84 (59.2%)	22 (15.5%)	142
Colon cancer	1 (0.7%)	16 (11.3%)	84 (59.2%)	41 (28.9%)	142
Pyelonephritis	8 (5.6%)	45 (31.7%)	69 (48.6%)	20 (14.1%)	142
Fistula	21 (14.8%)	52 (36.6%)	64 (45.1%)	5 (3.5%)	142
Inability to afford medication	11 (7.8%)	32 (22.7%)	68 (48.2%)	30 (21.3%)	141
Nerve compression	1 (0.7%)	33 (23.4%)	86 (61.0%)	21 (14.9%)	141
Immune thrombocytopenia	7 (5.0%)	34 (24.1%)	68 (48.2%)	32 (22.7%)	141
Tendon rupture	5 (3.5%)	26 (18.4%)	81 (57.4%)	29 (20.6%)	141
Mouth haemorrhage	45 (32.1%)	25 (17.9%)	52 (37.1%)	18 (12.9%)	140
Erythema multiforme	12 (8.6%)	22 (15.7%)	80 (57.1%)	26 (18.6%)	140
Tooth fracture	6 (4.3%)	30 (21.4%)	94 (67.1%)	10 (7.1%)	140
Hypothermia	22 (15.7%)	35 (25.0%)	58 (41.4%)	25 (17.9%)	140
Blood pressure diastolic increased	9 (6.5%)	60 (43.2%)	59 (42.4%)	11 (7.9%)	139
Muscle strain	15 (10.8%)	43 (30.9%)	68 (48.9%)	13 (9.4%)	139
Thinking abnormal	7 (5.0%)	39 (28.1%)	65 (46.8%)	28 (20.1%)	139
Product administered to patient of inappropriate age	117 (84.2%)	11 (7.9%)	10 (7.2%)	1 (0.7%)	139
Malignant melanoma	3 (2.2%)	21 (15.2%)	87 (63.0%)	27 (19.6%)	138
Arteriosclerosis coronary artery	3 (2.2%)	17 (12.3%)	86 (62.3%)	32 (23.2%)	138
Discouragement	13 (9.5%)	46 (33.6%)	66 (48.2%)	12 (8.8%)	137
Subdural haematoma	2 (1.5%)	9 (6.6%)	70 (51.1%)	56 (40.9%)	137
Pseudomonas infection	18 (13.1%)	41 (29.9%)	63 (46.0%)	15 (10.9%)	137
Respiratory arrest	32 (23.4%)	31 (22.6%)	63 (46.0%)	11 (8.0%)	137
Pancreatic carcinoma	0 (0.0%)	9 (6.6%)	94 (68.6%)	34 (24.8%)	137
Eye discharge	19 (13.9%)	34 (24.8%)	67 (48.9%)	17 (12.4%)	137

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Expired device used	86 (62.8%)	18 (13.1%)	29 (21.2%)	4 (2.9%)	137
Renal pain	7 (5.1%)	48 (35.0%)	73 (53.3%)	9 (6.6%)	137
Breast cancer metastatic	0 (0.0%)	42 (30.7%)	87 (63.5%)	8 (5.8%)	137
Rhinitis	20 (14.7%)	42 (30.9%)	65 (47.8%)	9 (6.6%)	136
Therapy change	14 (10.3%)	28 (20.6%)	63 (46.3%)	31 (22.8%)	136
Cutaneous vasculitis	21 (15.6%)	37 (27.4%)	55 (40.7%)	22 (16.3%)	135
Breath sounds abnormal	14 (10.4%)	10 (7.4%)	77 (57.0%)	34 (25.2%)	135
Pulmonary alveolar haemorrhage	6 (4.4%)	35 (25.9%)	72 (53.3%)	22 (16.3%)	135
Iron deficiency anaemia	5 (3.7%)	43 (31.9%)	57 (42.2%)	30 (22.2%)	135
Flank pain	5 (3.7%)	28 (20.7%)	88 (65.2%)	14 (10.4%)	135
Ocular discomfort	13 (9.6%)	48 (35.6%)	59 (43.7%)	15 (11.1%)	135
Blood thyroid stimulating hormone increased	3 (2.2%)	18 (13.3%)	73 (54.1%)	41 (30.4%)	135
Myositis	5 (3.7%)	21 (15.7%)	72 (53.7%)	36 (26.9%)	134
Atelectasis	23 (17.2%)	23 (17.2%)	58 (43.3%)	30 (22.4%)	134
Rales	5 (3.7%)	16 (11.9%)	65 (48.5%)	48 (35.8%)	134
Coeliac disease	11 (8.2%)	67 (50.0%)	54 (40.3%)	2 (1.5%)	134
Coordination abnormal	13 (9.8%)	70 (52.6%)	44 (33.1%)	6 (4.5%)	133
Arthropod bite	19 (14.3%)	33 (24.8%)	74 (55.6%)	7 (5.3%)	133
Pemphigoid	4 (3.0%)	3 (2.3%)	68 (51.5%)	57 (43.2%)	132
Toxic skin eruption	5 (3.8%)	26 (19.7%)	76 (57.6%)	25 (18.9%)	132
Brain injury	15 (11.4%)	62 (47.0%)	45 (34.1%)	10 (7.6%)	132
Metastases to lymph nodes	0 (0.0%)	29 (22.0%)	91 (68.9%)	12 (9.1%)	132
Device operational issue	18 (13.6%)	15 (11.4%)	80 (60.6%)	19 (14.4%)	132
Postoperative wound infection	7 (5.3%)	32 (24.4%)	83 (63.4%)	9 (6.9%)	131
Exostosis	1 (0.8%)	50 (38.2%)	64 (48.9%)	16 (12.2%)	131
Living in residential institution	6 (4.6%)	21 (16.2%)	86 (66.2%)	17 (13.1%)	130
Skin weeping	38 (29.2%)	48 (36.9%)	37 (28.5%)	7 (5.4%)	130

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Diarrhoea haemorrhagic	12 (9.2%)	51 (39.2%)	53 (40.8%)	14 (10.8%)	130
Inflammatory marker increased	18 (13.8%)	24 (18.5%)	66 (50.8%)	22 (16.9%)	130
Nephropathy	3 (2.3%)	34 (26.4%)	70 (54.3%)	22 (17.1%)	129
Cardiomyopathy	8 (6.2%)	37 (28.7%)	64 (49.6%)	20 (15.5%)	129
Concussion	7 (5.4%)	28 (21.7%)	73 (56.6%)	21 (16.3%)	129
Retinal detachment	3 (2.3%)	27 (21.1%)	75 (58.6%)	23 (18.0%)	128
Hypophosphataemia	4 (3.1%)	25 (19.5%)	51 (39.8%)	48 (37.5%)	128
Muscle haemorrhage	61 (47.7%)	44 (34.4%)	17 (13.3%)	6 (4.7%)	128
Injection site discolouration	19 (14.8%)	39 (30.5%)	65 (50.8%)	5 (3.9%)	128
Hidradenitis	23 (18.0%)	75 (58.6%)	29 (22.7%)	1 (0.8%)	128
Troponin increased	28 (21.9%)	24 (18.8%)	42 (32.8%)	34 (26.6%)	128
Bladder disorder	6 (4.7%)	29 (22.7%)	73 (57.0%)	20 (15.6%)	128
Rhinovirus infection	77 (60.2%)	11 (8.6%)	37 (28.9%)	3 (2.3%)	128
Drug use disorder	32 (25.0%)	62 (48.4%)	32 (25.0%)	2 (1.6%)	128
Application site pain	16 (12.6%)	40 (31.5%)	61 (48.0%)	10 (7.9%)	127
Polyp	4 (3.1%)	17 (13.4%)	94 (74.0%)	12 (9.4%)	127
Hypertensive crisis	5 (3.9%)	26 (20.5%)	81 (63.8%)	15 (11.8%)	127
Transplant rejection	16 (12.6%)	57 (44.9%)	54 (42.5%)	0 (0.0%)	127
Haemodynamic instability	22 (17.5%)	23 (18.3%)	71 (56.3%)	10 (7.9%)	126
Sluggishness	11 (8.7%)	33 (26.2%)	65 (51.6%)	17 (13.5%)	126
Ear pruritus	2 (1.6%)	44 (34.9%)	79 (62.7%)	1 (0.8%)	126
Feeling jittery	12 (9.5%)	43 (34.1%)	51 (40.5%)	20 (15.9%)	126
Shock haemorrhagic	6 (4.8%)	21 (16.7%)	56 (44.4%)	43 (34.1%)	126
Sensation of foreign body	10 (8.0%)	33 (26.4%)	66 (52.8%)	16 (12.8%)	125
Euglycaemic diabetic ketoacidosis	1 (0.8%)	31 (24.8%)	71 (56.8%)	22 (17.6%)	125
Organising pneumonia	13 (10.4%)	14 (11.2%)	67 (53.6%)	31 (24.8%)	125
Cholecystectomy	4 (3.2%)	40 (32.3%)	73 (58.9%)	7 (5.6%)	124

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hepatomegaly	30 (24.2%)	39 (31.5%)	50 (40.3%)	5 (4.0%)	124
Rebound effect	25 (20.2%)	34 (27.4%)	56 (45.2%)	9 (7.3%)	124
Complication of device insertion	41 (33.1%)	82 (66.1%)	1 (0.8%)	0 (0.0%)	124
Hypogammaglobulinaemia	23 (18.7%)	17 (13.8%)	81 (65.9%)	2 (1.6%)	123
Blindness unilateral	8 (6.5%)	22 (17.9%)	57 (46.3%)	36 (29.3%)	123
Vitreous floaters	3 (2.4%)	24 (19.5%)	73 (59.3%)	23 (18.7%)	123
Ataxia	17 (13.9%)	37 (30.3%)	56 (45.9%)	12 (9.8%)	122
Blood pressure diastolic abnormal	7 (5.7%)	43 (35.2%)	68 (55.7%)	4 (3.3%)	122
Thyroiditis	2 (1.6%)	36 (29.5%)	71 (58.2%)	13 (10.7%)	122
Hypertriglyceridaemia	28 (23.0%)	51 (41.8%)	40 (32.8%)	3 (2.5%)	122
Attention deficit hyperactivity disorder	84 (68.9%)	26 (21.3%)	11 (9.0%)	1 (0.8%)	122
Post procedural haemorrhage	22 (18.0%)	18 (14.8%)	56 (45.9%)	26 (21.3%)	122
Skin abrasion	17 (13.9%)	24 (19.7%)	57 (46.7%)	24 (19.7%)	122
Venoocclusive liver disease	29 (23.8%)	37 (30.3%)	55 (45.1%)	1 (0.8%)	122
Respiration abnormal	12 (9.9%)	26 (21.5%)	68 (56.2%)	15 (12.4%)	121
Gingival pain	2 (1.7%)	33 (27.3%)	76 (62.8%)	10 (8.3%)	121
Spinal stenosis	1 (0.8%)	14 (11.6%)	79 (65.3%)	27 (22.3%)	121
Blood pressure systolic abnormal	2 (1.7%)	26 (21.5%)	85 (70.2%)	8 (6.6%)	121
Magnetic resonance imaging head abnormal	104 (86.0%)	8 (6.6%)	9 (7.4%)	0 (0.0%)	121
Genital haemorrhage	31 (25.6%)	83 (68.6%)	7 (5.8%)	0 (0.0%)	121
Dry throat	7 (5.8%)	37 (30.6%)	64 (52.9%)	13 (10.7%)	121
Blepharospasm	9 (7.5%)	97 (80.8%)	10 (8.3%)	4 (3.3%)	120
Behaviour disorder	49 (40.8%)	30 (25.0%)	33 (27.5%)	8 (6.7%)	120
Cardiomegaly	9 (7.5%)	27 (22.5%)	57 (47.5%)	27 (22.5%)	120
Polyuria	21 (17.5%)	33 (27.5%)	48 (40.0%)	18 (15.0%)	120
Parkinsonism	4 (3.3%)	17 (14.2%)	81 (67.5%)	18 (15.0%)	120
Electric shock sensation	9 (7.6%)	60 (50.4%)	44 (37.0%)	6 (5.0%)	119

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hydronephrosis	9 (7.6%)	18 (15.1%)	57 (47.9%)	35 (29.4%)	119
Injection site irritation	27 (22.7%)	49 (41.2%)	42 (35.3%)	1 (0.8%)	119
Papule	18 (15.1%)	39 (32.8%)	51 (42.9%)	11 (9.2%)	119
Cytomegalovirus infection reactivation	23 (19.3%)	42 (35.3%)	53 (44.5%)	1 (0.8%)	119
Breast mass	3 (2.5%)	52 (43.7%)	60 (50.4%)	4 (3.4%)	119
Intestinal perforation	6 (5.1%)	18 (15.3%)	80 (67.8%)	14 (11.9%)	118
Hyperaesthesia	6 (5.1%)	42 (35.6%)	59 (50.0%)	11 (9.3%)	118
Oral discomfort	5 (4.2%)	20 (16.9%)	77 (65.3%)	16 (13.6%)	118
Breast cancer female	1 (0.8%)	32 (27.1%)	75 (63.6%)	10 (8.5%)	118
Product adhesion issue	14 (11.9%)	26 (22.0%)	63 (53.4%)	15 (12.7%)	118
Haematological infection	7 (5.9%)	22 (18.6%)	70 (59.3%)	19 (16.1%)	118
Vitamin D decreased	10 (8.5%)	36 (30.8%)	68 (58.1%)	3 (2.6%)	117
Cholangitis	2 (1.7%)	17 (14.5%)	57 (48.7%)	41 (35.0%)	117
Hospice care	2 (1.7%)	9 (7.7%)	56 (47.9%)	50 (42.7%)	117
Hyperthermia	17 (14.5%)	40 (34.2%)	54 (46.2%)	6 (5.1%)	117
Chronic sinusitis	11 (9.4%)	22 (18.8%)	79 (67.5%)	5 (4.3%)	117
Hysterectomy	4 (3.4%)	62 (53.0%)	50 (42.7%)	1 (0.9%)	117
Infusion site discharge	16 (13.7%)	21 (17.9%)	60 (51.3%)	20 (17.1%)	117
Oesophagitis	10 (8.5%)	21 (17.9%)	70 (59.8%)	16 (13.7%)	117
Ventricular extrasystoles	9 (7.7%)	33 (28.2%)	57 (48.7%)	18 (15.4%)	117
Product leakage	10 (8.6%)	51 (44.0%)	44 (37.9%)	11 (9.5%)	116
Pelvic fracture	0 (0.0%)	7 (6.0%)	54 (46.6%)	55 (47.4%)	116
Tardive dyskinesia	14 (12.1%)	28 (24.1%)	52 (44.8%)	22 (19.0%)	116
Deep vein thrombosis postoperative	0 (0.0%)	111 (95.7%)	3 (2.6%)	2 (1.7%)	116
Device power source issue	79 (68.7%)	9 (7.8%)	23 (20.0%)	4 (3.5%)	115
Nasal polyps	3 (2.6%)	28 (24.3%)	82 (71.3%)	2 (1.7%)	115
Emphysema	3 (2.6%)	16 (13.9%)	77 (67.0%)	19 (16.5%)	115

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Suspected COVID-19	13 (11.3%)	41 (35.7%)	52 (45.2%)	9 (7.8%)	115
Rhinitis allergic	7 (6.1%)	21 (18.3%)	82 (71.3%)	5 (4.3%)	115
Maternal exposure before pregnancy	27 (23.5%)	88 (76.5%)	0 (0.0%)	0 (0.0%)	115
Streptococcal infection	39 (33.9%)	44 (38.3%)	25 (21.7%)	7 (6.1%)	115
Appetite disorder	15 (13.0%)	22 (19.1%)	55 (47.8%)	23 (20.0%)	115
Dental caries	14 (12.2%)	40 (34.8%)	41 (35.7%)	20 (17.4%)	115
Inguinal hernia	12 (10.4%)	31 (27.0%)	52 (45.2%)	20 (17.4%)	115
Injection site induration	15 (13.0%)	43 (37.4%)	51 (44.3%)	6 (5.2%)	115
Autoimmune hepatitis	9 (7.8%)	25 (21.7%)	69 (60.0%)	12 (10.4%)	115
Incontinence	6 (5.3%)	31 (27.2%)	62 (54.4%)	15 (13.2%)	114
Encephalitis	15 (13.2%)	25 (21.9%)	65 (57.0%)	9 (7.9%)	114
Anal fistula	14 (12.3%)	61 (53.5%)	39 (34.2%)	0 (0.0%)	114
Skin mass	5 (4.4%)	29 (25.4%)	66 (57.9%)	14 (12.3%)	114
Mitral valve incompetence	22 (19.3%)	21 (18.4%)	46 (40.4%)	25 (21.9%)	114
Blood uric acid increased	6 (5.3%)	27 (23.7%)	48 (42.1%)	33 (28.9%)	114
Status epilepticus	35 (31.0%)	35 (31.0%)	31 (27.4%)	12 (10.6%)	113
Brain neoplasm	12 (10.6%)	37 (32.7%)	50 (44.2%)	14 (12.4%)	113
Hepatic encephalopathy	10 (8.9%)	14 (12.5%)	74 (66.1%)	14 (12.5%)	112
Product preparation issue	26 (23.2%)	36 (32.1%)	39 (34.8%)	11 (9.8%)	112
Product packaging quantity issue	8 (7.1%)	8 (7.1%)	63 (56.3%)	33 (29.5%)	112
Blood calcium increased	1 (0.9%)	10 (8.9%)	60 (53.6%)	41 (36.6%)	112
Sensitive skin	15 (13.5%)	44 (39.6%)	44 (39.6%)	8 (7.2%)	111
Myopathy	17 (15.3%)	19 (17.1%)	60 (54.1%)	15 (13.5%)	111
Cardiac operation	7 (6.3%)	5 (4.5%)	72 (64.9%)	27 (24.3%)	111
Enterocolitis	6 (5.4%)	20 (18.0%)	60 (54.1%)	25 (22.5%)	111
Tendon pain	3 (2.7%)	54 (48.6%)	40 (36.0%)	14 (12.6%)	111
Breast pain	8 (7.2%)	28 (25.2%)	61 (55.0%)	14 (12.6%)	111

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bone demineralisation	4 (3.6%)	49 (44.1%)	57 (51.4%)	1 (0.9%)	111
Dissociation	10 (9.0%)	61 (55.0%)	38 (34.2%)	2 (1.8%)	111
Klebsiella infection	13 (11.8%)	42 (38.2%)	50 (45.5%)	5 (4.5%)	110
Polyarthritis	14 (12.7%)	22 (20.0%)	59 (53.6%)	15 (13.6%)	110
Major depression	13 (11.8%)	65 (59.1%)	30 (27.3%)	2 (1.8%)	110
Amenorrhoea	20 (18.2%)	84 (76.4%)	6 (5.5%)	0 (0.0%)	110
Sinus bradycardia	6 (5.5%)	39 (35.5%)	45 (40.9%)	20 (18.2%)	110
Hip surgery	0 (0.0%)	17 (15.5%)	69 (62.7%)	24 (21.8%)	110
Eyelid ptosis	9 (8.3%)	33 (30.3%)	39 (35.8%)	28 (25.7%)	109
Internal haemorrhage	10 (9.2%)	16 (14.7%)	49 (45.0%)	34 (31.2%)	109
Hand fracture	6 (5.5%)	38 (34.9%)	52 (47.7%)	13 (11.9%)	109
Proctalgia	24 (22.0%)	34 (31.2%)	44 (40.4%)	7 (6.4%)	109
Blood cholesterol abnormal	1 (0.9%)	7 (6.4%)	93 (85.3%)	8 (7.3%)	109
White blood cell count abnormal	5 (4.6%)	12 (11.1%)	75 (69.4%)	16 (14.8%)	108
Large intestine polyp	4 (3.7%)	23 (21.3%)	66 (61.1%)	15 (13.9%)	108
Drug specific antibody present	33 (30.6%)	32 (29.6%)	42 (38.9%)	1 (0.9%)	108
Red cell distribution width increased	2 (1.9%)	32 (29.6%)	63 (58.3%)	11 (10.2%)	108
Arteriosclerosis	1 (0.9%)	15 (13.9%)	77 (71.3%)	15 (13.9%)	108
Ovarian cyst	15 (14.0%)	65 (60.7%)	27 (25.2%)	0 (0.0%)	107
Infusion site haemorrhage	16 (15.0%)	22 (20.6%)	53 (49.5%)	16 (15.0%)	107
Electrocardiogram QRS complex prolonged	26 (24.3%)	40 (37.4%)	40 (37.4%)	1 (0.9%)	107
Pathogen resistance	6 (5.6%)	40 (37.4%)	43 (40.2%)	18 (16.8%)	107
Concomitant disease aggravated	11 (10.3%)	22 (20.6%)	50 (46.7%)	24 (22.4%)	107
Leukaemia	2 (1.9%)	20 (18.7%)	65 (60.7%)	20 (18.7%)	107
Blood disorder	4 (3.7%)	10 (9.3%)	68 (63.6%)	25 (23.4%)	107
Foot operation	4 (3.7%)	15 (14.0%)	84 (78.5%)	4 (3.7%)	107
Immune reconstitution inflammatory syndrome	4 (3.7%)	65 (60.7%)	35 (32.7%)	3 (2.8%)	107

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Onychomycosis	1 (0.9%)	52 (48.6%)	49 (45.8%)	5 (4.7%)	107
Food poisoning	11 (10.3%)	39 (36.4%)	48 (44.9%)	9 (8.4%)	107
Pigmentation disorder	5 (4.7%)	32 (30.2%)	59 (55.7%)	10 (9.4%)	106
Hordeolum	17 (16.0%)	31 (29.2%)	51 (48.1%)	7 (6.6%)	106
Distributive shock	52 (49.1%)	16 (15.1%)	35 (33.0%)	3 (2.8%)	106
Bipolar disorder	7 (6.6%)	52 (49.1%)	42 (39.6%)	5 (4.7%)	106
Stoma site discharge	1 (0.9%)	3 (2.8%)	70 (66.0%)	32 (30.2%)	106
Left ventricular failure	2 (1.9%)	7 (6.6%)	60 (56.6%)	37 (34.9%)	106
Dialysis	2 (1.9%)	16 (15.1%)	62 (58.5%)	26 (24.5%)	106
Droling	39 (36.8%)	28 (26.4%)	28 (26.4%)	11 (10.4%)	106
Furuncle	14 (13.2%)	27 (25.5%)	55 (51.9%)	10 (9.4%)	106
Intermenstrual bleeding	32 (30.2%)	58 (54.7%)	14 (13.2%)	2 (1.9%)	106
Infusion site pruritus	14 (13.3%)	23 (21.9%)	57 (54.3%)	11 (10.5%)	105
Menstruation irregular	17 (16.2%)	82 (78.1%)	6 (5.7%)	0 (0.0%)	105
Renal cyst	3 (2.9%)	31 (29.5%)	52 (49.5%)	19 (18.1%)	105
Adverse reaction	6 (5.7%)	42 (40.0%)	42 (40.0%)	15 (14.3%)	105
Splenomegaly	18 (17.1%)	30 (28.6%)	48 (45.7%)	9 (8.6%)	105
Dermatitis exfoliative generalised	11 (10.5%)	7 (6.7%)	53 (50.5%)	34 (32.4%)	105
Optic neuritis	8 (7.6%)	59 (56.2%)	35 (33.3%)	3 (2.9%)	105
Skeletal injury	5 (4.8%)	42 (40.0%)	57 (54.3%)	1 (1.0%)	105
Meniscus injury	2 (1.9%)	21 (20.0%)	77 (73.3%)	5 (4.8%)	105
Injection site vesicles	22 (21.0%)	41 (39.0%)	38 (36.2%)	4 (3.8%)	105
Toxic encephalopathy	26 (25.0%)	19 (18.3%)	41 (39.4%)	18 (17.3%)	104
Hiccups	0 (0.0%)	24 (23.1%)	56 (53.8%)	24 (23.1%)	104
Tension	4 (3.8%)	41 (39.4%)	45 (43.3%)	14 (13.5%)	104
Type 1 diabetes mellitus	7 (6.7%)	21 (20.2%)	56 (53.8%)	20 (19.2%)	104
Shoulder fracture	2 (1.9%)	12 (11.5%)	58 (55.8%)	32 (30.8%)	104

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Meningitis	12 (11.7%)	36 (35.0%)	46 (44.7%)	9 (8.7%)	103
Sensory loss	7 (6.8%)	45 (43.7%)	45 (43.7%)	6 (5.8%)	103
International normalised ratio increased	11 (10.7%)	9 (8.7%)	55 (53.4%)	28 (27.2%)	103
Immune-mediated hypothyroidism	1 (1.0%)	17 (16.5%)	67 (65.0%)	18 (17.5%)	103
Iron deficiency	11 (10.7%)	28 (27.2%)	34 (33.0%)	30 (29.1%)	103
Cardiac failure acute	7 (6.8%)	18 (17.5%)	48 (46.6%)	30 (29.1%)	103
Platelet count abnormal	10 (9.7%)	18 (17.5%)	61 (59.2%)	14 (13.6%)	103
Tendon disorder	4 (3.9%)	35 (34.3%)	54 (52.9%)	9 (8.8%)	102
Monocyte count increased	16 (15.7%)	36 (35.3%)	39 (38.2%)	11 (10.8%)	102
Cardiotoxicity	15 (14.7%)	39 (38.2%)	41 (40.2%)	7 (6.9%)	102
Refusal of treatment by patient	40 (39.2%)	16 (15.7%)	27 (26.5%)	19 (18.6%)	102
Dyslipidaemia	7 (6.9%)	36 (35.3%)	37 (36.3%)	22 (21.6%)	102
Finger deformity	3 (2.9%)	49 (48.0%)	32 (31.4%)	18 (17.6%)	102
Facial pain	7 (6.9%)	37 (36.3%)	49 (48.0%)	9 (8.8%)	102
Acidosis	26 (25.5%)	27 (26.5%)	35 (34.3%)	14 (13.7%)	102
Breast cancer stage III	0 (0.0%)	98 (96.1%)	4 (3.9%)	0 (0.0%)	102
Psychiatric symptom	6 (5.9%)	25 (24.5%)	50 (49.0%)	21 (20.6%)	102
Tonsillitis	30 (29.4%)	39 (38.2%)	32 (31.4%)	1 (1.0%)	102
Spinal osteoarthritis	1 (1.0%)	29 (28.7%)	57 (56.4%)	14 (13.9%)	101
Respiratory symptom	17 (16.8%)	20 (19.8%)	60 (59.4%)	4 (4.0%)	101
Central nervous system lesion	9 (8.9%)	37 (36.6%)	52 (51.5%)	3 (3.0%)	101
Complication of device removal	15 (15.0%)	77 (77.0%)	8 (8.0%)	0 (0.0%)	100
Dermatitis acneiform	20 (20.0%)	15 (15.0%)	50 (50.0%)	15 (15.0%)	100
Forced expiratory volume decreased	5 (5.0%)	30 (30.0%)	61 (61.0%)	4 (4.0%)	100
Squamous cell carcinoma of skin	1 (1.0%)	11 (11.1%)	65 (65.7%)	22 (22.2%)	99
Haemolytic anaemia	14 (14.1%)	8 (8.1%)	60 (60.6%)	17 (17.2%)	99
Hyperlipidaemia	4 (4.0%)	16 (16.2%)	71 (71.7%)	8 (8.1%)	99

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Walking aid user	2 (2.0%)	33 (33.3%)	43 (43.4%)	21 (21.2%)	99
Supraventricular tachycardia	3 (3.0%)	23 (23.2%)	59 (59.6%)	14 (14.1%)	99
Cytomegalovirus viraemia	20 (20.2%)	27 (27.3%)	48 (48.5%)	4 (4.0%)	99
Oral disorder	14 (14.1%)	19 (19.2%)	57 (57.6%)	9 (9.1%)	99
General physical condition abnormal	5 (5.1%)	33 (33.3%)	36 (36.4%)	25 (25.3%)	99
Eye movement disorder	23 (23.2%)	32 (32.3%)	29 (29.3%)	15 (15.2%)	99
Decubitus ulcer	9 (9.1%)	13 (13.1%)	53 (53.5%)	24 (24.2%)	99
Odynophagia	16 (16.2%)	34 (34.3%)	46 (46.5%)	3 (3.0%)	99
Embedded device	16 (16.3%)	54 (55.1%)	20 (20.4%)	8 (8.2%)	98
Maternal exposure during breast feeding	18 (18.4%)	80 (81.6%)	0 (0.0%)	0 (0.0%)	98
Hemiplegia	8 (8.2%)	22 (22.4%)	52 (53.1%)	16 (16.3%)	98
Hyperpyrexia	15 (15.3%)	34 (34.7%)	47 (48.0%)	2 (2.0%)	98
Increased tendency to bruise	4 (4.1%)	22 (22.4%)	58 (59.2%)	14 (14.3%)	98
Mean cell volume increased	7 (7.1%)	16 (16.3%)	58 (59.2%)	17 (17.3%)	98
Groin pain	5 (5.2%)	20 (20.6%)	60 (61.9%)	12 (12.4%)	97
Electrocardiogram abnormal	16 (16.5%)	15 (15.5%)	47 (48.5%)	19 (19.6%)	97
Hepatocellular injury	13 (13.5%)	22 (22.9%)	57 (59.4%)	4 (4.2%)	96
Blood immunoglobulin G decreased	10 (10.4%)	34 (35.4%)	47 (49.0%)	5 (5.2%)	96
Atrioventricular block	3 (3.1%)	4 (4.2%)	42 (43.8%)	47 (49.0%)	96
BRASH syndrome	0 (0.0%)	5 (5.2%)	37 (38.5%)	54 (56.3%)	96
Staphylococcal bacteraemia	7 (7.3%)	21 (21.9%)	45 (46.9%)	23 (24.0%)	96
Hepatocellular carcinoma	3 (3.1%)	13 (13.5%)	62 (64.6%)	18 (18.8%)	96
Exercise tolerance decreased	2 (2.1%)	34 (35.4%)	46 (47.9%)	14 (14.6%)	96
Blood albumin decreased	21 (22.1%)	13 (13.7%)	51 (53.7%)	10 (10.5%)	95
Blood pressure systolic decreased	8 (8.4%)	39 (41.1%)	41 (43.2%)	7 (7.4%)	95
Intracranial pressure increased	31 (32.6%)	47 (49.5%)	11 (11.6%)	6 (6.3%)	95
Low density lipoprotein increased	6 (6.3%)	27 (28.4%)	51 (53.7%)	11 (11.6%)	95

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Loss of libido	20 (21.1%)	60 (63.2%)	13 (13.7%)	2 (2.1%)	95
Meningitis aseptic	9 (9.5%)	45 (47.4%)	31 (32.6%)	10 (10.5%)	95
Neurodermatitis	8 (8.4%)	25 (26.3%)	60 (63.2%)	2 (2.1%)	95
Peripheral sensory neuropathy	11 (11.6%)	11 (11.6%)	60 (63.2%)	13 (13.7%)	95
Febrile bone marrow aplasia	9 (9.5%)	17 (17.9%)	64 (67.4%)	5 (5.3%)	95
Infusion site extravasation	15 (15.8%)	22 (23.2%)	47 (49.5%)	11 (11.6%)	95
Libido decreased	10 (10.6%)	47 (50.0%)	33 (35.1%)	4 (4.3%)	94
Limb operation	2 (2.1%)	17 (18.1%)	66 (70.2%)	9 (9.6%)	94
Obstruction	17 (18.1%)	15 (16.0%)	48 (51.1%)	14 (14.9%)	94
Embolism	12 (12.8%)	12 (12.8%)	56 (59.6%)	14 (14.9%)	94
Adjustment disorder with depressed mood	1 (1.1%)	87 (92.6%)	5 (5.3%)	1 (1.1%)	94
Herpes virus infection	8 (8.6%)	38 (40.9%)	38 (40.9%)	9 (9.7%)	93
Post-traumatic stress disorder	11 (11.8%)	41 (44.1%)	40 (43.0%)	1 (1.1%)	93
Vaginal discharge	11 (11.8%)	22 (23.7%)	56 (60.2%)	4 (4.3%)	93
Bladder cancer	0 (0.0%)	2 (2.2%)	65 (69.9%)	26 (28.0%)	93
Immune-mediated myositis	1 (1.1%)	18 (19.4%)	58 (62.4%)	16 (17.2%)	93
Blood lactic acid increased	11 (11.8%)	22 (23.7%)	54 (58.1%)	6 (6.5%)	93
Pneumonia fungal	9 (9.7%)	8 (8.6%)	71 (76.3%)	5 (5.4%)	93
Shoulder operation	1 (1.1%)	20 (21.5%)	65 (69.9%)	7 (7.5%)	93
Parosmia	5 (5.4%)	26 (28.3%)	56 (60.9%)	5 (5.4%)	92
Erysipelas	4 (4.3%)	23 (25.0%)	50 (54.3%)	15 (16.3%)	92
Throat clearing	3 (3.3%)	26 (28.3%)	51 (55.4%)	12 (13.0%)	92
Loss of therapeutic response	4 (4.3%)	39 (42.4%)	43 (46.7%)	6 (6.5%)	92
Intervertebral disc degeneration	3 (3.3%)	23 (25.0%)	58 (63.0%)	8 (8.7%)	92
Gastrointestinal motility disorder	9 (9.8%)	22 (23.9%)	47 (51.1%)	14 (15.2%)	92
Anti-neutrophil cytoplasmic antibody positive vasculi	1 (1.1%)	13 (14.1%)	50 (54.3%)	28 (30.4%)	92
Joint effusion	13 (14.3%)	19 (20.9%)	52 (57.1%)	7 (7.7%)	91

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Spondylitis	2 (2.2%)	42 (46.2%)	41 (45.1%)	6 (6.6%)	91
Dyschezia	7 (7.7%)	24 (26.4%)	47 (51.6%)	13 (14.3%)	91
Feeling of despair	16 (17.6%)	34 (37.4%)	35 (38.5%)	6 (6.6%)	91
Skin toxicity	14 (15.6%)	10 (11.1%)	55 (61.1%)	11 (12.2%)	90
Paronychia	9 (10.0%)	18 (20.0%)	50 (55.6%)	13 (14.4%)	90
Neutropenic sepsis	1 (1.1%)	28 (31.1%)	55 (61.1%)	6 (6.7%)	90
Oral mucosal blistering	7 (7.8%)	20 (22.2%)	48 (53.3%)	15 (16.7%)	90
Sjogren's syndrome	0 (0.0%)	25 (27.8%)	54 (60.0%)	11 (12.2%)	90
Anal fissure	10 (11.1%)	42 (46.7%)	34 (37.8%)	4 (4.4%)	90
Dementia Alzheimer's type	0 (0.0%)	2 (2.2%)	33 (36.7%)	55 (61.1%)	90
Intraocular pressure increased	14 (15.6%)	7 (7.8%)	46 (51.1%)	23 (25.6%)	90
Abnormal loss of weight	2 (2.2%)	14 (15.6%)	65 (72.2%)	9 (10.0%)	90
Ketoacidosis	3 (3.3%)	23 (25.6%)	49 (54.4%)	15 (16.7%)	90
Diabetes insipidus	18 (20.2%)	20 (22.5%)	48 (53.9%)	3 (3.4%)	89
Transfusion	8 (9.0%)	11 (12.4%)	38 (42.7%)	32 (36.0%)	89
Heart rate abnormal	4 (4.5%)	34 (38.2%)	39 (43.8%)	12 (13.5%)	89
Eyelid oedema	19 (21.3%)	26 (29.2%)	32 (36.0%)	12 (13.5%)	89
Torsade de pointes	15 (16.9%)	18 (20.2%)	47 (52.8%)	9 (10.1%)	89
Pustule	7 (7.9%)	24 (27.0%)	53 (59.6%)	5 (5.6%)	89
Post transplant lymphoproliferative disorder	37 (41.6%)	26 (29.2%)	24 (27.0%)	2 (2.2%)	89
Proctitis	1 (1.1%)	21 (23.6%)	65 (73.0%)	2 (2.2%)	89
Squamous cell carcinoma	1 (1.1%)	11 (12.4%)	57 (64.0%)	20 (22.5%)	89
Scoliosis	30 (33.7%)	7 (7.9%)	33 (37.1%)	19 (21.3%)	89
Eye operation	1 (1.1%)	5 (5.6%)	68 (76.4%)	15 (16.9%)	89
Foreign body in throat	1 (1.1%)	10 (11.2%)	49 (55.1%)	29 (32.6%)	89
Urine output decreased	22 (24.7%)	10 (11.2%)	40 (44.9%)	17 (19.1%)	89
Wrong product administered	15 (17.0%)	23 (26.1%)	35 (39.8%)	15 (17.0%)	88

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skin atrophy	5 (5.7%)	20 (22.7%)	41 (46.6%)	22 (25.0%)	88
Metastases to spine	0 (0.0%)	16 (18.2%)	65 (73.9%)	7 (8.0%)	88
Haemoglobin abnormal	6 (6.8%)	18 (20.5%)	48 (54.5%)	16 (18.2%)	88
Nephrotic syndrome	17 (19.3%)	13 (14.8%)	38 (43.2%)	20 (22.7%)	88
Obstructive sleep apnoea syndrome	8 (9.1%)	19 (21.6%)	52 (59.1%)	9 (10.2%)	88
Bradyphrenia	12 (13.6%)	36 (40.9%)	28 (31.8%)	12 (13.6%)	88
Renal cancer	0 (0.0%)	18 (20.5%)	57 (64.8%)	13 (14.8%)	88
Colitis ischaemic	3 (3.4%)	12 (13.8%)	56 (64.4%)	16 (18.4%)	87
Duodenal ulcer	9 (10.3%)	6 (6.9%)	45 (51.7%)	27 (31.0%)	87
Urine abnormality	10 (11.5%)	13 (14.9%)	55 (63.2%)	9 (10.3%)	87
Hyperuricaemia	10 (11.5%)	14 (16.1%)	51 (58.6%)	12 (13.8%)	87
Depressive symptom	10 (11.5%)	24 (27.6%)	51 (58.6%)	2 (2.3%)	87
Product odour abnormal	27 (31.0%)	11 (12.6%)	44 (50.6%)	5 (5.7%)	87
Protein urine present	7 (8.0%)	25 (28.7%)	46 (52.9%)	9 (10.3%)	87
Infusion site bruising	13 (14.9%)	22 (25.3%)	41 (47.1%)	11 (12.6%)	87
Euphoric mood	5 (5.7%)	55 (63.2%)	24 (27.6%)	3 (3.4%)	87
Tooth injury	4 (4.7%)	34 (39.5%)	47 (54.7%)	1 (1.2%)	86
Synovial cyst	3 (3.5%)	28 (32.6%)	50 (58.1%)	5 (5.8%)	86
Sexual dysfunction	19 (22.1%)	52 (60.5%)	13 (15.1%)	2 (2.3%)	86
Hepatic enzyme abnormal	8 (9.3%)	28 (32.6%)	43 (50.0%)	7 (8.1%)	86
Cushing's syndrome	10 (11.6%)	55 (64.0%)	19 (22.1%)	2 (2.3%)	86
Post-acute COVID-19 syndrome	1 (1.2%)	18 (20.9%)	53 (61.6%)	14 (16.3%)	86
Lipase increased	3 (3.5%)	19 (22.1%)	54 (62.8%)	10 (11.6%)	86
Labelled drug-drug interaction medication error	4 (4.7%)	18 (20.9%)	44 (51.2%)	20 (23.3%)	86
Lichenoid keratosis	1 (1.2%)	12 (14.0%)	58 (67.4%)	15 (17.4%)	86
Acute generalised exanthematous pustulosis	11 (12.8%)	15 (17.4%)	47 (54.7%)	13 (15.1%)	86
Hypernatraemia	13 (15.1%)	19 (22.1%)	35 (40.7%)	19 (22.1%)	86

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Prescription drug used without a prescription	12 (14.0%)	32 (37.2%)	33 (38.4%)	9 (10.5%)	86
Dermatitis bullous	4 (4.7%)	17 (19.8%)	40 (46.5%)	25 (29.1%)	86
Gingivitis	1 (1.2%)	28 (32.6%)	48 (55.8%)	9 (10.5%)	86
Arteriospasm coronary	4 (4.7%)	34 (40.0%)	44 (51.8%)	3 (3.5%)	85
Purpura	3 (3.5%)	14 (16.5%)	39 (45.9%)	29 (34.1%)	85
Atrial flutter	2 (2.4%)	9 (10.6%)	46 (54.1%)	28 (32.9%)	85
Catatonia	20 (23.5%)	40 (47.1%)	3 (3.5%)	22 (25.9%)	85
Dysgraphia	9 (10.6%)	10 (11.8%)	51 (60.0%)	15 (17.6%)	85
Cardiac dysfunction	14 (16.7%)	12 (14.3%)	38 (45.2%)	20 (23.8%)	84
Panic reaction	4 (4.8%)	23 (27.4%)	47 (56.0%)	10 (11.9%)	84
Tricuspid valve incompetence	24 (28.6%)	9 (10.7%)	36 (42.9%)	15 (17.9%)	84
Sudden death	2 (2.4%)	9 (10.7%)	39 (46.4%)	34 (40.5%)	84
Hypotonia	32 (38.1%)	20 (23.8%)	21 (25.0%)	11 (13.1%)	84
B-lymphocyte count decreased	5 (6.0%)	49 (59.0%)	28 (33.7%)	1 (1.2%)	83
Respiratory acidosis	13 (15.7%)	24 (28.9%)	27 (32.5%)	19 (22.9%)	83
Femoral neck fracture	0 (0.0%)	11 (13.3%)	32 (38.6%)	40 (48.2%)	83
Dislocation of vertebra	0 (0.0%)	72 (86.7%)	9 (10.8%)	2 (2.4%)	83
Peritonitis bacterial	9 (10.8%)	13 (15.7%)	46 (55.4%)	15 (18.1%)	83
Physical deconditioning	2 (2.4%)	18 (21.7%)	31 (37.3%)	32 (38.6%)	83
Impaired driving ability	5 (6.0%)	18 (21.7%)	49 (59.0%)	11 (13.3%)	83
Screaming	34 (41.0%)	20 (24.1%)	14 (16.9%)	15 (18.1%)	83
Freezing phenomenon	0 (0.0%)	2 (2.4%)	54 (65.9%)	26 (31.7%)	82
Vaginal infection	5 (6.1%)	41 (50.0%)	33 (40.2%)	3 (3.7%)	82
Hepatitis acute	9 (11.0%)	26 (31.7%)	35 (42.7%)	12 (14.6%)	82
Plasma cell myeloma recurrent	0 (0.0%)	4 (4.9%)	66 (80.5%)	12 (14.6%)	82
Macular oedema	3 (3.7%)	15 (18.3%)	53 (64.6%)	11 (13.4%)	82
Enterococcal infection	11 (13.4%)	23 (28.0%)	35 (42.7%)	13 (15.9%)	82

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Laryngeal oedema	10 (12.2%)	35 (42.7%)	32 (39.0%)	5 (6.1%)	82
Maculopathy	4 (4.9%)	28 (34.1%)	46 (56.1%)	4 (4.9%)	82
Varicose vein	0 (0.0%)	17 (21.0%)	53 (65.4%)	11 (13.6%)	81
Immune-mediated lung disease	2 (2.5%)	5 (6.2%)	59 (72.8%)	15 (18.5%)	81
Arthritis infective	0 (0.0%)	15 (18.5%)	53 (65.4%)	13 (16.0%)	81
Skin warm	10 (12.3%)	22 (27.2%)	46 (56.8%)	3 (3.7%)	81
Neoplasm recurrence	8 (9.9%)	8 (9.9%)	45 (55.6%)	20 (24.7%)	81
Ear disorder	4 (4.9%)	25 (30.9%)	42 (51.9%)	10 (12.3%)	81
Immune-mediated myocarditis	2 (2.5%)	7 (8.6%)	43 (53.1%)	29 (35.8%)	81
Endocarditis	4 (4.9%)	28 (34.6%)	41 (50.6%)	8 (9.9%)	81
Bronchiolitis	45 (55.6%)	10 (12.3%)	21 (25.9%)	5 (6.2%)	81
Partial seizures	35 (43.2%)	17 (21.0%)	25 (30.9%)	4 (4.9%)	81
Nasal discomfort	5 (6.3%)	25 (31.3%)	45 (56.3%)	5 (6.3%)	80
Secondary adrenocortical insufficiency	3 (3.8%)	16 (20.0%)	43 (53.8%)	18 (22.5%)	80
Onychoclasia	1 (1.3%)	14 (17.5%)	51 (63.8%)	14 (17.5%)	80
Sleep terror	15 (18.8%)	13 (16.3%)	45 (56.3%)	7 (8.8%)	80
Sunburn	7 (8.8%)	24 (30.0%)	41 (51.3%)	8 (10.0%)	80
Oliguria	16 (20.0%)	14 (17.5%)	33 (41.3%)	17 (21.3%)	80
Peroneal nerve palsy	6 (7.5%)	28 (35.0%)	44 (55.0%)	2 (2.5%)	80
Haemolysis	10 (12.5%)	15 (18.8%)	41 (51.3%)	14 (17.5%)	80
Glucose tolerance impaired	10 (12.5%)	19 (23.8%)	45 (56.3%)	6 (7.5%)	80
Eosinophil count decreased	4 (5.0%)	31 (38.8%)	43 (53.8%)	2 (2.5%)	80
Cardiac tamponade	5 (6.3%)	28 (35.0%)	37 (46.3%)	10 (12.5%)	80
Multiple-drug resistance	26 (32.5%)	30 (37.5%)	20 (25.0%)	4 (5.0%)	80
Large intestine perforation	7 (8.8%)	8 (10.0%)	53 (66.3%)	12 (15.0%)	80
Lumbar vertebral fracture	1 (1.3%)	8 (10.0%)	48 (60.0%)	23 (28.8%)	80
Premature baby	68 (85.0%)	12 (15.0%)	0 (0.0%)	0 (0.0%)	80

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Myocardial ischaemia	7 (8.9%)	12 (15.2%)	44 (55.7%)	16 (20.3%)	79
Faeces hard	6 (7.6%)	10 (12.7%)	44 (55.7%)	19 (24.1%)	79
Personality change	25 (31.6%)	30 (38.0%)	17 (21.5%)	7 (8.9%)	79
Mouth swelling	1 (1.3%)	22 (27.8%)	47 (59.5%)	9 (11.4%)	79
Sedation complication	12 (15.2%)	21 (26.6%)	12 (15.2%)	34 (43.0%)	79
Anuria	14 (17.7%)	10 (12.7%)	44 (55.7%)	11 (13.9%)	79
Lung infiltration	16 (20.3%)	18 (22.8%)	36 (45.6%)	9 (11.4%)	79
Inflammatory bowel disease	19 (24.1%)	19 (24.1%)	37 (46.8%)	4 (5.1%)	79
Tibia fracture	7 (8.9%)	16 (20.3%)	48 (60.8%)	8 (10.1%)	79
Caesarean section	20 (25.3%)	59 (74.7%)	0 (0.0%)	0 (0.0%)	79
Serum ferritin increased	13 (16.5%)	9 (11.4%)	45 (57.0%)	12 (15.2%)	79
Raynaud's phenomenon	8 (10.1%)	22 (27.8%)	33 (41.8%)	16 (20.3%)	79
Product taste abnormal	9 (11.4%)	11 (13.9%)	44 (55.7%)	15 (19.0%)	79
Onychomadesis	0 (0.0%)	38 (48.1%)	34 (43.0%)	7 (8.9%)	79
Cholecystitis acute	1 (1.3%)	19 (24.4%)	39 (50.0%)	19 (24.4%)	78
Melanocytic naevus	3 (3.8%)	21 (26.9%)	47 (60.3%)	7 (9.0%)	78
Hyperprolactinaemia	23 (29.5%)	43 (55.1%)	11 (14.1%)	1 (1.3%)	78
Intestinal haemorrhage	4 (5.1%)	18 (23.1%)	38 (48.7%)	18 (23.1%)	78
Diverticulum	0 (0.0%)	8 (10.3%)	51 (65.4%)	19 (24.4%)	78
Cystitis noninfective	8 (10.4%)	40 (51.9%)	27 (35.1%)	2 (2.6%)	77
Hair growth abnormal	5 (6.5%)	23 (29.9%)	35 (45.5%)	14 (18.2%)	77
Hyperammonaemia	29 (37.7%)	20 (26.0%)	19 (24.7%)	9 (11.7%)	77
Bone erosion	3 (3.9%)	43 (55.8%)	29 (37.7%)	2 (2.6%)	77
Atrioventricular block complete	5 (6.5%)	9 (11.7%)	29 (37.7%)	34 (44.2%)	77
Stress cardiomyopathy	7 (9.1%)	6 (7.8%)	52 (67.5%)	12 (15.6%)	77
Contrast media allergy	4 (5.2%)	22 (28.6%)	43 (55.8%)	8 (10.4%)	77
Application site erythema	16 (21.1%)	24 (31.6%)	30 (39.5%)	6 (7.9%)	76

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pre-eclampsia	12 (15.8%)	64 (84.2%)	0 (0.0%)	0 (0.0%)	76
Vein disorder	2 (2.6%)	17 (22.4%)	42 (55.3%)	15 (19.7%)	76
Hepatic cancer	0 (0.0%)	10 (13.2%)	53 (69.7%)	13 (17.1%)	76
Cheilitis	16 (21.1%)	22 (28.9%)	29 (38.2%)	9 (11.8%)	76
Sleep deficit	5 (6.6%)	23 (30.3%)	44 (57.9%)	4 (5.3%)	76
Immune-mediated hepatitis	0 (0.0%)	12 (15.8%)	46 (60.5%)	18 (23.7%)	76
Iridocyclitis	14 (18.4%)	13 (17.1%)	37 (48.7%)	12 (15.8%)	76
Cardiac failure chronic	0 (0.0%)	2 (2.6%)	17 (22.4%)	57 (75.0%)	76
Unintended pregnancy	40 (52.6%)	36 (47.4%)	0 (0.0%)	0 (0.0%)	76
Pleurisy	1 (1.3%)	23 (30.3%)	43 (56.6%)	9 (11.8%)	76
Acute coronary syndrome	1 (1.3%)	15 (19.7%)	41 (53.9%)	19 (25.0%)	76
Gastric haemorrhage	3 (4.0%)	14 (18.7%)	37 (49.3%)	21 (28.0%)	75
Renal function test abnormal	1 (1.3%)	6 (8.0%)	37 (49.3%)	31 (41.3%)	75
Overweight	11 (14.7%)	15 (20.0%)	32 (42.7%)	17 (22.7%)	75
Eosinophilic granulomatosis with polyangiitis	3 (4.0%)	10 (13.3%)	58 (77.3%)	4 (5.3%)	75
Injection site inflammation	18 (24.0%)	23 (30.7%)	32 (42.7%)	2 (2.7%)	75
Blood glucose fluctuation	4 (5.3%)	10 (13.3%)	44 (58.7%)	17 (22.7%)	75
Epstein-Barr virus infection	35 (46.7%)	9 (12.0%)	25 (33.3%)	6 (8.0%)	75
Substance abuse	18 (24.0%)	54 (72.0%)	3 (4.0%)	0 (0.0%)	75
Ileus paralytic	5 (6.7%)	14 (18.7%)	47 (62.7%)	9 (12.0%)	75
Product label issue	7 (9.3%)	14 (18.7%)	36 (48.0%)	18 (24.0%)	75
Device safety feature issue	4 (5.3%)	11 (14.7%)	43 (57.3%)	17 (22.7%)	75
Brain natriuretic peptide increased	7 (9.3%)	12 (16.0%)	32 (42.7%)	24 (32.0%)	75
Performance status decreased	6 (8.0%)	18 (24.0%)	35 (46.7%)	16 (21.3%)	75
Cardiac murmur	17 (23.0%)	5 (6.8%)	33 (44.6%)	19 (25.7%)	74
Urine odour abnormal	5 (6.8%)	18 (24.3%)	39 (52.7%)	12 (16.2%)	74
Therapeutic product effect delayed	3 (4.1%)	25 (33.8%)	35 (47.3%)	11 (14.9%)	74

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Demyelination	13 (17.6%)	34 (45.9%)	20 (27.0%)	7 (9.5%)	74
Graft versus host disease	17 (23.0%)	17 (23.0%)	40 (54.1%)	0 (0.0%)	74
Hyperkeratosis	3 (4.1%)	10 (13.5%)	49 (66.2%)	12 (16.2%)	74
Injection site injury	5 (6.8%)	31 (41.9%)	36 (48.6%)	2 (2.7%)	74
Idiopathic pulmonary fibrosis	0 (0.0%)	1 (1.4%)	47 (63.5%)	26 (35.1%)	74
Blepharitis	13 (17.6%)	20 (27.0%)	34 (45.9%)	7 (9.5%)	74
Endophthalmitis	0 (0.0%)	8 (10.8%)	42 (56.8%)	24 (32.4%)	74
Type IV hypersensitivity reaction	7 (9.6%)	20 (27.4%)	39 (53.4%)	7 (9.6%)	73
Ligament rupture	7 (9.6%)	26 (35.6%)	36 (49.3%)	4 (5.5%)	73
Spontaneous haemorrhage	19 (26.0%)	38 (52.1%)	15 (20.5%)	1 (1.4%)	73
Food intolerance	5 (6.8%)	31 (42.5%)	26 (35.6%)	11 (15.1%)	73
Haemoglobin increased	9 (12.3%)	12 (16.4%)	48 (65.8%)	4 (5.5%)	73
Hepatic lesion	3 (4.1%)	19 (26.0%)	45 (61.6%)	6 (8.2%)	73
Mixed liver injury	0 (0.0%)	9 (12.3%)	48 (65.8%)	16 (21.9%)	73
Incorrect dosage administered	9 (12.3%)	11 (15.1%)	36 (49.3%)	17 (23.3%)	73
Lymphocyte count increased	16 (21.9%)	22 (30.1%)	26 (35.6%)	9 (12.3%)	73
Tongue disorder	4 (5.5%)	6 (8.2%)	53 (72.6%)	10 (13.7%)	73
Neurological symptom	2 (2.7%)	12 (16.4%)	50 (68.5%)	9 (12.3%)	73
Dysmenorrhoea	22 (30.1%)	47 (64.4%)	3 (4.1%)	1 (1.4%)	73
Rosacea	2 (2.8%)	29 (40.3%)	38 (52.8%)	3 (4.2%)	72
Device infusion issue	11 (15.3%)	13 (18.1%)	39 (54.2%)	9 (12.5%)	72
Listless	6 (8.3%)	35 (48.6%)	22 (30.6%)	9 (12.5%)	72
Gastric infection	11 (15.3%)	24 (33.3%)	30 (41.7%)	7 (9.7%)	72
Abdominal hernia	5 (6.9%)	16 (22.2%)	40 (55.6%)	11 (15.3%)	72
Herpes simplex	12 (16.7%)	16 (22.2%)	37 (51.4%)	7 (9.7%)	72
Product container issue	5 (6.9%)	14 (19.4%)	40 (55.6%)	13 (18.1%)	72
Obsessive-compulsive disorder	28 (38.9%)	27 (37.5%)	13 (18.1%)	4 (5.6%)	72

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lack of injection site rotation	18 (25.0%)	14 (19.4%)	30 (41.7%)	10 (13.9%)	72
Pathological fracture	2 (2.8%)	12 (16.9%)	40 (56.3%)	17 (23.9%)	71
Liver abscess	5 (7.0%)	7 (9.9%)	52 (73.2%)	7 (9.9%)	71
Benign prostatic hyperplasia	0 (0.0%)	1 (1.4%)	39 (54.9%)	31 (43.7%)	71
Hepatitis C	0 (0.0%)	28 (39.4%)	41 (57.7%)	2 (2.8%)	71
Uterine leiomyoma	1 (1.4%)	47 (66.2%)	23 (32.4%)	0 (0.0%)	71
Asthenopia	1 (1.4%)	23 (32.4%)	36 (50.7%)	11 (15.5%)	71
Cachexia	2 (2.8%)	13 (18.3%)	40 (56.3%)	16 (22.5%)	71
Blindness transient	6 (8.5%)	25 (35.2%)	31 (43.7%)	9 (12.7%)	71
Oral infection	3 (4.2%)	22 (31.0%)	39 (54.9%)	7 (9.9%)	71
Umbilical hernia	11 (15.5%)	20 (28.2%)	35 (49.3%)	5 (7.0%)	71
Intestinal stenosis	6 (8.6%)	40 (57.1%)	22 (31.4%)	2 (2.9%)	70
Azotaemia	3 (4.3%)	16 (22.9%)	41 (58.6%)	10 (14.3%)	70
Muscle disorder	4 (5.7%)	10 (14.3%)	45 (64.3%)	11 (15.7%)	70
Application site pruritus	7 (10.0%)	26 (37.1%)	25 (35.7%)	12 (17.1%)	70
Hyperventilation	9 (12.9%)	34 (48.6%)	25 (35.7%)	2 (2.9%)	70
Colectomy	7 (10.0%)	28 (40.0%)	33 (47.1%)	2 (2.9%)	70
Abscess limb	2 (2.9%)	34 (48.6%)	32 (45.7%)	2 (2.9%)	70
Hypovolaemic shock	6 (8.6%)	15 (21.4%)	35 (50.0%)	14 (20.0%)	70
Hair texture abnormal	1 (1.4%)	9 (12.9%)	42 (60.0%)	18 (25.7%)	70
Cardiac pacemaker insertion	0 (0.0%)	4 (5.8%)	33 (47.8%)	32 (46.4%)	69
Fine motor skill dysfunction	2 (2.9%)	24 (34.8%)	32 (46.4%)	11 (15.9%)	69
Adrenocorticotrophic hormone deficiency	0 (0.0%)	12 (17.4%)	37 (53.6%)	20 (29.0%)	69
Hormone level abnormal	14 (20.3%)	26 (37.7%)	25 (36.2%)	4 (5.8%)	69
BK virus infection	25 (36.2%)	28 (40.6%)	16 (23.2%)	0 (0.0%)	69
Thermal burn	2 (2.9%)	18 (26.1%)	35 (50.7%)	14 (20.3%)	69
Wheelchair user	4 (5.8%)	15 (21.7%)	41 (59.4%)	9 (13.0%)	69

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Nasal obstruction	8 (11.6%)	34 (49.3%)	27 (39.1%)	0 (0.0%)	69
Abdominal tenderness	15 (21.7%)	22 (31.9%)	27 (39.1%)	5 (7.2%)	69
Petit mal epilepsy	35 (50.7%)	24 (34.8%)	5 (7.2%)	5 (7.2%)	69
Foetal death	1 (1.4%)	52 (75.4%)	16 (23.2%)	0 (0.0%)	69
Skin discomfort	19 (27.5%)	27 (39.1%)	21 (30.4%)	2 (2.9%)	69
Gastrointestinal toxicity	9 (13.0%)	10 (14.5%)	47 (68.1%)	3 (4.3%)	69
Pulmonary haemorrhage	15 (21.7%)	21 (30.4%)	25 (36.2%)	8 (11.6%)	69
Kounis syndrome	3 (4.3%)	31 (44.9%)	30 (43.5%)	5 (7.2%)	69
Hepatic pain	1 (1.4%)	21 (30.4%)	42 (60.9%)	5 (7.2%)	69
Adenovirus infection	49 (71.0%)	8 (11.6%)	11 (15.9%)	1 (1.4%)	69
Escherichia urinary tract infection	6 (8.7%)	12 (17.4%)	43 (62.3%)	8 (11.6%)	69
Vitamin B12 deficiency	6 (8.7%)	20 (29.0%)	31 (44.9%)	12 (17.4%)	69
Dysaesthesia	5 (7.2%)	30 (43.5%)	34 (49.3%)	0 (0.0%)	69
Creatinine renal clearance decreased	1 (1.4%)	6 (8.7%)	17 (24.6%)	45 (65.2%)	69
Blood creatinine abnormal	1 (1.4%)	12 (17.4%)	44 (63.8%)	12 (17.4%)	69
Device placement issue	11 (16.2%)	28 (41.2%)	22 (32.4%)	7 (10.3%)	68
Tearfulness	7 (10.3%)	16 (23.5%)	43 (63.2%)	2 (2.9%)	68
Hepatitis cholestatic	7 (10.3%)	14 (20.6%)	28 (41.2%)	19 (27.9%)	68
Muscle fatigue	1 (1.5%)	21 (30.9%)	40 (58.8%)	6 (8.8%)	68
Amylase increased	10 (14.7%)	15 (22.1%)	33 (48.5%)	10 (14.7%)	68
Labelled drug-drug interaction issue	7 (10.3%)	13 (19.1%)	35 (51.5%)	13 (19.1%)	68
Erythema of eyelid	31 (45.6%)	12 (17.6%)	19 (27.9%)	6 (8.8%)	68
Thyroid mass	4 (5.9%)	22 (32.4%)	38 (55.9%)	4 (5.9%)	68
Hallucinations, mixed	3 (4.5%)	17 (25.4%)	29 (43.3%)	18 (26.9%)	67
Nasal dryness	6 (9.0%)	19 (28.4%)	36 (53.7%)	6 (9.0%)	67
Aortic aneurysm	0 (0.0%)	2 (3.0%)	50 (74.6%)	15 (22.4%)	67
Periorbital oedema	11 (16.4%)	20 (29.9%)	33 (49.3%)	3 (4.5%)	67

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pre-existing condition improved	5 (7.5%)	27 (40.3%)	29 (43.3%)	6 (9.0%)	67
Hypersensitivity pneumonitis	1 (1.5%)	7 (10.4%)	40 (59.7%)	19 (28.4%)	67
Vulvovaginal mycotic infection	1 (1.5%)	21 (31.3%)	38 (56.7%)	7 (10.4%)	67
Dilated cardiomyopathy	1 (1.5%)	25 (37.3%)	22 (32.8%)	19 (28.4%)	67
Immune-mediated adrenal insufficiency	0 (0.0%)	12 (17.9%)	44 (65.7%)	11 (16.4%)	67
Apnoea	24 (35.8%)	20 (29.9%)	18 (26.9%)	5 (7.5%)	67
Cancer pain	1 (1.5%)	7 (10.4%)	49 (73.1%)	10 (14.9%)	67
Face injury	19 (28.8%)	12 (18.2%)	24 (36.4%)	11 (16.7%)	66
Atypical pneumonia	4 (6.1%)	26 (39.4%)	32 (48.5%)	4 (6.1%)	66
Mycobacterium haemophilum infection	1 (1.5%)	14 (21.2%)	39 (59.1%)	12 (18.2%)	66
Respiratory tract infection viral	13 (19.7%)	15 (22.7%)	34 (51.5%)	4 (6.1%)	66
Hyperacusis	9 (13.6%)	30 (45.5%)	25 (37.9%)	2 (3.0%)	66
Pulmonary pain	0 (0.0%)	15 (22.7%)	47 (71.2%)	4 (6.1%)	66
Pyoderma gangrenosum	7 (10.6%)	26 (39.4%)	32 (48.5%)	1 (1.5%)	66
Hair colour changes	5 (7.6%)	16 (24.2%)	31 (47.0%)	14 (21.2%)	66
Spinal fusion surgery	3 (4.5%)	21 (31.8%)	39 (59.1%)	3 (4.5%)	66
Intestinal resection	8 (12.1%)	23 (34.8%)	32 (48.5%)	3 (4.5%)	66
Ulcer haemorrhage	1 (1.5%)	14 (21.2%)	39 (59.1%)	12 (18.2%)	66
Coronary artery occlusion	0 (0.0%)	5 (7.6%)	49 (74.2%)	12 (18.2%)	66
Necrotising fasciitis	5 (7.7%)	16 (24.6%)	33 (50.8%)	11 (16.9%)	65
Cystitis haemorrhagic	12 (18.5%)	27 (41.5%)	18 (27.7%)	8 (12.3%)	65
Left ventricular dysfunction	18 (27.7%)	12 (18.5%)	28 (43.1%)	7 (10.8%)	65
Ecchymosis	8 (12.3%)	11 (16.9%)	35 (53.8%)	11 (16.9%)	65
Ovarian hyperstimulation syndrome	2 (3.1%)	63 (96.9%)	0 (0.0%)	0 (0.0%)	65
Self-medication	17 (26.2%)	18 (27.7%)	28 (43.1%)	2 (3.1%)	65
Normochromic normocytic anaemia	3 (4.6%)	7 (10.8%)	48 (73.8%)	7 (10.8%)	65
Tongue discomfort	2 (3.1%)	9 (13.8%)	42 (64.6%)	12 (18.5%)	65

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Trigeminal neuralgia	0 (0.0%)	23 (35.4%)	34 (52.3%)	8 (12.3%)	65
Hypertonic bladder	1 (1.5%)	16 (24.6%)	42 (64.6%)	6 (9.2%)	65
Tension headache	11 (16.9%)	28 (43.1%)	25 (38.5%)	1 (1.5%)	65
Diffuse large B-cell lymphoma recurrent	1 (1.5%)	15 (23.1%)	40 (61.5%)	9 (13.8%)	65
Type I hypersensitivity	11 (16.9%)	22 (33.8%)	29 (44.6%)	3 (4.6%)	65
Thrombocytosis	17 (26.2%)	20 (30.8%)	22 (33.8%)	6 (9.2%)	65
Yellow skin	4 (6.2%)	24 (36.9%)	26 (40.0%)	11 (16.9%)	65
Injection site nodule	8 (12.3%)	22 (33.8%)	30 (46.2%)	5 (7.7%)	65
Sinus pain	5 (7.7%)	19 (29.2%)	34 (52.3%)	7 (10.8%)	65
Product packaging issue	2 (3.1%)	9 (13.8%)	44 (67.7%)	10 (15.4%)	65
Product temperature excursion issue	10 (15.4%)	21 (32.3%)	28 (43.1%)	6 (9.2%)	65
Nail discolouration	5 (7.8%)	8 (12.5%)	30 (46.9%)	21 (32.8%)	64
Tongue oedema	0 (0.0%)	28 (43.8%)	27 (42.2%)	9 (14.1%)	64
Pneumonia viral	5 (7.8%)	7 (10.9%)	34 (53.1%)	18 (28.1%)	64
Muscle contractions involuntary	12 (18.8%)	27 (42.2%)	21 (32.8%)	4 (6.3%)	64
Disorganised speech	6 (9.4%)	22 (34.4%)	18 (28.1%)	18 (28.1%)	64
Visual field defect	5 (7.8%)	29 (45.3%)	24 (37.5%)	6 (9.4%)	64
Fournier's gangrene	1 (1.6%)	19 (29.7%)	41 (64.1%)	3 (4.7%)	64
Anorectal discomfort	6 (9.4%)	13 (20.3%)	39 (60.9%)	6 (9.4%)	64
Clavicle fracture	5 (7.8%)	7 (10.9%)	41 (64.1%)	11 (17.2%)	64
Enuresis	17 (26.6%)	24 (37.5%)	19 (29.7%)	4 (6.3%)	64
Deafness unilateral	5 (7.8%)	12 (18.8%)	42 (65.6%)	5 (7.8%)	64
Dry age-related macular degeneration	2 (3.1%)	9 (14.1%)	42 (65.6%)	11 (17.2%)	64
Aplastic anaemia	33 (51.6%)	3 (4.7%)	11 (17.2%)	17 (26.6%)	64
Female genital tract fistula	1 (1.6%)	9 (14.3%)	53 (84.1%)	0 (0.0%)	63
Eyelid margin crusting	9 (14.3%)	10 (15.9%)	38 (60.3%)	6 (9.5%)	63
Rehabilitation therapy	1 (1.6%)	7 (11.1%)	29 (46.0%)	26 (41.3%)	63

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Photopsia	0 (0.0%)	22 (34.9%)	33 (52.4%)	8 (12.7%)	63
Hepatitis B	0 (0.0%)	20 (31.7%)	38 (60.3%)	5 (7.9%)	63
Muscle rupture	1 (1.6%)	22 (34.9%)	36 (57.1%)	4 (6.3%)	63
Clostridium test positive	1 (1.6%)	7 (11.1%)	19 (30.2%)	36 (57.1%)	63
Gastrointestinal sounds abnormal	5 (7.9%)	10 (15.9%)	40 (63.5%)	8 (12.7%)	63
Slow speech	13 (20.6%)	24 (38.1%)	23 (36.5%)	3 (4.8%)	63
Drug tolerance decreased	0 (0.0%)	43 (68.3%)	16 (25.4%)	4 (6.3%)	63
Mean cell haemoglobin concentration decreased	2 (3.2%)	20 (31.7%)	37 (58.7%)	4 (6.3%)	63
Accidental exposure to product by child	63 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	63
Drug level above therapeutic	9 (14.3%)	10 (15.9%)	42 (66.7%)	2 (3.2%)	63
Acute pulmonary oedema	6 (9.7%)	17 (27.4%)	28 (45.2%)	11 (17.7%)	62
Eyelids pruritus	14 (22.6%)	12 (19.4%)	32 (51.6%)	4 (6.5%)	62
Faecal calprotectin increased	14 (22.6%)	25 (40.3%)	20 (32.3%)	3 (4.8%)	62
Traumatic haemorrhage	33 (53.2%)	18 (29.0%)	9 (14.5%)	2 (3.2%)	62
Cardiac flutter	3 (4.8%)	20 (32.3%)	28 (45.2%)	11 (17.7%)	62
Arterial occlusive disease	0 (0.0%)	4 (6.5%)	42 (67.7%)	16 (25.8%)	62
Paranasal sinus discomfort	3 (4.8%)	16 (25.8%)	41 (66.1%)	2 (3.2%)	62
Affect lability	10 (16.1%)	15 (24.2%)	29 (46.8%)	8 (12.9%)	62
Dust allergy	1 (1.6%)	12 (19.4%)	48 (77.4%)	1 (1.6%)	62
Necrosis	5 (8.1%)	10 (16.1%)	41 (66.1%)	6 (9.7%)	62
Nephritis	4 (6.5%)	17 (27.4%)	35 (56.5%)	6 (9.7%)	62
Endometriosis	13 (21.0%)	41 (66.1%)	7 (11.3%)	1 (1.6%)	62
Hyperlactacidaemia	17 (27.4%)	8 (12.9%)	36 (58.1%)	1 (1.6%)	62
Procedural complication	4 (6.5%)	17 (27.4%)	35 (56.5%)	6 (9.7%)	62
Gastrointestinal perforation	1 (1.6%)	12 (19.4%)	37 (59.7%)	12 (19.4%)	62
Haemorrhoidal haemorrhage	2 (3.2%)	10 (16.1%)	37 (59.7%)	13 (21.0%)	62
Glomerulonephritis	8 (13.1%)	17 (27.9%)	26 (42.6%)	10 (16.4%)	61

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Shoulder arthroplasty	0 (0.0%)	3 (4.9%)	46 (75.4%)	12 (19.7%)	61
Substance-induced psychotic disorder	19 (31.1%)	16 (26.2%)	21 (34.4%)	5 (8.2%)	61
Subcutaneous abscess	8 (13.1%)	32 (52.5%)	14 (23.0%)	7 (11.5%)	61
Skin papilloma	13 (21.3%)	21 (34.4%)	22 (36.1%)	5 (8.2%)	61
Graves' disease	3 (4.9%)	27 (44.3%)	30 (49.2%)	1 (1.6%)	61
Neutrophil count abnormal	10 (16.4%)	10 (16.4%)	35 (57.4%)	6 (9.8%)	61
Joint noise	2 (3.3%)	25 (41.0%)	28 (45.9%)	6 (9.8%)	61
Abdominal abscess	7 (11.5%)	23 (37.7%)	28 (45.9%)	3 (4.9%)	61
Eosinophilic pneumonia	1 (1.6%)	10 (16.4%)	33 (54.1%)	17 (27.9%)	61
X-ray abnormal	3 (4.9%)	50 (82.0%)	8 (13.1%)	0 (0.0%)	61
Radiculopathy	1 (1.6%)	6 (9.8%)	53 (86.9%)	1 (1.6%)	61
Rhinalgia	2 (3.3%)	13 (21.3%)	38 (62.3%)	8 (13.1%)	61
Product dispensing issue	5 (8.2%)	13 (21.3%)	27 (44.3%)	16 (26.2%)	61
Renal tubular injury	0 (0.0%)	17 (27.9%)	34 (55.7%)	10 (16.4%)	61
Faecaloma	3 (5.0%)	6 (10.0%)	41 (68.3%)	10 (16.7%)	60
Incoherent	7 (11.7%)	14 (23.3%)	20 (33.3%)	19 (31.7%)	60
Humerus fracture	1 (1.7%)	6 (10.0%)	36 (60.0%)	17 (28.3%)	60
Body height increased	38 (63.3%)	12 (20.0%)	7 (11.7%)	3 (5.0%)	60
Lower gastrointestinal haemorrhage	0 (0.0%)	3 (5.0%)	34 (56.7%)	23 (38.3%)	60
Blood creatinine decreased	12 (20.0%)	18 (30.0%)	28 (46.7%)	2 (3.3%)	60
Procedural haemorrhage	10 (16.7%)	24 (40.0%)	21 (35.0%)	5 (8.3%)	60
Metabolic disorder	13 (21.7%)	21 (35.0%)	20 (33.3%)	6 (10.0%)	60
Craniofacial fracture	3 (5.0%)	12 (20.0%)	33 (55.0%)	12 (20.0%)	60
Retinal haemorrhage	2 (3.3%)	15 (25.0%)	29 (48.3%)	14 (23.3%)	60
Cervical vertebral fracture	0 (0.0%)	7 (11.7%)	33 (55.0%)	20 (33.3%)	60
Sinus headache	3 (5.0%)	12 (20.0%)	42 (70.0%)	3 (5.0%)	60
Fibrin D dimer increased	5 (8.5%)	12 (20.3%)	30 (50.8%)	12 (20.3%)	59

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hepatic neoplasm	2 (3.4%)	9 (15.3%)	43 (72.9%)	5 (8.5%)	59
Trigger finger	0 (0.0%)	7 (11.9%)	43 (72.9%)	9 (15.3%)	59
Feeling of body temperature change	8 (13.6%)	22 (37.3%)	28 (47.5%)	1 (1.7%)	59
Intestinal ischaemia	4 (6.8%)	11 (18.6%)	31 (52.5%)	13 (22.0%)	59
Skin hyperpigmentation	7 (11.9%)	24 (40.7%)	24 (40.7%)	4 (6.8%)	59
Psychiatric decompensation	4 (6.8%)	26 (44.1%)	29 (49.2%)	0 (0.0%)	59
Abnormal weight gain	18 (30.5%)	28 (47.5%)	11 (18.6%)	2 (3.4%)	59
Product size issue	2 (3.4%)	8 (13.6%)	31 (52.5%)	18 (30.5%)	59
Immunoglobulins decreased	5 (8.5%)	23 (39.0%)	26 (44.1%)	5 (8.5%)	59
Lip oedema	7 (11.9%)	18 (30.5%)	27 (45.8%)	7 (11.9%)	59
Stoma site erythema	6 (10.3%)	1 (1.7%)	36 (62.1%)	15 (25.9%)	58
Arthritis bacterial	2 (3.4%)	22 (37.9%)	30 (51.7%)	4 (6.9%)	58
Lyme disease	11 (19.0%)	18 (31.0%)	26 (44.8%)	3 (5.2%)	58
Hydrocephalus	18 (31.0%)	16 (27.6%)	15 (25.9%)	9 (15.5%)	58
Cataract operation	1 (1.7%)	1 (1.7%)	42 (72.4%)	14 (24.1%)	58
Choking sensation	6 (10.3%)	21 (36.2%)	28 (48.3%)	3 (5.2%)	58
Dacryostenosis acquired	2 (3.4%)	20 (34.5%)	33 (56.9%)	3 (5.2%)	58
Lupus nephritis	3 (5.2%)	33 (56.9%)	16 (27.6%)	6 (10.3%)	58
Food craving	4 (6.9%)	27 (46.6%)	25 (43.1%)	2 (3.4%)	58
Sarcoidosis	3 (5.2%)	17 (29.3%)	33 (56.9%)	5 (8.6%)	58
Pharyngeal paraesthesia	6 (10.3%)	32 (55.2%)	20 (34.5%)	0 (0.0%)	58
Meningioma	2 (3.4%)	18 (31.0%)	32 (55.2%)	6 (10.3%)	58
Autoimmune thyroiditis	8 (13.8%)	20 (34.5%)	27 (46.6%)	3 (5.2%)	58
Infection susceptibility increased	2 (3.4%)	34 (58.6%)	18 (31.0%)	4 (6.9%)	58
Pulse absent	4 (6.9%)	14 (24.1%)	31 (53.4%)	9 (15.5%)	58
Lupus vulgaris	0 (0.0%)	53 (91.4%)	5 (8.6%)	0 (0.0%)	58
Polymyalgia rheumatica	0 (0.0%)	0 (0.0%)	38 (65.5%)	20 (34.5%)	58

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Wound haemorrhage	4 (6.9%)	11 (19.0%)	25 (43.1%)	18 (31.0%)	58
Chapped lips	11 (19.0%)	21 (36.2%)	20 (34.5%)	6 (10.3%)	58
Varicella zoster virus infection	16 (27.6%)	13 (22.4%)	28 (48.3%)	1 (1.7%)	58
Plantar fasciitis	0 (0.0%)	8 (13.8%)	32 (55.2%)	18 (31.0%)	58
Animal bite	6 (10.3%)	21 (36.2%)	28 (48.3%)	3 (5.2%)	58
Near death experience	5 (8.6%)	8 (13.8%)	36 (62.1%)	9 (15.5%)	58
Vitamin B12 decreased	0 (0.0%)	16 (28.1%)	34 (59.6%)	7 (12.3%)	57
Methaemoglobinaemia	11 (19.3%)	16 (28.1%)	26 (45.6%)	4 (7.0%)	57
Blood creatine increased	4 (7.0%)	12 (21.1%)	28 (49.1%)	13 (22.8%)	57
Bone lesion	1 (1.8%)	12 (21.1%)	43 (75.4%)	1 (1.8%)	57
Hypovolaemia	3 (5.3%)	5 (8.8%)	29 (50.9%)	20 (35.1%)	57
Fungal skin infection	2 (3.5%)	13 (22.8%)	37 (64.9%)	5 (8.8%)	57
Autonomic nervous system imbalance	7 (12.3%)	13 (22.8%)	32 (56.1%)	5 (8.8%)	57
Monoplegia	7 (12.3%)	21 (36.8%)	22 (38.6%)	7 (12.3%)	57
Hyperphosphataemia	4 (7.0%)	10 (17.5%)	18 (31.6%)	25 (43.9%)	57
Bell's palsy	2 (3.5%)	15 (26.3%)	36 (63.2%)	4 (7.0%)	57
Guillain-Barre syndrome	2 (3.5%)	14 (24.6%)	34 (59.6%)	7 (12.3%)	57
Juvenile idiopathic arthritis	56 (98.2%)	1 (1.8%)	0 (0.0%)	0 (0.0%)	57
Clonus	21 (36.8%)	9 (15.8%)	24 (42.1%)	3 (5.3%)	57
Dermatomyositis	6 (10.5%)	12 (21.1%)	36 (63.2%)	3 (5.3%)	57
Norovirus infection	15 (26.3%)	16 (28.1%)	24 (42.1%)	2 (3.5%)	57
Paradoxical drug reaction	18 (31.6%)	15 (26.3%)	16 (28.1%)	8 (14.0%)	57
Thyroid cancer	0 (0.0%)	20 (35.1%)	33 (57.9%)	4 (7.0%)	57
Stress fracture	2 (3.5%)	14 (24.6%)	34 (59.6%)	7 (12.3%)	57
Foreign body sensation in eyes	3 (5.3%)	8 (14.0%)	34 (59.6%)	12 (21.1%)	57
Eye injury	12 (21.4%)	22 (39.3%)	16 (28.6%)	6 (10.7%)	56
Hypopnoea	3 (5.4%)	19 (33.9%)	30 (53.6%)	4 (7.1%)	56

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastric cancer	0 (0.0%)	3 (5.4%)	35 (62.5%)	18 (32.1%)	56
Feeling drunk	10 (17.9%)	23 (41.1%)	17 (30.4%)	6 (10.7%)	56
Heparin-induced thrombocytopenia	1 (1.8%)	7 (12.5%)	40 (71.4%)	8 (14.3%)	56
Mean cell haemoglobin increased	5 (8.9%)	14 (25.0%)	29 (51.8%)	8 (14.3%)	56
Chronic gastritis	3 (5.4%)	17 (30.4%)	28 (50.0%)	8 (14.3%)	56
Neck surgery	0 (0.0%)	13 (23.2%)	41 (73.2%)	2 (3.6%)	56
Normal newborn	15 (26.8%)	41 (73.2%)	0 (0.0%)	0 (0.0%)	56
Mucosal dryness	15 (26.8%)	16 (28.6%)	19 (33.9%)	6 (10.7%)	56
Energy increased	1 (1.8%)	17 (30.4%)	30 (53.6%)	8 (14.3%)	56
Acute graft versus host disease	28 (50.0%)	11 (19.6%)	15 (26.8%)	2 (3.6%)	56
Escherichia bacteraemia	13 (23.2%)	10 (17.9%)	24 (42.9%)	9 (16.1%)	56
Mycobacterium avium complex infection	0 (0.0%)	5 (8.9%)	47 (83.9%)	4 (7.1%)	56
C-reactive protein	0 (0.0%)	55 (98.2%)	1 (1.8%)	0 (0.0%)	56
Potentiating drug interaction	5 (8.9%)	17 (30.4%)	21 (37.5%)	13 (23.2%)	56
Deformity	3 (5.4%)	29 (51.8%)	19 (33.9%)	5 (8.9%)	56
Papilloedema	25 (44.6%)	8 (14.3%)	20 (35.7%)	3 (5.4%)	56
Menstrual disorder	8 (14.3%)	39 (69.6%)	9 (16.1%)	0 (0.0%)	56
Ileostomy	4 (7.3%)	28 (50.9%)	22 (40.0%)	1 (1.8%)	55
Bone cancer	0 (0.0%)	2 (3.6%)	43 (78.2%)	10 (18.2%)	55
Pneumonia klebsiella	5 (9.1%)	17 (30.9%)	26 (47.3%)	7 (12.7%)	55
Troponin I increased	33 (60.0%)	4 (7.3%)	14 (25.5%)	4 (7.3%)	55
Drug level below therapeutic	17 (30.9%)	22 (40.0%)	13 (23.6%)	3 (5.5%)	55
Cholestatic liver injury	0 (0.0%)	10 (18.2%)	34 (61.8%)	11 (20.0%)	55
Aplasia	8 (14.5%)	7 (12.7%)	37 (67.3%)	3 (5.5%)	55
Malabsorption	8 (14.5%)	24 (43.6%)	20 (36.4%)	3 (5.5%)	55
Carcinoembryonic antigen increased	0 (0.0%)	9 (16.7%)	40 (74.1%)	5 (9.3%)	54
Skin necrosis	4 (7.4%)	7 (13.0%)	36 (66.7%)	7 (13.0%)	54

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Erythema nodosum	5 (9.3%)	28 (51.9%)	21 (38.9%)	0 (0.0%)	54
Right ventricular failure	3 (5.6%)	12 (22.2%)	30 (55.6%)	9 (16.7%)	54
Localised oedema	5 (9.3%)	9 (16.7%)	33 (61.1%)	7 (13.0%)	54
Epigastric discomfort	1 (1.9%)	14 (25.9%)	33 (61.1%)	6 (11.1%)	54
Stoma complication	8 (14.8%)	14 (25.9%)	30 (55.6%)	2 (3.7%)	54
Skin erosion	7 (13.0%)	7 (13.0%)	30 (55.6%)	10 (18.5%)	54
Leukoencephalopathy	9 (16.7%)	8 (14.8%)	23 (42.6%)	14 (25.9%)	54
Tenosynovitis	5 (9.3%)	14 (25.9%)	31 (57.4%)	4 (7.4%)	54
Fluid intake reduced	6 (11.1%)	7 (13.0%)	28 (51.9%)	13 (24.1%)	54
Exposure to SARS-CoV-2	1 (1.9%)	13 (24.1%)	33 (61.1%)	7 (13.0%)	54
Anaphylactoid reaction	3 (5.6%)	12 (22.2%)	31 (57.4%)	8 (14.8%)	54
Renal tubular acidosis	8 (14.8%)	23 (42.6%)	15 (27.8%)	8 (14.8%)	54
Ocular icterus	9 (16.7%)	11 (20.4%)	23 (42.6%)	11 (20.4%)	54
Temperature regulation disorder	3 (5.6%)	28 (51.9%)	20 (37.0%)	3 (5.6%)	54
Abdominal mass	2 (3.7%)	15 (27.8%)	31 (57.4%)	6 (11.1%)	54
Product physical consistency issue	9 (16.7%)	6 (11.1%)	24 (44.4%)	15 (27.8%)	54
Hypopituitarism	3 (5.7%)	10 (18.9%)	28 (52.8%)	12 (22.6%)	53
Systemic inflammatory response syndrome	9 (17.0%)	12 (22.6%)	27 (50.9%)	5 (9.4%)	53
Recurrent cancer	2 (3.8%)	5 (9.4%)	39 (73.6%)	7 (13.2%)	53
Nystagmus	12 (22.6%)	17 (32.1%)	21 (39.6%)	3 (5.7%)	53
Abortion induced	22 (41.5%)	31 (58.5%)	0 (0.0%)	0 (0.0%)	53
Rash pustular	5 (9.4%)	14 (26.4%)	31 (58.5%)	3 (5.7%)	53
Oesophageal pain	1 (1.9%)	13 (24.5%)	36 (67.9%)	3 (5.7%)	53
Aneurysm	0 (0.0%)	13 (24.5%)	26 (49.1%)	14 (26.4%)	53
Hepatic cyst	0 (0.0%)	14 (26.4%)	34 (64.2%)	5 (9.4%)	53
Fulminant type 1 diabetes mellitus	0 (0.0%)	5 (9.4%)	37 (69.8%)	11 (20.8%)	53
Depression suicidal	8 (15.1%)	18 (34.0%)	27 (50.9%)	0 (0.0%)	53

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chronic myeloid leukaemia	2 (3.8%)	18 (34.0%)	23 (43.4%)	10 (18.9%)	53
Sputum increased	5 (9.4%)	12 (22.6%)	28 (52.8%)	8 (15.1%)	53
Small for dates baby	53 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	53
Product label confusion	4 (7.5%)	31 (58.5%)	13 (24.5%)	5 (9.4%)	53
Eastern Cooperative Oncology Group performance status	0 (0.0%)	7 (13.2%)	30 (56.6%)	16 (30.2%)	53
Menopause	0 (0.0%)	26 (49.1%)	26 (49.1%)	1 (1.9%)	53
Large intestinal ulcer	1 (1.9%)	14 (26.9%)	29 (55.8%)	8 (15.4%)	52
Red blood cell count increased	5 (9.6%)	14 (26.9%)	29 (55.8%)	4 (7.7%)	52
Systemic candida	11 (21.2%)	11 (21.2%)	27 (51.9%)	3 (5.8%)	52
Therapeutic product effect variable	3 (5.8%)	21 (40.4%)	20 (38.5%)	8 (15.4%)	52
Venous thrombosis	7 (13.5%)	6 (11.5%)	34 (65.4%)	5 (9.6%)	52
Pustular psoriasis	4 (7.7%)	15 (28.8%)	31 (59.6%)	2 (3.8%)	52
Autoimmune haemolytic anaemia	7 (13.5%)	11 (21.2%)	27 (51.9%)	7 (13.5%)	52
Gallbladder operation	4 (7.7%)	15 (28.8%)	24 (46.2%)	9 (17.3%)	52
Polyomavirus viraemia	15 (28.8%)	11 (21.2%)	25 (48.1%)	1 (1.9%)	52
Neurological decompensation	2 (3.8%)	20 (38.5%)	23 (44.2%)	7 (13.5%)	52
Mean cell haemoglobin decreased	2 (3.8%)	32 (61.5%)	18 (34.6%)	0 (0.0%)	52
Bile duct stone	2 (3.8%)	8 (15.4%)	31 (59.6%)	11 (21.2%)	52
Increased upper airway secretion	8 (15.4%)	10 (19.2%)	24 (46.2%)	10 (19.2%)	52
Granuloma	7 (13.5%)	13 (25.0%)	29 (55.8%)	3 (5.8%)	52
Otitis media	18 (35.3%)	20 (39.2%)	9 (17.6%)	4 (7.8%)	51
Prostate cancer metastatic	0 (0.0%)	2 (3.9%)	23 (45.1%)	26 (51.0%)	51
Ear swelling	7 (13.7%)	20 (39.2%)	21 (41.2%)	3 (5.9%)	51
Blood immunoglobulin E increased	9 (17.6%)	16 (31.4%)	25 (49.0%)	1 (2.0%)	51
Peripheral ischaemia	5 (9.8%)	15 (29.4%)	22 (43.1%)	9 (17.6%)	51
Hepatic fibrosis	5 (9.8%)	19 (37.3%)	25 (49.0%)	2 (3.9%)	51
Pneumomediastinum	19 (37.3%)	18 (35.3%)	9 (17.6%)	5 (9.8%)	51

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Body temperature abnormal	15 (29.4%)	18 (35.3%)	13 (25.5%)	5 (9.8%)	51
Staphylococcal sepsis	11 (21.6%)	10 (19.6%)	24 (47.1%)	6 (11.8%)	51
Drug tolerance	5 (9.8%)	18 (35.3%)	26 (51.0%)	2 (3.9%)	51
Immune-mediated dermatitis	0 (0.0%)	6 (11.8%)	37 (72.5%)	8 (15.7%)	51
Bladder pain	4 (7.8%)	10 (19.6%)	28 (54.9%)	9 (17.6%)	51
Breast cancer stage II	0 (0.0%)	48 (94.1%)	3 (5.9%)	0 (0.0%)	51
Product residue present	3 (5.9%)	22 (43.1%)	22 (43.1%)	4 (7.8%)	51
Conjunctivitis allergic	1 (2.0%)	5 (9.8%)	43 (84.3%)	2 (3.9%)	51
Metastases to peritoneum	2 (4.0%)	11 (22.0%)	29 (58.0%)	8 (16.0%)	50
Central venous catheterisation	9 (18.0%)	16 (32.0%)	22 (44.0%)	3 (6.0%)	50
Bronchopulmonary aspergillosis allergic	0 (0.0%)	3 (6.0%)	21 (42.0%)	26 (52.0%)	50
Contraindicated product prescribed	1 (2.0%)	17 (34.0%)	24 (48.0%)	8 (16.0%)	50
Ingrowing nail	8 (16.0%)	12 (24.0%)	27 (54.0%)	3 (6.0%)	50
Vulvovaginal dryness	3 (6.0%)	11 (22.0%)	31 (62.0%)	5 (10.0%)	50
Haemorrhage subcutaneous	4 (8.0%)	5 (10.0%)	24 (48.0%)	17 (34.0%)	50
Drug delivery system malfunction	4 (8.0%)	16 (32.0%)	27 (54.0%)	3 (6.0%)	50
Snoring	8 (16.0%)	16 (32.0%)	23 (46.0%)	3 (6.0%)	50
Vulvovaginal pruritus	4 (8.0%)	8 (16.0%)	31 (62.0%)	7 (14.0%)	50
Stoma site pain	0 (0.0%)	6 (12.0%)	31 (62.0%)	13 (26.0%)	50
Injection site hypersensitivity	7 (14.0%)	14 (28.0%)	28 (56.0%)	1 (2.0%)	50
Immunisation reaction	3 (6.0%)	24 (48.0%)	19 (38.0%)	4 (8.0%)	50
Parainfluenzae virus infection	21 (42.0%)	5 (10.0%)	18 (36.0%)	6 (12.0%)	50
N-terminal prohormone brain natriuretic peptide incre	2 (4.0%)	14 (28.0%)	28 (56.0%)	6 (12.0%)	50
Seronegative arthritis	0 (0.0%)	42 (84.0%)	5 (10.0%)	3 (6.0%)	50
Limb mass	1 (2.0%)	10 (20.0%)	27 (54.0%)	12 (24.0%)	50
Ammonia increased	6 (12.0%)	5 (10.0%)	32 (64.0%)	7 (14.0%)	50
Pregnancy with contraceptive device	11 (22.0%)	39 (78.0%)	0 (0.0%)	0 (0.0%)	50

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rash vesicular	7 (14.0%)	15 (30.0%)	22 (44.0%)	6 (12.0%)	50
Wound complication	4 (8.0%)	14 (28.0%)	27 (54.0%)	5 (10.0%)	50
Total lung capacity decreased	1 (2.0%)	7 (14.0%)	15 (30.0%)	27 (54.0%)	50
Cerebral ischaemia	5 (10.0%)	4 (8.0%)	32 (64.0%)	9 (18.0%)	50
Ophthalmic herpes zoster	2 (4.0%)	9 (18.0%)	29 (58.0%)	10 (20.0%)	50
Psychomotor skills impaired	7 (14.0%)	10 (20.0%)	30 (60.0%)	3 (6.0%)	50
Thoracic vertebral fracture	1 (2.0%)	9 (18.4%)	28 (57.1%)	11 (22.4%)	49
Lymphoproliferative disorder	5 (10.2%)	3 (6.1%)	23 (46.9%)	18 (36.7%)	49
Renal cell carcinoma	0 (0.0%)	6 (12.2%)	37 (75.5%)	6 (12.2%)	49
Phlebitis	0 (0.0%)	15 (30.6%)	27 (55.1%)	7 (14.3%)	49
Communication disorder	5 (10.2%)	11 (22.4%)	20 (40.8%)	13 (26.5%)	49
Blood thyroid stimulating hormone decreased	3 (6.1%)	16 (32.7%)	23 (46.9%)	7 (14.3%)	49
Infarction	1 (2.0%)	2 (4.1%)	33 (67.3%)	13 (26.5%)	49
Bundle branch block right	4 (8.2%)	12 (24.5%)	23 (46.9%)	10 (20.4%)	49
Functional gastrointestinal disorder	2 (4.1%)	22 (44.9%)	18 (36.7%)	7 (14.3%)	49
Hypertonia	14 (28.6%)	19 (38.8%)	9 (18.4%)	7 (14.3%)	49
Immune-mediated hypophysitis	0 (0.0%)	20 (40.8%)	21 (42.9%)	8 (16.3%)	49
Portal vein thrombosis	0 (0.0%)	8 (16.3%)	39 (79.6%)	2 (4.1%)	49
Cardiac valve disease	2 (4.1%)	3 (6.1%)	24 (49.0%)	20 (40.8%)	49
Prostatic disorder	0 (0.0%)	0 (0.0%)	31 (63.3%)	18 (36.7%)	49
Wrong patient received product	7 (14.6%)	8 (16.7%)	14 (29.2%)	19 (39.6%)	48
Acute myeloid leukaemia recurrent	8 (16.7%)	9 (18.8%)	26 (54.2%)	5 (10.4%)	48
Pulseless electrical activity	1 (2.1%)	10 (20.8%)	28 (58.3%)	9 (18.8%)	48
Wound secretion	2 (4.2%)	9 (18.8%)	30 (62.5%)	7 (14.6%)	48
Cortisol decreased	6 (12.5%)	14 (29.2%)	21 (43.8%)	7 (14.6%)	48
Oxygen saturation abnormal	10 (20.8%)	11 (22.9%)	21 (43.8%)	6 (12.5%)	48
Maternal exposure timing unspecified	6 (12.5%)	41 (85.4%)	1 (2.1%)	0 (0.0%)	48

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tongue ulceration	2 (4.2%)	8 (16.7%)	31 (64.6%)	7 (14.6%)	48
Body mass index increased	0 (0.0%)	20 (41.7%)	27 (56.3%)	1 (2.1%)	48
Compression fracture	0 (0.0%)	5 (10.4%)	27 (56.3%)	16 (33.3%)	48
Immunosuppressant drug level increased	4 (8.3%)	9 (18.8%)	32 (66.7%)	3 (6.3%)	48
Hyperphagia	13 (27.1%)	11 (22.9%)	19 (39.6%)	5 (10.4%)	48
Viral upper respiratory tract infection	14 (29.2%)	14 (29.2%)	18 (37.5%)	2 (4.2%)	48
Intervertebral discitis	0 (0.0%)	13 (27.1%)	34 (70.8%)	1 (2.1%)	48
Weight abnormal	5 (10.4%)	14 (29.2%)	22 (45.8%)	7 (14.6%)	48
Skin tightness	10 (20.8%)	12 (25.0%)	23 (47.9%)	3 (6.3%)	48
Deafness neurosensory	18 (37.5%)	11 (22.9%)	14 (29.2%)	5 (10.4%)	48
Gingival swelling	4 (8.3%)	13 (27.1%)	29 (60.4%)	2 (4.2%)	48
Haemorrhagic stroke	0 (0.0%)	12 (25.0%)	20 (41.7%)	16 (33.3%)	48
Pancreatic disorder	5 (10.4%)	5 (10.4%)	32 (66.7%)	6 (12.5%)	48
Prostatomegaly	0 (0.0%)	8 (17.0%)	31 (66.0%)	8 (17.0%)	47
Respiratory rate decreased	13 (27.7%)	12 (25.5%)	17 (36.2%)	5 (10.6%)	47
Oesophageal candidiasis	0 (0.0%)	13 (27.7%)	30 (63.8%)	4 (8.5%)	47
Oxygen therapy	3 (6.4%)	5 (10.6%)	24 (51.1%)	15 (31.9%)	47
Hypoventilation	13 (27.7%)	8 (17.0%)	24 (51.1%)	2 (4.3%)	47
Sialoadenitis	2 (4.3%)	14 (29.8%)	26 (55.3%)	5 (10.6%)	47
Lung adenocarcinoma	0 (0.0%)	4 (8.5%)	32 (68.1%)	11 (23.4%)	47
Mastication disorder	7 (14.9%)	14 (29.8%)	21 (44.7%)	5 (10.6%)	47
Glossitis	1 (2.1%)	9 (19.1%)	36 (76.6%)	1 (2.1%)	47
Mycotic allergy	3 (6.4%)	4 (8.5%)	38 (80.9%)	2 (4.3%)	47
Chest X-ray abnormal	5 (10.6%)	2 (4.3%)	37 (78.7%)	3 (6.4%)	47
Ischaemia	7 (14.9%)	8 (17.0%)	24 (51.1%)	8 (17.0%)	47
Nasal oedema	2 (4.3%)	12 (25.5%)	33 (70.2%)	0 (0.0%)	47
Cerebral atrophy	12 (25.5%)	6 (12.8%)	20 (42.6%)	9 (19.1%)	47

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tetany	10 (21.3%)	16 (34.0%)	20 (42.6%)	1 (2.1%)	47
Hodgkin's disease	6 (12.8%)	18 (38.3%)	20 (42.6%)	3 (6.4%)	47
Asthmatic crisis	9 (19.1%)	13 (27.7%)	23 (48.9%)	2 (4.3%)	47
Retinal artery occlusion	0 (0.0%)	14 (29.8%)	20 (42.6%)	13 (27.7%)	47
Adenocarcinoma of colon	0 (0.0%)	6 (12.8%)	35 (74.5%)	6 (12.8%)	47
Pulmonary function test decreased	6 (12.8%)	10 (21.3%)	22 (46.8%)	9 (19.1%)	47
Angiopathy	3 (6.4%)	12 (25.5%)	25 (53.2%)	7 (14.9%)	47
Product colour issue	4 (8.5%)	4 (8.5%)	30 (63.8%)	9 (19.1%)	47
Cholangitis sclerosing	7 (14.9%)	10 (21.3%)	25 (53.2%)	5 (10.6%)	47
Peritoneal cloudy effluent	7 (14.9%)	9 (19.1%)	22 (46.8%)	9 (19.1%)	47
Urinary tract disorder	4 (8.7%)	4 (8.7%)	30 (65.2%)	8 (17.4%)	46
Atypical mycobacterial infection	4 (8.7%)	12 (26.1%)	25 (54.3%)	5 (10.9%)	46
Eyelid skin dryness	21 (45.7%)	13 (28.3%)	10 (21.7%)	2 (4.3%)	46
Panniculitis	2 (4.3%)	10 (21.7%)	29 (63.0%)	5 (10.9%)	46
Contrast media reaction	4 (8.7%)	12 (26.1%)	24 (52.2%)	6 (13.0%)	46
Idiopathic intracranial hypertension	18 (39.1%)	27 (58.7%)	1 (2.2%)	0 (0.0%)	46
Mite allergy	1 (2.2%)	4 (8.7%)	40 (87.0%)	1 (2.2%)	46
Menopausal symptoms	0 (0.0%)	20 (43.5%)	25 (54.3%)	1 (2.2%)	46
Somnambulism	4 (8.7%)	17 (37.0%)	17 (37.0%)	8 (17.4%)	46
Underweight	13 (28.3%)	10 (21.7%)	13 (28.3%)	10 (21.7%)	46
Hyperaesthesia teeth	2 (4.3%)	16 (34.8%)	23 (50.0%)	5 (10.9%)	46
Biliary colic	3 (6.5%)	17 (37.0%)	21 (45.7%)	5 (10.9%)	46
Hepatic necrosis	3 (6.5%)	18 (39.1%)	22 (47.8%)	3 (6.5%)	46
Catheter site infection	6 (13.0%)	12 (26.1%)	24 (52.2%)	4 (8.7%)	46
Superficial vein thrombosis	1 (2.2%)	23 (50.0%)	19 (41.3%)	3 (6.5%)	46
Quadripareisis	11 (23.9%)	8 (17.4%)	17 (37.0%)	10 (21.7%)	46
Enthesopathy	3 (6.5%)	20 (43.5%)	18 (39.1%)	5 (10.9%)	46

Reaction Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Neovascular age-related macular degeneration	0 (0.0%)	5 (10.9%)	25 (54.3%)	16 (34.8%)	46
Formication	7 (15.2%)	15 (32.6%)	20 (43.5%)	4 (8.7%)	46
Gastric perforation	4 (8.7%)	7 (15.2%)	25 (54.3%)	10 (21.7%)	46
Polyomavirus-associated nephropathy	11 (23.9%)	2 (4.3%)	33 (71.7%)	0 (0.0%)	46
Paranasal sinus hypersecretion	0 (0.0%)	5 (10.9%)	35 (76.1%)	6 (13.0%)	46
Bradypnoea	7 (15.2%)	14 (30.4%)	18 (39.1%)	7 (15.2%)	46
Priapism	3 (6.5%)	27 (58.7%)	16 (34.8%)	0 (0.0%)	46
Intervertebral disc disorder	0 (0.0%)	17 (37.0%)	27 (58.7%)	2 (4.3%)	46
Neck mass	0 (0.0%)	11 (23.9%)	31 (67.4%)	4 (8.7%)	46
Blood loss anaemia	5 (10.9%)	8 (17.4%)	18 (39.1%)	15 (32.6%)	46
Venous thrombosis limb	2 (4.4%)	18 (40.0%)	21 (46.7%)	4 (8.9%)	45
Oral surgery	1 (2.2%)	6 (13.3%)	29 (64.4%)	9 (20.0%)	45
Exposure via breast milk	42 (93.3%)	3 (6.7%)	0 (0.0%)	0 (0.0%)	45
Renal transplant	5 (11.1%)	12 (26.7%)	28 (62.2%)	0 (0.0%)	45
Infusion site mass	5 (11.1%)	7 (15.6%)	25 (55.6%)	8 (17.8%)	45
Vein rupture	7 (15.6%)	14 (31.1%)	20 (44.4%)	4 (8.9%)	45
Platelet disorder	0 (0.0%)	11 (24.4%)	28 (62.2%)	6 (13.3%)	45
Varices oesophageal	4 (8.9%)	9 (20.0%)	29 (64.4%)	3 (6.7%)	45
Sacroiliitis	7 (15.6%)	20 (44.4%)	18 (40.0%)	0 (0.0%)	45
Salmonellosis	7 (15.6%)	11 (24.4%)	24 (53.3%)	3 (6.7%)	45
Stridor	7 (15.6%)	7 (15.6%)	16 (35.6%)	15 (33.3%)	45
Patella fracture	2 (4.4%)	4 (8.9%)	31 (68.9%)	8 (17.8%)	45
Hypertrophic cardiomyopathy	11 (24.4%)	20 (44.4%)	10 (22.2%)	4 (8.9%)	45
Spinal cord compression	2 (4.4%)	7 (15.6%)	33 (73.3%)	3 (6.7%)	45
Brain abscess	8 (17.8%)	8 (17.8%)	20 (44.4%)	9 (20.0%)	45
Periarthritis	0 (0.0%)	15 (33.3%)	29 (64.4%)	1 (2.2%)	45
Tendon injury	7 (15.6%)	16 (35.6%)	19 (42.2%)	3 (6.7%)	45

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Terminal insomnia	2 (4.4%)	23 (51.1%)	17 (37.8%)	3 (6.7%)	45
Blood blister	3 (6.7%)	5 (11.1%)	30 (66.7%)	7 (15.6%)	45
Stent placement	0 (0.0%)	4 (8.9%)	32 (71.1%)	9 (20.0%)	45
Anxiety disorder	13 (28.9%)	14 (31.1%)	17 (37.8%)	1 (2.2%)	45
Suicidal behaviour	12 (26.7%)	30 (66.7%)	3 (6.7%)	0 (0.0%)	45
Persecutory delusion	6 (13.3%)	22 (48.9%)	10 (22.2%)	7 (15.6%)	45
Injection site extravasation	10 (22.2%)	4 (8.9%)	25 (55.6%)	6 (13.3%)	45
Gingival disorder	2 (4.4%)	11 (24.4%)	23 (51.1%)	9 (20.0%)	45
Sacral pain	0 (0.0%)	22 (50.0%)	19 (43.2%)	3 (6.8%)	44
Conjunctival hyperaemia	10 (22.7%)	14 (31.8%)	17 (38.6%)	3 (6.8%)	44
Activated partial thromboplastin time prolonged	16 (36.4%)	3 (6.8%)	13 (29.5%)	12 (27.3%)	44
Ovarian cancer	1 (2.3%)	6 (13.6%)	30 (68.2%)	7 (15.9%)	44
Self-injurious ideation	3 (6.8%)	33 (75.0%)	7 (15.9%)	1 (2.3%)	44
Pigmentary maculopathy	1 (2.3%)	13 (29.5%)	26 (59.1%)	4 (9.1%)	44
Pulse abnormal	4 (9.1%)	10 (22.7%)	25 (56.8%)	5 (11.4%)	44
Device related sepsis	10 (22.7%)	12 (27.3%)	19 (43.2%)	3 (6.8%)	44
Eye contusion	6 (13.6%)	5 (11.4%)	25 (56.8%)	8 (18.2%)	44
Bruxism	18 (40.9%)	12 (27.3%)	11 (25.0%)	3 (6.8%)	44
Metabolic alkalosis	4 (9.1%)	7 (15.9%)	24 (54.5%)	9 (20.5%)	44
Lower respiratory tract congestion	3 (6.8%)	15 (34.1%)	24 (54.5%)	2 (4.5%)	44
White blood cells urine positive	3 (6.8%)	16 (36.4%)	17 (38.6%)	8 (18.2%)	44
Appendicectomy	4 (9.1%)	19 (43.2%)	21 (47.7%)	0 (0.0%)	44
Chorea	5 (11.4%)	16 (36.4%)	17 (38.6%)	6 (13.6%)	44
Extrasystoles	1 (2.3%)	14 (31.8%)	22 (50.0%)	7 (15.9%)	44
Alanine aminotransferase abnormal	5 (11.4%)	6 (13.6%)	27 (61.4%)	6 (13.6%)	44
Sinus operation	1 (2.3%)	14 (31.8%)	22 (50.0%)	7 (15.9%)	44
Neuritis	0 (0.0%)	7 (15.9%)	33 (75.0%)	4 (9.1%)	44

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Hypophysitis	0 (0.0%)	7 (15.9%)	29 (65.9%)	8 (18.2%)	44
Neutropenic colitis	8 (18.2%)	6 (13.6%)	24 (54.5%)	6 (13.6%)	44
Wrong dose	13 (29.5%)	5 (11.4%)	19 (43.2%)	7 (15.9%)	44
Tongue coated	0 (0.0%)	5 (11.4%)	35 (79.5%)	4 (9.1%)	44
Atrial septal defect	37 (84.1%)	5 (11.4%)	2 (4.5%)	0 (0.0%)	44
Urinary tract infection bacterial	1 (2.3%)	15 (34.1%)	18 (40.9%)	10 (22.7%)	44
Weight bearing difficulty	3 (6.8%)	15 (34.1%)	23 (52.3%)	3 (6.8%)	44
Volvulus	3 (6.8%)	5 (11.4%)	24 (54.5%)	12 (27.3%)	44
Anaemia macrocytic	4 (9.3%)	10 (23.3%)	16 (37.2%)	13 (30.2%)	43
Insulin-like growth factor increased	10 (23.3%)	13 (30.2%)	19 (44.2%)	1 (2.3%)	43
Carbohydrate antigen 15-3 increased	0 (0.0%)	15 (34.9%)	24 (55.8%)	4 (9.3%)	43
Fibrosis	1 (2.3%)	8 (18.6%)	20 (46.5%)	14 (32.6%)	43
Febrile infection	5 (11.6%)	13 (30.2%)	14 (32.6%)	11 (25.6%)	43
Dysphemia	4 (9.3%)	18 (41.9%)	19 (44.2%)	2 (4.7%)	43
Menstruation delayed	9 (20.9%)	33 (76.7%)	1 (2.3%)	0 (0.0%)	43
Protein total decreased	5 (11.6%)	7 (16.3%)	24 (55.8%)	7 (16.3%)	43
Prostatitis	1 (2.3%)	11 (25.6%)	27 (62.8%)	4 (9.3%)	43
Lung consolidation	6 (14.0%)	8 (18.6%)	20 (46.5%)	9 (20.9%)	43
Upper respiratory tract congestion	4 (9.3%)	11 (25.6%)	24 (55.8%)	4 (9.3%)	43
Neuromyelitis optica spectrum disorder	6 (14.0%)	12 (27.9%)	24 (55.8%)	1 (2.3%)	43
Hyperreflexia	19 (44.2%)	11 (25.6%)	9 (20.9%)	4 (9.3%)	43
Chronic spontaneous urticaria	4 (9.3%)	21 (48.8%)	15 (34.9%)	3 (7.0%)	43
Encephalitis autoimmune	9 (20.9%)	7 (16.3%)	22 (51.2%)	5 (11.6%)	43
Adrenocortical insufficiency acute	2 (4.7%)	5 (11.6%)	34 (79.1%)	2 (4.7%)	43
Therapeutic product ineffective	6 (14.0%)	9 (20.9%)	23 (53.5%)	5 (11.6%)	43
Thrombophlebitis	3 (7.0%)	20 (46.5%)	15 (34.9%)	5 (11.6%)	43
Vulvovaginal pain	3 (7.0%)	13 (30.2%)	23 (53.5%)	4 (9.3%)	43

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Foreign body in reproductive tract	5 (11.6%)	36 (83.7%)	2 (4.7%)	0 (0.0%)	43
Vitiligo	4 (9.3%)	7 (16.3%)	30 (69.8%)	2 (4.7%)	43
Blood prolactin increased	21 (48.8%)	14 (32.6%)	8 (18.6%)	0 (0.0%)	43
Tic	22 (51.2%)	10 (23.3%)	10 (23.3%)	1 (2.3%)	43
Urinary tract obstruction	7 (16.3%)	5 (11.6%)	19 (44.2%)	12 (27.9%)	43
Acute psychosis	8 (18.6%)	6 (14.0%)	28 (65.1%)	1 (2.3%)	43
Pneumonia cytomegaloviral	6 (14.0%)	11 (25.6%)	25 (58.1%)	1 (2.3%)	43
Gastrointestinal stoma output increased	8 (18.6%)	9 (20.9%)	24 (55.8%)	2 (4.7%)	43
JC polyomavirus test positive	0 (0.0%)	24 (55.8%)	18 (41.9%)	1 (2.3%)	43
Regurgitation	10 (23.3%)	9 (20.9%)	19 (44.2%)	5 (11.6%)	43
Joint lock	3 (7.1%)	11 (26.2%)	26 (61.9%)	2 (4.8%)	42
Lipoma	1 (2.4%)	12 (28.6%)	29 (69.0%)	0 (0.0%)	42
Eosinophilic oesophagitis	15 (35.7%)	16 (38.1%)	9 (21.4%)	2 (4.8%)	42
Embolic stroke	0 (0.0%)	4 (9.5%)	23 (54.8%)	15 (35.7%)	42
Skin hypertrophy	1 (2.4%)	20 (47.6%)	20 (47.6%)	1 (2.4%)	42
Catheterisation cardiac	3 (7.1%)	6 (14.3%)	26 (61.9%)	7 (16.7%)	42
Bone marrow disorder	1 (2.4%)	6 (14.3%)	32 (76.2%)	3 (7.1%)	42
Steroid dependence	21 (50.0%)	2 (4.8%)	19 (45.2%)	0 (0.0%)	42
Recalled product administered	14 (33.3%)	4 (9.5%)	22 (52.4%)	2 (4.8%)	42
Madarosis	5 (11.9%)	18 (42.9%)	17 (40.5%)	2 (4.8%)	42
Pneumonia pseudomonal	1 (2.4%)	7 (16.7%)	29 (69.0%)	5 (11.9%)	42
Aortic arteriosclerosis	0 (0.0%)	4 (9.5%)	25 (59.5%)	13 (31.0%)	42
Postural orthostatic tachycardia syndrome	10 (23.8%)	21 (50.0%)	11 (26.2%)	0 (0.0%)	42
Suspected suicide	1 (2.4%)	11 (26.2%)	24 (57.1%)	6 (14.3%)	42
Infrequent bowel movements	5 (11.9%)	15 (35.7%)	14 (33.3%)	8 (19.0%)	42
Skin injury	4 (9.5%)	9 (21.4%)	29 (69.0%)	0 (0.0%)	42
Vitreous haemorrhage	1 (2.4%)	6 (14.3%)	31 (73.8%)	4 (9.5%)	42

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Impulse-control disorder	4 (9.5%)	27 (64.3%)	9 (21.4%)	2 (4.8%)	42
Abdominal infection	2 (4.8%)	9 (21.4%)	26 (61.9%)	5 (11.9%)	42
Gastritis erosive	5 (11.9%)	6 (14.3%)	22 (52.4%)	9 (21.4%)	42
Injection site scar	4 (9.5%)	23 (54.8%)	14 (33.3%)	1 (2.4%)	42
Neck injury	7 (16.7%)	11 (26.2%)	20 (47.6%)	4 (9.5%)	42
Bacterial sepsis	10 (23.8%)	7 (16.7%)	21 (50.0%)	4 (9.5%)	42
Angina unstable	0 (0.0%)	12 (29.3%)	22 (53.7%)	7 (17.1%)	41
Jaundice cholestatic	0 (0.0%)	2 (4.9%)	26 (63.4%)	13 (31.7%)	41
Liver transplant	9 (22.0%)	11 (26.8%)	21 (51.2%)	0 (0.0%)	41
Pregnancy with implant contraceptive	17 (41.5%)	24 (58.5%)	0 (0.0%)	0 (0.0%)	41
Metastatic neoplasm	0 (0.0%)	3 (7.3%)	28 (68.3%)	10 (24.4%)	41
Hyperammonaemic encephalopathy	16 (39.0%)	17 (41.5%)	7 (17.1%)	1 (2.4%)	41
Adrenal disorder	0 (0.0%)	12 (29.3%)	25 (61.0%)	4 (9.8%)	41
Atrioventricular block second degree	9 (22.0%)	6 (14.6%)	14 (34.1%)	12 (29.3%)	41
Anaesthetic complication	5 (12.2%)	15 (36.6%)	19 (46.3%)	2 (4.9%)	41
Negative thoughts	6 (14.6%)	16 (39.0%)	18 (43.9%)	1 (2.4%)	41
Electrocardiogram ST segment elevation	3 (7.3%)	9 (22.0%)	25 (61.0%)	4 (9.8%)	41
Change in seizure presentation	30 (73.2%)	4 (9.8%)	6 (14.6%)	1 (2.4%)	41
Substance use	13 (31.7%)	23 (56.1%)	5 (12.2%)	0 (0.0%)	41
Cushingoid	11 (26.8%)	16 (39.0%)	12 (29.3%)	2 (4.9%)	41
Metabolic encephalopathy	4 (9.8%)	2 (4.9%)	22 (53.7%)	13 (31.7%)	41
Pneumonia staphylococcal	1 (2.4%)	21 (51.2%)	12 (29.3%)	7 (17.1%)	41
Trismus	7 (17.1%)	10 (24.4%)	19 (46.3%)	5 (12.2%)	41
Retinopathy	2 (4.9%)	6 (14.6%)	24 (58.5%)	9 (22.0%)	41
Decreased interest	4 (9.8%)	14 (34.1%)	19 (46.3%)	4 (9.8%)	41
Dental operation	4 (9.8%)	9 (22.0%)	26 (63.4%)	2 (4.9%)	41
Steroid diabetes	7 (17.1%)	10 (24.4%)	22 (53.7%)	2 (4.9%)	41

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dengue fever	5 (12.2%)	18 (43.9%)	16 (39.0%)	2 (4.9%)	41
Allergy to animal	4 (9.8%)	11 (26.8%)	25 (61.0%)	1 (2.4%)	41
Product contamination	21 (51.2%)	5 (12.2%)	14 (34.1%)	1 (2.4%)	41
Oculogyric crisis	27 (65.9%)	11 (26.8%)	3 (7.3%)	0 (0.0%)	41
Retinal vein occlusion	0 (0.0%)	21 (51.2%)	16 (39.0%)	4 (9.8%)	41
Oesophageal stenosis	4 (9.8%)	8 (19.5%)	24 (58.5%)	5 (12.2%)	41
Monoparesis	3 (7.3%)	17 (41.5%)	18 (43.9%)	3 (7.3%)	41
SARS-CoV-2 antibody test negative	1 (2.4%)	22 (53.7%)	18 (43.9%)	0 (0.0%)	41
Atrioventricular block first degree	4 (10.0%)	2 (5.0%)	21 (52.5%)	13 (32.5%)	40
Gangrene	0 (0.0%)	3 (7.5%)	32 (80.0%)	5 (12.5%)	40
Pulmonary tuberculosis	2 (5.0%)	9 (22.5%)	19 (47.5%)	10 (25.0%)	40
Goitre	0 (0.0%)	13 (32.5%)	24 (60.0%)	3 (7.5%)	40
Product solubility abnormal	21 (52.5%)	5 (12.5%)	10 (25.0%)	4 (10.0%)	40
Cardiac amyloidosis	1 (2.5%)	1 (2.5%)	9 (22.5%)	29 (72.5%)	40
Noninfective gingivitis	4 (10.0%)	11 (27.5%)	24 (60.0%)	1 (2.5%)	40
Uterine cancer	1 (2.5%)	6 (15.0%)	29 (72.5%)	4 (10.0%)	40
Multiple use of single-use product	14 (35.0%)	5 (12.5%)	15 (37.5%)	6 (15.0%)	40
Dermal cyst	5 (12.5%)	14 (35.0%)	19 (47.5%)	2 (5.0%)	40
Aortic dissection	0 (0.0%)	4 (10.0%)	24 (60.0%)	12 (30.0%)	40
Supraventricular extrasystoles	0 (0.0%)	7 (17.5%)	22 (55.0%)	11 (27.5%)	40
Graft versus host disease in skin	14 (35.0%)	8 (20.0%)	16 (40.0%)	2 (5.0%)	40
Injection site haematoma	4 (10.0%)	12 (30.0%)	19 (47.5%)	5 (12.5%)	40
Macule	3 (7.5%)	13 (32.5%)	18 (45.0%)	6 (15.0%)	40
Sleep paralysis	7 (17.5%)	20 (50.0%)	13 (32.5%)	0 (0.0%)	40
Sternal fracture	0 (0.0%)	6 (15.0%)	28 (70.0%)	6 (15.0%)	40
Wound dehiscence	2 (5.0%)	8 (20.0%)	24 (60.0%)	6 (15.0%)	40
Ileal stenosis	5 (12.5%)	20 (50.0%)	14 (35.0%)	1 (2.5%)	40

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Respiratory alkalosis	0 (0.0%)	12 (30.0%)	23 (57.5%)	5 (12.5%)	40
Product formulation issue	6 (15.0%)	13 (32.5%)	15 (37.5%)	6 (15.0%)	40
Retinitis	1 (2.5%)	24 (60.0%)	14 (35.0%)	1 (2.5%)	40
Protein total increased	1 (2.5%)	14 (35.0%)	22 (55.0%)	3 (7.5%)	40
Biliary obstruction	1 (2.5%)	3 (7.5%)	32 (80.0%)	4 (10.0%)	40
Dyspnoea at rest	1 (2.6%)	7 (17.9%)	26 (66.7%)	5 (12.8%)	39
Dysphoria	2 (5.1%)	14 (35.9%)	13 (33.3%)	10 (25.6%)	39
Ear congestion	0 (0.0%)	10 (25.6%)	25 (64.1%)	4 (10.3%)	39
Abnormal uterine bleeding	21 (53.8%)	17 (43.6%)	1 (2.6%)	0 (0.0%)	39
Bicytopenia	3 (7.7%)	5 (12.8%)	25 (64.1%)	6 (15.4%)	39
Haematoma muscle	2 (5.1%)	2 (5.1%)	18 (46.2%)	17 (43.6%)	39
Polydipsia	1 (2.6%)	17 (43.6%)	19 (48.7%)	2 (5.1%)	39
Anti-cyclic citrullinated peptide antibody	0 (0.0%)	30 (76.9%)	9 (23.1%)	0 (0.0%)	39
Hangover	1 (2.6%)	21 (53.8%)	15 (38.5%)	2 (5.1%)	39
Panic disorder	8 (20.5%)	12 (30.8%)	14 (35.9%)	5 (12.8%)	39
Infusion site rash	7 (17.9%)	3 (7.7%)	21 (53.8%)	8 (20.5%)	39
Mucormycosis	5 (12.8%)	12 (30.8%)	20 (51.3%)	2 (5.1%)	39
Posture abnormal	3 (7.7%)	8 (20.5%)	18 (46.2%)	10 (25.6%)	39
Acute lymphocytic leukaemia	7 (17.9%)	11 (28.2%)	20 (51.3%)	1 (2.6%)	39
Vaccination failure	6 (15.4%)	6 (15.4%)	23 (59.0%)	4 (10.3%)	39
Application site rash	3 (7.7%)	16 (41.0%)	15 (38.5%)	5 (12.8%)	39
Diastolic dysfunction	2 (5.1%)	2 (5.1%)	22 (56.4%)	13 (33.3%)	39
Xerophthalmia	0 (0.0%)	9 (23.1%)	25 (64.1%)	5 (12.8%)	39
Dermatitis psoriasiform	4 (10.3%)	4 (10.3%)	28 (71.8%)	3 (7.7%)	39
Micturition disorder	4 (10.3%)	12 (30.8%)	15 (38.5%)	8 (20.5%)	39
Granulocyte count decreased	6 (15.4%)	4 (10.3%)	25 (64.1%)	4 (10.3%)	39
Aplasia pure red cell	4 (10.3%)	8 (20.5%)	20 (51.3%)	7 (17.9%)	39

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood phosphorus decreased	5 (12.8%)	14 (35.9%)	17 (43.6%)	3 (7.7%)	39
Hypoproteinaemia	2 (5.1%)	10 (25.6%)	26 (66.7%)	1 (2.6%)	39
Radiation pneumonitis	1 (2.6%)	4 (10.3%)	32 (82.1%)	2 (5.1%)	39
Terminal state	1 (2.6%)	1 (2.6%)	19 (48.7%)	18 (46.2%)	39
Vulvovaginal burning sensation	3 (7.7%)	11 (28.2%)	22 (56.4%)	3 (7.7%)	39
Anal haemorrhage	2 (5.1%)	7 (17.9%)	25 (64.1%)	5 (12.8%)	39
Carbohydrate antigen 125 increased	0 (0.0%)	6 (15.8%)	29 (76.3%)	3 (7.9%)	38
Osteolysis	0 (0.0%)	10 (26.3%)	25 (65.8%)	3 (7.9%)	38
Auditory disorder	3 (7.9%)	5 (13.2%)	16 (42.1%)	14 (36.8%)	38
Cardiovascular insufficiency	4 (10.5%)	14 (36.8%)	17 (44.7%)	3 (7.9%)	38
Suspected counterfeit product	5 (13.2%)	15 (39.5%)	15 (39.5%)	3 (7.9%)	38
Skin wrinkling	0 (0.0%)	9 (23.7%)	13 (34.2%)	16 (42.1%)	38
Oesophageal carcinoma	0 (0.0%)	1 (2.6%)	27 (71.1%)	10 (26.3%)	38
Fixed eruption	2 (5.3%)	16 (42.1%)	12 (31.6%)	8 (21.1%)	38
Gene mutation	7 (18.4%)	7 (18.4%)	23 (60.5%)	1 (2.6%)	38
Myasthenia gravis crisis	3 (7.9%)	19 (50.0%)	12 (31.6%)	4 (10.5%)	38
Nasal discharge discolouration	3 (7.9%)	12 (31.6%)	23 (60.5%)	0 (0.0%)	38
Logorrhoea	11 (28.9%)	14 (36.8%)	10 (26.3%)	3 (7.9%)	38
Actinic keratosis	1 (2.6%)	1 (2.6%)	33 (86.8%)	3 (7.9%)	38
Pancreatic failure	4 (10.5%)	13 (34.2%)	18 (47.4%)	3 (7.9%)	38
Lacrimal structure injury	0 (0.0%)	17 (44.7%)	21 (55.3%)	0 (0.0%)	38
Keratitis	5 (13.2%)	8 (21.1%)	21 (55.3%)	4 (10.5%)	38
Tachyarrhythmia	5 (13.2%)	5 (13.2%)	17 (44.7%)	11 (28.9%)	38
Hypoxic-ischaemic encephalopathy	12 (31.6%)	2 (5.3%)	16 (42.1%)	8 (21.1%)	38
Plasma cell myeloma refractory	0 (0.0%)	1 (2.6%)	26 (68.4%)	11 (28.9%)	38
Blood phosphorus increased	2 (5.3%)	3 (7.9%)	9 (23.7%)	24 (63.2%)	38
Scleroderma	6 (15.8%)	10 (26.3%)	22 (57.9%)	0 (0.0%)	38

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Psychotic symptom	12 (31.6%)	11 (28.9%)	11 (28.9%)	4 (10.5%)	38
Craniocerebral injury	4 (10.5%)	6 (15.8%)	18 (47.4%)	10 (26.3%)	38
Arthropod sting	2 (5.3%)	8 (21.1%)	26 (68.4%)	2 (5.3%)	38
Acute graft versus host disease in skin	19 (50.0%)	15 (39.5%)	4 (10.5%)	0 (0.0%)	38
Pancreatitis necrotising	4 (10.5%)	13 (34.2%)	21 (55.3%)	0 (0.0%)	38
Tumour pseudoprogression	1 (2.6%)	8 (21.1%)	22 (57.9%)	7 (18.4%)	38
Intracranial aneurysm	0 (0.0%)	6 (15.8%)	29 (76.3%)	3 (7.9%)	38
Device alarm issue	5 (13.2%)	9 (23.7%)	18 (47.4%)	6 (15.8%)	38
Granulocytopenia	6 (15.8%)	10 (26.3%)	20 (52.6%)	2 (5.3%)	38
Hypothalamo-pituitary disorder	1 (2.6%)	6 (15.8%)	13 (34.2%)	18 (47.4%)	38
Cerebral haematoma	3 (7.9%)	3 (7.9%)	19 (50.0%)	13 (34.2%)	38
Oral mucosal eruption	4 (10.8%)	5 (13.5%)	24 (64.9%)	4 (10.8%)	37
Left ventricular hypertrophy	3 (8.1%)	10 (27.0%)	18 (48.6%)	6 (16.2%)	37
Metastases to meninges	1 (2.7%)	8 (21.6%)	20 (54.1%)	8 (21.6%)	37
Pericardial haemorrhage	0 (0.0%)	21 (56.8%)	10 (27.0%)	6 (16.2%)	37
Intentional underdose	5 (13.5%)	8 (21.6%)	17 (45.9%)	7 (18.9%)	37
Urine output increased	6 (16.2%)	5 (13.5%)	17 (45.9%)	9 (24.3%)	37
Blood potassium abnormal	2 (5.4%)	5 (13.5%)	25 (67.6%)	5 (13.5%)	37
Nocardiosis	0 (0.0%)	12 (32.4%)	16 (43.2%)	9 (24.3%)	37
Pruritus genital	3 (8.1%)	9 (24.3%)	22 (59.5%)	3 (8.1%)	37
Sensitisation	3 (8.1%)	3 (8.1%)	29 (78.4%)	2 (5.4%)	37
Hyperthermia malignant	10 (27.0%)	16 (43.2%)	11 (29.7%)	0 (0.0%)	37
Prostatic specific antigen abnormal	0 (0.0%)	2 (5.4%)	18 (48.6%)	17 (45.9%)	37
Unmasking of previously unidentified disease	14 (37.8%)	5 (13.5%)	17 (45.9%)	1 (2.7%)	37
Skin depigmentation	7 (18.9%)	12 (32.4%)	14 (37.8%)	4 (10.8%)	37
Purulent discharge	3 (8.1%)	12 (32.4%)	17 (45.9%)	5 (13.5%)	37
Endotracheal intubation	10 (27.0%)	10 (27.0%)	15 (40.5%)	2 (5.4%)	37

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Myoglobin blood increased	2 (5.4%)	5 (13.5%)	9 (24.3%)	21 (56.8%)	37
Large intestine infection	1 (2.7%)	6 (16.2%)	20 (54.1%)	10 (27.0%)	37
Colorectal cancer metastatic	0 (0.0%)	15 (40.5%)	20 (54.1%)	2 (5.4%)	37
Tumour haemorrhage	0 (0.0%)	6 (16.2%)	27 (73.0%)	4 (10.8%)	37
Aortic valve incompetence	6 (16.2%)	10 (27.0%)	15 (40.5%)	6 (16.2%)	37
Stoma site haemorrhage	2 (5.4%)	4 (10.8%)	18 (48.6%)	13 (35.1%)	37
Brain death	10 (27.0%)	16 (43.2%)	8 (21.6%)	3 (8.1%)	37
Drug diversion	1 (2.7%)	18 (48.6%)	15 (40.5%)	3 (8.1%)	37
Transplant	4 (10.8%)	12 (32.4%)	20 (54.1%)	1 (2.7%)	37
Visceral congestion	4 (10.8%)	27 (73.0%)	5 (13.5%)	1 (2.7%)	37
Implant site pain	11 (29.7%)	16 (43.2%)	9 (24.3%)	1 (2.7%)	37
Testicular pain	11 (29.7%)	18 (48.6%)	7 (18.9%)	1 (2.7%)	37
Jaw disorder	1 (2.7%)	5 (13.5%)	26 (70.3%)	5 (13.5%)	37
Strabismus	11 (29.7%)	8 (21.6%)	16 (43.2%)	2 (5.4%)	37
Pulmonary sepsis	2 (5.4%)	2 (5.4%)	24 (64.9%)	9 (24.3%)	37
Reduced facial expression	0 (0.0%)	5 (13.5%)	22 (59.5%)	10 (27.0%)	37
Infusion site discomfort	1 (2.7%)	12 (32.4%)	22 (59.5%)	2 (5.4%)	37
Onycholysis	0 (0.0%)	14 (37.8%)	21 (56.8%)	2 (5.4%)	37
JC virus infection	0 (0.0%)	11 (29.7%)	22 (59.5%)	4 (10.8%)	37
Labyrinthitis	1 (2.7%)	9 (24.3%)	24 (64.9%)	3 (8.1%)	37
Hypofibrinogenaemia	18 (48.6%)	8 (21.6%)	9 (24.3%)	2 (5.4%)	37
Radius fracture	3 (8.1%)	9 (24.3%)	18 (48.6%)	7 (18.9%)	37
Developmental delay	34 (91.9%)	2 (5.4%)	1 (2.7%)	0 (0.0%)	37
Joint arthroplasty	0 (0.0%)	11 (29.7%)	18 (48.6%)	8 (21.6%)	37
Disseminated aspergillosis	2 (5.6%)	11 (30.6%)	23 (63.9%)	0 (0.0%)	36
Pyroglutamic acidosis	0 (0.0%)	10 (27.8%)	19 (52.8%)	7 (19.4%)	36
Haemorrhage urinary tract	2 (5.6%)	7 (19.4%)	21 (58.3%)	6 (16.7%)	36

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Non-Hodgkin's lymphoma	3 (8.3%)	4 (11.1%)	25 (69.4%)	4 (11.1%)	36
Peripheral arterial occlusive disease	0 (0.0%)	2 (5.6%)	26 (72.2%)	8 (22.2%)	36
Ischaemic hepatitis	9 (25.0%)	5 (13.9%)	16 (44.4%)	6 (16.7%)	36
Antinuclear antibody positive	0 (0.0%)	16 (44.4%)	19 (52.8%)	1 (2.8%)	36
Mental fatigue	0 (0.0%)	16 (44.4%)	17 (47.2%)	3 (8.3%)	36
Stenosis	2 (5.6%)	13 (36.1%)	15 (41.7%)	6 (16.7%)	36
Lip haemorrhage	13 (36.1%)	13 (36.1%)	7 (19.4%)	3 (8.3%)	36
Pharyngeal erythema	10 (27.8%)	7 (19.4%)	16 (44.4%)	3 (8.3%)	36
Lymphadenitis	3 (8.3%)	18 (50.0%)	13 (36.1%)	2 (5.6%)	36
Thrombotic thrombocytopenic purpura	0 (0.0%)	5 (13.9%)	25 (69.4%)	6 (16.7%)	36
Vaginal flatulence	0 (0.0%)	0 (0.0%)	36 (100.0%)	0 (0.0%)	36
Injection site indentation	3 (8.3%)	9 (25.0%)	20 (55.6%)	4 (11.1%)	36
Intracardiac thrombus	6 (16.7%)	1 (2.8%)	19 (52.8%)	10 (27.8%)	36
Chronic inflammatory demyelinating polyradiculoneurop	1 (2.8%)	11 (30.6%)	22 (61.1%)	2 (5.6%)	36
Chronic lymphocytic leukaemia	0 (0.0%)	1 (2.8%)	28 (77.8%)	7 (19.4%)	36
Loose tooth	9 (25.0%)	2 (5.6%)	22 (61.1%)	3 (8.3%)	36
Portal hypertension	3 (8.3%)	9 (25.0%)	24 (66.7%)	0 (0.0%)	36
Neurogenic bladder	4 (11.1%)	6 (16.7%)	24 (66.7%)	2 (5.6%)	36
Gastrointestinal bacterial overgrowth	4 (11.1%)	18 (50.0%)	14 (38.9%)	0 (0.0%)	36
Epstein-Barr virus infection reactivation	13 (36.1%)	11 (30.6%)	12 (33.3%)	0 (0.0%)	36
Blood immunoglobulin G increased	8 (22.2%)	8 (22.2%)	16 (44.4%)	4 (11.1%)	36
Chondrocalcinosis	0 (0.0%)	1 (2.8%)	25 (69.4%)	10 (27.8%)	36
Vitritis	2 (5.6%)	6 (16.7%)	15 (41.7%)	13 (36.1%)	36
Oesophageal disorder	1 (2.8%)	6 (16.7%)	20 (55.6%)	9 (25.0%)	36
Duodenitis	4 (11.1%)	8 (22.2%)	21 (58.3%)	3 (8.3%)	36
Vitreous detachment	0 (0.0%)	6 (16.7%)	26 (72.2%)	4 (11.1%)	36
Meningitis cryptococcal	1 (2.8%)	14 (38.9%)	14 (38.9%)	7 (19.4%)	36

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vomiting projectile	9 (25.0%)	11 (30.6%)	15 (41.7%)	1 (2.8%)	36
Hernia repair	1 (2.8%)	8 (22.2%)	24 (66.7%)	3 (8.3%)	36
Carcinoid tumour	0 (0.0%)	8 (22.9%)	26 (74.3%)	1 (2.9%)	35
Rebound eczema	14 (40.0%)	13 (37.1%)	6 (17.1%)	2 (5.7%)	35
Amyloid related imaging abnormality-oedema/effusion	0 (0.0%)	0 (0.0%)	21 (60.0%)	14 (40.0%)	35
Rheumatic disorder	0 (0.0%)	8 (22.9%)	24 (68.6%)	3 (8.6%)	35
Renal transplant failure	4 (11.4%)	13 (37.1%)	11 (31.4%)	7 (20.0%)	35
Ototoxicity	1 (2.9%)	3 (8.6%)	20 (57.1%)	11 (31.4%)	35
Lichen planus	0 (0.0%)	12 (34.3%)	20 (57.1%)	3 (8.6%)	35
Appendicitis perforated	4 (11.4%)	4 (11.4%)	18 (51.4%)	9 (25.7%)	35
Vasoplegia syndrome	20 (57.1%)	3 (8.6%)	12 (34.3%)	0 (0.0%)	35
Acute lymphocytic leukaemia recurrent	18 (51.4%)	6 (17.1%)	10 (28.6%)	1 (2.9%)	35
Fibula fracture	1 (2.9%)	9 (25.7%)	21 (60.0%)	4 (11.4%)	35
Clumsiness	5 (14.3%)	18 (51.4%)	10 (28.6%)	2 (5.7%)	35
Serous retinal detachment	1 (2.9%)	6 (17.1%)	21 (60.0%)	7 (20.0%)	35
Ear haemorrhage	8 (22.9%)	6 (17.1%)	15 (42.9%)	6 (17.1%)	35
Medical device discomfort	9 (25.7%)	17 (48.6%)	7 (20.0%)	2 (5.7%)	35
Mastitis	0 (0.0%)	15 (42.9%)	19 (54.3%)	1 (2.9%)	35
Body temperature fluctuation	4 (11.4%)	14 (40.0%)	14 (40.0%)	3 (8.6%)	35
Low birth weight baby	33 (94.3%)	2 (5.7%)	0 (0.0%)	0 (0.0%)	35
Abscess oral	1 (2.9%)	14 (40.0%)	18 (51.4%)	2 (5.7%)	35
Failure to thrive	10 (28.6%)	3 (8.6%)	11 (31.4%)	11 (31.4%)	35
Iritis	0 (0.0%)	13 (37.1%)	13 (37.1%)	9 (25.7%)	35
Subcutaneous emphysema	4 (11.4%)	19 (54.3%)	10 (28.6%)	2 (5.7%)	35
COVID-19 immunisation	0 (0.0%)	10 (28.6%)	22 (62.9%)	3 (8.6%)	35
Aortic stenosis	0 (0.0%)	2 (5.7%)	15 (42.9%)	18 (51.4%)	35
Abdominal rigidity	3 (8.6%)	12 (34.3%)	19 (54.3%)	1 (2.9%)	35

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Deafness bilateral	5 (14.3%)	11 (31.4%)	17 (48.6%)	2 (5.7%)	35
Immobile	1 (2.9%)	12 (34.3%)	14 (40.0%)	8 (22.9%)	35
Polycythaemia	0 (0.0%)	4 (11.4%)	30 (85.7%)	1 (2.9%)	35
Hepatosplenomegaly	11 (31.4%)	11 (31.4%)	12 (34.3%)	1 (2.9%)	35
Gastric ulcer haemorrhage	4 (11.4%)	3 (8.6%)	13 (37.1%)	15 (42.9%)	35
Human chorionic gonadotropin increased	0 (0.0%)	29 (82.9%)	6 (17.1%)	0 (0.0%)	35
Small intestinal perforation	2 (5.7%)	7 (20.0%)	17 (48.6%)	9 (25.7%)	35
Blood testosterone decreased	1 (2.9%)	19 (54.3%)	13 (37.1%)	2 (5.7%)	35
Growth retardation	35 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	35
Graft versus host disease in gastrointestinal tract	9 (25.7%)	12 (34.3%)	12 (34.3%)	2 (5.7%)	35
Prothrombin time prolonged	7 (20.0%)	1 (2.9%)	16 (45.7%)	11 (31.4%)	35
Breast cancer recurrent	0 (0.0%)	10 (28.6%)	22 (62.9%)	3 (8.6%)	35
Hyperchlorhydria	1 (2.9%)	10 (28.6%)	24 (68.6%)	0 (0.0%)	35
Pleuritic pain	1 (2.9%)	10 (29.4%)	13 (38.2%)	10 (29.4%)	34
Fanconi syndrome acquired	2 (5.9%)	6 (17.6%)	24 (70.6%)	2 (5.9%)	34
Pneumatosis intestinalis	14 (41.2%)	2 (5.9%)	11 (32.4%)	7 (20.6%)	34
Bacterial vaginosis	2 (5.9%)	25 (73.5%)	7 (20.6%)	0 (0.0%)	34
Cardiac discomfort	3 (8.8%)	13 (38.2%)	15 (44.1%)	3 (8.8%)	34
Ventricular arrhythmia	9 (26.5%)	8 (23.5%)	8 (23.5%)	9 (26.5%)	34
Transplant dysfunction	5 (14.7%)	10 (29.4%)	19 (55.9%)	0 (0.0%)	34
Spirometry abnormal	0 (0.0%)	1 (2.9%)	33 (97.1%)	0 (0.0%)	34
Serum sickness	9 (26.5%)	9 (26.5%)	15 (44.1%)	1 (2.9%)	34
Rectal abscess	5 (14.7%)	18 (52.9%)	10 (29.4%)	1 (2.9%)	34
Oral pruritus	2 (5.9%)	15 (44.1%)	16 (47.1%)	1 (2.9%)	34
Stoma site infection	1 (2.9%)	5 (14.7%)	24 (70.6%)	4 (11.8%)	34
Miliaria	3 (8.8%)	11 (32.4%)	17 (50.0%)	3 (8.8%)	34
Bone contusion	1 (2.9%)	9 (26.5%)	15 (44.1%)	9 (26.5%)	34

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Coma scale abnormal	6 (17.6%)	6 (17.6%)	11 (32.4%)	11 (32.4%)	34
Suffocation feeling	0 (0.0%)	14 (41.2%)	14 (41.2%)	6 (17.6%)	34
Differential white blood cell count abnormal	1 (2.9%)	10 (29.4%)	23 (67.6%)	0 (0.0%)	34
Cardiopulmonary failure	5 (14.7%)	9 (26.5%)	12 (35.3%)	8 (23.5%)	34
Serum ferritin decreased	4 (11.8%)	15 (44.1%)	13 (38.2%)	2 (5.9%)	34
Lumbar spinal stenosis	0 (0.0%)	2 (5.9%)	21 (61.8%)	11 (32.4%)	34
Loss of control of legs	0 (0.0%)	5 (14.7%)	16 (47.1%)	13 (38.2%)	34
Diabetic foot	0 (0.0%)	1 (2.9%)	27 (79.4%)	6 (17.6%)	34
Axillary pain	3 (8.8%)	14 (41.2%)	16 (47.1%)	1 (2.9%)	34
Stenotrophomonas infection	16 (47.1%)	5 (14.7%)	13 (38.2%)	0 (0.0%)	34
B-cell lymphoma	2 (5.9%)	6 (17.6%)	24 (70.6%)	2 (5.9%)	34
Dactylitis	2 (5.9%)	18 (52.9%)	14 (41.2%)	0 (0.0%)	34
Middle ear effusion	3 (8.8%)	7 (20.6%)	19 (55.9%)	5 (14.7%)	34
Plasmacytoma	1 (2.9%)	4 (11.8%)	28 (82.4%)	1 (2.9%)	34
Chest injury	2 (5.9%)	8 (23.5%)	17 (50.0%)	7 (20.6%)	34
Eye allergy	5 (14.7%)	7 (20.6%)	21 (61.8%)	1 (2.9%)	34
Thyrototoxic crisis	5 (14.7%)	6 (17.6%)	20 (58.8%)	3 (8.8%)	34
Therapeutic response delayed	5 (14.7%)	8 (23.5%)	15 (44.1%)	6 (17.6%)	34
Poor peripheral circulation	4 (11.8%)	9 (26.5%)	15 (44.1%)	6 (17.6%)	34
Marasmus	0 (0.0%)	1 (2.9%)	14 (41.2%)	19 (55.9%)	34
Postmenopausal haemorrhage	0 (0.0%)	10 (29.4%)	23 (67.6%)	1 (2.9%)	34
Premature labour	10 (29.4%)	24 (70.6%)	0 (0.0%)	0 (0.0%)	34
Pyelonephritis acute	2 (5.9%)	5 (14.7%)	17 (50.0%)	10 (29.4%)	34
Rash morbilliform	8 (23.5%)	7 (20.6%)	11 (32.4%)	8 (23.5%)	34
Cerebrospinal fluid leakage	4 (11.8%)	11 (32.4%)	18 (52.9%)	1 (2.9%)	34
Intensive care	8 (23.5%)	5 (14.7%)	16 (47.1%)	5 (14.7%)	34
Pulmonary function test abnormal	0 (0.0%)	0 (0.0%)	30 (88.2%)	4 (11.8%)	34

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chronic graft versus host disease	9 (26.5%)	10 (29.4%)	14 (41.2%)	1 (2.9%)	34
Genital herpes	0 (0.0%)	14 (41.2%)	18 (52.9%)	2 (5.9%)	34
Acidosis hyperchloreaemic	1 (3.0%)	12 (36.4%)	17 (51.5%)	3 (9.1%)	33
Cytomegalovirus colitis	0 (0.0%)	5 (15.2%)	23 (69.7%)	5 (15.2%)	33
Groin abscess	5 (15.2%)	18 (54.5%)	9 (27.3%)	1 (3.0%)	33
Renal neoplasm	0 (0.0%)	4 (12.1%)	19 (57.6%)	10 (30.3%)	33
Cholecystitis infective	0 (0.0%)	4 (12.1%)	23 (69.7%)	6 (18.2%)	33
Facial paresis	6 (18.2%)	7 (21.2%)	15 (45.5%)	5 (15.2%)	33
Cytomegalovirus chorioretinitis	4 (12.1%)	12 (36.4%)	14 (42.4%)	3 (9.1%)	33
Optic ischaemic neuropathy	0 (0.0%)	19 (57.6%)	10 (30.3%)	4 (12.1%)	33
Injection site infection	2 (6.1%)	10 (30.3%)	20 (60.6%)	1 (3.0%)	33
Red blood cell sedimentation rate abnormal	8 (24.2%)	5 (15.2%)	20 (60.6%)	0 (0.0%)	33
Multiple drug therapy	0 (0.0%)	3 (9.1%)	3 (9.1%)	27 (81.8%)	33
Follicular lymphoma	0 (0.0%)	9 (27.3%)	21 (63.6%)	3 (9.1%)	33
Drug titration error	2 (6.1%)	19 (57.6%)	7 (21.2%)	5 (15.2%)	33
Increased bronchial secretion	17 (51.5%)	4 (12.1%)	7 (21.2%)	5 (15.2%)	33
Injection related reaction	5 (15.2%)	16 (48.5%)	10 (30.3%)	2 (6.1%)	33
Disseminated mycobacterium avium complex infection	0 (0.0%)	13 (39.4%)	19 (57.6%)	1 (3.0%)	33
Lactose intolerance	4 (12.1%)	6 (18.2%)	20 (60.6%)	3 (9.1%)	33
Ulcerative keratitis	4 (12.1%)	7 (21.2%)	17 (51.5%)	5 (15.2%)	33
Conjunctival haemorrhage	1 (3.0%)	5 (15.2%)	23 (69.7%)	4 (12.1%)	33
IgA nephropathy	6 (18.2%)	11 (33.3%)	15 (45.5%)	1 (3.0%)	33
Diverticulum intestinal	0 (0.0%)	0 (0.0%)	26 (78.8%)	7 (21.2%)	33
Abnormal sensation in eye	0 (0.0%)	3 (9.1%)	22 (66.7%)	8 (24.2%)	33
Ketosis	3 (9.1%)	6 (18.2%)	12 (36.4%)	12 (36.4%)	33
Gastrointestinal stromal tumour	2 (6.1%)	6 (18.2%)	22 (66.7%)	3 (9.1%)	33
Henoch-Schonlein purpura	6 (18.2%)	7 (21.2%)	17 (51.5%)	3 (9.1%)	33

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bezoar	2 (6.1%)	8 (24.2%)	19 (57.6%)	4 (12.1%)	33
Cervix carcinoma	0 (0.0%)	18 (54.5%)	13 (39.4%)	2 (6.1%)	33
Barrett's oesophagus	1 (3.0%)	5 (15.2%)	26 (78.8%)	1 (3.0%)	33
Glomerular filtration rate increased	2 (6.1%)	12 (36.4%)	15 (45.5%)	4 (12.1%)	33
Malignant pleural effusion	0 (0.0%)	6 (18.8%)	23 (71.9%)	3 (9.4%)	32
Pneumocystis jirovecii infection	0 (0.0%)	4 (12.5%)	23 (71.9%)	5 (15.6%)	32
Chronic fatigue syndrome	1 (3.1%)	19 (59.4%)	8 (25.0%)	4 (12.5%)	32
Skin wound	4 (12.5%)	10 (31.3%)	14 (43.8%)	4 (12.5%)	32
Large intestinal haemorrhage	2 (6.3%)	6 (18.8%)	15 (46.9%)	9 (28.1%)	32
Oxygen consumption increased	5 (15.6%)	4 (12.5%)	18 (56.3%)	5 (15.6%)	32
Migraine with aura	6 (18.8%)	11 (34.4%)	14 (43.8%)	1 (3.1%)	32
Oesophageal ulcer	4 (12.5%)	3 (9.4%)	20 (62.5%)	5 (15.6%)	32
Heart valve incompetence	5 (15.6%)	5 (15.6%)	15 (46.9%)	7 (21.9%)	32
Hepatitis B reactivation	1 (3.1%)	6 (18.8%)	17 (53.1%)	8 (25.0%)	32
Nephrectomy	1 (3.1%)	1 (3.1%)	23 (71.9%)	7 (21.9%)	32
Myopericarditis	8 (25.0%)	9 (28.1%)	8 (25.0%)	7 (21.9%)	32
Motion sickness	3 (9.4%)	13 (40.6%)	15 (46.9%)	1 (3.1%)	32
Weight gain poor	16 (50.0%)	6 (18.8%)	8 (25.0%)	2 (6.3%)	32
Brain herniation	4 (12.5%)	11 (34.4%)	14 (43.8%)	3 (9.4%)	32
Secondary immunodeficiency	10 (31.3%)	11 (34.4%)	11 (34.4%)	0 (0.0%)	32
Histoplasmosis disseminated	14 (43.8%)	9 (28.1%)	6 (18.8%)	3 (9.4%)	32
Bone density abnormal	2 (6.3%)	7 (21.9%)	23 (71.9%)	0 (0.0%)	32
Lip blister	4 (12.5%)	12 (37.5%)	11 (34.4%)	5 (15.6%)	32
Bladder neoplasm	0 (0.0%)	1 (3.1%)	21 (65.6%)	10 (31.3%)	32
Tumour pain	6 (18.8%)	6 (18.8%)	19 (59.4%)	1 (3.1%)	32
Hyperparathyroidism secondary	3 (9.4%)	10 (31.3%)	16 (50.0%)	3 (9.4%)	32
Schizoaffective disorder	2 (6.3%)	19 (59.4%)	11 (34.4%)	0 (0.0%)	32

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Social anxiety disorder	4 (12.5%)	24 (75.0%)	4 (12.5%)	0 (0.0%)	32
Microcytic anaemia	3 (9.4%)	6 (18.8%)	17 (53.1%)	6 (18.8%)	32
Cell death	4 (12.5%)	7 (21.9%)	17 (53.1%)	4 (12.5%)	32
Impetigo	12 (37.5%)	9 (28.1%)	9 (28.1%)	2 (6.3%)	32
Corneal disorder	2 (6.3%)	6 (18.8%)	14 (43.8%)	10 (31.3%)	32
Cystic fibrosis	9 (28.1%)	15 (46.9%)	8 (25.0%)	0 (0.0%)	32
Hypoglycaemic coma	0 (0.0%)	2 (6.3%)	13 (40.6%)	17 (53.1%)	32
Incorrect dose administered by product	1 (3.1%)	6 (18.8%)	14 (43.8%)	11 (34.4%)	32
Antipsychotic drug level increased	7 (21.9%)	18 (56.3%)	6 (18.8%)	1 (3.1%)	32
Foaming at mouth	7 (21.9%)	8 (25.0%)	15 (46.9%)	2 (6.3%)	32
Bacterial test positive	2 (6.3%)	10 (31.3%)	13 (40.6%)	7 (21.9%)	32
Gastrointestinal oedema	0 (0.0%)	16 (50.0%)	12 (37.5%)	4 (12.5%)	32
Escherichia sepsis	11 (34.4%)	1 (3.1%)	16 (50.0%)	4 (12.5%)	32
Haematocrit increased	2 (6.3%)	6 (18.8%)	22 (68.8%)	2 (6.3%)	32
White blood cell disorder	1 (3.1%)	3 (9.4%)	22 (68.8%)	6 (18.8%)	32
Psychomotor retardation	10 (31.3%)	8 (25.0%)	8 (25.0%)	6 (18.8%)	32
Pulmonary nocardiosis	0 (0.0%)	4 (12.5%)	28 (87.5%)	0 (0.0%)	32
Generalised bullous fixed drug eruption	1 (3.1%)	30 (93.8%)	1 (3.1%)	0 (0.0%)	32
Gastrointestinal obstruction	5 (15.6%)	4 (12.5%)	23 (71.9%)	0 (0.0%)	32
Central serous chorioretinopathy	1 (3.2%)	18 (58.1%)	11 (35.5%)	1 (3.2%)	31
Glomerular filtration rate abnormal	1 (3.2%)	7 (22.6%)	19 (61.3%)	4 (12.9%)	31
Pleural thickening	0 (0.0%)	7 (22.6%)	23 (74.2%)	1 (3.2%)	31
Pulmonary vasculitis	1 (3.2%)	0 (0.0%)	30 (96.8%)	0 (0.0%)	31
Eyelid irritation	5 (16.1%)	10 (32.3%)	12 (38.7%)	4 (12.9%)	31
Nephrogenic anaemia	1 (3.2%)	7 (22.6%)	14 (45.2%)	9 (29.0%)	31
Fear of death	0 (0.0%)	10 (32.3%)	15 (48.4%)	6 (19.4%)	31
Renal colic	0 (0.0%)	8 (25.8%)	22 (71.0%)	1 (3.2%)	31

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Amyloid related imaging abnormality-microhaemorrhages	0 (0.0%)	0 (0.0%)	13 (41.9%)	18 (58.1%)	31
Respiratory disorder neonatal	31 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	31
Hyperaemia	9 (29.0%)	6 (19.4%)	14 (45.2%)	2 (6.5%)	31
Accident at work	3 (9.7%)	13 (41.9%)	13 (41.9%)	2 (6.5%)	31
Aspartate aminotransferase abnormal	3 (9.7%)	4 (12.9%)	18 (58.1%)	6 (19.4%)	31
Pneumonia respiratory syncytial viral	11 (35.5%)	1 (3.2%)	17 (54.8%)	2 (6.5%)	31
Infective pulmonary exacerbation of cystic fibrosis	17 (54.8%)	9 (29.0%)	5 (16.1%)	0 (0.0%)	31
Hepatic mass	0 (0.0%)	5 (16.1%)	21 (67.7%)	5 (16.1%)	31
Sinus node dysfunction	0 (0.0%)	1 (3.2%)	16 (51.6%)	14 (45.2%)	31
Tongue haemorrhage	10 (32.3%)	2 (6.5%)	19 (61.3%)	0 (0.0%)	31
Rectal tenesmus	8 (25.8%)	13 (41.9%)	10 (32.3%)	0 (0.0%)	31
Drug detoxification	2 (6.5%)	22 (71.0%)	7 (22.6%)	0 (0.0%)	31
Periodontitis	0 (0.0%)	3 (9.7%)	22 (71.0%)	6 (19.4%)	31
Disease complication	2 (6.5%)	5 (16.1%)	13 (41.9%)	11 (35.5%)	31
Discharge	4 (12.9%)	9 (29.0%)	17 (54.8%)	1 (3.2%)	31
Perioral dermatitis	14 (45.2%)	12 (38.7%)	4 (12.9%)	1 (3.2%)	31
Catheter site haemorrhage	8 (25.8%)	10 (32.3%)	9 (29.0%)	4 (12.9%)	31
Retinal tear	1 (3.2%)	4 (12.9%)	25 (80.6%)	1 (3.2%)	31
Social problem	2 (6.5%)	12 (38.7%)	15 (48.4%)	2 (6.5%)	31
Kidney transplant rejection	8 (25.8%)	13 (41.9%)	9 (29.0%)	1 (3.2%)	31
Blood pressure inadequately controlled	0 (0.0%)	3 (9.7%)	24 (77.4%)	4 (12.9%)	31
Mycobacterium tuberculosis complex test positive	1 (3.2%)	11 (35.5%)	19 (61.3%)	0 (0.0%)	31
Stoma site hypergranulation	1 (3.2%)	1 (3.2%)	21 (67.7%)	8 (25.8%)	31
Ventricular septal defect	29 (93.5%)	1 (3.2%)	1 (3.2%)	0 (0.0%)	31
Hypomania	3 (9.7%)	12 (38.7%)	16 (51.6%)	0 (0.0%)	31
Blood HIV RNA increased	0 (0.0%)	22 (71.0%)	9 (29.0%)	0 (0.0%)	31
Galactorrhoea	19 (61.3%)	9 (29.0%)	2 (6.5%)	1 (3.2%)	31

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rheumatoid nodule	0 (0.0%)	11 (35.5%)	19 (61.3%)	1 (3.2%)	31
Pneumonia legionella	0 (0.0%)	6 (19.4%)	23 (74.2%)	2 (6.5%)	31
Substance use disorder	10 (32.3%)	17 (54.8%)	4 (12.9%)	0 (0.0%)	31
Crepitations	2 (6.5%)	7 (22.6%)	17 (54.8%)	5 (16.1%)	31
Eye oedema	2 (6.5%)	13 (41.9%)	15 (48.4%)	1 (3.2%)	31
Mean cell volume decreased	1 (3.2%)	18 (58.1%)	11 (35.5%)	1 (3.2%)	31
Coccydynia	1 (3.2%)	8 (25.8%)	20 (64.5%)	2 (6.5%)	31
Reaction to excipient	2 (6.5%)	9 (29.0%)	19 (61.3%)	1 (3.2%)	31
Hyperglycaemic hyperosmolar nonketotic syndrome	0 (0.0%)	1 (3.2%)	25 (80.6%)	5 (16.1%)	31
Retinal pigmentation	1 (3.2%)	14 (45.2%)	14 (45.2%)	2 (6.5%)	31
Intra-abdominal fluid collection	3 (9.7%)	8 (25.8%)	17 (54.8%)	3 (9.7%)	31
Exposure to chemical pollution	1 (3.2%)	4 (12.9%)	12 (38.7%)	14 (45.2%)	31
Vulvovaginal discomfort	1 (3.2%)	4 (12.9%)	24 (77.4%)	2 (6.5%)	31
Device connection issue	6 (19.4%)	3 (9.7%)	15 (48.4%)	7 (22.6%)	31
Monocyte percentage increased	3 (10.0%)	6 (20.0%)	18 (60.0%)	3 (10.0%)	30
Coronary artery stenosis	0 (0.0%)	6 (20.0%)	17 (56.7%)	7 (23.3%)	30
Normocytic anaemia	0 (0.0%)	4 (13.3%)	21 (70.0%)	5 (16.7%)	30
Pharyngeal disorder	3 (10.0%)	11 (36.7%)	13 (43.3%)	3 (10.0%)	30
Otitis externa	9 (30.0%)	6 (20.0%)	15 (50.0%)	0 (0.0%)	30
Rectal cancer	0 (0.0%)	4 (13.3%)	23 (76.7%)	3 (10.0%)	30
SARS-CoV-2 test negative	13 (43.3%)	7 (23.3%)	10 (33.3%)	0 (0.0%)	30
Eosinophilic pneumonia acute	1 (3.3%)	7 (23.3%)	16 (53.3%)	6 (20.0%)	30
Bronchial secretion retention	3 (10.0%)	1 (3.3%)	15 (50.0%)	11 (36.7%)	30
Cutaneous T-cell lymphoma	1 (3.3%)	9 (30.0%)	13 (43.3%)	7 (23.3%)	30
Cataplexy	1 (3.3%)	14 (46.7%)	2 (6.7%)	13 (43.3%)	30
Tongue blistering	1 (3.3%)	7 (23.3%)	17 (56.7%)	5 (16.7%)	30
Lung abscess	0 (0.0%)	9 (30.0%)	17 (56.7%)	4 (13.3%)	30

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Food aversion	3 (10.0%)	8 (26.7%)	13 (43.3%)	6 (20.0%)	30
Lip injury	8 (26.7%)	12 (40.0%)	9 (30.0%)	1 (3.3%)	30
Dependence	4 (13.3%)	15 (50.0%)	10 (33.3%)	1 (3.3%)	30
Stoma site reaction	1 (3.3%)	0 (0.0%)	24 (80.0%)	5 (16.7%)	30
Abdominal adhesions	2 (6.7%)	10 (33.3%)	17 (56.7%)	1 (3.3%)	30
Abscess intestinal	4 (13.3%)	15 (50.0%)	9 (30.0%)	2 (6.7%)	30
Coronavirus test positive	0 (0.0%)	8 (26.7%)	21 (70.0%)	1 (3.3%)	30
Crystal nephropathy	0 (0.0%)	1 (3.3%)	16 (53.3%)	13 (43.3%)	30
Terminal ileitis	3 (10.0%)	14 (46.7%)	13 (43.3%)	0 (0.0%)	30
Ileal ulcer	2 (6.7%)	17 (56.7%)	8 (26.7%)	3 (10.0%)	30
Virologic failure	5 (16.7%)	11 (36.7%)	14 (46.7%)	0 (0.0%)	30
Tonic clonic movements	1 (3.3%)	13 (43.3%)	8 (26.7%)	8 (26.7%)	30
Nasal septum deviation	3 (10.0%)	19 (63.3%)	8 (26.7%)	0 (0.0%)	30
Treatment delayed	3 (10.0%)	7 (23.3%)	17 (56.7%)	3 (10.0%)	30
Mast cell activation syndrome	5 (16.7%)	17 (56.7%)	8 (26.7%)	0 (0.0%)	30
Infectious mononucleosis	17 (56.7%)	10 (33.3%)	3 (10.0%)	0 (0.0%)	30
White coat hypertension	0 (0.0%)	3 (10.0%)	23 (76.7%)	4 (13.3%)	30
Procalcitonin increased	5 (16.7%)	6 (20.0%)	18 (60.0%)	1 (3.3%)	30
Gastrointestinal ulcer	3 (10.0%)	14 (46.7%)	11 (36.7%)	2 (6.7%)	30
Blood chloride increased	1 (3.3%)	8 (26.7%)	17 (56.7%)	4 (13.3%)	30
Change of bowel habit	3 (10.0%)	3 (10.0%)	21 (70.0%)	3 (10.0%)	30
Cerebral thrombosis	1 (3.3%)	8 (26.7%)	17 (56.7%)	4 (13.3%)	30
Tympanic membrane perforation	8 (26.7%)	11 (36.7%)	10 (33.3%)	1 (3.3%)	30
Carotid artery stenosis	1 (3.3%)	2 (6.7%)	17 (56.7%)	10 (33.3%)	30
Intra-abdominal haemorrhage	3 (10.0%)	12 (40.0%)	13 (43.3%)	2 (6.7%)	30
Blood sodium increased	2 (6.7%)	5 (16.7%)	17 (56.7%)	6 (20.0%)	30
Lymphocyte count abnormal	2 (6.7%)	8 (26.7%)	20 (66.7%)	0 (0.0%)	30

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Capillary leak syndrome	6 (20.0%)	5 (16.7%)	16 (53.3%)	3 (10.0%)	30
Urinary bladder haemorrhage	1 (3.3%)	2 (6.7%)	19 (63.3%)	8 (26.7%)	30
Dyschromatopsia	2 (6.7%)	7 (23.3%)	17 (56.7%)	4 (13.3%)	30
Hair disorder	0 (0.0%)	9 (30.0%)	14 (46.7%)	7 (23.3%)	30
Cryptococcosis	0 (0.0%)	5 (16.7%)	22 (73.3%)	3 (10.0%)	30
Latent tuberculosis	0 (0.0%)	14 (48.3%)	13 (44.8%)	2 (6.9%)	29
Chemotherapy	0 (0.0%)	5 (17.2%)	19 (65.5%)	5 (17.2%)	29
Myocardial injury	6 (20.7%)	4 (13.8%)	14 (48.3%)	5 (17.2%)	29
Addison's disease	1 (3.4%)	7 (24.1%)	16 (55.2%)	5 (17.2%)	29
Granulomatosis with polyangiitis	2 (6.9%)	8 (27.6%)	18 (62.1%)	1 (3.4%)	29
Faeces pale	1 (3.4%)	2 (6.9%)	20 (69.0%)	6 (20.7%)	29
Osteitis	2 (6.9%)	8 (27.6%)	18 (62.1%)	1 (3.4%)	29
Peripheral motor neuropathy	10 (34.5%)	0 (0.0%)	15 (51.7%)	4 (13.8%)	29
Calculus urinary	4 (13.8%)	8 (27.6%)	13 (44.8%)	4 (13.8%)	29
Bronchial disorder	3 (10.3%)	4 (13.8%)	20 (69.0%)	2 (6.9%)	29
Nosocomial infection	12 (41.4%)	3 (10.3%)	11 (37.9%)	3 (10.3%)	29
B-cell type acute leukaemia	7 (24.1%)	6 (20.7%)	16 (55.2%)	0 (0.0%)	29
Hostility	4 (13.8%)	4 (13.8%)	21 (72.4%)	0 (0.0%)	29
Bundle branch block left	0 (0.0%)	4 (13.8%)	15 (51.7%)	10 (34.5%)	29
Age-related macular degeneration	0 (0.0%)	7 (24.1%)	14 (48.3%)	8 (27.6%)	29
Skin induration	0 (0.0%)	7 (24.1%)	20 (69.0%)	2 (6.9%)	29
Diffuse alveolar damage	2 (6.9%)	2 (6.9%)	22 (75.9%)	3 (10.3%)	29
Lymphocyte adoptive therapy	0 (0.0%)	3 (10.3%)	25 (86.2%)	1 (3.4%)	29
Lung neoplasm	1 (3.4%)	1 (3.4%)	21 (72.4%)	6 (20.7%)	29
Radiation necrosis	2 (6.9%)	3 (10.3%)	18 (62.1%)	6 (20.7%)	29
Spleen disorder	5 (17.2%)	8 (27.6%)	15 (51.7%)	1 (3.4%)	29
Mastectomy	0 (0.0%)	10 (34.5%)	15 (51.7%)	4 (13.8%)	29

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Device loosening	2 (6.9%)	3 (10.3%)	20 (69.0%)	4 (13.8%)	29
Personality disorder	0 (0.0%)	3 (10.3%)	26 (89.7%)	0 (0.0%)	29
Gastrointestinal wall thickening	2 (6.9%)	10 (34.5%)	13 (44.8%)	4 (13.8%)	29
Subacute cutaneous lupus erythematosus	1 (3.4%)	6 (20.7%)	20 (69.0%)	2 (6.9%)	29
Vitamin B12 increased	1 (3.4%)	9 (31.0%)	14 (48.3%)	5 (17.2%)	29
Traumatic fracture	0 (0.0%)	5 (17.2%)	12 (41.4%)	12 (41.4%)	29
Walking disability	1 (3.4%)	6 (20.7%)	16 (55.2%)	6 (20.7%)	29
Subileus	6 (20.7%)	14 (48.3%)	8 (27.6%)	1 (3.4%)	29
Impulsive behaviour	17 (58.6%)	9 (31.0%)	3 (10.3%)	0 (0.0%)	29
Enterovirus infection	18 (62.1%)	8 (27.6%)	3 (10.3%)	0 (0.0%)	29
Anticholinergic syndrome	11 (37.9%)	4 (13.8%)	11 (37.9%)	3 (10.3%)	29
Antibiotic therapy	1 (3.4%)	4 (13.8%)	19 (65.5%)	5 (17.2%)	29
Brain operation	3 (10.3%)	6 (20.7%)	18 (62.1%)	2 (6.9%)	29
Allergic sinusitis	3 (10.3%)	5 (17.2%)	19 (65.5%)	2 (6.9%)	29
Nephrogenic diabetes insipidus	12 (41.4%)	7 (24.1%)	10 (34.5%)	0 (0.0%)	29
Oral mucosal erythema	5 (17.2%)	8 (27.6%)	14 (48.3%)	2 (6.9%)	29
Gastrointestinal necrosis	4 (13.8%)	8 (27.6%)	10 (34.5%)	7 (24.1%)	29
Prerenal failure	0 (0.0%)	1 (3.4%)	23 (79.3%)	5 (17.2%)	29
Bacterial disease carrier	6 (20.7%)	1 (3.4%)	13 (44.8%)	9 (31.0%)	29
Ventricular dysfunction	2 (6.9%)	9 (31.0%)	15 (51.7%)	3 (10.3%)	29
Cytokine storm	1 (3.4%)	3 (10.3%)	16 (55.2%)	9 (31.0%)	29
Choreoathetosis	9 (31.0%)	8 (27.6%)	6 (20.7%)	6 (20.7%)	29
Product packaging difficult to open	0 (0.0%)	1 (3.4%)	15 (51.7%)	13 (44.8%)	29
Glycosylated haemoglobin decreased	0 (0.0%)	3 (10.3%)	19 (65.5%)	7 (24.1%)	29
Ventricular hypokinesia	4 (13.8%)	4 (13.8%)	16 (55.2%)	5 (17.2%)	29
Oesophageal varices haemorrhage	2 (6.9%)	9 (31.0%)	17 (58.6%)	1 (3.4%)	29
Defaecation disorder	7 (24.1%)	8 (27.6%)	11 (37.9%)	3 (10.3%)	29

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Herpes ophthalmic	1 (3.6%)	6 (21.4%)	18 (64.3%)	3 (10.7%)	28
Hypercapnia	7 (25.0%)	4 (14.3%)	10 (35.7%)	7 (25.0%)	28
Renal mass	0 (0.0%)	1 (3.6%)	19 (67.9%)	8 (28.6%)	28
Chondropathy	0 (0.0%)	11 (39.3%)	13 (46.4%)	4 (14.3%)	28
Cytokine increased	1 (3.6%)	10 (35.7%)	17 (60.7%)	0 (0.0%)	28
Haemorrhagic diathesis	3 (10.7%)	1 (3.6%)	11 (39.3%)	13 (46.4%)	28
Infusion site infection	4 (14.3%)	12 (42.9%)	12 (42.9%)	0 (0.0%)	28
Nasal disorder	1 (3.6%)	11 (39.3%)	14 (50.0%)	2 (7.1%)	28
Torticollis	10 (35.7%)	7 (25.0%)	11 (39.3%)	0 (0.0%)	28
Tonsillar hypertrophy	17 (60.7%)	5 (17.9%)	6 (21.4%)	0 (0.0%)	28
Muscle strength abnormal	8 (28.6%)	6 (21.4%)	9 (32.1%)	5 (17.9%)	28
Emotional poverty	8 (28.6%)	18 (64.3%)	2 (7.1%)	0 (0.0%)	28
Seizure like phenomena	5 (17.9%)	5 (17.9%)	18 (64.3%)	0 (0.0%)	28
Brugada syndrome	11 (39.3%)	15 (53.6%)	2 (7.1%)	0 (0.0%)	28
Butterfly rash	3 (10.7%)	17 (60.7%)	8 (28.6%)	0 (0.0%)	28
Application site irritation	8 (28.6%)	10 (35.7%)	9 (32.1%)	1 (3.6%)	28
Disseminated tuberculosis	2 (7.1%)	6 (21.4%)	16 (57.1%)	4 (14.3%)	28
Spinal column injury	2 (7.1%)	3 (10.7%)	19 (67.9%)	4 (14.3%)	28
Spinal cord injury	2 (7.1%)	9 (32.1%)	12 (42.9%)	5 (17.9%)	28
Acute febrile neutrophilic dermatosis	1 (3.6%)	5 (17.9%)	20 (71.4%)	2 (7.1%)	28
Atrial thrombosis	3 (10.7%)	3 (10.7%)	11 (39.3%)	11 (39.3%)	28
Peripheral vascular disorder	1 (3.6%)	1 (3.6%)	21 (75.0%)	5 (17.9%)	28
Peritoneal dialysis complication	2 (7.1%)	8 (28.6%)	14 (50.0%)	4 (14.3%)	28
Large intestinal stenosis	9 (32.1%)	7 (25.0%)	8 (28.6%)	4 (14.3%)	28
Uterine perforation	2 (7.1%)	25 (89.3%)	1 (3.6%)	0 (0.0%)	28
Relapsing-remitting multiple sclerosis	1 (3.6%)	13 (46.4%)	14 (50.0%)	0 (0.0%)	28
White matter lesion	2 (7.1%)	10 (35.7%)	13 (46.4%)	3 (10.7%)	28

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Coronary arterial stent insertion	0 (0.0%)	1 (3.6%)	23 (82.1%)	4 (14.3%)	28
Ureterolithiasis	5 (17.9%)	4 (14.3%)	11 (39.3%)	8 (28.6%)	28
Blood calcium abnormal	0 (0.0%)	14 (50.0%)	13 (46.4%)	1 (3.6%)	28
Gastric polyps	1 (3.6%)	4 (14.3%)	21 (75.0%)	2 (7.1%)	28
Epstein-Barr viraemia	11 (39.3%)	10 (35.7%)	6 (21.4%)	1 (3.6%)	28
Post procedural swelling	4 (14.3%)	6 (21.4%)	18 (64.3%)	0 (0.0%)	28
Gastrointestinal stoma complication	5 (17.9%)	4 (14.3%)	11 (39.3%)	8 (28.6%)	28
Urine analysis abnormal	3 (10.7%)	8 (28.6%)	13 (46.4%)	4 (14.3%)	28
Reversible cerebral vasoconstriction syndrome	2 (7.1%)	18 (64.3%)	8 (28.6%)	0 (0.0%)	28
Restrictive pulmonary disease	6 (21.4%)	7 (25.0%)	13 (46.4%)	2 (7.1%)	28
Insulin resistance	9 (32.1%)	7 (25.0%)	11 (39.3%)	1 (3.6%)	28
Medical device site infection	9 (32.1%)	5 (17.9%)	12 (42.9%)	2 (7.1%)	28
Vertigo positional	0 (0.0%)	6 (21.4%)	17 (60.7%)	5 (17.9%)	28
Blood parathyroid hormone decreased	3 (10.7%)	4 (14.3%)	11 (39.3%)	10 (35.7%)	28
Cerebral venous thrombosis	15 (53.6%)	10 (35.7%)	3 (10.7%)	0 (0.0%)	28
Cerebral venous sinus thrombosis	14 (50.0%)	5 (17.9%)	8 (28.6%)	1 (3.6%)	28
Band sensation	0 (0.0%)	15 (53.6%)	13 (46.4%)	0 (0.0%)	28
Emergency care	8 (29.6%)	7 (25.9%)	9 (33.3%)	3 (11.1%)	27
Chronic cutaneous lupus erythematosus	0 (0.0%)	14 (51.9%)	12 (44.4%)	1 (3.7%)	27
Catheter site pain	7 (25.9%)	8 (29.6%)	11 (40.7%)	1 (3.7%)	27
Atypical femur fracture	0 (0.0%)	2 (7.4%)	20 (74.1%)	5 (18.5%)	27
Leg amputation	1 (3.7%)	3 (11.1%)	21 (77.8%)	2 (7.4%)	27
Laziness	5 (18.5%)	0 (0.0%)	15 (55.6%)	7 (25.9%)	27
Atypical haemolytic uraemic syndrome	5 (18.5%)	9 (33.3%)	11 (40.7%)	2 (7.4%)	27
Blood alkaline phosphatase abnormal	0 (0.0%)	2 (7.4%)	20 (74.1%)	5 (18.5%)	27
Osteosclerosis	0 (0.0%)	7 (25.9%)	16 (59.3%)	4 (14.8%)	27
Respiratory syncytial virus test positive	13 (48.1%)	2 (7.4%)	10 (37.0%)	2 (7.4%)	27

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Peptic ulcer	1 (3.7%)	10 (37.0%)	14 (51.9%)	2 (7.4%)	27
Ocular hypertension	7 (25.9%)	15 (55.6%)	4 (14.8%)	1 (3.7%)	27
Lip pain	2 (7.4%)	6 (22.2%)	14 (51.9%)	5 (18.5%)	27
Epicondylitis	0 (0.0%)	8 (29.6%)	16 (59.3%)	3 (11.1%)	27
Myocardial necrosis marker increased	5 (18.5%)	5 (18.5%)	13 (48.1%)	4 (14.8%)	27
Bronchitis chronic	1 (3.7%)	6 (22.2%)	13 (48.1%)	7 (25.9%)	27
Breast tenderness	5 (18.5%)	10 (37.0%)	9 (33.3%)	3 (11.1%)	27
Troponin T increased	5 (18.5%)	6 (22.2%)	10 (37.0%)	6 (22.2%)	27
Allergy to chemicals	4 (14.8%)	11 (40.7%)	9 (33.3%)	3 (11.1%)	27
Toe amputation	0 (0.0%)	7 (25.9%)	15 (55.6%)	5 (18.5%)	27
Mean platelet volume increased	1 (3.7%)	11 (40.7%)	11 (40.7%)	4 (14.8%)	27
Skin odour abnormal	3 (11.1%)	10 (37.0%)	11 (40.7%)	3 (11.1%)	27
Colorectal adenoma	0 (0.0%)	10 (37.0%)	14 (51.9%)	3 (11.1%)	27
Cartilage injury	1 (3.7%)	9 (33.3%)	16 (59.3%)	1 (3.7%)	27
Interleukin level increased	7 (25.9%)	6 (22.2%)	11 (40.7%)	3 (11.1%)	27
Long QT syndrome	0 (0.0%)	9 (33.3%)	9 (33.3%)	9 (33.3%)	27
Local anaesthetic systemic toxicity	8 (29.6%)	1 (3.7%)	18 (66.7%)	0 (0.0%)	27
Intrusive thoughts	4 (14.8%)	18 (66.7%)	4 (14.8%)	1 (3.7%)	27
Peripheral artery thrombosis	3 (11.1%)	6 (22.2%)	13 (48.1%)	5 (18.5%)	27
Appendicolith	0 (0.0%)	2 (7.4%)	0 (0.0%)	25 (92.6%)	27
Solar lentigo	1 (3.7%)	6 (22.2%)	16 (59.3%)	4 (14.8%)	27
Lymph node pain	4 (14.8%)	9 (33.3%)	12 (44.4%)	2 (7.4%)	27
Myopia	3 (11.1%)	9 (33.3%)	13 (48.1%)	2 (7.4%)	27
Kaposi's sarcoma	0 (0.0%)	10 (37.0%)	16 (59.3%)	1 (3.7%)	27
Still's disease	13 (48.1%)	11 (40.7%)	2 (7.4%)	1 (3.7%)	27
Invasive ductal breast carcinoma	0 (0.0%)	8 (29.6%)	18 (66.7%)	1 (3.7%)	27
Stress at work	3 (11.1%)	13 (48.1%)	11 (40.7%)	0 (0.0%)	27

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intestinal operation	4 (14.8%)	6 (22.2%)	14 (51.9%)	3 (11.1%)	27
Lack of administration site rotation	4 (14.8%)	3 (11.1%)	19 (70.4%)	1 (3.7%)	27
Renal haemorrhage	2 (7.4%)	7 (25.9%)	11 (40.7%)	7 (25.9%)	27
Coronary artery bypass	0 (0.0%)	0 (0.0%)	22 (81.5%)	5 (18.5%)	27
Polycystic ovaries	5 (18.5%)	4 (14.8%)	18 (66.7%)	0 (0.0%)	27
High density lipoprotein decreased	4 (14.8%)	12 (44.4%)	7 (25.9%)	4 (14.8%)	27
Blood electrolytes decreased	1 (3.7%)	2 (7.4%)	20 (74.1%)	4 (14.8%)	27
Investigation abnormal	2 (7.4%)	5 (18.5%)	19 (70.4%)	1 (3.7%)	27
Scleritis	1 (3.7%)	10 (37.0%)	13 (48.1%)	3 (11.1%)	27
Vanishing bile duct syndrome	1 (3.7%)	5 (18.5%)	14 (51.9%)	7 (25.9%)	27
Intestinal mass	1 (3.7%)	2 (7.4%)	13 (48.1%)	11 (40.7%)	27
Temporomandibular joint syndrome	3 (11.1%)	10 (37.0%)	11 (40.7%)	3 (11.1%)	27
Neuroendocrine tumour	1 (3.7%)	6 (22.2%)	17 (63.0%)	3 (11.1%)	27
Dysentery	1 (3.7%)	12 (44.4%)	10 (37.0%)	4 (14.8%)	27
Acne cystic	6 (22.2%)	19 (70.4%)	2 (7.4%)	0 (0.0%)	27
Pneumonia cryptococcal	0 (0.0%)	3 (11.5%)	21 (80.8%)	2 (7.7%)	26
Purulence	5 (19.2%)	5 (19.2%)	12 (46.2%)	4 (15.4%)	26
Spondyloarthropathy	1 (3.8%)	13 (50.0%)	11 (42.3%)	1 (3.8%)	26
Metabolic syndrome	5 (19.2%)	14 (53.8%)	7 (26.9%)	0 (0.0%)	26
Laryngospasm	5 (19.2%)	7 (26.9%)	13 (50.0%)	1 (3.8%)	26
Ovarian cancer recurrent	0 (0.0%)	6 (23.1%)	20 (76.9%)	0 (0.0%)	26
Complications of transplanted kidney	5 (19.2%)	6 (23.1%)	13 (50.0%)	2 (7.7%)	26
Echocardiogram abnormal	17 (65.4%)	6 (23.1%)	3 (11.5%)	0 (0.0%)	26
Pancreatic enzymes increased	2 (7.7%)	5 (19.2%)	12 (46.2%)	7 (26.9%)	26
Intellectual disability	16 (61.5%)	2 (7.7%)	8 (30.8%)	0 (0.0%)	26
Rectal discharge	2 (7.7%)	8 (30.8%)	11 (42.3%)	5 (19.2%)	26
Pancreatic cyst	1 (3.8%)	0 (0.0%)	18 (69.2%)	7 (26.9%)	26

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intentional device misuse	11 (42.3%)	4 (15.4%)	8 (30.8%)	3 (11.5%)	26
Pancreatitis chronic	1 (3.8%)	6 (23.1%)	13 (50.0%)	6 (23.1%)	26
Campylobacter infection	0 (0.0%)	7 (26.9%)	14 (53.8%)	5 (19.2%)	26
Exfoliative rash	6 (23.1%)	5 (19.2%)	14 (53.8%)	1 (3.8%)	26
Muscle contracture	3 (11.5%)	7 (26.9%)	13 (50.0%)	3 (11.5%)	26
Enterobacter infection	8 (30.8%)	6 (23.1%)	11 (42.3%)	1 (3.8%)	26
Mucosal disorder	2 (7.7%)	8 (30.8%)	12 (46.2%)	4 (15.4%)	26
Multi-organ disorder	2 (7.7%)	3 (11.5%)	16 (61.5%)	5 (19.2%)	26
Electrocardiogram ST segment depression	7 (26.9%)	0 (0.0%)	14 (53.8%)	5 (19.2%)	26
Social avoidant behaviour	6 (23.1%)	11 (42.3%)	6 (23.1%)	3 (11.5%)	26
Ejection fraction abnormal	1 (3.8%)	4 (15.4%)	20 (76.9%)	1 (3.8%)	26
Sinusitis bacterial	3 (11.5%)	8 (30.8%)	14 (53.8%)	1 (3.8%)	26
Drug-genetic interaction	12 (46.2%)	4 (15.4%)	8 (30.8%)	2 (7.7%)	26
Gastrointestinal carcinoma	1 (3.8%)	4 (15.4%)	11 (42.3%)	10 (38.5%)	26
Radiotherapy	0 (0.0%)	8 (30.8%)	11 (42.3%)	7 (26.9%)	26
Bone marrow transplant	3 (11.5%)	7 (26.9%)	16 (61.5%)	0 (0.0%)	26
Livedo reticularis	6 (23.1%)	7 (26.9%)	13 (50.0%)	0 (0.0%)	26
Hypercoagulation	5 (19.2%)	3 (11.5%)	13 (50.0%)	5 (19.2%)	26
Induration	4 (15.4%)	6 (23.1%)	16 (61.5%)	0 (0.0%)	26
Tunnel vision	4 (15.4%)	8 (30.8%)	13 (50.0%)	1 (3.8%)	26
Hyperparathyroidism	0 (0.0%)	9 (34.6%)	14 (53.8%)	3 (11.5%)	26
Pharyngeal oedema	1 (3.8%)	7 (26.9%)	17 (65.4%)	1 (3.8%)	26
Subdural haemorrhage	0 (0.0%)	2 (7.7%)	9 (34.6%)	15 (57.7%)	26
Fungaemia	10 (38.5%)	3 (11.5%)	12 (46.2%)	1 (3.8%)	26
Pituitary tumour benign	4 (15.4%)	11 (42.3%)	8 (30.8%)	3 (11.5%)	26
Hepatic infection	3 (11.5%)	8 (30.8%)	13 (50.0%)	2 (7.7%)	26
Paraplegia	1 (3.8%)	14 (53.8%)	8 (30.8%)	3 (11.5%)	26

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Illusion	4 (15.4%)	8 (30.8%)	10 (38.5%)	4 (15.4%)	26
Immune-mediated thyroiditis	0 (0.0%)	4 (15.4%)	17 (65.4%)	5 (19.2%)	26
Lymphadenopathy mediastinal	0 (0.0%)	8 (30.8%)	17 (65.4%)	1 (3.8%)	26
Focal segmental glomerulosclerosis	10 (38.5%)	5 (19.2%)	10 (38.5%)	1 (3.8%)	26
Blood alkaline phosphatase decreased	9 (34.6%)	8 (30.8%)	8 (30.8%)	1 (3.8%)	26
Trichorrhexis	2 (7.7%)	10 (38.5%)	12 (46.2%)	2 (7.7%)	26
Mantle cell lymphoma	0 (0.0%)	1 (3.8%)	25 (96.2%)	0 (0.0%)	26
Cerebellar syndrome	1 (3.8%)	0 (0.0%)	8 (30.8%)	17 (65.4%)	26
Infectious pleural effusion	2 (7.7%)	4 (15.4%)	14 (53.8%)	6 (23.1%)	26
Post herpetic neuralgia	0 (0.0%)	2 (7.7%)	23 (88.5%)	1 (3.8%)	26
Herpes simplex reactivation	1 (3.8%)	9 (34.6%)	16 (61.5%)	0 (0.0%)	26
Hepatitis toxic	2 (7.7%)	6 (23.1%)	17 (65.4%)	1 (3.8%)	26
Retroperitoneal haemorrhage	1 (3.8%)	4 (15.4%)	16 (61.5%)	5 (19.2%)	26
Red blood cell count abnormal	1 (3.8%)	3 (11.5%)	18 (69.2%)	4 (15.4%)	26
Dandruff	5 (19.2%)	11 (42.3%)	8 (30.8%)	2 (7.7%)	26
Basophil count increased	3 (11.5%)	5 (19.2%)	17 (65.4%)	1 (3.8%)	26
Arterial disorder	1 (3.8%)	5 (19.2%)	16 (61.5%)	4 (15.4%)	26
Extravasation	5 (19.2%)	6 (23.1%)	9 (34.6%)	6 (23.1%)	26
Hyporeflexia	2 (8.0%)	3 (12.0%)	20 (80.0%)	0 (0.0%)	25
Orthopnoea	4 (16.0%)	12 (48.0%)	8 (32.0%)	1 (4.0%)	25
Peripheral artery occlusion	0 (0.0%)	3 (12.0%)	17 (68.0%)	5 (20.0%)	25
Axial spondyloarthritis	3 (12.0%)	18 (72.0%)	4 (16.0%)	0 (0.0%)	25
Embolism venous	0 (0.0%)	6 (24.0%)	18 (72.0%)	1 (4.0%)	25
Perforation	1 (4.0%)	12 (48.0%)	12 (48.0%)	0 (0.0%)	25
Otorrhoea	10 (40.0%)	3 (12.0%)	11 (44.0%)	1 (4.0%)	25
Blood iron increased	5 (20.0%)	5 (20.0%)	13 (52.0%)	2 (8.0%)	25
Papilloma viral infection	2 (8.0%)	17 (68.0%)	6 (24.0%)	0 (0.0%)	25

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Wrong patient	0 (0.0%)	3 (12.0%)	4 (16.0%)	18 (72.0%)	25
Vascular stent thrombosis	0 (0.0%)	6 (24.0%)	13 (52.0%)	6 (24.0%)	25
Minimal residual disease	4 (16.0%)	6 (24.0%)	14 (56.0%)	1 (4.0%)	25
Optic neuropathy	1 (4.0%)	11 (44.0%)	9 (36.0%)	4 (16.0%)	25
Ejaculation disorder	1 (4.0%)	21 (84.0%)	2 (8.0%)	1 (4.0%)	25
Off label use of device	14 (56.0%)	8 (32.0%)	2 (8.0%)	1 (4.0%)	25
Acquired gene mutation	1 (4.0%)	2 (8.0%)	19 (76.0%)	3 (12.0%)	25
Lip disorder	2 (8.0%)	11 (44.0%)	10 (40.0%)	2 (8.0%)	25
Calcinosis	0 (0.0%)	5 (20.0%)	17 (68.0%)	3 (12.0%)	25
Coagulation time prolonged	0 (0.0%)	3 (12.0%)	15 (60.0%)	7 (28.0%)	25
Papillary thyroid cancer	2 (8.0%)	16 (64.0%)	6 (24.0%)	1 (4.0%)	25
Monocyte count decreased	1 (4.0%)	6 (24.0%)	16 (64.0%)	2 (8.0%)	25
Injection site oedema	7 (28.0%)	6 (24.0%)	11 (44.0%)	1 (4.0%)	25
Rubber sensitivity	0 (0.0%)	8 (32.0%)	16 (64.0%)	1 (4.0%)	25
Nasal injury	5 (20.0%)	7 (28.0%)	10 (40.0%)	3 (12.0%)	25
Mouth injury	3 (12.0%)	4 (16.0%)	15 (60.0%)	3 (12.0%)	25
Meniere's disease	3 (12.0%)	5 (20.0%)	17 (68.0%)	0 (0.0%)	25
Medical procedure	1 (4.0%)	7 (28.0%)	14 (56.0%)	3 (12.0%)	25
Cutaneous lupus erythematosus	1 (4.0%)	11 (44.0%)	8 (32.0%)	5 (20.0%)	25
Soft tissue injury	1 (4.0%)	7 (28.0%)	16 (64.0%)	1 (4.0%)	25
Rotator cuff repair	0 (0.0%)	0 (0.0%)	25 (100.0%)	0 (0.0%)	25
Seborrheic keratosis	0 (0.0%)	2 (8.0%)	20 (80.0%)	3 (12.0%)	25
Diabetic retinopathy	2 (8.0%)	2 (8.0%)	21 (84.0%)	0 (0.0%)	25
Diabetic neuropathy	0 (0.0%)	8 (32.0%)	15 (60.0%)	2 (8.0%)	25
Immune-mediated myasthenia gravis	0 (0.0%)	4 (16.0%)	13 (52.0%)	8 (32.0%)	25
Computerised tomogram abnormal	0 (0.0%)	4 (16.0%)	14 (56.0%)	7 (28.0%)	25
Infected skin ulcer	2 (8.0%)	8 (32.0%)	14 (56.0%)	1 (4.0%)	25

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Large intestinal obstruction	1 (4.0%)	12 (48.0%)	9 (36.0%)	3 (12.0%)	25
Klebsiella bacteraemia	4 (16.0%)	10 (40.0%)	7 (28.0%)	4 (16.0%)	25
Jugular vein thrombosis	6 (24.0%)	6 (24.0%)	9 (36.0%)	4 (16.0%)	25
Joint destruction	5 (20.0%)	3 (12.0%)	17 (68.0%)	0 (0.0%)	25
Increased viscosity of upper respiratory secretion	9 (36.0%)	6 (24.0%)	6 (24.0%)	4 (16.0%)	25
Viral mutation identified	0 (0.0%)	15 (60.0%)	10 (40.0%)	0 (0.0%)	25
Pulmonary granuloma	0 (0.0%)	10 (40.0%)	15 (60.0%)	0 (0.0%)	25
Sudden hearing loss	0 (0.0%)	7 (28.0%)	12 (48.0%)	6 (24.0%)	25
Traumatic lung injury	1 (4.0%)	2 (8.0%)	18 (72.0%)	4 (16.0%)	25
Pituitary apoplexy	1 (4.0%)	11 (44.0%)	9 (36.0%)	4 (16.0%)	25
Tachyphrenia	1 (4.0%)	15 (60.0%)	9 (36.0%)	0 (0.0%)	25
Tongue discolouration	1 (4.0%)	8 (32.0%)	11 (44.0%)	5 (20.0%)	25
Infusion site induration	3 (12.0%)	5 (20.0%)	13 (52.0%)	4 (16.0%)	25
Small intestinal stenosis	1 (4.0%)	14 (56.0%)	9 (36.0%)	1 (4.0%)	25
Therapeutic product effect prolonged	2 (8.0%)	6 (24.0%)	14 (56.0%)	3 (12.0%)	25
Stillbirth	5 (20.0%)	20 (80.0%)	0 (0.0%)	0 (0.0%)	25
Device kink	2 (8.0%)	8 (32.0%)	13 (52.0%)	2 (8.0%)	25
Xerosis	6 (24.0%)	9 (36.0%)	8 (32.0%)	2 (8.0%)	25
Asterixis	0 (0.0%)	4 (16.0%)	19 (76.0%)	2 (8.0%)	25
Accidental death	2 (8.0%)	12 (48.0%)	7 (28.0%)	4 (16.0%)	25
Stupor	2 (8.0%)	2 (8.0%)	14 (56.0%)	7 (28.0%)	25
Aortic valve stenosis	1 (4.0%)	1 (4.0%)	8 (32.0%)	15 (60.0%)	25
Soft tissue infection	1 (4.0%)	7 (28.0%)	15 (60.0%)	2 (8.0%)	25
Bipolar I disorder	7 (28.0%)	13 (52.0%)	5 (20.0%)	0 (0.0%)	25
Ankle operation	1 (4.0%)	9 (36.0%)	12 (48.0%)	3 (12.0%)	25
Wisdom teeth removal	12 (48.0%)	6 (24.0%)	7 (28.0%)	0 (0.0%)	25
Gastrointestinal viral infection	5 (20.0%)	10 (40.0%)	9 (36.0%)	1 (4.0%)	25

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Product contamination physical	9 (36.0%)	9 (36.0%)	4 (16.0%)	3 (12.0%)	25
Renal infarct	2 (8.0%)	5 (20.0%)	15 (60.0%)	3 (12.0%)	25
Weight loss poor	1 (4.0%)	12 (48.0%)	11 (44.0%)	1 (4.0%)	25
Pancreatic neoplasm	0 (0.0%)	3 (12.0%)	18 (72.0%)	4 (16.0%)	25
Mesothelioma	0 (0.0%)	1 (4.2%)	12 (50.0%)	11 (45.8%)	24
Cardioversion	0 (0.0%)	1 (4.2%)	15 (62.5%)	8 (33.3%)	24
Amyloidosis	2 (8.3%)	2 (8.3%)	11 (45.8%)	9 (37.5%)	24
Injection site cellulitis	3 (12.5%)	15 (62.5%)	5 (20.8%)	1 (4.2%)	24
Pancreatitis haemorrhagic	1 (4.2%)	0 (0.0%)	22 (91.7%)	1 (4.2%)	24
Cardiac hypertrophy	1 (4.2%)	9 (37.5%)	7 (29.2%)	7 (29.2%)	24
Blood immunoglobulin M decreased	1 (4.2%)	13 (54.2%)	10 (41.7%)	0 (0.0%)	24
Amyotrophic lateral sclerosis	0 (0.0%)	4 (16.7%)	17 (70.8%)	3 (12.5%)	24
Eyelid rash	11 (45.8%)	7 (29.2%)	6 (25.0%)	0 (0.0%)	24
Organ failure	1 (4.2%)	7 (29.2%)	9 (37.5%)	7 (29.2%)	24
Cystoid macular oedema	0 (0.0%)	8 (33.3%)	11 (45.8%)	5 (20.8%)	24
Resuscitation	5 (20.8%)	1 (4.2%)	17 (70.8%)	1 (4.2%)	24
Monkeypox	0 (0.0%)	15 (62.5%)	9 (37.5%)	0 (0.0%)	24
Lip erythema	6 (25.0%)	7 (29.2%)	9 (37.5%)	2 (8.3%)	24
Nipple pain	2 (8.3%)	4 (16.7%)	17 (70.8%)	1 (4.2%)	24
Vancomycin infusion reaction	2 (8.3%)	13 (54.2%)	7 (29.2%)	2 (8.3%)	24
Hypochloraemia	0 (0.0%)	9 (37.5%)	9 (37.5%)	6 (25.0%)	24
Application site burn	3 (12.5%)	12 (50.0%)	5 (20.8%)	4 (16.7%)	24
Pneumoperitoneum	1 (4.2%)	6 (25.0%)	14 (58.3%)	3 (12.5%)	24
Injection site dryness	5 (20.8%)	11 (45.8%)	7 (29.2%)	1 (4.2%)	24
Myofascial pain syndrome	1 (4.2%)	10 (41.7%)	13 (54.2%)	0 (0.0%)	24
Glomerulonephritis membranous	7 (29.2%)	5 (20.8%)	12 (50.0%)	0 (0.0%)	24
Dysbiosis	0 (0.0%)	12 (50.0%)	10 (41.7%)	2 (8.3%)	24

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Infusion site reaction	6 (25.0%)	3 (12.5%)	12 (50.0%)	3 (12.5%)	24
Ejection fraction	0 (0.0%)	2 (8.3%)	22 (91.7%)	0 (0.0%)	24
Antineutrophil cytoplasmic antibody positive	1 (4.2%)	3 (12.5%)	19 (79.2%)	1 (4.2%)	24
Metamorphopsia	3 (12.5%)	2 (8.3%)	11 (45.8%)	8 (33.3%)	24
Drug screen positive	4 (16.7%)	13 (54.2%)	7 (29.2%)	0 (0.0%)	24
Application site vesicles	8 (33.3%)	7 (29.2%)	7 (29.2%)	2 (8.3%)	24
Maternal exposure during delivery	7 (29.2%)	17 (70.8%)	0 (0.0%)	0 (0.0%)	24
Myelitis	2 (8.3%)	13 (54.2%)	9 (37.5%)	0 (0.0%)	24
Malignant catatonia	8 (33.3%)	8 (33.3%)	6 (25.0%)	2 (8.3%)	24
Magnetic resonance imaging abnormal	3 (12.5%)	11 (45.8%)	8 (33.3%)	2 (8.3%)	24
Small intestinal haemorrhage	1 (4.2%)	5 (20.8%)	12 (50.0%)	6 (25.0%)	24
Lymphocytosis	2 (8.3%)	2 (8.3%)	14 (58.3%)	6 (25.0%)	24
Bladder dysfunction	2 (8.3%)	13 (54.2%)	8 (33.3%)	1 (4.2%)	24
Macrocytosis	2 (8.3%)	3 (12.5%)	16 (66.7%)	3 (12.5%)	24
Alcoholism	2 (8.3%)	12 (50.0%)	8 (33.3%)	2 (8.3%)	24
Lipids increased	0 (0.0%)	7 (29.2%)	15 (62.5%)	2 (8.3%)	24
Infection reactivation	5 (20.8%)	10 (41.7%)	3 (12.5%)	6 (25.0%)	24
Seborrhoeic dermatitis	3 (12.5%)	11 (45.8%)	9 (37.5%)	1 (4.2%)	24
Dental implantation	0 (0.0%)	1 (4.2%)	19 (79.2%)	4 (16.7%)	24
Dark circles under eyes	7 (29.2%)	6 (25.0%)	9 (37.5%)	2 (8.3%)	24
Colorectal cancer	0 (0.0%)	9 (37.5%)	12 (50.0%)	3 (12.5%)	24
Hypochromic anaemia	1 (4.2%)	16 (66.7%)	6 (25.0%)	1 (4.2%)	24
Viral load increased	0 (0.0%)	13 (54.2%)	10 (41.7%)	1 (4.2%)	24
Glomerulonephritis rapidly progressive	1 (4.2%)	1 (4.2%)	19 (79.2%)	3 (12.5%)	24
Infected cyst	2 (8.3%)	9 (37.5%)	10 (41.7%)	3 (12.5%)	24
Psychogenic seizure	7 (29.2%)	12 (50.0%)	4 (16.7%)	1 (4.2%)	24
Blood chloride decreased	3 (12.5%)	5 (20.8%)	12 (50.0%)	4 (16.7%)	24

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Post procedural discomfort	8 (33.3%)	7 (29.2%)	8 (33.3%)	1 (4.2%)	24
Cerebellar infarction	1 (4.2%)	3 (12.5%)	14 (58.3%)	6 (25.0%)	24
Gastrointestinal bacterial infection	5 (20.8%)	8 (33.3%)	9 (37.5%)	2 (8.3%)	24
Cryptosporidiosis infection	1 (4.2%)	11 (45.8%)	12 (50.0%)	0 (0.0%)	24
Rhonchi	2 (8.3%)	9 (37.5%)	11 (45.8%)	2 (8.3%)	24
Pseudomeningocele	0 (0.0%)	6 (25.0%)	18 (75.0%)	0 (0.0%)	24
Testicular atrophy	5 (20.8%)	15 (62.5%)	4 (16.7%)	0 (0.0%)	24
Injection site paraesthesia	4 (16.7%)	12 (50.0%)	7 (29.2%)	1 (4.2%)	24
Cerebrospinal fistula	0 (0.0%)	6 (25.0%)	18 (75.0%)	0 (0.0%)	24
Hand-foot-and-mouth disease	12 (50.0%)	9 (37.5%)	3 (12.5%)	0 (0.0%)	24
Gestational diabetes	4 (16.7%)	20 (83.3%)	0 (0.0%)	0 (0.0%)	24
Blood parathyroid hormone increased	2 (8.3%)	5 (20.8%)	14 (58.3%)	3 (12.5%)	24
Immune-mediated renal disorder	0 (0.0%)	3 (12.5%)	15 (62.5%)	6 (25.0%)	24
Non-small cell lung cancer metastatic	0 (0.0%)	4 (16.7%)	18 (75.0%)	2 (8.3%)	24
Bacillus infection	6 (26.1%)	4 (17.4%)	12 (52.2%)	1 (4.3%)	23
Oral fungal infection	1 (4.3%)	6 (26.1%)	14 (60.9%)	2 (8.7%)	23
Pupil fixed	8 (34.8%)	11 (47.8%)	4 (17.4%)	0 (0.0%)	23
Graft versus host disease in liver	3 (13.0%)	8 (34.8%)	10 (43.5%)	2 (8.7%)	23
Catheter site erythema	12 (52.2%)	4 (17.4%)	7 (30.4%)	0 (0.0%)	23
Eyelid disorder	1 (4.3%)	4 (17.4%)	15 (65.2%)	3 (13.0%)	23
Connective tissue disorder	1 (4.3%)	10 (43.5%)	7 (30.4%)	5 (21.7%)	23
Cardiac infection	10 (43.5%)	0 (0.0%)	10 (43.5%)	3 (13.0%)	23
Haemolytic uraemic syndrome	1 (4.3%)	3 (13.0%)	18 (78.3%)	1 (4.3%)	23
Polycythaemia vera	0 (0.0%)	4 (17.4%)	17 (73.9%)	2 (8.7%)	23
Ectopic pregnancy with contraceptive device	7 (30.4%)	16 (69.6%)	0 (0.0%)	0 (0.0%)	23
Suspected drug-induced liver injury	1 (4.3%)	2 (8.7%)	17 (73.9%)	3 (13.0%)	23
Urine ketone body present	2 (8.7%)	9 (39.1%)	10 (43.5%)	2 (8.7%)	23

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Biliary dilatation	3 (13.0%)	5 (21.7%)	14 (60.9%)	1 (4.3%)	23
Bronchial obstruction	9 (39.1%)	3 (13.0%)	9 (39.1%)	2 (8.7%)	23
Eosinophilic myocarditis	1 (4.3%)	15 (65.2%)	7 (30.4%)	0 (0.0%)	23
Neoplasm skin	2 (8.7%)	1 (4.3%)	17 (73.9%)	3 (13.0%)	23
Pulmonary cavitation	0 (0.0%)	15 (65.2%)	7 (30.4%)	1 (4.3%)	23
Subretinal fluid	1 (4.3%)	0 (0.0%)	15 (65.2%)	7 (30.4%)	23
Tongue dry	0 (0.0%)	5 (21.7%)	9 (39.1%)	9 (39.1%)	23
Embolia cutis medicamentosa	0 (0.0%)	16 (69.6%)	7 (30.4%)	0 (0.0%)	23
Drug specific antibody	11 (47.8%)	10 (43.5%)	2 (8.7%)	0 (0.0%)	23
Drug monitoring procedure not performed	1 (4.3%)	6 (26.1%)	11 (47.8%)	5 (21.7%)	23
Malignant melanoma in situ	0 (0.0%)	2 (8.7%)	4 (17.4%)	17 (73.9%)	23
Application site haemorrhage	1 (4.3%)	4 (17.4%)	14 (60.9%)	4 (17.4%)	23
Disability assessment scale score increased	0 (0.0%)	12 (52.2%)	11 (47.8%)	0 (0.0%)	23
Linear IgA disease	1 (4.3%)	14 (60.9%)	7 (30.4%)	1 (4.3%)	23
Hypereosinophilic syndrome	1 (4.3%)	1 (4.3%)	11 (47.8%)	10 (43.5%)	23
Device dispensing error	9 (39.1%)	5 (21.7%)	6 (26.1%)	3 (13.0%)	23
Kidney fibrosis	2 (8.7%)	1 (4.3%)	18 (78.3%)	2 (8.7%)	23
Depersonalisation/derealisation disorder	6 (26.1%)	13 (56.5%)	4 (17.4%)	0 (0.0%)	23
Blood pressure immeasurable	1 (4.3%)	7 (30.4%)	14 (60.9%)	1 (4.3%)	23
Strongyloidiasis	1 (4.3%)	6 (26.1%)	16 (69.6%)	0 (0.0%)	23
Immune-mediated cholangitis	0 (0.0%)	2 (8.7%)	16 (69.6%)	5 (21.7%)	23
Superinfection	6 (26.1%)	2 (8.7%)	4 (17.4%)	11 (47.8%)	23
Ophthalmic migraine	1 (4.3%)	7 (30.4%)	12 (52.2%)	3 (13.0%)	23
Piloerection	1 (4.3%)	12 (52.2%)	9 (39.1%)	1 (4.3%)	23
Amaurosis	1 (4.3%)	9 (39.1%)	11 (47.8%)	2 (8.7%)	23
Anorgasmia	6 (26.1%)	14 (60.9%)	3 (13.0%)	0 (0.0%)	23
Injection site hypoaesthesia	3 (13.0%)	12 (52.2%)	6 (26.1%)	2 (8.7%)	23

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Colostomy	2 (8.7%)	4 (17.4%)	16 (69.6%)	1 (4.3%)	23
Necrotising myositis	0 (0.0%)	2 (8.7%)	19 (82.6%)	2 (8.7%)	23
Glucose urine present	0 (0.0%)	5 (21.7%)	14 (60.9%)	4 (17.4%)	23
Pneumonia pneumococcal	2 (8.7%)	4 (17.4%)	15 (65.2%)	2 (8.7%)	23
Throat cancer	0 (0.0%)	0 (0.0%)	18 (78.3%)	5 (21.7%)	23
CD4 lymphocytes decreased	1 (4.3%)	7 (30.4%)	13 (56.5%)	2 (8.7%)	23
Small fibre neuropathy	3 (13.0%)	12 (52.2%)	7 (30.4%)	1 (4.3%)	23
Precancerous skin lesion	0 (0.0%)	3 (13.0%)	13 (56.5%)	7 (30.4%)	23
Pseudomonal sepsis	7 (30.4%)	2 (8.7%)	12 (52.2%)	2 (8.7%)	23
Gingival recession	1 (4.3%)	10 (43.5%)	9 (39.1%)	3 (13.0%)	23
Electric shock	2 (8.7%)	10 (43.5%)	9 (39.1%)	2 (8.7%)	23
Retinal disorder	1 (4.3%)	0 (0.0%)	12 (52.2%)	10 (43.5%)	23
Occult blood positive	1 (4.3%)	3 (13.0%)	16 (69.6%)	3 (13.0%)	23
Essential hypertension	0 (0.0%)	5 (21.7%)	9 (39.1%)	9 (39.1%)	23
Product selection error	8 (34.8%)	6 (26.1%)	5 (21.7%)	4 (17.4%)	23
Cervical dysplasia	3 (13.0%)	11 (47.8%)	8 (34.8%)	1 (4.3%)	23
Retinal vasculitis	3 (13.0%)	4 (17.4%)	12 (52.2%)	4 (17.4%)	23
Megacolon	4 (17.4%)	8 (34.8%)	8 (34.8%)	3 (13.0%)	23
Vocal cord paralysis	0 (0.0%)	6 (26.1%)	12 (52.2%)	5 (21.7%)	23
Intercepted product storage error	4 (17.4%)	4 (17.4%)	11 (47.8%)	4 (17.4%)	23
Adhesion	5 (22.7%)	4 (18.2%)	11 (50.0%)	2 (9.1%)	22
Atrophy	1 (4.5%)	5 (22.7%)	15 (68.2%)	1 (4.5%)	22
Catheter site swelling	5 (22.7%)	6 (27.3%)	11 (50.0%)	0 (0.0%)	22
Cardiac ablation	1 (4.5%)	0 (0.0%)	15 (68.2%)	6 (27.3%)	22
Reading disorder	5 (22.7%)	3 (13.6%)	8 (36.4%)	6 (27.3%)	22
Catarrh	4 (18.2%)	5 (22.7%)	13 (59.1%)	0 (0.0%)	22
Familial mediterranean fever	5 (22.7%)	11 (50.0%)	5 (22.7%)	1 (4.5%)	22

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Breast swelling	1 (4.5%)	7 (31.8%)	11 (50.0%)	3 (13.6%)	22
Vasodilatation	0 (0.0%)	6 (27.3%)	12 (54.5%)	4 (18.2%)	22
Osteoporotic fracture	1 (4.5%)	5 (22.7%)	12 (54.5%)	4 (18.2%)	22
Hepatitis fulminant	0 (0.0%)	8 (36.4%)	9 (40.9%)	5 (22.7%)	22
Hallucination, tactile	1 (4.5%)	9 (40.9%)	6 (27.3%)	6 (27.3%)	22
Pancreatic neuroendocrine tumour	0 (0.0%)	9 (40.9%)	13 (59.1%)	0 (0.0%)	22
Intercepted product prescribing error	1 (4.5%)	2 (9.1%)	14 (63.6%)	5 (22.7%)	22
Retinal degeneration	2 (9.1%)	7 (31.8%)	11 (50.0%)	2 (9.1%)	22
Enterocolitis haemorrhagic	1 (4.5%)	4 (18.2%)	11 (50.0%)	6 (27.3%)	22
Endodontic procedure	2 (9.1%)	4 (18.2%)	14 (63.6%)	2 (9.1%)	22
Uterine disorder	0 (0.0%)	12 (54.5%)	9 (40.9%)	1 (4.5%)	22
Muscle discomfort	1 (4.5%)	7 (31.8%)	13 (59.1%)	1 (4.5%)	22
Intestinal fistula	2 (9.1%)	14 (63.6%)	5 (22.7%)	1 (4.5%)	22
Spinal cord disorder	1 (4.5%)	8 (36.4%)	12 (54.5%)	1 (4.5%)	22
Monoclonal immunoglobulin present	0 (0.0%)	0 (0.0%)	11 (50.0%)	11 (50.0%)	22
Breath odour	4 (18.2%)	1 (4.5%)	13 (59.1%)	4 (18.2%)	22
Arterial thrombosis	1 (4.5%)	5 (22.7%)	11 (50.0%)	5 (22.7%)	22
Breast disorder	0 (0.0%)	9 (40.9%)	11 (50.0%)	2 (9.1%)	22
Bowen's disease	0 (0.0%)	6 (27.3%)	7 (31.8%)	9 (40.9%)	22
Lymphocyte percentage decreased	1 (4.5%)	4 (18.2%)	14 (63.6%)	3 (13.6%)	22
Bone marrow oedema	1 (4.5%)	10 (45.5%)	11 (50.0%)	0 (0.0%)	22
Myelopathy	0 (0.0%)	5 (22.7%)	14 (63.6%)	3 (13.6%)	22
Pharyngeal haemorrhage	4 (18.2%)	5 (22.7%)	9 (40.9%)	4 (18.2%)	22
Lymphadenectomy	4 (18.2%)	3 (13.6%)	11 (50.0%)	4 (18.2%)	22
Bladder spasm	1 (4.5%)	8 (36.4%)	11 (50.0%)	2 (9.1%)	22
Language disorder	8 (36.4%)	7 (31.8%)	4 (18.2%)	3 (13.6%)	22
Kyphosis	2 (9.1%)	4 (18.2%)	13 (59.1%)	3 (13.6%)	22

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Dermatitis diaper	20 (90.9%)	1 (4.5%)	1 (4.5%)	0 (0.0%)	22
Blood growth hormone increased	4 (18.2%)	8 (36.4%)	10 (45.5%)	0 (0.0%)	22
Dementia with Lewy bodies	0 (0.0%)	1 (4.5%)	14 (63.6%)	7 (31.8%)	22
Adverse food reaction	1 (4.5%)	4 (18.2%)	13 (59.1%)	4 (18.2%)	22
Hypersexuality	7 (31.8%)	10 (45.5%)	4 (18.2%)	1 (4.5%)	22
Decompensated hypothyroidism	9 (40.9%)	3 (13.6%)	9 (40.9%)	1 (4.5%)	22
Blast cell count increased	3 (13.6%)	3 (13.6%)	9 (40.9%)	7 (31.8%)	22
Blood bilirubin abnormal	3 (13.6%)	3 (13.6%)	13 (59.1%)	3 (13.6%)	22
Enteritis infectious	1 (4.5%)	6 (27.3%)	10 (45.5%)	5 (22.7%)	22
Cardiac ventricular thrombosis	1 (4.5%)	2 (9.1%)	15 (68.2%)	4 (18.2%)	22
Fungal foot infection	0 (0.0%)	1 (4.5%)	15 (68.2%)	6 (27.3%)	22
Antiphospholipid syndrome	3 (13.6%)	11 (50.0%)	8 (36.4%)	0 (0.0%)	22
Gastrointestinal injury	1 (4.5%)	8 (36.4%)	10 (45.5%)	3 (13.6%)	22
Ultrafiltration failure	1 (4.5%)	9 (40.9%)	10 (45.5%)	2 (9.1%)	22
Tonsillectomy	10 (45.5%)	10 (45.5%)	2 (9.1%)	0 (0.0%)	22
Hirsutism	3 (13.6%)	11 (50.0%)	8 (36.4%)	0 (0.0%)	22
Gallbladder enlargement	3 (13.6%)	2 (9.1%)	11 (50.0%)	6 (27.3%)	22
Heat stroke	0 (0.0%)	7 (31.8%)	14 (63.6%)	1 (4.5%)	22
Adjustment disorder	3 (13.6%)	1 (4.5%)	15 (68.2%)	3 (13.6%)	22
Sick leave	2 (9.1%)	12 (54.5%)	8 (36.4%)	0 (0.0%)	22
Non-cardiac chest pain	1 (4.5%)	6 (27.3%)	14 (63.6%)	1 (4.5%)	22
Noninfective encephalitis	6 (27.3%)	8 (36.4%)	6 (27.3%)	2 (9.1%)	22
Calciphylaxis	0 (0.0%)	5 (22.7%)	13 (59.1%)	4 (18.2%)	22
Alcohol abuse	2 (9.1%)	13 (59.1%)	6 (27.3%)	1 (4.5%)	22
Renal vein thrombosis	1 (4.5%)	7 (31.8%)	14 (63.6%)	0 (0.0%)	22
Lymphangiosis carcinomatosa	0 (0.0%)	4 (18.2%)	15 (68.2%)	3 (13.6%)	22
Product reconstitution quality issue	11 (50.0%)	4 (18.2%)	6 (27.3%)	1 (4.5%)	22

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intestinal ulcer	1 (4.5%)	5 (22.7%)	15 (68.2%)	1 (4.5%)	22
Mycobacterium abscessus infection	1 (4.5%)	10 (45.5%)	9 (40.9%)	2 (9.1%)	22
Carbon dioxide decreased	4 (19.0%)	3 (14.3%)	12 (57.1%)	2 (9.5%)	21
Palmoplantar pustulosis	0 (0.0%)	4 (19.0%)	16 (76.2%)	1 (4.8%)	21
Oropharyngeal blistering	2 (9.5%)	2 (9.5%)	17 (81.0%)	0 (0.0%)	21
Infusion site irritation	3 (14.3%)	7 (33.3%)	7 (33.3%)	4 (19.0%)	21
Metastases to pelvis	0 (0.0%)	5 (23.8%)	13 (61.9%)	3 (14.3%)	21
Splenic infarction	1 (4.8%)	5 (23.8%)	8 (38.1%)	7 (33.3%)	21
Early satiety	1 (4.8%)	10 (47.6%)	10 (47.6%)	0 (0.0%)	21
Rectal prolapse	0 (0.0%)	5 (23.8%)	11 (52.4%)	5 (23.8%)	21
Haemophilus infection	4 (19.0%)	7 (33.3%)	9 (42.9%)	1 (4.8%)	21
Eczema eyelids	6 (28.6%)	9 (42.9%)	4 (19.0%)	2 (9.5%)	21
Painful respiration	2 (9.5%)	5 (23.8%)	13 (61.9%)	1 (4.8%)	21
Lip discolouration	7 (33.3%)	4 (19.0%)	6 (28.6%)	4 (19.0%)	21
Escherichia test positive	3 (14.3%)	2 (9.5%)	12 (57.1%)	4 (19.0%)	21
Lymphoma transformation	0 (0.0%)	5 (23.8%)	14 (66.7%)	2 (9.5%)	21
Acquired haemophilia	0 (0.0%)	12 (57.1%)	5 (23.8%)	4 (19.0%)	21
Paresis	1 (4.8%)	5 (23.8%)	11 (52.4%)	4 (19.0%)	21
Seborrhoea	4 (19.0%)	10 (47.6%)	7 (33.3%)	0 (0.0%)	21
Diverticular perforation	0 (0.0%)	6 (28.6%)	8 (38.1%)	7 (33.3%)	21
Mycobacterial infection	1 (4.8%)	5 (23.8%)	12 (57.1%)	3 (14.3%)	21
Empyema	0 (0.0%)	9 (42.9%)	9 (42.9%)	3 (14.3%)	21
Urine protein/creatinine ratio increased	3 (14.3%)	12 (57.1%)	5 (23.8%)	1 (4.8%)	21
Acarodermatitis	4 (19.0%)	5 (23.8%)	8 (38.1%)	4 (19.0%)	21
Metastatic malignant melanoma	0 (0.0%)	8 (38.1%)	9 (42.9%)	4 (19.0%)	21
Carotid artery occlusion	0 (0.0%)	0 (0.0%)	17 (81.0%)	4 (19.0%)	21
Drug clearance decreased	12 (57.1%)	1 (4.8%)	8 (38.1%)	0 (0.0%)	21

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Somatic symptom disorder	1 (4.8%)	14 (66.7%)	3 (14.3%)	3 (14.3%)	21
Blood culture positive	2 (9.5%)	5 (23.8%)	9 (42.9%)	5 (23.8%)	21
Blood thyroid stimulating hormone abnormal	0 (0.0%)	8 (38.1%)	8 (38.1%)	5 (23.8%)	21
Kidney enlargement	4 (19.0%)	10 (47.6%)	7 (33.3%)	0 (0.0%)	21
Joint instability	1 (4.8%)	9 (42.9%)	10 (47.6%)	1 (4.8%)	21
Blood pressure measurement	0 (0.0%)	11 (52.4%)	8 (38.1%)	2 (9.5%)	21
Phaeochromocytoma	0 (0.0%)	7 (33.3%)	14 (66.7%)	0 (0.0%)	21
Injection site abscess	5 (23.8%)	9 (42.9%)	6 (28.6%)	1 (4.8%)	21
Vital functions abnormal	4 (19.0%)	3 (14.3%)	12 (57.1%)	2 (9.5%)	21
Physical disability	1 (4.8%)	6 (28.6%)	12 (57.1%)	2 (9.5%)	21
Vascular pain	3 (14.3%)	9 (42.9%)	5 (23.8%)	4 (19.0%)	21
Pituitary tumour	0 (0.0%)	10 (47.6%)	9 (42.9%)	2 (9.5%)	21
Diverticulum intestinal haemorrhagic	0 (0.0%)	2 (9.5%)	5 (23.8%)	14 (66.7%)	21
Tooth discolouration	1 (4.8%)	9 (42.9%)	10 (47.6%)	1 (4.8%)	21
Daydreaming	2 (9.5%)	1 (4.8%)	12 (57.1%)	6 (28.6%)	21
Behcet's syndrome	1 (4.8%)	4 (19.0%)	14 (66.7%)	2 (9.5%)	21
Thyroidectomy	0 (0.0%)	7 (33.3%)	12 (57.1%)	2 (9.5%)	21
Immune-mediated nephritis	2 (9.5%)	2 (9.5%)	16 (76.2%)	1 (4.8%)	21
Ulna fracture	1 (4.8%)	5 (23.8%)	10 (47.6%)	5 (23.8%)	21
Cerebellar haemorrhage	2 (9.5%)	1 (4.8%)	11 (52.4%)	7 (33.3%)	21
Staphylococcal skin infection	1 (4.8%)	11 (52.4%)	8 (38.1%)	1 (4.8%)	21
Administration site pain	3 (14.3%)	12 (57.1%)	6 (28.6%)	0 (0.0%)	21
Gastrostomy	11 (52.4%)	2 (9.5%)	5 (23.8%)	3 (14.3%)	21
Respiratory tract infection bacterial	3 (14.3%)	7 (33.3%)	11 (52.4%)	0 (0.0%)	21
Respiratory syncytial virus bronchiolitis	20 (95.2%)	1 (4.8%)	0 (0.0%)	0 (0.0%)	21
Retinal oedema	0 (0.0%)	3 (14.3%)	12 (57.1%)	6 (28.6%)	21
Protein total abnormal	0 (0.0%)	5 (23.8%)	14 (66.7%)	2 (9.5%)	21

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Genital pain	4 (19.0%)	7 (33.3%)	7 (33.3%)	3 (14.3%)	21
Protein urine	1 (4.8%)	4 (19.0%)	15 (71.4%)	1 (4.8%)	21
Giant cell arteritis	0 (0.0%)	0 (0.0%)	7 (33.3%)	14 (66.7%)	21
Prolonged expiration	3 (14.3%)	1 (4.8%)	17 (81.0%)	0 (0.0%)	21
Product delivery mechanism issue	0 (0.0%)	1 (4.8%)	12 (57.1%)	8 (38.1%)	21
Gastrointestinal tract irritation	2 (9.5%)	4 (19.0%)	11 (52.4%)	4 (19.0%)	21
Analgesic drug level increased	15 (71.4%)	1 (4.8%)	5 (23.8%)	0 (0.0%)	21
Abdominal wall abscess	10 (47.6%)	5 (23.8%)	6 (28.6%)	0 (0.0%)	21
Post-traumatic neck syndrome	0 (0.0%)	6 (28.6%)	14 (66.7%)	1 (4.8%)	21
Central obesity	2 (10.0%)	15 (75.0%)	3 (15.0%)	0 (0.0%)	20
Gastric dilatation	1 (5.0%)	8 (40.0%)	9 (45.0%)	2 (10.0%)	20
Gastric bypass	0 (0.0%)	7 (35.0%)	13 (65.0%)	0 (0.0%)	20
Central hypothyroidism	7 (35.0%)	0 (0.0%)	13 (65.0%)	0 (0.0%)	20
Anal inflammation	13 (65.0%)	0 (0.0%)	6 (30.0%)	1 (5.0%)	20
Pulpitis dental	1 (5.0%)	14 (70.0%)	5 (25.0%)	0 (0.0%)	20
Pharyngeal abscess	12 (60.0%)	2 (10.0%)	6 (30.0%)	0 (0.0%)	20
Cytomegalovirus test positive	3 (15.0%)	2 (10.0%)	12 (60.0%)	3 (15.0%)	20
Perfume sensitivity	3 (15.0%)	8 (40.0%)	9 (45.0%)	0 (0.0%)	20
Periodontal disease	0 (0.0%)	1 (5.0%)	18 (90.0%)	1 (5.0%)	20
Abdominal wall haematoma	1 (5.0%)	1 (5.0%)	14 (70.0%)	4 (20.0%)	20
Fear of falling	0 (0.0%)	5 (25.0%)	10 (50.0%)	5 (25.0%)	20
Cytomegalovirus enterocolitis	0 (0.0%)	2 (10.0%)	11 (55.0%)	7 (35.0%)	20
Orchitis	0 (0.0%)	5 (25.0%)	15 (75.0%)	0 (0.0%)	20
Mitral valve prolapse	5 (25.0%)	7 (35.0%)	6 (30.0%)	2 (10.0%)	20
Haemothorax	0 (0.0%)	4 (20.0%)	8 (40.0%)	8 (40.0%)	20
Oligomenorrhoea	4 (20.0%)	15 (75.0%)	1 (5.0%)	0 (0.0%)	20
Enterococcal bacteraemia	2 (10.0%)	7 (35.0%)	10 (50.0%)	1 (5.0%)	20

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Arthrodesis	3 (15.0%)	4 (20.0%)	12 (60.0%)	1 (5.0%)	20
Hepatitis E	2 (10.0%)	7 (35.0%)	8 (40.0%)	3 (15.0%)	20
Allergy to plants	1 (5.0%)	5 (25.0%)	13 (65.0%)	1 (5.0%)	20
Drug dose titration not performed	3 (15.0%)	11 (55.0%)	4 (20.0%)	2 (10.0%)	20
Glioblastoma	1 (5.0%)	4 (20.0%)	13 (65.0%)	2 (10.0%)	20
Ureteric obstruction	3 (15.0%)	3 (15.0%)	12 (60.0%)	2 (10.0%)	20
Macular hole	1 (5.0%)	5 (25.0%)	9 (45.0%)	5 (25.0%)	20
Homicidal ideation	3 (15.0%)	13 (65.0%)	4 (20.0%)	0 (0.0%)	20
Histoplasmosis	2 (10.0%)	8 (40.0%)	10 (50.0%)	0 (0.0%)	20
Lung cancer metastatic	0 (0.0%)	2 (10.0%)	13 (65.0%)	5 (25.0%)	20
Diplegia	1 (5.0%)	7 (35.0%)	12 (60.0%)	0 (0.0%)	20
Lipodystrophy acquired	0 (0.0%)	7 (35.0%)	13 (65.0%)	0 (0.0%)	20
Libido increased	2 (10.0%)	3 (15.0%)	15 (75.0%)	0 (0.0%)	20
Hypercreatininaemia	1 (5.0%)	0 (0.0%)	17 (85.0%)	2 (10.0%)	20
Sputum retention	3 (15.0%)	1 (5.0%)	8 (40.0%)	8 (40.0%)	20
Soft tissue disorder	1 (5.0%)	6 (30.0%)	13 (65.0%)	0 (0.0%)	20
Aortic thrombosis	0 (0.0%)	4 (20.0%)	14 (70.0%)	2 (10.0%)	20
Delusion of grandeur	0 (0.0%)	0 (0.0%)	20 (100.0%)	0 (0.0%)	20
Blood corticotrophin decreased	2 (10.0%)	3 (15.0%)	11 (55.0%)	4 (20.0%)	20
Culture urine positive	3 (15.0%)	3 (15.0%)	5 (25.0%)	9 (45.0%)	20
Inappropriate schedule of product discontinuation	1 (5.0%)	5 (25.0%)	14 (70.0%)	0 (0.0%)	20
Immune-mediated pancreatitis	0 (0.0%)	3 (15.0%)	12 (60.0%)	5 (25.0%)	20
Tongue biting	8 (40.0%)	9 (45.0%)	3 (15.0%)	0 (0.0%)	20
Central nervous system infection	0 (0.0%)	5 (25.0%)	13 (65.0%)	2 (10.0%)	20
Retroperitoneal haematoma	0 (0.0%)	1 (5.0%)	13 (65.0%)	6 (30.0%)	20
Hypovitaminosis	1 (5.0%)	5 (25.0%)	13 (65.0%)	1 (5.0%)	20
Joint warmth	3 (15.0%)	1 (5.0%)	12 (60.0%)	4 (20.0%)	20

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Transitional cell carcinoma	0 (0.0%)	5 (25.0%)	10 (50.0%)	5 (25.0%)	20
Superinfection bacterial	1 (5.0%)	3 (15.0%)	11 (55.0%)	5 (25.0%)	20
Colonoscopy	0 (0.0%)	7 (35.0%)	12 (60.0%)	1 (5.0%)	20
Post procedural haematoma	0 (0.0%)	7 (35.0%)	8 (40.0%)	5 (25.0%)	20
Viraemia	6 (30.0%)	7 (35.0%)	7 (35.0%)	0 (0.0%)	20
Spondylolisthesis	1 (5.0%)	2 (10.0%)	15 (75.0%)	2 (10.0%)	20
Bladder catheterisation	0 (0.0%)	4 (20.0%)	13 (65.0%)	3 (15.0%)	20
Primary biliary cholangitis	2 (10.0%)	5 (25.0%)	8 (40.0%)	5 (25.0%)	20
Brain neoplasm malignant	1 (5.0%)	3 (15.0%)	14 (70.0%)	2 (10.0%)	20
Seizure cluster	15 (75.0%)	2 (10.0%)	2 (10.0%)	1 (5.0%)	20
Cluster headache	1 (5.0%)	13 (65.0%)	6 (30.0%)	0 (0.0%)	20
Anisocytosis	1 (5.0%)	2 (10.0%)	16 (80.0%)	1 (5.0%)	20
Vascular graft	0 (0.0%)	1 (5.0%)	17 (85.0%)	2 (10.0%)	20
Porphyria acute	1 (5.0%)	18 (90.0%)	1 (5.0%)	0 (0.0%)	20
Vena cava thrombosis	1 (5.0%)	8 (40.0%)	9 (45.0%)	2 (10.0%)	20
Areflexia	8 (40.0%)	7 (35.0%)	5 (25.0%)	0 (0.0%)	20
Oesophageal haemorrhage	3 (15.0%)	5 (25.0%)	10 (50.0%)	2 (10.0%)	20
Intestinal polyp	0 (0.0%)	4 (20.0%)	12 (60.0%)	4 (20.0%)	20
Pruritus allergic	4 (20.0%)	2 (10.0%)	11 (55.0%)	3 (15.0%)	20
Product used for unknown indication	3 (15.0%)	2 (10.0%)	14 (70.0%)	1 (5.0%)	20
Gastrointestinal tube insertion	9 (45.0%)	0 (0.0%)	6 (30.0%)	5 (25.0%)	20
Dyspareunia	7 (35.0%)	10 (50.0%)	3 (15.0%)	0 (0.0%)	20
Extremity necrosis	3 (15.8%)	6 (31.6%)	5 (26.3%)	5 (26.3%)	19
Anorectal disorder	2 (10.5%)	7 (36.8%)	9 (47.4%)	1 (5.3%)	19
Hyporesponsive to stimuli	4 (21.1%)	4 (21.1%)	5 (26.3%)	6 (31.6%)	19
Fusarium infection	2 (10.5%)	4 (21.1%)	13 (68.4%)	0 (0.0%)	19
Pilonidal disease	5 (26.3%)	10 (52.6%)	4 (21.1%)	0 (0.0%)	19

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Radiation injury	0 (0.0%)	1 (5.3%)	13 (68.4%)	5 (26.3%)	19
Cholangitis acute	0 (0.0%)	5 (26.3%)	11 (57.9%)	3 (15.8%)	19
Device related thrombosis	1 (5.3%)	9 (47.4%)	5 (26.3%)	4 (21.1%)	19
Vascular pseudoaneurysm	1 (5.3%)	8 (42.1%)	7 (36.8%)	3 (15.8%)	19
Choroidal effusion	0 (0.0%)	9 (47.4%)	6 (31.6%)	4 (21.1%)	19
Myeloproliferative neoplasm	1 (5.3%)	2 (10.5%)	12 (63.2%)	4 (21.1%)	19
Bladder discomfort	0 (0.0%)	3 (15.8%)	11 (57.9%)	5 (26.3%)	19
Carbon dioxide increased	2 (10.5%)	2 (10.5%)	15 (78.9%)	0 (0.0%)	19
Mitochondrial toxicity	1 (5.3%)	11 (57.9%)	7 (36.8%)	0 (0.0%)	19
Optic atrophy	2 (10.5%)	10 (52.6%)	6 (31.6%)	1 (5.3%)	19
Angioplasty	0 (0.0%)	2 (10.5%)	5 (26.3%)	12 (63.2%)	19
HIV infection	1 (5.3%)	8 (42.1%)	9 (47.4%)	1 (5.3%)	19
Head titubation	1 (5.3%)	3 (15.8%)	14 (73.7%)	1 (5.3%)	19
Heart rate	4 (21.1%)	6 (31.6%)	3 (15.8%)	6 (31.6%)	19
Reflux gastritis	0 (0.0%)	8 (42.1%)	8 (42.1%)	3 (15.8%)	19
Paraparesis	2 (10.5%)	6 (31.6%)	8 (42.1%)	3 (15.8%)	19
Astigmatism	3 (15.8%)	3 (15.8%)	11 (57.9%)	2 (10.5%)	19
Infusion site urticaria	2 (10.5%)	2 (10.5%)	14 (73.7%)	1 (5.3%)	19
Nephrocalcinosis	6 (31.6%)	7 (36.8%)	3 (15.8%)	3 (15.8%)	19
Bronchial wall thickening	0 (0.0%)	1 (5.3%)	14 (73.7%)	4 (21.1%)	19
Necrosis ischaemic	7 (36.8%)	1 (5.3%)	10 (52.6%)	1 (5.3%)	19
Burns second degree	2 (10.5%)	3 (15.8%)	13 (68.4%)	1 (5.3%)	19
Thyroid function test abnormal	1 (5.3%)	6 (31.6%)	9 (47.4%)	3 (15.8%)	19
Skin striae	7 (36.8%)	7 (36.8%)	4 (21.1%)	1 (5.3%)	19
Infusion site oedema	5 (26.3%)	6 (31.6%)	3 (15.8%)	5 (26.3%)	19
Mucosal ulceration	0 (0.0%)	13 (68.4%)	3 (15.8%)	3 (15.8%)	19
Alpha haemolytic streptococcal infection	6 (31.6%)	6 (31.6%)	6 (31.6%)	1 (5.3%)	19

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Monoclonal immunoglobulin increased	0 (0.0%)	0 (0.0%)	12 (63.2%)	7 (36.8%)	19
Effusion	1 (5.3%)	5 (26.3%)	8 (42.1%)	5 (26.3%)	19
Alopecia areata	7 (36.8%)	10 (52.6%)	2 (10.5%)	0 (0.0%)	19
Metastases to skin	0 (0.0%)	3 (15.8%)	15 (78.9%)	1 (5.3%)	19
Breast abscess	0 (0.0%)	14 (73.7%)	5 (26.3%)	0 (0.0%)	19
Breakthrough pain	0 (0.0%)	2 (10.5%)	15 (78.9%)	2 (10.5%)	19
Herpes zoster disseminated	1 (5.3%)	7 (36.8%)	9 (47.4%)	2 (10.5%)	19
Application site swelling	4 (21.1%)	7 (36.8%)	6 (31.6%)	2 (10.5%)	19
Cystocele	0 (0.0%)	3 (15.8%)	14 (73.7%)	2 (10.5%)	19
Bronchostenosis	1 (5.3%)	2 (10.5%)	16 (84.2%)	0 (0.0%)	19
Forced vital capacity decreased	0 (0.0%)	7 (36.8%)	10 (52.6%)	2 (10.5%)	19
Acute disseminated encephalomyelitis	15 (78.9%)	2 (10.5%)	2 (10.5%)	0 (0.0%)	19
Dermatitis infected	2 (10.5%)	2 (10.5%)	14 (73.7%)	1 (5.3%)	19
Dental discomfort	1 (5.3%)	5 (26.3%)	13 (68.4%)	0 (0.0%)	19
Staphylococcus test positive	4 (21.1%)	1 (5.3%)	13 (68.4%)	1 (5.3%)	19
Philadelphia chromosome positive	1 (5.3%)	9 (47.4%)	7 (36.8%)	2 (10.5%)	19
Full blood count increased	2 (10.5%)	2 (10.5%)	13 (68.4%)	2 (10.5%)	19
Hypogeusia	0 (0.0%)	4 (21.1%)	10 (52.6%)	5 (26.3%)	19
Hyperkinesia	0 (0.0%)	7 (36.8%)	8 (42.1%)	4 (21.1%)	19
Syphilis	0 (0.0%)	14 (73.7%)	5 (26.3%)	0 (0.0%)	19
Pulmonary valve incompetence	5 (26.3%)	2 (10.5%)	10 (52.6%)	2 (10.5%)	19
Coronary artery dissection	0 (0.0%)	13 (68.4%)	6 (31.6%)	0 (0.0%)	19
Urinary hesitation	1 (5.3%)	3 (15.8%)	8 (42.1%)	7 (36.8%)	19
Blood immunoglobulin A decreased	4 (21.1%)	4 (21.1%)	11 (57.9%)	0 (0.0%)	19
Acrochordon	2 (10.5%)	3 (15.8%)	13 (68.4%)	1 (5.3%)	19
Impatience	2 (10.5%)	6 (31.6%)	9 (47.4%)	2 (10.5%)	19
Immune-mediated adverse reaction	7 (36.8%)	1 (5.3%)	9 (47.4%)	2 (10.5%)	19

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cellulitis gangrenous	4 (21.1%)	0 (0.0%)	15 (78.9%)	0 (0.0%)	19
Stoma site inflammation	1 (5.3%)	1 (5.3%)	12 (63.2%)	5 (26.3%)	19
Bilirubin conjugated increased	3 (15.8%)	3 (15.8%)	12 (63.2%)	1 (5.3%)	19
Conversion disorder	7 (36.8%)	10 (52.6%)	2 (10.5%)	0 (0.0%)	19
Polymyositis	4 (21.1%)	7 (36.8%)	5 (26.3%)	3 (15.8%)	19
Varicella	9 (47.4%)	4 (21.1%)	4 (21.1%)	2 (10.5%)	19
Dental care	2 (10.5%)	2 (10.5%)	11 (57.9%)	4 (21.1%)	19
Anion gap increased	6 (31.6%)	6 (31.6%)	5 (26.3%)	2 (10.5%)	19
Wrong strength	0 (0.0%)	1 (5.3%)	12 (63.2%)	6 (31.6%)	19
Hormone-refractory prostate cancer	0 (0.0%)	0 (0.0%)	8 (42.1%)	11 (57.9%)	19
Psychotic behaviour	0 (0.0%)	16 (84.2%)	1 (5.3%)	2 (10.5%)	19
Skin oedema	2 (10.5%)	12 (63.2%)	4 (21.1%)	1 (5.3%)	19
Sinus arrest	1 (5.3%)	2 (10.5%)	8 (42.1%)	8 (42.1%)	19
Analgesic therapy	0 (0.0%)	1 (5.3%)	0 (0.0%)	18 (94.7%)	19
Non-alcoholic steatohepatitis	1 (5.3%)	8 (42.1%)	10 (52.6%)	0 (0.0%)	19
Abortion	4 (21.1%)	15 (78.9%)	0 (0.0%)	0 (0.0%)	19
Binge eating	2 (10.5%)	15 (78.9%)	2 (10.5%)	0 (0.0%)	19
Vaccination site pain	2 (10.5%)	2 (10.5%)	15 (78.9%)	0 (0.0%)	19
Rheumatoid factor increased	1 (5.3%)	8 (42.1%)	9 (47.4%)	1 (5.3%)	19
Medical device implantation	0 (0.0%)	3 (15.8%)	9 (47.4%)	7 (36.8%)	19
Essential tremor	0 (0.0%)	3 (15.8%)	12 (63.2%)	4 (21.1%)	19
Beta haemolytic streptococcal infection	1 (5.3%)	7 (36.8%)	10 (52.6%)	1 (5.3%)	19
Animal scratch	1 (5.3%)	0 (0.0%)	16 (84.2%)	2 (10.5%)	19
Prostatic pain	0 (0.0%)	11 (57.9%)	5 (26.3%)	3 (15.8%)	19
Vulvovaginal candidiasis	0 (0.0%)	9 (47.4%)	9 (47.4%)	1 (5.3%)	19
Product deposit	3 (15.8%)	3 (15.8%)	11 (57.9%)	2 (10.5%)	19
Device electrical finding	8 (42.1%)	3 (15.8%)	5 (26.3%)	3 (15.8%)	19

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dysplasia	1 (5.6%)	4 (22.2%)	11 (61.1%)	2 (11.1%)	18
Breast discomfort	0 (0.0%)	9 (50.0%)	8 (44.4%)	1 (5.6%)	18
Polycystic ovarian syndrome	4 (22.2%)	11 (61.1%)	3 (16.7%)	0 (0.0%)	18
Circumstance or information capable of leading to dev	14 (77.8%)	2 (11.1%)	1 (5.6%)	1 (5.6%)	18
Abdominal lymphadenopathy	3 (16.7%)	10 (55.6%)	3 (16.7%)	2 (11.1%)	18
Cardiorenal syndrome	0 (0.0%)	1 (5.6%)	14 (77.8%)	3 (16.7%)	18
Haemangioma of liver	7 (38.9%)	7 (38.9%)	4 (22.2%)	0 (0.0%)	18
Adenocarcinoma pancreas	0 (0.0%)	0 (0.0%)	15 (83.3%)	3 (16.7%)	18
Fear of disease	0 (0.0%)	9 (50.0%)	7 (38.9%)	2 (11.1%)	18
Red blood cell transfusion	2 (11.1%)	0 (0.0%)	11 (61.1%)	5 (27.8%)	18
Coccidioidomycosis	2 (11.1%)	12 (66.7%)	4 (22.2%)	0 (0.0%)	18
Renal-limited thrombotic microangiopathy	0 (0.0%)	10 (55.6%)	8 (44.4%)	0 (0.0%)	18
Palliative care	0 (0.0%)	0 (0.0%)	6 (33.3%)	12 (66.7%)	18
Mixed anxiety and depressive disorder	1 (5.6%)	7 (38.9%)	9 (50.0%)	1 (5.6%)	18
Pancreatic carcinoma metastatic	0 (0.0%)	3 (16.7%)	6 (33.3%)	9 (50.0%)	18
Onychalgia	1 (5.6%)	3 (16.7%)	11 (61.1%)	3 (16.7%)	18
Oligohydramnios	6 (33.3%)	12 (66.7%)	0 (0.0%)	0 (0.0%)	18
Oedematous pancreatitis	1 (5.6%)	12 (66.7%)	3 (16.7%)	2 (11.1%)	18
Abulia	4 (22.2%)	3 (16.7%)	9 (50.0%)	2 (11.1%)	18
Calcium deficiency	0 (0.0%)	4 (22.2%)	11 (61.1%)	3 (16.7%)	18
Neutrophil percentage decreased	2 (11.1%)	3 (16.7%)	12 (66.7%)	1 (5.6%)	18
Eosinophilic cellulitis	1 (5.6%)	7 (38.9%)	2 (11.1%)	8 (44.4%)	18
Nasal ulcer	2 (11.1%)	2 (11.1%)	12 (66.7%)	2 (11.1%)	18
Endocrine ophthalmopathy	0 (0.0%)	7 (38.9%)	9 (50.0%)	2 (11.1%)	18
Myasthenic syndrome	0 (0.0%)	0 (0.0%)	17 (94.4%)	1 (5.6%)	18
Spinal deformity	3 (16.7%)	4 (22.2%)	10 (55.6%)	1 (5.6%)	18
Narcolepsy	0 (0.0%)	11 (61.1%)	7 (38.9%)	0 (0.0%)	18

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Breast enlargement	5 (27.8%)	5 (27.8%)	5 (27.8%)	3 (16.7%)	18
Breast cyst	0 (0.0%)	11 (61.1%)	7 (38.9%)	0 (0.0%)	18
Tonsillar disorder	9 (50.0%)	4 (22.2%)	4 (22.2%)	1 (5.6%)	18
Mean platelet volume decreased	3 (16.7%)	7 (38.9%)	8 (44.4%)	0 (0.0%)	18
Skin texture abnormal	0 (0.0%)	9 (50.0%)	7 (38.9%)	2 (11.1%)	18
Drug delivery system issue	3 (16.7%)	5 (27.8%)	9 (50.0%)	1 (5.6%)	18
Bradyarrhythmia	0 (0.0%)	2 (11.1%)	6 (33.3%)	10 (55.6%)	18
Allergic reaction to excipient	0 (0.0%)	5 (27.8%)	12 (66.7%)	1 (5.6%)	18
Tryptase increased	1 (5.6%)	4 (22.2%)	9 (50.0%)	4 (22.2%)	18
Lower respiratory tract infection viral	0 (0.0%)	8 (44.4%)	9 (50.0%)	1 (5.6%)	18
Infertility	5 (27.8%)	13 (72.2%)	0 (0.0%)	0 (0.0%)	18
Ankle arthroplasty	0 (0.0%)	4 (22.2%)	14 (77.8%)	0 (0.0%)	18
Light chain analysis increased	0 (0.0%)	1 (5.6%)	11 (61.1%)	6 (33.3%)	18
Myelofibrosis	0 (0.0%)	2 (11.1%)	15 (83.3%)	1 (5.6%)	18
Uterine polyp	1 (5.6%)	8 (44.4%)	9 (50.0%)	0 (0.0%)	18
Leukaemia recurrent	9 (50.0%)	1 (5.6%)	6 (33.3%)	2 (11.1%)	18
Hyperferritinaemia	1 (5.6%)	4 (22.2%)	13 (72.2%)	0 (0.0%)	18
Creatinine renal clearance increased	2 (11.1%)	1 (5.6%)	3 (16.7%)	12 (66.7%)	18
Lacunar infarction	0 (0.0%)	2 (11.1%)	9 (50.0%)	7 (38.9%)	18
Foreign body in eye	0 (0.0%)	6 (33.3%)	10 (55.6%)	2 (11.1%)	18
Knee deformity	4 (22.2%)	3 (16.7%)	9 (50.0%)	2 (11.1%)	18
Derealisation	2 (11.1%)	8 (44.4%)	5 (27.8%)	3 (16.7%)	18
Adrenal haemorrhage	0 (0.0%)	5 (27.8%)	11 (61.1%)	2 (11.1%)	18
Autoimmune myositis	0 (0.0%)	1 (5.6%)	14 (77.8%)	3 (16.7%)	18
Corneal oedema	3 (16.7%)	4 (22.2%)	8 (44.4%)	3 (16.7%)	18
Nail ridging	0 (0.0%)	5 (27.8%)	2 (11.1%)	11 (61.1%)	18
Intervertebral disc operation	0 (0.0%)	3 (16.7%)	15 (83.3%)	0 (0.0%)	18

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood cholesterol decreased	0 (0.0%)	0 (0.0%)	12 (66.7%)	6 (33.3%)	18
Ileocaecal resection	0 (0.0%)	14 (77.8%)	4 (22.2%)	0 (0.0%)	18
Pulmonary mucormycosis	0 (0.0%)	11 (61.1%)	6 (33.3%)	1 (5.6%)	18
Joint ankylosis	1 (5.6%)	7 (38.9%)	7 (38.9%)	3 (16.7%)	18
Systemic mycosis	3 (16.7%)	6 (33.3%)	6 (33.3%)	3 (16.7%)	18
Inflammatory pain	0 (0.0%)	7 (38.9%)	11 (61.1%)	0 (0.0%)	18
Tongue neoplasm malignant stage unspecified	0 (0.0%)	1 (5.6%)	13 (72.2%)	4 (22.2%)	18
Wound infection staphylococcal	0 (0.0%)	7 (38.9%)	9 (50.0%)	2 (11.1%)	18
Pulmonary arterial pressure increased	5 (27.8%)	4 (22.2%)	6 (33.3%)	3 (16.7%)	18
Neuroendocrine carcinoma of the skin	0 (0.0%)	5 (27.8%)	11 (61.1%)	2 (11.1%)	18
Post lumbar puncture syndrome	9 (50.0%)	4 (22.2%)	5 (27.8%)	0 (0.0%)	18
Stoma creation	3 (16.7%)	8 (44.4%)	6 (33.3%)	1 (5.6%)	18
Small intestine carcinoma	0 (0.0%)	1 (5.6%)	16 (88.9%)	1 (5.6%)	18
Wrong schedule	3 (16.7%)	4 (22.2%)	5 (27.8%)	6 (33.3%)	18
Postoperative wound complication	0 (0.0%)	3 (16.7%)	15 (83.3%)	0 (0.0%)	18
Mean cell haemoglobin concentration increased	5 (27.8%)	5 (27.8%)	8 (44.4%)	0 (0.0%)	18
Primary adrenal insufficiency	1 (5.6%)	1 (5.6%)	14 (77.8%)	2 (11.1%)	18
Uterine haemorrhage	0 (0.0%)	14 (77.8%)	4 (22.2%)	0 (0.0%)	18
Gastroduodenal ulcer	1 (5.6%)	0 (0.0%)	14 (77.8%)	3 (16.7%)	18
Pseudo Cushing's syndrome	2 (11.1%)	8 (44.4%)	8 (44.4%)	0 (0.0%)	18
Duodenal ulcer haemorrhage	3 (16.7%)	0 (0.0%)	11 (61.1%)	4 (22.2%)	18
Meibomian gland dysfunction	0 (0.0%)	7 (38.9%)	9 (50.0%)	2 (11.1%)	18
Gouty arthritis	0 (0.0%)	3 (16.7%)	11 (61.1%)	4 (22.2%)	18
Oesophageal spasm	2 (11.1%)	3 (16.7%)	13 (72.2%)	0 (0.0%)	18
Genital abscess	1 (5.6%)	9 (50.0%)	8 (44.4%)	0 (0.0%)	18
Product container seal issue	2 (11.1%)	1 (5.6%)	11 (61.1%)	4 (22.2%)	18
Inner ear disorder	0 (0.0%)	2 (11.1%)	14 (77.8%)	2 (11.1%)	18

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Prinzmetal angina	0 (0.0%)	5 (27.8%)	10 (55.6%)	3 (16.7%)	18
Cerebral mass effect	1 (5.6%)	3 (16.7%)	11 (61.1%)	3 (16.7%)	18
Premature rupture of membranes	4 (22.2%)	14 (77.8%)	0 (0.0%)	0 (0.0%)	18
Pseudomonal bacteraemia	2 (11.1%)	3 (16.7%)	10 (55.6%)	3 (16.7%)	18
Cerebellar atrophy	7 (38.9%)	7 (38.9%)	3 (16.7%)	1 (5.6%)	18
Optic nerve injury	1 (5.9%)	7 (41.2%)	8 (47.1%)	1 (5.9%)	17
Glycosylated haemoglobin abnormal	0 (0.0%)	2 (11.8%)	13 (76.5%)	2 (11.8%)	17
Fluid replacement	3 (17.6%)	2 (11.8%)	9 (52.9%)	3 (17.6%)	17
Radiation skin injury	1 (5.9%)	3 (17.6%)	13 (76.5%)	0 (0.0%)	17
Pelvic venous thrombosis	1 (5.9%)	4 (23.5%)	12 (70.6%)	0 (0.0%)	17
Fistula discharge	1 (5.9%)	5 (29.4%)	11 (64.7%)	0 (0.0%)	17
Ear inflammation	3 (17.6%)	5 (29.4%)	9 (52.9%)	0 (0.0%)	17
Febrile convulsion	13 (76.5%)	0 (0.0%)	2 (11.8%)	2 (11.8%)	17
Ovarian cyst ruptured	4 (23.5%)	12 (70.6%)	1 (5.9%)	0 (0.0%)	17
Osteochondrosis	5 (29.4%)	5 (29.4%)	6 (35.3%)	1 (5.9%)	17
Eyelid infection	5 (29.4%)	3 (17.6%)	9 (52.9%)	0 (0.0%)	17
Oral mucosal exfoliation	1 (5.9%)	4 (23.5%)	9 (52.9%)	3 (17.6%)	17
Hand dermatitis	1 (5.9%)	7 (41.2%)	9 (52.9%)	0 (0.0%)	17
Patient dissatisfaction with treatment	1 (5.9%)	7 (41.2%)	7 (41.2%)	2 (11.8%)	17
Nocturnal dyspnoea	0 (0.0%)	9 (52.9%)	8 (47.1%)	0 (0.0%)	17
Lip pruritus	7 (41.2%)	6 (35.3%)	4 (23.5%)	0 (0.0%)	17
Injection site necrosis	0 (0.0%)	10 (58.8%)	5 (29.4%)	2 (11.8%)	17
Blood immunoglobulin A increased	1 (5.9%)	10 (58.8%)	6 (35.3%)	0 (0.0%)	17
Enterococcal sepsis	11 (64.7%)	2 (11.8%)	3 (17.6%)	1 (5.9%)	17
Nasal pruritus	1 (5.9%)	5 (29.4%)	11 (64.7%)	0 (0.0%)	17
Scleroderma renal crisis	0 (0.0%)	4 (23.5%)	13 (76.5%)	0 (0.0%)	17
Vaccine interaction	3 (17.6%)	8 (47.1%)	4 (23.5%)	2 (11.8%)	17

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Endometrial cancer	0 (0.0%)	1 (5.9%)	14 (82.4%)	2 (11.8%)	17
Clostridial infection	1 (5.9%)	5 (29.4%)	6 (35.3%)	5 (29.4%)	17
Endocrine disorder	1 (5.9%)	10 (58.8%)	5 (29.4%)	1 (5.9%)	17
Patent ductus arteriosus	17 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	17
Patient uncooperative	5 (29.4%)	7 (41.2%)	5 (29.4%)	0 (0.0%)	17
Muscle abscess	2 (11.8%)	4 (23.5%)	7 (41.2%)	4 (23.5%)	17
Breathing-related sleep disorder	3 (17.6%)	11 (64.7%)	2 (11.8%)	1 (5.9%)	17
Pseudomembranous colitis	0 (0.0%)	4 (23.5%)	10 (58.8%)	3 (17.6%)	17
Carotid artery thrombosis	0 (0.0%)	4 (23.5%)	12 (70.6%)	1 (5.9%)	17
Colon cancer metastatic	0 (0.0%)	3 (17.6%)	10 (58.8%)	4 (23.5%)	17
Drug screen negative	0 (0.0%)	13 (76.5%)	4 (23.5%)	0 (0.0%)	17
Drug level abnormal	11 (64.7%)	1 (5.9%)	5 (29.4%)	0 (0.0%)	17
Distractibility	0 (0.0%)	4 (23.5%)	12 (70.6%)	1 (5.9%)	17
Cholangiocarcinoma	2 (11.8%)	5 (29.4%)	9 (52.9%)	1 (5.9%)	17
Disseminated cryptococcosis	0 (0.0%)	10 (58.8%)	4 (23.5%)	3 (17.6%)	17
Fracture pain	0 (0.0%)	0 (0.0%)	13 (76.5%)	4 (23.5%)	17
Acute graft versus host disease in intestine	8 (47.1%)	2 (11.8%)	7 (41.2%)	0 (0.0%)	17
Bone giant cell tumour	9 (52.9%)	5 (29.4%)	3 (17.6%)	0 (0.0%)	17
Soft tissue swelling	0 (0.0%)	5 (29.4%)	12 (70.6%)	0 (0.0%)	17
Diabetic metabolic decompensation	1 (5.9%)	2 (11.8%)	12 (70.6%)	2 (11.8%)	17
Leukocyturia	1 (5.9%)	2 (11.8%)	13 (76.5%)	1 (5.9%)	17
Stem cell transplant	0 (0.0%)	10 (58.8%)	7 (41.2%)	0 (0.0%)	17
Starvation	0 (0.0%)	4 (23.5%)	5 (29.4%)	8 (47.1%)	17
Keratopathy	0 (0.0%)	8 (47.1%)	5 (29.4%)	4 (23.5%)	17
Tumour necrosis	0 (0.0%)	2 (11.8%)	11 (64.7%)	4 (23.5%)	17
Catheter site discharge	2 (11.8%)	5 (29.4%)	10 (58.8%)	0 (0.0%)	17
Akinesia	4 (23.5%)	1 (5.9%)	6 (35.3%)	6 (35.3%)	17

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Costochondritis	4 (23.5%)	9 (52.9%)	3 (17.6%)	1 (5.9%)	17
Vitreous opacities	1 (5.9%)	7 (41.2%)	5 (29.4%)	4 (23.5%)	17
Vascular device occlusion	4 (23.5%)	5 (29.4%)	7 (41.2%)	1 (5.9%)	17
Adulterated product	2 (11.8%)	13 (76.5%)	2 (11.8%)	0 (0.0%)	17
Thrombophlebitis migrans	0 (0.0%)	0 (0.0%)	12 (70.6%)	5 (29.4%)	17
Incision site impaired healing	0 (0.0%)	2 (11.8%)	14 (82.4%)	1 (5.9%)	17
Thyroid hormones decreased	2 (11.8%)	1 (5.9%)	12 (70.6%)	2 (11.8%)	17
Foetal growth restriction	14 (82.4%)	3 (17.6%)	0 (0.0%)	0 (0.0%)	17
Tinea pedis	1 (5.9%)	7 (41.2%)	8 (47.1%)	1 (5.9%)	17
Tongue erythema	1 (5.9%)	4 (23.5%)	9 (52.9%)	3 (17.6%)	17
Tendon discomfort	1 (5.9%)	10 (58.8%)	6 (35.3%)	0 (0.0%)	17
Hypertensive urgency	0 (0.0%)	7 (41.2%)	10 (58.8%)	0 (0.0%)	17
Streptococcal bacteraemia	8 (47.1%)	3 (17.6%)	4 (23.5%)	2 (11.8%)	17
Neuropsychological symptoms	2 (11.8%)	9 (52.9%)	6 (35.3%)	0 (0.0%)	17
Episcleritis	3 (17.6%)	2 (11.8%)	11 (64.7%)	1 (5.9%)	17
Brain hypoxia	2 (11.8%)	7 (41.2%)	8 (47.1%)	0 (0.0%)	17
Sleep talking	1 (5.9%)	6 (35.3%)	6 (35.3%)	4 (23.5%)	17
Nicotine dependence	0 (0.0%)	4 (23.5%)	9 (52.9%)	4 (23.5%)	17
Colonic abscess	1 (5.9%)	4 (23.5%)	11 (64.7%)	1 (5.9%)	17
Blood fibrinogen decreased	4 (23.5%)	3 (17.6%)	7 (41.2%)	3 (17.6%)	17
Ingrown hair	0 (0.0%)	16 (94.1%)	1 (5.9%)	0 (0.0%)	17
Ballismus	0 (0.0%)	10 (58.8%)	6 (35.3%)	1 (5.9%)	17
Heat exhaustion	1 (5.9%)	4 (23.5%)	11 (64.7%)	1 (5.9%)	17
Medical device removal	1 (5.9%)	3 (17.6%)	10 (58.8%)	3 (17.6%)	17
Calculus bladder	0 (0.0%)	3 (17.6%)	10 (58.8%)	4 (23.5%)	17
Genital burning sensation	2 (11.8%)	2 (11.8%)	13 (76.5%)	0 (0.0%)	17
Product packaging confusion	4 (23.5%)	1 (5.9%)	8 (47.1%)	4 (23.5%)	17

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cholinergic rebound syndrome	0 (0.0%)	0 (0.0%)	13 (76.5%)	4 (23.5%)	17
Campylobacter gastroenteritis	0 (0.0%)	2 (11.8%)	12 (70.6%)	3 (17.6%)	17
Incision site pain	0 (0.0%)	6 (35.3%)	11 (64.7%)	0 (0.0%)	17
Cancer surgery	0 (0.0%)	2 (11.8%)	13 (76.5%)	2 (11.8%)	17
Cervical spinal stenosis	0 (0.0%)	8 (47.1%)	7 (41.2%)	2 (11.8%)	17
Intra-abdominal haematoma	1 (5.9%)	4 (23.5%)	10 (58.8%)	2 (11.8%)	17
Anastomotic stenosis	0 (0.0%)	9 (52.9%)	8 (47.1%)	0 (0.0%)	17
Prolactin-producing pituitary tumour	0 (0.0%)	10 (58.8%)	4 (23.5%)	3 (17.6%)	17
Prostate infection	0 (0.0%)	4 (23.5%)	11 (64.7%)	2 (11.8%)	17
Prothrombin time shortened	9 (52.9%)	3 (17.6%)	3 (17.6%)	2 (11.8%)	17
Prostatic operation	0 (0.0%)	0 (0.0%)	14 (82.4%)	3 (17.6%)	17
Acute abdomen	4 (23.5%)	2 (11.8%)	5 (29.4%)	6 (35.3%)	17
Dyslexia	2 (11.8%)	2 (11.8%)	12 (70.6%)	1 (5.9%)	17
Wrist surgery	1 (5.9%)	3 (17.6%)	10 (58.8%)	3 (17.6%)	17
Anaesthesia	2 (11.8%)	11 (64.7%)	3 (17.6%)	1 (5.9%)	17
Dehiscence	0 (0.0%)	0 (0.0%)	5 (29.4%)	12 (70.6%)	17
Intussusception	3 (17.6%)	5 (29.4%)	8 (47.1%)	1 (5.9%)	17
Yawning	1 (5.9%)	12 (70.6%)	4 (23.5%)	0 (0.0%)	17
Poor feeding infant	16 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	16
Allodynia	1 (6.3%)	8 (50.0%)	5 (31.3%)	2 (12.5%)	16
Hyposmia	0 (0.0%)	7 (43.8%)	8 (50.0%)	1 (6.3%)	16
Teeth brittle	0 (0.0%)	9 (56.3%)	7 (43.8%)	0 (0.0%)	16
Anaemia megaloblastic	8 (50.0%)	0 (0.0%)	2 (12.5%)	6 (37.5%)	16
Hemihypoaesthesia	2 (12.5%)	7 (43.8%)	6 (37.5%)	1 (6.3%)	16
Pharyngeal ulceration	0 (0.0%)	3 (18.8%)	13 (81.3%)	0 (0.0%)	16
Fractured coccyx	0 (0.0%)	4 (25.0%)	4 (25.0%)	8 (50.0%)	16
Reproductive complication associated with device	2 (12.5%)	14 (87.5%)	0 (0.0%)	0 (0.0%)	16

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Food refusal	4 (25.0%)	0 (0.0%)	10 (62.5%)	2 (12.5%)	16
Metastases to the mediastinum	0 (0.0%)	2 (12.5%)	14 (87.5%)	0 (0.0%)	16
Rectal polyp	0 (0.0%)	1 (6.3%)	14 (87.5%)	1 (6.3%)	16
Cytomegalovirus oesophagitis	0 (0.0%)	1 (6.3%)	15 (93.8%)	0 (0.0%)	16
Facial discomfort	2 (12.5%)	4 (25.0%)	9 (56.3%)	1 (6.3%)	16
Diabetic coma	0 (0.0%)	5 (31.3%)	7 (43.8%)	4 (25.0%)	16
Alveolar proteinosis	0 (0.0%)	1 (6.3%)	15 (93.8%)	0 (0.0%)	16
Anaemia vitamin B12 deficiency	0 (0.0%)	0 (0.0%)	8 (50.0%)	8 (50.0%)	16
Aura	2 (12.5%)	4 (25.0%)	9 (56.3%)	1 (6.3%)	16
Anastomotic ulcer	3 (18.8%)	8 (50.0%)	4 (25.0%)	1 (6.3%)	16
Infusion site nodule	1 (6.3%)	3 (18.8%)	10 (62.5%)	2 (12.5%)	16
Angle closure glaucoma	0 (0.0%)	8 (50.0%)	5 (31.3%)	3 (18.8%)	16
Renal artery stenosis	5 (31.3%)	0 (0.0%)	10 (62.5%)	1 (6.3%)	16
Nutritional condition abnormal	4 (25.0%)	2 (12.5%)	8 (50.0%)	2 (12.5%)	16
Neutrophil percentage increased	3 (18.8%)	2 (12.5%)	9 (56.3%)	2 (12.5%)	16
Heart valve replacement	1 (6.3%)	0 (0.0%)	10 (62.5%)	5 (31.3%)	16
Epididymitis	3 (18.8%)	6 (37.5%)	5 (31.3%)	2 (12.5%)	16
Saliva altered	1 (6.3%)	4 (25.0%)	7 (43.8%)	4 (25.0%)	16
Haemangioma	3 (18.8%)	7 (43.8%)	4 (25.0%)	2 (12.5%)	16
Enterobacter pneumonia	1 (6.3%)	0 (0.0%)	5 (31.3%)	10 (62.5%)	16
Enteral nutrition	2 (12.5%)	3 (18.8%)	9 (56.3%)	2 (12.5%)	16
Parathyroid tumour benign	0 (0.0%)	3 (18.8%)	8 (50.0%)	5 (31.3%)	16
Nail infection	1 (6.3%)	6 (37.5%)	6 (37.5%)	3 (18.8%)	16
Sciatic nerve injury	0 (0.0%)	0 (0.0%)	13 (81.3%)	3 (18.8%)	16
Injection site coldness	2 (12.5%)	12 (75.0%)	2 (12.5%)	0 (0.0%)	16
Clostridium colitis	1 (6.3%)	6 (37.5%)	7 (43.8%)	2 (12.5%)	16
Encephalitis cytomegalovirus	0 (0.0%)	14 (87.5%)	2 (12.5%)	0 (0.0%)	16

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Self esteem decreased	6 (37.5%)	7 (43.8%)	2 (12.5%)	1 (6.3%)	16
Uterine enlargement	2 (12.5%)	14 (87.5%)	0 (0.0%)	0 (0.0%)	16
Multiple sclerosis pseudo relapse	2 (12.5%)	8 (50.0%)	6 (37.5%)	0 (0.0%)	16
Electroencephalogram abnormal	5 (31.3%)	4 (25.0%)	4 (25.0%)	3 (18.8%)	16
Uterine cervix stenosis	3 (18.8%)	12 (75.0%)	1 (6.3%)	0 (0.0%)	16
Mononeuropathy multiplex	0 (0.0%)	6 (37.5%)	5 (31.3%)	5 (31.3%)	16
Monocytosis	3 (18.8%)	6 (37.5%)	7 (43.8%)	0 (0.0%)	16
Hepatitis viral	0 (0.0%)	9 (56.3%)	7 (43.8%)	0 (0.0%)	16
Intercepted product dispensing error	3 (18.8%)	4 (25.0%)	8 (50.0%)	1 (6.3%)	16
Microangiopathy	1 (6.3%)	1 (6.3%)	9 (56.3%)	5 (31.3%)	16
Rebound atopic dermatitis	2 (12.5%)	4 (25.0%)	8 (50.0%)	2 (12.5%)	16
Meningitis bacterial	4 (25.0%)	3 (18.8%)	5 (31.3%)	4 (25.0%)	16
Dupuytren's contracture	0 (0.0%)	2 (12.5%)	13 (81.3%)	1 (6.3%)	16
Duodenal perforation	0 (0.0%)	0 (0.0%)	11 (68.8%)	5 (31.3%)	16
Apraxia	1 (6.3%)	4 (25.0%)	11 (68.8%)	0 (0.0%)	16
Infusion related hypersensitivity reaction	5 (31.3%)	2 (12.5%)	5 (31.3%)	4 (25.0%)	16
Drug administered in wrong device	12 (75.0%)	1 (6.3%)	3 (18.8%)	0 (0.0%)	16
Drainage	0 (0.0%)	8 (50.0%)	7 (43.8%)	1 (6.3%)	16
Lung transplant	3 (18.8%)	5 (31.3%)	8 (50.0%)	0 (0.0%)	16
Discontinued product administered	2 (12.5%)	2 (12.5%)	11 (68.8%)	1 (6.3%)	16
Compartment syndrome	2 (12.5%)	3 (18.8%)	11 (68.8%)	0 (0.0%)	16
Lip exfoliation	2 (12.5%)	3 (18.8%)	7 (43.8%)	4 (25.0%)	16
Infected bite	2 (12.5%)	4 (25.0%)	10 (62.5%)	0 (0.0%)	16
Spinal cord infection	0 (0.0%)	3 (18.8%)	12 (75.0%)	1 (6.3%)	16
Dependence on oxygen therapy	1 (6.3%)	0 (0.0%)	11 (68.8%)	4 (25.0%)	16
Aortic valve disease	2 (12.5%)	1 (6.3%)	6 (37.5%)	7 (43.8%)	16
Iron overload	3 (18.8%)	2 (12.5%)	6 (37.5%)	5 (31.3%)	16

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pharyngeal inflammation	3 (18.8%)	8 (50.0%)	5 (31.3%)	0 (0.0%)	16
Vocal cord dysfunction	1 (6.3%)	7 (43.8%)	7 (43.8%)	1 (6.3%)	16
Immune-mediated arthritis	1 (6.3%)	3 (18.8%)	12 (75.0%)	0 (0.0%)	16
Implantable defibrillator insertion	0 (0.0%)	1 (6.3%)	11 (68.8%)	4 (25.0%)	16
Antipsychotic drug level below therapeutic	1 (6.3%)	10 (62.5%)	5 (31.3%)	0 (0.0%)	16
Cystitis viral	3 (18.8%)	11 (68.8%)	2 (12.5%)	0 (0.0%)	16
Tumour flare	0 (0.0%)	3 (18.8%)	13 (81.3%)	0 (0.0%)	16
Inappropriate affect	3 (18.8%)	10 (62.5%)	3 (18.8%)	0 (0.0%)	16
Hypothalamic pituitary adrenal axis suppression	5 (31.3%)	8 (50.0%)	3 (18.8%)	0 (0.0%)	16
Cellulite	1 (6.3%)	8 (50.0%)	7 (43.8%)	0 (0.0%)	16
Immature granulocyte count increased	1 (6.3%)	7 (43.8%)	8 (50.0%)	0 (0.0%)	16
Agoraphobia	1 (6.3%)	13 (81.3%)	2 (12.5%)	0 (0.0%)	16
Tissue infiltration	1 (6.3%)	15 (93.8%)	0 (0.0%)	0 (0.0%)	16
Cellulitis orbital	0 (0.0%)	6 (37.5%)	7 (43.8%)	3 (18.8%)	16
Tonic convulsion	9 (56.3%)	4 (25.0%)	3 (18.8%)	0 (0.0%)	16
Polypectomy	1 (6.3%)	4 (25.0%)	8 (50.0%)	3 (18.8%)	16
Polymenorrhoea	4 (25.0%)	11 (68.8%)	1 (6.3%)	0 (0.0%)	16
Inadequate analgesia	1 (6.3%)	7 (43.8%)	7 (43.8%)	1 (6.3%)	16
Counterfeit product administered	4 (25.0%)	6 (37.5%)	5 (31.3%)	1 (6.3%)	16
Hyperleukocytosis	2 (12.5%)	6 (37.5%)	5 (31.3%)	3 (18.8%)	16
Staring	6 (37.5%)	1 (6.3%)	7 (43.8%)	2 (12.5%)	16
Asthma-chronic obstructive pulmonary disease overlap	0 (0.0%)	0 (0.0%)	16 (100.0%)	0 (0.0%)	16
Anosognosia	5 (31.3%)	2 (12.5%)	7 (43.8%)	2 (12.5%)	16
Congenital hiatus hernia	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (100.0%)	16
Upper respiratory tract infection bacterial	6 (37.5%)	4 (25.0%)	6 (37.5%)	0 (0.0%)	16
Right ventricular dysfunction	4 (25.0%)	3 (18.8%)	4 (25.0%)	5 (31.3%)	16
Erosive oesophagitis	4 (25.0%)	1 (6.3%)	7 (43.8%)	4 (25.0%)	16

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Injection site exfoliation	3 (18.8%)	5 (31.3%)	8 (50.0%)	0 (0.0%)	16
Intraductal proliferative breast lesion	0 (0.0%)	1 (6.3%)	14 (87.5%)	1 (6.3%)	16
Reversible airways obstruction	0 (0.0%)	3 (18.8%)	12 (75.0%)	1 (6.3%)	16
Vascular access complication	1 (6.3%)	1 (6.3%)	12 (75.0%)	2 (12.5%)	16
Angular cheilitis	3 (18.8%)	5 (31.3%)	8 (50.0%)	0 (0.0%)	16
Groin infection	2 (12.5%)	8 (50.0%)	5 (31.3%)	1 (6.3%)	16
Exophthalmos	0 (0.0%)	3 (18.8%)	9 (56.3%)	4 (25.0%)	16
Pyuria	6 (37.5%)	3 (18.8%)	2 (12.5%)	5 (31.3%)	16
Vitamin D increased	3 (18.8%)	1 (6.3%)	12 (75.0%)	0 (0.0%)	16
Vocal cord disorder	0 (0.0%)	4 (25.0%)	7 (43.8%)	5 (31.3%)	16
Bile duct stenosis	2 (12.5%)	2 (12.5%)	7 (43.8%)	5 (31.3%)	16
Aortic disorder	0 (0.0%)	4 (25.0%)	11 (68.8%)	1 (6.3%)	16
Neuroendocrine carcinoma	0 (0.0%)	0 (0.0%)	11 (68.8%)	5 (31.3%)	16
Symmetrical drug-related intertriginous and flexural	4 (25.0%)	0 (0.0%)	6 (37.5%)	6 (37.5%)	16
Generalised anxiety disorder	2 (12.5%)	8 (50.0%)	6 (37.5%)	0 (0.0%)	16
Product after taste	0 (0.0%)	3 (18.8%)	12 (75.0%)	1 (6.3%)	16
Product administered by wrong person	1 (6.3%)	7 (43.8%)	6 (37.5%)	2 (12.5%)	16
Precancerous condition	0 (0.0%)	2 (12.5%)	12 (75.0%)	2 (12.5%)	16
Pouchitis	2 (12.5%)	10 (62.5%)	3 (18.8%)	1 (6.3%)	16
Gastroenteritis salmonella	1 (6.3%)	5 (31.3%)	10 (62.5%)	0 (0.0%)	16
Pneumonia streptococcal	7 (46.7%)	3 (20.0%)	4 (26.7%)	1 (6.7%)	15
Eye infection toxoplasmal	5 (33.3%)	0 (0.0%)	10 (66.7%)	0 (0.0%)	15
Administration site extravasation	3 (20.0%)	3 (20.0%)	6 (40.0%)	3 (20.0%)	15
Metapneumovirus infection	12 (80.0%)	1 (6.7%)	2 (13.3%)	0 (0.0%)	15
Peritonsillar abscess	1 (6.7%)	9 (60.0%)	4 (26.7%)	1 (6.7%)	15
Eyelid exfoliation	8 (53.3%)	4 (26.7%)	1 (6.7%)	2 (13.3%)	15
Foreign body aspiration	0 (0.0%)	14 (93.3%)	1 (6.7%)	0 (0.0%)	15

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Peripheral sensorimotor neuropathy	0 (0.0%)	2 (13.3%)	6 (40.0%)	7 (46.7%)	15
Carotid arteriosclerosis	0 (0.0%)	1 (6.7%)	8 (53.3%)	6 (40.0%)	15
Crystalluria	0 (0.0%)	2 (13.3%)	10 (66.7%)	3 (20.0%)	15
Fat tissue increased	1 (6.7%)	1 (6.7%)	9 (60.0%)	4 (26.7%)	15
Faecal volume decreased	5 (33.3%)	2 (13.3%)	6 (40.0%)	2 (13.3%)	15
Pancreatic mass	0 (0.0%)	3 (20.0%)	9 (60.0%)	3 (20.0%)	15
Axillary mass	0 (0.0%)	9 (60.0%)	6 (40.0%)	0 (0.0%)	15
Expanded disability status scale score increased	0 (0.0%)	11 (73.3%)	4 (26.7%)	0 (0.0%)	15
Executive dysfunction	1 (6.7%)	4 (26.7%)	8 (53.3%)	2 (13.3%)	15
Agitated depression	0 (0.0%)	12 (80.0%)	3 (20.0%)	0 (0.0%)	15
Injection site papule	2 (13.3%)	6 (40.0%)	6 (40.0%)	1 (6.7%)	15
Chronic respiratory failure	2 (13.3%)	2 (13.3%)	7 (46.7%)	4 (26.7%)	15
Epstein-Barr virus associated lymphoma	2 (13.3%)	5 (33.3%)	7 (46.7%)	1 (6.7%)	15
Neurogenic shock	4 (26.7%)	4 (26.7%)	7 (46.7%)	0 (0.0%)	15
Ephelides	3 (20.0%)	4 (26.7%)	7 (46.7%)	1 (6.7%)	15
Electrocardiogram T wave abnormal	2 (13.3%)	6 (40.0%)	6 (40.0%)	1 (6.7%)	15
Enterocolitis infectious	0 (0.0%)	2 (13.3%)	13 (86.7%)	0 (0.0%)	15
Myocardial fibrosis	0 (0.0%)	8 (53.3%)	6 (40.0%)	1 (6.7%)	15
Myelitis transverse	1 (6.7%)	9 (60.0%)	4 (26.7%)	1 (6.7%)	15
Mycoplasma infection	4 (26.7%)	3 (20.0%)	8 (53.3%)	0 (0.0%)	15
Self-consciousness	0 (0.0%)	8 (53.3%)	7 (46.7%)	0 (0.0%)	15
Electrocardiogram ST-T segment abnormal	2 (13.3%)	2 (13.3%)	10 (66.7%)	1 (6.7%)	15
Septic embolus	7 (46.7%)	1 (6.7%)	7 (46.7%)	0 (0.0%)	15
Optic nerve disorder	2 (13.3%)	7 (46.7%)	5 (33.3%)	1 (6.7%)	15
Moaning	7 (46.7%)	2 (13.3%)	4 (26.7%)	2 (13.3%)	15
Ectopic pregnancy	2 (13.3%)	12 (80.0%)	1 (6.7%)	0 (0.0%)	15
Acute lung injury	2 (13.3%)	1 (6.7%)	11 (73.3%)	1 (6.7%)	15

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Metabolic surgery	1 (6.7%)	7 (46.7%)	7 (46.7%)	0 (0.0%)	15
Breast discharge	3 (20.0%)	4 (26.7%)	8 (53.3%)	0 (0.0%)	15
Sinusitis fungal	0 (0.0%)	6 (40.0%)	8 (53.3%)	1 (6.7%)	15
Penile size reduced	1 (6.7%)	8 (53.3%)	4 (26.7%)	2 (13.3%)	15
Mastoiditis	5 (33.3%)	3 (20.0%)	4 (26.7%)	3 (20.0%)	15
Application site exfoliation	4 (26.7%)	4 (26.7%)	7 (46.7%)	0 (0.0%)	15
Application site reaction	2 (13.3%)	8 (53.3%)	5 (33.3%)	0 (0.0%)	15
Slow response to stimuli	1 (6.7%)	1 (6.7%)	10 (66.7%)	3 (20.0%)	15
Fibroma	1 (6.7%)	2 (13.3%)	7 (46.7%)	5 (33.3%)	15
Smoke sensitivity	0 (0.0%)	4 (26.7%)	10 (66.7%)	1 (6.7%)	15
Disseminated varicella zoster virus infection	9 (60.0%)	1 (6.7%)	4 (26.7%)	1 (6.7%)	15
Disseminated strongyloidiasis	0 (0.0%)	4 (26.7%)	11 (73.3%)	0 (0.0%)	15
Lung operation	1 (6.7%)	3 (20.0%)	9 (60.0%)	2 (13.3%)	15
Disinhibition	3 (20.0%)	10 (66.7%)	2 (13.3%)	0 (0.0%)	15
Periorbital cellulitis	6 (40.0%)	4 (26.7%)	4 (26.7%)	1 (6.7%)	15
Human herpesvirus 6 infection	6 (40.0%)	2 (13.3%)	7 (46.7%)	0 (0.0%)	15
Lower respiratory tract infection bacterial	1 (6.7%)	9 (60.0%)	5 (33.3%)	0 (0.0%)	15
Bone neoplasm	1 (6.7%)	1 (6.7%)	11 (73.3%)	2 (13.3%)	15
Spinal cord neoplasm	1 (6.7%)	3 (20.0%)	11 (73.3%)	0 (0.0%)	15
Spinal laminectomy	1 (6.7%)	1 (6.7%)	8 (53.3%)	5 (33.3%)	15
Ligament injury	1 (6.7%)	2 (13.3%)	12 (80.0%)	0 (0.0%)	15
Peripheral nerve injury	0 (0.0%)	6 (40.0%)	9 (60.0%)	0 (0.0%)	15
Device wireless communication issue	1 (6.7%)	5 (33.3%)	9 (60.0%)	0 (0.0%)	15
Alcohol poisoning	4 (26.7%)	7 (46.7%)	4 (26.7%)	0 (0.0%)	15
Dermo-hypodermatitis	0 (0.0%)	0 (0.0%)	13 (86.7%)	2 (13.3%)	15
Dermatosis	1 (6.7%)	8 (53.3%)	4 (26.7%)	2 (13.3%)	15
Concomitant disease progression	0 (0.0%)	7 (46.7%)	3 (20.0%)	5 (33.3%)	15

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
KL-6 increased	0 (0.0%)	1 (6.7%)	10 (66.7%)	4 (26.7%)	15
Ischaemic cardiomyopathy	0 (0.0%)	1 (6.7%)	11 (73.3%)	3 (20.0%)	15
Trichodysplasia spinulosa	7 (46.7%)	8 (53.3%)	0 (0.0%)	0 (0.0%)	15
Transplant failure	4 (26.7%)	4 (26.7%)	7 (46.7%)	0 (0.0%)	15
Suspected product quality issue	1 (6.7%)	5 (33.3%)	8 (53.3%)	1 (6.7%)	15
Hypoglycaemic unconsciousness	1 (6.7%)	2 (13.3%)	7 (46.7%)	5 (33.3%)	15
Pertussis	6 (40.0%)	2 (13.3%)	7 (46.7%)	0 (0.0%)	15
Tracheobronchitis	0 (0.0%)	2 (13.3%)	12 (80.0%)	1 (6.7%)	15
Tenosynovitis stenosans	0 (0.0%)	9 (60.0%)	5 (33.3%)	1 (6.7%)	15
Toxic leukoencephalopathy	3 (20.0%)	5 (33.3%)	6 (40.0%)	1 (6.7%)	15
Topical steroid withdrawal reaction	4 (26.7%)	8 (53.3%)	3 (20.0%)	0 (0.0%)	15
Conjunctival oedema	4 (26.7%)	4 (26.7%)	6 (40.0%)	1 (6.7%)	15
Necrotising retinitis	0 (0.0%)	2 (13.3%)	13 (86.7%)	0 (0.0%)	15
Corneal opacity	3 (20.0%)	6 (40.0%)	6 (40.0%)	0 (0.0%)	15
Corneal abrasion	2 (13.3%)	5 (33.3%)	6 (40.0%)	2 (13.3%)	15
Transaminases abnormal	6 (40.0%)	8 (53.3%)	1 (6.7%)	0 (0.0%)	15
Biliary tract disorder	2 (13.3%)	8 (53.3%)	4 (26.7%)	1 (6.7%)	15
Blood bilirubin decreased	5 (33.3%)	4 (26.7%)	5 (33.3%)	1 (6.7%)	15
Tinea infection	1 (6.7%)	5 (33.3%)	8 (53.3%)	1 (6.7%)	15
Corneal perforation	0 (0.0%)	3 (20.0%)	9 (60.0%)	3 (20.0%)	15
Blood albumin increased	1 (6.7%)	3 (20.0%)	11 (73.3%)	0 (0.0%)	15
Drug dispensed to wrong patient	5 (33.3%)	1 (6.7%)	7 (46.7%)	2 (13.3%)	15
Hypoaesthesia eye	0 (0.0%)	8 (53.3%)	7 (46.7%)	0 (0.0%)	15
Gastroenteritis Escherichia coli	1 (6.7%)	0 (0.0%)	12 (80.0%)	2 (13.3%)	15
Subcutaneous haematoma	6 (40.0%)	0 (0.0%)	6 (40.0%)	3 (20.0%)	15
Intestinal dilatation	1 (6.7%)	8 (53.3%)	6 (40.0%)	0 (0.0%)	15
Globotriaosylsphingosine increased	5 (33.3%)	6 (40.0%)	4 (26.7%)	0 (0.0%)	15

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Sputum purulent	0 (0.0%)	4 (26.7%)	10 (66.7%)	1 (6.7%)	15
Small intestinal resection	2 (13.3%)	5 (33.3%)	8 (53.3%)	0 (0.0%)	15
Bite	2 (13.3%)	4 (26.7%)	9 (60.0%)	0 (0.0%)	15
High density lipoprotein increased	1 (6.7%)	4 (26.7%)	6 (40.0%)	4 (26.7%)	15
Skin sensitisation	0 (0.0%)	8 (53.3%)	7 (46.7%)	0 (0.0%)	15
Urine albumin/creatinine ratio increased	0 (0.0%)	5 (33.3%)	7 (46.7%)	3 (20.0%)	15
Drug therapy	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (100.0%)	15
Drug withdrawal convulsions	5 (33.3%)	6 (40.0%)	4 (26.7%)	0 (0.0%)	15
Anisocoria	7 (46.7%)	7 (46.7%)	0 (0.0%)	1 (6.7%)	15
Heat illness	1 (6.7%)	0 (0.0%)	6 (40.0%)	8 (53.3%)	15
Gaze palsy	4 (26.7%)	2 (13.3%)	5 (33.3%)	4 (26.7%)	15
Excessive cerumen production	0 (0.0%)	4 (26.7%)	9 (60.0%)	2 (13.3%)	15
Vascular purpura	0 (0.0%)	2 (13.3%)	5 (33.3%)	8 (53.3%)	15
Vein collapse	3 (20.0%)	3 (20.0%)	8 (53.3%)	1 (6.7%)	15
Renal haematoma	0 (0.0%)	4 (26.7%)	8 (53.3%)	3 (20.0%)	15
Haemodialysis	3 (20.0%)	1 (6.7%)	6 (40.0%)	5 (33.3%)	15
Blood iron abnormal	0 (0.0%)	2 (13.3%)	12 (80.0%)	1 (6.7%)	15
Insulinoma	0 (0.0%)	10 (66.7%)	1 (6.7%)	4 (26.7%)	15
Cystitis bacterial	4 (26.7%)	3 (20.0%)	5 (33.3%)	3 (20.0%)	15
Viral haemorrhagic cystitis	8 (53.3%)	2 (13.3%)	5 (33.3%)	0 (0.0%)	15
Proteus infection	3 (20.0%)	3 (20.0%)	7 (46.7%)	2 (13.3%)	15
Intestinal pseudo-obstruction	0 (0.0%)	4 (26.7%)	11 (73.3%)	0 (0.0%)	15
Genital hypoaesthesia	8 (53.3%)	7 (46.7%)	0 (0.0%)	0 (0.0%)	15
Intra-ocular injection complication	0 (0.0%)	0 (0.0%)	6 (40.0%)	9 (60.0%)	15
Cerebrovascular disorder	1 (6.7%)	4 (26.7%)	7 (46.7%)	3 (20.0%)	15
Gastrointestinal scarring	2 (13.3%)	3 (20.0%)	7 (46.7%)	3 (20.0%)	15
Intraventricular haemorrhage	2 (13.3%)	3 (20.0%)	4 (26.7%)	6 (40.0%)	15

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intraventricular haemorrhage neonatal	15 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15
Abscess drainage	1 (6.7%)	8 (53.3%)	5 (33.3%)	1 (6.7%)	15
Central nervous system vasculitis	0 (0.0%)	7 (50.0%)	7 (50.0%)	0 (0.0%)	14
Gastric pH decreased	1 (7.1%)	2 (14.3%)	11 (78.6%)	0 (0.0%)	14
Acinetobacter infection	2 (14.3%)	3 (21.4%)	9 (64.3%)	0 (0.0%)	14
Hepatorenal syndrome	4 (28.6%)	2 (14.3%)	7 (50.0%)	1 (7.1%)	14
Quadriplegia	3 (21.4%)	3 (21.4%)	7 (50.0%)	1 (7.1%)	14
Short-bowel syndrome	5 (35.7%)	1 (7.1%)	8 (57.1%)	0 (0.0%)	14
Ear operation	2 (14.3%)	2 (14.3%)	8 (57.1%)	2 (14.3%)	14
Autonomic neuropathy	1 (7.1%)	7 (50.0%)	3 (21.4%)	3 (21.4%)	14
Pelvic abscess	0 (0.0%)	3 (21.4%)	8 (57.1%)	3 (21.4%)	14
Eye ulcer	1 (7.1%)	5 (35.7%)	5 (35.7%)	3 (21.4%)	14
Breast operation	0 (0.0%)	3 (21.4%)	8 (57.1%)	3 (21.4%)	14
Faecal volume increased	2 (14.3%)	4 (28.6%)	6 (42.9%)	2 (14.3%)	14
Overlap syndrome	0 (0.0%)	6 (42.9%)	7 (50.0%)	1 (7.1%)	14
Blood insulin increased	0 (0.0%)	10 (71.4%)	3 (21.4%)	1 (7.1%)	14
Rectal adenocarcinoma	0 (0.0%)	3 (21.4%)	9 (64.3%)	2 (14.3%)	14
Limb deformity	1 (7.1%)	6 (42.9%)	4 (28.6%)	3 (21.4%)	14
Vascular rupture	0 (0.0%)	6 (42.9%)	6 (42.9%)	2 (14.3%)	14
Uhthoff's phenomenon	0 (0.0%)	12 (85.7%)	2 (14.3%)	0 (0.0%)	14
Oncologic complication	0 (0.0%)	2 (14.3%)	8 (57.1%)	4 (28.6%)	14
Chronic graft versus host disease in skin	6 (42.9%)	4 (28.6%)	4 (28.6%)	0 (0.0%)	14
Oedema mucosal	4 (28.6%)	2 (14.3%)	7 (50.0%)	1 (7.1%)	14
Occipital neuralgia	1 (7.1%)	7 (50.0%)	6 (42.9%)	0 (0.0%)	14
No device malfunction	11 (78.6%)	0 (0.0%)	3 (21.4%)	0 (0.0%)	14
Epstein Barr virus positive mucocutaneous ulcer	0 (0.0%)	0 (0.0%)	6 (42.9%)	8 (57.1%)	14
Neurologic neglect syndrome	0 (0.0%)	1 (7.1%)	12 (85.7%)	1 (7.1%)	14

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Feeding intolerance	13 (92.9%)	1 (7.1%)	0 (0.0%)	0 (0.0%)	14
SJS-TEN overlap	4 (28.6%)	6 (42.9%)	3 (21.4%)	1 (7.1%)	14
Circadian rhythm sleep disorder	0 (0.0%)	2 (14.3%)	12 (85.7%)	0 (0.0%)	14
Nail operation	0 (0.0%)	0 (0.0%)	13 (92.9%)	1 (7.1%)	14
Endometrial thickening	0 (0.0%)	4 (28.6%)	10 (71.4%)	0 (0.0%)	14
Myosclerosis	0 (0.0%)	8 (57.1%)	6 (42.9%)	0 (0.0%)	14
Encephalomalacia	1 (7.1%)	2 (14.3%)	10 (71.4%)	1 (7.1%)	14
Mutism	0 (0.0%)	3 (21.4%)	8 (57.1%)	3 (21.4%)	14
Electrocardiogram QRS complex shortened	6 (42.9%)	5 (35.7%)	1 (7.1%)	2 (14.3%)	14
Morton's neuralgia	0 (0.0%)	1 (7.1%)	13 (92.9%)	0 (0.0%)	14
Bronchial hyperreactivity	1 (7.1%)	3 (21.4%)	9 (64.3%)	1 (7.1%)	14
Alpha 1 foetoprotein increased	0 (0.0%)	0 (0.0%)	11 (78.6%)	3 (21.4%)	14
Monoclonal gammopathy	0 (0.0%)	4 (28.6%)	6 (42.9%)	4 (28.6%)	14
Metastatic renal cell carcinoma	0 (0.0%)	4 (28.6%)	8 (57.1%)	2 (14.3%)	14
Pelvic inflammatory disease	3 (21.4%)	7 (50.0%)	3 (21.4%)	1 (7.1%)	14
Urinary tract infection enterococcal	1 (7.1%)	1 (7.1%)	9 (64.3%)	3 (21.4%)	14
Mesenteric panniculitis	0 (0.0%)	7 (50.0%)	5 (35.7%)	2 (14.3%)	14
Meningitis pneumococcal	1 (7.1%)	3 (21.4%)	10 (71.4%)	0 (0.0%)	14
Skin bacterial infection	1 (7.1%)	4 (28.6%)	8 (57.1%)	1 (7.1%)	14
Penis disorder	4 (28.6%)	4 (28.6%)	5 (35.7%)	1 (7.1%)	14
Measles	8 (57.1%)	3 (21.4%)	3 (21.4%)	0 (0.0%)	14
Colon neoplasm	0 (0.0%)	3 (21.4%)	6 (42.9%)	5 (35.7%)	14
Colon operation	0 (0.0%)	3 (21.4%)	8 (57.1%)	3 (21.4%)	14
Drug level fluctuating	9 (64.3%)	2 (14.3%)	3 (21.4%)	0 (0.0%)	14
Brain contusion	0 (0.0%)	2 (14.3%)	7 (50.0%)	5 (35.7%)	14
Skull fracture	3 (21.4%)	4 (28.6%)	5 (35.7%)	2 (14.3%)	14
Sleep disorder therapy	0 (0.0%)	0 (0.0%)	0 (0.0%)	14 (100.0%)	14

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Drug abuser	7 (50.0%)	2 (14.3%)	5 (35.7%)	0 (0.0%)	14
Malignant ascites	1 (7.1%)	2 (14.3%)	6 (42.9%)	5 (35.7%)	14
Botulism	0 (0.0%)	9 (64.3%)	5 (35.7%)	0 (0.0%)	14
Disturbance in social behaviour	5 (35.7%)	5 (35.7%)	3 (21.4%)	1 (7.1%)	14
Soliloquy	0 (0.0%)	8 (57.1%)	5 (35.7%)	1 (7.1%)	14
Lung carcinoma cell type unspecified stage IV	0 (0.0%)	0 (0.0%)	11 (78.6%)	3 (21.4%)	14
Low density lipoprotein decreased	0 (0.0%)	0 (0.0%)	11 (78.6%)	3 (21.4%)	14
Application site discolouration	1 (7.1%)	4 (28.6%)	8 (57.1%)	1 (7.1%)	14
Cross sensitivity reaction	3 (21.4%)	1 (7.1%)	6 (42.9%)	4 (28.6%)	14
Lipoedema	1 (7.1%)	10 (71.4%)	2 (14.3%)	1 (7.1%)	14
Lipids abnormal	1 (7.1%)	5 (35.7%)	7 (50.0%)	1 (7.1%)	14
Lipid metabolism disorder	0 (0.0%)	3 (21.4%)	10 (71.4%)	1 (7.1%)	14
Critical illness	3 (21.4%)	2 (14.3%)	7 (50.0%)	2 (14.3%)	14
Foetal heart rate abnormal	1 (7.1%)	13 (92.9%)	0 (0.0%)	0 (0.0%)	14
Bladder operation	0 (0.0%)	2 (14.3%)	11 (78.6%)	1 (7.1%)	14
Infection parasitic	2 (14.3%)	7 (50.0%)	5 (35.7%)	0 (0.0%)	14
Catheter placement	2 (14.3%)	1 (7.1%)	7 (50.0%)	4 (28.6%)	14
Blood urea abnormal	1 (7.1%)	4 (28.6%)	6 (42.9%)	3 (21.4%)	14
Dissociative disorder	1 (7.1%)	12 (85.7%)	1 (7.1%)	0 (0.0%)	14
Dermatitis exfoliative	1 (7.1%)	2 (14.3%)	10 (71.4%)	1 (7.1%)	14
Klebsiella urinary tract infection	0 (0.0%)	3 (21.4%)	7 (50.0%)	4 (28.6%)	14
Klebsiella test positive	0 (0.0%)	5 (35.7%)	9 (64.3%)	0 (0.0%)	14
Klebsiella sepsis	2 (14.3%)	5 (35.7%)	5 (35.7%)	2 (14.3%)	14
Dental restoration failure	0 (0.0%)	2 (14.3%)	7 (50.0%)	5 (35.7%)	14
Pupillary reflex impaired	6 (42.9%)	4 (28.6%)	3 (21.4%)	1 (7.1%)	14
Stoma prolapse	4 (28.6%)	5 (35.7%)	5 (35.7%)	0 (0.0%)	14
Nail bed inflammation	0 (0.0%)	8 (57.1%)	5 (35.7%)	1 (7.1%)	14

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Injection site atrophy	5 (35.7%)	6 (42.9%)	3 (21.4%)	0 (0.0%)	14
Testicular swelling	0 (0.0%)	4 (28.6%)	8 (57.1%)	2 (14.3%)	14
Implant site infection	1 (7.1%)	8 (57.1%)	5 (35.7%)	0 (0.0%)	14
Infected fistula	4 (28.6%)	4 (28.6%)	5 (35.7%)	1 (7.1%)	14
Tumour marker abnormal	0 (0.0%)	2 (14.3%)	10 (71.4%)	2 (14.3%)	14
Needle fatigue	2 (14.3%)	2 (14.3%)	10 (71.4%)	0 (0.0%)	14
Incisional hernia	0 (0.0%)	6 (42.9%)	6 (42.9%)	2 (14.3%)	14
Thyroid hormones increased	0 (0.0%)	2 (14.3%)	10 (71.4%)	2 (14.3%)	14
Immune-mediated cystitis	0 (0.0%)	1 (7.1%)	12 (85.7%)	1 (7.1%)	14
Anticoagulant-related nephropathy	0 (0.0%)	0 (0.0%)	9 (64.3%)	5 (35.7%)	14
Dose calculation error	10 (71.4%)	2 (14.3%)	2 (14.3%)	0 (0.0%)	14
Cyanosis neonatal	14 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	14
Thyroiditis subacute	0 (0.0%)	4 (28.6%)	9 (64.3%)	1 (7.1%)	14
Immune-mediated hyperthyroidism	0 (0.0%)	3 (21.4%)	10 (71.4%)	1 (7.1%)	14
Immune-mediated encephalitis	0 (0.0%)	1 (7.1%)	10 (71.4%)	3 (21.4%)	14
Thrombocytopenic purpura	1 (7.1%)	3 (21.4%)	6 (42.9%)	4 (28.6%)	14
Pneumonia influenzal	3 (21.4%)	5 (35.7%)	6 (42.9%)	0 (0.0%)	14
Therapeutic response changed	4 (28.6%)	5 (35.7%)	5 (35.7%)	0 (0.0%)	14
Tracheitis	10 (71.4%)	2 (14.3%)	0 (0.0%)	2 (14.3%)	14
Post 5-alpha-reductase inhibitor syndrome	0 (0.0%)	10 (71.4%)	4 (28.6%)	0 (0.0%)	14
Epiglottitis	1 (7.1%)	1 (7.1%)	12 (85.7%)	0 (0.0%)	14
Hypertensive emergency	0 (0.0%)	1 (7.1%)	13 (92.9%)	0 (0.0%)	14
Tuberculin test positive	0 (0.0%)	4 (28.6%)	10 (71.4%)	0 (0.0%)	14
Computerised tomogram thorax abnormal	1 (7.1%)	7 (50.0%)	3 (21.4%)	3 (21.4%)	14
Coagulation factor deficiency	0 (0.0%)	0 (0.0%)	12 (85.7%)	2 (14.3%)	14
Infusion site warmth	4 (28.6%)	2 (14.3%)	7 (50.0%)	1 (7.1%)	14
Hepatitis A	0 (0.0%)	3 (21.4%)	11 (78.6%)	0 (0.0%)	14

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Urine flow decreased	0 (0.0%)	5 (35.7%)	7 (50.0%)	2 (14.3%)	14
Administration site swelling	1 (7.1%)	5 (35.7%)	5 (35.7%)	3 (21.4%)	14
Cortisol increased	0 (0.0%)	8 (57.1%)	6 (42.9%)	0 (0.0%)	14
Clear cell renal cell carcinoma	0 (0.0%)	9 (64.3%)	5 (35.7%)	0 (0.0%)	14
Injection site ulcer	2 (14.3%)	4 (28.6%)	8 (57.1%)	0 (0.0%)	14
Vascular occlusion	1 (7.1%)	2 (14.3%)	9 (64.3%)	2 (14.3%)	14
Whipple's disease	0 (0.0%)	4 (28.6%)	10 (71.4%)	0 (0.0%)	14
Haemorrhagic cyst	5 (35.7%)	4 (28.6%)	5 (35.7%)	0 (0.0%)	14
Chronic allograft nephropathy	1 (7.1%)	5 (35.7%)	8 (57.1%)	0 (0.0%)	14
Renal abscess	2 (14.3%)	5 (35.7%)	6 (42.9%)	1 (7.1%)	14
Ocular myasthenia	0 (0.0%)	0 (0.0%)	10 (71.4%)	4 (28.6%)	14
Angiocentric lymphoma	10 (71.4%)	0 (0.0%)	3 (21.4%)	1 (7.1%)	14
Cystitis interstitial	1 (7.1%)	3 (21.4%)	9 (64.3%)	1 (7.1%)	14
Vitamin B complex deficiency	0 (0.0%)	7 (50.0%)	5 (35.7%)	2 (14.3%)	14
Intestinal angioedema	0 (0.0%)	2 (14.3%)	7 (50.0%)	5 (35.7%)	14
Vulvovaginal swelling	1 (7.1%)	3 (21.4%)	10 (71.4%)	0 (0.0%)	14
Accidental poisoning	2 (14.3%)	6 (42.9%)	5 (35.7%)	1 (7.1%)	14
Gestational hypertension	1 (7.1%)	13 (92.9%)	0 (0.0%)	0 (0.0%)	14
Penile discomfort	0 (0.0%)	9 (64.3%)	4 (28.6%)	1 (7.1%)	14
Acute sinusitis	1 (7.1%)	5 (35.7%)	7 (50.0%)	1 (7.1%)	14
Cerebral toxoplasmosis	3 (21.4%)	1 (7.1%)	9 (64.3%)	1 (7.1%)	14
Cerebral microhaemorrhage	1 (7.1%)	4 (28.6%)	9 (64.3%)	0 (0.0%)	14
Postrenal failure	0 (0.0%)	1 (7.1%)	4 (28.6%)	9 (64.3%)	14
Haemobilia	1 (7.7%)	2 (15.4%)	4 (30.8%)	6 (46.2%)	13
Opportunistic infection	1 (7.7%)	8 (61.5%)	3 (23.1%)	1 (7.7%)	13
Death neonatal	8 (61.5%)	3 (23.1%)	2 (15.4%)	0 (0.0%)	13
Glycosuria	4 (30.8%)	2 (15.4%)	6 (46.2%)	1 (7.7%)	13

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gait spastic	0 (0.0%)	2 (15.4%)	11 (84.6%)	0 (0.0%)	13
B-lymphocyte count increased	0 (0.0%)	8 (61.5%)	5 (38.5%)	0 (0.0%)	13
Food interaction	1 (7.7%)	6 (46.2%)	5 (38.5%)	1 (7.7%)	13
Renal vasculitis	1 (7.7%)	2 (15.4%)	9 (69.2%)	1 (7.7%)	13
Perineal abscess	1 (7.7%)	8 (61.5%)	4 (30.8%)	0 (0.0%)	13
Metastases to pleura	0 (0.0%)	4 (30.8%)	8 (61.5%)	1 (7.7%)	13
Ear injury	0 (0.0%)	1 (7.7%)	12 (92.3%)	0 (0.0%)	13
Paraesthesia ear	0 (0.0%)	3 (23.1%)	10 (76.9%)	0 (0.0%)	13
Vasospasm	1 (7.7%)	7 (53.8%)	5 (38.5%)	0 (0.0%)	13
Ovarian mass	0 (0.0%)	4 (30.8%)	8 (61.5%)	1 (7.7%)	13
Migraine without aura	1 (7.7%)	11 (84.6%)	1 (7.7%)	0 (0.0%)	13
Haemorrhage in pregnancy	3 (23.1%)	10 (76.9%)	0 (0.0%)	0 (0.0%)	13
Carbuncle	0 (0.0%)	2 (15.4%)	2 (15.4%)	9 (69.2%)	13
Renal tubular atrophy	2 (15.4%)	1 (7.7%)	7 (53.8%)	3 (23.1%)	13
Ophthalmoplegia	2 (15.4%)	2 (15.4%)	9 (69.2%)	0 (0.0%)	13
Ejaculation failure	0 (0.0%)	8 (61.5%)	5 (38.5%)	0 (0.0%)	13
Amniotic cavity infection	7 (53.8%)	6 (46.2%)	0 (0.0%)	0 (0.0%)	13
Obsessive-compulsive symptom	11 (84.6%)	1 (7.7%)	1 (7.7%)	0 (0.0%)	13
Essential thrombocythaemia	0 (0.0%)	2 (15.4%)	8 (61.5%)	3 (23.1%)	13
Non-cardiogenic pulmonary oedema	1 (7.7%)	10 (76.9%)	2 (15.4%)	0 (0.0%)	13
Non-alcoholic fatty liver	1 (7.7%)	6 (46.2%)	5 (38.5%)	1 (7.7%)	13
Neuromuscular toxicity	0 (0.0%)	2 (15.4%)	7 (53.8%)	4 (30.8%)	13
Feeling guilty	5 (38.5%)	5 (38.5%)	3 (23.1%)	0 (0.0%)	13
Parathyroid disorder	0 (0.0%)	2 (15.4%)	11 (84.6%)	0 (0.0%)	13
Bullous haemorrhagic dermatosis	0 (0.0%)	1 (7.7%)	5 (38.5%)	7 (53.8%)	13
Urticarial vasculitis	4 (30.8%)	3 (23.1%)	5 (38.5%)	1 (7.7%)	13
Bronchitis bacterial	2 (15.4%)	4 (30.8%)	7 (53.8%)	0 (0.0%)	13

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Multimorbidity	1 (7.7%)	1 (7.7%)	7 (53.8%)	4 (30.8%)	13
Mucosal haemorrhage	3 (23.1%)	5 (38.5%)	3 (23.1%)	2 (15.4%)	13
Hepatobiliary disease	1 (7.7%)	4 (30.8%)	8 (61.5%)	0 (0.0%)	13
Microangiopathic haemolytic anaemia	0 (0.0%)	4 (30.8%)	6 (46.2%)	3 (23.1%)	13
Metastatic squamous cell carcinoma	0 (0.0%)	2 (15.4%)	10 (76.9%)	1 (7.7%)	13
Blood folate decreased	1 (7.7%)	4 (30.8%)	6 (46.2%)	2 (15.4%)	13
Breast conserving surgery	0 (0.0%)	5 (38.5%)	7 (53.8%)	1 (7.7%)	13
Carotid artery disease	0 (0.0%)	1 (7.7%)	6 (46.2%)	6 (46.2%)	13
Dyshidrotic eczema	1 (7.7%)	7 (53.8%)	4 (30.8%)	1 (7.7%)	13
Meningitis viral	3 (23.1%)	7 (53.8%)	3 (23.1%)	0 (0.0%)	13
Medical device pain	3 (23.1%)	3 (23.1%)	4 (30.8%)	3 (23.1%)	13
Drug withdrawal syndrome neonatal	13 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13
Mechanical ventilation	4 (30.8%)	1 (7.7%)	7 (53.8%)	1 (7.7%)	13
Mechanical ileus	0 (0.0%)	0 (0.0%)	7 (53.8%)	6 (46.2%)	13
Mastocytosis	2 (15.4%)	7 (53.8%)	3 (23.1%)	1 (7.7%)	13
Mammoplasty	0 (0.0%)	8 (61.5%)	5 (38.5%)	0 (0.0%)	13
Malocclusion	6 (46.2%)	1 (7.7%)	6 (46.2%)	0 (0.0%)	13
Intermittent claudication	0 (0.0%)	2 (15.4%)	8 (61.5%)	3 (23.1%)	13
Bladder dilatation	1 (7.7%)	8 (61.5%)	2 (15.4%)	2 (15.4%)	13
Allergic cough	1 (7.7%)	1 (7.7%)	10 (76.9%)	1 (7.7%)	13
Lung hyperinflation	0 (0.0%)	4 (30.8%)	7 (53.8%)	2 (15.4%)	13
Lung diffusion test decreased	0 (0.0%)	1 (7.7%)	10 (76.9%)	2 (15.4%)	13
Folate deficiency	0 (0.0%)	2 (15.4%)	4 (30.8%)	7 (53.8%)	13
Discoloured vomit	1 (7.7%)	0 (0.0%)	7 (53.8%)	5 (38.5%)	13
Myelodysplastic syndrome with excess blasts	1 (7.7%)	2 (15.4%)	9 (69.2%)	1 (7.7%)	13
Human rhinovirus test positive	7 (53.8%)	3 (23.1%)	3 (23.1%)	0 (0.0%)	13
Humidity intolerance	0 (0.0%)	2 (15.4%)	9 (69.2%)	2 (15.4%)	13

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Liver carcinoma ruptured	0 (0.0%)	2 (15.4%)	8 (61.5%)	3 (23.1%)	13
Croup infectious	11 (84.6%)	0 (0.0%)	1 (7.7%)	1 (7.7%)	13
Lip ulceration	2 (15.4%)	5 (38.5%)	4 (30.8%)	2 (15.4%)	13
Diaphragmalgia	0 (0.0%)	2 (15.4%)	11 (84.6%)	0 (0.0%)	13
Lip erosion	0 (0.0%)	3 (23.1%)	8 (61.5%)	2 (15.4%)	13
Appendix disorder	2 (15.4%)	1 (7.7%)	8 (61.5%)	2 (15.4%)	13
Body surface area increased	0 (0.0%)	5 (38.5%)	8 (61.5%)	0 (0.0%)	13
Anterior chamber inflammation	0 (0.0%)	1 (7.7%)	8 (61.5%)	4 (30.8%)	13
Device maintenance issue	3 (23.1%)	2 (15.4%)	5 (38.5%)	3 (23.1%)	13
Bloody discharge	2 (15.4%)	1 (7.7%)	6 (46.2%)	4 (30.8%)	13
Blood urea decreased	4 (30.8%)	5 (38.5%)	3 (23.1%)	1 (7.7%)	13
Granulocyte count increased	0 (0.0%)	7 (53.8%)	5 (38.5%)	1 (7.7%)	13
Apallic syndrome	2 (15.4%)	1 (7.7%)	8 (61.5%)	2 (15.4%)	13
Aortitis	0 (0.0%)	1 (7.7%)	9 (69.2%)	3 (23.1%)	13
Aortic valve replacement	0 (0.0%)	0 (0.0%)	6 (46.2%)	7 (53.8%)	13
Invasive breast carcinoma	0 (0.0%)	9 (69.2%)	4 (30.8%)	0 (0.0%)	13
Wrong drug	1 (7.7%)	0 (0.0%)	0 (0.0%)	12 (92.3%)	13
Intracranial mass	0 (0.0%)	1 (7.7%)	11 (84.6%)	1 (7.7%)	13
Stress urinary incontinence	0 (0.0%)	4 (30.8%)	6 (46.2%)	3 (23.1%)	13
Cryopyrin associated periodic syndrome	1 (7.7%)	10 (76.9%)	1 (7.7%)	1 (7.7%)	13
Nasal crusting	0 (0.0%)	3 (23.1%)	9 (69.2%)	1 (7.7%)	13
Puncture site pain	5 (38.5%)	2 (15.4%)	6 (46.2%)	0 (0.0%)	13
Venous injury	4 (30.8%)	1 (7.7%)	6 (46.2%)	2 (15.4%)	13
Coronary artery thrombosis	2 (15.4%)	1 (7.7%)	6 (46.2%)	4 (30.8%)	13
T-lymphocyte count decreased	2 (15.4%)	2 (15.4%)	5 (38.5%)	4 (30.8%)	13
Enterococcus test positive	2 (15.4%)	4 (30.8%)	6 (46.2%)	1 (7.7%)	13
Therapeutic product effect increased	2 (15.4%)	2 (15.4%)	6 (46.2%)	3 (23.1%)	13

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Amaurosis fugax	0 (0.0%)	3 (23.1%)	9 (69.2%)	1 (7.7%)	13
Abdominal symptom	3 (23.1%)	2 (15.4%)	7 (53.8%)	1 (7.7%)	13
Infection in an immunocompromised host	1 (7.7%)	4 (30.8%)	5 (38.5%)	3 (23.1%)	13
Jaw fracture	0 (0.0%)	0 (0.0%)	10 (76.9%)	3 (23.1%)	13
Pseudostroke	1 (7.7%)	1 (7.7%)	10 (76.9%)	1 (7.7%)	13
C-reactive protein decreased	0 (0.0%)	2 (15.4%)	10 (76.9%)	1 (7.7%)	13
Gambling disorder	1 (7.7%)	3 (23.1%)	9 (69.2%)	0 (0.0%)	13
Transient global amnesia	1 (7.7%)	1 (7.7%)	10 (76.9%)	1 (7.7%)	13
Total lung capacity abnormal	0 (0.0%)	1 (7.7%)	12 (92.3%)	0 (0.0%)	13
Fungal oesophagitis	0 (0.0%)	6 (46.2%)	5 (38.5%)	2 (15.4%)	13
Pneumonia mycoplasmal	7 (53.8%)	1 (7.7%)	4 (30.8%)	1 (7.7%)	13
Gastric fistula	0 (0.0%)	2 (15.4%)	10 (76.9%)	1 (7.7%)	13
Contrast encephalopathy	0 (0.0%)	3 (23.1%)	6 (46.2%)	4 (30.8%)	13
Central nervous system lupus	0 (0.0%)	13 (100.0%)	0 (0.0%)	0 (0.0%)	13
Central nervous system lymphoma	0 (0.0%)	2 (15.4%)	9 (69.2%)	2 (15.4%)	13
Consciousness fluctuating	1 (7.7%)	0 (0.0%)	10 (76.9%)	2 (15.4%)	13
Tracheal stenosis	2 (15.4%)	2 (15.4%)	8 (61.5%)	1 (7.7%)	13
Anticoagulation drug level above therapeutic	1 (7.7%)	0 (0.0%)	8 (61.5%)	4 (30.8%)	13
Superior vena cava syndrome	2 (15.4%)	3 (23.1%)	6 (46.2%)	2 (15.4%)	13
Sudden cardiac death	1 (7.7%)	0 (0.0%)	9 (69.2%)	3 (23.1%)	13
Biliary tract infection	0 (0.0%)	4 (30.8%)	8 (61.5%)	1 (7.7%)	13
Streptococcus test positive	2 (15.4%)	4 (30.8%)	7 (53.8%)	0 (0.0%)	13
Splenic rupture	0 (0.0%)	2 (15.4%)	5 (38.5%)	6 (46.2%)	13
Gastrointestinal anastomotic leak	0 (0.0%)	1 (7.7%)	12 (92.3%)	0 (0.0%)	13
Hyperadrenocorticism	0 (0.0%)	1 (7.7%)	12 (92.3%)	0 (0.0%)	13
Soft tissue mass	0 (0.0%)	5 (38.5%)	6 (46.2%)	2 (15.4%)	13
Hilar lymphadenopathy	1 (7.7%)	4 (30.8%)	7 (53.8%)	1 (7.7%)	13

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Sitting disability	0 (0.0%)	8 (61.5%)	1 (7.7%)	4 (30.8%)	13
Heart sounds	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Primary hypothyroidism	1 (7.7%)	0 (0.0%)	9 (69.2%)	3 (23.1%)	13
Biopsy	0 (0.0%)	2 (15.4%)	8 (61.5%)	3 (23.1%)	13
Proctectomy	1 (7.7%)	10 (76.9%)	2 (15.4%)	0 (0.0%)	13
Hemianopia	0 (0.0%)	10 (76.9%)	3 (23.1%)	0 (0.0%)	13
Chronic myelomonocytic leukaemia	0 (0.0%)	0 (0.0%)	8 (61.5%)	5 (38.5%)	13
Retinal pigment epitheliopathy	0 (0.0%)	4 (30.8%)	4 (30.8%)	5 (38.5%)	13
Blood triglycerides abnormal	1 (7.7%)	3 (23.1%)	8 (61.5%)	1 (7.7%)	13
Obstruction gastric	2 (15.4%)	1 (7.7%)	8 (61.5%)	2 (15.4%)	13
Retinal dystrophy	1 (7.7%)	7 (53.8%)	5 (38.5%)	0 (0.0%)	13
Product contamination microbial	3 (23.1%)	3 (23.1%)	6 (46.2%)	1 (7.7%)	13
Traumatic haematoma	4 (30.8%)	1 (7.7%)	5 (38.5%)	3 (23.1%)	13
Wernicke's encephalopathy	3 (23.1%)	1 (7.7%)	9 (69.2%)	0 (0.0%)	13
Abdominal operation	1 (7.7%)	4 (30.8%)	6 (46.2%)	2 (15.4%)	13
Intertrigo	1 (7.7%)	2 (15.4%)	9 (69.2%)	1 (7.7%)	13
Pulmonary infarction	2 (15.4%)	6 (46.2%)	3 (23.1%)	2 (15.4%)	13
Glomerulonephritis minimal lesion	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Polyserositis	1 (7.7%)	10 (76.9%)	2 (15.4%)	0 (0.0%)	13
Viral diarrhoea	5 (38.5%)	1 (7.7%)	3 (23.1%)	4 (30.8%)	13
Acne pustular	2 (15.4%)	3 (23.1%)	7 (53.8%)	1 (7.7%)	13
Product tampering	0 (0.0%)	6 (46.2%)	7 (53.8%)	0 (0.0%)	13
Product package associated injury	0 (0.0%)	1 (7.7%)	7 (53.8%)	5 (38.5%)	13
Family stress	0 (0.0%)	3 (23.1%)	8 (61.5%)	2 (15.4%)	13
Defect conduction intraventricular	1 (7.7%)	6 (46.2%)	4 (30.8%)	2 (15.4%)	13
Breast cellulitis	0 (0.0%)	4 (30.8%)	8 (61.5%)	1 (7.7%)	13
Premature menopause	1 (7.7%)	12 (92.3%)	0 (0.0%)	0 (0.0%)	13

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vascular injury	0 (0.0%)	2 (15.4%)	5 (38.5%)	6 (46.2%)	13
Delayed graft function	0 (0.0%)	5 (38.5%)	8 (61.5%)	0 (0.0%)	13
Intestinal infarction	0 (0.0%)	0 (0.0%)	9 (69.2%)	4 (30.8%)	13
Post-injection delirium sedation syndrome	3 (23.1%)	7 (53.8%)	3 (23.1%)	0 (0.0%)	13
International normalised ratio abnormal	1 (7.7%)	1 (7.7%)	9 (69.2%)	2 (15.4%)	13
Device ineffective	3 (25.0%)	1 (8.3%)	5 (41.7%)	3 (25.0%)	12
Gastric varices	0 (0.0%)	1 (8.3%)	11 (91.7%)	0 (0.0%)	12
Pneumonitis aspiration	1 (8.3%)	7 (58.3%)	1 (8.3%)	3 (25.0%)	12
Vascular calcification	2 (16.7%)	8 (66.7%)	2 (16.7%)	0 (0.0%)	12
Haemorrhagic infarction	0 (0.0%)	6 (50.0%)	2 (16.7%)	4 (33.3%)	12
Granulomatous liver disease	2 (16.7%)	4 (33.3%)	6 (50.0%)	0 (0.0%)	12
Ear neoplasm	0 (0.0%)	2 (16.7%)	6 (50.0%)	4 (33.3%)	12
Device related bacteraemia	5 (41.7%)	0 (0.0%)	7 (58.3%)	0 (0.0%)	12
Otitis media acute	7 (58.3%)	2 (16.7%)	3 (25.0%)	0 (0.0%)	12
Parotitis	0 (0.0%)	2 (16.7%)	10 (83.3%)	0 (0.0%)	12
Paraneoplastic syndrome	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Renal amyloidosis	1 (8.3%)	2 (16.7%)	3 (25.0%)	6 (50.0%)	12
Anaemia of chronic disease	2 (16.7%)	4 (33.3%)	4 (33.3%)	2 (16.7%)	12
Cardiac fibrillation	0 (0.0%)	1 (8.3%)	9 (75.0%)	2 (16.7%)	12
Venous occlusion	0 (0.0%)	3 (25.0%)	6 (50.0%)	3 (25.0%)	12
Facial spasm	3 (25.0%)	5 (41.7%)	1 (8.3%)	3 (25.0%)	12
Ovarian disorder	0 (0.0%)	7 (58.3%)	4 (33.3%)	1 (8.3%)	12
Atrial tachycardia	0 (0.0%)	2 (16.7%)	8 (66.7%)	2 (16.7%)	12
Extradural haematoma	1 (8.3%)	3 (25.0%)	6 (50.0%)	2 (16.7%)	12
Oligoarthritis	1 (8.3%)	4 (33.3%)	7 (58.3%)	0 (0.0%)	12
Respiratory tract oedema	4 (33.3%)	3 (25.0%)	4 (33.3%)	1 (8.3%)	12
Oesophageal infection	1 (8.3%)	1 (8.3%)	8 (66.7%)	2 (16.7%)	12

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Injection site scab	0 (0.0%)	7 (58.3%)	5 (41.7%)	0 (0.0%)	12
Eschar	1 (8.3%)	2 (16.7%)	7 (58.3%)	2 (16.7%)	12
Neutropenic infection	1 (8.3%)	6 (50.0%)	4 (33.3%)	1 (8.3%)	12
Salpingectomy	1 (8.3%)	10 (83.3%)	1 (8.3%)	0 (0.0%)	12
Enzyme level increased	0 (0.0%)	6 (50.0%)	6 (50.0%)	0 (0.0%)	12
Infusion site scar	1 (8.3%)	1 (8.3%)	9 (75.0%)	1 (8.3%)	12
Sarcoid-like reaction	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Enterovesical fistula	0 (0.0%)	5 (41.7%)	5 (41.7%)	2 (16.7%)	12
Nasal operation	1 (8.3%)	6 (50.0%)	5 (41.7%)	0 (0.0%)	12
Listeriosis	0 (0.0%)	1 (8.3%)	8 (66.7%)	3 (25.0%)	12
Violence-related symptom	1 (8.3%)	8 (66.7%)	3 (25.0%)	0 (0.0%)	12
Benign neoplasm of thyroid gland	0 (0.0%)	5 (41.7%)	7 (58.3%)	0 (0.0%)	12
Paroxysmal nocturnal haemoglobinuria	1 (8.3%)	4 (33.3%)	5 (41.7%)	2 (16.7%)	12
Endocarditis staphylococcal	0 (0.0%)	3 (25.0%)	4 (33.3%)	5 (41.7%)	12
Mycotic endophthalmitis	0 (0.0%)	1 (8.3%)	10 (83.3%)	1 (8.3%)	12
Clubbing	5 (41.7%)	1 (8.3%)	5 (41.7%)	1 (8.3%)	12
Uterine spasm	4 (33.3%)	5 (41.7%)	3 (25.0%)	0 (0.0%)	12
Muscle mass	0 (0.0%)	6 (50.0%)	5 (41.7%)	1 (8.3%)	12
Embolism arterial	2 (16.7%)	2 (16.7%)	8 (66.7%)	0 (0.0%)	12
Morphoea	0 (0.0%)	9 (75.0%)	3 (25.0%)	0 (0.0%)	12
Carditis	2 (16.7%)	3 (25.0%)	5 (41.7%)	2 (16.7%)	12
Arterial injury	0 (0.0%)	3 (25.0%)	5 (41.7%)	4 (33.3%)	12
Arrhythmic storm	0 (0.0%)	6 (50.0%)	6 (50.0%)	0 (0.0%)	12
Allergy to metals	1 (8.3%)	4 (33.3%)	6 (50.0%)	1 (8.3%)	12
Medication overuse headache	2 (16.7%)	6 (50.0%)	3 (25.0%)	1 (8.3%)	12
Muscle tension dysphonia	0 (0.0%)	11 (91.7%)	1 (8.3%)	0 (0.0%)	12
Drug-disease interaction	0 (0.0%)	8 (66.7%)	4 (33.3%)	0 (0.0%)	12

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Adnexa uteri pain	1 (8.3%)	7 (58.3%)	4 (33.3%)	0 (0.0%)	12
Mediastinitis	1 (8.3%)	0 (0.0%)	10 (83.3%)	1 (8.3%)	12
Mechanical urticaria	3 (25.0%)	7 (58.3%)	2 (16.7%)	0 (0.0%)	12
Drug monitoring procedure incorrectly performed	2 (16.7%)	5 (41.7%)	4 (33.3%)	1 (8.3%)	12
Skin neoplasm excision	0 (0.0%)	0 (0.0%)	7 (58.3%)	5 (41.7%)	12
Malignant neoplasm oligoprogession	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Male sexual dysfunction	3 (25.0%)	6 (50.0%)	3 (25.0%)	0 (0.0%)	12
Sleeve gastrectomy	1 (8.3%)	9 (75.0%)	2 (16.7%)	0 (0.0%)	12
Diverticulitis intestinal perforated	0 (0.0%)	5 (41.7%)	6 (50.0%)	1 (8.3%)	12
Lymphoid tissue hypoplasia	3 (25.0%)	9 (75.0%)	0 (0.0%)	0 (0.0%)	12
Lymphocyte percentage increased	1 (8.3%)	3 (25.0%)	7 (58.3%)	1 (8.3%)	12
Unintentional use for unapproved indication	0 (0.0%)	6 (50.0%)	6 (50.0%)	0 (0.0%)	12
Periorbital irritation	6 (50.0%)	2 (16.7%)	3 (25.0%)	1 (8.3%)	12
Bone fissure	0 (0.0%)	1 (8.3%)	7 (58.3%)	4 (33.3%)	12
Bone deformity	2 (16.7%)	2 (16.7%)	8 (66.7%)	0 (0.0%)	12
Light chain disease	0 (0.0%)	0 (0.0%)	11 (91.7%)	1 (8.3%)	12
Inflammatory myofibroblastic tumour	0 (0.0%)	12 (100.0%)	0 (0.0%)	0 (0.0%)	12
Lichen sclerosis	1 (8.3%)	1 (8.3%)	8 (66.7%)	2 (16.7%)	12
Diabetic complication	0 (0.0%)	2 (16.7%)	4 (33.3%)	6 (50.0%)	12
Libido disorder	2 (16.7%)	5 (41.7%)	4 (33.3%)	1 (8.3%)	12
Splenic abscess	3 (25.0%)	5 (41.7%)	4 (33.3%)	0 (0.0%)	12
QRS axis abnormal	0 (0.0%)	1 (8.3%)	8 (66.7%)	3 (25.0%)	12
Blood urea nitrogen/creatinine ratio increased	0 (0.0%)	1 (8.3%)	6 (50.0%)	5 (41.7%)	12
Detachment of retinal pigment epithelium	0 (0.0%)	0 (0.0%)	11 (91.7%)	1 (8.3%)	12
Infantile vomiting	12 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12
Blood testosterone increased	2 (16.7%)	3 (25.0%)	5 (41.7%)	2 (16.7%)	12
Labile blood pressure	1 (8.3%)	1 (8.3%)	6 (50.0%)	4 (33.3%)	12

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anterograde amnesia	4 (33.3%)	5 (41.7%)	1 (8.3%)	2 (16.7%)	12
Jugular vein distension	0 (0.0%)	4 (33.3%)	4 (33.3%)	4 (33.3%)	12
Vlth nerve paralysis	3 (25.0%)	3 (25.0%)	4 (33.3%)	2 (16.7%)	12
Conduction disorder	5 (41.7%)	3 (25.0%)	4 (33.3%)	0 (0.0%)	12
Bladder sphincter atony	1 (8.3%)	0 (0.0%)	11 (91.7%)	0 (0.0%)	12
Alanine aminotransferase decreased	0 (0.0%)	2 (16.7%)	6 (50.0%)	4 (33.3%)	12
Delusion of parasitosis	0 (0.0%)	3 (25.0%)	9 (75.0%)	0 (0.0%)	12
Tumour associated fever	1 (8.3%)	0 (0.0%)	9 (75.0%)	2 (16.7%)	12
Fractured sacrum	0 (0.0%)	4 (33.3%)	7 (58.3%)	1 (8.3%)	12
Hypervigilance	4 (33.3%)	3 (25.0%)	4 (33.3%)	1 (8.3%)	12
Phimosis	4 (33.3%)	1 (8.3%)	5 (41.7%)	2 (16.7%)	12
Nasal inflammation	2 (16.7%)	6 (50.0%)	3 (25.0%)	1 (8.3%)	12
Traumatic intracranial haemorrhage	1 (8.3%)	0 (0.0%)	4 (33.3%)	7 (58.3%)	12
Suture rupture	0 (0.0%)	1 (8.3%)	11 (91.7%)	0 (0.0%)	12
Suspected transmission of an infectious agent via pro	1 (8.3%)	4 (33.3%)	6 (50.0%)	1 (8.3%)	12
Blister infected	0 (0.0%)	1 (8.3%)	9 (75.0%)	2 (16.7%)	12
Vagal nerve stimulator implantation	9 (75.0%)	2 (16.7%)	1 (8.3%)	0 (0.0%)	12
Enterocolitis viral	4 (33.3%)	2 (16.7%)	5 (41.7%)	1 (8.3%)	12
Telangiectasia	2 (16.7%)	4 (33.3%)	6 (50.0%)	0 (0.0%)	12
Fractional exhaled nitric oxide increased	3 (25.0%)	0 (0.0%)	0 (0.0%)	9 (75.0%)	12
Immediate post-injection reaction	0 (0.0%)	7 (58.3%)	5 (41.7%)	0 (0.0%)	12
Immune-mediated gastritis	0 (0.0%)	1 (8.3%)	10 (83.3%)	1 (8.3%)	12
Carpal tunnel decompression	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Gamma-glutamyltransferase abnormal	1 (8.3%)	3 (25.0%)	8 (66.7%)	0 (0.0%)	12
Immunosuppressant drug level decreased	0 (0.0%)	5 (41.7%)	7 (58.3%)	0 (0.0%)	12
Tongue movement disturbance	4 (33.3%)	2 (16.7%)	4 (33.3%)	2 (16.7%)	12
Thymus hypoplasia	3 (25.0%)	9 (75.0%)	0 (0.0%)	0 (0.0%)	12

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Ileostomy closure	1 (8.3%)	6 (50.0%)	5 (41.7%)	0 (0.0%)	12
Hypotonia neonatal	12 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12
Systemic scleroderma	0 (0.0%)	5 (41.7%)	6 (50.0%)	1 (8.3%)	12
Surgical failure	0 (0.0%)	1 (8.3%)	10 (83.3%)	1 (8.3%)	12
Globulins decreased	1 (8.3%)	4 (33.3%)	4 (33.3%)	3 (25.0%)	12
Subclavian vein thrombosis	5 (41.7%)	3 (25.0%)	2 (16.7%)	2 (16.7%)	12
Streptococcal sepsis	3 (25.0%)	1 (8.3%)	4 (33.3%)	4 (33.3%)	12
Congenital anomaly	3 (25.0%)	4 (33.3%)	5 (41.7%)	0 (0.0%)	12
Anal ulcer	1 (8.3%)	4 (33.3%)	5 (41.7%)	2 (16.7%)	12
Postictal paralysis	1 (8.3%)	4 (33.3%)	7 (58.3%)	0 (0.0%)	12
Postoperative abscess	4 (33.3%)	5 (41.7%)	2 (16.7%)	1 (8.3%)	12
Spasmodic dysphonia	0 (0.0%)	10 (83.3%)	2 (16.7%)	0 (0.0%)	12
Gastrointestinal fistula	1 (8.3%)	0 (0.0%)	10 (83.3%)	1 (8.3%)	12
Infusion site discolouration	2 (16.7%)	3 (25.0%)	7 (58.3%)	0 (0.0%)	12
Sinus rhythm	0 (0.0%)	3 (25.0%)	5 (41.7%)	4 (33.3%)	12
Urinary tract pain	0 (0.0%)	0 (0.0%)	8 (66.7%)	4 (33.3%)	12
Seroma	1 (8.3%)	0 (0.0%)	7 (58.3%)	4 (33.3%)	12
Sense of oppression	0 (0.0%)	0 (0.0%)	11 (91.7%)	1 (8.3%)	12
Degenerative bone disease	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Gastrointestinal stoma output decreased	6 (50.0%)	0 (0.0%)	6 (50.0%)	0 (0.0%)	12
Obliterative bronchiolitis	2 (16.7%)	3 (25.0%)	7 (58.3%)	0 (0.0%)	12
Instillation site irritation	0 (0.0%)	5 (41.7%)	2 (16.7%)	5 (41.7%)	12
Haematocrit abnormal	1 (8.3%)	3 (25.0%)	6 (50.0%)	2 (16.7%)	12
Blood ketone body increased	2 (16.7%)	4 (33.3%)	6 (50.0%)	0 (0.0%)	12
Rebound psoriasis	1 (8.3%)	8 (66.7%)	3 (25.0%)	0 (0.0%)	12
Granuloma annulare	0 (0.0%)	6 (50.0%)	6 (50.0%)	0 (0.0%)	12
Chlamydial infection	3 (25.0%)	4 (33.3%)	5 (41.7%)	0 (0.0%)	12

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Occupational exposure to product	0 (0.0%)	5 (41.7%)	5 (41.7%)	2 (16.7%)	12
Purpura fulminans	1 (8.3%)	3 (25.0%)	8 (66.7%)	0 (0.0%)	12
Punctate keratitis	0 (0.0%)	4 (33.3%)	8 (66.7%)	0 (0.0%)	12
Vital capacity decreased	0 (0.0%)	2 (16.7%)	8 (66.7%)	2 (16.7%)	12
Pulmonary histoplasmosis	8 (66.7%)	4 (33.3%)	0 (0.0%)	0 (0.0%)	12
Retinal injury	1 (8.3%)	5 (41.7%)	6 (50.0%)	0 (0.0%)	12
Pseudoaldosteronism	0 (0.0%)	0 (0.0%)	10 (83.3%)	2 (16.7%)	12
Prothrombin time ratio decreased	8 (66.7%)	1 (8.3%)	0 (0.0%)	3 (25.0%)	12
Vulval abscess	1 (8.3%)	4 (33.3%)	7 (58.3%)	0 (0.0%)	12
Fanconi syndrome	0 (0.0%)	3 (25.0%)	6 (50.0%)	3 (25.0%)	12
Gingival abscess	0 (0.0%)	1 (8.3%)	11 (91.7%)	0 (0.0%)	12
General symptom	0 (0.0%)	1 (8.3%)	10 (83.3%)	1 (8.3%)	12
Intestinal metastasis	0 (0.0%)	1 (8.3%)	8 (66.7%)	3 (25.0%)	12
Cerebral nocardiosis	0 (0.0%)	3 (25.0%)	7 (58.3%)	2 (16.7%)	12
Gastrointestinal stoma output abnormal	3 (25.0%)	1 (8.3%)	3 (25.0%)	5 (41.7%)	12
Gastrointestinal stenosis	1 (8.3%)	6 (50.0%)	5 (41.7%)	0 (0.0%)	12
Bacterial vulvovaginitis	1 (8.3%)	7 (58.3%)	4 (33.3%)	0 (0.0%)	12
Gastrointestinal hypomotility	1 (8.3%)	4 (33.3%)	3 (25.0%)	4 (33.3%)	12
Anal stenosis	1 (8.3%)	6 (50.0%)	5 (41.7%)	0 (0.0%)	12
Positron emission tomogram abnormal	0 (0.0%)	3 (27.3%)	6 (54.5%)	2 (18.2%)	11
Central venous catheter removal	2 (18.2%)	6 (54.5%)	3 (27.3%)	0 (0.0%)	11
Positive airway pressure therapy	3 (27.3%)	1 (9.1%)	6 (54.5%)	1 (9.1%)	11
Pneumonia haemophilus	0 (0.0%)	4 (36.4%)	6 (54.5%)	1 (9.1%)	11
B-lymphocyte abnormalities	0 (0.0%)	8 (72.7%)	3 (27.3%)	0 (0.0%)	11
Catheter site injury	0 (0.0%)	6 (54.5%)	5 (45.5%)	0 (0.0%)	11
Atypical fracture	0 (0.0%)	1 (9.1%)	7 (63.6%)	3 (27.3%)	11
Persistent depressive disorder	1 (9.1%)	7 (63.6%)	3 (27.3%)	0 (0.0%)	11

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Peripheral T-cell lymphoma unspecified	0 (0.0%)	1 (9.1%)	7 (63.6%)	3 (27.3%)	11
Cardiac septal defect	6 (54.5%)	0 (0.0%)	4 (36.4%)	1 (9.1%)	11
Cardiac output increased	8 (72.7%)	1 (9.1%)	2 (18.2%)	0 (0.0%)	11
Ovarian failure	2 (18.2%)	9 (81.8%)	0 (0.0%)	0 (0.0%)	11
Vasculitis necrotising	0 (0.0%)	2 (18.2%)	9 (81.8%)	0 (0.0%)	11
Haemoperitoneum	1 (9.1%)	4 (36.4%)	5 (45.5%)	1 (9.1%)	11
Insulin C-peptide decreased	0 (0.0%)	10 (90.9%)	1 (9.1%)	0 (0.0%)	11
Adenocarcinoma	1 (9.1%)	0 (0.0%)	6 (54.5%)	4 (36.4%)	11
Osteogenesis imperfecta	0 (0.0%)	2 (18.2%)	7 (63.6%)	2 (18.2%)	11
Oral mucosa erosion	2 (18.2%)	0 (0.0%)	5 (45.5%)	4 (36.4%)	11
Eye colour change	1 (9.1%)	4 (36.4%)	5 (45.5%)	1 (9.1%)	11
Omphalitis	1 (9.1%)	4 (36.4%)	6 (54.5%)	0 (0.0%)	11
Halo vision	1 (9.1%)	6 (54.5%)	4 (36.4%)	0 (0.0%)	11
Excessive granulation tissue	3 (27.3%)	1 (9.1%)	7 (63.6%)	0 (0.0%)	11
Atopy	3 (27.3%)	4 (36.4%)	4 (36.4%)	0 (0.0%)	11
Excessive eye blinking	6 (54.5%)	3 (27.3%)	2 (18.2%)	0 (0.0%)	11
Obstructive pancreatitis	0 (0.0%)	4 (36.4%)	5 (45.5%)	2 (18.2%)	11
Epstein-Barr virus associated lymphoproliferative dis	4 (36.4%)	0 (0.0%)	4 (36.4%)	3 (27.3%)	11
Helicobacter test positive	0 (0.0%)	3 (27.3%)	7 (63.6%)	1 (9.1%)	11
Nephrostomy	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Neonatal respiratory distress syndrome	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Eosinophil count abnormal	0 (0.0%)	3 (27.3%)	5 (45.5%)	3 (27.3%)	11
Hemiplegic migraine	1 (9.1%)	4 (36.4%)	5 (45.5%)	1 (9.1%)	11
Pancreatitis relapsing	5 (45.5%)	4 (36.4%)	2 (18.2%)	0 (0.0%)	11
Feelings of worthlessness	4 (36.4%)	3 (27.3%)	4 (36.4%)	0 (0.0%)	11
Scedosporium infection	4 (36.4%)	1 (9.1%)	6 (54.5%)	0 (0.0%)	11
Scapula fracture	0 (0.0%)	1 (9.1%)	7 (63.6%)	3 (27.3%)	11

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Uterine prolapse	0 (0.0%)	4 (36.4%)	7 (63.6%)	0 (0.0%)	11
Secondary progressive multiple sclerosis	0 (0.0%)	6 (54.5%)	5 (45.5%)	0 (0.0%)	11
Multisystem inflammatory syndrome	1 (9.1%)	7 (63.6%)	3 (27.3%)	0 (0.0%)	11
Multiple injuries	0 (0.0%)	6 (54.5%)	4 (36.4%)	1 (9.1%)	11
Electrocardiogram T wave inversion	2 (18.2%)	2 (18.2%)	3 (27.3%)	4 (36.4%)	11
Infusion site vesicles	1 (9.1%)	1 (9.1%)	8 (72.7%)	1 (9.1%)	11
Mouth breathing	1 (9.1%)	0 (0.0%)	9 (81.8%)	1 (9.1%)	11
Eczema herpeticum	4 (36.4%)	5 (45.5%)	2 (18.2%)	0 (0.0%)	11
Breath holding	5 (45.5%)	1 (9.1%)	5 (45.5%)	0 (0.0%)	11
Metastatic cutaneous Crohn's disease	4 (36.4%)	7 (63.6%)	0 (0.0%)	0 (0.0%)	11
Metastases to thorax	0 (0.0%)	3 (27.3%)	6 (54.5%)	2 (18.2%)	11
Recall phenomenon	0 (0.0%)	4 (36.4%)	7 (63.6%)	0 (0.0%)	11
Infusion site inflammation	2 (18.2%)	5 (45.5%)	3 (27.3%)	1 (9.1%)	11
Mesenteric vein thrombosis	0 (0.0%)	2 (18.2%)	8 (72.7%)	1 (9.1%)	11
Cold urticaria	0 (0.0%)	7 (63.6%)	2 (18.2%)	2 (18.2%)	11
Urinary tract discomfort	1 (9.1%)	1 (9.1%)	7 (63.6%)	2 (18.2%)	11
Dysmetria	1 (9.1%)	0 (0.0%)	10 (90.9%)	0 (0.0%)	11
Dyslalia	8 (72.7%)	1 (9.1%)	1 (9.1%)	1 (9.1%)	11
Bone infarction	2 (18.2%)	1 (9.1%)	8 (72.7%)	0 (0.0%)	11
Arrhythmia supraventricular	0 (0.0%)	1 (9.1%)	8 (72.7%)	2 (18.2%)	11
Anal cancer	0 (0.0%)	7 (63.6%)	4 (36.4%)	0 (0.0%)	11
Maternal drugs affecting foetus	5 (45.5%)	6 (54.5%)	0 (0.0%)	0 (0.0%)	11
Mammogram abnormal	0 (0.0%)	4 (36.4%)	6 (54.5%)	1 (9.1%)	11
Grimacing	1 (9.1%)	4 (36.4%)	2 (18.2%)	4 (36.4%)	11
Male orgasmic disorder	7 (63.6%)	3 (27.3%)	1 (9.1%)	0 (0.0%)	11
Malacoplakia	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Dizziness exertional	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Borderline personality disorder	5 (45.5%)	6 (54.5%)	0 (0.0%)	0 (0.0%)	11
Mycoplasma test positive	1 (9.1%)	0 (0.0%)	9 (81.8%)	1 (9.1%)	11
Lymphocele	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Lymph gland infection	0 (0.0%)	3 (27.3%)	8 (72.7%)	0 (0.0%)	11
Dihydropyrimidine dehydrogenase deficiency	0 (0.0%)	5 (45.5%)	6 (54.5%)	0 (0.0%)	11
Loss of employment	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Humoral immune defect	1 (9.1%)	8 (72.7%)	2 (18.2%)	0 (0.0%)	11
Diffuse large B-cell lymphoma refractory	0 (0.0%)	0 (0.0%)	10 (90.9%)	1 (9.1%)	11
Bladder hypertrophy	1 (9.1%)	4 (36.4%)	4 (36.4%)	2 (18.2%)	11
Application site discomfort	1 (9.1%)	4 (36.4%)	4 (36.4%)	2 (18.2%)	11
Differentiation syndrome	0 (0.0%)	4 (36.4%)	4 (36.4%)	3 (27.3%)	11
Diarrhoea infectious	0 (0.0%)	4 (36.4%)	7 (63.6%)	0 (0.0%)	11
Diabetic ketoacidotic hyperglycaemic coma	2 (18.2%)	0 (0.0%)	5 (45.5%)	4 (36.4%)	11
Ligament disorder	1 (9.1%)	2 (18.2%)	6 (54.5%)	2 (18.2%)	11
Lichenification	1 (9.1%)	5 (45.5%)	5 (45.5%)	0 (0.0%)	11
Lentigo maligna	0 (0.0%)	1 (9.1%)	10 (90.9%)	0 (0.0%)	11
Splenic vein thrombosis	1 (9.1%)	2 (18.2%)	8 (72.7%)	0 (0.0%)	11
Body height abnormal	1 (9.1%)	5 (45.5%)	5 (45.5%)	0 (0.0%)	11
Device material issue	2 (18.2%)	3 (27.3%)	4 (36.4%)	2 (18.2%)	11
Left atrial enlargement	1 (9.1%)	2 (18.2%)	5 (45.5%)	3 (27.3%)	11
Perirectal abscess	1 (9.1%)	3 (27.3%)	7 (63.6%)	0 (0.0%)	11
Laryngeal stenosis	3 (27.3%)	3 (27.3%)	5 (45.5%)	0 (0.0%)	11
Hypergammaglobulinaemia benign monoclonal	0 (0.0%)	0 (0.0%)	9 (81.8%)	2 (18.2%)	11
Endometrial hyperplasia	0 (0.0%)	2 (18.2%)	8 (72.7%)	1 (9.1%)	11
Large granular lymphocytosis	0 (0.0%)	5 (45.5%)	6 (54.5%)	0 (0.0%)	11
Hyperhomocysteinaemia	2 (18.2%)	2 (18.2%)	7 (63.6%)	0 (0.0%)	11
Blood testosterone abnormal	0 (0.0%)	0 (0.0%)	9 (81.8%)	2 (18.2%)	11

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Joint space narrowing	0 (0.0%)	5 (45.5%)	6 (54.5%)	0 (0.0%)	11
Joint contracture	6 (54.5%)	2 (18.2%)	2 (18.2%)	1 (9.1%)	11
Demyelinating polyneuropathy	1 (9.1%)	2 (18.2%)	8 (72.7%)	0 (0.0%)	11
Nail bed bleeding	2 (18.2%)	4 (36.4%)	3 (27.3%)	2 (18.2%)	11
Stomach mass	1 (9.1%)	4 (36.4%)	6 (54.5%)	0 (0.0%)	11
Wrong device used	5 (45.5%)	1 (9.1%)	4 (36.4%)	1 (9.1%)	11
Nail psoriasis	0 (0.0%)	6 (54.5%)	5 (45.5%)	0 (0.0%)	11
Hypersensitivity vasculitis	1 (9.1%)	1 (9.1%)	8 (72.7%)	1 (9.1%)	11
Hypertrichosis	6 (54.5%)	2 (18.2%)	3 (27.3%)	0 (0.0%)	11
Intestinal anastomosis	1 (9.1%)	8 (72.7%)	1 (9.1%)	1 (9.1%)	11
Visceral leishmaniasis	0 (0.0%)	4 (36.4%)	7 (63.6%)	0 (0.0%)	11
Blood lactate dehydrogenase abnormal	0 (0.0%)	0 (0.0%)	4 (36.4%)	7 (63.6%)	11
Congestive hepatopathy	1 (9.1%)	4 (36.4%)	4 (36.4%)	2 (18.2%)	11
Vasogenic cerebral oedema	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11
Tracheostomy	1 (9.1%)	0 (0.0%)	8 (72.7%)	2 (18.2%)	11
Transfusion-related circulatory overload	1 (9.1%)	0 (0.0%)	7 (63.6%)	3 (27.3%)	11
Blister rupture	0 (0.0%)	6 (54.5%)	4 (36.4%)	1 (9.1%)	11
Talipes	10 (90.9%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	11
Implant site swelling	4 (36.4%)	6 (54.5%)	0 (0.0%)	1 (9.1%)	11
Urinary tract infection fungal	0 (0.0%)	2 (18.2%)	8 (72.7%)	1 (9.1%)	11
Total lung capacity increased	1 (9.1%)	0 (0.0%)	10 (90.9%)	0 (0.0%)	11
Umbilical haemorrhage	0 (0.0%)	9 (81.8%)	1 (9.1%)	1 (9.1%)	11
Influenza A virus test positive	3 (27.3%)	3 (27.3%)	5 (45.5%)	0 (0.0%)	11
Toxic shock syndrome	1 (9.1%)	0 (0.0%)	10 (90.9%)	0 (0.0%)	11
Platelet transfusion	1 (9.1%)	1 (9.1%)	6 (54.5%)	3 (27.3%)	11
Toe operation	0 (0.0%)	2 (18.2%)	8 (72.7%)	1 (9.1%)	11
Immunodeficiency common variable	1 (9.1%)	3 (27.3%)	7 (63.6%)	0 (0.0%)	11

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Thyroxine increased	1 (9.1%)	4 (36.4%)	3 (27.3%)	3 (27.3%)	11
Thyroid neoplasm	0 (0.0%)	1 (9.1%)	9 (81.8%)	1 (9.1%)	11
Thrombosis in device	1 (9.1%)	6 (54.5%)	4 (36.4%)	0 (0.0%)	11
Polychondritis	0 (0.0%)	4 (36.4%)	7 (63.6%)	0 (0.0%)	11
Anal pruritus	2 (18.2%)	2 (18.2%)	7 (63.6%)	0 (0.0%)	11
Toxoplasmosis	2 (18.2%)	6 (54.5%)	2 (18.2%)	1 (9.1%)	11
Conjunctivitis viral	2 (18.2%)	5 (45.5%)	2 (18.2%)	2 (18.2%)	11
Takayasu's arteritis	8 (72.7%)	3 (27.3%)	0 (0.0%)	0 (0.0%)	11
Gastric ulcer perforation	0 (0.0%)	2 (18.2%)	7 (63.6%)	2 (18.2%)	11
Hypoparathyroidism	0 (0.0%)	4 (36.4%)	6 (54.5%)	1 (9.1%)	11
Congenital cystic kidney disease	1 (9.1%)	4 (36.4%)	5 (45.5%)	1 (9.1%)	11
Blood creatine phosphokinase MB increased	4 (36.4%)	1 (9.1%)	6 (54.5%)	0 (0.0%)	11
Infantile haemangioma	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Epithelioid mesothelioma	1 (9.1%)	1 (9.1%)	7 (63.6%)	2 (18.2%)	11
Glassy eyes	4 (36.4%)	1 (9.1%)	6 (54.5%)	0 (0.0%)	11
Hydrocele	1 (9.1%)	3 (27.3%)	7 (63.6%)	0 (0.0%)	11
Crush syndrome	0 (0.0%)	0 (0.0%)	5 (45.5%)	6 (54.5%)	11
Ureaplasma infection	4 (36.4%)	0 (0.0%)	7 (63.6%)	0 (0.0%)	11
Night blindness	1 (9.1%)	4 (36.4%)	5 (45.5%)	1 (9.1%)	11
Pregnancy on contraceptive	8 (72.7%)	3 (27.3%)	0 (0.0%)	0 (0.0%)	11
Pregnancy of partner	1 (9.1%)	9 (81.8%)	1 (9.1%)	0 (0.0%)	11
Silent thyroiditis	1 (9.1%)	2 (18.2%)	5 (45.5%)	3 (27.3%)	11
Nodal arrhythmia	0 (0.0%)	8 (72.7%)	3 (27.3%)	0 (0.0%)	11
Antinuclear antibody increased	1 (9.1%)	3 (27.3%)	7 (63.6%)	0 (0.0%)	11
Salmonella bacteraemia	0 (0.0%)	3 (27.3%)	6 (54.5%)	2 (18.2%)	11
Root canal infection	1 (9.1%)	5 (45.5%)	4 (36.4%)	1 (9.1%)	11
Richter's syndrome	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rhegmatogenous retinal detachment	0 (0.0%)	1 (9.1%)	9 (81.8%)	1 (9.1%)	11
Retroperitoneal fibrosis	0 (0.0%)	0 (0.0%)	4 (36.4%)	7 (63.6%)	11
Product closure removal difficult	1 (9.1%)	0 (0.0%)	4 (36.4%)	6 (54.5%)	11
Chronic kidney disease-mineral and bone disorder	2 (18.2%)	3 (27.3%)	5 (45.5%)	1 (9.1%)	11
Chronic idiopathic pain syndrome	0 (0.0%)	9 (81.8%)	2 (18.2%)	0 (0.0%)	11
Bile acid malabsorption	0 (0.0%)	6 (54.5%)	5 (45.5%)	0 (0.0%)	11
Haemorrhagic transformation stroke	0 (0.0%)	2 (18.2%)	4 (36.4%)	5 (45.5%)	11
Prothrombin level decreased	1 (9.1%)	3 (27.3%)	3 (27.3%)	4 (36.4%)	11
Agonal respiration	1 (9.1%)	4 (36.4%)	6 (54.5%)	0 (0.0%)	11
Greater trochanteric pain syndrome	0 (0.0%)	2 (18.2%)	8 (72.7%)	1 (9.1%)	11
Exposure to fungus	1 (9.1%)	6 (54.5%)	4 (36.4%)	0 (0.0%)	11
Cervical radiculopathy	0 (0.0%)	3 (27.3%)	8 (72.7%)	0 (0.0%)	11
Vitamin B1 decreased	8 (72.7%)	1 (9.1%)	2 (18.2%)	0 (0.0%)	11
Gingival ulceration	2 (18.2%)	0 (0.0%)	8 (72.7%)	1 (9.1%)	11
Candida sepsis	4 (36.4%)	3 (27.3%)	1 (9.1%)	3 (27.3%)	11
Aortic dilatation	1 (9.1%)	4 (36.4%)	6 (54.5%)	0 (0.0%)	11
Basal ganglion degeneration	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Giardiasis	2 (18.2%)	3 (27.3%)	6 (54.5%)	0 (0.0%)	11
Genital rash	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11
Product dose confusion	1 (9.1%)	1 (9.1%)	5 (45.5%)	4 (36.4%)	11
Proctitis ulcerative	1 (9.1%)	5 (45.5%)	4 (36.4%)	1 (9.1%)	11
Systemic infection	4 (36.4%)	3 (27.3%)	4 (36.4%)	0 (0.0%)	11
Post inflammatory pigmentation change	2 (20.0%)	4 (40.0%)	3 (30.0%)	1 (10.0%)	10
Post cholecystectomy syndrome	0 (0.0%)	7 (70.0%)	3 (30.0%)	0 (0.0%)	10
Anal spasm	0 (0.0%)	0 (0.0%)	2 (20.0%)	8 (80.0%)	10
Pulmonary artery thrombosis	0 (0.0%)	4 (40.0%)	3 (30.0%)	3 (30.0%)	10
Cellulitis staphylococcal	0 (0.0%)	3 (30.0%)	3 (30.0%)	4 (40.0%)	10

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Pneumococcal infection	1 (10.0%)	5 (50.0%)	4 (40.0%)	0 (0.0%)	10
Anal infection	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Pulmonary sarcoidosis	0 (0.0%)	4 (40.0%)	4 (40.0%)	2 (20.0%)	10
Fungal peritonitis	1 (10.0%)	2 (20.0%)	5 (50.0%)	2 (20.0%)	10
Blood lactic acid decreased	8 (80.0%)	1 (10.0%)	1 (10.0%)	0 (0.0%)	10
Pharyngeal operation	0 (0.0%)	3 (30.0%)	5 (50.0%)	2 (20.0%)	10
Pharyngeal hypoaesthesia	2 (20.0%)	2 (20.0%)	5 (50.0%)	1 (10.0%)	10
Phaeochromocytoma crisis	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Peyronie's disease	1 (10.0%)	4 (40.0%)	5 (50.0%)	0 (0.0%)	10
Victim of crime	1 (10.0%)	4 (40.0%)	4 (40.0%)	1 (10.0%)	10
Granuloma skin	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10
Gravitational oedema	0 (0.0%)	1 (10.0%)	2 (20.0%)	7 (70.0%)	10
Penile pain	2 (20.0%)	3 (30.0%)	2 (20.0%)	3 (30.0%)	10
Parkinsonian gait	0 (0.0%)	0 (0.0%)	8 (80.0%)	2 (20.0%)	10
Red blood cell abnormality	1 (10.0%)	5 (50.0%)	3 (30.0%)	1 (10.0%)	10
Cardioactive drug level increased	0 (0.0%)	0 (0.0%)	6 (60.0%)	4 (40.0%)	10
Intercepted medication error	3 (30.0%)	3 (30.0%)	3 (30.0%)	1 (10.0%)	10
Fat tissue decreased	1 (10.0%)	0 (0.0%)	7 (70.0%)	2 (20.0%)	10
Overgrowth bacterial	1 (10.0%)	3 (30.0%)	6 (60.0%)	0 (0.0%)	10
Ostomy bag placement	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10
Orthostatic hypertension	0 (0.0%)	1 (10.0%)	2 (20.0%)	7 (70.0%)	10
Organic brain syndrome	3 (30.0%)	3 (30.0%)	3 (30.0%)	1 (10.0%)	10
Palmar erythema	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Oral contusion	2 (20.0%)	1 (10.0%)	5 (50.0%)	2 (20.0%)	10
Serum amyloid A protein increased	3 (30.0%)	1 (10.0%)	4 (40.0%)	2 (20.0%)	10
Respiratory tract inflammation	1 (10.0%)	2 (20.0%)	6 (60.0%)	1 (10.0%)	10
Open angle glaucoma	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pancreatic carcinoma stage IV	0 (0.0%)	0 (0.0%)	7 (70.0%)	3 (30.0%)	10
Oophorectomy	0 (0.0%)	7 (70.0%)	3 (30.0%)	0 (0.0%)	10
Pancreatic enlargement	1 (10.0%)	3 (30.0%)	5 (50.0%)	1 (10.0%)	10
Amputation	0 (0.0%)	3 (30.0%)	5 (50.0%)	2 (20.0%)	10
Chronic hepatitis	1 (10.0%)	3 (30.0%)	5 (50.0%)	1 (10.0%)	10
Hallucination, olfactory	0 (0.0%)	1 (10.0%)	9 (90.0%)	0 (0.0%)	10
Oesophageal obstruction	0 (0.0%)	3 (30.0%)	6 (60.0%)	1 (10.0%)	10
Oesophageal dilatation	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Retinogram abnormal	10 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10
Ocular vascular disorder	0 (0.0%)	6 (60.0%)	3 (30.0%)	1 (10.0%)	10
Obsessive thoughts	1 (10.0%)	5 (50.0%)	2 (20.0%)	2 (20.0%)	10
Atonic seizures	6 (60.0%)	4 (40.0%)	0 (0.0%)	0 (0.0%)	10
Heart transplant rejection	4 (40.0%)	2 (20.0%)	4 (40.0%)	0 (0.0%)	10
Biliary sepsis	0 (0.0%)	4 (40.0%)	2 (20.0%)	4 (40.0%)	10
Paradoxical psoriasis	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Heart transplant	1 (10.0%)	2 (20.0%)	6 (60.0%)	1 (10.0%)	10
Helicobacter gastritis	3 (30.0%)	1 (10.0%)	5 (50.0%)	1 (10.0%)	10
Eosinophilic colitis	2 (20.0%)	1 (10.0%)	2 (20.0%)	5 (50.0%)	10
Eosinophil percentage increased	1 (10.0%)	3 (30.0%)	4 (40.0%)	2 (20.0%)	10
Acute painful neuropathy of rapid glycaemic control	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Bursitis infective	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Aspartate aminotransferase decreased	0 (0.0%)	1 (10.0%)	6 (60.0%)	3 (30.0%)	10
Claustrophobia	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Nail toxicity	1 (10.0%)	3 (30.0%)	6 (60.0%)	0 (0.0%)	10
Engraftment syndrome	2 (20.0%)	4 (40.0%)	4 (40.0%)	0 (0.0%)	10
Myoglobinuria	0 (0.0%)	9 (90.0%)	1 (10.0%)	0 (0.0%)	10
Scrotal swelling	0 (0.0%)	4 (40.0%)	5 (50.0%)	1 (10.0%)	10

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Arthritis enteropathic	2 (20.0%)	5 (50.0%)	3 (30.0%)	0 (0.0%)	10
Moyamoya disease	2 (20.0%)	5 (50.0%)	3 (30.0%)	0 (0.0%)	10
Bronchial haemorrhage	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Milk-alkali syndrome	0 (0.0%)	2 (20.0%)	2 (20.0%)	6 (60.0%)	10
Ecthyma	1 (10.0%)	1 (10.0%)	3 (30.0%)	5 (50.0%)	10
Metastases to pancreas	0 (0.0%)	1 (10.0%)	6 (60.0%)	3 (30.0%)	10
Ear infection fungal	0 (0.0%)	2 (20.0%)	6 (60.0%)	2 (20.0%)	10
Acute leukaemia	0 (0.0%)	3 (30.0%)	6 (60.0%)	1 (10.0%)	10
Inhibitory drug interaction	1 (10.0%)	5 (50.0%)	3 (30.0%)	1 (10.0%)	10
Hernia pain	2 (20.0%)	0 (0.0%)	7 (70.0%)	1 (10.0%)	10
Duodenal polyp	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10
Brain stem infarction	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Administration site induration	1 (10.0%)	1 (10.0%)	7 (70.0%)	1 (10.0%)	10
Drug resistance mutation	0 (0.0%)	1 (10.0%)	9 (90.0%)	0 (0.0%)	10
Allergy test positive	0 (0.0%)	1 (10.0%)	9 (90.0%)	0 (0.0%)	10
Rapid eye movement sleep behaviour disorder	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Macroglossia	3 (30.0%)	1 (10.0%)	1 (10.0%)	5 (50.0%)	10
Lymphomatoid papulosis	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Bone swelling	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Disseminated mucormycosis	9 (90.0%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	10
Smear cervix abnormal	1 (10.0%)	3 (30.0%)	6 (60.0%)	0 (0.0%)	10
Lumbar radiculopathy	0 (0.0%)	4 (40.0%)	3 (30.0%)	3 (30.0%)	10
Periorbital inflammation	2 (20.0%)	4 (40.0%)	4 (40.0%)	0 (0.0%)	10
Low density lipoprotein abnormal	0 (0.0%)	1 (10.0%)	9 (90.0%)	0 (0.0%)	10
Human polyomavirus infection	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Complex regional pain syndrome	0 (0.0%)	7 (70.0%)	2 (20.0%)	1 (10.0%)	10
Bone cyst	1 (10.0%)	2 (20.0%)	7 (70.0%)	0 (0.0%)	10

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Secondary hypertension	1 (10.0%)	3 (30.0%)	3 (30.0%)	3 (30.0%)	10
Foot amputation	0 (0.0%)	3 (30.0%)	5 (50.0%)	2 (20.0%)	10
Compulsive shopping	3 (30.0%)	1 (10.0%)	6 (60.0%)	0 (0.0%)	10
Alcohol interaction	1 (10.0%)	5 (50.0%)	4 (40.0%)	0 (0.0%)	10
Tumour rupture	1 (10.0%)	2 (20.0%)	7 (70.0%)	0 (0.0%)	10
Abscess jaw	1 (10.0%)	3 (30.0%)	4 (40.0%)	2 (20.0%)	10
Blood sodium abnormal	1 (10.0%)	3 (30.0%)	3 (30.0%)	3 (30.0%)	10
Hypermagnesaemia	3 (30.0%)	3 (30.0%)	2 (20.0%)	2 (20.0%)	10
ADAMTS13 activity decreased	3 (30.0%)	4 (40.0%)	3 (30.0%)	0 (0.0%)	10
Lymphocytic infiltration	0 (0.0%)	8 (80.0%)	2 (20.0%)	0 (0.0%)	10
Cranial nerve disorder	4 (40.0%)	1 (10.0%)	2 (20.0%)	3 (30.0%)	10
Stoma closure	2 (20.0%)	5 (50.0%)	3 (30.0%)	0 (0.0%)	10
Activation syndrome	6 (60.0%)	1 (10.0%)	3 (30.0%)	0 (0.0%)	10
Corynebacterium infection	1 (10.0%)	2 (20.0%)	7 (70.0%)	0 (0.0%)	10
Superficial injury of eye	2 (20.0%)	1 (10.0%)	4 (40.0%)	3 (30.0%)	10
International normalised ratio decreased	1 (10.0%)	1 (10.0%)	3 (30.0%)	5 (50.0%)	10
Incision site swelling	0 (0.0%)	6 (60.0%)	4 (40.0%)	0 (0.0%)	10
Intentional device use issue	2 (20.0%)	0 (0.0%)	2 (20.0%)	6 (60.0%)	10
Vascular pseudoaneurysm ruptured	0 (0.0%)	3 (30.0%)	4 (40.0%)	3 (30.0%)	10
Hypoosmolar state	0 (0.0%)	0 (0.0%)	5 (50.0%)	5 (50.0%)	10
Systolic dysfunction	4 (40.0%)	1 (10.0%)	4 (40.0%)	1 (10.0%)	10
T-cell lymphoma	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Tourette's disorder	7 (70.0%)	1 (10.0%)	2 (20.0%)	0 (0.0%)	10
Uterine dilation and curettage	0 (0.0%)	6 (60.0%)	4 (40.0%)	0 (0.0%)	10
Placental insufficiency	2 (20.0%)	8 (80.0%)	0 (0.0%)	0 (0.0%)	10
Urticaria thermal	0 (0.0%)	9 (90.0%)	1 (10.0%)	0 (0.0%)	10
Creatinine renal clearance abnormal	0 (0.0%)	4 (40.0%)	3 (30.0%)	3 (30.0%)	10

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Triple negative breast cancer	0 (0.0%)	3 (30.0%)	6 (60.0%)	1 (10.0%)	10
Anticoagulation drug level increased	0 (0.0%)	0 (0.0%)	5 (50.0%)	5 (50.0%)	10
Thermal burns of eye	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10
Gallbladder rupture	0 (0.0%)	0 (0.0%)	8 (80.0%)	2 (20.0%)	10
Transfusion-related acute lung injury	0 (0.0%)	2 (20.0%)	6 (60.0%)	2 (20.0%)	10
Pneumococcal sepsis	1 (10.0%)	1 (10.0%)	7 (70.0%)	1 (10.0%)	10
Thyroxine free decreased	2 (20.0%)	0 (0.0%)	5 (50.0%)	3 (30.0%)	10
Blood cholesterol	1 (10.0%)	3 (30.0%)	6 (60.0%)	0 (0.0%)	10
Tongue pruritus	1 (10.0%)	7 (70.0%)	2 (20.0%)	0 (0.0%)	10
Tonsillar inflammation	3 (30.0%)	6 (60.0%)	1 (10.0%)	0 (0.0%)	10
Immunoglobulins increased	1 (10.0%)	2 (20.0%)	7 (70.0%)	0 (0.0%)	10
Tinea versicolour	1 (10.0%)	6 (60.0%)	1 (10.0%)	2 (20.0%)	10
Pneumothorax spontaneous	0 (0.0%)	1 (10.0%)	6 (60.0%)	3 (30.0%)	10
Thymus disorder	1 (10.0%)	3 (30.0%)	6 (60.0%)	0 (0.0%)	10
Therapeutic procedure	1 (10.0%)	4 (40.0%)	5 (50.0%)	0 (0.0%)	10
Implant site extravasation	3 (30.0%)	3 (30.0%)	3 (30.0%)	1 (10.0%)	10
Conjunctivitis bacterial	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Gliososis	1 (10.0%)	7 (70.0%)	2 (20.0%)	0 (0.0%)	10
Inadequate diet	2 (20.0%)	2 (20.0%)	6 (60.0%)	0 (0.0%)	10
Hypometabolism	0 (0.0%)	2 (20.0%)	7 (70.0%)	1 (10.0%)	10
Hypomenorrhoea	1 (10.0%)	9 (90.0%)	0 (0.0%)	0 (0.0%)	10
Adhesive tape use	3 (30.0%)	2 (20.0%)	5 (50.0%)	0 (0.0%)	10
Post procedural diarrhoea	1 (10.0%)	2 (20.0%)	6 (60.0%)	1 (10.0%)	10
Subcapsular renal haematoma	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Gastroenteritis norovirus	4 (40.0%)	5 (50.0%)	1 (10.0%)	0 (0.0%)	10
Tumour thrombosis	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Tumour marker decreased	0 (0.0%)	2 (20.0%)	6 (60.0%)	2 (20.0%)	10

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Complication of pregnancy	4 (40.0%)	6 (60.0%)	0 (0.0%)	0 (0.0%)	10
Anterior chamber cell	0 (0.0%)	0 (0.0%)	7 (70.0%)	3 (30.0%)	10
Hungry bone syndrome	0 (0.0%)	4 (40.0%)	5 (50.0%)	1 (10.0%)	10
Cerebral artery occlusion	0 (0.0%)	1 (10.0%)	6 (60.0%)	3 (30.0%)	10
Colonic fistula	0 (0.0%)	4 (40.0%)	4 (40.0%)	2 (20.0%)	10
Herpes zoster reactivation	1 (10.0%)	3 (30.0%)	4 (40.0%)	2 (20.0%)	10
Infusion site cellulitis	5 (50.0%)	4 (40.0%)	1 (10.0%)	0 (0.0%)	10
Skin fragility	0 (0.0%)	1 (10.0%)	3 (30.0%)	6 (60.0%)	10
Collagen disorder	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Sinus arrhythmia	2 (20.0%)	2 (20.0%)	4 (40.0%)	2 (20.0%)	10
Nodal rhythm	7 (70.0%)	0 (0.0%)	2 (20.0%)	1 (10.0%)	10
Nikolsky's sign	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Anogenital warts	1 (10.0%)	5 (50.0%)	4 (40.0%)	0 (0.0%)	10
Semen liquefaction	5 (50.0%)	2 (20.0%)	3 (30.0%)	0 (0.0%)	10
Clostridium bacteriaemia	0 (0.0%)	1 (10.0%)	8 (80.0%)	1 (10.0%)	10
Balanoposthitis	0 (0.0%)	1 (10.0%)	3 (30.0%)	6 (60.0%)	10
Hepatic adenoma	6 (60.0%)	4 (40.0%)	0 (0.0%)	0 (0.0%)	10
Vaginal disorder	0 (0.0%)	4 (40.0%)	4 (40.0%)	2 (20.0%)	10
Anion gap decreased	0 (0.0%)	2 (20.0%)	6 (60.0%)	2 (20.0%)	10
Retinal toxicity	0 (0.0%)	7 (70.0%)	3 (30.0%)	0 (0.0%)	10
Reticulocyte count increased	3 (30.0%)	0 (0.0%)	7 (70.0%)	0 (0.0%)	10
Respiratory fume inhalation disorder	0 (0.0%)	5 (50.0%)	4 (40.0%)	1 (10.0%)	10
Renal tubular disorder	6 (60.0%)	3 (30.0%)	0 (0.0%)	1 (10.0%)	10
Renal ischaemia	1 (10.0%)	4 (40.0%)	5 (50.0%)	0 (0.0%)	10
Chorioretinitis	3 (30.0%)	3 (30.0%)	3 (30.0%)	1 (10.0%)	10
Genital atrophy	4 (40.0%)	5 (50.0%)	1 (10.0%)	0 (0.0%)	10
Brain stem syndrome	0 (0.0%)	5 (50.0%)	4 (40.0%)	1 (10.0%)	10

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intentional medical device removal by patient	2 (20.0%)	2 (20.0%)	5 (50.0%)	1 (10.0%)	10
Rectal perforation	0 (0.0%)	4 (40.0%)	5 (50.0%)	1 (10.0%)	10
Recalled product	0 (0.0%)	6 (60.0%)	3 (30.0%)	1 (10.0%)	10
Interferon gamma release assay positive	1 (10.0%)	7 (70.0%)	1 (10.0%)	1 (10.0%)	10
Vestibular neuronitis	0 (0.0%)	3 (30.0%)	4 (40.0%)	3 (30.0%)	10
Flat affect	3 (30.0%)	4 (40.0%)	2 (20.0%)	1 (10.0%)	10
Pulmonary resection	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Vulvovaginal rash	1 (10.0%)	1 (10.0%)	8 (80.0%)	0 (0.0%)	10
Chemical burn	1 (10.0%)	2 (20.0%)	6 (60.0%)	1 (10.0%)	10
Volume blood decreased	0 (0.0%)	0 (0.0%)	7 (70.0%)	3 (30.0%)	10
Gingival discolouration	0 (0.0%)	3 (30.0%)	6 (60.0%)	1 (10.0%)	10
Vulval cancer	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Vulval disorder	2 (20.0%)	2 (20.0%)	5 (50.0%)	1 (10.0%)	10
Vulvovaginal inflammation	1 (10.0%)	6 (60.0%)	2 (20.0%)	1 (10.0%)	10
Prostate cancer stage IV	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Protein induced by vitamin K absence or antagonist II	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Genital tract inflammation	0 (0.0%)	2 (20.0%)	7 (70.0%)	1 (10.0%)	10
Administration site bruise	0 (0.0%)	2 (20.0%)	4 (40.0%)	4 (40.0%)	10
Anastomotic leak	2 (20.0%)	3 (30.0%)	5 (50.0%)	0 (0.0%)	10
Product use in unapproved therapeutic environment	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Product confusion	1 (10.0%)	1 (10.0%)	7 (70.0%)	1 (10.0%)	10
Blood magnesium increased	1 (10.0%)	2 (20.0%)	6 (60.0%)	1 (10.0%)	10
Gastrointestinal ulcer haemorrhage	0 (0.0%)	1 (10.0%)	8 (80.0%)	1 (10.0%)	10
Menstrual clots	2 (20.0%)	8 (80.0%)	0 (0.0%)	0 (0.0%)	10
Cerebral aspergillosis	4 (40.0%)	0 (0.0%)	5 (50.0%)	1 (10.0%)	10
Gitelman's syndrome	6 (60.0%)	0 (0.0%)	4 (40.0%)	0 (0.0%)	10
Iris adhesions	4 (40.0%)	0 (0.0%)	5 (50.0%)	1 (10.0%)	10

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
T-cell type acute leukaemia	4 (44.4%)	5 (55.6%)	0 (0.0%)	0 (0.0%)	9
Gastric operation	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Polyarteritis nodosa	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Pulmonary calcification	1 (11.1%)	0 (0.0%)	7 (77.8%)	1 (11.1%)	9
Gastric hypomotility	4 (44.4%)	3 (33.3%)	2 (22.2%)	0 (0.0%)	9
Pneumonia necrotising	0 (0.0%)	4 (44.4%)	3 (33.3%)	2 (22.2%)	9
Pneumonia acinetobacter	0 (0.0%)	1 (11.1%)	2 (22.2%)	6 (66.7%)	9
Gallbladder polyp	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Catheter site related reaction	3 (33.3%)	1 (11.1%)	5 (55.6%)	0 (0.0%)	9
Pulmonary veno-occlusive disease	1 (11.1%)	0 (0.0%)	7 (77.8%)	1 (11.1%)	9
Shunt occlusion	4 (44.4%)	3 (33.3%)	2 (22.2%)	0 (0.0%)	9
Eye symptom	1 (11.1%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	9
Pernicious anaemia	0 (0.0%)	0 (0.0%)	3 (33.3%)	6 (66.7%)	9
Metastases to bone marrow	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Forearm fracture	3 (33.3%)	2 (22.2%)	4 (44.4%)	0 (0.0%)	9
Axonal neuropathy	2 (22.2%)	0 (0.0%)	6 (66.7%)	1 (11.1%)	9
Periorbital pain	0 (0.0%)	5 (55.6%)	2 (22.2%)	2 (22.2%)	9
Adenomyosis	1 (11.1%)	8 (88.9%)	0 (0.0%)	0 (0.0%)	9
Cholangitis infective	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Metastases to ovary	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Guttate psoriasis	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Autoinflammatory disease	2 (22.2%)	3 (33.3%)	3 (33.3%)	1 (11.1%)	9
Patient elopement	0 (0.0%)	0 (0.0%)	5 (55.6%)	4 (44.4%)	9
Facial asymmetry	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Cardiac stress test abnormal	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Activated partial thromboplastin time shortened	7 (77.8%)	1 (11.1%)	1 (11.1%)	0 (0.0%)	9
Faecal calprotectin abnormal	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Factor V Leiden mutation	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Factitious disorder	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
PO2 decreased	1 (11.1%)	4 (44.4%)	3 (33.3%)	1 (11.1%)	9
Osteonecrosis of external auditory canal	0 (0.0%)	0 (0.0%)	6 (66.7%)	3 (33.3%)	9
Osteomalacia	0 (0.0%)	3 (33.3%)	5 (55.6%)	1 (11.1%)	9
Eyelid pain	1 (11.1%)	1 (11.1%)	5 (55.6%)	2 (22.2%)	9
Oropharyngeal candidiasis	1 (11.1%)	1 (11.1%)	5 (55.6%)	2 (22.2%)	9
Amyloid arthropathy	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Oral lichenoid reaction	0 (0.0%)	1 (11.1%)	4 (44.4%)	4 (44.4%)	9
Eye infection bacterial	3 (33.3%)	2 (22.2%)	4 (44.4%)	0 (0.0%)	9
Capillary disorder	1 (11.1%)	2 (22.2%)	6 (66.7%)	0 (0.0%)	9
Oesophageal discomfort	1 (11.1%)	1 (11.1%)	7 (77.8%)	0 (0.0%)	9
Oesophageal achalasia	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Athetosis	0 (0.0%)	4 (44.4%)	3 (33.3%)	2 (22.2%)	9
Heart disease congenital	4 (44.4%)	1 (11.1%)	2 (22.2%)	2 (22.2%)	9
Non-Hodgkin's lymphoma recurrent	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Nitrite urine present	3 (33.3%)	0 (0.0%)	4 (44.4%)	2 (22.2%)	9
Neuropathic arthropathy	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Nephrosclerosis	2 (22.2%)	2 (22.2%)	5 (55.6%)	0 (0.0%)	9
Nephritic syndrome	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Eosinophil percentage decreased	2 (22.2%)	3 (33.3%)	3 (33.3%)	1 (11.1%)	9
Neonatal hypoxia	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Enterocutaneous fistula	1 (11.1%)	4 (44.4%)	3 (33.3%)	1 (11.1%)	9
Burns third degree	1 (11.1%)	0 (0.0%)	7 (77.8%)	1 (11.1%)	9
Enterobacter bacteraemia	2 (22.2%)	1 (11.1%)	5 (55.6%)	1 (11.1%)	9
Alveolar osteitis	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Arthroscopy	2 (22.2%)	1 (11.1%)	6 (66.7%)	0 (0.0%)	9

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mycobacterium test positive	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Muscle necrosis	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Electrolyte depletion	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Mucosal erosion	1 (11.1%)	0 (0.0%)	2 (22.2%)	6 (66.7%)	9
Mucocutaneous ulceration	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Motor neurone disease	2 (22.2%)	0 (0.0%)	7 (77.8%)	0 (0.0%)	9
Electrocardiogram J wave	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Bronchial carcinoma	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Elbow operation	1 (11.1%)	2 (22.2%)	6 (66.7%)	0 (0.0%)	9
Ejaculation delayed	1 (11.1%)	8 (88.9%)	0 (0.0%)	0 (0.0%)	9
Breast neoplasm	0 (0.0%)	2 (22.2%)	7 (77.8%)	0 (0.0%)	9
Arterial stenosis	0 (0.0%)	2 (22.2%)	4 (44.4%)	3 (33.3%)	9
Metastases to spinal cord	0 (0.0%)	2 (22.2%)	7 (77.8%)	0 (0.0%)	9
Metastases to adrenals	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Coital bleeding	3 (33.3%)	6 (66.7%)	0 (0.0%)	0 (0.0%)	9
Metapneumovirus pneumonia	1 (11.1%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	9
EGFR gene mutation	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Metabolic function test abnormal	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Arterial haemorrhage	0 (0.0%)	2 (22.2%)	3 (33.3%)	4 (44.4%)	9
Mesenteric artery thrombosis	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Cholecystitis chronic	2 (22.2%)	4 (44.4%)	3 (33.3%)	0 (0.0%)	9
Cold-stimulus headache	0 (0.0%)	2 (22.2%)	7 (77.8%)	0 (0.0%)	9
Autoimmune pancreatitis	1 (11.1%)	2 (22.2%)	5 (55.6%)	1 (11.1%)	9
Meningoencephalitis herpetic	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Breast cancer stage I	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Acute left ventricular failure	2 (22.2%)	1 (11.1%)	4 (44.4%)	2 (22.2%)	9
Carotid artery dissection	0 (0.0%)	7 (77.8%)	2 (22.2%)	0 (0.0%)	9

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Duodenal stenosis	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Aptyalism	1 (11.1%)	3 (33.3%)	4 (44.4%)	1 (11.1%)	9
Mean cell volume abnormal	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Drug screen false positive	1 (11.1%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	9
Bradycardia neonatal	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Brachiocephalic vein thrombosis	1 (11.1%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	9
Encephalitis viral	1 (11.1%)	1 (11.1%)	5 (55.6%)	2 (22.2%)	9
Small cell lung cancer	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Magnetic resonance imaging spinal abnormal	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Hepatitis B core antibody positive	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Borrelia infection	0 (0.0%)	1 (11.1%)	4 (44.4%)	4 (44.4%)	9
Boredom	3 (33.3%)	1 (11.1%)	4 (44.4%)	1 (11.1%)	9
Retrograde ejaculation	1 (11.1%)	5 (55.6%)	3 (33.3%)	0 (0.0%)	9
Lymph node tuberculosis	2 (22.2%)	4 (44.4%)	2 (22.2%)	1 (11.1%)	9
Upper airway obstruction	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Disease risk factor	0 (0.0%)	5 (55.6%)	4 (44.4%)	0 (0.0%)	9
Periorbital haematoma	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Lung carcinoma cell type unspecified recurrent	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Locked-in syndrome	0 (0.0%)	5 (55.6%)	3 (33.3%)	1 (11.1%)	9
Local reaction	2 (22.2%)	3 (33.3%)	3 (33.3%)	1 (11.1%)	9
Diaphragmatic hernia	0 (0.0%)	3 (33.3%)	5 (55.6%)	1 (11.1%)	9
Dialysis related complication	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Diabetic hyperosmolar coma	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Device use confusion	3 (33.3%)	0 (0.0%)	5 (55.6%)	1 (11.1%)	9
Complications of transplanted lung	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Splenic lesion	1 (11.1%)	0 (0.0%)	7 (77.8%)	1 (11.1%)	9
Splenic artery aneurysm	1 (11.1%)	1 (11.1%)	7 (77.8%)	0 (0.0%)	9

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lentigo	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Left atrial dilatation	1 (11.1%)	0 (0.0%)	4 (44.4%)	4 (44.4%)	9
Laryngopharyngitis	1 (11.1%)	6 (66.7%)	2 (22.2%)	0 (0.0%)	9
Apnoeic attack	3 (33.3%)	4 (44.4%)	2 (22.2%)	0 (0.0%)	9
Laryngeal discomfort	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Bladder tamponade	0 (0.0%)	2 (22.2%)	3 (33.3%)	4 (44.4%)	9
Acute myelomonocytic leukaemia	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Albumin globulin ratio increased	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Judgement impaired	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Perinatal depression	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Job dissatisfaction	1 (11.1%)	5 (55.6%)	3 (33.3%)	0 (0.0%)	9
Jaw fistula	0 (0.0%)	2 (22.2%)	7 (77.8%)	0 (0.0%)	9
Tumour excision	1 (11.1%)	4 (44.4%)	3 (33.3%)	1 (11.1%)	9
Ischaemic cerebral infarction	1 (11.1%)	1 (11.1%)	4 (44.4%)	3 (33.3%)	9
Pyelocaliectasis	4 (44.4%)	1 (11.1%)	3 (33.3%)	1 (11.1%)	9
Iodine allergy	1 (11.1%)	1 (11.1%)	4 (44.4%)	3 (33.3%)	9
Blood oestrogen increased	0 (0.0%)	7 (77.8%)	0 (0.0%)	2 (22.2%)	9
Antipsychotic drug level above therapeutic	2 (22.2%)	4 (44.4%)	2 (22.2%)	1 (11.1%)	9
Ventricular tachyarrhythmia	3 (33.3%)	0 (0.0%)	6 (66.7%)	0 (0.0%)	9
Ventilation perfusion mismatch	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Suture insertion	2 (22.2%)	4 (44.4%)	1 (11.1%)	2 (22.2%)	9
Insulin-like growth factor abnormal	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Anticoagulation drug level below therapeutic	0 (0.0%)	1 (11.1%)	4 (44.4%)	4 (44.4%)	9
Vascular access site pain	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Transient acantholytic dermatosis	0 (0.0%)	1 (11.1%)	5 (55.6%)	3 (33.3%)	9
Cyst rupture	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Cutaneous symptom	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Urticaria chronic	1 (11.1%)	5 (55.6%)	2 (22.2%)	1 (11.1%)	9
Tender joint count increased	0 (0.0%)	0 (0.0%)	7 (77.8%)	2 (22.2%)	9
Toxic neuropathy	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Blood fibrinogen increased	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Idiopathic interstitial pneumonia	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Adult failure to thrive	0 (0.0%)	0 (0.0%)	3 (33.3%)	6 (66.7%)	9
Upper respiratory tract inflammation	1 (11.1%)	2 (22.2%)	6 (66.7%)	0 (0.0%)	9
Blood electrolytes abnormal	2 (22.2%)	0 (0.0%)	6 (66.7%)	1 (11.1%)	9
Thalamus haemorrhage	0 (0.0%)	1 (11.1%)	5 (55.6%)	3 (33.3%)	9
Type V hyperlipidaemia	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Aspergillus test positive	3 (33.3%)	2 (22.2%)	3 (33.3%)	1 (11.1%)	9
Incorrect product formulation administered	2 (22.2%)	5 (55.6%)	2 (22.2%)	0 (0.0%)	9
Pleurothotonus	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Blood corticotrophin increased	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Thunderclap headache	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Tobacco user	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Corneal lesion	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Immune-mediated pericarditis	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Tonsil cancer	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Adrenomegaly	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Thyroxine free increased	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Antibiotic level above therapeutic	0 (0.0%)	5 (55.6%)	4 (44.4%)	0 (0.0%)	9
Thyroid operation	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Immune-mediated endocrinopathy	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Antibody test positive	6 (66.7%)	2 (22.2%)	1 (11.1%)	0 (0.0%)	9
Aspiration pleural cavity	0 (0.0%)	1 (11.1%)	5 (55.6%)	3 (33.3%)	9
Immobilisation syndrome	0 (0.0%)	0 (0.0%)	4 (44.4%)	5 (55.6%)	9

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Abortion missed	1 (11.1%)	8 (88.9%)	0 (0.0%)	0 (0.0%)	9
Thalamic infarction	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Corneal transplant	1 (11.1%)	2 (22.2%)	5 (55.6%)	1 (11.1%)	9
Epidermal necrosis	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Imprisonment	2 (22.2%)	5 (55.6%)	2 (22.2%)	0 (0.0%)	9
Gastric stenosis	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Hypospadias	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Transferrin saturation decreased	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Synovial disorder	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Symptom masked	2 (22.2%)	5 (55.6%)	1 (11.1%)	1 (11.1%)	9
Coronavirus pneumonia	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Portal hypertensive gastropathy	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Gastritis bacterial	0 (0.0%)	7 (77.8%)	2 (22.2%)	0 (0.0%)	9
Neuroblastoma recurrent	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Sudden unexplained death in epilepsy	4 (44.4%)	4 (44.4%)	1 (11.1%)	0 (0.0%)	9
Bleeding time prolonged	2 (22.2%)	4 (44.4%)	2 (22.2%)	1 (11.1%)	9
Subdiaphragmatic abscess	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Gastroenteritis rotavirus	7 (77.8%)	0 (0.0%)	2 (22.2%)	0 (0.0%)	9
Increased viscosity of bronchial secretion	2 (22.2%)	2 (22.2%)	5 (55.6%)	0 (0.0%)	9
Stoma site discomfort	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Acute polyneuropathy	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Sticky skin	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Steroid withdrawal syndrome	2 (22.2%)	1 (11.1%)	6 (66.7%)	0 (0.0%)	9
Blood creatine phosphokinase abnormal	0 (0.0%)	2 (22.2%)	2 (22.2%)	5 (55.6%)	9
Steatohepatitis	5 (55.6%)	0 (0.0%)	4 (44.4%)	0 (0.0%)	9
Sprue-like enteropathy	0 (0.0%)	0 (0.0%)	6 (66.7%)	3 (33.3%)	9
Epiretinal membrane	1 (11.1%)	1 (11.1%)	5 (55.6%)	2 (22.2%)	9

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Splenectomy	1 (11.1%)	1 (11.1%)	5 (55.6%)	2 (22.2%)	9
Sleep-related eating disorder	2 (22.2%)	4 (44.4%)	3 (33.3%)	0 (0.0%)	9
Colon injury	0 (0.0%)	2 (22.2%)	7 (77.8%)	0 (0.0%)	9
Sinus polyp	1 (11.1%)	2 (22.2%)	6 (66.7%)	0 (0.0%)	9
Herbal interaction	0 (0.0%)	4 (44.4%)	2 (22.2%)	3 (33.3%)	9
Secondary hypogonadism	1 (11.1%)	0 (0.0%)	8 (88.9%)	0 (0.0%)	9
Uterine infection	0 (0.0%)	8 (88.9%)	1 (11.1%)	0 (0.0%)	9
Hepatic enzyme decreased	1 (11.1%)	2 (22.2%)	3 (33.3%)	3 (33.3%)	9
Injection site eczema	1 (11.1%)	7 (77.8%)	1 (11.1%)	0 (0.0%)	9
Injection site erosion	3 (33.3%)	3 (33.3%)	3 (33.3%)	0 (0.0%)	9
Citrobacter infection	4 (44.4%)	3 (33.3%)	1 (11.1%)	1 (11.1%)	9
Salivary gland disorder	1 (11.1%)	2 (22.2%)	4 (44.4%)	2 (22.2%)	9
Cystic lung disease	0 (0.0%)	6 (66.7%)	2 (22.2%)	1 (11.1%)	9
Rheumatoid lung	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Hearing aid user	0 (0.0%)	0 (0.0%)	6 (66.7%)	3 (33.3%)	9
Retroperitoneal lymphadenopathy	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Retinitis pigmentosa	0 (0.0%)	3 (33.3%)	5 (55.6%)	1 (11.1%)	9
Bile duct cancer	0 (0.0%)	1 (11.1%)	5 (55.6%)	3 (33.3%)	9
Acquired factor V deficiency	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Vasoconstriction	4 (44.4%)	3 (33.3%)	2 (22.2%)	0 (0.0%)	9
Renal cancer metastatic	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Haematoma infection	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Haematological malignancy	0 (0.0%)	0 (0.0%)	8 (88.9%)	1 (11.1%)	9
Vertebral lesion	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Interchange of vaccine products	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Growth failure	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Abnormal sleep-related event	1 (11.1%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	9

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Oesophageal motility disorder	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Gluten sensitivity	2 (22.2%)	4 (44.4%)	2 (22.2%)	1 (11.1%)	9
Administration site erythema	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Basophil percentage increased	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Pseudopolyp	2 (22.2%)	1 (11.1%)	6 (66.7%)	0 (0.0%)	9
Chalazion	2 (22.2%)	1 (11.1%)	6 (66.7%)	0 (0.0%)	9
Blood oestrogen decreased	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Basal ganglia haemorrhage	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Genital ulceration	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Propofol infusion syndrome	2 (22.2%)	7 (77.8%)	0 (0.0%)	0 (0.0%)	9
Abdominal neoplasm	1 (11.1%)	1 (11.1%)	5 (55.6%)	2 (22.2%)	9
Genital erosion	0 (0.0%)	0 (0.0%)	2 (22.2%)	7 (77.8%)	9
Genital anaesthesia	4 (44.4%)	5 (55.6%)	0 (0.0%)	0 (0.0%)	9
West Nile viral infection	1 (11.1%)	5 (55.6%)	3 (33.3%)	0 (0.0%)	9
Product design issue	4 (44.4%)	0 (0.0%)	1 (11.1%)	4 (44.4%)	9
Gingival hypertrophy	2 (22.2%)	3 (33.3%)	4 (44.4%)	0 (0.0%)	9
Gene mutation identification test positive	0 (0.0%)	4 (44.4%)	2 (22.2%)	3 (33.3%)	9
Vogt-Koyanagi-Harada disease	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Primary amyloidosis	0 (0.0%)	0 (0.0%)	2 (22.2%)	7 (77.8%)	9
Wound necrosis	3 (33.3%)	1 (11.1%)	5 (55.6%)	0 (0.0%)	9
Gastrointestinal mucormycosis	4 (44.4%)	2 (22.2%)	2 (22.2%)	1 (11.1%)	9
Precancerous cells present	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Gastrointestinal fungal infection	2 (22.2%)	1 (11.1%)	5 (55.6%)	1 (11.1%)	9
Glare	2 (22.2%)	4 (44.4%)	2 (22.2%)	1 (11.1%)	9
Infusion site haematoma	1 (11.1%)	3 (33.3%)	2 (22.2%)	3 (33.3%)	9
Autoscopy	0 (0.0%)	5 (55.6%)	3 (33.3%)	1 (11.1%)	9
Adjusted calcium decreased	0 (0.0%)	0 (0.0%)	6 (66.7%)	3 (33.3%)	9

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Psychological trauma	2 (25.0%)	3 (37.5%)	2 (25.0%)	1 (12.5%)	8
Portal venous gas	0 (0.0%)	0 (0.0%)	3 (37.5%)	5 (62.5%)	8
Globulins increased	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Gastric mucosal lesion	1 (12.5%)	1 (12.5%)	4 (50.0%)	2 (25.0%)	8
Polychromasia	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Gallbladder cancer	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Fungal disease carrier	2 (25.0%)	0 (0.0%)	6 (75.0%)	0 (0.0%)	8
Catheter site pruritus	1 (12.5%)	2 (25.0%)	5 (62.5%)	0 (0.0%)	8
Physical assault	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
International normalised ratio fluctuation	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Viral rash	3 (37.5%)	0 (0.0%)	5 (62.5%)	0 (0.0%)	8
Pyelitis	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Pelvic neoplasm	1 (12.5%)	1 (12.5%)	6 (75.0%)	0 (0.0%)	8
Q fever	0 (0.0%)	6 (75.0%)	1 (12.5%)	1 (12.5%)	8
Cataract subcapsular	3 (37.5%)	2 (25.0%)	3 (37.5%)	0 (0.0%)	8
Penile infection	1 (12.5%)	1 (12.5%)	4 (50.0%)	2 (25.0%)	8
Penile haemorrhage	2 (25.0%)	1 (12.5%)	3 (37.5%)	2 (25.0%)	8
Abdominal injury	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Pelvic fluid collection	1 (12.5%)	5 (62.5%)	2 (25.0%)	0 (0.0%)	8
HER2 positive breast cancer	0 (0.0%)	5 (62.5%)	3 (37.5%)	0 (0.0%)	8
Adenocarcinoma gastric	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Cardiac procedure complication	1 (12.5%)	0 (0.0%)	7 (87.5%)	0 (0.0%)	8
Autoimmune colitis	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Palatal disorder	1 (12.5%)	1 (12.5%)	4 (50.0%)	2 (25.0%)	8
Faecal vomiting	2 (25.0%)	3 (37.5%)	2 (25.0%)	1 (12.5%)	8
Haemophilic arthropathy	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
Acetabulum fracture	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Osmotic demyelination syndrome	2 (25.0%)	0 (0.0%)	5 (62.5%)	1 (12.5%)	8
Orthostatic intolerance	1 (12.5%)	0 (0.0%)	4 (50.0%)	3 (37.5%)	8
Orthopaedic procedure	0 (0.0%)	1 (12.5%)	5 (62.5%)	2 (25.0%)	8
Oropharyngeal swelling	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Palatal oedema	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Carcinoid crisis	0 (0.0%)	3 (37.5%)	4 (50.0%)	1 (12.5%)	8
Orbital oedema	2 (25.0%)	2 (25.0%)	3 (37.5%)	1 (12.5%)	8
Carbon dioxide abnormal	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Oppositional defiant disorder	6 (75.0%)	1 (12.5%)	1 (12.5%)	0 (0.0%)	8
Mixed hepatocellular cholangiocarcinoma	1 (12.5%)	3 (37.5%)	3 (37.5%)	1 (12.5%)	8
Oesophageal rupture	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Cancer fatigue	1 (12.5%)	1 (12.5%)	5 (62.5%)	1 (12.5%)	8
Exostosis of jaw	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Ocular toxicity	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Ocular lymphoma	0 (0.0%)	5 (62.5%)	3 (37.5%)	0 (0.0%)	8
Erythema induratum	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Nipple swelling	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
CSF protein increased	5 (62.5%)	1 (12.5%)	1 (12.5%)	1 (12.5%)	8
Neutrophil count	1 (12.5%)	3 (37.5%)	4 (50.0%)	0 (0.0%)	8
Neutralising antibodies positive	2 (25.0%)	3 (37.5%)	3 (37.5%)	0 (0.0%)	8
Neurosarcoidosis	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Epiploic appendagitis	0 (0.0%)	2 (25.0%)	4 (50.0%)	2 (25.0%)	8
Neuromyopathy	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Nephritis allergic	0 (0.0%)	0 (0.0%)	2 (25.0%)	6 (75.0%)	8
Acute phase reaction	1 (12.5%)	0 (0.0%)	7 (87.5%)	0 (0.0%)	8
Necrotising soft tissue infection	1 (12.5%)	2 (25.0%)	4 (50.0%)	1 (12.5%)	8
Entropion	0 (0.0%)	2 (25.0%)	3 (37.5%)	3 (37.5%)	8

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Enterobiasis	2 (25.0%)	5 (62.5%)	1 (12.5%)	0 (0.0%)	8
Binocular eye movement disorder	0 (0.0%)	6 (75.0%)	2 (25.0%)	0 (0.0%)	8
Vaccination complication	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
Endoscopy	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
Scleral hyperaemia	1 (12.5%)	2 (25.0%)	3 (37.5%)	2 (25.0%)	8
Myoclonic epilepsy	6 (75.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	8
Scrotal abscess	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Fibroadenoma of breast	0 (0.0%)	4 (50.0%)	1 (12.5%)	3 (37.5%)	8
Endometrial ablation	0 (0.0%)	5 (62.5%)	3 (37.5%)	0 (0.0%)	8
Mycobacterium fortuitum infection	6 (75.0%)	1 (12.5%)	1 (12.5%)	0 (0.0%)	8
Encephalomyelitis	5 (62.5%)	0 (0.0%)	3 (37.5%)	0 (0.0%)	8
Emphysematous cystitis	0 (0.0%)	0 (0.0%)	4 (50.0%)	4 (50.0%)	8
Bronchitis viral	1 (12.5%)	2 (25.0%)	4 (50.0%)	1 (12.5%)	8
Pasteurella infection	1 (12.5%)	0 (0.0%)	5 (62.5%)	2 (25.0%)	8
Parvovirus B19 infection	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
Morning sickness	1 (12.5%)	5 (62.5%)	2 (25.0%)	0 (0.0%)	8
Electrocardiogram PR prolongation	0 (0.0%)	4 (50.0%)	1 (12.5%)	3 (37.5%)	8
Mole excision	1 (12.5%)	3 (37.5%)	4 (50.0%)	0 (0.0%)	8
Serratia infection	1 (12.5%)	3 (37.5%)	3 (37.5%)	1 (12.5%)	8
Ehlers-Danlos syndrome	1 (12.5%)	3 (37.5%)	4 (50.0%)	0 (0.0%)	8
Educational problem	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Mitral valve disease	0 (0.0%)	0 (0.0%)	3 (37.5%)	5 (62.5%)	8
Alopecia scarring	0 (0.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)	8
Metastatic lymphoma	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Ear tube insertion	7 (87.5%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	8
Metastatic bronchial carcinoma	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Breast haemorrhage	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Metastases to breast	1 (12.5%)	2 (25.0%)	5 (62.5%)	0 (0.0%)	8
Vitreous degeneration	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Dysmorphism	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Breakthrough haemolysis	2 (25.0%)	1 (12.5%)	4 (50.0%)	1 (12.5%)	8
Muscular dystrophy	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Skin candida	0 (0.0%)	6 (75.0%)	2 (25.0%)	0 (0.0%)	8
Dry gangrene	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Fluid imbalance	0 (0.0%)	2 (25.0%)	3 (37.5%)	3 (37.5%)	8
Medical device site discomfort	2 (25.0%)	2 (25.0%)	3 (37.5%)	1 (12.5%)	8
Allergy to arthropod sting	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Allergy to arthropod bite	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Mean cell haemoglobin	1 (12.5%)	3 (37.5%)	3 (37.5%)	1 (12.5%)	8
Mallory-Weiss syndrome	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Autophobia	0 (0.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)	8
Drowning	2 (25.0%)	1 (12.5%)	2 (25.0%)	3 (37.5%)	8
Documented hypersensitivity to administered product	1 (12.5%)	3 (37.5%)	4 (50.0%)	0 (0.0%)	8
Smooth muscle cell neoplasm	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Speech disorder developmental	6 (75.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	8
Bone hypertrophy	1 (12.5%)	5 (62.5%)	1 (12.5%)	1 (12.5%)	8
Lipohypertrophy	2 (25.0%)	4 (50.0%)	2 (25.0%)	0 (0.0%)	8
Lip infection	6 (75.0%)	1 (12.5%)	1 (12.5%)	0 (0.0%)	8
Diabetic nephropathy	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Limb reduction defect	7 (87.5%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	8
Bone cancer metastatic	0 (0.0%)	1 (12.5%)	3 (37.5%)	4 (50.0%)	8
Body temperature	5 (62.5%)	1 (12.5%)	1 (12.5%)	1 (12.5%)	8
Body mass index decreased	1 (12.5%)	3 (37.5%)	4 (50.0%)	0 (0.0%)	8
Legal problem	0 (0.0%)	4 (50.0%)	2 (25.0%)	2 (25.0%)	8

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Left ventricular dilatation	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Alcohol use	1 (12.5%)	6 (75.0%)	1 (12.5%)	0 (0.0%)	8
Laryngeal cancer	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Alcohol intolerance	1 (12.5%)	3 (37.5%)	3 (37.5%)	1 (12.5%)	8
Dermatophytosis	1 (12.5%)	1 (12.5%)	5 (62.5%)	1 (12.5%)	8
Labelled drug-food interaction issue	3 (37.5%)	3 (37.5%)	2 (25.0%)	0 (0.0%)	8
Albuminuria	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Blood stem cell transplant failure	7 (87.5%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	8
Acute chest syndrome	4 (50.0%)	4 (50.0%)	0 (0.0%)	0 (0.0%)	8
Keratouveitis	1 (12.5%)	0 (0.0%)	5 (62.5%)	2 (25.0%)	8
Jaw operation	2 (25.0%)	2 (25.0%)	3 (37.5%)	1 (12.5%)	8
Delivery	4 (50.0%)	4 (50.0%)	0 (0.0%)	0 (0.0%)	8
Nail growth abnormal	0 (0.0%)	1 (12.5%)	4 (50.0%)	3 (37.5%)	8
Wolff-Parkinson-White syndrome	0 (0.0%)	5 (62.5%)	2 (25.0%)	1 (12.5%)	8
Congenital central nervous system anomaly	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Intraductal papillary mucinous neoplasm	0 (0.0%)	2 (25.0%)	4 (50.0%)	2 (25.0%)	8
Hypertensive heart disease	1 (12.5%)	0 (0.0%)	6 (75.0%)	1 (12.5%)	8
Air embolism	0 (0.0%)	3 (37.5%)	2 (25.0%)	3 (37.5%)	8
Vulvovaginal erythema	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Vertebral foraminal stenosis	1 (12.5%)	1 (12.5%)	5 (62.5%)	1 (12.5%)	8
Agnosia	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Incarcerated hernia	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Blood immunoglobulin M increased	1 (12.5%)	1 (12.5%)	3 (37.5%)	3 (37.5%)	8
Blood immunoglobulin G abnormal	2 (25.0%)	2 (25.0%)	4 (50.0%)	0 (0.0%)	8
Use of accessory respiratory muscles	3 (37.5%)	3 (37.5%)	2 (25.0%)	0 (0.0%)	8
Teething	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	8
Implant site necrosis	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	8

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Implant site erythema	1 (12.5%)	7 (87.5%)	0 (0.0%)	0 (0.0%)	8
UGT1A1 gene mutation	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Blood creatine phosphokinase decreased	1 (12.5%)	3 (37.5%)	3 (37.5%)	1 (12.5%)	8
Thrombotic cerebral infarction	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Thyrototoxic periodic paralysis	0 (0.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)	8
Antibody test abnormal	2 (25.0%)	2 (25.0%)	4 (50.0%)	0 (0.0%)	8
Corneal epithelium defect	2 (25.0%)	2 (25.0%)	2 (25.0%)	2 (25.0%)	8
Nephroangiosclerosis	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Testicular seminoma (pure)	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Tooth socket haemorrhage	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Blood 25-hydroxycholecalciferol decreased	3 (37.5%)	0 (0.0%)	4 (50.0%)	1 (12.5%)	8
Transcription medication error	2 (25.0%)	2 (25.0%)	3 (37.5%)	1 (12.5%)	8
Systemic lupus erythematosus rash	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Hypophosphataemic osteomalacia	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Hypoperfusion	0 (0.0%)	3 (37.5%)	4 (50.0%)	1 (12.5%)	8
Swollen joint count	0 (0.0%)	5 (62.5%)	3 (37.5%)	0 (0.0%)	8
Suture related complication	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Hypoaldosteronism	2 (25.0%)	0 (0.0%)	1 (12.5%)	5 (62.5%)	8
Anti factor VIII antibody positive	3 (37.5%)	5 (62.5%)	0 (0.0%)	0 (0.0%)	8
Stubbornness	1 (12.5%)	5 (62.5%)	1 (12.5%)	1 (12.5%)	8
Post procedural discharge	0 (0.0%)	2 (25.0%)	2 (25.0%)	4 (50.0%)	8
Cranial nerve paralysis	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Tumefactive multiple sclerosis	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Stoma site dermatitis	0 (0.0%)	2 (25.0%)	1 (12.5%)	5 (62.5%)	8
Stoma obstruction	0 (0.0%)	3 (37.5%)	4 (50.0%)	1 (12.5%)	8
Indifference	3 (37.5%)	0 (0.0%)	5 (62.5%)	0 (0.0%)	8
Tumour hyperprogression	0 (0.0%)	2 (25.0%)	3 (37.5%)	3 (37.5%)	8

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Stasis dermatitis	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Stab wound	1 (12.5%)	5 (62.5%)	2 (25.0%)	0 (0.0%)	8
Twin pregnancy	1 (12.5%)	7 (87.5%)	0 (0.0%)	0 (0.0%)	8
Sputum abnormal	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Infected neoplasm	1 (12.5%)	4 (50.0%)	2 (25.0%)	1 (12.5%)	8
Neurosyphilis	3 (37.5%)	1 (12.5%)	4 (50.0%)	0 (0.0%)	8
Ulcerative gastritis	0 (0.0%)	6 (75.0%)	0 (0.0%)	2 (25.0%)	8
Infective aneurysm	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Hydrothorax	0 (0.0%)	3 (37.5%)	3 (37.5%)	2 (25.0%)	8
Infective keratitis	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	8
Spinal cord abscess	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Soft tissue necrosis	0 (0.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)	8
Horner's syndrome	0 (0.0%)	4 (50.0%)	3 (37.5%)	1 (12.5%)	8
Colour blindness	0 (0.0%)	4 (50.0%)	2 (25.0%)	2 (25.0%)	8
Small intestine ulcer	0 (0.0%)	2 (25.0%)	4 (50.0%)	2 (25.0%)	8
Cerebral artery stenosis	0 (0.0%)	4 (50.0%)	3 (37.5%)	1 (12.5%)	8
Ureteric compression	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Adnexal torsion	3 (37.5%)	5 (62.5%)	0 (0.0%)	0 (0.0%)	8
Cerebral amyloid angiopathy	0 (0.0%)	1 (12.5%)	4 (50.0%)	3 (37.5%)	8
Skin discharge	2 (25.0%)	2 (25.0%)	2 (25.0%)	2 (25.0%)	8
Serum serotonin decreased	0 (0.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)	8
Coagulation test abnormal	1 (12.5%)	2 (25.0%)	4 (50.0%)	1 (12.5%)	8
Hepatic vein thrombosis	3 (37.5%)	2 (25.0%)	3 (37.5%)	0 (0.0%)	8
Hepatic infarction	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Scleroderma-like reaction	1 (12.5%)	4 (50.0%)	2 (25.0%)	1 (12.5%)	8
Procedural dizziness	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Sciatic nerve neuropathy	1 (12.5%)	1 (12.5%)	6 (75.0%)	0 (0.0%)	8

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Procedural headache	2 (25.0%)	2 (25.0%)	4 (50.0%)	0 (0.0%)	8
Sarcoma	0 (0.0%)	4 (50.0%)	2 (25.0%)	2 (25.0%)	8
Cyst removal	1 (12.5%)	3 (37.5%)	4 (50.0%)	0 (0.0%)	8
Administration site pruritus	1 (12.5%)	6 (75.0%)	1 (12.5%)	0 (0.0%)	8
Chronic myeloid leukaemia recurrent	0 (0.0%)	3 (37.5%)	4 (50.0%)	1 (12.5%)	8
Head banging	4 (50.0%)	1 (12.5%)	2 (25.0%)	1 (12.5%)	8
Anaplastic large cell lymphoma T- and null-cell types	0 (0.0%)	3 (37.5%)	4 (50.0%)	1 (12.5%)	8
Product closure issue	0 (0.0%)	3 (37.5%)	3 (37.5%)	2 (25.0%)	8
Retinal vascular disorder	2 (25.0%)	2 (25.0%)	2 (25.0%)	2 (25.0%)	8
Chronic hepatitis B	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Retinal operation	0 (0.0%)	1 (12.5%)	5 (62.5%)	2 (25.0%)	8
Haemorrhagic disorder	0 (0.0%)	2 (25.0%)	3 (37.5%)	3 (37.5%)	8
Cytogenetic abnormality	1 (12.5%)	1 (12.5%)	6 (75.0%)	0 (0.0%)	8
Renal surgery	0 (0.0%)	1 (12.5%)	5 (62.5%)	2 (25.0%)	8
Insulin autoimmune syndrome	0 (0.0%)	4 (50.0%)	3 (37.5%)	1 (12.5%)	8
Renal hypertension	6 (75.0%)	1 (12.5%)	1 (12.5%)	0 (0.0%)	8
Remission not achieved	0 (0.0%)	5 (62.5%)	1 (12.5%)	2 (25.0%)	8
Genital blister	3 (37.5%)	1 (12.5%)	4 (50.0%)	0 (0.0%)	8
Reflux laryngitis	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Rectal fissure	3 (37.5%)	2 (25.0%)	3 (37.5%)	0 (0.0%)	8
Reaction to colouring	3 (37.5%)	2 (25.0%)	3 (37.5%)	0 (0.0%)	8
Benign neoplasm	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Growth disorder	6 (75.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	8
Vestibular disorder	1 (12.5%)	3 (37.5%)	1 (12.5%)	3 (37.5%)	8
Radiation oesophagitis	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Pyoderma	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Exposure to communicable disease	1 (12.5%)	5 (62.5%)	2 (25.0%)	0 (0.0%)	8

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Aneurysm ruptured	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Aortic aneurysm rupture	0 (0.0%)	1 (12.5%)	4 (50.0%)	3 (37.5%)	8
Chemotherapeutic drug level increased	7 (87.5%)	0 (0.0%)	1 (12.5%)	0 (0.0%)	8
Intestinal fibrosis	0 (0.0%)	2 (25.0%)	3 (37.5%)	3 (37.5%)	8
Vitamin D abnormal	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
Pterygium	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Prostatectomy	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Protothecosis	0 (0.0%)	5 (62.5%)	0 (0.0%)	3 (37.5%)	8
Gingival erythema	2 (25.0%)	0 (0.0%)	6 (75.0%)	0 (0.0%)	8
Product expiration date issue	1 (12.5%)	2 (25.0%)	4 (50.0%)	1 (12.5%)	8
Product blister packaging issue	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Defiant behaviour	7 (87.5%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	8
Pseudocirrhosis	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Gastrointestinal procedural complication	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Gastrointestinal polyp haemorrhage	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Presbyopia	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Gastrointestinal neoplasm	0 (0.0%)	1 (12.5%)	5 (62.5%)	2 (25.0%)	8
Pregnenolone deficiency	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Bacterial translocation	2 (25.0%)	1 (12.5%)	1 (12.5%)	4 (50.0%)	8
Postoperative ileus	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Postoperative adhesion	0 (0.0%)	5 (62.5%)	3 (37.5%)	0 (0.0%)	8
Extravasation blood	0 (0.0%)	4 (50.0%)	3 (37.5%)	1 (12.5%)	8
Iris atrophy	6 (75.0%)	1 (12.5%)	1 (12.5%)	0 (0.0%)	8
Bacterial endophthalmitis	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Central sleep apnoea syndrome	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Pleural disorder	1 (14.3%)	1 (14.3%)	4 (57.1%)	1 (14.3%)	7
Cauda equina syndrome	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Fungal pharyngitis	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Personality change due to a general medical condition	2 (28.6%)	0 (0.0%)	5 (71.4%)	0 (0.0%)	7
Peritoneal disorder	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Adenoidectomy	6 (85.7%)	1 (14.3%)	0 (0.0%)	0 (0.0%)	7
Grief reaction	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Paternal exposure during pregnancy	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Fibrocystic breast disease	0 (0.0%)	4 (57.1%)	0 (0.0%)	3 (42.9%)	7
Fibroblast growth factor 23 increased	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Femoroacetabular impingement	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Parasomnia	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Paraneoplastic neurological syndrome	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Acquired diaphragmatic eventration	1 (14.3%)	3 (42.9%)	2 (28.6%)	1 (14.3%)	7
Paranasal sinus inflammation	0 (0.0%)	4 (57.1%)	2 (28.6%)	1 (14.3%)	7
Autoimmune heparin-induced thrombocytopenia	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Red blood cells urine positive	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Anaemia of malignant disease	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Pancreatic neuroendocrine tumour metastatic	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Cardiac pacemaker replacement	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
PCO2 increased	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Oxygen consumption decreased	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Factor VIII inhibition	3 (42.9%)	3 (42.9%)	1 (14.3%)	0 (0.0%)	7
Anaemia folate deficiency	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Facial nerve disorder	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Resorption bone increased	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Eyelid cyst	1 (14.3%)	4 (57.1%)	0 (0.0%)	2 (28.6%)	7
Oral lichen planus	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Oral blood blister	1 (14.3%)	0 (0.0%)	5 (71.4%)	1 (14.3%)	7

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
False negative investigation result	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Injury corneal	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Extra-axial haemorrhage	6 (85.7%)	0 (0.0%)	0 (0.0%)	1 (14.3%)	7
Oesophagitis ulcerative	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Candida pneumonia	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Fascicular block	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Atrial appendage closure	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Occult blood	1 (14.3%)	0 (0.0%)	2 (28.6%)	4 (57.1%)	7
Atonic urinary bladder	0 (0.0%)	2 (28.6%)	3 (42.9%)	2 (28.6%)	7
Chronic myeloid leukaemia transformation	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Erythromelalgia	1 (14.3%)	0 (0.0%)	5 (71.4%)	1 (14.3%)	7
Morganella infection	0 (0.0%)	0 (0.0%)	3 (42.9%)	4 (57.1%)	7
Cardiac sarcoidosis	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Abdominoplasty	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Acute promyelocytic leukaemia	0 (0.0%)	3 (42.9%)	2 (28.6%)	2 (28.6%)	7
Neutropenia neonatal	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Vaginal odour	1 (14.3%)	3 (42.9%)	2 (28.6%)	1 (14.3%)	7
Eosinophilic fasciitis	1 (14.3%)	1 (14.3%)	3 (42.9%)	2 (28.6%)	7
Autoimmune hypothyroidism	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Needle track marks	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Enterovirus test positive	5 (71.4%)	1 (14.3%)	1 (14.3%)	0 (0.0%)	7
Nasal turbinate hypertrophy	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Burnout syndrome	1 (14.3%)	5 (71.4%)	1 (14.3%)	0 (0.0%)	7
Enlarged uvula	1 (14.3%)	2 (28.6%)	4 (57.1%)	0 (0.0%)	7
Nail pigmentation	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Nail injury	1 (14.3%)	2 (28.6%)	4 (57.1%)	0 (0.0%)	7
Rectal stenosis	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Endometritis	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Myoglobinaemia	5 (71.4%)	1 (14.3%)	1 (14.3%)	0 (0.0%)	7
Accident at home	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Endocarditis bacterial	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Arthritis reactive	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Bronchospasm paradoxical	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Emergency care examination	0 (0.0%)	4 (57.1%)	1 (14.3%)	2 (28.6%)	7
Coagulation factor V level abnormal	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Electrocardiogram change	0 (0.0%)	1 (14.3%)	3 (42.9%)	3 (42.9%)	7
Electrocardiogram T wave amplitude decreased	1 (14.3%)	0 (0.0%)	3 (42.9%)	3 (42.9%)	7
Mucosal discolouration	0 (0.0%)	0 (0.0%)	3 (42.9%)	4 (57.1%)	7
Moraxella infection	4 (57.1%)	1 (14.3%)	2 (28.6%)	0 (0.0%)	7
Coating in mouth	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Serum serotonin increased	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Eczema asteatotic	3 (42.9%)	1 (14.3%)	3 (42.9%)	0 (0.0%)	7
Ectropion	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Micturition frequency decreased	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Breast reconstruction	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Microcephaly	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Microalbuminuria	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Metatarsalgia	0 (0.0%)	3 (42.9%)	2 (28.6%)	2 (28.6%)	7
Urinary tract inflammation	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Ear infection bacterial	3 (42.9%)	2 (28.6%)	2 (28.6%)	0 (0.0%)	7
Mesothelioma malignant	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Mesenteric artery stenosis	0 (0.0%)	1 (14.3%)	2 (28.6%)	4 (57.1%)	7
Urinary sediment present	0 (0.0%)	1 (14.3%)	3 (42.9%)	3 (42.9%)	7
Mental disability	1 (14.3%)	6 (85.7%)	0 (0.0%)	0 (0.0%)	7

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Menopausal disorder	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Meningitis listeria	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Colectomy total	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Melanoma recurrent	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Duodenogastric reflux	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Simple partial seizures	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Medical device site haemorrhage	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Mediastinal mass	2 (28.6%)	1 (14.3%)	1 (14.3%)	3 (42.9%)	7
Skin hypopigmentation	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Marginal zone lymphoma	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Skin squamous cell carcinoma recurrent	0 (0.0%)	3 (42.9%)	0 (0.0%)	4 (57.1%)	7
Allergic transfusion reaction	2 (28.6%)	3 (42.9%)	2 (28.6%)	0 (0.0%)	7
Malignant hypertension	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Male reproductive tract disorder	5 (71.4%)	1 (14.3%)	0 (0.0%)	1 (14.3%)	7
Malacoplakia gastrointestinal	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Double stranded DNA antibody positive	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Intermittent explosive disorder	1 (14.3%)	5 (71.4%)	1 (14.3%)	0 (0.0%)	7
Perineal pain	1 (14.3%)	2 (28.6%)	3 (42.9%)	1 (14.3%)	7
Bone scan abnormal	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Bone operation	0 (0.0%)	2 (28.6%)	3 (42.9%)	2 (28.6%)	7
Lung transplant rejection	2 (28.6%)	1 (14.3%)	4 (57.1%)	0 (0.0%)	7
Acute graft versus host disease in liver	3 (42.9%)	1 (14.3%)	3 (42.9%)	0 (0.0%)	7
Lung perforation	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Avulsion fracture	2 (28.6%)	2 (28.6%)	3 (42.9%)	0 (0.0%)	7
Lumbar hernia	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Lower urinary tract symptoms	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Liver transplant rejection	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Antimicrobial susceptibility test resistant	3 (42.9%)	0 (0.0%)	4 (57.1%)	0 (0.0%)	7
Bone graft	2 (28.6%)	3 (42.9%)	1 (14.3%)	1 (14.3%)	7
Diffuse alopecia	1 (14.3%)	2 (28.6%)	2 (28.6%)	2 (28.6%)	7
Lithiasis	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Adrenal cyst	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Application site bruise	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Lip squamous cell carcinoma	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Limb crushing injury	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Body tinea	1 (14.3%)	3 (42.9%)	0 (0.0%)	3 (42.9%)	7
Body surface area decreased	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Leukoerythroblastosis	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Body mass index	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Hypercalciuria	4 (57.1%)	1 (14.3%)	2 (28.6%)	0 (0.0%)	7
Left ventricle outflow tract obstruction	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Abscess neck	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Learning disability	3 (42.9%)	3 (42.9%)	1 (14.3%)	0 (0.0%)	7
Typhoid fever	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Blood urine	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Squamous cell carcinoma of lung	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Blood uric acid abnormal	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Large intestine erosion	0 (0.0%)	4 (57.1%)	1 (14.3%)	2 (28.6%)	7
Lagophthalmos	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Dermoid cyst	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Steatorrhoea	1 (14.3%)	0 (0.0%)	3 (42.9%)	3 (42.9%)	7
Ketonuria	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Keratitis bacterial	2 (28.6%)	2 (28.6%)	3 (42.9%)	0 (0.0%)	7
Blood prolactin decreased	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood prolactin abnormal	5 (71.4%)	2 (28.6%)	0 (0.0%)	0 (0.0%)	7
Dental prosthesis placement	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Joint hyperextension	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Jaw cyst	1 (14.3%)	2 (28.6%)	4 (57.1%)	0 (0.0%)	7
Delayed recovery from anaesthesia	1 (14.3%)	2 (28.6%)	1 (14.3%)	3 (42.9%)	7
B-cell lymphoma recurrent	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Blood pH decreased	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Intracardiac mass	0 (0.0%)	1 (14.3%)	2 (28.6%)	4 (57.1%)	7
Waist circumference increased	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Blood creatine abnormal	1 (14.3%)	2 (28.6%)	3 (42.9%)	1 (14.3%)	7
Subcutaneous drug absorption impaired	2 (28.6%)	2 (28.6%)	3 (42.9%)	0 (0.0%)	7
Substance abuser	4 (57.1%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	7
Hyphaema	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Visual brightness	1 (14.3%)	5 (71.4%)	0 (0.0%)	1 (14.3%)	7
Burning mouth syndrome	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Viral pharyngitis	2 (28.6%)	3 (42.9%)	2 (28.6%)	0 (0.0%)	7
Superior sagittal sinus thrombosis	4 (57.1%)	2 (28.6%)	1 (14.3%)	0 (0.0%)	7
Blood ketone body present	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Alveolitis	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Hypoglycaemic seizure	3 (42.9%)	0 (0.0%)	0 (0.0%)	4 (57.1%)	7
Cytomegalovirus enteritis	0 (0.0%)	4 (57.1%)	1 (14.3%)	2 (28.6%)	7
Insulin-like growth factor decreased	2 (28.6%)	4 (57.1%)	1 (14.3%)	0 (0.0%)	7
Vein discolouration	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Cyclic vomiting syndrome	3 (42.9%)	4 (57.1%)	0 (0.0%)	0 (0.0%)	7
Catheter site thrombosis	1 (14.3%)	1 (14.3%)	3 (42.9%)	2 (28.6%)	7
Tachycardia induced cardiomyopathy	4 (57.1%)	0 (0.0%)	1 (14.3%)	2 (28.6%)	7
Uterine pain	1 (14.3%)	5 (71.4%)	1 (14.3%)	0 (0.0%)	7

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Placenta praevia	2 (28.6%)	5 (71.4%)	0 (0.0%)	0 (0.0%)	7
Urticaria pressure	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Tenoplasty	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Testis discomfort	4 (57.1%)	1 (14.3%)	2 (28.6%)	0 (0.0%)	7
Ureteric stenosis	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Infective myositis	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Blood catecholamines increased	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Illness anxiety disorder	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Tooth erosion	0 (0.0%)	5 (71.4%)	1 (14.3%)	1 (14.3%)	7
Cough decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Corneal deposits	5 (71.4%)	0 (0.0%)	1 (14.3%)	1 (14.3%)	7
Toxic shock syndrome streptococcal	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Tongue fungal infection	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Tongue injury	2 (28.6%)	1 (14.3%)	4 (57.1%)	0 (0.0%)	7
Gastrectomy	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Immune-mediated pancytopenia	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Tissue injury	2 (28.6%)	3 (42.9%)	2 (28.6%)	0 (0.0%)	7
Thyroxine decreased	2 (28.6%)	2 (28.6%)	2 (28.6%)	1 (14.3%)	7
Thrombotic stroke	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Abdominal sepsis	1 (14.3%)	4 (57.1%)	1 (14.3%)	1 (14.3%)	7
Convulsions local	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Therapeutic product ineffective for unapproved indica	1 (14.3%)	3 (42.9%)	1 (14.3%)	2 (28.6%)	7
Ileal perforation	1 (14.3%)	3 (42.9%)	2 (28.6%)	1 (14.3%)	7
Idiopathic orbital inflammation	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Tracheal disorder	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Hypotensive crisis	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Syndactyly	6 (85.7%)	1 (14.3%)	0 (0.0%)	0 (0.0%)	7

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blindness day	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Epidural injection	0 (0.0%)	4 (57.1%)	2 (28.6%)	1 (14.3%)	7
Blood chromogranin A increased	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Sudden onset of sleep	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Tri-iodothyronine free decreased	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Trichoglossia	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Post procedural contusion	1 (14.3%)	0 (0.0%)	4 (57.1%)	2 (28.6%)	7
Increased need for sleep	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Stoma site extravasation	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Stiff person syndrome	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Hypermetropia	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Hypermetabolism	1 (14.3%)	1 (14.3%)	4 (57.1%)	1 (14.3%)	7
Hypercreatinaemia	1 (14.3%)	1 (14.3%)	2 (28.6%)	3 (42.9%)	7
Splenic cyst	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Hyperaldosteronism	1 (14.3%)	2 (28.6%)	3 (42.9%)	1 (14.3%)	7
Spinal cord haemorrhage	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Soft tissue haemorrhage	4 (57.1%)	0 (0.0%)	3 (42.9%)	0 (0.0%)	7
Gastrointestinal hypermotility	2 (28.6%)	4 (57.1%)	1 (14.3%)	0 (0.0%)	7
Influenza immunisation	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Colorectal cancer recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Adrenal adenoma	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Colony stimulating factor therapy	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Skin turgor decreased	5 (71.4%)	0 (0.0%)	2 (28.6%)	0 (0.0%)	7
Urethral pain	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Herpes zoster oticus	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Right ventricle outflow tract obstruction	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Sinonasal obstruction	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Culture positive	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Urinary bladder suspension	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Serositis	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Erythrodermic psoriasis	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Senile dementia	0 (0.0%)	0 (0.0%)	2 (28.6%)	5 (71.4%)	7
Selective eating disorder	4 (57.1%)	2 (28.6%)	1 (14.3%)	0 (0.0%)	7
Gastrointestinal surgery	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Hepatic cyst infection	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Hepatic cancer metastatic	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Procedural nausea	2 (28.6%)	4 (57.1%)	1 (14.3%)	0 (0.0%)	7
Scan abnormal	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Hepatectomy	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Heparin resistance	1 (14.3%)	0 (0.0%)	3 (42.9%)	3 (42.9%)	7
Chylothorax	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Varicella zoster pneumonia	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Injection site pustule	2 (28.6%)	3 (42.9%)	2 (28.6%)	0 (0.0%)	7
Chronic lymphocytic leukaemia recurrent	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Retinitis viral	4 (57.1%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	7
Retinal thickening	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Resting tremor	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Haemorrhoids thrombosed	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Respiratory rate	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Residual urine volume increased	0 (0.0%)	4 (57.1%)	1 (14.3%)	2 (28.6%)	7
Renal atrophy	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Cytomegalovirus duodenitis	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Hanging	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Refusal of examination	2 (28.6%)	3 (42.9%)	1 (14.3%)	1 (14.3%)	7

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Recurrence of neuromuscular blockade	1 (14.3%)	3 (42.9%)	3 (42.9%)	0 (0.0%)	7
Administration site infection	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Benign neoplasm of adrenal gland	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Very low density lipoprotein increased	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Chloasma	0 (0.0%)	4 (57.1%)	2 (28.6%)	1 (14.3%)	7
Pulpless tooth	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Pulmonary vascular disorder	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Pulmonary renal syndrome	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Vitamin B6 deficiency	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Globotriaosylceramide increased	2 (28.6%)	2 (28.6%)	3 (42.9%)	0 (0.0%)	7
Vitamin B6 decreased	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Psoas abscess	0 (0.0%)	2 (28.6%)	3 (42.9%)	2 (28.6%)	7
Pseudomonas test positive	1 (14.3%)	3 (42.9%)	2 (28.6%)	1 (14.3%)	7
Gingival discomfort	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Extensor plantar response	0 (0.0%)	4 (57.1%)	2 (28.6%)	1 (14.3%)	7
Vulval ulceration	4 (57.1%)	2 (28.6%)	1 (14.3%)	0 (0.0%)	7
Genital swelling	1 (14.3%)	1 (14.3%)	3 (42.9%)	2 (28.6%)	7
Prolapse	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Genital lesion	2 (28.6%)	0 (0.0%)	3 (42.9%)	2 (28.6%)	7
Genital infection fungal	0 (0.0%)	2 (28.6%)	3 (42.9%)	2 (28.6%)	7
Genital infection	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Administration site discolouration	2 (28.6%)	1 (14.3%)	3 (42.9%)	1 (14.3%)	7
Cerebral small vessel ischaemic disease	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Intraocular pressure test abnormal	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Preterm premature rupture of membranes	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Premenstrual syndrome	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Precancerous lesion of digestive tract	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Cerebral calcification	2 (28.6%)	0 (0.0%)	5 (71.4%)	0 (0.0%)	7
Postural tremor	0 (0.0%)	0 (0.0%)	2 (28.6%)	5 (71.4%)	7
Postpartum haemorrhage	1 (14.3%)	6 (85.7%)	0 (0.0%)	0 (0.0%)	7
Postoperative thrombosis	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Xeroderma	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Cerebellar stroke	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Wound abscess	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Post procedural sepsis	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Gastroenteritis radiation	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Post concussion syndrome	1 (16.7%)	3 (50.0%)	1 (16.7%)	1 (16.7%)	6
Gastritis haemorrhagic	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Central nervous system viral infection	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Pulmonary artery stenosis	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Bacterial abdominal infection	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Glomerulonephritis membranoproliferative	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Poikilocytosis	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Pneumonia parainfluenzae viral	1 (16.7%)	2 (33.3%)	2 (33.3%)	1 (16.7%)	6
Babesiosis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Pneumobilia	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Pneumatoxis	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Pleuropericarditis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Pleural mesothelioma	0 (0.0%)	1 (16.7%)	2 (33.3%)	3 (50.0%)	6
BCG related cystitis	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Plasma cell leukaemia	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Chest wall haematoma	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Pituitary-dependent Cushing's syndrome	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Fungal endocarditis	1 (16.7%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	6

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pica	5 (83.3%)	1 (16.7%)	0 (0.0%)	0 (0.0%)	6
Catheter site irritation	3 (50.0%)	0 (0.0%)	2 (33.3%)	1 (16.7%)	6
Catheter site inflammation	0 (0.0%)	5 (83.3%)	0 (0.0%)	1 (16.7%)	6
Fracture nonunion	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Adenotonsillectomy	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
B-cell aplasia	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Periprosthetic fracture	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Peripheral nerve lesion	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Anal cyst	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Granulomatous dermatitis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Penile ulceration	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Pelvic haematoma	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
Peak expiratory flow rate decreased	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Viral test positive	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Parathyroidectomy	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Autoimmune lung disease	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Paraneoplastic pemphigus	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Cardiac ventricular disorder	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Fear-related avoidance of activities	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
Cytomegalovirus gastritis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Fat necrosis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Blood insulin abnormal	4 (66.7%)	1 (16.7%)	0 (0.0%)	1 (16.7%)	6
Fallopian tube disorder	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Angiosarcoma	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Pachymeningitis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Oxygen saturation increased	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Cardiac function test abnormal	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Overflow diarrhoea	2 (33.3%)	2 (33.3%)	2 (33.3%)	0 (0.0%)	6
Cardiac failure high output	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Ovarian granulosa cell tumour	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Amyotrophy	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Atypical mycobacterium test positive	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Osteosarcoma	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Osteomyelitis chronic	2 (33.3%)	2 (33.3%)	2 (33.3%)	0 (0.0%)	6
Eyelid operation	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Carcinoid tumour pulmonary	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Orthosis user	3 (50.0%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	6
Eye infection viral	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Eye infection fungal	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Optic nerve neoplasm	0 (0.0%)	4 (66.7%)	1 (16.7%)	1 (16.7%)	6
Cardiac output decreased	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Open fracture	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Extranodal marginal zone B-cell lymphoma (MALT type)	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Capillary fragility	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Capillaritis	2 (33.3%)	1 (16.7%)	3 (50.0%)	0 (0.0%)	6
Candida test positive	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Oesophageal perforation	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Exposure to household chemicals	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Oesophageal irritation	1 (16.7%)	0 (0.0%)	4 (66.7%)	1 (16.7%)	6
Oesophageal injury	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Oesophageal food impaction	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Oedema genital	0 (0.0%)	3 (50.0%)	1 (16.7%)	2 (33.3%)	6
Ocular neoplasm	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Pancreatic atrophy	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chronic left ventricular failure	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Obstructive defaecation	0 (0.0%)	0 (0.0%)	1 (16.7%)	5 (83.3%)	6
Hearing disability	1 (16.7%)	0 (0.0%)	3 (50.0%)	2 (33.3%)	6
Erythematotelangiectatic rosacea	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Neurofibroma	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Neuroendocrine tumour of the rectum	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Epidural analgesia	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Hemiparaesthesia	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Amimia	0 (0.0%)	5 (83.3%)	0 (0.0%)	1 (16.7%)	6
CD19 lymphocytes decreased	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
Neovascularisation	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Neonatal respiratory acidosis	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Buttock injury	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Enterostomy	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Neck deformity	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Acute on chronic liver failure	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Nasal septum perforation	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Nasal polypectomy	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Nasal mucosal disorder	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Nasal cavity cancer	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Nail dystrophy	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Nail bed disorder	2 (33.3%)	2 (33.3%)	2 (33.3%)	0 (0.0%)	6
NSAID exacerbated respiratory disease	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Myxoedema	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Hepatic haemorrhage	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Myocardial strain imaging abnormal	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Myocardial oedema	2 (33.3%)	2 (33.3%)	1 (16.7%)	1 (16.7%)	6

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Budd-Chiari syndrome	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Myeloid leukaemia	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Rectal ulcer	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Alternaria infection	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Mycobacterium marinum infection	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Altered visual depth perception	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Muscle swelling	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Elliptocytosis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Bronchiolitis obliterans syndrome	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Mucosal hypertrophy	1 (16.7%)	3 (50.0%)	1 (16.7%)	1 (16.7%)	6
Arteriovenous malformation	1 (16.7%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	6
Electrocardiogram ST-T change	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Muckle-Wells syndrome	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Electrocardiogram QT shortened	2 (33.3%)	1 (16.7%)	1 (16.7%)	2 (33.3%)	6
Electrocardiogram QT interval abnormal	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Morbid thoughts	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Patient isolation	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Elbow deformity	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Brief psychotic disorder with marked stressors	0 (0.0%)	3 (50.0%)	0 (0.0%)	3 (50.0%)	6
Mitral valve thickening	4 (66.7%)	0 (0.0%)	2 (33.3%)	0 (0.0%)	6
Eczema weeping	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Mitochondrial encephalomyopathy	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Acute macular neuroretinopathy	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Breast ulceration	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Arterial therapeutic procedure	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Eating disorder symptom	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Ear neoplasm malignant	0 (0.0%)	0 (0.0%)	1 (16.7%)	5 (83.3%)	6

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Shock symptom	0 (0.0%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	6
Breast feeding	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Pelvic mass	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Shunt malfunction	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Meningococcal sepsis	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Dysdiadochokinesis	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Dysaesthesia pharynx	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Arnold-Chiari malformation	2 (33.3%)	3 (50.0%)	1 (16.7%)	0 (0.0%)	6
Breast calcifications	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Anal blister	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Medical induction of coma	1 (16.7%)	2 (33.3%)	2 (33.3%)	1 (16.7%)	6
Penile curvature	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Medical device site pain	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Medical device change	2 (33.3%)	0 (0.0%)	1 (16.7%)	3 (50.0%)	6
Flashback	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Acute hepatitis B	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Drug rechallenge positive	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Application site scab	3 (50.0%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	6
Brain cancer metastatic	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Dropped head syndrome	2 (33.3%)	1 (16.7%)	2 (33.3%)	1 (16.7%)	6
Male genital atrophy	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Pericarditis fungal	0 (0.0%)	3 (50.0%)	0 (0.0%)	3 (50.0%)	6
Macrocephaly	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Uraemic encephalopathy	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Foetal hypokinesia	5 (83.3%)	1 (16.7%)	0 (0.0%)	0 (0.0%)	6
Disseminated toxoplasmosis	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Foetal malformation	4 (66.7%)	2 (33.3%)	0 (0.0%)	0 (0.0%)	6

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Lung diffusion test abnormal	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Lung cyst	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Ludwig angina	1 (16.7%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	6
Unexpected vaginal bleeding on hormonal IUD	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Diffuse large B-cell lymphoma stage IV	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Application site dryness	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Liver function test decreased	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Diet refusal	2 (33.3%)	0 (0.0%)	2 (33.3%)	2 (33.3%)	6
Complicated appendicitis	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Bone fragmentation	1 (16.7%)	0 (0.0%)	4 (66.7%)	1 (16.7%)	6
Infective exacerbation of chronic obstructive airways	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Diaphragmatic paralysis	1 (16.7%)	0 (0.0%)	2 (33.3%)	3 (50.0%)	6
Bladder irritation	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Limb asymmetry	0 (0.0%)	1 (16.7%)	1 (16.7%)	4 (66.7%)	6
Leukoplakia oral	0 (0.0%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	6
Leukoderma	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Leukaemoid reaction	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Splenic infection viral	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Apparent death	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Left atrial appendage closure implant	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Bloody peritoneal effluent	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Learning disorder	4 (66.7%)	0 (0.0%)	2 (33.3%)	0 (0.0%)	6
Blood zinc decreased	0 (0.0%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	6
Spontaneous bacterial peritonitis	2 (33.3%)	0 (0.0%)	4 (66.7%)	0 (0.0%)	6
Blood viscosity decreased	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Laryngeal inflammation	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Laryngeal disorder	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood uric acid decreased	1 (16.7%)	2 (33.3%)	2 (33.3%)	1 (16.7%)	6
Device colour issue	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Developmental hip dysplasia	3 (50.0%)	0 (0.0%)	3 (50.0%)	0 (0.0%)	6
Lactation insufficiency	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Lactation disorder	3 (50.0%)	3 (50.0%)	0 (0.0%)	0 (0.0%)	6
Lack of spontaneous speech	3 (50.0%)	0 (0.0%)	2 (33.3%)	1 (16.7%)	6
Labelled drug-food interaction medication error	4 (66.7%)	0 (0.0%)	2 (33.3%)	0 (0.0%)	6
Kwashiorkor	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Keratoacanthoma	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Keratic precipitates	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Dependence on respirator	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Catheter site bruise	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Jaundice neonatal	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Irregular sleep wake rhythm disorder	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Irregular breathing	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Anal fissure haemorrhage	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Stomatitis haemorrhagic	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Deja vu	4 (66.7%)	0 (0.0%)	1 (16.7%)	1 (16.7%)	6
Intravascular haemolysis	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Wound sepsis	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Pharyngeal mass	1 (16.7%)	4 (66.7%)	0 (0.0%)	1 (16.7%)	6
Deep brain stimulation	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Blood osmolarity decreased	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Blood magnesium abnormal	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Vitamin C deficiency	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Deafness transitory	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Vitamin B1 deficiency	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intervertebral disc injury	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Graft complication	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Viral skin infection	3 (50.0%)	0 (0.0%)	3 (50.0%)	0 (0.0%)	6
Incision site haemorrhage	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Benign breast neoplasm	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Adrenal neoplasm	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Cytomegalovirus gastrointestinal infection	2 (33.3%)	3 (50.0%)	0 (0.0%)	1 (16.7%)	6
Nasal neoplasm	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Vascular stenosis	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Vascular malformation	2 (33.3%)	1 (16.7%)	3 (50.0%)	0 (0.0%)	6
Vascular hyalinosis	0 (0.0%)	2 (33.3%)	0 (0.0%)	4 (66.7%)	6
Hypopyon	0 (0.0%)	1 (16.7%)	2 (33.3%)	3 (50.0%)	6
Vaginal abscess	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
VEXAS syndrome	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Cutaneous nocardiosis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Toxic cardiomyopathy	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Infusion site injury	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Idiopathic environmental intolerance	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Testicular disorder	0 (0.0%)	2 (33.3%)	0 (0.0%)	4 (66.7%)	6
Urinary bladder polyp	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Contraindication to medical treatment	2 (33.3%)	0 (0.0%)	3 (50.0%)	1 (16.7%)	6
Tethered oral tissue	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Tumour compression	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Tubulointerstitial nephritis and uveitis syndrome	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Trigger points	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Trichophytosis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Transplantation complication	3 (50.0%)	3 (50.0%)	0 (0.0%)	0 (0.0%)	6

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Nematodiasis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Transferrin decreased	0 (0.0%)	1 (16.7%)	1 (16.7%)	4 (66.7%)	6
Tractional retinal detachment	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Toxic nodular goitre	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Corneal toxicity	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Tooth avulsion	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Tongue spasm	2 (33.3%)	3 (50.0%)	1 (16.7%)	0 (0.0%)	6
Tongue rough	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Corneal infection	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Immune-mediated neuropathy	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Cor pulmonale	0 (0.0%)	2 (33.3%)	1 (16.7%)	3 (50.0%)	6
Tooth deposit	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Coombs positive haemolytic anaemia	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Coombs negative haemolytic anaemia	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Thoracic cavity drainage	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Iliotibial band syndrome	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Therapeutic response increased	1 (16.7%)	2 (33.3%)	0 (0.0%)	3 (50.0%)	6
Testis cancer	2 (33.3%)	2 (33.3%)	1 (16.7%)	1 (16.7%)	6
Testicular mass	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Toxicologic test abnormal	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Iatrogenic injury	1 (16.7%)	3 (50.0%)	1 (16.7%)	1 (16.7%)	6
Contact lens intolerance	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Illrd nerve paralysis	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Blood albumin abnormal	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Tracheal injury	0 (0.0%)	5 (83.3%)	0 (0.0%)	1 (16.7%)	6
Transfusion reaction	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Synovial rupture	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypohidrosis	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Hypogonadism male	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Suspected product tampering	1 (16.7%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	6
Suspected product contamination	1 (16.7%)	4 (66.7%)	0 (0.0%)	1 (16.7%)	6
Adrenal mass	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Hypnagogic hallucination	1 (16.7%)	1 (16.7%)	0 (0.0%)	4 (66.7%)	6
Trisomy 18	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Hypersensitivity myocarditis	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Stoma site oedema	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Hyperplasia	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Bladder ulcer	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Hyperinsulinaemic hypoglycaemia	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Computerised tomogram thorax	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Hypergammaglobulinaemia	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Sports injury	3 (50.0%)	1 (16.7%)	2 (33.3%)	0 (0.0%)	6
Spontaneous haematoma	0 (0.0%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	6
Type III immune complex mediated reaction	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Hyperchloraemia	4 (66.7%)	0 (0.0%)	1 (16.7%)	1 (16.7%)	6
Hypercalcaemia of malignancy	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Posthaemorrhagic hydrocephalus	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Spinal nerve stimulator implantation	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Spinal flattening	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
Spinal epidural haemorrhage	0 (0.0%)	5 (83.3%)	0 (0.0%)	1 (16.7%)	6
Complement factor decreased	3 (50.0%)	1 (16.7%)	2 (33.3%)	0 (0.0%)	6
Solar dermatitis	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Sodium retention	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Cryptitis	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Cryptococcal fungaemia	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Histone antibody positive	0 (0.0%)	4 (66.7%)	1 (16.7%)	1 (16.7%)	6
Tumour invasion	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Colonoscopy abnormal	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Urethral obstruction	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Infusion	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Colon dysplasia	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Herpes zoster meningoencephalitis	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Urethral haemorrhage	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Anorectal infection	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Shock hypoglycaemic	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Sexually inappropriate behaviour	0 (0.0%)	2 (33.3%)	1 (16.7%)	3 (50.0%)	6
Hepatitis alcoholic	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Septic pulmonary embolism	2 (33.3%)	2 (33.3%)	2 (33.3%)	0 (0.0%)	6
Septic arthritis staphylococcal	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Sensorimotor disorder	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Inguinal mass	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Biopsy kidney	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Secondary syphilis	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Hepatic vascular thrombosis	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Secondary amyloidosis	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Uterine cyst	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Second degree chemical burn of skin	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Seasonal affective disorder	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Scrotal oedema	1 (16.7%)	2 (33.3%)	2 (33.3%)	1 (16.7%)	6
Scrotal cellulitis	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Clonic convulsion	3 (50.0%)	1 (16.7%)	1 (16.7%)	1 (16.7%)	6

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Abnormal menstrual clots	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Scleral discolouration	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Schizoaffective disorder bipolar type	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Scarlet fever	2 (33.3%)	4 (66.7%)	0 (0.0%)	0 (0.0%)	6
Hepatic atrophy	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Sarcopenia	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Salpingo-oophorectomy bilateral	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Salivary gland enlargement	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Injection site nerve damage	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Right ventricular dilatation	4 (66.7%)	2 (33.3%)	0 (0.0%)	0 (0.0%)	6
Right atrial dilatation	2 (33.3%)	1 (16.7%)	0 (0.0%)	3 (50.0%)	6
Injection site laceration	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Retinal occlusive vasculitis	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Chronic hepatic failure	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Vascular dementia	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Rest regimen	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Vascular stent stenosis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Renal tubular dysfunction	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Beta 2 microglobulin increased	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Haemochromatosis	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Reflexes abnormal	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Haemangioma of skin	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Product monitoring error	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Cholinergic syndrome	0 (0.0%)	1 (16.7%)	0 (0.0%)	5 (83.3%)	6
Vertebrobasilar artery dissection	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Radioisotope scan abnormal	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Grip strength	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Victim of sexual abuse	3 (50.0%)	3 (50.0%)	0 (0.0%)	0 (0.0%)	6
Chloroma	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Pyomyositis	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Oedema mouth	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Graft versus host disease oral	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Interstitial lung abnormality	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Child abuse	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Intervertebral disc compression	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Glucocorticoid deficiency	0 (0.0%)	3 (50.0%)	1 (16.7%)	2 (33.3%)	6
Glomerulosclerosis	3 (50.0%)	0 (0.0%)	3 (50.0%)	0 (0.0%)	6
Pulmonary blastomycosis	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Pulmonary angioplasty	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Gingivitis ulcerative	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Basophil count decreased	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Androgenetic alopecia	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Protrusion tongue	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Gingival blister	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Protein deficiency	1 (16.7%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	6
Cervix disorder	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Vulvovaginitis	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Genital ulcer syndrome	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Progressive multiple sclerosis	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Cervical polyp	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Genital discomfort	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
General physical condition	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Product commingling	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Product coating issue	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastrostomy tube site complication	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Gastroesophageal reflux in neonate	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Change in sustained attention	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Withdrawal catatonia	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Cerebral palsy	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Cerebral microinfarction	0 (0.0%)	1 (16.7%)	1 (16.7%)	4 (66.7%)	6
Cerebral microangiopathy	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Wound infection bacterial	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Wrist deformity	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Cerebral cyst	3 (50.0%)	1 (16.7%)	2 (33.3%)	0 (0.0%)	6
Aortic occlusion	0 (0.0%)	4 (66.7%)	1 (16.7%)	1 (16.7%)	6
Gastrointestinal candidiasis	2 (33.3%)	0 (0.0%)	4 (66.7%)	0 (0.0%)	6
Posterior capsule opacification	2 (33.3%)	1 (16.7%)	1 (16.7%)	2 (33.3%)	6
Acinetobacter test positive	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Post procedural fistula	1 (16.7%)	0 (0.0%)	4 (66.7%)	1 (16.7%)	6
Anal squamous cell carcinoma	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Central vision loss	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Post infection glomerulonephritis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Polypoidal choroidal vasculopathy	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Polymerase chain reaction positive	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Gastric neoplasm	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Bed bug infestation	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Pneumonia lipoid	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Plicated tongue	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Pleural fibrosis	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Pleocytosis	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Platelet count	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Pulmonary venous thrombosis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Frostbite	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Frontotemporal dementia	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Pharyngitis bacterial	1 (20.0%)	3 (60.0%)	1 (20.0%)	0 (0.0%)	5
Free fatty acids increased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Catheter site extravasation	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Phaeohyphomycosis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pyloric stenosis	4 (80.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	5
Foreign body in respiratory tract	1 (20.0%)	0 (0.0%)	1 (20.0%)	3 (60.0%)	5
Granulomatous lymphadenitis	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Periostitis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Follicular lymphoma stage IV	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Catabolic state	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Foetal disorder	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
Breast injury	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Autonomic dysreflexia	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Penile erythema	1 (20.0%)	1 (20.0%)	1 (20.0%)	2 (40.0%)	5
Pelvic discomfort	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Finger amputation	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Pelvi-ureteric obstruction	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Fibrous histiocytoma	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Fibromuscular dysplasia	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Patellofemoral pain syndrome	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
HLA marker study positive	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Parapsoriasis	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Paraproteinaemia	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Paraphimosis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Paranasal sinus hyposecretion	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Feeding tube user	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Febrile nonhaemolytic transfusion reaction	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Pancreatolithiasis	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Autoimmune dermatitis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Pancreatic duct dilatation	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pancreatic carcinoma recurrent	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Autoimmune arthritis	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Palmoplantar keratoderma	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Adenocarcinoma of appendix	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Palatal swelling	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Faecaluria	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
PIK3CA-activated mutation	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Adenocarcinoma metastatic	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Ovarian cancer metastatic	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Atypical mycobacterial pneumonia	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Choroiditis	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Repetitive speech	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Eyelid injury	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Carcinoma in situ	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Bickerstaff's encephalitis	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Carcinoid tumour of the small bowel	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Oropharyngeal plaque	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Oropharyngeal cancer	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Eye paraesthesia	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Respiratory paralysis	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Carboxyhaemoglobin increased	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Respiratory muscle weakness	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Carbon monoxide poisoning	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Eye haematoma	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Oral administration complication	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Optic perineuritis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Acute stress disorder	0 (0.0%)	3 (60.0%)	0 (0.0%)	2 (40.0%)	5
Opisthotonus	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Extremity contracture	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Ophthalmic herpes simplex	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Oophorectomy bilateral	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Retinal exudates	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Oesophagogastroduodenoscopy	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Exposure via eye contact	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Exposure via direct contact	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pancreatic toxicity	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Exposure to allergen	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Oesophageal cancer metastatic	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Expiratory reserve volume decreased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Retracted nipple	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Haptoglobin decreased	1 (20.0%)	3 (60.0%)	1 (20.0%)	0 (0.0%)	5
Exercise lack of	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Nuchal rigidity	1 (20.0%)	1 (20.0%)	2 (40.0%)	1 (20.0%)	5
Norepinephrine decreased	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Erythema annulare	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Nodal osteoarthritis	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Chronic rhinosinusitis with nasal polyps	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Neurosurgery	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Neurosis	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Epidural haemorrhage	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Neurodegenerative disorder	3 (60.0%)	1 (20.0%)	0 (0.0%)	1 (20.0%)	5
Saccadic eye movement	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Neuroblastoma	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Hemianopia homonymous	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Nerve block	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
American trypanosomiasis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
C3 glomerulopathy	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Salivary gland calculus	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Negative symptoms in schizophrenia	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Necrotising oesophagitis	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Enthesophyte	0 (0.0%)	2 (40.0%)	0 (0.0%)	3 (60.0%)	5
Near drowning	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Felty's syndrome	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Enterobacter sepsis	0 (0.0%)	1 (20.0%)	1 (20.0%)	3 (60.0%)	5
Nasal herpes	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Burning sensation mucosal	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Vaccination site erythema	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Asocial behaviour	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Nail pitting	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Burn oesophageal	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Endotracheal intubation complication	1 (20.0%)	1 (20.0%)	2 (40.0%)	1 (20.0%)	5
Artificial crown procedure	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Burkitt's lymphoma recurrent	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Nail bed infection	1 (20.0%)	2 (40.0%)	1 (20.0%)	1 (20.0%)	5
Endoscopy upper gastrointestinal tract	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bunion operation	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Bundle branch block	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Parkinsonian crisis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Bulbar palsy	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Brow ptosis	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Myelin oligodendrocyte glycoprotein antibody-associat	3 (60.0%)	1 (20.0%)	0 (0.0%)	1 (20.0%)	5
Encephalomyelitis viral	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Mycobacterium chelonae infection	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Partial seizures with secondary generalisation	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Enanthema	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Bronchopleural fistula	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Muscle hypertrophy	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Muscle enzyme increased	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Embolc cerebral infarction	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Artery dissection	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Inguinal hernia repair	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Alpha tumour necrosis factor increased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Biopsy lung	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Mood disorder due to a general medical condition	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Cutaneous calcification	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5
Septic cerebral embolism	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Monocyte chemotactic protein-1 increased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Arteriovenous fistula	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Mixed connective tissue disease	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Breech presentation	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Eczema infected	2 (40.0%)	1 (20.0%)	0 (0.0%)	2 (40.0%)	5
Mineral supplementation	2 (40.0%)	1 (20.0%)	1 (20.0%)	1 (20.0%)	5

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Milk allergy	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Middle ear inflammation	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Microsporidia infection	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Ear, nose and throat infection	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Metastases to stomach	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Metastases to spleen	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Breast inflammation	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Metastases to neck	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Allogenic stem cell transplantation	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Metastases to eye	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Metastases to chest wall	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Metastases to abdominal cavity	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Dyspnoea paroxysmal nocturnal	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Dysplastic naevus	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Meralgia paraesthetica	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Seminoma	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Meniscus operation	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Meningoradiculitis	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Meningoencephalitis bacterial	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Dyscalculia	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Meningitis enterococcal	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Dysania	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Meningitis Escherichia	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Melanoderma	1 (20.0%)	0 (0.0%)	2 (40.0%)	2 (40.0%)	5
Duplicate therapy error	0 (0.0%)	1 (20.0%)	0 (0.0%)	4 (80.0%)	5
Ductus arteriosus stenosis foetal	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Medical device site joint infection	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Brain stem haemorrhage	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Herpes zoster meningitis	1 (20.0%)	1 (20.0%)	2 (40.0%)	1 (20.0%)	5
Brain neoplasm benign	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Drug metabolite level high	1 (20.0%)	1 (20.0%)	1 (20.0%)	2 (40.0%)	5
Brain compression	2 (40.0%)	0 (0.0%)	2 (40.0%)	1 (20.0%)	5
Periarticular thenar erythema with onycholysis	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Drain placement	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Magnesium deficiency	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Macular ischaemia	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
MELAS syndrome	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Diverticulitis intestinal haemorrhagic	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Lymphocytic hypophysitis	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Dissociative amnesia	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Lymphatic disorder	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Lymphangitis	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Disseminated varicella zoster vaccine virus infection	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Application site hypoaesthesia	1 (20.0%)	3 (60.0%)	1 (20.0%)	0 (0.0%)	5
Disseminated coccidioidomycosis	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Disseminated Bacillus Calmette-Guerin infection	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Lumbar puncture	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Alkalosis hypochloraemic	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Loss of proprioception	2 (40.0%)	2 (40.0%)	0 (0.0%)	1 (20.0%)	5
Abdominal wall haemorrhage	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Long QT syndrome congenital	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Follicular thyroid cancer	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Lipoprotein (a) increased	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Lipoatrophy	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bone density increased	4 (80.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	5
Diagnostic procedure	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Lineage switch leukaemia	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Appendix cancer	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Diabetic ketosis	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Light chain analysis abnormal	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Ligament operation	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Follicular lymphoma stage III	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Alcoholic hangover	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Body mass index abnormal	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Lenticular opacities	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Leiomyoma	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Alcohol withdrawal syndrome	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Legionella infection	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Apoptotic colonopathy	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Laryngitis bacterial	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Blood viscosity increased	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Laryngeal pain	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Device deposit issue	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Device calibration failure	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Lacunar stroke	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Laboratory test interference	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Foreign body	2 (40.0%)	1 (20.0%)	1 (20.0%)	1 (20.0%)	5
Blood product transfusion dependent	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
B precursor type acute leukaemia	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
Joint abscess	1 (20.0%)	2 (40.0%)	1 (20.0%)	1 (20.0%)	5
Jealous delusion	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Jaw clicking	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Wound drainage	0 (0.0%)	2 (40.0%)	1 (20.0%)	2 (40.0%)	5
Airway complication of anaesthesia	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Intracranial infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Intracranial haematoma	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Vulvovaginal injury	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Vulvitis	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Blood oestrogen abnormal	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Death of relative	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Vitamin B6 increased	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Puncture site swelling	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Superficial siderosis of central nervous system	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Cytotoxic oedema	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Interleukin-2 receptor increased	1 (20.0%)	1 (20.0%)	2 (40.0%)	1 (20.0%)	5
Intercepted product selection error	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Vertebral end plate inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Ventricular hypertrophy	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Physical product label issue	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Agitation neonatal	4 (80.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	5
Vascular insufficiency	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Cystitis radiation	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Varicose vein operation	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Varicella virus test positive	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Cystic fibrosis respiratory infection suppression	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Antipsychotic drug level decreased	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Vaginal cyst	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
T-lymphocyte count increased	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Tracheostomy infection	2 (40.0%)	1 (20.0%)	0 (0.0%)	2 (40.0%)	5
In vitro fertilisation	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Uterine neoplasm	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Urine calcium increased	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Cubital tunnel syndrome	1 (20.0%)	3 (60.0%)	1 (20.0%)	0 (0.0%)	5
Tooth impacted	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Tumour perforation	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Infantile diarrhoea	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Tumour inflammation	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Thrombectomy	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Tubo-ovarian abscess	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Tuberculous pleurisy	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Blood creatine decreased	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Adverse event following immunisation	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5
Trichiasis	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Cor pulmonale chronic	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Incision site haematoma	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Incision site complication	1 (20.0%)	3 (60.0%)	0 (0.0%)	1 (20.0%)	5
Thyroid cyst	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Coronary angioplasty	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Blood catecholamines decreased	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Tonsillitis bacterial	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Tongue eruption	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Immunology test abnormal	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Immune-mediated uveitis	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Thyroxine abnormal	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Blood bilirubin unconjugated decreased	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Thyroid cancer metastatic	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Immune reconstitution inflammatory syndrome associate	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Antiacetylcholine receptor antibody positive	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Blood bicarbonate increased	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Blood bicarbonate decreased	3 (60.0%)	0 (0.0%)	2 (40.0%)	0 (0.0%)	5
Coombs direct test positive	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Blood beta-D-glucan increased	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Corneal thinning	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Anti-thyroid antibody increased	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Contrast media deposition	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Idiopathic urticaria	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Polymers allergy	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Ichthyosis	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Tooth development disorder	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5
Hypotony of eye	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Symblepharon	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Conjunctival bleb	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Hypogonadism	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Hypoglycaemic encephalopathy	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Incarcerated inguinal hernia	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Cortical visual impairment	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Suprapubic pain	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Suicide threat	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Neurogenic bowel	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Acquired tracheo-oesophageal fistula	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Substance dependence	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Bleeding varicose vein	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Subchorionic haematoma	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Post procedural erythema	1 (20.0%)	0 (0.0%)	2 (40.0%)	2 (40.0%)	5
Blast crisis in myelogenous leukaemia	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Streptococcal endocarditis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Blast cells present	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Stomatitis necrotising	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Hyperproteinaemia	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Stoma site induration	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Conductive deafness	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Stent removal	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Antidepressant discontinuation syndrome	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Hyperlipasaemia	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Bladder transitional cell carcinoma	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Hyperkinetic heart syndrome	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Tumour ulceration	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Sputum culture positive	1 (20.0%)	0 (0.0%)	1 (20.0%)	3 (60.0%)	5
Splenic haemorrhage	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Spinal synovial cyst	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Spinal fusion acquired	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Spinal decompression	1 (20.0%)	1 (20.0%)	2 (40.0%)	1 (20.0%)	5
Spinal cord operation	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Spinal cord herniation	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Anoxia	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Human papilloma virus test positive	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Human herpesvirus 6 infection reactivation	3 (60.0%)	0 (0.0%)	2 (40.0%)	0 (0.0%)	5
Specific gravity urine abnormal	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Comminuted fracture	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Human antichimeric antibody positive	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Housebound	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Small intestine neuroendocrine tumour	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Small cell carcinoma	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Bladder cancer recurrent	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Cryptorchism	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Colon cancer stage IV	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Skin graft	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Single functional kidney	2 (40.0%)	0 (0.0%)	1 (20.0%)	2 (40.0%)	5
Urinary tract candidiasis	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Hepatosplenic candidiasis	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Cogwheel rigidity	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Short stature	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Gastrointestinal mucosa hyperaemia	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Acquired left ventricle outflow tract obstruction	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Serum ferritin abnormal	2 (40.0%)	0 (0.0%)	1 (20.0%)	2 (40.0%)	5
Actinomycosis	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Blood follicle stimulating hormone increased	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Hepatitis B surface antigen positive	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Coagulation factor decreased	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Selenium deficiency	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Biopsy bone marrow	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Clostridial sepsis	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Scrotal infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Injection site cyst	1 (20.0%)	3 (60.0%)	1 (20.0%)	0 (0.0%)	5
Uterine scar	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Ankle deformity	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gingival operation	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Circumcision	4 (80.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	5
Vaginal prolapse	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
SARS-CoV-2 antibody test positive	0 (0.0%)	2 (40.0%)	1 (20.0%)	2 (40.0%)	5
SARS-CoV-2 RNA increased	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
SAPHO syndrome	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Ruptured cerebral aneurysm	0 (0.0%)	2 (40.0%)	1 (20.0%)	2 (40.0%)	5
Rotavirus infection	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Right-to-left cardiac shunt	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Heart valve operation	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Chronic recurrent multifocal osteomyelitis	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Varicose veins vulval	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Rhinocerebral mucormycosis	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Biliary fistula	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Cystitis escherichia	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Bile duct stent insertion	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Anhidrosis	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Bile acids increased	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Respiratory tract irritation	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Respiratory tract haemorrhage	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Respiratory syncytial virus bronchitis	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Bifidobacterium infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Chromatopsia	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Renal salt-wasting syndrome	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Choroidal detachment	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Renal failure neonatal	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Haemofiltration	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Haematospermia	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Renal aplasia	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Refeeding syndrome	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Cholestasis of pregnancy	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Vertebrobasilar stroke	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Angiogram	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Rebound acid hypersecretion	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Reactive gastropathy	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Genital erythema	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Anastomotic infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Radicular pain	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Radial nerve compression	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5
Pyogenic granuloma	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Pyelonephritis fungal	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Puncture site haemorrhage	2 (40.0%)	0 (0.0%)	2 (40.0%)	1 (20.0%)	5
Intervertebral disc displacement	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pulmonary valve stenosis	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
Intervertebral disc space narrowing	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Pulmonary haematoma	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pulmonary contusion	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Pulmonary arterial pressure abnormal	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Psychosexual disorder	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Vitreous cells	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Psoriasis area severity index increased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Prurigo	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Cervix dystocia	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Gilbert's syndrome	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Prostatic mass	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Prostate cancer recurrent	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Cervicitis	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Prolonged labour	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Walking distance test abnormal	1 (20.0%)	0 (0.0%)	2 (40.0%)	2 (40.0%)	5
Progesterone decreased	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Product substitution	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Product outer packaging issue	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Product counterfeit	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Intracranial tumour haemorrhage	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Cerebral salt-wasting syndrome	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Procedural vomiting	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Procedural pneumothorax	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Procedural hypotension	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Procedural failure	2 (40.0%)	0 (0.0%)	2 (40.0%)	1 (20.0%)	5
Primary immunodeficiency syndrome	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Bacteroides infection	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Pressure of speech	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Gastrointestinal polyp	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Bacteriuria	3 (60.0%)	0 (0.0%)	1 (20.0%)	1 (20.0%)	5
Premature separation of placenta	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Pregnancy test positive	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Pregnancy on oral contraceptive	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Pseudopapilloedema	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Cerebral artery embolism	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Xanthoma	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Zinc deficiency	2 (40.0%)	0 (0.0%)	2 (40.0%)	1 (20.0%)	5

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Post procedural oedema	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Post procedural inflammation	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Post procedural fever	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Portal vein occlusion	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Poor school attendance	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Pulmonary artery dilatation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Central nervous system neoplasm	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Gastric pneumatosis	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Acinetobacter sepsis	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Anal rash	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Central nervous system inflammation	1 (25.0%)	1 (25.0%)	0 (0.0%)	2 (50.0%)	4
Gastric antral vascular ectasia	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Pneumonia escherichia	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Ganglioglioma	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Gamma-glutamyltransferase	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Gambling	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Gallbladder hypofunction	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Adenovirus interstitial nephritis	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Plasmapheresis	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Gadolinium deposition disease	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Placental disorder	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Pituitary tumour recurrent	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Physiotherapy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Physical examination abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Catheter site oedema	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Pharyngeal injury	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Catheter site granuloma	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Fracture displacement	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Fracture delayed union	1 (25.0%)	0 (0.0%)	1 (25.0%)	2 (50.0%)	4
Foreign body ingestion	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Foreign body in skin or subcutaneous tissue	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Azoospermia	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Peritoneal effluent abnormal	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Catheter management	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4
Axonal and demyelinating polyneuropathy	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Peripheral vein occlusion	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Rabbit syndrome	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Peripheral paralysis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Cataract operation complication	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Peripheral embolism	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Peripheral circulatory failure	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Peripancreatic fluid collection	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Periorbital dermatitis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Cat scratch disease	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Graft thrombosis	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Periodic limb movement disorder	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Foetal heart rate decreased	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Anal cancer stage 0	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Foetal growth abnormality	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Perichondritis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Pericarditis infective	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Pericarditis constrictive	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Focal peritonitis	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Peptic ulcer perforation	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Penile swelling	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Adenoma benign	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Penile blister	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Penicillium infection	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Fistula of small intestine	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Pelvic bone injury	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Rectal cancer metastatic	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Autoimmune thyroid disorder	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Patient-device incompatibility	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Cardiospasm	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Adenoidal hypertrophy	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Partner stress	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Fibrinolysis	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Autoimmune neutropenia	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Fibrin degradation products increased	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Parotid gland enlargement	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Parkinson's disease psychosis	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Parenteral nutrition	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Adenoidal disorder	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Paratracheal lymphadenopathy	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Parathyroid tumour malignant	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Female orgasmic disorder	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Paraspinal abscess	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Parasitic gastroenteritis	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Paraneoplastic dermatomyositis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Inspiratory capacity decreased	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Paracentesis	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cardiac therapeutic procedure	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Autoimmune eye disorder	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Cardiac steatosis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Pancreatic steatosis	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
False positive investigation result	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Pancreatectomy	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Cardiac neoplasm unspecified	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Painful erection	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Painful ejaculation	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Venous haemorrhage	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
POEMS syndrome	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Oxygen saturation	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Cardiac fibroma	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Ovarian vein thrombosis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Ovarian rupture	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Ovarian haemorrhage	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Facial wasting	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Ovarian abscess	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Cardiac death	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Fabry's disease	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
FEV1/FVC ratio decreased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Eyelid thickening	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Renovascular hypertension	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Oscillopsia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Oroticaciduria	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Pain management	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Amyloid related imaging abnormalities	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Orgasm abnormal	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Oral neoplasm	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Carbohydrate antigen 27.29 increased	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Carbohydrate antigen 19-9 increased	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Amylase abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Extradural abscess	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Atrial standstill	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Oestradiol decreased	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Hair injury	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Cancer with a high tumour mutational burden	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cancer in remission	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Amniotic fluid volume decreased	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Injection site thrombosis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Campylobacter colitis	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Atrial conduction time prolongation	1 (25.0%)	0 (0.0%)	0 (0.0%)	3 (75.0%)	4
Euthanasia	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Eustachian tube dysfunction	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Obsessive rumination	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Nucleated red cells	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Norovirus test positive	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Calcification metastatic	1 (25.0%)	0 (0.0%)	0 (0.0%)	3 (75.0%)	4
Non-small cell lung cancer recurrent	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Non-pitting oedema	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Non-cirrhotic portal hypertension	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Non-Hodgkin's lymphoma stage IV	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
CSF volume increased	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Asymptomatic bacteriuria	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
CSF test abnormal	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Erosive duodenitis	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Nipple disorder	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Astrocytoma malignant	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Erection increased	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Newborn persistent pulmonary hypertension	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
CSF pressure increased	2 (50.0%)	0 (0.0%)	1 (25.0%)	1 (25.0%)	4
New onset diabetes after transplantation	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Epstein-Barr virus test positive	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Neuropsychiatric syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Neuromuscular blockade	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
CNS ventriculitis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Neurological examination abnormal	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Paranasal cyst	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Epidural lipomatosis	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Hemianaesthesia	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
CD4/CD8 ratio decreased	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
CD4 lymphocytes increased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Nerve root injury lumbar	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Eosinophilic pneumonia chronic	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Eosinophilic pleural effusion	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Eosinophilic bronchitis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Aspiration bone marrow	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Enzyme level abnormal	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Harlequin syndrome	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Enzyme abnormality	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Environmental exposure	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vaccination site swelling	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Necrotic lymphadenopathy	1 (25.0%)	0 (0.0%)	1 (25.0%)	2 (50.0%)	4
Enterocolonic fistula	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Natural killer cell count decreased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Bursa disorder	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Aspartate aminotransferase	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Nasal mucosal blistering	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Autoimmune myocarditis	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Scar pain	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Female sterilisation	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Nail hypertrophy	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Articular calcification	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Mycobacterial peritonitis	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Bronchopulmonary disease	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Acute myeloid leukaemia refractory	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Empty sella syndrome	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Emphysematous pyelonephritis	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Muscle tone disorder	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Passenger lymphocyte syndrome	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Rectal ulcer haemorrhage	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Electrocardiogram repolarisation abnormality	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Retroperitoneal abscess	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Mucosal toxicity	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Electrocardiogram ST segment abnormal	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Mucocutaneous haemorrhage	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Mucocutaneous disorder	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Bronchial neoplasm	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Electrocardiogram Q wave abnormal	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Electrocardiogram PR shortened	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Mitral valve calcification	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Mitochondrial cytopathy	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Alopecia universalis	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Alopecia totalis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Ectopic ACTH syndrome	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Microvascular coronary artery disease	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Echocardiogram	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Metastases to thyroid	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Arterial rupture	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Metastases to soft tissue	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Arterial repair	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Ear infection viral	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Breast haematoma	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Breast fibrosis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Metaplasia	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Breast disorder male	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Metal poisoning	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Dystrophic calcification	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Breast disorder female	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Cold type haemolytic anaemia	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Allergy to vaccine	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Breast cancer stage IV	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Meningoencephalitis viral	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Meningococcal infection	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Dysacusis	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Medullary thyroid cancer	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Breakthrough COVID-19	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Medical diet	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Medical device site swelling	1 (25.0%)	0 (0.0%)	1 (25.0%)	2 (50.0%)	4
Acute interstitial pneumonitis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Arachnoiditis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Medical device site erosion	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Medical device battery replacement	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Drug tolerance increased	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Meconium in amniotic fluid	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Mechanical ventilation complication	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Application site warmth	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Drug specific antibody absent	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Mean arterial pressure decreased	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Masked fever	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Marrow hyperplasia	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Manufacturing product shipping issue	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4
Mantle cell lymphoma recurrent	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Adenomatous polyposis coli	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Malignant polyp	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Malignant peritoneal neoplasm	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Malignant neoplasm of unknown primary site	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Malignant neoplasm of pleura	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Malignant neoplasm of eyelid	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Malignant neoplasm of eye	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Application site oedema	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Malabsorption from injection site	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Allergic respiratory symptom	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Dopamine dysregulation syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Dolichocolon	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Application site mass	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Allergic oedema	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Lymphoplasmacytoid lymphoma/immunocytoma	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Lymphocytic leukaemia	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Borderline leprosy	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Lymphocyte stimulation test positive	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Distal intestinal obstruction syndrome	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Lymphadenitis bacterial	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Lymph nodes scan abnormal	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Lymph node abscess	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Disseminated cytomegaloviral infection	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Abscess rupture	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Bone metabolism biochemical marker increased	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Lung lobectomy	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Lung carcinoma cell type unspecified stage III	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lung adenocarcinoma recurrent	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Lumbosacral radiculopathy	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Bone marrow infiltration	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cytotoxic lesions of corpus callosum	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Application site erosion	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Crowned dens syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Alkalosis	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Diffuse axonal injury	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Application site discharge	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Application site dermatitis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Liposuction	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Bone formation decreased	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lipoprotein (a) decreased	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Diaphragmatic rupture	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Diaphragmatic disorder	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Lip scab	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Limb traumatic amputation	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Limb reconstructive surgery	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Limb hypoplasia congenital	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Diabetic gastroparesis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Lid sulcus deepened	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Diabetic eye disease	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Abscess of eyelid	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Device temperature issue	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Leukaemic infiltration extramedullary	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Compulsions	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4
Body height below normal	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Body fat disorder	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Acute encephalitis with refractory, repetitive partia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Alcohol use disorder	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Laser therapy	2 (50.0%)	1 (25.0%)	0 (0.0%)	1 (25.0%)	4
Laryngitis fungal	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Large intestine operation	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Large intestine benign neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Large intestinal polypectomy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Apical granuloma	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Laparoscopic surgery	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lacrimation disorder	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Lacrimation decreased	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Desmoplastic small round cell tumour	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Peritoneal mesothelioma malignant	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Peritoneal tuberculosis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Koebner phenomenon	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Klippel-Feil syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Dermatillomania	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Albumin urine present	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Joint injection	1 (25.0%)	1 (25.0%)	0 (0.0%)	2 (50.0%)	4
Blood pressure orthostatic decreased	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Jejunostomy	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Delusional perception	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Aortic surgery	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Itching scar	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Irregular sleep phase	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Delirium febrile	1 (25.0%)	0 (0.0%)	0 (0.0%)	3 (75.0%)	4
Delayed light adaptation	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
pH urine increased	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Tuberculosis of central nervous system	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Invasive lobular breast carcinoma	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Wrong rate	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Wrong dosage formulation	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Intrauterine infection	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Blood phosphorus abnormal	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Intracranial haemangioma	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Intra-abdominal pressure increased	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Waldenstrom's macroglobulinaemia	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
WT1 gene mutation	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Intestinal metaplasia	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Vocal cord inflammation	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Vitamin A increased	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Vitamin A deficiency	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Visual snow syndrome	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Viral sinusitis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Viral load abnormal	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Vesical fistula	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Hypoglobulinaemia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Intentional misuse of drug delivery system	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Vasculitic rash	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Vascular operation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Vascular encephalopathy	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Antisynthetase syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Vascular access site bruising	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Uterine rupture	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Uterine mass	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Uterine contractions during pregnancy	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Cutaneous mucormycosis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Urogenital fistula	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Testicular cyst	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Urinary tract infection pseudomonal	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Plasma cells increased	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Urinary retention postoperative	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Crystal urine present	2 (50.0%)	0 (0.0%)	1 (25.0%)	1 (25.0%)	4
Urge incontinence	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Crystal arthropathy	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Total cholesterol/HDL ratio decreased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Influenza virus test positive	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Ureteritis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Ureteric dilatation	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Antimitochondrial antibody positive	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Cryoglobulinaemia	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Plantar erythema	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Infective tenosynovitis	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Umbilical hernia repair	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Craniopharyngioma	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Infantile apnoea	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Tumour embolism	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Tumour cavitation	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Anticonvulsant drug level increased	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Tuberculosis liver	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Tryptase	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Anticonvulsant drug level below therapeutic	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Incision site discharge	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Traumatic haemothorax	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Transfusion-associated dyspnoea	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Transferrin saturation increased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Tracheal obstruction	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Toxic optic neuropathy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Implant site inflammation	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Implant site haematoma	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Corneal reflex decreased	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Imperception	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Immunoglobulin G4 related disease	0 (0.0%)	2 (50.0%)	0 (0.0%)	2 (50.0%)	4
Tongue paralysis	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Immunoglobulins abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Tongue geographic	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Tongue exfoliation	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Antibody test negative	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Tobacco abuse	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Immune-mediated neurological disorder	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Cornea verticillata	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Thyroid calcification	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Thyroglobulin increased	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Corneal neovascularisation	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Immature granulocyte percentage increased	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Thrombin time prolonged	2 (50.0%)	1 (25.0%)	0 (0.0%)	1 (25.0%)	4
Thought blocking	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Thirst decreased	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
ADAMTS13 activity abnormal	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Contrast media toxicity	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Therapeutic product effective for unapproved indicati	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Therapeutic nerve ablation	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Idiosyncratic drug reaction	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Idiopathic pneumonia syndrome	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Testicular neoplasm	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4
Blood alcohol increased	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Teratoma	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Tender joint count decreased	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Hypotrichosis	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Tanning	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Coronary artery embolism	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Blood 1,25-dihydroxycholecalciferol increased	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4
Tracheostomy malfunction	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Blood cholinesterase decreased	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Conjunctival pallor	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Anti-glomerular basement membrane disease	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Hypophosphatasia	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Transformation to acute myeloid leukaemia	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Conjunctival disorder	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Swollen joint count decreased	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Sweat gland infection	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Abortion infected	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Sudden visual loss	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Tri-iodothyronine decreased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Congenital multiplex arthrogryposis	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Blastomycosis	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Gastroenteritis eosinophilic	1 (25.0%)	0 (0.0%)	0 (0.0%)	3 (75.0%)	4
Blastocystis infection	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Hypertensive encephalopathy	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Hyperresponsive to stimuli	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Stoma site irritation	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Stoma site abscess	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Hyperparathyroidism primary	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hyperosmolar state	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Hypermobility syndrome	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Abdominal cavity drainage	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Infantile spasms	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Starvation ketoacidosis	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Squamous cell carcinoma of the tongue	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Adrenal gland cancer metastatic	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Squamous cell carcinoma of head and neck	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Infected dermal cyst	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Computerised tomogram abdomen abnormal	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Hyperdynamic left ventricle	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Splinter	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Splenic infection fungal	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Hyperamylasaemia	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Aeromonas infection	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Spinal muscular atrophy	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Spinal instability	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Spinal cord oedema	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Infective corneal ulcer	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Hydrocholecystis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Undifferentiated connective tissue disease	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Spinal X-ray abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Spina bifida	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Complement factor C3 increased	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Spermatozoa abnormal	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Human metapneumovirus test positive	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Human herpesvirus 8 infection	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Human ehrlichiosis	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Inflammation of wound	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Human bocavirus infection	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Solar urticaria	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Coma hepatic	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Bladder cyst	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Ureteral stent insertion	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Blood ethanol increased	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4
Sleep disorder due to general medical condition, hype	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
High-pitched crying	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Acquired oesophageal web	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
High density lipoprotein abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Skin operation	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Urethral stenosis	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Antineutrophil cytoplasmic antibody increased	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Bipolar II disorder	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Colon cancer stage II	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Herpes zoster cutaneous disseminated	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Herpes simplex viraemia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Herpes simplex test positive	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Acquired macroglossia	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Adnexa uteri mass	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Sinoatrial block	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Shunt stenosis	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Urine albumin/creatinine ratio abnormal	0 (0.0%)	2 (50.0%)	0 (0.0%)	2 (50.0%)	4
Severe cutaneous adverse reaction	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Serum sickness-like reaction	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cutaneous T-cell lymphoma stage IV	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Serous retinopathy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hepatitis G	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Hepatitis C virus test positive	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Administration site warmth	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Sepsis neonatal	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Semen volume decreased	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Semen liquefaction abnormal	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Acquired immunodeficiency syndrome	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Uterine hypertonus	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Biopsy bone marrow abnormal	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Injection site dermatitis	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Urethral disorder	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Sclerodactylia	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Schwannoma	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Hepatic cancer recurrent	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Administration site rash	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Salivary gland neoplasm	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
SLE arthritis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Heavy metal increased	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Cystatin C increased	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Rouleaux formation	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Rocky mountain spotted fever	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Right ventricular hypertrophy	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Heart valve calcification	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Varicose ulceration	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Chronic respiratory disease	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Heart sounds abnormal	1 (25.0%)	0 (0.0%)	1 (25.0%)	2 (50.0%)	4
Antisocial behaviour	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Anion gap	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Head deformity	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Retrognathia	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Retinal vascular thrombosis	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Retinal vascular occlusion	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Hand amputation	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Vascular compression	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Haemorrhoid operation	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Haemorrhagic occlusive retinal vasculitis	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Bifascicular block	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Repetitive strain injury	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Haemophilus test positive	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Choroidal neovascularisation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cytogenetic analysis abnormal	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Choroidal haemorrhage	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Renal hamartoma	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Administration site irritation	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Venous aneurysm	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Choroid melanoma	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Haemoconcentration	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Blood insulin decreased	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Refractoriness to platelet transfusion	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Refraction disorder	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Chondrolysis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Red blood cell sedimentation rate decreased	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Red blood cell nucleated morphology present	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Red blood cell elliptocytes present	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Benign ovarian tumour	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Rectocele	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Angioimmunoblastic T-cell lymphoma	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Growth hormone-producing pituitary tumour	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Rash papulosquamous	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Rapid eye movements sleep abnormal	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Raoultella ornithinolytica infection	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Vibratory sense increased	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Chloropsia	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Vesicoureteric reflux	2 (50.0%)	0 (0.0%)	1 (25.0%)	1 (25.0%)	4
Benign familial pemphigus	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Gram stain positive	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Pupillary disorder	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Benign ear neoplasm	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Graft infection	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Puncture site injury	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Puncture site induration	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Puncture site erythema	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Dairy intolerance	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Chest wall mass	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Chest wall abscess	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Acquired apparent mineralocorticoid excess	2 (50.0%)	0 (0.0%)	0 (0.0%)	2 (50.0%)	4
Pulmonary septal thickening	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Pulmonary radiation injury	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Pulmonary imaging procedure abnormal	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pulmonary hypertensive crisis	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Vitamin B12 abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Intestinal barrier dysfunction	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Pseudoporphyria	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Pseudolymphoma	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Pseudohallucination	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Pseudocyst	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Vocal cord polyp	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Prothrombin level increased	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Proteus test positive	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Acoustic neuroma	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Protein-losing gastroenteropathy	2 (50.0%)	0 (0.0%)	0 (0.0%)	2 (50.0%)	4
Prosthesis implantation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Prostatic haemorrhage	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Genotype drug resistance test positive	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Cervicobrachial syndrome	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Decompression sickness	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Cervical incompetence	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Bartholinitis	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Cervical conisation	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Product shape issue	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Anastomotic haemorrhage	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Genital candidiasis	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Product name confusion	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Product measured potency issue	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Product lot number issue	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Cerebral vasoconstriction	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cerebral vascular occlusion	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Product appearance confusion	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Product advertising issue	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Proctitis bacterial	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Procedure aborted	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Intraductal papilloma of breast	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4
Gastrointestinal tract mucosal pigmentation	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Procedural anxiety	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Intracranial hypotension	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Primary syphilis	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Balamuthia infection	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Gastrointestinal submucosal tumour	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Cerebral hypoperfusion	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Premature ejaculation	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Pregnancy test false positive	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Precocious puberty	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Gastrointestinal ischaemia	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4
Cerebral artery thrombosis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Abscess fungal	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Postprandial hypoglycaemia	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Postmortem blood drug level abnormal	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Cerebellar tumour	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Postictal state	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Postictal psychosis	0 (0.0%)	2 (50.0%)	0 (0.0%)	2 (50.0%)	4
Gastrointestinal angiectasia	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Post-traumatic pain	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Gastroenteropancreatic neuroendocrine tumour disease	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cerebellar cognitive affective syndrome	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Post procedural haematuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Cerebellar ataxia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastroenteritis cryptosporidial	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Gastroenteritis astroviral	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Post procedural bile leak	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Portosplenomesenteric venous thrombosis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Central pain syndrome	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Gastric volvulus	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Gastric varices haemorrhage	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Poor personal hygiene	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Central nervous system necrosis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Central nervous system mass	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Polymorphic light eruption	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Polydactyly	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Anal prolapse	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Central nervous system haemorrhage	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Bacillus bacteraemia	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Anal polyp	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Central nervous system abscess	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Gamma-glutamyltransferase decreased	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Anal injury	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Gaming disorder	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Pneumocephalus	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Gallbladder injury	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pleural adhesion	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Platelet dysfunction	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Plasmablastic lymphoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Placenta accreta	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Pituitary enlargement	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
B-lymphocyte count abnormal	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pinguecula	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Adenoviral haemorrhagic cystitis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Functional residual capacity decreased	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Photodermatosis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Anal fistula infection	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
B-cell small lymphocytic lymphoma	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Phlebotomy	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Philadelphia positive acute lymphocytic leukaemia	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Pharyngotonsillitis	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Pharyngolaryngeal abscess	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Pharyngeal haematoma	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Catheter site discolouration	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Personal relationship issue	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Persistent genital arousal disorder	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Peritoneal perforation	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Foreign body in gastrointestinal tract	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Peritoneal fluid analysis abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Anal erosion	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Peritoneal abscess	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Forced expiratory volume abnormal	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Catastrophic reaction	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Peripheral artery aneurysm	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Axillary lymphadenectomy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Periorbital haemorrhage	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Perinephric abscess	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cast application	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Perineal cellulitis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Cartilage atrophy	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Pericarditis malignant	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Foetal exposure during delivery	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Foetal distress syndrome	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Foetal cardiac disorder	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Carotid pulse decreased	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pericardial disease	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pericardial calcification	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Periarthritis calcarea	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Focal dyscognitive seizures	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Performance enhancing product use	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Perforated ulcer	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Fluid intake restriction	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Penis injury	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Penile vascular disorder	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Carotid artery stent insertion	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Acid fast bacilli infection	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Penile dermatitis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pelvic organ prolapse	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pelvic operation	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Fistula inflammation	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Pelvic infection	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pelvic haemorrhage	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pelvic congestion	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Peau d'orange	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Abnormal clotting factor	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Anaesthesia oral	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Parophthalmia	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Autoimmune neuropathy	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Parkinsonian rest tremor	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Parechovirus infection	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Red blood cell morphology abnormal	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Parathyroid gland enlargement	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Paranoid personality disorder	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Paradoxical psoriatic arthritis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Paradoxical pain	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Papulopustular rosacea	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Papillary renal cell carcinoma	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Autoimmune enteropathy	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Autoimmune encephalopathy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Fasciitis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Pancreatic injury	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Autoimmune blistering disease	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pancreatic abscess	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Pancreas infection	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Palpable purpura	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Fallopian tube cancer	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Palate injury	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Pain threshold decreased	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Autoantibody positive	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cardiac monitoring	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Paediatric acute-onset neuropsychiatric syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Auricular swelling	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Oxygen saturation immeasurable	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Ovarian neoplasm	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Ovarian enlargement	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Ovarian cystectomy	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Ovarian cancer stage IV	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Cardiac device implantation	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Osteosarcoma recurrent	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Atypical mycobacterial lower respiratory tract infect	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Osteoporosis postmenopausal	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Cardiac arrest neonatal	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Osteomyelitis fungal	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Failed induction of labour	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Osteomyelitis acute	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Orthodontic procedure	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Oropharyngeal surgery	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Carcinoid syndrome	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Eyelash changes	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Oropharyngeal discolouration	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Oromandibular dystonia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Orchitis noninfective	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Carcinoembryonic antigen decreased	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Atrophic vulvovaginitis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Oral mucosal discolouration	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Atrioventricular septal defect	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Eye infection staphylococcal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Oral herpes zoster	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Oral discharge	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Amylase decreased	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Oral bacterial infection	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Eye abscess	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Optic disc disorder	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Opsoclonus myoclonus	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Opiates positive	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Extravascular haemolysis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ophthalmological examination abnormal	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Ophthalmic vascular thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Onychophagia	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Omental infarction	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Retinal deposits	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Cannabinoid hyperemesis syndrome	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Oesophagitis haemorrhagic	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Venous pressure increased	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Oesophageal ulcer haemorrhage	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Amphetamines positive	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Oesophageal polyp	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Exposure to extreme temperature	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Amoebic dysentery	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Oesophageal fistula	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Oesophageal carcinoma recurrent	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Exposed bone in jaw	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Amoebiasis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Oedema due to cardiac disease	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Atrial enlargement	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
AST/ALT ratio abnormal	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Camptocormia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ocular ischaemic syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Excessive skin	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Excessive masturbation	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Ochronosis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Evans syndrome	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Calcium metabolism disorder	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Eustachian tube disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Normal pressure hydrocephalus	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Noonan syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Escherichia peritonitis	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Noninfective sialoadenitis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Noninfectious peritonitis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Atheroembolism	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Non-small cell lung cancer stage II	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Chronic myocarditis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Erythroopenia	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Non-scarring alopecia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Non-high-density lipoprotein cholesterol increased	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Non-consummation	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Nodular vasculitis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Nodular rash	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Amnestic disorder	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
CSF protein abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Epstein-Barr virus antigen positive	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Neurotrophic keratopathy	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
CREST syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Neurorrhaphy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Neuroprosthesis implantation	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Asthma exercise induced	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Ammonia decreased	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Epiphysiolysis	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Epileptic psychosis	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Neuroma	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Ammonia abnormal	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Neurological infection	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
CFTR gene mutation	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Neurofibrosarcoma	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Neuroendocrine carcinoma metastatic	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Epidermolysis bullosa	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
CD4/CD8 ratio increased	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Epidermodysplasia verruciformis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
CD4 lymphocyte percentage decreased	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Nephrogenic systemic fibrosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Aspiration joint	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Neoplasm of thymus	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Neonatal infection	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Eosinopenia	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Neonatal asphyxia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Enzyme inhibition	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Negative pressure pulmonary oedema	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Necrotising scleritis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Necrotising enterocolitis neonatal	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Necrobiosis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Nasopharyngeal cancer metastatic	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Nasal septal operation	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Enterobacter test positive	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Nasal abscess	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Nail discomfort	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Myxoid liposarcoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Myringitis	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Myotonia	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Bullous erysipelas	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Endometrial adenocarcinoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Myocardial calcification	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Myiasis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Myelodysplastic syndrome with single lineage dysplasi	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Myelocyte count increased	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Mycetoma mycotic	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Bronchopulmonary dysplasia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Musculoskeletal toxicity	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Bronchopneumopathy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Muscle operation	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Muscle fibrosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Alport's syndrome	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Mumps	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Alpha-1 antitrypsin deficiency	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Multifocal motor neuropathy	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Electrocardiogram T wave peaked	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Arteritis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Cutaneous contour deformity	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Mucocutaneous toxicity	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Acute motor-sensory axonal neuropathy	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Electrocardiogram QRS complex abnormal	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Electrocardiogram P wave abnormal	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Monocyte percentage decreased	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Arteriovenous fistula site complication	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Acute monocytic leukaemia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Accelerated hypertension	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Brief resolved unexplained event	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Mitral valve stenosis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Mitral valve replacement	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Mitral valve repair	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Eczema nummular	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Minimum inhibitory concentration	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Mineral metabolism disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Miller Fisher syndrome	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Milia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Eclampsia	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Microcytosis	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Metastatic carcinoma of the bladder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Metastases to salivary gland	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Breast hyperplasia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Ear dryness	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Mesenteritis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mesenteric lymphadenitis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Mesenteric haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Merycism	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Dysphotopsia	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Menometrorrhagia	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Meningorrhagia	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Abdominal hernia obstructive	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Meningitis tuberculous	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Breast cancer in situ	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Breast atrophy	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Medical observation abnormal	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Allergy to immunoglobulin therapy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Medical device site thrombosis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Dumping syndrome	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Medical device site scab	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Medical device site rash	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Ductus arteriosus premature closure	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Arachnoid cyst	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Brain stem haematoma	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Medical device site abscess	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Brain sarcoma	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Acute hepatitis C	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Medial tibial stress syndrome	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Application site wound	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Brain natriuretic peptide abnormal	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Mean cell haemoglobin concentration abnormal	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Mean cell haemoglobin concentration	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
May-Thurner syndrome	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Drug exposure before pregnancy	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Malignant urinary tract neoplasm	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Malignant neoplasm of spinal cord	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Malignant neoplasm of renal pelvis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Angiodysplasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Malignant melanoma stage I	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Brachiocephalic artery stenosis	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Malignant anorectal neoplasm	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Drain site complication	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Malaria	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Macular pigmentation	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Macular detachment	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Abdominal wall infection	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Bordetella infection	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lymphocytic lymphoma	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Lymphocyte morphology abnormal	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Application site inflammation	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Lymphocyte count	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Aversion	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Application site infection	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Lymphangioma	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Disseminated varicella	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Lymph node palpable	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Lymph node fibrosis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Lung squamous cell carcinoma stage III	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Disorder of sex development	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Application site haematoma	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Lung adenocarcinoma stage IV	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Alkalosis hypokalaemic	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Application site extravasation	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Low lung compliance	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Dilatation ventricular	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Dilatation intrahepatic duct acquired	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Low cardiac output syndrome	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Loss of visual contrast sensitivity	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Bone lesion excision	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Loose body in joint	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Liver operation	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Listeria sepsis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Lipase abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lip neoplasm malignant stage unspecified	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Application site acne	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Limb immobilisation	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Bone abscess	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Ligamentitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lichen planus pemphigoides	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Anterior chamber cleavage syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Abdominal fat apron	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Lichen nitidus	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Lhermitte's sign	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Leukostasis syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Appendiceal abscess	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Device programming error	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Leishmaniasis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Leiomyosarcoma metastatic	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Leiomyosarcoma	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Body dysmorphic disorder	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Left ventricular enlargement	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Blunted affect	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Apoptosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Laryngomalacia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Laryngitis allergic	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Laryngeal obstruction	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Laryngeal neoplasm	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Abdominal wall disorder	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Large intestinal ulcer haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Device audio issue	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Device allergy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Laparotomy	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Desmoid tumour	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Lack of satiety	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Lack of infusion site rotation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Dermatoporosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Dermatofibrosarcoma protuberans	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Dermatochalasis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Kyphoscoliosis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Blood test	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Aortoenteric fistula	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Ketosis-prone diabetes mellitus	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Keratosis pilaris	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Keratosi follicular	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Keratomileusis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Aortic valve thickening	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Deprescribing error	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Juvenile chronic myelomonocytic leukaemia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Joint tuberculosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Albumin globulin ratio decreased	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Joint surgery	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Aortic valve sclerosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Dental plaque	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Blood pressure systolic	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Joint fluid drainage	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Jessner's lymphocytic infiltration	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Abdominal wall cyst	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Aortic valve calcification	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Ischaemic enteritis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Delusion of reference	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Iron metabolism disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Iron binding capacity total decreased	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Iris hypopigmentation	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Iris discolouration	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Delayed ischaemic neurological deficit	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Yersinia infection	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Delayed delivery	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Airway remodelling	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Deformity thorax	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Wound closure	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Increased insulin requirement	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Streptobacillus infection	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
White blood cells urine	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
White blood cell count	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Aortic elongation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Stroke volume increased	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Water intoxication	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Decreased vibratory sense	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Decreased gait velocity	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vulval haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Von Willebrand's disease	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Intestinal mucosal tear	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Volume blood	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Vitreous disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Vitello-intestinal duct remnant	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Blood luteinising hormone increased	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Intestinal fistula infection	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Intestinal congestion	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Visual perseveration	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Visceral oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Visceral larva migrans	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Virilism	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Intervertebral disc annular tear	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Viral acanthoma	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Victim of child abuse	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Superinfection fungal	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Blood lactate dehydrogenase decreased	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Incision site abscess	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Supportive care	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Ventricular dyssynchrony	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Intensive care unit acquired weakness	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Cytology abnormal	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Vasectomy	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Vasculitic ulcer	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Instillation site reaction	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Vascular stent occlusion	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Vascular headache	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Vascular graft complication	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vascular access site swelling	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Varicose vein ruptured	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Varicocele	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Injection site pallor	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Cystic fibrosis related diabetes	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Hypoglycaemia neonatal	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Vaginal fistula	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Vaginal cancer	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vaccination site reaction	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Cyclothymic disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vaccination site cellulitis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Blood growth hormone decreased	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Antiphospholipid antibodies positive	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Uterine haematoma	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Urticaria physical	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Cutaneous leishmaniasis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Urticaria papular	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Urostomy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Infusion site scab	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Urine output fluctuation	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Plagiocephaly	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Infusion site paraesthesia	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Abortion threatened	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Urinary occult blood positive	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Urethritis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Infrapatellar fat pad inflammation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Ureteral disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pituitary gland operation	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Upper motor neurone lesion	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Upper airway resistance syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Unwanted pregnancy	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Abortion spontaneous incomplete	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Ulnar nerve injury	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Creatinine urine increased	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Creatinine urine decreased	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Type 1 lepra reaction	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Antidepressant drug level above therapeutic	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Craniotomy	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Infantile spitting up	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Induced labour	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Craniofacial deformity	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Tuberculosis gastrointestinal	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Anticonvulsant drug level above therapeutic	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Trichotillomania	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Trichosporon infection	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Traumatic liver injury	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Transplant evaluation	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Inadvertent injection air bubble	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Inadequate peritoneal dialysis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Inadequate aseptic technique in use of product	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Tracheomalacia	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Acromegaly	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Tracheal haemorrhage	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Tracheal deviation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Anticoagulant therapy	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Toxic anterior segment syndrome	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Implant site haemorrhage	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Tooth restoration	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Implant site erosion	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Tooth malformation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Implant site discolouration	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Implant site cellulitis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Tonsillar ulcer	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Impaired fasting glucose	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Immunisation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Immune-mediated vasculitis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Corneal epithelial microcysts	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Tissue rupture	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Corneal infiltrates	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Corneal dystrophy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Blood bilirubin unconjugated increased	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Corneal degeneration	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Tonsillar haemorrhage	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Thyroid gland injury	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Thyroid cancer recurrent	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Immune-mediated cholestasis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Cord blood transplant therapy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Thymus enlargement	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Cor pulmonale acute	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Thymoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Thymectomy	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Anti-transglutaminase antibody increased	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Thrombocytopenia neonatal	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Throat lesion	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Convulsive threshold lowered	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Ilium fracture	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Iliac artery stenosis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Gastric mucosal hypertrophy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ileectomy	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Contraindication to vaccination	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Blood chloride abnormal	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Contraindicated device used	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Ictal bradycardia syndrome	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Testicular abscess	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Illrd nerve disorder	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Tracheal compression	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Tenodesis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tendon operation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Tendon calcification	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Conjunctivochalasis	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Tender joint count	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Temperature difference of extremities	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Tarsal tunnel syndrome	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Target skin lesion	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Implant site scar	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Tracheo-oesophageal fistula	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Tachyphylaxis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Conjunctival retraction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Blood 1,25-dihydroxycholecalciferol decreased	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Conjunctival pigmentation	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Systolic hypertension	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hypoprothrombinaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Systemic mastocytosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Synovial fluid analysis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Hyponatraemic encephalopathy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Adrenal suppression	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Sweating fever	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Hypokinetic dysarthria	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Bacterial colitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Corpus callosotomy	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Corrective lens user	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Hypocomplementaemia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Incision site erythema	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Corynebacterium bacteraemia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Transvalvular pressure gradient increased	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hypocapnia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Superficial inflammatory dermatosis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hypobarism	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Subdural hygroma	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Tricuspid valve disease	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Hypertrophy	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Anti factor X activity increased	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Subclavian vein stenosis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Subclavian artery stenosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Coxsackie viral infection	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Congenital cytomegalovirus infection	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Streptococcal urinary tract infection	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Hypertelorism	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Strangury	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Anti factor V antibody positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Stomal hernia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Stoma site pruritus	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Stiff leg syndrome	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Concomitant drug effect decreased	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Status migrainosus	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Hyperinsulinaemia	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Staphylococcal abscess	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Squamous cell carcinoma of pharynx	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Hypergastrinaemia	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Spontaneous penile erection	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Bladder perforation	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hyperemesis gravidarum	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Spondylolysis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Adrenal gland cancer	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Bladder outlet obstruction	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Splenic thrombosis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Splenic injury	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Anterior chamber flare	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Splenic infection	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Splenic embolism	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Splenic artery thrombosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Bladder obstruction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Hyperarousal	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Ultrasound scan abnormal	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Bladder mass	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Hyperactive pharyngeal reflex	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Antacid therapy	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Spinal cord paralysis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hydrometra	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Spider vein	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Sperm concentration decreased	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Speech sound disorder	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Infective spondylitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Specific gravity urine decreased	1 (33.3%)	0 (0.0%)	0 (0.0%)	2 (66.7%)	3
Antimitochondrial antibody	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Human chorionic gonadotropin decreased	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Solitary fibrous tumour	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Soft tissue inflammation	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Soft tissue atrophy	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Coma acidotic	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Colour blindness acquired	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hormone receptor positive breast cancer	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Hormone receptor positive HER2 negative breast cancer	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Small intestine polyp	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Influenza B virus test positive	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Sleep inertia	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Hippocampal sclerosis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Hip deformity	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Sleep attacks	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
High-grade B-cell lymphoma	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
High risk sexual behaviour	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Skin test positive	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Infusion site abscess	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Skin lesion inflammation	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Infusion site coldness	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Anorectal swelling	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Colon cancer stage I	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Herpes simplex encephalitis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Anorectal operation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Colitis erosive	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Herpes oesophagitis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Hernia hiatus repair	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Infusion site hypersensitivity	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Sickle cell disease	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Hereditary motor and sensory neuropathy	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Urinary casts present	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Hereditary angioedema with C1 esterase inhibitor defi	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Shunt infection	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Coinfection	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Biopsy prostate	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hepatopulmonary syndrome	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Sexually transmitted disease	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Abortion early	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Administration site wound	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Cochlea implant	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Sertoli-cell-only syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Blood gases abnormal	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Septic cardiomyopathy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Hepatitis C RNA positive	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Sepsis syndrome	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Sensory processing sensitivity	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Hepatitis B virus test positive	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Urticaria pigmentosa	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Seminal vesicular disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Hepatitis B antibody positive	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Infusion site thrombosis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Selective IgG subclass deficiency	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Segmented hyalinising vasculitis	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Hepatic vein dilatation	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hepatic rupture	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Uterine inflammation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Hepatic neuroendocrine tumour	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Administration site ulcer	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Scrotal operation	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Scleral oedema	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Scleral disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cleft lip and palate	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Binge drinking	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Hepatic artery thrombosis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Salpingo-oophorectomy unilateral	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Circumoral swelling	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Circumoral oedema	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Salivary gland cancer	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Salivary duct obstruction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Sacroiliac joint dysfunction	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Sacroiliac fusion	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Helplessness	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Helminthic infection	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Heliotrope rash	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
SARS-CoV-2 test	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Ruptured ectopic pregnancy	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Chronic tonsillitis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Heart valve stenosis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Right ventricular systolic pressure increased	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Right ventricular enlargement	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Rhodococcus infection	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Rhinoplasty	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Rheumatoid vasculitis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Biliary ischaemia	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rheumatoid arthritis-associated interstitial lung dis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Vascular access site haemorrhage	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Administration site oedema	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Retroperitoneal cancer	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Chronic leukaemia	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Haptoglobin increased	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Retinopathy hypertensive	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Hangnail	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Hand-eye coordination impaired	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Retinal vein thrombosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Animal attack	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Retinal pigment epithelial tear	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Retinal neovascularisation	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Retinal migraine	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Retinal ischaemia	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Retinal drusen	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hairy cell leukaemia	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Retinal depigmentation	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Retinal aneurysm	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Reticulocytosis	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Reticulocyte count decreased	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Retained products of conception	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Haemostasis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Chronic gastrointestinal bleeding	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Haemorrhagic ovarian cyst	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Antithrombin III decreased	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Chronic disease	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Respiratory moniliasis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Respiratory gas exchange disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cytarabine syndrome	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Haemorrhagic cerebral infarction	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Chronic active Epstein-Barr virus infection	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Renin increased	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Instillation site pain	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Renal vascular thrombosis	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Renal stone removal	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Renal scan abnormal	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Renal phospholipidosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Renal oncocytoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Haemolytic transfusion reaction	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Renal artery occlusion	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Haematoma evacuation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Removal of foreign body from eye	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Haematology test abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Regressive behaviour	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Red cell distribution width decreased	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Chondritis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Red cell distribution width abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Red blood cells urine	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Administration site inflammation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Red blood cell sedimentation rate	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Angiomyolipoma	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Abscess bacterial	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
HRD gene mutation assay positive	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rectosigmoid cancer	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
HELLP syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
HCoV-HKU1 infection	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Gynaecological chlamydia infection	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Gut fermentation syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Growth hormone deficiency	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Growth accelerated	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Benign lung neoplasm	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Growing pains	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Radiation proctitis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Vessel puncture site pain	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Radiation mucositis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Radiation associated pain	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Radial pulse abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Benign hepatic neoplasm	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Benign gastrointestinal neoplasm	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Internal hernia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Angiocardiogram	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Pyramidal tract syndrome	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Administration site haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pyometra	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pyelonephritis chronic	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Putamen haemorrhage	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Viral myelitis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Graft versus host disease in lung	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Dacryocanalculitis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Purine metabolism disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pupillary light reflex tests abnormal	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Child-Pugh-Turcotte score increased	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Graft loss	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Gradenigo's syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gouty tophus	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Gonadotrophin deficiency	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pulmonary tumour thrombotic microangiopathy	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Pulmonary pneumatocele	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Glutamate dehydrogenase increased	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Pulmonary malformation	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Pulmonary interstitial emphysema syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Glossopharyngeal nerve paralysis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pulmonary capillary haemangiomatosis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Chemotherapeutic drug level above therapeutic	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Chemokine increased	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Pulmonary artery occlusion	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Bauhin's valve syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Chemical poisoning	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Pulmonary artery aneurysm	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Chemical burns of eye	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Pulmonary air leakage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Anembryonic gestation	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Intestinal gangrene	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Glioblastoma multiforme	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Pseudophakia	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Gingival pruritus	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pseudoendophthalmitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Intestinal mucosal atrophy	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Gingival injury	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Pseudarthrosis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Basilar artery stenosis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Gingival graft	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cervix operation	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Decorticate posture	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Protein S decreased	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Prosthetic cardiac valve thrombosis	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Prosthesis user	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Prostatic specific antigen decreased	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Prostatic obstruction	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Prostatic calcification	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Prostate examination abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Prostate cancer stage I	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Genital infection male	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Intra-uterine contraceptive device insertion	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Blood osmolarity increased	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Bartholin's gland disorder	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Product sterility issue	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Cerumen impaction	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Genital discolouration	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Bartholin's cyst	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Cerebrovascular insufficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Product intolerance	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Administration related reaction	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Product dosage form issue	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Product contamination with body fluid	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Product contamination chemical	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Gaucher's disease	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Bandaemia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastrooesophageal sphincter insufficiency	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Gastrolithiasis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastrointestinal vascular malformation haemorrhagic	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Procedural site reaction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastrointestinal tract adenoma	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Adjustment disorder with mixed anxiety and depressed	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Primary hypoparathyroidism	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Cerebral congestion	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Gastrointestinal mucosal disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastrointestinal lymphoma	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Intraocular lens implant	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Gastrointestinal erosion	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Cerebral arteriosclerosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Investigation noncompliance	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Bacterial pyelonephritis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Anal ulcer haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Gastrointestinal arteriovenous malformation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastrointestinal anastomotic stenosis	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Gastrointestinal amyloidosis	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Post-traumatic neuralgia	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Gastroenterostomy	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Wall motion score index abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Post procedural pneumonia	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Bacterial gingivitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Bacterial food poisoning	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Gastroenteritis clostridial	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Cephalhaematoma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gastroenteritis bacterial	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Post procedural constipation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Central venous pressure increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gastritis viral	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Positron emission tomogram	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gastritis fungal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Portal vein cavernous transformation	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Portal shunt procedure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Porokeratosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Porcelain gallbladder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Central nervous system stimulation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Poor dental condition	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Polyradiculoneuropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Polyneuropathy in malignant disease	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Gastric neuroendocrine carcinoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Polyhydramnios	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Central nervous system leukaemia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Gastric mucosa erythema	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Polycystic liver disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gastric infarction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Poikiloderma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pneumothorax traumatic	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pneumopericardium	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Gastric cancer stage IV	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pneumonitis chemical	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Central nervous system fungal infection	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Gastric banding	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Central nervous system function test abnormal	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Gammopathy	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Pneumonia chlamydial	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pneumonia adenoviral	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Pneumoconiosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gallbladder obstruction	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gallbladder neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pleural mesothelioma malignant	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pleural mass	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pleural calcification	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cell-mediated immune deficiency	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Plethoric face	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cell marker increased	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Gallbladder cancer metastatic	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Platelet aggregation abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Plastic surgery to the face	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Plastic surgery	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Catheterisation cardiac abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gait deviation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Planning to become pregnant	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Catheter site warmth	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Fungating wound	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Fungal test positive	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Anal hypoaesthesia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Catheter site ulcer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pityriasis rubra pilaris	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pityriasis rosea	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Fungal sepsis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Catheter site scab	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Pituitary cyst	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Piriformis syndrome	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Anal fungal infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Phrenic nerve paralysis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Photorefractive keratectomy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Phospholipidosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Phonophobia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Phobia of driving	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Phobia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Phlebolith	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fuchs' syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Fructose intolerance	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Phenylketonuria	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Frigophobia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Catheter site induration	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pharyngeal stenosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pharyngeal polyp	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Catheter site haematoma	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Fracture of penis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fracture malunion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pharyngeal cyst	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Phantom limb syndrome	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Foveal reflex abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Perthes disease	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Foreskin oedema	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anal erythema	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Catheter site cellulitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Periumbilical abscess	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Peritoneocutaneous fistula	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Peritoneal neoplasm	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Peritoneal lesion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Peritoneal haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Catheter removal	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Peritoneal cyst	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Peritoneal adhesions	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Forced expiratory volume	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Forced expiratory flow decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Peripheral vascular haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Peripheral spondyloarthritis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Peripheral nerve palsy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Peripheral nerve operation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Food protein-induced enterocolitis syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Cataract nuclear	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Abnormal cord insertion	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Follicular lymphoma recurrent	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Periorbital infection	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Periorbital disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Periorbital discomfort	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Foetal monitoring abnormal	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Periorbital abscess	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Castleman's disease	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Foetal malposition	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Perineal ulceration	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Perineal infection	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Perineal fistula	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Perineal erythema	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Foetal heart rate deceleration abnormality	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Perineal cyst	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pericardial mesothelioma malignant	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Carotidynia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Focal nodular hyperplasia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Fluorosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Carotid bruit	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Autonomic failure syndrome	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Penile oedema	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Penile necrosis	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Penile haematoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Penile erosion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Automatism	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Penile discharge	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Penile burning sensation	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Flap surgery	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Penile abscess	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Carotid artery aneurysm	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Flail chest	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Carotid arterial embolus	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Fistula repair	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pelvic misalignment	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pelvic floor hernia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Peliosis hepatis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fibrous cortical defect	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiothoracic ratio increased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Autoimmune pancytopenia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pathergy reaction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Paternal exposure before pregnancy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cardiopulmonary exercise test abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Parvovirus infection	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cardiopulmonary bypass	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Parkinsonism hyperpyrexia syndrome	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Autoimmune nephritis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Parietal lobe stroke	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Paravenous drug administration	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Parathyroid tumour	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Parathyroid gland operation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Parasitic pneumonia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Parasitic encephalitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Achromobacter infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Cardiac valve vegetation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Paranasal sinus mucosal hypertrophy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiac valve thickening	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Paranasal sinus abscess	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Paralysis recurrent laryngeal nerve	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Paraganglion neoplasm	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Cardiac valve abscess	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Paradoxical embolism	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Papillitis	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Pancreatogenous diabetes	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Relapsing multiple sclerosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fasting	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Pancreaticoduodenectomy	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pancreatic pseudocyst	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pancreatic leak	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Fascial infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Pancreatic haemorrhage	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pancreatic enzymes decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pancreatic enzyme abnormality	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Familial periodic paralysis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pancreatic duct obstruction	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pancreatic cyst rupture	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anaemia neonatal	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Fallopian tube obstruction	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Autoimmune anaemia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Fallopian tube abscess	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Palatal ulcer	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Failure to suspend medication	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pain assessment	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Paedophilia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Packaging design issue	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
PaO2/FiO2 ratio decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiac imaging procedure abnormal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
PO2 increased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
PCO2 decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Factor XIII inhibition	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Factor VIII deficiency	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Overgrowth fungal	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Auditory nerve disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Factor VII deficiency	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ovarian operation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Faciobrachial dystonic seizure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ovarian fibroma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ovarian cancer stage III	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiac contractility decreased	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Cardiac cirrhosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Osteotomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Abiotrophia defectiva endocarditis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiac asthma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Osteopetrosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Eyelid scar	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Cardiac aneurysm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Eyelid retraction	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Osteomyelitis bacterial	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Osteoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Osteochondroma	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Osmolar gap increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Eyelid haematoma	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Eyelid function disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Oropharyngeal squamous cell carcinoma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Carcinoid tumour in the large intestine	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Eyelid contusion	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Eyelid bleeding	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Eyelash discolouration	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oropharyngeal gonococcal infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Carcinogenicity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Orgasmic sensation decreased	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Adams-Stokes syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Organic erectile dysfunction	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Orchidectomy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Orbital myositis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Eye naevus	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oral viral infection	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Eye laser surgery	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oral mucosal scar	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Oral mucosal roughening	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Oral hyperaesthesia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Oral dysaesthesia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Eye degenerative disorder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Optic nerve sheath meningioma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Optic nerve hypoplasia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Optic nerve cupping	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Optic nerve compression	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Optic disc haemorrhage	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Extubation	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Open reduction of fracture	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Open globe injury	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Capnogram abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Extrapulmonary tuberculosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Extraocular muscle disorder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Extramedullary haemopoiesis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Amputation stump pain	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oligospermia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Oligodipsia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oestrogen receptor assay positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Expulsion of medication	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Oestrogen deficiency	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Exposure via partner	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Oesophagobronchial fistula	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Exposure via ingestion	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Oesophageal variceal ligation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Acute right ventricular failure	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Exposure via body fluid	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Exposure to unspecified agent	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Candida endophthalmitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Oesophageal neoplasm	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Atrial natriuretic peptide increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Exposure to radiation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cancer screening	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oesophageal compression	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Oesophageal atresia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Oedematous kidney	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Oedema due to renal disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Campylobacter sepsis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Oedema blister	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oculomucocutaneous syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oculocephalogyric reflex absent	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ocular vasculitis	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Ocular sarcoidosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Exercise tolerance increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ocular retrobulbar haemorrhage	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Aberrant aortic arch	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Callus formation delayed	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Occipital lobe stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Calculus urethral	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Calculus prostatic	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Obstructive nephropathy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Atopic keratoconjunctivitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ewing's sarcoma metastatic	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Eustachian tube obstruction	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Calcium ionised increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Amniotic cavity disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Atlantoaxial subluxation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Normochromic anaemia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Nontherapeutic agent urine positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Calcineurin inhibitor induced pain syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Noninfective conjunctivitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Noninfective chorioretinitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Calcification of muscle	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Amniorrhoea	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Atherectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Erythroid dysplasia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
CSWS syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Non-Hodgkin's lymphoma refractory	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Erythema migrans	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Nodular regenerative hyperplasia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Erysipeloid	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
New onset refractory status epilepticus	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Astrocytoma	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Neutrophilic dermatosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Epstein-Barr virus antibody positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
CSF HIV escape syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Epithelioid sarcoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neurone-specific enolase increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Epiphyses premature fusion	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Asthenospermia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
CHANTER syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Neurofibromatosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Neuroendocrine tumour of the lung	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Amino acid level increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
CD8 lymphocytes decreased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Neurodevelopmental disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Saliva discolouration	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Neuritis cranial	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Amino acid level abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Nervous system injury	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Asplenia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Eosinophilic cystitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Eosinophilia myalgia syndrome	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Neonatal tachypnoea	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Neonatal respiratory failure	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Neonatal respiratory distress	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Neonatal dyspnoea	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Enzyme level decreased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Neisseria infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neglect of personal appearance	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Abdominal wound dehiscence	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Negativism	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Aspergilloma	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Enteropathy-associated T-cell lymphoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Natural killer-cell lymphoblastic lymphoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Natural killer-cell leukaemia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Natural killer cell activity abnormal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Bursal fluid accumulation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Enterocolitis bacterial	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Nasopharyngeal cancer	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Nasal sinus cancer	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Nasal mucosal hypertrophy	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Nasal mucosal discolouration	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Burning feet syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Burn oral cavity	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Asbestosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Endovenous ablation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Burkitt's lymphoma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Nail avulsion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Burkholderia pseudomallei infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Endoscopy abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acute myopia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Endoscopic retrograde cholangiopancreatography	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
N-terminal prohormone brain natriuretic peptide abnor	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Myxomatous mitral valve degeneration	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Endometrial neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Alveolar lung disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endometrial hyperplasia with cellular atypia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Myopathy toxic	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Abdominal wall wound	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bulimia nervosa	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Myocarditis infectious	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endometrial cancer stage I	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Myocarditis bacterial	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Bulbospinal muscular atrophy congenital	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endometrial cancer metastatic	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Myocardial depression	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Endocrine pancreatic disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Myeloma cast nephropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endocrine gland operation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Arthritis-dermatitis syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Myelodysplastic syndrome transformation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bronchoscopy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Enamel anomaly	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Musculoskeletal injury	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Elephantiasis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Multiple system atrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Electroconvulsive therapy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Electrocardiogram low voltage	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Electrocardiogram high voltage	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Multicentric reticulohistiocytosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Mucous membrane pemphigoid	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mucosal pain	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Abdominal hernia repair	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Electrocardiogram T wave amplitude increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mucosal infection	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Alpha hydroxybutyrate dehydrogenase increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Electrocardiogram QT interval	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Mouth cyst	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Arteriovenous fistula thrombosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bronchial irritation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bronchial injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Electrocardiogram J wave increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Mononucleosis syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Electrocardiogram J wave abnormal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Monocyte morphology abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Elective surgery	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Bronchial aspiration procedure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Arteriovenous fistula operation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Molluscum contagiosum	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Model for end stage liver disease score increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Arteriovenous fistula aneurysm	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Eczema vesicular	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Misophonia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Breath sounds	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Migrainous infarction	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Arterioenteric fistula	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Middle cerebral artery stroke	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Microvillous inclusion disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Microscopic polyangiitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Micrographic skin surgery	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Echolalia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Micrococcus infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Echo virus infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Methylenetetrahydrofolate reductase gene mutation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Arterial stent insertion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Early retirement	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Ear, nose and throat examination abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Metastatic gastric cancer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Breast necrosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Metastases to nasal sinuses	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Metastases to heart	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Metastases to fallopian tube	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Metastases to bladder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acanthosis nigricans	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Breast engorgement	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Metaphyseal dysplasia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Arterial insufficiency	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dystonic tremor	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Dyspraxia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Mesenteric neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Mephisto sign	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Menstrual discomfort	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Menopause delayed	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Meniscus removal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Meniscus cyst	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Meniscopathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acanthosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Penile contusion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Meningitis meningococcal	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Meningitis enteroviral	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Meningism	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Melanosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Meige's syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Meibomianitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Megakaryocytes decreased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Medulloblastoma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Medication dilution	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Medical device site scar	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Medical device site odour	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Acanthamoeba infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Brain stem ischaemia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Medical device site erythema	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Medical device site dryness	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Medical device site cellulitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Medical device site burn	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Medical device monitoring error	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Mediastinum neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mediastinal shift	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Mediastinal fibrosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mediastinal effusion	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Drug titration	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Mean platelet volume abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Brain malformation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Mean arterial pressure increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Application site urticaria	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Application site ulcer	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Drug metabolising enzyme increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mastoid disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Application site scar	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Marfan's syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Manufacturing materials issue	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Manufacturing issue	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Malignant transformation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Malignant splenic neoplasm	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Malignant palate neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bradycardia foetal	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Malignant neoplasm of thorax	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Allergic stomatitis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Drug delivery system removal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Malignant neoplasm of conjunctiva	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acute haemorrhagic ulcerative colitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Application site paraesthesia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Drug delivery device placement	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Malignant melanoma stage III	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Brachioradial pruritus	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Malignant glioma	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Malignant fibrous histiocytoma	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Brachial plexus injury	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Dreamy state	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Malaria recrudescence	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Malabsorption from administration site	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Magnetic resonance imaging	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Dopamine agonist withdrawal syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Lysozyme increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
5-hydroxyindolacetic acid increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Application site laceration	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diverticular fistula	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Borderline ovarian tumour	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Bone tuberculosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Lymphocyte percentage abnormal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Allergic fungal rhinosinusitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lymphatic fistula	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Bone sequestrum	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bone prosthesis insertion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Disseminated gonococcal infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lupus pneumonitis	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Lupus pleurisy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lupus enteritis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Bone metabolism disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Lung squamous cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Lung diffusion disorder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Lung carcinoma cell type unspecified stage II	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Application site folliculitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lung carcinoma cell type unspecified stage I	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Bone marrow necrosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Bone marrow myelogram abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Bone marrow haemorrhage	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bone marrow granuloma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Dilatation atrial	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Diffuse panbronchiolitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diffuse mesangial sclerosis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Diffuse large B-cell lymphoma stage II	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Diffuse idiopathic skeletal hyperostosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lividity	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Liver scan abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Dieulafoy's vascular malformation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Liver ablation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Liposarcoma metastatic	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Diastasis recti abdominis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Diaphragmatic spasm	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lipids decreased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Diaphragmatic injury	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Lipase	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Dialysis hypotension	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Application site abscess	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Lip and/or oral cavity cancer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Linitis plastica	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diabetic retinal oedema	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Alcoholic liver disease	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Limb fracture	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Limb amputation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ligneous conjunctivitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Light chain analysis decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Ligament laxity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diabetic foot infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Life support	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Life expectancy shortened	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Lid lag	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Appendicitis noninfective	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
DiGeorge's syndrome	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Leukoerythroblastic anaemia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Leukodystrophy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Alcoholic	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Leptotrichia infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Leptospirosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Leprosy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Axillary web syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Apparent mineralocorticoid excess	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Lennox-Gastaut syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Left ventricular end-diastolic pressure increased	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Left ventricular end-diastolic pressure decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Leclercia bacteraemia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lateral medullary syndrome	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Latent autoimmune diabetes in adults	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Apolipoprotein B increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Device end of service	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Device effect incomplete	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Laryngeal injury	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Laryngeal dyspnoea	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Device computer issue	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Large intestine anastomosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Acute cutaneous lupus erythematosus	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Blood urea nitrogen/creatinine ratio decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Langerhans' cell histiocytosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Blood triglycerides decreased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Lacrimal haemorrhage	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Laboratory test	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Labile hypertension	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood testosterone free increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Labelled drug-disease interaction medication error	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Labelled drug-disease interaction issue	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Dermatitis papillaris capillitii	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Kniest dysplasia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Dermal absorption impaired	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Keratorhexis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Keratoplasty	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Keratoconus	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Keratitis fungal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Keloid scar	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Kawasaki's disease	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Kaposi sarcoma inflammatory cytokine syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Acute cardiac event	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Joint stabilisation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Joint prosthesis user	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Joint microhaemorrhage	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Dental paraesthesia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Dental fistula	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Dental cleaning	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Joint debridement	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Dental attrition	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Dengue virus test positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Jejunal stenosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Jejunal perforation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Demodicidosis	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Demodex blepharitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Jaundice acholuric	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Jarisch-Herxheimer reaction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Delusional disorder, unspecified type	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Delusional disorder, somatic type	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Delusional disorder, persecutory type	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Aortic rupture	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Delirium tremens	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Iris transillumination defect	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Iris neovascularisation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
pH body fluid abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Delayed haemolytic transfusion reaction	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Xanthopsia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Xanthelasma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
XIIth nerve injury	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
X-linked lymphoproliferative syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Dehydroepiandrosterone decreased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Wrong dosage form	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Intrauterine contraception	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Intrathecal pump insertion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Wound infection pseudomonas	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Wound evisceration	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Wound cellulitis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Weight loss diet	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Wallerian degeneration	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Intestinal ulcer perforation	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Intestinal transit time decreased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Vulvar dysplasia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Agraphia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vocal cord thickening	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Decidual cast	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Debridement	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Intestinal malrotation	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Aortic bruit	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vitamin C decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Intestinal diaphragm disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Intestinal cyst	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Vitamin B1 increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vitamin A decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dandy-Walker syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Visual acuity tests abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Viruria	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Viral uveitis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Viral tonsillitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Blood lactic acid abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Dacryocystitis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Agonal rhythm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Viral pericarditis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Viral myocarditis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
DNA antibody positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vipoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Internal injury	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Victim of abuse	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Internal fixation of fracture	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Vessel puncture site haemorrhage	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Vertebroplasty	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Vertebrobasilar insufficiency	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vertebral osteophyte	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Vertebral end plate impression	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vertebral column mass	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vertebral artery occlusion	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Intercapillary glomerulosclerosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cytomegalovirus hepatitis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ventricular enlargement	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Antiviral prophylaxis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Venous operation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Venous angioma of brain	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cytokine abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vasculitis gastrointestinal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vascular procedure complication	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Inner ear inflammation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Injection site vasculitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Vascular cauterisation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Vascular anastomotic haemorrhage	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Vascular access site extravasation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Injection site plaque	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Varicophlebitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cystine urine present	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vagus nerve disorder	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Vaginitis gardnerella	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Injection site muscle weakness	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Vaginal ulceration	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Blood immunoglobulin E	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Injection site muscle atrophy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vaginal polyp	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vaginal lesion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Injection site hyperaesthesia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vaccination site inflammation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
VIIIth nerve injury	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Uterine tachysystole	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Cyanopsia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Injection site abscess sterile	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Cutaneous tuberculosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Uterine hypotonus	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cutaneous lymphoma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Uterine atony	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Uterine abscess	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Urine protein/creatinine ratio decreased	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Cutaneous T-cell lymphoma recurrent	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Antinuclear antibody	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Urine glucose/creatinine ratio increased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Infusion site mobility decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infusion site laceration	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Urinary tract stoma complication	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood folate increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Idiopathic angioedema	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Urinary occult blood	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Urinary hexose tetrasaccharide increased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Urinary bladder rupture	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Urethritis noninfective	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Urethral injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Antineutrophil cytoplasmic antibody	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cryptococcal cutaneous infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Inflammatory carcinoma of the breast	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Urachal abnormality	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Upper respiratory fungal infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Infestation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Infertility female	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Unwanted awareness during anaesthesia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infective thrombosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Unevaluable investigation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infective scleritis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Unevaluable device issue	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Unemployment	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Undersensing	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Infective glossitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Creutzfeldt-Jakob disease	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ulnar neuritis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ulcerative duodenitis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Antidepressant drug level increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Typical aura without headache	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Type 2 lepra reaction	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Blood creatinine	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Turbinectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Craniosynostosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Tumour necrosis factor receptor-associated periodic s	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Infant irritability	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Craniectomy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cranial nerve injury	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Tryptase decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Trousseau's sign	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Troponin abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Trisomy 21	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Cough variant asthma	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Tri-iodothyronine free abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Blood corticotrophin abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Traumatic shock	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Traumatic lumbar puncture	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Anticoagulation drug level decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Transposition of the great vessels	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood citric acid increased	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Transient tachypnoea of the newborn	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Transient psychosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Transcatheter aortic valve implantation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Implantable cardiac monitor insertion	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Tracheal ulcer	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Coronary artery dilatation	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Toxic erythema of chemotherapy	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Implant site irritation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Implant site injury	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Total cholesterol/HDL ratio increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Implant site hypoaesthesia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Torus fracture	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Tooth whitening	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Tooth resorption	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Implant site dehiscence	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Implant site bruising	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Tooth dislocation	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Abdominal compartment syndrome	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Corneal operation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Tonsillolith	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Abortion of ectopic pregnancy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Impaired reasoning	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Blood cannabinoids increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tongue neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tongue haematoma	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Tongue erosion	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Corneal exfoliation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Corneal erosion	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Tolosa-Hunt syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Blood calcitonin increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Tobacco interaction	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Immune-mediated oesophagitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Corneal endothelial cell loss	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Tinea cruris	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tick-borne viral encephalitis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Thyroxine free abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Thyroid stimulating immunoglobulin increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Corneal decompensation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Corneal abscess	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Immune-mediated encephalopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Antibiotic associated colitis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Immune-mediated cytopenia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Thyroid adenoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Thymic cyst	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Copper deficiency	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Thrombosis mesenteric vessel	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Thrombophlebitis septic	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Threatened labour	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Imaging procedure abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Thoracotomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anti-thyroid antibody positive	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Thoracic operation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cooling therapy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Illiteracy	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Therapy responder	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Iliac artery occlusion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Iliac artery disease	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Therapeutic drug monitoring analysis not performed	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Thalassaemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood alkaline phosphatase	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tethered cord syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Testicular torsion	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Anti-thyroid antibody	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Implant site mass	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Blood aldosterone decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Idiopathic generalised epilepsy	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Testicular haemorrhage	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Testicular failure	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Continuous haemodiafiltration	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Anti-polyethylene glycol antibody present	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Ichthyosis acquired	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Illrd nerve paresis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Implant site pustules	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Adrenalitis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Hypozincaemia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Tendinous contracture	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Temporal lobe epilepsy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Abortion late	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Tangentiality	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Implantation complication	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Conjunctival staining	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tachycardia foetal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
T-lymphocyte count abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Systolic anterior motion of mitral valve	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Systemic viral infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Systemic toxicity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Conjunctival irritation	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Syringomyelia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Synovial cyst removal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Syndesmophyte	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Conjunctival erosion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Symphysiolysis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hyponatriuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Conjunctival deposit	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Sweat gland tumour	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Sweat gland disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Suspiciousness	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Suspected suicide attempt	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Hypoglycaemia unawareness	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Congenital tricuspid valve incompetence	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Surgical procedure repeated	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Congenital torticollis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Supraventricular tachyarrhythmia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypoglossal nerve disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cortisol abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Transverse sinus thrombosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Incision site cellulitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Supine hypertension	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypocoagulable state	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Superinfection viral	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Incarcerated umbilical hernia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anti-Muellerian hormone level decreased	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Blepharoplasty	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Superficial vein prominence	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Superficial spreading melanoma stage unspecified	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Congenital musculoskeletal disorder of spine	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Blepharal pigmentation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Congenital musculoskeletal disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Subretinal fibrosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Incision site ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Hypervitaminosis D	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Incision site vesicles	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Subglottic laryngitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Tri-iodothyronine free increased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hypertrophy of tongue papillae	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Subclavian artery thrombosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Subchorionic haemorrhage	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Subarachnoid haematoma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Congenital dyskeratosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hypertensive nephropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Stroke in evolution	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Stress ulcer	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Stress echocardiogram abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anti factor VIII antibody increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Streptococcal bronchitis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hypersplenism	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Blood creatine phosphokinase MB abnormal	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Stool pH decreased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Congenital arterial malformation	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Stomal varices	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Stoma site ulcer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blast cell crisis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Stoma site odour	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Stoma site cellulitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anti factor IX antibody increased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hyperoxia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Stitch abscess	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Condom catheter placement	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Adrenal gland operation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Stereotypy	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Stenotrophomonas test positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anti A antibody positive	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Computerised tomogram liver abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Squamous cell carcinoma of the parotid gland	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Computerised tomogram heart abnormal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Computerised tomogram head abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Squamous cell carcinoma antigen increased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Anterior chamber opacity	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bladder repair	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Compulsive sexual behaviour	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Spondylitic myelopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Hyperchromic anaemia	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Splenic marginal zone lymphoma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Complications of transplanted liver	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Splenic granuloma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Splenic calcification	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Complications of transplanted heart	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hyperbaric oxygen therapy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Complications of transplant surgery	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Spirochaetal infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Spinocerebellar disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Spindle cell sarcoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Complications of bone marrow transplant	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Spinal stroke	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Spinal nerve stimulator removal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hyper IgE syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Spinal cord injury cervical	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Spinal cord infarction	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Spinal cord haematoma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Spinal claudication	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Complement factor C4 increased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Spigelian hernia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sphincter of Oddi dysfunction	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Complement factor C3 decreased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Bladder diverticulum	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Human herpesvirus 6 encephalitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Combined pulmonary fibrosis and emphysema	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Human anaplasmosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Soft tissue neoplasm	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Snapping hip syndrome	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Smooth muscle antibody positive	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Homicide	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Colostomy closure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Small intestinal ulcer haemorrhage	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Ureteric cancer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Small intestinal anastomosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hodgkin's disease recurrent	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Small cell lung cancer metastatic	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Histamine level increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Histamine abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sleep study	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Colorectal adenocarcinoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Skull fractured base	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Skin ulcer haemorrhage	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Anorectal varices	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Birdshot chorioretinopathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Skin pressure mark	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Hiatus hernia strangulated	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Herpes zoster meningomyelitis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Skin indentation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Crystal urine	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Colon cancer recurrent	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skin cancer metastatic	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Herpes simplex oesophagitis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Skin angiosarcoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Biopsy thyroid gland abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Herpes simplex meningitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Infusion site dryness	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Herpes simplex hepatitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Herpes dermatitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hernia obstructive	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Similar reaction on previous exposure to drug	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Silent myocardial infarction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Biopsy skin abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Sick relative	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Hereditary haemorrhagic telangiectasia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Adnexa uteri cyst	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Shunt thrombosis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Biopsy site unspecified abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Shoulder girdle pain	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Shoulder deformity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Shortened cervix	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hepatosplenic abscess	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hepatorenal failure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infusion site necrosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Severe acute respiratory syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Anonychia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cockroach allergy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Serum colour abnormal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Hepatitis chronic active	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Biopsy lymph gland	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Urine protein/creatinine ratio abnormal	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Septic rash	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Urobilinogen urine increased	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Septal panniculitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Sepsis pasteurella	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Coagulation time abnormal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Sensory processing disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hepatitis B surface antibody positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Coagulation factor VIII level decreased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Coagulation factor V level decreased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hepatitis B DNA assay positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Uterine contractions abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Self-destructive behaviour	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Annular elastolytic giant cell granuloma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Selective mutism	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Selective IgA immunodeficiency	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hepatic venous pressure gradient abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Hepatic vascular disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Secondary cerebellar degeneration	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Scrotal ulcer	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Hepatic ischaemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hepatic infection fungal	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Scrotal inflammation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Scrotal discomfort	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Hepatic haemangioma rupture	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Scoliosis surgery	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Sclerotherapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Scleromalacia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Cyanosis central	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Biochemical pregnancy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Clinical death	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Scleral thinning	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Cleft palate	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Scleral haemorrhage	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Sciatic nerve palsy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Schistocytosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hepatic cancer stage IV	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Vaccination site injury	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hepatic calcification	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Scalp haematoma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Vaccination site haematoma	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Administration site reaction	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vaccination site rash	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sarcomatoid mesothelioma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Sarcoma metastatic	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Cirrhosis alcoholic	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bilirubin urine present	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Salpingo-oophoritis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Salmonella test positive	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Salmonella sepsis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Salivary gland pain	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Salivary gland mass	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Hemianopia heteronymous	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Saliva analysis abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bilirubin conjugated abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vaginal perforation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ciliary hyperaemia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Heavy exposure to ultraviolet light	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Rubella	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Heavy chain disease	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Rickets	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Rib deformity	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Heart rate variability increased	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Rheumatoid meningitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Heart alternation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Rheumatoid factor negative	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Rhabdomyosarcoma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Reversal of sedation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Rett syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Retroperitoneal neoplasm metastatic	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Hashimoto's encephalopathy	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Retrograde amnesia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cystitis klebsiella	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Retinoschisis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Retinopathy proliferative	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Retinopathy of prematurity	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hand repair operation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Retinal scar	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Retinal infarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Retinal fovea disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chronic graft versus host disease oral	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Reticulocytopenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Reticulocyte count abnormal	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Chronic graft versus host disease in liver	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Chronic graft versus host disease in eye	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Respiratory syncytial virus test	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Administration site joint pain	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Haemorrhagic erosive gastritis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Chronic coronary syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Respiratory depth decreased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Reproductive tract disorder	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Haemorrhagic ascites	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Chromosome analysis abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Administration site joint infection	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Angiotensin converting enzyme increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Renal replacement therapy	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Renal necrosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Haemoglobinaemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Renal dysplasia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Benzodiazepine drug level increased	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Renal cyst haemorrhage	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Benign uterine neoplasm	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Renal cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Renal cancer stage II	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Benign tumour excision	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Renal artery thrombosis	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Venous pressure jugular increased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Intention tremor	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Renal arteriosclerosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Removal of foreign body	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Chondrosarcoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Haematological neoplasm	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Relapsing fever	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Refractory cancer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ventricular failure	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Haemangioma of bone	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Angiopathic neuropathy	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Red blood cell schistocytes present	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Red blood cell microcytes present	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Red blood cell hypochromic morphology present	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Habit cough	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Cholesteatoma	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
HLA-B*27 positive	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
HIV-associated neurocognitive disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
HIV viraemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Benign neoplasm of spinal cord	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
HIV test positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Rectal spasm	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Cholelithotomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Rectal injury	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Benign neoplasm of skin	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
HCoV-OC43 infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Rebound psychosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rebound nasal congestion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
H1N1 influenza	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Reactive capillary endothelial proliferation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Reaction to sweetener	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acquired cardiac septal defect	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gun shot wound	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Rathke's cleft cyst	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Rasmussen encephalitis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Gross motor delay	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Vessel puncture site inflammation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Benign laryngeal neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Radiotherapy to brain	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Radiculotomy	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Internal carotid artery deformity	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Radical prostatectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Radiation retinopathy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Granulomatous rosacea	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Radial nerve palsy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
RET gene mutation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Quadrantanopia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Victim of chemical submission	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Granulocytosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Benign gastric neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chitotriosidase increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chillblains	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Graft versus host disease in eye	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Puncture site bruise	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gorham's disease	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gonorrhoea	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Gonococcal infection	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Pulmonary vein occlusion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Aneurysm thrombosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pulmonary valve thickening	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pulmonary valve disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chest tube insertion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bence Jones protein urine present	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Glycosylated haemoglobin	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Glycogen storage disease type II	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Glycated albumin increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pulmonary necrosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pulmonary microemboli	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Glossoptosis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Pulmonary fistula	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Glomerulonephropathy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Pulmonary eosinophilia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pulmonary endarterectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Glomerulonephritis proliferative	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pulmonary artery therapeutic procedure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chemical cystitis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Pulmonary arterial wedge pressure increased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pulmonary arterial wedge pressure decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Pulmonary arterial pressure	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Pubic pain	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chemical burn of genitalia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vitreous cyst	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Glioma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Andropause	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Psychiatric care	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Glaucoma surgery	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pseudomyopia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Charles Bonnet syndrome	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pseudomonal skin infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pseudohypoadosteronism	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Cestode infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Prothrombin time ratio increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Gingival cancer	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Androgen deficiency	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Protein S deficiency	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Protein C deficiency	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Von Willebrand's factor inhibition	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Vulvar erosion	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Basal ganglia stroke	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cervix carcinoma stage I	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Cervix carcinoma stage 0	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Geotrichum infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cervix cancer metastatic	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Genitourinary tract neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Genitourinary tract infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Prophylaxis against transplant rejection	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Prophylaxis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Genital neoplasm malignant female	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Prohormone brain natriuretic peptide increased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Genital injury	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Progressive familial intrahepatic cholestasis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Progressive external ophthalmoplegia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Bartonellosis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Genital infection female	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Genital infection bacterial	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Genital herpes zoster	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Cervical cyst	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Genital dysaesthesia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Product primary packaging issue	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Administration site abscess	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cerebrovascular stenosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Product label on wrong product	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Product impurity	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Generalised resistance to thyroid hormone	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Anaplastic thyroid cancer	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Product design confusion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cerebral ventricle dilatation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
General anaesthesia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gender dysphoria	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Product compounding quality issue	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Product cleaning inadequate	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gastrostomy failure	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Proctocolectomy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Procrastination	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Procedural intestinal perforation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Withdrawal hypertension	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Intra-ocular injection	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gastrointestinal tract mucosal discolouration	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Intranasal paraesthesia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Primary stabbing headache	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bacteroides bacteraemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Premenstrual pain	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Premenstrual dysphoric disorder	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Gastrointestinal neuroendocrine carcinoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Gastrointestinal mucosal exfoliation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bacterial tracheitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pre-engraftment immune reaction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cerebral ataxia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Poverty of speech	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Posturing	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Postoperative respiratory failure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Postoperative renal failure	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Gastrointestinal decompression	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Postoperative delirium	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Postmortem blood drug level increased	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Postmortem blood drug level	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Gastrointestinal angiodysplasia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Posterior tibial tendon dysfunction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cerebellar ischaemia	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
pH urine decreased	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Post-traumatic headache	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
11-beta-hydroxylase deficiency	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Post transfusion purpura	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Post procedural urine leak	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Cerebellar haematoma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gastroenteritis sapovirus	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Post procedural pruritus	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
5-hydroxyindolacetic acid in urine	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Post procedural hypoparathyroidism	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gastroenteritis listeria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Post procedural drainage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post procedural cellulitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post procedural cardiac valve avulsion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post polio syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Post intensive care syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastroduodenal haemorrhage	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Post angioplasty restenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Positive end-expiratory pressure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Portopulmonary hypertension	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bacterial diarrhoea	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastritis alcoholic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Portal vein pressure increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Portal vein embolisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gastrinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrin-releasing peptide precursor increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Portal hypertensive colopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Portal fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Porphyria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anal skin tags	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bacterial abscess central nervous system	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Porionomania	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Poor weight gain neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastric tube reconstruction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gastric stent removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastric prolapse	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Polyneuropathy chronic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastric pH increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Polyneuropathy alcoholic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Polyglandular autoimmune syndrome type II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastric ischaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Central nervous system injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gastric ileus	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adhesiolysis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pneumovirus test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Central nervous system immune reconstitution inflamma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastric cancer recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pneumonia serratia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gastric atony	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bacillary angiomatosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pneumonia moraxella	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gardnerella infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ganglioneuroma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Central auditory processing disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adenovirus test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cellulitis streptococcal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
BRCA2 gene mutation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Pneumectomy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pneumocentesis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
BRCA1 gene mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cellulitis of male external genital organ	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gallbladder volvulus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pneumaturia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pleuroparenchymal fibroelastosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pleural rub	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gallbladder necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
BRAF gene mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cells in urine	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gallbladder mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pleural infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pleural cyst	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Plethysmography	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
BRAF V600E mutation positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gallbladder cholesterolosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Platypnoea-orthodeoxia syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Platelet toxicity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Platelet distribution width increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gallbladder abscess	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cavernous sinus syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Galactostasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Platelet anisocytosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Platelet aggregation increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
BK polyomavirus test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Catheterisation venous	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Plasmodium falciparum infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acinetobacter bacteraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fusobacterium infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Plantar fascial fibromatosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fungal test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pityriasis lichenoides et varioliformis acuta	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pityriasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fungal rhinitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pituitary tumour removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pituitary infarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pituitary haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fungal myositis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Catheter site rash	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pineal gland cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Piercing associated complication	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Catheter site pustule	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Fungal cystitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pickwickian syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fundoscopy abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Physical fitness training	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Functional residual capacity increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
B-cell unclassifiable lymphoma high grade	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Catheter site phlebitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Physical abuse	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Functional residual capacity abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Phototherapeutic keratectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Photosensitive seizure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Functional endoscopic sinus surgery	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fumbling	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Phosphaturic mesenchymal tumour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Catheter site mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Phobic postural vertigo	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Phlyctenular keratoconjunctivitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Phlebitis superficial	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Phlebitis deep	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
B-cell lymphoma stage IV	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Phlebectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adenoviral conjunctivitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
B-cell lymphoma stage II	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Philadelphia chromosome negative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Catheter site hypoaesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
B-cell lymphoma refractory	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fracture treatment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal exudate	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pharyngeal enanthema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fracture infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal dystonia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pharyngeal contusion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pharyngeal chlamydia infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Catheter site exfoliation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fracture blisters	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pharmaceutical nomadism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Catheter site erosion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fractional exhaled nitric oxide abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Persistent postural-perceptual dizziness	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Foreign body reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Catheter site dehiscence	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pernio-like erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Catheter site abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peritoneal mesothelial hyperplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adenosquamous cell carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peritoneal fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fordyce spots	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Peritoneal dialysis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Forced vital capacity increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perisplenitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Catecholamines urine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Periportal sinus dilatation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Periportal oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anal eczema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral vein thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral vein stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Foot and mouth disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Peripheral pulse decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral oedema neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Adenosquamous carcinoma of the cervix	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Peripheral nerve infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral nerve decompression	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Peripheral artery stent insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral artery stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral artery aneurysm rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cataract cortical	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fontanelle bulging	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anal chlamydia infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Peripartum haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Folliculitis genital	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripartum cardiomyopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Peripancreatic varices	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acid peptic disease	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Catamenial pneumothorax	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Periorbital injury	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Follicle centre lymphoma, follicular grade I, II, III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anal cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Avian influenza	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Foetal macrosomia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Perineal rash	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perineal necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Foetal heart rate increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Perineal injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cartilage graft	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perinatal stroke	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Perihepatic discomfort	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perihepatic abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pericoronitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pericarditis tuberculous	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Pericarditis lupus	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pericardial mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pericardial effusion malignant	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anal cancer recurrent	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Autonomic seizure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pericardial drainage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carotid pulse abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carotid intima-media thickness increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Performance fear	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Percutaneous coronary intervention	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carotid endarterectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Peptic ulcer haemorrhage	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Penoscrotal fusion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fluid balance positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Penile prosthesis insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Floppy iris syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Penile odour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Floppy infant	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Floating patella	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Penile gangrene	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Flight of ideas	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Penile exfoliation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Flat anterior chamber of eye	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Penetrating aortic ulcer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pemphigus disease area index	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Automatic bladder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Flagellate dermatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pelvic pouch procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Autologous blood patching	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fixed bowel loop	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pelvic organ injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic girdle pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
First degree chemical burn of skin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic floor muscle weakness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anaesthetic complication neurological	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiovascular symptom	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Finger repair operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic floor dysfunction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pelvic cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic adhesions	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fine motor delay	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pedal pulse increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Filariasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pedal pulse decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiovascular deconditioning	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fight in school	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pectus excavatum	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
ASXL1 gene mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Patient dissatisfaction with device	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pathological tooth fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acid base balance abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fibrosarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pathological doubt	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pathologic myopia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anaesthesia procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paternal exposure timing unspecified	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fibroblast growth factor 23	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paroxysmal perceptual alteration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiomyopathy neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fibrin degradation products	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paroxysmal atrioventricular block	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Fibrin D dimer decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cardiomyopathy acute	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fibrillary glomerulonephritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fever neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Femoral nerve injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Femoral hernia incarcerated	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Paratonia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Femoral hernia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Femoral anteversion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Parathyroid hyperplasia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Parathyroid hormone-related protein increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardioactive drug level decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Female reproductive tract disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardio-respiratory arrest neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Parathyroid gland abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anaemia vitamin B6 deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Female genital operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Parapharyngeal space infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac ventricular scarring	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Paraneoplastic pleural effusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Paraneoplastic hypoglycaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Paranasal sinus necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Paranasal sinus haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac valve rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac valve replacement complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Parakeratosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anaemia postoperative	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Paradoxical skin reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paracusis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Fear of weight gain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paracoccidioides infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fear of surgery	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Papilloma excision	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Papilloma conjunctival	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fear of eating	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Papilloma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adenocarcinoma of the cervix	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anaemia of pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Papillary cystadenoma lymphomatosum	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pantoea agglomerans infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Panophthalmitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Panniculitis lobular	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fat overload syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cardiac resynchronisation therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fat embolism syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac rehabilitation therapy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fat embolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pancreatitis bacterial	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fasciola test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pancreatic operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac perfusion defect	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fascial rupture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Achlorhydria	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fascial operation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac perforation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pancreatic infarction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pancreatic enzymes abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pancreatic duct stenosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Autoimmune cholangitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac pacemaker evaluation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Familial cold autoinflammatory syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Familial amyloidosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
False positive tuberculosis test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fallopian tube perforation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pancoast's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fallopian tube operation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Palpatory finding abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac myxoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fallopian tube cancer stage III	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Palliative sedation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cardiac monitoring abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Failure to anastomose	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Failure of child resistant product closure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac index abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pachydermoperiostosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
PRIDE syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
PO2 abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Achenbach syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
PCDH19 gene-related epilepsy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
PASH syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac haemolytic anaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Oxygen saturation normal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aural polyp	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Faecal calprotectin decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Factor Xa activity increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oxidative stress	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ovulation pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ovulation disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Overwork	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Overgrowth syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Factor VIII activity increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Factor VIII activity decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Overchelation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Factor V deficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Ovarian prolapse	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ovarian neoplasm surgery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Factor IX deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian haematoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Audiogram abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ovarian germ cell teratoma benign	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ovarian germ cell teratoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ovarian cyst torsion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Facial operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian adenoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Otorhinolaryngological surgery	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Otolithiasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Otitis media staphylococcal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Face lift	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Otitis media haemophilus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Otitis media chronic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Face crushing	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Otitis externa bacterial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
FLT3 gene mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Osteorrhagia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
FEV1/FVC ratio abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Osteoradionecrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eyelid tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Osteomyelitis drainage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Amyloidoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atypical migraine	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Osteochondritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Osteochondral fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eyelid myoclonus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Osteocalcin decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atypical lymphocytes increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carcinoma in situ of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Osteitis deformans	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Ostectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Osmophobia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Osmolar gap abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Osmolar gap	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carcinoid tumour of the stomach	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Eyelid cyst removal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oropharyngitis fungal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oropharyngeal spasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Atypical fibroxanthoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oropharyngeal oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eyelash thickening	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oropharyngeal neoplasm benign	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Accommodation disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oronasal fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oroantral fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Organ transplant	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eye opacity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Orbital swelling	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Orbital infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oral pigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Oral papilloma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eye laser scar	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Oral neoplasm benign	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atrophic glossitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Oral mucosa haematoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Acute vestibular syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Carbon dioxide combining power decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Eye infection syphilitic	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oral mucosa atrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carbohydrate metabolism disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oral dysplasia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Atrioventricular dissociation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carbohydrate intolerance	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eye haemangioma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carbohydrate antigen 72-4	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eye excision	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oral allergy syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aberrant motor behaviour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carbohydrate antigen 242 increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Optic nerve infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Optic glioma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eye abrasion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carbohydrate antigen 125	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ophthalmic vein thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Capsular contracture associated with breast implant	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ophthalmic fluid drainage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Extraskelatal ossification	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ophthalmic artery occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Amputee	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Capripox viral infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Extrarenal pelvis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oophoritis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oocyte harvest	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Capnocytophaga sepsis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Onychomalacia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Capillary permeability increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oncocytoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atrial switch operation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
External ear pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
External ear neoplasm malignant	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
External ear inflammation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Olfactory dysfunction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
External ear disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oestrone increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oestrone decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exposure via unknown route	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oestradiol increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Atrial septal defect repair	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oesophagomediastinal fistula	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Oesophagogastroduodenoscopy abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophagogastric fundoplasty	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exposure via mucosa	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Exposure via inhalation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oesophagitis bacterial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Atrial septal defect acquired	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oesophagectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Candida nappy rash	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oesophageal squamous cell carcinoma stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exposure to violent event	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oesophageal operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophageal oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Exposure to tobacco	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oesophageal mucosal tear	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oesophageal mucosal blister	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophageal motility test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophageal mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophageal hypomotility	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atrial natriuretic peptide	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cancer screening abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exposure to contaminated device	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Atrial hypertrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophageal dilation procedure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oesophageal atony	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exploding head syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oesophageal adenocarcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cancer cells present	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oedema due to hepatic disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Expanded disability status scale score decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular surface squamous neoplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exeresis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular surface disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ocular rosacea	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
ABO incompatibility	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Campylobacter bacteraemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular procedural complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exercise electrocardiogram abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ocular melanoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ocular implant exposure	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Amniotic fluid index decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Calyceal diverticulum	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular dysmetria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Excessive gingival display	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Occupational problem environmental	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Occupational exposure to dust	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Excessive dynamic airway collapse	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exanthema subitum	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Obstructive shock	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exaggerated startle response	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Obstetric procedure complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nutritional supplementation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nucleic acid test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Calcium ionised decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nothing by mouth order	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Notalgia paraesthetica	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Nose deformity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Calcitonin secretion disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Amniotic band syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Normal tension glaucoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Escherichia pyelonephritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nontherapeutic agent blood positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erythrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Noninfectious myelitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erythrospia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Non-small cell lung cancer stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Acute pulmonary histoplasmosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Erythropoietin deficiency anaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Non-small cell lung cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Non-small cell lung cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Caffeine allergy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erythroid maturation arrest	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Non-obstructive cardiomyopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Non-Hodgkin's lymphoma stage II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Amniocentesis abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Non-24-hour sleep-wake disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
CSF white blood cell count increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Erythema infectiosum	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nodular melanoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erythema ab igne	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
CSF red blood cell count positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erysipelothrix infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nocardia sepsis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Astrocytoma, low grade	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nipple inflammation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nipple exudate bloody	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nipple enlargement	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ergot poisoning	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
CSF protein	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nicotinic acid deficiency	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Erdheim-Chester disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
New daily persistent headache	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
CSF pressure decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Epulis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neutrophilic panniculitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Neutrophil toxic granulation present	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
CSF lymphocyte count increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neutrophil percentage abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
CSF lactate decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neutrophil morphology abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neutrophil hypersegmented morphology present	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
CSF culture positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
CSF cell count decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Epithelioid sarcoma recurrent	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neurotransmitter level altered	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
COVID-19 treatment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neuropathy vitamin B6 deficiency	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Neuropathic pruritus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Epiphysiodesis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neuromyotonia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Epinephrine abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neuromuscular pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neuromuscular block prolonged	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Epileptic encephalopathy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Acute postoperative sialadenitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
COPA syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neurological rehabilitation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neurological procedural complication	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Epilepsia partialis continua	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Epiglottic oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Neuroleptic-induced deficit syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Epiglottic cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neuroglycopenia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neurogenic cough	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
CD8 lymphocytes increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Epidural anaesthesia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neuroendocrine carcinoma of the bladder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neuroendocrine cancer of the prostate metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
CD8 lymphocyte percentage increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Epididymal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neurodevelopmental delay	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neurocysticercosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Epidermolysis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neurocryptococcosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Accidental device ingestion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Neuroborreliosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Asteatosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Neurectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Ependymoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Eosinophilic pustular folliculitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nervous system cyst	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Assisted suicide	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
CD4 lymphocytes abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nerve conduction studies abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
CD34 cell count decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
CD19 lymphocytes increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
CALR gene mutation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Neoplasm prostate	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neoplasm of appendix	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
C1q nephropathy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neonatal seizure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eosinophil count normal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
C-telopeptide increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neonatal pneumothorax	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neonatal pneumonia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neonatal leukaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
C-telopeptide decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neonatal intestinal perforation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neonatal epileptic seizure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neonatal behavioural syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal incarcerated hernia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Enzyme activity abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ameloblastoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Negative cardiac inotropic effect	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
C-kit gene mutation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Necrotising colitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Necrosis of artery	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Butanol-extractable iodine decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bursitis infective staphylococcal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Natural killer cell count	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nasopharyngeal reflux	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nasal septum ulceration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nasal odour	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nasal necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Burns first degree	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nasal mucosal erosion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nasal flaring	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Enteric neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nasal cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enophthalmos	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nasal aspiration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute oesophageal mucosal lesion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enlarged clitoris	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enlarged cerebral perivascular spaces	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Narcissistic personality disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Engraft failure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nail necrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Burn of internal organs	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enema administration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Alveolar oxygen partial pressure decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nail cuticle fissure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endotoxic shock	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nail bed tenderness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endoscopy upper gastrointestinal tract abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endoscopy gastrointestinal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nail atrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Naevus spilus	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Naevus haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
NYHA classification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
NIH stroke scale score increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
NIH stroke scale abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
N-telopeptide abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Myxoid cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endometrial thinning	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Myxofibrosarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mysophobia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Myringotomy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bundle branch block bilateral	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endometrial stromal sarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myringosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endometrial sarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myopic traction maculopathy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Arthropod infestation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Endometrial hypoplasia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Myopic chorioretinal degeneration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endometrial dysplasia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Myoglobin urine present	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endometrial disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Endometrial cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alveolar bone resorption	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Myocardial stunning	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Myocardial rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myocardial necrosis marker	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myocardial necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endolymphatic hydrops	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Myocardial hypoxia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arthrofibrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Endocrine toxicity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Myocardial haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Brunner's gland hyperplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endocrine test abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alveolar bone defect	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endocrine neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myelomalacia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Brown tumour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Myelodysplastic syndrome with multilineage dysplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endocarditis pseudomonal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Endocarditis noninfective	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myeloblast percentage increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchus compression	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Endocarditis enterococcal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arthritis viral	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Myectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mycotoxicosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
End-tidal CO2 increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bronchoscopy abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mycobacterium avium complex immune restoration diseases	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Encephalocele	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mycobacterial disease carrier	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchoscopic lung volume reduction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Encephalitis protozoal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arthritis gonococcal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mutagenic effect	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Musculoskeletal procedural complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arthritis fungal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Musculoskeletal complication associated with device	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Emphysematous cholecystitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Altered pitch perception	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Muscle relaxant therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Muscle relaxant drug level above therapeutic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bronchoplasty	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Muscle oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchogram abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Muscle neoplasm	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Arthritis allergic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchoalveolar lavage abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchoalveolar lavage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Embolic pneumonia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Murphy's sign positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Multivisceral transplantation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bronchitis pneumococcal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Multisystem inflammatory syndrome in adults	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchitis haemophilus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Multiple pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Electroencephalogram	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Multiple endocrine neoplasia Type 1	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
AST/ALT ratio	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Arteritis coronary	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Multiple congenital abnormalities	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal wall operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Accelerated idioventricular rhythm	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mucositis management	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mucosal roughness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mucosal prolapse syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mucosal hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mucosal exfoliation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bronchial stent insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Electrocardiogram ST-T segment elevation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mucolipidosis type I	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mucoepidermoid carcinoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mucocutaneous rash	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arteriovenous graft site necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bronchial oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mucocutaneous leishmaniasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arteriovenous graft site infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Electrocardiogram RR interval prolonged	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchial mucosa hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Motor developmental delay	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Electrocardiogram QRS complex	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Morose	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arteriovenous fistula site infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Moraxella test positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mononucleosis heterophile test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Arteriovenous fistula site haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchial dysplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mononeuropathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Monogenic diabetes	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Electrocardiogram	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Monocytopenia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Electrical burn	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Monocyte count abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Elective procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alpha 1 foetoprotein abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Monoclonal B-cell lymphocytosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bronchial artery hypertrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Molybdenum deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Elastofibroma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Modified radical mastectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Modified Rodnan skin score abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Brief psychotic disorder, with postpartum onset	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Model for end stage liver disease score abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alpers disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mixed deafness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Breech delivery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mitral valve disease mixed	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Edentulous	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mitral commissurotomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mitochondrial myopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Breath sounds absent	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arteriosclerotic retinopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Misleading laboratory test result	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mineralocorticoid deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Milk soy protein intolerance	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ectropion of cervix	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Migraine-triggered seizure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ectopic gastric mucosa	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Abdominal wall oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Breast tumour excision	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Echovirus test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Micrographia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Microglossia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Breast prosthesis user	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Microbiology test abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mevalonate kinase deficiency	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Metastatic uterine cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Metastatic salivary gland cancer	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metastatic mesothelioma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ear, nose and throat disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metastatic carcinoid tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Metastases to uterus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Metastases to rectum	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Breast induration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ear lobe infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arterial perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Metastases to muscle	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ear infection staphylococcal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metastases to diaphragm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Metastases to biliary tract	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ear deformity acquired	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metastases to abdominal wall	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Allogenic bone marrow transplantation therapy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arterial intramural haematoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metapneumovirus bronchiolitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
ECG signs of myocardial ischaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metaphyseal corner fracture	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Metabolic myopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dyssomnia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mesoblastic nephroma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Breast discolouration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Breast discharge infected	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mesenteric haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mesenteric artery embolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mesenteric arterial occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mesangioproliferative glomerulonephritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Allergy to venom	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arterial graft	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Breast cyst rupture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mental status changes postoperative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arterial fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Menstruation normal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal wall neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Meningococcal bacteraemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Allergy to synthetic fabric	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meningitis trypanosomal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meningitis streptococcal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meningitis neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Breast cancer male	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Meningitis leptospiral	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meningitis haemophilus	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arrested labour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Meningitis chemical	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Meningeal thickening	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Meningeal repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Menarche	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dural arteriovenous fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Melanaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arm amputation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Duodenostomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Megakaryocytes increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Megakaryocytes abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Megakaryocytes	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Duodenectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arginase deficiency	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Medium-chain acyl-coenzyme A dehydrogenase deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical observation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Brain tumour operation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Medical device site warmth	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site ulcer	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Duodenal obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arboviral infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Brain stem stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Medical device site reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site joint pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site irritation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Medical device site injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Medical device site hypertrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site extravasation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Medical device site eczema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device site discharge	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Medical device site calcification	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Brain scan abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug-device interaction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aqueductal stenosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Drug-device incompatibility	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Medical device entrapment	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Brain radiation necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Drug withdrawal maintenance therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug withdrawal headache	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mediastinal lymphadenectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mediastinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mediastinal disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mediastinal abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meconium ileus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mechanic's hand	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug therapeutic incompatibility	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Measles antibody positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Brain natriuretic peptide	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abdominal wall mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Maxillofacial pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug rehabilitation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Maxillofacial operation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Brain lobectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Matrix metalloproteinase-3 increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Maternal hypertension affecting foetus	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Maternal exposure via partner during pregnancy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Maternal death	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Drug metabolite level	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mastoidectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mastoid effusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug metabolising enzyme decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mastitis bacterial	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Allergy test negative	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Brain dislocation syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mass excision	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Marginal zone lymphoma stage I	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Manufacturing materials contamination	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Allergy test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Manual lymphatic drainage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mantle cell lymphoma refractory	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Manic symptom	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug half-life increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mammary duct ectasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malpositioned teeth	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Malignant urinary tract obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Drug effect faster than expected	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Malignant syphilis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant pericardial neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Abscess sweat gland	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Malignant nervous system neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Malignant neoplasm of uterine adnexa	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Malignant neoplasm of lacrimal gland	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Malignant muscle neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Drug clearance increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Malignant melanoma of sites other than skin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant mediastinal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Application site papules	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Drug chemical incompatibility	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant lymphoid neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant hypertensive heart disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant genitourinary tract neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant gastrointestinal obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant biliary obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant atrophic papulosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Brachial plexopathy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Male genital tract operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bowenoid papulosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Malaria relapse	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Drain removal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acute haemolytic transfusion reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Application site odour	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bowel preparation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Double outlet right ventricle	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Magnetic resonance imaging heart	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bowel obstruction surgery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dosage not adjusted	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Application site nodule	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Magnetic resonance imaging abdominal abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Donor specific antibody present	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Macular telangiectasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Application site necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Botulinum toxin injection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Macular fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Macular dystrophy congenital	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
22q11.2 deletion syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Botryomycosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Macroprolactinaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Macroamylasaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
ALK gene rearrangement positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abscess soft tissue	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acute graft versus host disease oral	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
MAGIC syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lysosomal storage disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lymphorrhoea	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lymphoplasmacytoid lymphoma/immunocytoma recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diversion proctitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lymphoid tissue hyperplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diversion colitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lymphoid hyperplasia of intestine	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Borderline mucinous tumour of ovary	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diuretic therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lymphodepletion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Allergic gastroenteritis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Application site injury	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Disturbance in sexual arousal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bone trimming	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Distal clavicle excision	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lymphatic system neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lymphatic malformation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lymphangiosarcoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lymphangioliomyomatosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Application site induration	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bone scan	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Allergic eosinophilia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lymph node calcification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lupus vasculitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Application site hypersensitivity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone non-union	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lupus endocarditis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lupus encephalitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Application site hyperaesthesia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lung squamous cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dislocation of sternum	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lung induration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bone marrow tumour cell infiltration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lung hypoinflation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Allergic bronchitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone marrow transplant rejection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Disease susceptibility	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bone marrow oedema syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Disease prodromal stage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lumbosacral radiculoplexus neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lumbosacral plexopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lumbar spinal drainage complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone marrow leukaemic cell infiltration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Disability assessment scale score decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lower respiratory tract infection fungal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diminished ovarian reserve	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lower motor neurone lesion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dilated pores	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lower gastrointestinal perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Low density lipoprotein	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Low anterior resection syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Digital pulpitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Digestive enzyme abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diffuse uveal melanocytic proliferation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute graft versus host disease in eye	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Application site eczema	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Loss of bladder sensation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Loss of CAR T-cell persistence	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lordosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Long-chain acyl-coenzyme A dehydrogenase deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diffuse large B-cell lymphoma stage III	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Loefgren syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diffuse large B-cell lymphoma stage I	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Loeffler's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alice in wonderland syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Localised lipodystrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bone graft removal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diffuse idiopathic pulmonary neuroendocrine cell hype	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Liver tenderness	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Liver sarcoidosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bone giant cell tumour malignant	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Liver iron concentration increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Alexithymia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone giant cell tumour benign	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Diet noncompliance	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dientamoeba infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Diastolic hypotension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Liposarcoma recurrent	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Liposarcoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diastema	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lipoprotein increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lipoprotein abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lipomatosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Application site cellulitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lipoma of breast	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lipoma excision	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lipogranuloma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abscess of salivary gland	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Alcoholic seizure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diaphragmatic operation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lipase decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone densitometry	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diaphragm muscle weakness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Lip neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alcoholic pancreatitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dialysis efficacy test abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dialysis device insertion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diabetic wound	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lip and/or oral cavity cancer recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bone cement implantation syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Limbal swelling	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Limbal stem cell deficiency	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diabetic microangiopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Limb prosthesis user	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diabetic macroangiopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic hyperglycaemic coma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic hepatopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Alcoholic ketoacidosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic gastropathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Light chain analysis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic gangrene	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic dermopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute fatty liver of pregnancy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lichen myxoedematosus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetes mellitus management	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lice infestation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Leukotriene increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Leukoplakia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alcoholic coma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Body modification	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Device user interface issue	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Leukapheresis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Leukaemic retinopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Leukaemic lymphoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Appendiceal mucocoele	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Leukaemic infiltration renal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Leukaemia in remission	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Acute endocarditis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Leukaemia granulocytic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Leriche syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lens extraction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lens disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lens dislocation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lens discolouration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Device optical issue	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lemmel's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lemierre syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Legionella test positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Device material opacification	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Left atrial volume increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blue toe syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Device lead issue	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Left atrial volume abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Device intolerance	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Latent syphilis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Apolipoprotein E abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bloodborne infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laser brain ablation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lasegue's test negative	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Larynx irritation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Device extrusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngoscopy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood volume expansion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Device environmental compatibility issue	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Laryngectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Device embolisation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Laryngeal ulceration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Laryngeal squamous cell carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngeal repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Device effect decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngeal operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alcohol septal ablation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Laryngeal leukoplakia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngeal haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngeal haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Laryngeal erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngeal cancer stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Device chemical property issue	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Large for dates baby	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Large cell lung cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Developmental coordination disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lactation puerperal increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Detoxification	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lactate pyruvate ratio increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Detachment of macular retinal pigment epithelium	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lacrima structural disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lacrima disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lacrima atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lack of application site rotation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Labour pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Apheresis related complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dermatophytosis of nail	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Labour complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
LDL/HDL ratio decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dermatitis herpetiformis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Knuckle pads	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood test normal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Kleefstra syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Kidney rupture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Kidney malformation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood stem cell harvest	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Kidney duplex	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Kidney contusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aorto-oesophageal fistula	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dermal absorption increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ketogenic diet	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Depressive delusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Keratolysis exfoliativa acquired	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood selenium decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Deposit eye	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Juvenile spondyloarthritis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dependent personality disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Jugular vein haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Denture wearer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood pressure systolic inspiratory decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dental root perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint resurfacing surgery	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint manipulation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint laxity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint irrigation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint impingement	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Joint dislocation reduction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood pressure orthostatic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acute biphenotypic leukaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dengue haemorrhagic fever	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood pressure management	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Jejunectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Janus kinase 2 mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Jamestown Canyon encephalitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Isosporiasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood pressure difference of extremities	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ischaemic skin ulcer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ischaemic pancreatitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acute aseptic arthritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Delusional disorder, mixed type	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Delusion of theft	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ischaemic demyelination	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Delusion of replacement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iron binding capacity unsaturated decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iron binding capacity total increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Aortic root enlargement procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood pressure ambulatory abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iron binding capacity total abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iris haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aortic pseudoaneurysm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iris cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iris bombe	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Yersinia test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Delayed haematopoietic reconstitution	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Iodine overload	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Involuntary commitment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Xeroderma pigmentosum	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Investigation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
X-ray gastrointestinal tract abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Acute aortic syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Delayed dark adaptation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Wrong product stored	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aortic intramural haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intrinsic factor deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Wound infection fungal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aortic injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Degeneration of uterine leiomyoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intrapericardial thrombosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Wound haematoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intraocular pressure decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Wolfram syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Deficiency of bile secretion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intranasal hypoaesthesia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Withdrawal of life support	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Deficiency anaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Wiskott-Aldrich syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aortic embolus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood parathyroid hormone abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intraductal papillary-mucinous carcinoma of pancreas	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Winged scapula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
White blood cells urine abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
White blood cells stool positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood pH increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
White blood cell morphology abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
White blood cell analysis abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intracranial germ cell tumour	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
West Nile virus test negative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intracranial artery dissection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Wernicke-Korsakoff syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood pH abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Intracardiac pressure increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Weight control	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intra-uterine contraceptive device removal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Waxy flexibility	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Waterhouse-Friderichsen syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Warm autoimmune haemolytic anaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Decreased nasolabial fold	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Walled-off pancreatic necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Waist circumference decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Waist circumference	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intra-abdominal haemangioma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Wagner's disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intra-abdominal calcification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intestinal tuberculosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vulvovaginal exfoliation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Decreased bronchial secretion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intestinal transit time increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intestinal strangulation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intestinal steatosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vulval neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vulval leukoplakia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vulval cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intestinal prolapse	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vulval cancer stage 0	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vth nerve injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood methaemoglobin	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Decompressive craniectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Von Willebrand's factor activity abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aortic bypass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Von Hippel-Lindau disease	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Volvulus of small bowel	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vocal cord paresis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Decerebrate posture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vocal cord operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute HIV infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vocal cord atrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Intestinal intraepithelial lymphocytes increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vitreous fibrin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Intestinal haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vitreous adhesions	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood magnesium	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vitreoretinal traction syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intestinal fistula repair	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vitamin K decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood luteinising hormone decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vitamin B12 absorption test normal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Intestinal atony	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood luteinising hormone abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intestinal anastomosis complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vitamin A abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intestinal adenocarcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Visual field tests abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Visceroptosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Visceral venous thrombosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Visceral pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intervertebral disc calcification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Viral titre decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Interventricular septum rupture	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Viral sepsis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dacryoadenitis acquired	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intersection syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood lactic acid	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Viral labyrinthitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Viral cardiomyopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
DNA antibody negative	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
International normalised ratio	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vibration syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vestibular migraine	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cytoreductive surgery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vessel puncture site swelling	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cytophagic histiocytic panniculitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vessel puncture site injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vessel puncture site haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vessel puncture site discolouration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vessel puncture site bruise	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vessel perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Interleukin level decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vesicocutaneous fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cytomegalovirus urinary tract infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intercostal neuralgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Antral follicle count low	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vertebrobasilar dolichoectasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vertebral artery hypoplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vertebral artery aneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Verbal abuse	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Ventriculo-peritoneal shunt	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ventricular remodelling	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ventricular internal diameter abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antiviral treatment	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intentional removal of drug delivery system by patien	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ventricular hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ventricular flutter	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cytomegalovirus gastroenteritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Intentional product misuse to child	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ventricular dyskinesia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ventricular cisternostomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ventricular assist device insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ventricle rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Venous stent insertion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Venous stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Venous repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intensive care unit delirium	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Venous oxygen saturation increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Venous intravasation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intelligence test abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Venous hypertension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antiviral drug level above therapeutic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Venomous sting	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Venogram abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vena cava injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vena cava embolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Velo-cardio-facial syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Antithyroid arthritis syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Insulin-like growth factor	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Insulin C-peptide increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood immunoglobulin M abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vascular stent insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular rings and slings	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Instillation site erythema	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vascular resistance systemic increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antithrombin III increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood immunoglobulin M	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cystoscopy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Instillation site complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular pseudoaneurysm thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular graft infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular fragility	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular dissection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular cognitive impairment	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular catheterisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vascular anastomosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vascular access site thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular access site rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular access site pruritus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood immunoglobulin G	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular access site occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular access site laceration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular access site inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular access site infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular access site erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Vascular access device culture negative	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site phlebitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood immunoglobulin E decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Injection site panniculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Varicella post vaccine	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood immunoglobulin E abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Varicella encephalitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vanishing twin syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vanillyl mandelic acid urine increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Activated partial thromboplastin time abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaginitis chlamydial	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vaginal wall congestion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cystic fibrosis lung	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vaginal ring placement	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Injection site macule	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaginal pH abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vaginal operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood immunoglobulin D increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vaginal necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaginal mucosal blistering	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cystatin C abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Injection site ischaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cyst drainage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vaccination site warmth	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaccination site vesicles	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vaccination site pruritus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaccination site paraesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Aggregatibacter infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood homocysteine increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vaccination site oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaccination site mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaccination site haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cyclitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaccination site discomfort	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaccination site discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vaccination site bruising	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vaccination error	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cyclic neutropenia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
VIIth nerve injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
VACTERL syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Uvulitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Uveitic glaucoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Uveal melanoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood growth hormone abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Uterine stenosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site deformation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Action tremor	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Uterine prolapse repair	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Uterine polypectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cutibacterium acnes infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Injection site calcification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Uterine operation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Uterine malposition	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Uterine injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Uterine fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Inhibiting antibodies positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Uterine cervix ulcer	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Uterine cervix canal atresia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Inguinal hernia, obstructive	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Uterine cervical laceration	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood glucose	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urticaria cholinergic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urostomy complication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood glucagon abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urogenital infection bacterial	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urogenital disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urobilinogen urine decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Urine viscosity increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urine viscosity abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cutaneous amyloidosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine uric acid increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine uric acid abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine protein/creatinine ratio	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infusion site pustule	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine output	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cutaneous T-cell lymphoma stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infusion site phlebitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine osmolarity increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urine magnesium increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urine ketone body	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Urine iodine increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood follicle stimulating hormone decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine electrolytes increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine calcium	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urine amphetamine positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood follicle stimulating hormone abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine albumin/creatinine ratio decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary tract toxicity	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Urinary tract procedural complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Culture throat positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Culture stool positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infusion site hypoaesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary straining	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Culture stool negative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infusion site hyperaesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary sediment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antineutrophil cytoplasmic antibody negative	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urinary control neurostimulator implantation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infusion site dysaesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary bladder sarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary bladder herniation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary bladder haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary bladder adenoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Urinary bladder abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary ascites	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood fibrinogen abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urethritis chlamydial	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urethral repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Urethral polyp	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood fibrinogen	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urethral operation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Urethral intrinsic sphincter deficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Actinomyces test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aerophagia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urethral fistula	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Urethral discharge	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urethral dilation procedure	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Urethral abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ureteric injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ureteric fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood erythropoietin decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Influenza A virus test	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ureteral stent removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ureteral neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urea renal clearance decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood erythropoietin abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urea cycle disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urate nephropathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aeromonas test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood electrolytes increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Inflammation scan	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Upper gastrointestinal perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Inferior vena caval occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Inferior vena cava stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Unknown schedule of product administration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Unhealthy lifestyle	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Unevaluable therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Crossmatch incompatible	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Umbilical cord compression	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Umbilical cord around neck	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Infective exacerbation of bronchiectasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Umbilical cord abnormality	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ultrasound thyroid abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ultrasound ovary abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ultrasound liver	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ultrasound kidney abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antidiuretic hormone abnormality	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infectious thyroiditis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ultrasound foetal abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ultrasound antenatal screen abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ultrasound antenatal screen	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ulnar tunnel syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Creatinine renal clearance normal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Infected varicose vein	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Type IIa hyperlipidaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infected lymphocele	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Type II hypersensitivity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Type 3 diabetes mellitus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tympanosclerosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tympanomastoidectomy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tympanic membrane disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tumour response assessment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Tumour obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Craniofacial injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Induced abortion failed	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Indolent systemic mastocytosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tumour fistulisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Actinic elastosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tumour biopsy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cranial operation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Increased steroid activity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tuberous sclerosis complex	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Increased liver stiffness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Increased intraperitoneal volume	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tuberculoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Trunk injury	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cranial nerve decompression	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Troponin decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Incorrect product dosage form administered	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tropical eosinophilia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Trigonitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Trigeminal palsy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Trigeminal neuropathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Trigeminal nerve disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Trifascicular block	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tricuspid valve thickening	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Incomplete spinal fusion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Costochondral separation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tri-iodothyronine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tri-iodothyronine abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Corynebacterium test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Treponema test false positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tremor neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Incision site inflammation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Trematode infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Acrophobia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Incision site hypoaesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Traumatic ulcer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Traumatic torticollis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood corticotrophin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Traumatic heart injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Traumatic delivery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Traumatic arthropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Traumatic amputation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transverse presentation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood copper decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Incarcerated parastomal hernia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transvalvular pressure gradient decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transurethral bladder resection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Incarcerated hiatus hernia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Transsphenoidal surgery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Inborn error of amino acid metabolism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Transmission of an infectious agent via product	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transitional cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Inappropriate release of product for distribution	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Transient lingual papillitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Transient aphasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood cholinesterase increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coronary vein stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transfusion related complication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Coronary vascular graft occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Inability to crawl	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Transferrin saturation abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transferrin receptor increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coronary artery surgery	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Transaminases decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anticoagulation drug level abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Transaminases	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Trance	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tracheostomy tube removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Implantable defibrillator replacement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tracheostomy closure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Coronary artery perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Implantable cardiac monitor removal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tracheobronchitis bacterial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Implant site warmth	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tracheal pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Implant site vesicles	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tracheal operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Implant site urticaria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tracheal inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tracheal atresia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Implant site pruritus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Toxoplasma serology positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Implant site paraesthesia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Implant site oedema	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anticipatory anxiety	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cornelia de Lange syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Implant site induration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Total complement activity decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Corneal thickening	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Implant site dermatitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tooth hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Corneal scar	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
5-hydroxyindolacetic acid in urine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Implant site abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood catecholamines abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tooth demineralisation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tooth agenesis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acrodynia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adult T-cell lymphoma/leukaemia recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood carbon monoxide increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tonsillitis streptococcal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tonsillar exudate	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tonsillar erythema	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood carbon monoxide abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tonsillar cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tongue tie operation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tongue thrust	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Corneal irritation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tongue operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immunology test	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tongue necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adult T-cell lymphoma/leukaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Corneal graft rejection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tongue dysplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tongue cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tongue cancer recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune-mediated scleritis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tongue abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Toe walking	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Corneal epithelial downgrowth	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tobacco withdrawal symptoms	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Corneal endotheliitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood calcitonin decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tissue expansion procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acrochordon excision	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tidal volume abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Antibiotic level below therapeutic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tick-borne fever	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune-mediated myelitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Corneal defect	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid tuberculosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid stimulating immunoglobulin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid stimulating hormone deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid dermatopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Adrenogenital syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroglobulin decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thymoma malignant	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thrombosis with thrombocytopenia syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune effector cell encephalopathy score	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thrombosed varicose vein	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coombs test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Immobilisation bandage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Thrombolysis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood bicarbonate abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thromboangiitis obliterans	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Immature granulocyte count	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Coombs indirect test negative	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Imaging procedure artifact	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood beta-D-glucan positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Threat of redundancy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thought insertion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Illogical thinking	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thoracic haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Third degree chemical burn of skin	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood antidiuretic hormone decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thermohypoaesthesia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Iliac artery rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iliac artery arteriosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Therapeutic embolisation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anti-thyroid antibody decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Theft	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Thanatophobia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thalassaemia beta	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Contrast echocardiogram	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thalamic stroke	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Testicular yolk sac tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acral overgrowth	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adrenergic syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood aldosterone increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Idiopathic pancreatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Testicular rupture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Testicular operation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Testicular oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Testicular microlithiasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Testicular infarction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Testicular hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Testicular germ cell tumour mixed	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Testicular germ cell cancer metastatic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Testicular embryonal carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Continuous glucose monitoring	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Testicular cancer metastatic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tertiary adrenal insufficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Contact stomatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Iatrogenic infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tenonectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti-platelet antibody	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Constricted affect	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hysterotomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tenon's capsule thickening	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hysterosalpingo-oophorectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tendon dislocation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hypoxanthine-guanine phosphoribosyl transferase defic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Temporomandibular joint surgery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Temperature perception test abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypotony maculopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood 25-hydroxycholecalciferol increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tear discolouration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hypotonic-hyporesponsive episode	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tattoo associated skin reaction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypotonic urinary bladder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tarsal tunnel decompression	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acral lentiginous melanoma stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adrenalectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti-neuronal antibody positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Conjunctivalisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tandem gait test abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Coronary artery restenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Conjunctival ulcer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Taciturnity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypothalamic hamartoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tachycardia paroxysmal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
TP53 gene mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti-melanoma differentiation-associated protein 5 an	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hyposplenism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
TET2 gene mutation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
T-cell prolymphocytic leukaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Block vertebra	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Conjunctival papillae	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
T-cell lymphoma refractory	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
T-cell lymphoma recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adrenal thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bloch-Sulzberger syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Systemic sclerosis pulmonary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hypopigmentation of eyelid	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Systemic bacterial infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Synovial fluid white blood cells positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti-erythrocyte antibody positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Conjunctival follicles	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypopharyngeal cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Conjunctival filtering bleb leak	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acral lentiginous melanoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Sympathomimetic effect	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sympathetic posterior cervical syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sympathetic ophthalmia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sympathetic nerve destruction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Conjunctival discolouration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Swollen tear duct	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Conjunctival cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sweat test abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sweat gland excision	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Suture removal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Congenital uterine anomaly	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital urethral anomaly	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Transurethral prostatectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blindness cortical	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Congenital umbilical hernia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Susac's syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Surgical stapling	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti-complement antibody	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Surgical skin tear	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypoglossal nerve paresis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Supplementation therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital thrombocyte disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Supernumerary teeth	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Superior vena cava occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital scoliosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Superior vena cava dilatation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Superior semicircular canal dehiscence	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital renal cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Superior mesenteric artery syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Congenital pulmonary airway malformation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypochromasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Superimposed pre-eclampsia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital perforated nasal septum	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Superficial spreading melanoma stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blepharitis allergic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital oral malformation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypocalcaemic seizure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti-JC virus antibody index	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital neurological disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sudden infant death syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Congenital musculoskeletal disorder of limbs	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Substance-induced mood disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypnopompic hallucination	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Subretinal hyperreflective exudation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anti-HLA antibody test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Submaxillary gland enlargement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital midline defect	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Submandibular abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypervitaminosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Subendocardial ischaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital megacolon	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Subendocardial haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital laryngeal stridor	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Subdural haematoma evacuation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital hypothyroidism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Subcutaneous biopsy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adrenal insufficiency neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bleeding time abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Congenital hydronephrosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Subclavian vein occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Subclavian arteriosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blau syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital genital malformation female	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypertonia neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Subcapsular hepatic haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Subarachnoid abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital genital malformation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Subacute kidney injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Subacute hepatic failure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital eye disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Subacute combined cord degeneration	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Troponin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Acquired syringomyelia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Struck by lightning	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Strongyloides test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypertensive hydrocephalus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Congenital choroid plexus cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypertensive cardiomyopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypertension neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Streptobacillary fever	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital brain damage	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Strangulated hernia repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Strangulated hernia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Congenital arterial occlusion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Stool analysis abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blast cells	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stomatococcus test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Stomatococcal infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital aortic valve incompetence	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Congenital aortic atresia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Stoma site paraesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anti factor IX antibody positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Stoma site ischaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperplastic cholecystopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stoma site hypersensitivity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Confusional arousal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperpituitarism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blast cell count decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Confusion postoperative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Confabulation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cone-rod dystrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stoma hernia repair	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bladder transitional cell carcinoma stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypermutation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal rebound tenderness	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abortion induced incomplete	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired right ventricle outflow obstruction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Steroid therapy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anti B antibody positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bladder transitional cell carcinoma recurrent	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Stereotactic electroencephalography	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Stent malfunction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stenotrophomonas maltophilia pneumonia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stenotrophomonas bacteraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stauffer's syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperkeratosis follicularis et parafollicularis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bladder trabeculation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Status dystonicus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Stasis syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperkaliuria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperinsulinism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Staphylococcal scalded skin syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Staphylococcal osteomyelitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Squamous cell carcinoma of the vulva	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperglycinaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Squamous cell carcinoma of the oral cavity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Computerised tomogram kidney abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperglycaemic unconsciousness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Squamous cell carcinoma of the cervix	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperglycaemic seizure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperglycaemic crisis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypergeusia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Computerised tomogram head	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sputum decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Sputum culture	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Spur cell anaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperfibrinolysis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sporotrichosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spontaneous heparin-induced thrombocytopenia syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired protein S deficiency	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spontaneous ejaculation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spontaneous cerebrospinal fluid leak syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Compulsive handwashing	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Splinter haemorrhages	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Splenic vein occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypercatabolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Splenic haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperbilirubinaemia neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spleen tuberculosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spleen contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Spleen atrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperandrogenism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spinal subdural haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Spinal subarachnoid haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bladder neck obstruction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hyperalbuminaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Spinal myelogram	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Spinal meningioma benign	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Spinal meningeal cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Complication of delivery	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spinal implantation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood cyanide increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Umbilical discharge	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spinal fusion fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Spinal epidural haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bladder leukoplakia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Complicated fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hydrops foetalis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Acquired plagiocephaly	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spinal corpectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hydromyelia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Spinal cord ischaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hydrocele operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bladder injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Complement factor increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spinal artery thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Spinal anaesthesia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spherocytic anaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Human placental lactogen increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spermatozoa progressive motility decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spermatogenesis abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Crush injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Complement deficiency disease	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Speech rehabilitation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Adrenal cortex necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anovulatory cycle	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Specific gravity urine increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Specialist consultation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Somatostatin receptor scan abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Somatic symptom disorder of pregnancy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Somatic dysfunction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Human chorionic gonadotropin abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Solid pseudopapillary tumour of the pancreas	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Solid organ transplant rejection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Combined immunodeficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acquired phimosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adrenal atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Huerthle cell carcinoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Social fear	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hormone-dependent prostate cancer	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Snake bite	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Smegma accumulation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urea urine abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Small intestine operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Colostomy infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hookworm infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bladder catheter permanent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Small intestinal ulcer perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Home care	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hodgkin's disease stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bladder cancer stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Colorectal cancer stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Small cell lung cancer recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cryptococcal meningoencephalitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Small cell carcinoma of the cervix	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Small airways disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anorexia nervosa	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Histiocytic necrotising lymphadenitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Slipping rib syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Histamine intolerance	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sleep study abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anorexia and bulimia syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bladder calculus removal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abortion incomplete	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bizarre personal appearance	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skull base tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
High frequency ablation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Skin squamous cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Heyde's syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anorectal ulcer	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Heteroplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Skin maceration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Heterophoria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Skin lesion removal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Heteronymous diplopia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Skin laxity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Colon cancer stage III	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Skin hyperplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Herpes zoster immunisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Skin graft infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Skin graft failure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary bladder atrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Biphasic mesothelioma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anorectal stenosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy vulva abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Herpes simplex pneumonia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Herpes simplex meningoencephalitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Skin adhesion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biopsy thyroid gland	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Herpes pharyngitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Herpangina	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sinuplasty	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Biopsy stomach abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hernia perforation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sinobronchitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Simple mastectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Signet-ring cell carcinoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sigmoidoscopy abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sigmoid sinus thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hereditary retinal dystrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sideroblastic anaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hereditary non-polyposis colorectal cancer syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biopsy skin	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sickle cell anaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hereditary haemochromatosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sialic acid increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hereditary disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cold agglutinins positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Shoulder dystocia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy rectum	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Shoshin beriberi	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Short-chain acyl-coenzyme A dehydrogenase deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Shigella infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Shift work disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Shagreen skin	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cogan's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sexual transmission of infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sexual life impairment	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sexual abuse	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Biopsy pancreas abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatoblastoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sex hormone binding globulin decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coeliac artery compression syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepato-lenticular degeneration	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy mucosa abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Serum serotonin	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Serum procollagen type I N-terminal propeptide decrea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hepatitis non-A non-B	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis infectious mononucleosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis immunisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Serratia test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy lymph gland abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Coccygectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Serratia sepsis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Serology positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Serology abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Serial transverse enteroplasty	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biopsy lung abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hepatitis D	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Septic endocarditis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Septic coagulopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cutaneous blastomycosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infusion site streaking	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Coagulation time shortened	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis C antibody positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Septic arthritis streptococcal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anogenital dysplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis C RNA increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis C RNA	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Separation anxiety disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sensory overload	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy liver abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis B test negative	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sensory level abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis B surface antigen	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Sensation of blood flow	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Annuloplasty	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biopsy liver	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis B core antigen positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Senile pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Coagulation factor XIII level decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Semen viscosity abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis B antibody abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy kidney abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis B DNA increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Semen analysis abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Inhalation therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Self-induced vomiting	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Administration site urticaria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis A antibody positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Self esteem inflated	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis A antibody abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biopsy cornea	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Coagulation factor IX level decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis A antibody	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy breast	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Secondary tic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic vein occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Secondary thrombocytosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Secondary hyperthyroidism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sebaceous hyperplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sebaceous gland disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sebaceous carcinoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Scrub typhus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Scrotum erosion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Scrotal pain	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatic infiltration eosinophilic	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy bone abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scrotal mass	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Scrotal irritation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Scrotal haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scrotal haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scrotal erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic hypoperfusion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Scrotal disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biopsy bone	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic hypertrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scrotal dermatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
ACTH-producing pituitary tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abdominal bruit	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hepatic haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Clitoris abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Clinically isolated syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sclerema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Scleral pigmentation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic embolisation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scleral deposits	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic dysplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cleft lip	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Schizotypal personality disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Schizophreniform disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Schimke immunosseous dysplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatic cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scar inflammation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Scar discomfort	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site fibrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Citrobacter test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Scan myocardial perfusion abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scalloped tongue	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anisomastia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bing-Neel syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Citrobacter sepsis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sarcopenic obesity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic artery occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sarcomatoid carcinoma of the lung	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sarcoma uterus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic artery flow decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Sarcoma of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hepatic angiosarcoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Biloma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatic amoebiasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sarcoidosis of lymph node	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sapovirus infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Salt intoxication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Salt craving	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Heparin-induced thrombocytopenia test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salpingo-oophorectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bilirubin urine	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Salpingitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired growth hormone resistance	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salivary gland operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salivary gland fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hemidysaesthesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salivary gland cyst	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site lymphadenopathy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cinchonism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anisochromia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bilirubin conjugated	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ciliary body haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
SARS-CoV-2 test false positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
SARS-CoV-2 RNA	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Biliary tract operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chvostek's sign	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
SARS-CoV-1 test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rubulavirus test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chronic traumatic encephalopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Routine health maintenance	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rotavirus test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Heat oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Roseolovirus test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rosai-Dorfman syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Heart-type fatty acid-binding protein increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Romberg test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chronic rhinosinusitis without nasal polyps	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Right ventricular systolic pressure decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Right ventricular systolic pressure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Right ventricular hypertension	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Heart transplant failure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rickettsiosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rhythm idioventricular	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abnormal withdrawal bleeding	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired generalised lipodystrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Heart rate variability decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anion gap abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biliary neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Chronic pigmented purpura	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Rhinophyma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rheumatoid pleuritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Rheumatoid factor	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rhesus antibodies	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biliary dyskinesia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Reversible ischaemic neurological deficit	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chronic lymphocytic leukaemia stage 4	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Reverse tri-iodothyronine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Head and neck cancer metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retroperitoneal mass	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Head and neck cancer	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Retroperitoneal infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vascular access site warmth	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Harlequin skin reaction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Biliary catheter insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retinopathy haemorrhagic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Administration site odour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bile output increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anicteric leptospirosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chronic granulomatous disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hallucination, gustatory	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bile duct cancer recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Chronic graft versus host disease in lung	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hair growth rate abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Administration site necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hair follicle tumour benign	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Retained placenta or membranes	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chronic graft versus host disease in intestine	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Restless leg augmentation syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Restenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Haemosiderin stain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Respirovirus test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Respiratory tract procedural complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Respiratory tract infection fungal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemorrhagic vasculitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemorrhagic urticaria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chronic eosinophilic leukaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Haemorrhagic pneumonia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Respiratory sinus arrhythmia magnitude	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemorrhagic fever	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Respiratory fatigue	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Instillation site infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chronic cheek biting	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haemorrhagic cholecystitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Haemorrhagic cerebellar infarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Haemorrhagic arteriovenous malformation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renin decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Renal vein occlusion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bezold-Jarisch reflex	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Chromophobe renal cell carcinoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal vein compression	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haemophilic pseudotumour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haemophilia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal procedural complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Choroidal rupture	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Renal papillary necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Angiotensin converting enzyme decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Beta 2 microglobulin urine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Choroidal infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Renal hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Renal hypertrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haemoglobinuria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal hydrocele	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemoglobin urine	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Renal glycosuria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Insulin-requiring type 2 diabetes mellitus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal fusion anomaly	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired epidermolysis bullosa	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Angiosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Choroid neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal disorder in pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal cyst ruptured	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemodialysis complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal cyst aspiration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal cell carcinoma stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chorioretinopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal cell carcinoma stage I	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal cancer stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chorioretinal disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Renal artery stent placement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chorioamniotic separation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haematosalpinx	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal artery embolisation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign soft tissue neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Renal artery dissection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haematopoietic neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal arteritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Administration site injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Renal aneurysm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Removal of internal fixation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign small intestinal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chondrosarcoma metastatic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Benign renal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chondroporosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Refusal of treatment by relative	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Reflux nephropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haematuria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haematidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Red ear syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Benign pancreatic neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Red cell distribution width	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Choluria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Red blood cell spherocytes present	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Benign pancreatic hyperenzymaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haemangioma embolisation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Haemangioblastoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Habitual abortion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Red blood cell macrocytes present	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cholesterosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
HTLV-2 test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Red blood cell count	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
HTLV-1 test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Red blood cell burr cells present	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rectourethral fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rectal obstruction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
HIV antibody positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Rectal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
HER2 positive gastric cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rectal lesion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cholelithiasis obstructive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
HER2 mutant non-small cell lung cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rectal cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cholelithiasis migration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign neoplasm of eye	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
HCoV-NL63 infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign neoplasm of bladder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cholecystostomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
H3N2 influenza	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Reaction to preservatives	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Reaction to food additive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Reaction to flavouring	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Grunting	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rash scarlatiniform	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rash follicular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Growing teratoma syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Rapidly progressive osteoarthritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cholangitis chronic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rapid correction of hyponatraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Radioisotope uptake increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radioactive iodine therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign joint neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cholangiolitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Radiation thyroiditis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Radiation overdose	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Administration site indentation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Benign hydatidiform mole	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cholangiectasis acquired	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radiation myelopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Radiation induced fatigue	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radiation dysphagia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radiation associated haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radial head dislocation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Quarantine	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Granulocytes abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Granulocyte percentage increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pyopneumothorax	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired asplenia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chlamydia test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Granular cell tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Grandiosity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chimerism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign ethnic neutropenia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pus in stool	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Purple glove syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Purines abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Benign enlargement of the subarachnoid spaces	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Childhood asthma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Purging	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pure white cell aplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Graft overgrowth	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Puncture site reaction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Puncture site pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Puncture site oedema	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Administration site haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chikungunya virus infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Puncture site infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cheyne-Stokes respiration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Puncture site haematoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Chest wall tumour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pulse volume decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulse pressure increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Benign bone neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chest wall necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Good syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulse pressure decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Goniotomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Benign anorectal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gonadal dysgenesis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bendopnoea	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chest scan abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary sensitisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chest expansion decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Glucose-6-phosphate dehydrogenase deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Glucose tolerance impaired in pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary hypoperfusion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aneurysm repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chest crushing	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary hilum mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary hilar enlargement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary haemorrhage neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary function test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chemotherapeutic drug level decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary bullectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Glomerulonephritis chronic	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary artery stenosis congenital	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anencephaly	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Glomerular vascular disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary artery atresia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary arteriopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Glomerular filtration rate	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary ablation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Basosquamous carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chemical burn of skin	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Globulin abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pudendal canal syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Chemical burn of oral cavity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acquired ATTR amyloidosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Administration site dryness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Basophilia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Global longitudinal strain abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Global longitudinal strain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Psychological factor affecting medical condition	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Psychological abuse	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Psychogenic blindness	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cheilosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Psychiatric evaluation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Basophil percentage decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cheilitis granulomatosa	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Glaucomatous optic neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Checkpoint kinase 2 gene mutation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pseudomonas peritonitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudomonas bronchitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Administration site discomfort	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Androgens decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Charcot-Leyden crystals	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudohyponatraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudogynaecomastia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Basophil count abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudocholinesterase deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gingival oedema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudocellulitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gingival hyperpigmentation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Proximal focal femoral deficiency	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gingival erosion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prothrombin time abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Basilar artery occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cervix scarring	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prothrombin level abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gingival cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prothrombin index	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Base excess abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cervix inflammation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intestinal polypectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gingival atrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Protein total	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Protein intolerance	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Protein S increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Giant papillary conjunctivitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Protein C decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cervix carcinoma stage II	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Giant cell epulis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Prosthetic valve endocarditis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anastomotic ulcer haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prosthetic tracheal reconstruction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gianotti-Crosti syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Prosthetic cardiac valve failure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gestational trophoblastic detachment	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prostatism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Decreased eye contact	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Basal ganglia infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cervix carcinoma recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Germ cell neoplasm	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Administration site discharge	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Germ cell cancer	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Prostatic cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prostatic adenoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cervicogenic headache	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Genitourinary operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Basal cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prostate cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Genito-pelvic pain/penetration disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prostate cancer stage II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prostaglandin analogue periorbitopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prosopagnosia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Propulsive gait	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prohormone brain natriuretic peptide abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abnormal organ growth	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bartter's syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Genital labial adhesions	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Progressive supranuclear palsy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Progesterone receptor assay positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Progesterone increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Progesterone abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cervical discharge	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Genital hyperaesthesia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cervical dilatation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Genital herpes simplex	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Product substitution error	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bartholin's cyst removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Genital disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ceruloplasmin decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Genital discharge	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Genital cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Product packaging counterfeit	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bartholin's abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebrovascular pseudoaneurysm	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Genetic polymorphism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anastomotic complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebrovascular arteriovenous malformation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Product identification number issue	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Product gel formation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acne fulminans	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Barrel chest	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cerebrospinal fluid reservoir placement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Barotrauma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Barotitis media	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrostomy tube removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Product barcode issue	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gastrorrhaphy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastroparesis postoperative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adjuvant therapy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Product administered from unauthorised provider	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastroesophageal cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Proctitis gonococcal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebral revascularisation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Procoagulant therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cerebral reperfusion injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anaphylactic transfusion reaction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Balanitis candida	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cerebral radiation injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal tube removal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Procalcitonin decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Probiotic therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Primitive reflex test	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Primary pulmonary melanoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Primary progressive multiple sclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Primary progressive aphasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Primary mediastinal large B-cell lymphoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Primary hypogonadism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Primary hyperthyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Primary familial brain calcification	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Primary effusion lymphoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Primary cough headache	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Primary breast lymphoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intrapulmonary lymphadenopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cerebral lobotomy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Prevertebral soft tissue swelling of cervical space	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prescription form tampering	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prepuce redundant	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anamnestic reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal organ contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Premature recovery from anaesthesia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Preictal state	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pregnancy with young maternal age	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastrointestinal mucosal necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pregnancy with contraceptive patch	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pregnancy related infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cerebral cavernous malformation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gastrointestinal melanoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gastrointestinal malformation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Preauricular cyst	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prealbumin decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prader-Willi syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Poverty of thought content	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bacterial toxemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Potter's syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Postresuscitation encephalopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Postpartum uterine subinvolution	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Postpartum thrombosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Postpartum anxiety	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gastrointestinal disorder therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Analgesic drug level above therapeutic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Postoperative thoracic procedure complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal dilation procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Postoperative hypertension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bacterial rhinitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Postnatal growth restriction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Adjusted calcium increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Postmenopause	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Postmastectomy lymphoedema syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Reaction Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Posterior capsule rupture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Post-tussive vomiting	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bacterial prostatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal anastomotic complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Post-depletion B-cell recovery	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
11-deoxycorticosterone increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bacterial pericarditis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastroenteritis yersinia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post vaccination syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post stroke seizure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
ACTH stimulation test abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abdominal migraine	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastroenteritis shigella	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Post procedural stroke	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Post procedural hypothyroidism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cerebellar calcification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastroenteritis proteus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Outcome Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
DE	1042 (5.1%)	2967 (14.6%)	9734 (47.8%)	6618 (32.5%)	20361
LT	1260 (12.1%)	2777 (26.7%)	4783 (46.0%)	1579 (15.2%)	10399
HO	6292 (10.2%)	12992 (21.0%)	30802 (49.7%)	11828 (19.1%)	61914
DS	332 (8.1%)	1458 (35.5%)	1762 (42.9%)	552 (13.5%)	4104
CA	200 (49.0%)	127 (31.1%)	52 (12.7%)	29 (7.1%)	408
RI	103 (11.3%)	311 (34.0%)	397 (43.4%)	103 (11.3%)	914
OT	11393 (10.8%)	25993 (24.6%)	51032 (48.3%)	17321 (16.4%)	105739

Report Source Summary Table

Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
FGN	10 (12.0%)	37 (44.6%)	34 (41.0%)	2 (2.4%)	83
SDY	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0
LIT	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
CSM	243 (10.8%)	808 (35.9%)	1003 (44.6%)	196 (8.7%)	2250
HP	429 (6.3%)	1351 (19.8%)	3731 (54.8%)	1299 (19.1%)	6810
UF	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0
CR	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0
DT	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0
OTH	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0

Therapy Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
N	39719	100087	228377	65139	433322
MEAN	434589.00	433377.19	421505.42	459862.73	431212.83
MEDIAN	1.00	1.00	1.00	1.00	1.00
GM	434589.00	433377.19	421505.42	459862.73	431212.83
MIN	1.00	0.00	0.00	0.00	0.00
MAX	20229195.0	20229191.0	20229207.0	20229197.0	20229207.0
STD	2918037.30	2911195.68	2874128.10	3001043.07	2906142.07
RANGE	1-20229195	0-20229191	0-20229207	0-20229197	0-20229207

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Product used for unknown indication	15315 (6.1%)	60980 (24.2%)	125112 (49.7%)	50400 (20.0%)	251807
Rheumatoid arthritis	234 (0.8%)	15760 (53.8%)	10996 (37.6%)	2282 (7.8%)	29272
Plasma cell myeloma	6 (0.0%)	959 (6.2%)	10436 (67.3%)	4109 (26.5%)	15510
Hypertension	253 (2.4%)	1183 (11.1%)	5611 (52.7%)	3608 (33.9%)	10655
Prophylaxis	912 (9.2%)	1737 (17.5%)	5493 (55.4%)	1766 (17.8%)	9908
Dermatitis atopic	2931 (30.9%)	2568 (27.1%)	3320 (35.0%)	655 (6.9%)	9474
Asthma	746 (10.4%)	1692 (23.6%)	3560 (49.6%)	1183 (16.5%)	7181
Diffuse large B-cell lymphoma	168 (2.9%)	1381 (23.6%)	3523 (60.1%)	791 (13.5%)	5863
Type 2 diabetes mellitus	90 (1.5%)	856 (14.7%)	3790 (65.0%)	1094 (18.8%)	5830
Psoriasis	275 (4.7%)	1907 (32.9%)	3179 (54.9%)	432 (7.5%)	5793
Crohn's disease	948 (16.8%)	2151 (38.2%)	2208 (39.2%)	322 (5.7%)	5629
Pain	460 (8.2%)	1359 (24.3%)	2400 (42.9%)	1370 (24.5%)	5589
Colitis ulcerative	597 (12.3%)	1841 (38.0%)	2093 (43.2%)	318 (6.6%)	4849
Breast cancer	14 (0.3%)	1251 (28.5%)	2699 (61.4%)	430 (9.8%)	4394
Psoriatic arthropathy	72 (1.7%)	1925 (44.5%)	2068 (47.8%)	265 (6.1%)	4330
Depression	485 (11.4%)	1439 (33.8%)	1962 (46.1%)	369 (8.7%)	4255
Migraine	289 (7.2%)	1956 (48.7%)	1694 (42.2%)	75 (1.9%)	4014
Prostate cancer	5 (0.1%)	22 (0.6%)	2117 (53.1%)	1845 (46.3%)	3989
Diabetes mellitus	55 (1.4%)	525 (13.7%)	2395 (62.3%)	867 (22.6%)	3842
Multiple sclerosis	195 (5.2%)	1915 (50.8%)	1600 (42.4%)	60 (1.6%)	3770
HIV infection	175 (4.7%)	1808 (48.5%)	1709 (45.8%)	38 (1.0%)	3730
Short-bowel syndrome	905 (25.5%)	719 (20.3%)	1710 (48.3%)	209 (5.9%)	3543
Schizophrenia	732 (20.7%)	1557 (44.0%)	1200 (33.9%)	52 (1.5%)	3541
Breast cancer metastatic	2 (0.1%)	654 (19.0%)	2201 (64.0%)	584 (17.0%)	3441
Pulmonary arterial hypertension	181 (5.3%)	728 (21.4%)	1818 (53.4%)	678 (19.9%)	3405
Acute myeloid leukaemia	382 (11.8%)	392 (12.1%)	1448 (44.8%)	1013 (31.3%)	3235
Immunosuppressant drug therapy	721 (23.0%)	1027 (32.7%)	1302 (41.5%)	91 (2.9%)	3141

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
COVID-19 treatment	35 (1.2%)	599 (21.4%)	1677 (59.9%)	490 (17.5%)	2801
Constipation	145 (5.3%)	213 (7.8%)	814 (29.7%)	1570 (57.3%)	2742
Premedication	176 (6.7%)	733 (27.8%)	1404 (53.2%)	324 (12.3%)	2637
Non-small cell lung cancer	8 (0.3%)	216 (8.5%)	1830 (71.8%)	495 (19.4%)	2549
Ill-defined disorder	204 (8.2%)	540 (21.6%)	1272 (50.9%)	484 (19.4%)	2500
Parkinson's disease	0 (0.0%)	50 (2.0%)	1461 (59.8%)	934 (38.2%)	2445
Blood cholesterol increased	3 (0.1%)	138 (6.0%)	1538 (67.2%)	610 (26.6%)	2289
Atrial fibrillation	0 (0.0%)	62 (2.8%)	1004 (44.6%)	1187 (52.7%)	2253
Eczema	805 (37.4%)	548 (25.5%)	671 (31.2%)	128 (5.9%)	2152
Gastroesophageal reflux disease	83 (4.1%)	384 (18.9%)	1210 (59.6%)	352 (17.3%)	2029
Insomnia	77 (3.8%)	438 (21.6%)	808 (39.9%)	702 (34.7%)	2025
Relapsing-remitting multiple sclerosis	99 (4.9%)	1323 (65.7%)	586 (29.1%)	6 (0.3%)	2014
Anxiety	265 (13.4%)	692 (34.9%)	830 (41.9%)	193 (9.7%)	1980
Chronic lymphocytic leukaemia	1 (0.1%)	42 (2.1%)	1267 (64.4%)	658 (33.4%)	1968
Epilepsy	705 (37.3%)	606 (32.0%)	472 (24.9%)	109 (5.8%)	1892
HER2 positive breast cancer	1 (0.1%)	815 (43.7%)	911 (48.8%)	139 (7.4%)	1866
Hepatocellular carcinoma	6 (0.3%)	211 (12.0%)	1151 (65.2%)	397 (22.5%)	1765
Triple negative breast cancer	0 (0.0%)	651 (38.1%)	979 (57.4%)	77 (4.5%)	1707
Coronary artery disease	2 (0.1%)	68 (4.0%)	360 (21.2%)	1267 (74.7%)	1697
Blood cholesterol abnormal	5 (0.3%)	97 (5.7%)	1137 (67.4%)	448 (26.6%)	1687
Chemotherapy	372 (22.1%)	392 (23.3%)	788 (46.8%)	131 (7.8%)	1683
Acute lymphocytic leukaemia	1116 (66.7%)	345 (20.6%)	187 (11.2%)	25 (1.5%)	1673
Ankylosing spondylitis	71 (4.3%)	781 (46.9%)	749 (44.9%)	66 (4.0%)	1667
Follicular lymphoma	0 (0.0%)	204 (12.5%)	1166 (71.7%)	256 (15.7%)	1626
COVID-19	116 (7.2%)	386 (24.0%)	832 (51.7%)	275 (17.1%)	1609
Breast cancer female	1 (0.1%)	250 (15.7%)	971 (61.1%)	368 (23.1%)	1590
Seizure	661 (42.2%)	308 (19.6%)	320 (20.4%)	279 (17.8%)	1568

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Osteoporosis	14 (0.9%)	66 (4.3%)	910 (59.2%)	546 (35.5%)	1536
Renal cell carcinoma	6 (0.4%)	158 (10.5%)	1067 (70.9%)	274 (18.2%)	1505
Factor VIII deficiency	704 (49.1%)	521 (36.3%)	190 (13.2%)	19 (1.3%)	1434
Cardiac failure	24 (1.7%)	120 (8.6%)	649 (46.7%)	597 (42.9%)	1390
Chronic obstructive pulmonary disease	4 (0.3%)	60 (4.5%)	668 (50.2%)	600 (45.0%)	1332
Nausea	158 (12.3%)	284 (22.1%)	665 (51.8%)	178 (13.9%)	1285
Lung adenocarcinoma	14 (1.1%)	75 (5.9%)	1079 (84.5%)	109 (8.5%)	1277
Systemic lupus erythematosus	185 (14.9%)	666 (53.6%)	376 (30.3%)	15 (1.2%)	1242
Malignant melanoma	23 (1.9%)	213 (17.2%)	757 (61.2%)	244 (19.7%)	1237
Lung neoplasm malignant	4 (0.3%)	143 (11.7%)	809 (66.4%)	263 (21.6%)	1219
Chronic myeloid leukaemia	42 (3.5%)	281 (23.5%)	652 (54.4%)	223 (18.6%)	1198
Nasal polyps	52 (4.3%)	471 (39.3%)	597 (49.9%)	77 (6.4%)	1197
Hypothyroidism	84 (7.0%)	221 (18.5%)	662 (55.4%)	229 (19.1%)	1196
Contraception	351 (29.4%)	827 (69.2%)	17 (1.4%)	0 (0.0%)	1195
Hereditary angioedema	171 (14.4%)	610 (51.3%)	367 (30.8%)	42 (3.5%)	1190
Ovarian cancer	3 (0.3%)	136 (11.7%)	936 (80.3%)	91 (7.8%)	1166
Plasma cell myeloma refractory	1 (0.1%)	80 (6.9%)	897 (77.0%)	187 (16.1%)	1165
Angina pectoris	1 (0.1%)	17 (1.5%)	129 (11.1%)	1017 (87.4%)	1164
Prophylaxis against transplant rejection	207 (17.9%)	318 (27.5%)	625 (54.0%)	8 (0.7%)	1158
Bipolar disorder	186 (16.2%)	419 (36.6%)	521 (45.5%)	19 (1.7%)	1145
Off label use	153 (13.4%)	337 (29.6%)	194 (17.0%)	455 (39.9%)	1139
Pneumonia	123 (10.9%)	202 (17.9%)	613 (54.4%)	188 (16.7%)	1126
Immunosuppression	252 (22.5%)	343 (30.6%)	493 (43.9%)	34 (3.0%)	1122
Colon cancer	0 (0.0%)	122 (10.9%)	762 (68.2%)	234 (20.9%)	1118
Hypercholesterolaemia	11 (1.0%)	96 (8.7%)	706 (64.0%)	290 (26.3%)	1103
Mantle cell lymphoma	0 (0.0%)	70 (6.6%)	841 (79.3%)	149 (14.1%)	1060
Back pain	152 (15.1%)	209 (20.7%)	493 (48.9%)	155 (15.4%)	1009

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Supplementation therapy	81 (8.2%)	167 (16.8%)	492 (49.6%)	252 (25.4%)	992
Narcolepsy	119 (12.2%)	569 (58.2%)	262 (26.8%)	28 (2.9%)	978
Arthritis	17 (1.8%)	152 (15.8%)	420 (43.5%)	376 (39.0%)	965
Attention deficit hyperactivity disorder	575 (60.0%)	317 (33.1%)	66 (6.9%)	1 (0.1%)	959
Thrombosis prophylaxis	22 (2.3%)	156 (16.6%)	514 (54.7%)	248 (26.4%)	940
Anticoagulant therapy	44 (4.7%)	149 (15.9%)	424 (45.3%)	319 (34.1%)	936
COVID-19 immunisation	45 (4.8%)	183 (19.6%)	574 (61.4%)	133 (14.2%)	935
Hyperlipidaemia	8 (0.9%)	71 (7.6%)	639 (68.7%)	212 (22.8%)	930
Urinary tract infection	34 (3.7%)	190 (20.5%)	361 (38.9%)	343 (37.0%)	928
Infection prophylaxis	132 (14.3%)	161 (17.5%)	470 (51.1%)	157 (17.1%)	920
Chest pain	5 (0.5%)	30 (3.3%)	111 (12.2%)	767 (84.0%)	913
Colorectal cancer metastatic	0 (0.0%)	228 (25.4%)	509 (56.6%)	162 (18.0%)	899
Psychotic disorder	180 (20.2%)	367 (41.1%)	309 (34.6%)	37 (4.1%)	893
Neoplasm malignant	49 (5.5%)	141 (15.8%)	549 (61.5%)	154 (17.2%)	893
Headache	262 (29.4%)	303 (34.0%)	283 (31.8%)	42 (4.7%)	890
Gastric cancer	4 (0.5%)	80 (9.0%)	597 (67.5%)	204 (23.1%)	885
Endometrial cancer	5 (0.6%)	48 (5.5%)	698 (79.7%)	125 (14.3%)	876
Dyslipidaemia	5 (0.6%)	81 (9.3%)	579 (66.6%)	205 (23.6%)	870
Analgesic therapy	88 (10.1%)	238 (27.4%)	311 (35.8%)	232 (26.7%)	869
Infection	84 (9.7%)	211 (24.5%)	415 (48.1%)	152 (17.6%)	862
Relapsing multiple sclerosis	34 (4.0%)	502 (59.1%)	307 (36.2%)	6 (0.7%)	849
Vitamin supplementation	69 (8.4%)	89 (10.9%)	335 (41.0%)	325 (39.7%)	818
Immunodeficiency common variable	66 (8.1%)	166 (20.3%)	486 (59.6%)	98 (12.0%)	816
Chronic spontaneous urticaria	63 (7.8%)	433 (53.8%)	272 (33.8%)	37 (4.6%)	805
Eosinophilic oesophagitis	340 (42.4%)	330 (41.1%)	129 (16.1%)	3 (0.4%)	802
Major depression	168 (21.0%)	283 (35.4%)	304 (38.0%)	44 (5.5%)	799
Pyrexia	180 (22.8%)	194 (24.6%)	348 (44.1%)	68 (8.6%)	790

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Neuralgia	40 (5.1%)	285 (36.1%)	345 (43.7%)	120 (15.2%)	790
Arthralgia	26 (3.3%)	146 (18.6%)	507 (64.5%)	107 (13.6%)	786
Diarrhoea	66 (8.5%)	139 (17.8%)	433 (55.5%)	142 (18.2%)	780
Fibromyalgia	7 (0.9%)	117 (15.2%)	116 (15.1%)	530 (68.8%)	770
Antibiotic therapy	121 (15.7%)	229 (29.8%)	332 (43.2%)	87 (11.3%)	769
Hypersensitivity	116 (15.4%)	203 (27.0%)	331 (44.0%)	102 (13.6%)	752
Non-Hodgkin's lymphoma	60 (8.1%)	228 (30.6%)	409 (54.9%)	48 (6.4%)	745
Prophylaxis against graft versus host disease	275 (37.4%)	231 (31.4%)	222 (30.2%)	8 (1.1%)	736
Pancreatic carcinoma	2 (0.3%)	89 (12.1%)	516 (70.4%)	126 (17.2%)	733
Clear cell renal cell carcinoma	0 (0.0%)	92 (12.6%)	549 (75.0%)	91 (12.4%)	732
Renal transplant	94 (12.9%)	287 (39.4%)	320 (43.9%)	28 (3.8%)	729
Cataplexy	90 (12.6%)	400 (55.9%)	202 (28.3%)	23 (3.2%)	715
B-cell lymphoma	79 (11.4%)	141 (20.3%)	402 (57.8%)	74 (10.6%)	696
Non-small cell lung cancer metastatic	0 (0.0%)	57 (8.2%)	522 (75.1%)	116 (16.7%)	695
Sleep disorder	55 (7.9%)	237 (34.1%)	305 (43.9%)	97 (14.0%)	694
Bone marrow conditioning regimen	289 (42.4%)	198 (29.1%)	191 (28.0%)	3 (0.4%)	681
Nutritional supplementation	45 (6.7%)	48 (7.1%)	228 (33.7%)	355 (52.5%)	676
Myelodysplastic syndrome	17 (2.5%)	33 (4.9%)	319 (47.3%)	305 (45.3%)	674
Hodgkin's disease	94 (14.1%)	312 (46.8%)	219 (32.8%)	42 (6.3%)	667
Anaemia	65 (9.8%)	150 (22.6%)	295 (44.4%)	155 (23.3%)	665
Neurodermatitis	40 (6.0%)	147 (22.2%)	403 (60.8%)	73 (11.0%)	663
Pulmonary hypertension	73 (11.0%)	141 (21.3%)	295 (44.5%)	154 (23.2%)	663
Antiviral prophylaxis	160 (24.2%)	93 (14.1%)	345 (52.2%)	63 (9.5%)	661
Echocardiogram	13 (2.0%)	146 (22.2%)	423 (64.2%)	77 (11.7%)	659
Growth hormone deficiency	573 (87.9%)	32 (4.9%)	42 (6.4%)	5 (0.8%)	652
Invasive ductal breast carcinoma	24 (3.8%)	208 (32.6%)	319 (50.0%)	87 (13.6%)	638
Dyspnoea	22 (3.4%)	40 (6.3%)	172 (27.0%)	404 (63.3%)	638

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Oesophageal carcinoma	3 (0.5%)	35 (5.5%)	425 (66.7%)	174 (27.3%)	637
B-cell type acute leukaemia	426 (67.2%)	95 (15.0%)	112 (17.7%)	1 (0.2%)	634
IgA nephropathy	42 (6.7%)	321 (51.0%)	246 (39.1%)	20 (3.2%)	629
Prophylaxis of nausea and vomiting	41 (6.5%)	92 (14.7%)	390 (62.3%)	103 (16.5%)	626
Immune thrombocytopenia	140 (22.4%)	151 (24.2%)	229 (36.7%)	104 (16.7%)	624
Myasthenia gravis	12 (1.9%)	171 (27.4%)	343 (55.1%)	97 (15.6%)	623
Hidradenitis	123 (20.0%)	361 (58.6%)	129 (20.9%)	3 (0.5%)	616
Immune system disorder	52 (8.5%)	267 (43.5%)	260 (42.3%)	35 (5.7%)	614
Weight decreased	14 (2.3%)	332 (54.3%)	247 (40.4%)	18 (2.9%)	611
Colorectal cancer	0 (0.0%)	198 (32.4%)	353 (57.8%)	60 (9.8%)	611
Cardiac disorder	5 (0.8%)	30 (4.9%)	345 (56.6%)	230 (37.7%)	610
Cerebrovascular accident	3 (0.5%)	19 (3.1%)	121 (19.9%)	466 (76.5%)	609
Anaesthesia	98 (16.2%)	173 (28.5%)	309 (51.0%)	26 (4.3%)	606
Tuberculosis	96 (16.3%)	270 (45.9%)	197 (33.5%)	25 (4.3%)	588
Juvenile idiopathic arthritis	513 (88.4%)	39 (6.7%)	26 (4.5%)	2 (0.3%)	580
Cough	96 (16.6%)	121 (20.9%)	223 (38.6%)	138 (23.9%)	578
Oesophageal adenocarcinoma	1 (0.2%)	85 (14.7%)	430 (74.5%)	61 (10.6%)	577
COVID-19 pneumonia	9 (1.6%)	138 (24.4%)	382 (67.5%)	37 (6.5%)	566
Uterine cancer	0 (0.0%)	69 (12.2%)	391 (69.2%)	105 (18.6%)	565
Pruritus	55 (9.8%)	67 (11.9%)	334 (59.2%)	108 (19.1%)	564
Somnolence	56 (10.0%)	311 (55.7%)	168 (30.1%)	23 (4.1%)	558
Diffuse large B-cell lymphoma stage IV	28 (5.0%)	217 (39.1%)	191 (34.4%)	119 (21.4%)	555
Vomiting	70 (12.7%)	130 (23.6%)	273 (49.5%)	79 (14.3%)	552
Metastases to bone	24 (4.4%)	65 (11.9%)	378 (69.2%)	79 (14.5%)	546
Antifungal prophylaxis	136 (25.1%)	108 (20.0%)	254 (47.0%)	43 (7.9%)	541
Benign prostatic hyperplasia	3 (0.6%)	6 (1.1%)	271 (50.1%)	261 (48.2%)	541
Dermatitis	107 (19.9%)	174 (32.3%)	198 (36.8%)	59 (11.0%)	538

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Primary immunodeficiency syndrome	92 (17.3%)	111 (20.9%)	283 (53.3%)	45 (8.5%)	531
Metastatic malignant melanoma	5 (1.0%)	95 (18.1%)	351 (67.0%)	73 (13.9%)	524
Parkinson's disease psychosis	0 (0.0%)	2 (0.4%)	234 (45.8%)	275 (53.8%)	511
Haemorrhage	273 (53.6%)	145 (28.5%)	85 (16.7%)	6 (1.2%)	509
Rash	21 (4.2%)	116 (23.1%)	291 (57.9%)	75 (14.9%)	503
Immunisation	94 (18.7%)	75 (14.9%)	160 (31.9%)	173 (34.5%)	502
Granulomatosis with polyangiitis	41 (8.2%)	125 (24.9%)	261 (52.0%)	75 (14.9%)	502
Sepsis	58 (11.7%)	107 (21.7%)	232 (47.0%)	97 (19.6%)	494
Interstitial lung disease	29 (5.9%)	65 (13.2%)	291 (59.0%)	108 (21.9%)	493
Transitional cell carcinoma	0 (0.0%)	5 (1.0%)	306 (62.1%)	182 (36.9%)	493
Status epilepticus	97 (19.8%)	273 (55.6%)	105 (21.4%)	16 (3.3%)	491
Thyroid disorder	18 (3.7%)	50 (10.2%)	155 (31.7%)	266 (54.4%)	489
Small cell lung cancer extensive stage	0 (0.0%)	35 (7.2%)	379 (77.7%)	74 (15.2%)	488
Antibiotic prophylaxis	73 (15.3%)	80 (16.8%)	284 (59.5%)	40 (8.4%)	477
Deep vein thrombosis	16 (3.4%)	133 (27.9%)	267 (56.1%)	60 (12.6%)	476
Neutropenia	18 (3.8%)	96 (20.2%)	285 (59.9%)	77 (16.2%)	476
Blood cholesterol	1 (0.2%)	36 (7.6%)	301 (63.4%)	137 (28.8%)	475
Dyspepsia	15 (3.2%)	127 (26.7%)	248 (52.2%)	85 (17.9%)	475
Skin wrinkling	6 (1.3%)	290 (61.2%)	170 (35.9%)	8 (1.7%)	474
Type 1 diabetes mellitus	121 (25.6%)	159 (33.7%)	157 (33.3%)	35 (7.4%)	472
Small cell lung cancer	0 (0.0%)	29 (6.3%)	338 (73.0%)	96 (20.7%)	463
Bacterial infection	42 (9.2%)	96 (20.9%)	155 (33.8%)	166 (36.2%)	459
Idiopathic pulmonary fibrosis	1 (0.2%)	6 (1.3%)	233 (51.3%)	214 (47.1%)	454
Renal cancer	3 (0.7%)	50 (11.0%)	317 (69.8%)	84 (18.5%)	454
Suspected suicide	67 (14.9%)	137 (30.4%)	201 (44.7%)	45 (10.0%)	450
Evidence based treatment	70 (15.6%)	114 (25.4%)	219 (48.8%)	46 (10.2%)	449
Metastatic renal cell carcinoma	0 (0.0%)	36 (8.1%)	322 (72.2%)	88 (19.7%)	446

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Blood pressure abnormal	3 (0.7%)	27 (6.2%)	293 (67.2%)	113 (25.9%)	436
Osteoarthritis	2 (0.5%)	68 (15.6%)	267 (61.4%)	98 (22.5%)	435
Thrombosis	20 (4.6%)	46 (10.6%)	161 (37.3%)	205 (47.5%)	432
Still's disease	277 (64.3%)	71 (16.5%)	59 (13.7%)	24 (5.6%)	431
Dermatitis allergic	182 (42.6%)	100 (23.4%)	112 (26.2%)	33 (7.7%)	427
Lymphoma	26 (6.1%)	102 (24.1%)	235 (55.6%)	60 (14.2%)	423
Rett syndrome	345 (81.9%)	71 (16.9%)	5 (1.2%)	0 (0.0%)	421
Prostate cancer metastatic	0 (0.0%)	2 (0.5%)	230 (55.0%)	186 (44.5%)	418
General anaesthesia	59 (14.1%)	109 (26.1%)	234 (56.0%)	16 (3.8%)	418
Adenocarcinoma of colon	0 (0.0%)	78 (18.7%)	275 (65.9%)	64 (15.3%)	417
Cystic fibrosis	244 (58.7%)	119 (28.6%)	42 (10.1%)	11 (2.6%)	416
Blood pressure measurement	3 (0.7%)	56 (13.6%)	248 (60.2%)	105 (25.5%)	412
Primary amyloidosis	0 (0.0%)	46 (11.2%)	264 (64.4%)	100 (24.4%)	410
Partial seizures	163 (39.9%)	87 (21.3%)	150 (36.7%)	9 (2.2%)	409
Infantile spasms	403 (99.5%)	2 (0.5%)	0 (0.0%)	0 (0.0%)	405
Cardiac failure chronic	5 (1.2%)	46 (11.4%)	152 (37.5%)	202 (49.9%)	405
Glaucoma	32 (8.0%)	15 (3.8%)	195 (48.8%)	158 (39.5%)	400
Secondary progressive multiple sclerosis	3 (0.8%)	123 (31.0%)	269 (67.8%)	2 (0.5%)	397
Gout	0 (0.0%)	60 (15.1%)	234 (58.9%)	103 (25.9%)	397
Abdominal pain	74 (18.7%)	101 (25.5%)	179 (45.2%)	42 (10.6%)	396
Oedema	13 (3.3%)	48 (12.2%)	123 (31.2%)	210 (53.3%)	394
Intentional product misuse	1 (0.3%)	22 (5.6%)	57 (14.6%)	311 (79.5%)	391
Amyloidosis	0 (0.0%)	5 (1.3%)	156 (39.9%)	230 (58.8%)	391
Gastrointestinal stromal tumour	20 (5.1%)	37 (9.5%)	255 (65.4%)	78 (20.0%)	390
Cancer pain	9 (2.3%)	45 (11.6%)	292 (75.3%)	42 (10.8%)	388
Dermatomyositis	63 (16.2%)	100 (25.8%)	216 (55.7%)	9 (2.3%)	388
Cardiac amyloidosis	0 (0.0%)	1 (0.3%)	113 (29.4%)	271 (70.4%)	385

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Primary progressive multiple sclerosis	3 (0.8%)	115 (29.9%)	262 (68.1%)	5 (1.3%)	385
Pulmonary embolism	17 (4.4%)	78 (20.3%)	163 (42.4%)	126 (32.8%)	384
Adverse drug reaction	38 (9.9%)	106 (27.6%)	190 (49.5%)	50 (13.0%)	384
Petit mal epilepsy	379 (99.2%)	0 (0.0%)	3 (0.8%)	0 (0.0%)	382
Prophylaxis against gastrointestinal ulcer	25 (6.6%)	44 (11.6%)	193 (50.9%)	117 (30.9%)	379
Rectal cancer	0 (0.0%)	58 (15.4%)	257 (68.4%)	61 (16.2%)	376
Neoplasm	95 (25.4%)	103 (27.5%)	153 (40.9%)	23 (6.1%)	374
Seizure prophylaxis	23 (6.1%)	35 (9.4%)	55 (14.7%)	261 (69.8%)	374
Chronic kidney disease	14 (3.8%)	56 (15.0%)	185 (49.6%)	118 (31.6%)	373
Dementia	1 (0.3%)	0 (0.0%)	96 (25.8%)	275 (73.9%)	372
Adenocarcinoma gastric	0 (0.0%)	69 (18.6%)	264 (71.4%)	37 (10.0%)	370
Agitation	143 (39.5%)	112 (30.9%)	47 (13.0%)	60 (16.6%)	362
Burkitt's lymphoma	160 (44.2%)	166 (45.9%)	36 (9.9%)	0 (0.0%)	362
Alopecia	64 (17.9%)	143 (39.9%)	121 (33.8%)	30 (8.4%)	358
Hallucination	8 (2.3%)	8 (2.3%)	174 (49.0%)	165 (46.5%)	355
Hypokalaemia	25 (7.1%)	48 (13.6%)	202 (57.1%)	79 (22.3%)	354
Non-small cell lung cancer recurrent	0 (0.0%)	38 (10.8%)	252 (71.4%)	63 (17.8%)	353
Schizoaffective disorder	52 (14.8%)	200 (57.0%)	91 (25.9%)	8 (2.3%)	351
Muscle spasms	37 (10.6%)	66 (18.9%)	199 (56.9%)	48 (13.7%)	350
Lupus nephritis	85 (24.4%)	184 (52.7%)	80 (22.9%)	0 (0.0%)	349
Medication dilution	36 (10.4%)	110 (31.7%)	183 (52.7%)	18 (5.2%)	347
Sedation	53 (15.3%)	118 (34.1%)	146 (42.2%)	29 (8.4%)	346
Vitamin D deficiency	62 (18.2%)	86 (25.2%)	148 (43.4%)	45 (13.2%)	341
COVID-19 prophylaxis	14 (4.1%)	121 (35.7%)	153 (45.1%)	51 (15.0%)	339
Neuropathy peripheral	9 (2.7%)	48 (14.2%)	226 (66.9%)	55 (16.3%)	338
Mineral supplementation	16 (4.8%)	37 (11.0%)	229 (68.2%)	54 (16.1%)	336
Nephrotic syndrome	228 (68.1%)	43 (12.8%)	49 (14.6%)	15 (4.5%)	335

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Suicide attempt	143 (43.1%)	85 (25.6%)	60 (18.1%)	44 (13.3%)	332
Affective disorder	96 (29.0%)	153 (46.2%)	62 (18.7%)	20 (6.0%)	331
Spinal muscular atrophy	253 (77.6%)	54 (16.6%)	18 (5.5%)	1 (0.3%)	326
Allogenic stem cell transplantation	109 (33.7%)	112 (34.7%)	102 (31.6%)	0 (0.0%)	323
Migraine prophylaxis	24 (7.4%)	136 (42.1%)	145 (44.9%)	18 (5.6%)	323
Haemophagocytic lymphohistiocytosis	149 (46.1%)	88 (27.2%)	80 (24.8%)	6 (1.9%)	323
Glucose tolerance impaired	5 (1.5%)	160 (49.5%)	146 (45.2%)	12 (3.7%)	323
Lung adenocarcinoma stage IV	0 (0.0%)	18 (5.6%)	249 (77.3%)	55 (17.1%)	322
Cardiovascular event prophylaxis	2 (0.6%)	25 (7.8%)	176 (54.8%)	118 (36.8%)	321
Mycobacterium avium complex infection	29 (9.1%)	93 (29.2%)	160 (50.2%)	37 (11.6%)	319
Sickle cell disease	130 (40.8%)	131 (41.1%)	56 (17.6%)	2 (0.6%)	319
Urticaria	34 (10.7%)	112 (35.1%)	151 (47.3%)	22 (6.9%)	319
Hormone-refractory prostate cancer	0 (0.0%)	2 (0.6%)	180 (56.8%)	135 (42.6%)	317
Bile duct cancer	0 (0.0%)	7 (2.2%)	238 (75.8%)	69 (22.0%)	314
Non-small cell lung cancer stage IV	14 (4.5%)	42 (13.5%)	196 (63.0%)	59 (19.0%)	311
Myocardial infarction	6 (1.9%)	26 (8.4%)	220 (70.7%)	59 (19.0%)	311
Febrile neutropenia	55 (17.7%)	32 (10.3%)	202 (65.2%)	21 (6.8%)	310
Generalised tonic-clonic seizure	167 (54.2%)	85 (27.6%)	55 (17.9%)	1 (0.3%)	308
Neuromyelitis optica spectrum disorder	33 (10.7%)	77 (25.0%)	176 (57.1%)	22 (7.1%)	308
Metastases to liver	22 (7.1%)	65 (21.1%)	197 (64.0%)	24 (7.8%)	308
Induction of anaesthesia	58 (19.2%)	120 (39.7%)	94 (31.1%)	30 (9.9%)	302
Hyperuricaemia	5 (1.7%)	29 (9.6%)	160 (53.2%)	107 (35.5%)	301
Acne	156 (52.9%)	113 (38.3%)	23 (7.8%)	3 (1.0%)	295
Abdominal discomfort	6 (2.0%)	45 (15.3%)	222 (75.3%)	22 (7.5%)	295
Hormone receptor positive HER2 negative breast cance	0 (0.0%)	66 (22.4%)	154 (52.4%)	74 (25.2%)	294
Obesity	29 (9.9%)	159 (54.5%)	101 (34.6%)	3 (1.0%)	292
Inflammation	13 (4.5%)	146 (50.5%)	116 (40.1%)	14 (4.8%)	289

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Fungal infection	46 (16.0%)	74 (25.8%)	115 (40.1%)	52 (18.1%)	287
Cholangiocarcinoma	1 (0.3%)	55 (19.2%)	198 (69.2%)	32 (11.2%)	286
Acromegaly	8 (2.8%)	94 (33.2%)	165 (58.3%)	16 (5.7%)	283
Factor IX deficiency	149 (53.0%)	88 (31.3%)	43 (15.3%)	1 (0.4%)	281
Anti-infective therapy	70 (24.9%)	61 (21.7%)	116 (41.3%)	34 (12.1%)	281
Dementia Alzheimer's type	0 (0.0%)	5 (1.8%)	106 (38.3%)	166 (59.9%)	277
Gastrointestinal disorder	25 (9.0%)	41 (14.8%)	142 (51.3%)	69 (24.9%)	277
Renal cell carcinoma stage IV	2 (0.7%)	14 (5.1%)	159 (57.6%)	101 (36.6%)	276
Drug dependence	25 (9.1%)	212 (76.8%)	39 (14.1%)	0 (0.0%)	276
Chemotherapy side effect prophylaxis	4 (1.5%)	38 (13.8%)	167 (60.7%)	66 (24.0%)	275
Antiplatelet therapy	18 (6.6%)	53 (19.5%)	123 (45.2%)	78 (28.7%)	272
Dry eye	2 (0.7%)	35 (12.9%)	170 (62.5%)	65 (23.9%)	272
Herpes zoster	10 (3.7%)	70 (25.7%)	129 (47.4%)	63 (23.2%)	272
Complex regional pain syndrome	39 (14.3%)	212 (77.9%)	21 (7.7%)	0 (0.0%)	272
Hypoparathyroidism	5 (1.8%)	133 (48.9%)	121 (44.5%)	13 (4.8%)	272
Autism spectrum disorder	233 (86.9%)	19 (7.1%)	16 (6.0%)	0 (0.0%)	268
Adverse event	80 (30.0%)	43 (16.1%)	116 (43.4%)	28 (10.5%)	267
Hormone replacement therapy	8 (3.0%)	92 (34.6%)	147 (55.3%)	19 (7.1%)	266
Cellulitis	16 (6.0%)	127 (47.9%)	81 (30.6%)	41 (15.5%)	265
Transplant rejection	72 (27.2%)	111 (41.9%)	82 (30.9%)	0 (0.0%)	265
Weight control	8 (3.0%)	130 (49.2%)	121 (45.8%)	5 (1.9%)	264
Pain management	54 (20.5%)	98 (37.1%)	90 (34.1%)	22 (8.3%)	264
Myocardial ischaemia	3 (1.1%)	10 (3.8%)	164 (62.4%)	86 (32.7%)	263
Bladder cancer	0 (0.0%)	10 (3.8%)	158 (60.3%)	94 (35.9%)	262
Acute myocardial infarction	0 (0.0%)	39 (14.9%)	146 (55.9%)	76 (29.1%)	261
Mental disorder	32 (12.3%)	87 (33.3%)	136 (52.1%)	6 (2.3%)	261
Seasonal allergy	40 (15.3%)	73 (28.0%)	124 (47.5%)	24 (9.2%)	261

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Plasma cell myeloma in remission	0 (0.0%)	12 (4.6%)	192 (73.8%)	56 (21.5%)	260
Hypotension	64 (24.7%)	52 (20.1%)	108 (41.7%)	35 (13.5%)	259
Graft versus host disease	61 (23.6%)	56 (21.6%)	140 (54.1%)	2 (0.8%)	259
Nasopharyngitis	46 (17.8%)	52 (20.2%)	71 (27.5%)	89 (34.5%)	258
Staphylococcal infection	22 (8.6%)	33 (12.8%)	146 (56.8%)	56 (21.8%)	257
Pancreatic carcinoma metastatic	0 (0.0%)	43 (16.8%)	198 (77.3%)	15 (5.9%)	256
Pain in extremity	24 (9.4%)	68 (26.8%)	124 (48.8%)	38 (15.0%)	254
Muscle spasticity	21 (8.4%)	92 (36.7%)	120 (47.8%)	18 (7.2%)	251
Type IIa hyperlipidaemia	5 (2.0%)	58 (23.3%)	160 (64.3%)	26 (10.4%)	249
Iron deficiency	33 (13.3%)	60 (24.2%)	35 (14.1%)	120 (48.4%)	248
Sinusitis	29 (11.7%)	88 (35.5%)	113 (45.6%)	18 (7.3%)	248
Trigeminal neuralgia	3 (1.2%)	42 (17.1%)	138 (56.1%)	63 (25.6%)	246
Delusion	4 (1.6%)	6 (2.4%)	115 (46.9%)	120 (49.0%)	245
Adenocarcinoma pancreas	0 (0.0%)	53 (21.7%)	175 (71.7%)	16 (6.6%)	244
Hepatitis C	3 (1.2%)	114 (46.9%)	114 (46.9%)	12 (4.9%)	243
Ewing's sarcoma	180 (74.1%)	27 (11.1%)	35 (14.4%)	1 (0.4%)	243
Illness	44 (18.2%)	72 (29.8%)	101 (41.7%)	25 (10.3%)	242
Cytokine release syndrome	20 (8.3%)	32 (13.3%)	164 (68.0%)	25 (10.4%)	241
Amyotrophic lateral sclerosis	1 (0.4%)	18 (7.5%)	184 (76.7%)	37 (15.4%)	240
Neovascular age-related macular degeneration	0 (0.0%)	5 (2.1%)	90 (37.5%)	145 (60.4%)	240
Pemphigoid	1 (0.4%)	12 (5.0%)	120 (50.2%)	106 (44.4%)	239
Abdominal pain upper	12 (5.0%)	44 (18.5%)	143 (60.1%)	39 (16.4%)	238
Bronchitis	30 (12.7%)	44 (18.6%)	115 (48.5%)	48 (20.3%)	237
Vehicle solution use	37 (15.6%)	83 (35.0%)	102 (43.0%)	15 (6.3%)	237
Alpha-1 antitrypsin deficiency	1 (0.4%)	30 (12.8%)	172 (73.5%)	31 (13.2%)	234
Helicobacter infection	18 (7.7%)	92 (39.5%)	112 (48.1%)	11 (4.7%)	233
Squamous cell carcinoma of lung	0 (0.0%)	13 (5.6%)	195 (84.4%)	23 (10.0%)	231

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Uveitis	27 (11.7%)	114 (49.4%)	73 (31.6%)	17 (7.4%)	231
Radioactive iodine therapy	0 (0.0%)	0 (0.0%)	3 (1.3%)	228 (98.7%)	231
Squamous cell carcinoma	2 (0.9%)	36 (15.7%)	111 (48.3%)	81 (35.2%)	230
Diffuse large B-cell lymphoma stage II	0 (0.0%)	88 (38.3%)	135 (58.7%)	7 (3.0%)	230
Bipolar I disorder	53 (23.1%)	98 (42.8%)	78 (34.1%)	0 (0.0%)	229
Metastases to lung	11 (4.8%)	48 (21.1%)	137 (60.1%)	32 (14.0%)	228
Lennox-Gastaut syndrome	169 (74.4%)	39 (17.2%)	18 (7.9%)	1 (0.4%)	227
End stage renal disease	8 (3.5%)	51 (22.6%)	116 (51.3%)	51 (22.6%)	226
Adenocarcinoma	1 (0.4%)	54 (24.0%)	147 (65.3%)	23 (10.2%)	225
Colitis	22 (9.8%)	40 (17.9%)	136 (60.7%)	26 (11.6%)	224
Tardive dyskinesia	31 (13.8%)	85 (37.9%)	95 (42.4%)	13 (5.8%)	224
Antipsychotic therapy	70 (31.4%)	87 (39.0%)	55 (24.7%)	11 (4.9%)	223
Sedative therapy	30 (13.6%)	91 (41.2%)	80 (36.2%)	20 (9.0%)	221
Mixed anxiety and depressive disorder	7 (3.2%)	54 (24.7%)	86 (39.3%)	72 (32.9%)	219
Prinzmetal angina	0 (0.0%)	0 (0.0%)	219 (100.0%)	0 (0.0%)	219
Severe myoclonic epilepsy of infancy	204 (93.2%)	15 (6.8%)	0 (0.0%)	0 (0.0%)	219
Cardiac failure congestive	2 (0.9%)	32 (14.6%)	75 (34.2%)	110 (50.2%)	219
Diffuse large B-cell lymphoma stage III	9 (4.1%)	45 (20.6%)	106 (48.6%)	58 (26.6%)	218
Anti-neutrophil cytoplasmic antibody positive vascul	33 (15.1%)	31 (14.2%)	112 (51.4%)	42 (19.3%)	218
Drug therapy	16 (7.4%)	29 (13.4%)	69 (31.8%)	103 (47.5%)	217
Neuroendocrine tumour	1 (0.5%)	31 (14.4%)	148 (68.5%)	36 (16.7%)	216
Pulmonary tuberculosis	22 (10.2%)	90 (41.7%)	55 (25.5%)	49 (22.7%)	216
Neuroblastoma	210 (97.2%)	6 (2.8%)	0 (0.0%)	0 (0.0%)	216
Gastritis	15 (7.0%)	35 (16.3%)	122 (56.7%)	43 (20.0%)	215
Cervix carcinoma	1 (0.5%)	95 (44.4%)	115 (53.7%)	3 (1.4%)	214
Bronchial carcinoma	0 (0.0%)	11 (5.1%)	186 (86.9%)	17 (7.9%)	214
Diffuse large B-cell lymphoma refractory	2 (0.9%)	67 (31.6%)	125 (59.0%)	18 (8.5%)	212

Indication Summary Table Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Hypertrophic cardiomyopathy	2 (1.0%)	28 (13.3%)	126 (60.0%)	54 (25.7%)	210
Liver transplant	47 (22.4%)	25 (11.9%)	125 (59.5%)	13 (6.2%)	210
Breast cancer stage IV	0 (0.0%)	30 (14.3%)	134 (63.8%)	46 (21.9%)	210
Bulbospinal muscular atrophy congenital	0 (0.0%)	35 (16.7%)	132 (63.2%)	42 (20.1%)	209
Hypertonic bladder	0 (0.0%)	29 (13.9%)	97 (46.4%)	83 (39.7%)	209
Cystitis interstitial	7 (3.4%)	78 (37.5%)	109 (52.4%)	14 (6.7%)	208
Giant cell arteritis	0 (0.0%)	1 (0.5%)	99 (47.6%)	108 (51.9%)	208
Osteomyelitis	20 (9.6%)	12 (5.8%)	146 (70.2%)	30 (14.4%)	208
Disseminated tuberculosis	140 (67.3%)	23 (11.1%)	45 (21.6%)	0 (0.0%)	208
Diuretic therapy	2 (1.0%)	24 (11.6%)	121 (58.5%)	60 (29.0%)	207
Iron deficiency anaemia	32 (15.5%)	84 (40.6%)	59 (28.5%)	32 (15.5%)	207
Aplastic anaemia	73 (35.3%)	44 (21.3%)	59 (28.5%)	31 (15.0%)	207
Carcinoid tumour	0 (0.0%)	23 (11.1%)	156 (75.4%)	28 (13.5%)	207
Rhinitis allergic	37 (18.0%)	67 (32.5%)	76 (36.9%)	26 (12.6%)	206
Short stature	204 (99.5%)	1 (0.5%)	0 (0.0%)	0 (0.0%)	205
T-cell type acute leukaemia	192 (94.1%)	8 (3.9%)	4 (2.0%)	0 (0.0%)	204
Duodenal ulcer	9 (4.4%)	1 (0.5%)	20 (9.8%)	174 (85.3%)	204
Hepatic cancer	0 (0.0%)	41 (20.3%)	135 (66.8%)	26 (12.9%)	202
Restless legs syndrome	1 (0.5%)	39 (19.5%)	128 (64.0%)	32 (16.0%)	200
Arrhythmia	18 (9.0%)	18 (9.0%)	88 (44.0%)	76 (38.0%)	200
Foetal exposure during pregnancy	200 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	200
Computerised tomogram	6 (3.0%)	35 (17.7%)	120 (60.6%)	37 (18.7%)	198
Arteriosclerosis	0 (0.0%)	43 (21.9%)	104 (53.1%)	49 (25.0%)	196
Inflammatory bowel disease	70 (36.1%)	66 (34.0%)	56 (28.9%)	2 (1.0%)	194
Squamous cell carcinoma of head and neck	0 (0.0%)	38 (19.6%)	149 (76.8%)	7 (3.6%)	194
Hormone receptor positive breast cancer	0 (0.0%)	27 (14.1%)	140 (72.9%)	25 (13.0%)	192
Colon cancer metastatic	0 (0.0%)	50 (26.0%)	118 (61.5%)	24 (12.5%)	192

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Lymphodepletion	47 (24.5%)	40 (20.8%)	95 (49.5%)	10 (5.2%)	192
Polyarthritis	8 (4.2%)	31 (16.2%)	121 (63.4%)	31 (16.2%)	191
Cerebral infarction	0 (0.0%)	10 (5.3%)	115 (60.5%)	65 (34.2%)	190
Venoocclusive disease	63 (33.2%)	41 (21.6%)	85 (44.7%)	1 (0.5%)	190
Intentional overdose	75 (39.9%)	60 (31.9%)	46 (24.5%)	7 (3.7%)	188
Ventricular tachycardia	41 (21.9%)	34 (18.2%)	74 (39.6%)	38 (20.3%)	187
Cytomegalovirus infection	65 (34.8%)	38 (20.3%)	78 (41.7%)	6 (3.2%)	187
Lymphoma transformation	0 (0.0%)	18 (9.6%)	159 (85.0%)	10 (5.3%)	187
Atypical haemolytic uraemic syndrome	51 (27.3%)	103 (55.1%)	29 (15.5%)	4 (2.1%)	187
Microscopic polyangiitis	4 (2.2%)	22 (11.8%)	108 (58.1%)	52 (28.0%)	186
Polymyalgia rheumatica	0 (0.0%)	1 (0.5%)	101 (54.3%)	84 (45.2%)	186
Oedema peripheral	0 (0.0%)	21 (11.4%)	87 (47.0%)	77 (41.6%)	185
Heavy menstrual bleeding	38 (20.5%)	137 (74.1%)	10 (5.4%)	0 (0.0%)	185
Aspergillus infection	19 (10.3%)	62 (33.5%)	86 (46.5%)	18 (9.7%)	185
Renal failure	19 (10.3%)	36 (19.5%)	102 (55.1%)	28 (15.1%)	185
Pneumocystis jirovecii pneumonia	44 (23.9%)	29 (15.8%)	105 (57.1%)	6 (3.3%)	184
Post herpetic neuralgia	2 (1.1%)	1 (0.5%)	143 (77.7%)	38 (20.7%)	184
Waldenstrom's macroglobulinaemia	0 (0.0%)	1 (0.5%)	124 (67.8%)	58 (31.7%)	183
Parenteral nutrition	42 (23.1%)	15 (8.2%)	53 (29.1%)	72 (39.6%)	182
Condition aggravated	5 (2.8%)	124 (68.9%)	46 (25.6%)	5 (2.8%)	180
Post transplant lymphoproliferative disorder	135 (75.4%)	16 (8.9%)	23 (12.8%)	5 (2.8%)	179
Pemphigus	7 (3.9%)	81 (45.5%)	77 (43.3%)	13 (7.3%)	178
Essential hypertension	0 (0.0%)	13 (7.3%)	136 (76.8%)	28 (15.8%)	177
Surgery	14 (8.0%)	106 (60.6%)	30 (17.1%)	25 (14.3%)	175
Hepatitis B	1 (0.6%)	48 (27.6%)	107 (61.5%)	18 (10.3%)	174
Cardiovascular disorder	3 (1.7%)	19 (10.9%)	108 (62.1%)	44 (25.3%)	174
Gaucher's disease	39 (22.5%)	57 (32.9%)	64 (37.0%)	13 (7.5%)	173

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Post-traumatic stress disorder	33 (19.3%)	74 (43.3%)	55 (32.2%)	9 (5.3%)	171
Candida infection	29 (17.0%)	61 (35.7%)	73 (42.7%)	8 (4.7%)	171
Drug abuse	33 (19.3%)	83 (48.5%)	32 (18.7%)	23 (13.5%)	171
Paroxysmal nocturnal haemoglobinuria	18 (10.5%)	49 (28.7%)	73 (42.7%)	31 (18.1%)	171
Axial spondyloarthritis	7 (4.1%)	106 (62.4%)	57 (33.5%)	0 (0.0%)	170
Hypopituitarism	54 (32.0%)	40 (23.7%)	71 (42.0%)	4 (2.4%)	169
Thyroid cancer	2 (1.2%)	24 (14.2%)	103 (60.9%)	40 (23.7%)	169
Mycobacterium abscessus infection	38 (22.6%)	11 (6.5%)	106 (63.1%)	13 (7.7%)	168
Endometrial cancer recurrent	0 (0.0%)	12 (7.1%)	148 (88.1%)	8 (4.8%)	168
Hyperthyroidism	4 (2.4%)	56 (33.3%)	93 (55.4%)	15 (8.9%)	168
Hypercalcaemia	24 (14.4%)	25 (15.0%)	103 (61.7%)	15 (9.0%)	167
Heart transplant	56 (33.5%)	36 (21.6%)	74 (44.3%)	1 (0.6%)	167
Gastrointestinal disorder prophylaxis	6 (3.6%)	28 (16.8%)	109 (65.3%)	24 (14.4%)	167
Thrombotic thrombocytopenic purpura	38 (22.9%)	70 (42.2%)	47 (28.3%)	11 (6.6%)	166
Metastases to lymph nodes	16 (9.6%)	28 (16.9%)	111 (66.9%)	11 (6.6%)	166
Chronic hepatitis C	1 (0.6%)	98 (59.0%)	58 (34.9%)	9 (5.4%)	166
Bronchopulmonary aspergillosis	14 (8.4%)	20 (12.0%)	122 (73.5%)	10 (6.0%)	166
Chronic cutaneous lupus erythematosus	2 (1.2%)	83 (50.0%)	80 (48.2%)	1 (0.6%)	166
Precocious puberty	165 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	165
Hyperkalaemia	26 (15.8%)	19 (11.5%)	57 (34.5%)	63 (38.2%)	165
Rectal adenocarcinoma	0 (0.0%)	55 (33.3%)	97 (58.8%)	13 (7.9%)	165
Mucopolysaccharidosis II	150 (91.5%)	10 (6.1%)	4 (2.4%)	0 (0.0%)	164
Hypovitaminosis	37 (22.7%)	20 (12.3%)	74 (45.4%)	32 (19.6%)	163
Hormone-dependent prostate cancer	0 (0.0%)	1 (0.6%)	100 (61.7%)	61 (37.7%)	162
Cerebrovascular accident prophylaxis	0 (0.0%)	7 (4.3%)	81 (50.3%)	73 (45.3%)	161
Bladder disorder	3 (1.9%)	8 (5.0%)	34 (21.1%)	116 (72.0%)	161
Antidepressant therapy	21 (13.1%)	59 (36.9%)	73 (45.6%)	7 (4.4%)	160

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
B precursor type acute leukaemia	136 (85.0%)	9 (5.6%)	13 (8.1%)	2 (1.3%)	160
Lung cancer metastatic	0 (0.0%)	13 (8.1%)	131 (81.9%)	16 (10.0%)	160
Small intestine carcinoma	18 (11.3%)	30 (18.9%)	69 (43.4%)	42 (26.4%)	159
Gastric ulcer	5 (3.1%)	7 (4.4%)	82 (51.6%)	65 (40.9%)	159
Antiretroviral therapy	15 (9.5%)	100 (63.3%)	43 (27.2%)	0 (0.0%)	158
Lung disorder	12 (7.6%)	37 (23.4%)	67 (42.4%)	42 (26.6%)	158
Menopause	0 (0.0%)	34 (21.7%)	103 (65.6%)	20 (12.7%)	157
Chronic graft versus host disease	53 (33.8%)	29 (18.5%)	71 (45.2%)	4 (2.5%)	157
Hypersomnia	18 (11.5%)	90 (57.3%)	48 (30.6%)	1 (0.6%)	157
Hormone therapy	15 (9.6%)	42 (26.8%)	79 (50.3%)	21 (13.4%)	157
Stem cell transplant	59 (38.3%)	28 (18.2%)	66 (42.9%)	1 (0.6%)	154
Immunodeficiency	33 (21.4%)	24 (15.6%)	84 (54.5%)	13 (8.4%)	154
Pulmonary fibrosis	2 (1.3%)	14 (9.2%)	81 (52.9%)	56 (36.6%)	153
Hypogammaglobulinaemia	29 (19.0%)	30 (19.6%)	81 (52.9%)	13 (8.5%)	153
Gastritis prophylaxis	7 (4.6%)	24 (15.9%)	90 (59.6%)	30 (19.9%)	151
Thrombotic microangiopathy	53 (35.1%)	48 (31.8%)	46 (30.5%)	4 (2.6%)	151
Influenza	46 (30.5%)	41 (27.2%)	43 (28.5%)	21 (13.9%)	151
Eosinophilic granulomatosis with polyangiitis	5 (3.3%)	27 (17.9%)	111 (73.5%)	8 (5.3%)	151
Venoocclusive liver disease	43 (28.9%)	50 (33.6%)	56 (37.6%)	0 (0.0%)	149
Myalgia	7 (4.7%)	32 (21.5%)	71 (47.7%)	39 (26.2%)	149
Sleep disorder therapy	2 (1.4%)	7 (4.7%)	27 (18.2%)	112 (75.7%)	148
Systemic scleroderma	10 (6.8%)	38 (25.7%)	88 (59.5%)	12 (8.1%)	148
Blood pressure increased	1 (0.7%)	27 (18.2%)	104 (70.3%)	16 (10.8%)	148
Alopecia areata	39 (26.4%)	60 (40.5%)	46 (31.1%)	3 (2.0%)	148
Behaviour disorder	94 (63.9%)	13 (8.8%)	15 (10.2%)	25 (17.0%)	147
Erectile dysfunction	0 (0.0%)	28 (19.0%)	111 (75.5%)	8 (5.4%)	147
Central nervous system lymphoma	7 (4.8%)	52 (35.6%)	77 (52.7%)	10 (6.8%)	146

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chronic rhinosinusitis with nasal polyps	7 (4.8%)	54 (37.2%)	74 (51.0%)	10 (6.9%)	145
Bacteraemia	14 (9.7%)	28 (19.3%)	93 (64.1%)	10 (6.9%)	145
Chronic inflammatory demyelinating polyradiculoneuro	14 (9.7%)	27 (18.8%)	89 (61.8%)	14 (9.7%)	144
Light chain disease	0 (0.0%)	4 (2.8%)	136 (94.4%)	4 (2.8%)	144
Premature baby	143 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	143
HER2 negative breast cancer	0 (0.0%)	32 (22.5%)	81 (57.0%)	29 (20.4%)	142
Hepatic encephalopathy	0 (0.0%)	13 (9.2%)	107 (75.4%)	22 (15.5%)	142
Osteoporosis postmenopausal	1 (0.7%)	0 (0.0%)	94 (66.2%)	47 (33.1%)	142
Assisted reproductive technology	0 (0.0%)	141 (100.0%)	0 (0.0%)	0 (0.0%)	141
Metastases to central nervous system	8 (5.7%)	28 (19.9%)	98 (69.5%)	7 (5.0%)	141
Anxiety disorder	25 (17.9%)	47 (33.6%)	60 (42.9%)	8 (5.7%)	140
Device related infection	15 (10.7%)	22 (15.7%)	71 (50.7%)	32 (22.9%)	140
Mania	57 (40.7%)	64 (45.7%)	19 (13.6%)	0 (0.0%)	140
Decreased appetite	6 (4.3%)	14 (10.1%)	89 (64.0%)	30 (21.6%)	139
Intrauterine contraception	21 (15.2%)	116 (84.1%)	1 (0.7%)	0 (0.0%)	138
Hereditary angioedema with C1 esterase inhibitor def	9 (6.6%)	72 (52.6%)	49 (35.8%)	7 (5.1%)	137
Hypocalcaemia	24 (17.5%)	24 (17.5%)	73 (53.3%)	16 (11.7%)	137
Sarcoidosis	3 (2.2%)	41 (29.9%)	89 (65.0%)	4 (2.9%)	137
Fabry's disease	29 (21.2%)	52 (38.0%)	51 (37.2%)	5 (3.6%)	137
Haematuria	10 (7.4%)	65 (47.8%)	52 (38.2%)	9 (6.6%)	136
Groin abscess	0 (0.0%)	135 (99.3%)	1 (0.7%)	0 (0.0%)	136
Poisoning deliberate	20 (14.8%)	68 (50.4%)	31 (23.0%)	16 (11.9%)	135
Drug use disorder	20 (14.8%)	80 (59.3%)	33 (24.4%)	2 (1.5%)	135
Stress	2 (1.5%)	62 (45.9%)	23 (17.0%)	48 (35.6%)	135
Pancreatic neuroendocrine tumour	1 (0.7%)	24 (17.8%)	102 (75.6%)	8 (5.9%)	135
Hyperglycaemia	6 (4.5%)	16 (11.9%)	101 (75.4%)	11 (8.2%)	134
Obsessive-compulsive disorder	82 (61.2%)	36 (26.9%)	15 (11.2%)	1 (0.7%)	134

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Thrombocytopenia	36 (27.1%)	29 (21.8%)	51 (38.3%)	17 (12.8%)	133
Pain prophylaxis	1 (0.8%)	29 (21.8%)	86 (64.7%)	17 (12.8%)	133
Metastasis	7 (5.3%)	15 (11.4%)	100 (75.8%)	10 (7.6%)	132
Fluid replacement	12 (9.1%)	59 (44.7%)	57 (43.2%)	4 (3.0%)	132
Schizoaffective disorder bipolar type	64 (48.5%)	31 (23.5%)	37 (28.0%)	0 (0.0%)	132
Blood glucose increased	13 (9.8%)	18 (13.6%)	86 (65.2%)	15 (11.4%)	132
Hypoglycaemia	15 (11.4%)	24 (18.2%)	54 (40.9%)	39 (29.5%)	132
Nephrogenic anaemia	7 (5.3%)	19 (14.4%)	50 (37.9%)	56 (42.4%)	132
Diabetic retinal oedema	0 (0.0%)	11 (8.4%)	107 (81.7%)	13 (9.9%)	131
Psychotic symptom	39 (29.8%)	34 (26.0%)	28 (21.4%)	30 (22.9%)	131
Hypophosphatasia	63 (48.1%)	27 (20.6%)	39 (29.8%)	2 (1.5%)	131
Delirium	4 (3.1%)	49 (37.4%)	59 (45.0%)	19 (14.5%)	131
Acute myeloid leukaemia recurrent	21 (16.2%)	16 (12.3%)	61 (46.9%)	32 (24.6%)	130
Generalised anxiety disorder	5 (3.9%)	42 (32.6%)	78 (60.5%)	4 (3.1%)	129
Septic shock	25 (19.4%)	22 (17.1%)	68 (52.7%)	14 (10.9%)	129
Marginal zone lymphoma	0 (0.0%)	24 (18.6%)	90 (69.8%)	15 (11.6%)	129
Sjogren's syndrome	7 (5.4%)	41 (31.8%)	69 (53.5%)	12 (9.3%)	129
Osteitis	11 (8.5%)	36 (27.9%)	54 (41.9%)	28 (21.7%)	129
Local anaesthesia	18 (14.1%)	31 (24.2%)	56 (43.8%)	23 (18.0%)	128
Systemic mastocytosis	5 (3.9%)	24 (18.8%)	76 (59.4%)	23 (18.0%)	128
Blood pressure management	0 (0.0%)	28 (21.9%)	73 (57.0%)	27 (21.1%)	128
Plasma cell leukaemia	0 (0.0%)	23 (18.1%)	100 (78.7%)	4 (3.1%)	127
Ductal adenocarcinoma of pancreas	0 (0.0%)	7 (5.6%)	82 (65.1%)	37 (29.4%)	126
Fatigue	3 (2.4%)	36 (28.8%)	72 (57.6%)	14 (11.2%)	125
Haemophilia	59 (47.2%)	29 (23.2%)	23 (18.4%)	14 (11.2%)	125
Multiple allergies	26 (20.8%)	46 (36.8%)	48 (38.4%)	5 (4.0%)	125
Graves' disease	42 (33.6%)	45 (36.0%)	32 (25.6%)	6 (4.8%)	125

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Bone disorder	7 (5.7%)	10 (8.1%)	80 (65.0%)	26 (21.1%)	123
Irritable bowel syndrome	3 (2.4%)	34 (27.6%)	63 (51.2%)	23 (18.7%)	123
Sciatica	3 (2.4%)	28 (22.8%)	82 (66.7%)	10 (8.1%)	123
Breast neoplasm	0 (0.0%)	35 (28.5%)	77 (62.6%)	11 (8.9%)	123
Autoimmune thyroiditis	22 (18.0%)	38 (31.1%)	51 (41.8%)	11 (9.0%)	122
Fluid retention	2 (1.6%)	13 (10.7%)	61 (50.0%)	46 (37.7%)	122
Prophylaxis against HIV infection	27 (22.1%)	69 (56.6%)	26 (21.3%)	0 (0.0%)	122
Glioblastoma	10 (8.3%)	42 (34.7%)	59 (48.8%)	10 (8.3%)	121
Symptomatic treatment	9 (7.5%)	16 (13.3%)	75 (62.5%)	20 (16.7%)	120
Diffuse large B-cell lymphoma recurrent	1 (0.8%)	19 (15.8%)	91 (75.8%)	9 (7.5%)	120
Bone cancer	4 (3.3%)	7 (5.8%)	71 (59.2%)	38 (31.7%)	120
Supportive care	2 (1.7%)	57 (47.5%)	51 (42.5%)	10 (8.3%)	120
Procedural pain	11 (9.2%)	17 (14.3%)	83 (69.7%)	8 (6.7%)	119
Pseudomonas infection	19 (16.0%)	29 (24.4%)	52 (43.7%)	19 (16.0%)	119
Endocarditis	5 (4.2%)	15 (12.6%)	52 (43.7%)	47 (39.5%)	119
Adrenocortical carcinoma	8 (6.7%)	80 (67.2%)	31 (26.1%)	0 (0.0%)	119
Vascular device infection	31 (26.3%)	14 (11.9%)	53 (44.9%)	20 (16.9%)	118
Adrenal insufficiency	7 (5.9%)	53 (44.9%)	43 (36.4%)	15 (12.7%)	118
Upper respiratory tract infection	18 (15.3%)	39 (33.1%)	52 (44.1%)	9 (7.6%)	118
Behcet's syndrome	13 (11.0%)	70 (59.3%)	25 (21.2%)	10 (8.5%)	118
Secondary immunodeficiency	9 (7.7%)	11 (9.4%)	76 (65.0%)	21 (17.9%)	117
Ischaemic stroke	0 (0.0%)	12 (10.3%)	67 (57.3%)	38 (32.5%)	117
Enterococcal infection	29 (24.8%)	6 (5.1%)	70 (59.8%)	12 (10.3%)	117
Osteoporosis prophylaxis	3 (2.6%)	20 (17.1%)	76 (65.0%)	18 (15.4%)	117
Prostatitis	0 (0.0%)	49 (41.9%)	56 (47.9%)	12 (10.3%)	117
Peritoneal dialysis	0 (0.0%)	23 (19.7%)	61 (52.1%)	33 (28.2%)	117
Bone pain	1 (0.9%)	34 (29.3%)	62 (53.4%)	19 (16.4%)	116

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Respiratory tract infection	19 (16.5%)	22 (19.1%)	58 (50.4%)	16 (13.9%)	115
Antifungal treatment	20 (17.4%)	31 (27.0%)	57 (49.6%)	7 (6.1%)	115
Richter's syndrome	0 (0.0%)	5 (4.4%)	81 (71.1%)	28 (24.6%)	114
Productive cough	5 (4.4%)	14 (12.3%)	63 (55.3%)	32 (28.1%)	114
Product use in unapproved indication	16 (14.0%)	35 (30.7%)	46 (40.4%)	17 (14.9%)	114
Ovulation induction	1 (0.9%)	113 (99.1%)	0 (0.0%)	0 (0.0%)	114
Oesophageal squamous cell carcinoma	0 (0.0%)	9 (8.0%)	99 (87.6%)	5 (4.4%)	113
Smoking cessation therapy	0 (0.0%)	28 (24.8%)	74 (65.5%)	11 (9.7%)	113
Spondylitis	3 (2.7%)	75 (66.4%)	31 (27.4%)	4 (3.5%)	113
Stomatitis	1 (0.9%)	24 (21.4%)	72 (64.3%)	15 (13.4%)	112
Opportunistic infection prophylaxis	4 (3.6%)	10 (9.0%)	81 (73.0%)	16 (14.4%)	111
Congenital cystic kidney disease	3 (2.7%)	55 (49.5%)	52 (46.8%)	1 (0.9%)	111
Toxicity to various agents	54 (49.1%)	26 (23.6%)	28 (25.5%)	2 (1.8%)	110
Malignant peritoneal neoplasm	2 (1.8%)	13 (11.8%)	80 (72.7%)	15 (13.6%)	110
Constipation prophylaxis	2 (1.8%)	9 (8.2%)	85 (77.3%)	14 (12.7%)	110
Tachycardia	16 (14.7%)	26 (23.9%)	47 (43.1%)	20 (18.3%)	109
Swelling	6 (5.5%)	15 (13.8%)	30 (27.5%)	58 (53.2%)	109
Polyuria	15 (13.8%)	12 (11.0%)	59 (54.1%)	23 (21.1%)	109
Pyoderma gangrenosum	9 (8.3%)	55 (50.5%)	33 (30.3%)	12 (11.0%)	109
Anaphylactic reaction	42 (38.9%)	22 (20.4%)	43 (39.8%)	1 (0.9%)	108
Clostridium difficile infection	12 (11.1%)	29 (26.9%)	42 (38.9%)	25 (23.1%)	108
Intellectual disability	76 (70.4%)	20 (18.5%)	12 (11.1%)	0 (0.0%)	108
Menopausal symptoms	0 (0.0%)	15 (13.9%)	82 (75.9%)	11 (10.2%)	108
Neck pain	2 (1.9%)	46 (42.6%)	41 (38.0%)	19 (17.6%)	108
Leukaemia	37 (34.6%)	7 (6.5%)	43 (40.2%)	20 (18.7%)	107
Colonoscopy	4 (3.7%)	23 (21.5%)	65 (60.7%)	15 (14.0%)	107
Prostatomegaly	0 (0.0%)	3 (2.8%)	63 (58.9%)	41 (38.3%)	107

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastroenteropancreatic neuroendocrine tumour disease	1 (0.9%)	15 (14.0%)	72 (67.3%)	19 (17.8%)	107
Endometrial adenocarcinoma	0 (0.0%)	8 (7.5%)	93 (86.9%)	6 (5.6%)	107
Staphylococcal bacteraemia	17 (15.9%)	17 (15.9%)	48 (44.9%)	25 (23.4%)	107
Palliative care	80 (74.8%)	1 (0.9%)	23 (21.5%)	3 (2.8%)	107
Personality disorder	5 (4.7%)	34 (31.8%)	60 (56.1%)	8 (7.5%)	107
Insulin resistance	5 (4.7%)	75 (70.1%)	27 (25.2%)	0 (0.0%)	107
Diverticulitis	0 (0.0%)	35 (33.0%)	35 (33.0%)	36 (34.0%)	106
Oral herpes	5 (4.7%)	40 (37.7%)	54 (50.9%)	7 (6.6%)	106
Skin disorder	3 (2.8%)	27 (25.5%)	50 (47.2%)	26 (24.5%)	106
Pleural mesothelioma malignant	0 (0.0%)	2 (1.9%)	49 (46.7%)	54 (51.4%)	105
Hot flush	0 (0.0%)	10 (9.5%)	73 (69.5%)	22 (21.0%)	105
Oesophageal cancer metastatic	0 (0.0%)	8 (7.6%)	95 (90.5%)	2 (1.9%)	105
Coagulopathy	16 (15.2%)	4 (3.8%)	40 (38.1%)	45 (42.9%)	105
Polycythaemia vera	9 (8.7%)	12 (11.5%)	62 (59.6%)	21 (20.2%)	104
Rheumatic disorder	3 (2.9%)	21 (20.2%)	34 (32.7%)	46 (44.2%)	104
Medulloblastoma	94 (90.4%)	10 (9.6%)	0 (0.0%)	0 (0.0%)	104
Ventricular fibrillation	4 (3.8%)	2 (1.9%)	12 (11.5%)	86 (82.7%)	104
Skin infection	10 (9.6%)	16 (15.4%)	60 (57.7%)	18 (17.3%)	104
Low density lipoprotein increased	0 (0.0%)	7 (6.8%)	78 (75.7%)	18 (17.5%)	103
Acute myeloid leukaemia refractory	14 (13.7%)	14 (13.7%)	41 (40.2%)	33 (32.4%)	102
Vasculitis	7 (6.9%)	27 (26.7%)	54 (53.5%)	13 (12.9%)	101
Lung carcinoma cell type unspecified stage IV	1 (1.0%)	3 (3.0%)	91 (90.1%)	6 (5.9%)	101
Hypomagnesaemia	3 (3.0%)	6 (6.0%)	75 (75.0%)	16 (16.0%)	100
Antiinflammatory therapy	12 (12.0%)	24 (24.0%)	53 (53.0%)	11 (11.0%)	100
K-ras gene mutation	0 (0.0%)	4 (4.0%)	84 (84.0%)	12 (12.0%)	100
Atrial flutter	2 (2.0%)	5 (5.1%)	57 (57.6%)	35 (35.4%)	99
Allergy prophylaxis	2 (2.0%)	11 (11.1%)	83 (83.8%)	3 (3.0%)	99

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Antacid therapy	2 (2.0%)	5 (5.1%)	27 (27.6%)	64 (65.3%)	98
Suicidal ideation	23 (23.5%)	31 (31.6%)	44 (44.9%)	0 (0.0%)	98
Antiemetic supportive care	9 (9.2%)	36 (36.7%)	51 (52.0%)	2 (2.0%)	98
Acute promyelocytic leukaemia	10 (10.3%)	38 (39.2%)	32 (33.0%)	17 (17.5%)	97
Nervous system disorder	13 (13.4%)	47 (48.5%)	30 (30.9%)	7 (7.2%)	97
Glioma	26 (26.8%)	47 (48.5%)	24 (24.7%)	0 (0.0%)	97
Transplant	63 (65.6%)	10 (10.4%)	22 (22.9%)	1 (1.0%)	96
Wheezing	15 (15.6%)	13 (13.5%)	50 (52.1%)	18 (18.8%)	96
Antiallergic therapy	16 (16.7%)	14 (14.6%)	57 (59.4%)	9 (9.4%)	96
Dementia with Lewy bodies	0 (0.0%)	0 (0.0%)	62 (64.6%)	34 (35.4%)	96
Lung transplant	9 (9.5%)	14 (14.7%)	70 (73.7%)	2 (2.1%)	95
Haemorrhoids	22 (23.2%)	16 (16.8%)	52 (54.7%)	5 (5.3%)	95
Alcohol withdrawal syndrome	0 (0.0%)	67 (71.3%)	27 (28.7%)	0 (0.0%)	94
Computerised tomogram abdomen	3 (3.2%)	30 (31.9%)	43 (45.7%)	18 (19.1%)	94
Focal segmental glomerulosclerosis	65 (69.1%)	8 (8.5%)	16 (17.0%)	5 (5.3%)	94
Desmoplastic small round cell tumour	24 (25.5%)	70 (74.5%)	0 (0.0%)	0 (0.0%)	94
Atypical mycobacterial infection	5 (5.4%)	30 (32.3%)	54 (58.1%)	4 (4.3%)	93
Lung squamous cell carcinoma stage IV	0 (0.0%)	0 (0.0%)	83 (89.2%)	10 (10.8%)	93
Metastases to peritoneum	0 (0.0%)	21 (22.6%)	66 (71.0%)	6 (6.5%)	93
Angioedema	5 (5.4%)	45 (48.9%)	29 (31.5%)	13 (14.1%)	92
Familial mediterranean fever	51 (55.4%)	29 (31.5%)	10 (10.9%)	2 (2.2%)	92
Cardiogenic shock	0 (0.0%)	17 (18.5%)	31 (33.7%)	44 (47.8%)	92
Neutrophil count decreased	1 (1.1%)	19 (20.7%)	46 (50.0%)	26 (28.3%)	92
Hyperparathyroidism secondary	0 (0.0%)	18 (19.8%)	50 (54.9%)	23 (25.3%)	91
Phenylketonuria	57 (62.6%)	28 (30.8%)	6 (6.6%)	0 (0.0%)	91
Myelofibrosis	0 (0.0%)	1 (1.1%)	58 (63.7%)	32 (35.2%)	91
Osteopenia	7 (7.7%)	4 (4.4%)	55 (60.4%)	25 (27.5%)	91

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mycobacterial infection	13 (14.3%)	40 (44.0%)	27 (29.7%)	11 (12.1%)	91
Aggression	54 (59.3%)	25 (27.5%)	5 (5.5%)	7 (7.7%)	91
Osteosarcoma	64 (71.1%)	18 (20.0%)	8 (8.9%)	0 (0.0%)	90
Chronic sinusitis	0 (0.0%)	35 (38.9%)	48 (53.3%)	7 (7.8%)	90
Myocarditis	22 (24.4%)	18 (20.0%)	45 (50.0%)	5 (5.6%)	90
Graft versus host disease in gastrointestinal tract	7 (7.8%)	35 (38.9%)	48 (53.3%)	0 (0.0%)	90
HER2 positive gastric cancer	9 (10.0%)	1 (1.1%)	67 (74.4%)	13 (14.4%)	90
Colon neoplasm	0 (0.0%)	0 (0.0%)	78 (86.7%)	12 (13.3%)	90
Rheumatoid factor positive	2 (2.2%)	14 (15.7%)	62 (69.7%)	11 (12.4%)	89
Growth disorder	86 (96.6%)	1 (1.1%)	2 (2.2%)	0 (0.0%)	89
Invasive breast carcinoma	0 (0.0%)	52 (58.4%)	36 (40.4%)	1 (1.1%)	89
Dental local anaesthesia	22 (25.0%)	35 (39.8%)	28 (31.8%)	3 (3.4%)	88
Acute coronary syndrome	0 (0.0%)	12 (13.6%)	64 (72.7%)	12 (13.6%)	88
Endometriosis	23 (26.1%)	63 (71.6%)	1 (1.1%)	1 (1.1%)	88
Migraine without aura	14 (15.9%)	38 (43.2%)	35 (39.8%)	1 (1.1%)	88
Bipolar II disorder	23 (26.1%)	46 (52.3%)	19 (21.6%)	0 (0.0%)	88
Muscle relaxant therapy	8 (9.1%)	27 (30.7%)	50 (56.8%)	3 (3.4%)	88
Emphysema	0 (0.0%)	0 (0.0%)	64 (73.6%)	23 (26.4%)	87
Arthritis bacterial	5 (5.8%)	15 (17.4%)	31 (36.0%)	35 (40.7%)	86
Encephalitis autoimmune	35 (40.7%)	40 (46.5%)	11 (12.8%)	0 (0.0%)	86
Lower respiratory tract infection	15 (17.4%)	16 (18.6%)	51 (59.3%)	4 (4.7%)	86
Refractory cancer	85 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	85
Malabsorption	21 (24.7%)	22 (25.9%)	34 (40.0%)	8 (9.4%)	85
Combined immunodeficiency	34 (40.0%)	35 (41.2%)	13 (15.3%)	3 (3.5%)	85
Proteinuria	20 (23.5%)	24 (28.2%)	29 (34.1%)	12 (14.1%)	85
Acute leukaemia	7 (8.2%)	16 (18.8%)	57 (67.1%)	5 (5.9%)	85
Rhinitis	20 (23.5%)	12 (14.1%)	38 (44.7%)	15 (17.6%)	85

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Haemorrhage prophylaxis	29 (34.1%)	10 (11.8%)	43 (50.6%)	3 (3.5%)	85
Spinal pain	5 (5.9%)	31 (36.5%)	37 (43.5%)	12 (14.1%)	85
Monoclonal gammopathy	0 (0.0%)	12 (14.1%)	44 (51.8%)	29 (34.1%)	85
Pneumonia aspiration	1 (1.2%)	5 (5.9%)	52 (61.2%)	27 (31.8%)	85
Senile osteoporosis	0 (0.0%)	4 (4.8%)	55 (65.5%)	25 (29.8%)	84
Glycogen storage disease type II	40 (47.6%)	21 (25.0%)	21 (25.0%)	2 (2.4%)	84
Magnetic resonance imaging	8 (9.5%)	29 (34.5%)	36 (42.9%)	11 (13.1%)	84
Renal cancer metastatic	0 (0.0%)	2 (2.4%)	72 (85.7%)	10 (11.9%)	84
Philadelphia chromosome positive	1 (1.2%)	44 (53.0%)	33 (39.8%)	5 (6.0%)	83
Spinal anaesthesia	26 (31.3%)	28 (33.7%)	24 (28.9%)	5 (6.0%)	83
Glomerulonephritis membranous	5 (6.0%)	38 (45.8%)	38 (45.8%)	2 (2.4%)	83
Lung carcinoma cell type unspecified stage 0	0 (0.0%)	4 (4.9%)	50 (61.0%)	28 (34.1%)	82
Secretion discharge	4 (4.9%)	1 (1.2%)	4 (4.9%)	73 (89.0%)	82
Polyneuropathy	6 (7.3%)	47 (57.3%)	19 (23.2%)	10 (12.2%)	82
Idiopathic urticaria	7 (8.6%)	42 (51.9%)	28 (34.6%)	4 (4.9%)	81
Left ventricular failure	0 (0.0%)	9 (11.1%)	48 (59.3%)	24 (29.6%)	81
Atypical teratoid/rhabdoid tumour of CNS	77 (95.1%)	0 (0.0%)	4 (4.9%)	0 (0.0%)	81
Acute graft versus host disease	51 (63.0%)	10 (12.3%)	19 (23.5%)	1 (1.2%)	81
Langerhans' cell histiocytosis	52 (64.2%)	12 (14.8%)	3 (3.7%)	14 (17.3%)	81
Thyrototoxic crisis	6 (7.5%)	64 (80.0%)	10 (12.5%)	0 (0.0%)	80
Head and neck cancer	0 (0.0%)	4 (5.0%)	54 (67.5%)	22 (27.5%)	80
Bone marrow transplant	25 (31.3%)	5 (6.3%)	49 (61.3%)	1 (1.3%)	80
Transient ischaemic attack	0 (0.0%)	1 (1.3%)	39 (48.8%)	40 (50.0%)	80
Ovarian epithelial cancer	0 (0.0%)	42 (52.5%)	27 (33.8%)	11 (13.8%)	80
Multiple sclerosis relapse	3 (3.8%)	58 (72.5%)	19 (23.8%)	0 (0.0%)	80
Skin ulcer	2 (2.5%)	17 (21.3%)	52 (65.0%)	9 (11.3%)	80
Anal cancer	0 (0.0%)	17 (21.3%)	54 (67.5%)	9 (11.3%)	80

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Alcoholism	2 (2.5%)	49 (62.0%)	27 (34.2%)	1 (1.3%)	79
Metastatic neoplasm	5 (6.3%)	21 (26.6%)	46 (58.2%)	7 (8.9%)	79
Parkinsonism	0 (0.0%)	10 (12.7%)	55 (69.6%)	14 (17.7%)	79
Cystitis	3 (3.8%)	8 (10.1%)	43 (54.4%)	25 (31.6%)	79
Panic disorder	10 (12.7%)	39 (49.4%)	25 (31.6%)	5 (6.3%)	79
Astrocytoma	17 (21.5%)	44 (55.7%)	18 (22.8%)	0 (0.0%)	79
Maintenance of anaesthesia	26 (32.9%)	23 (29.1%)	21 (26.6%)	9 (11.4%)	79
Nasal congestion	16 (20.3%)	15 (19.0%)	41 (51.9%)	7 (8.9%)	79
Tremor	7 (8.9%)	4 (5.1%)	54 (68.4%)	14 (17.7%)	79
Intervertebral discitis	0 (0.0%)	17 (21.5%)	38 (48.1%)	24 (30.4%)	79
Arthritis infective	11 (14.1%)	6 (7.7%)	59 (75.6%)	2 (2.6%)	78
Spondyloarthropathy	2 (2.6%)	33 (42.3%)	40 (51.3%)	3 (3.8%)	78
Dyskinesia	7 (9.0%)	9 (11.5%)	44 (56.4%)	18 (23.1%)	78
B-cell small lymphocytic lymphoma	0 (0.0%)	2 (2.6%)	55 (70.5%)	21 (26.9%)	78
B-cell lymphoma refractory	0 (0.0%)	7 (9.0%)	71 (91.0%)	0 (0.0%)	78
Hiatus hernia	1 (1.3%)	4 (5.1%)	60 (76.9%)	13 (16.7%)	78
Pneumonia bacterial	2 (2.6%)	3 (3.9%)	48 (62.3%)	24 (31.2%)	77
Open angle glaucoma	0 (0.0%)	18 (23.4%)	33 (42.9%)	26 (33.8%)	77
Proctalgia	63 (81.8%)	7 (9.1%)	6 (7.8%)	1 (1.3%)	77
Bronchospasm	11 (14.3%)	14 (18.2%)	37 (48.1%)	15 (19.5%)	77
Peritonitis	21 (27.3%)	13 (16.9%)	24 (31.2%)	19 (24.7%)	77
General physical condition	13 (16.9%)	11 (14.3%)	46 (59.7%)	7 (9.1%)	77
Gestational diabetes	19 (24.7%)	58 (75.3%)	0 (0.0%)	0 (0.0%)	77
Dehydration	23 (29.9%)	8 (10.4%)	35 (45.5%)	11 (14.3%)	77
Breast cancer recurrent	0 (0.0%)	13 (16.9%)	49 (63.6%)	15 (19.5%)	77
Bladder transitional cell carcinoma	0 (0.0%)	1 (1.3%)	59 (77.6%)	16 (21.1%)	76
Follicular lymphoma stage IV	0 (0.0%)	13 (17.1%)	38 (50.0%)	25 (32.9%)	76

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Drug reaction with eosinophilia and systemic symptom	36 (47.4%)	6 (7.9%)	30 (39.5%)	4 (5.3%)	76
Myositis	4 (5.3%)	34 (44.7%)	32 (42.1%)	6 (7.9%)	76
Macular degeneration	0 (0.0%)	3 (3.9%)	26 (34.2%)	47 (61.8%)	76
Psychiatric symptom	12 (15.8%)	39 (51.3%)	25 (32.9%)	0 (0.0%)	76
Antiviral treatment	15 (20.0%)	21 (28.0%)	32 (42.7%)	7 (9.3%)	75
Overweight	1 (1.3%)	30 (40.0%)	43 (57.3%)	1 (1.3%)	75
Cluster headache	3 (4.0%)	53 (70.7%)	19 (25.3%)	0 (0.0%)	75
Bowel movement irregularity	0 (0.0%)	1 (1.3%)	44 (58.7%)	30 (40.0%)	75
Dizziness	10 (13.3%)	10 (13.3%)	45 (60.0%)	10 (13.3%)	75
Pneumothorax	1 (1.3%)	4 (5.3%)	4 (5.3%)	66 (88.0%)	75
Pustular psoriasis	13 (17.3%)	17 (22.7%)	35 (46.7%)	10 (13.3%)	75
Chronic gastritis	2 (2.7%)	15 (20.0%)	41 (54.7%)	17 (22.7%)	75
Dry skin	8 (10.7%)	11 (14.7%)	43 (57.3%)	13 (17.3%)	75
Liver disorder	8 (10.8%)	19 (25.7%)	42 (56.8%)	5 (6.8%)	74
Peripheral arterial occlusive disease	1 (1.4%)	0 (0.0%)	44 (59.5%)	29 (39.2%)	74
Pancreatic failure	5 (6.8%)	18 (24.3%)	35 (47.3%)	16 (21.6%)	74
Blood triglycerides increased	1 (1.4%)	6 (8.1%)	52 (70.3%)	15 (20.3%)	74
Cushing's syndrome	4 (5.4%)	23 (31.1%)	35 (47.3%)	12 (16.2%)	74
Ovarian cancer stage III	0 (0.0%)	7 (9.5%)	67 (90.5%)	0 (0.0%)	74
Cervix carcinoma stage IV	0 (0.0%)	29 (39.7%)	44 (60.3%)	0 (0.0%)	73
Pericarditis	4 (5.5%)	44 (60.3%)	17 (23.3%)	8 (11.0%)	73
Clinically isolated syndrome	2 (2.7%)	27 (37.0%)	43 (58.9%)	1 (1.4%)	73
Stiff person syndrome	14 (19.2%)	51 (69.9%)	8 (11.0%)	0 (0.0%)	73
Conjunctivitis	12 (16.4%)	9 (12.3%)	36 (49.3%)	16 (21.9%)	73
Duchenne muscular dystrophy	69 (94.5%)	4 (5.5%)	0 (0.0%)	0 (0.0%)	73
Ovarian cancer recurrent	0 (0.0%)	9 (12.3%)	60 (82.2%)	4 (5.5%)	73
Dermatitis contact	7 (9.6%)	24 (32.9%)	30 (41.1%)	12 (16.4%)	73

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tumour lysis syndrome	7 (9.6%)	14 (19.2%)	23 (31.5%)	29 (39.7%)	73
Primary mediastinal large B-cell lymphoma	56 (76.7%)	17 (23.3%)	0 (0.0%)	0 (0.0%)	73
Vitamin B12 deficiency	13 (17.8%)	16 (21.9%)	33 (45.2%)	11 (15.1%)	73
Selective IgG subclass deficiency	0 (0.0%)	15 (20.5%)	48 (65.8%)	10 (13.7%)	73
Autoimmune haemolytic anaemia	17 (23.6%)	3 (4.2%)	50 (69.4%)	2 (2.8%)	72
Meningitis tuberculous	24 (33.3%)	9 (12.5%)	35 (48.6%)	4 (5.6%)	72
Erythema	14 (19.4%)	12 (16.7%)	31 (43.1%)	15 (20.8%)	72
In vitro fertilisation	0 (0.0%)	72 (100.0%)	0 (0.0%)	0 (0.0%)	72
Burkitt's lymphoma stage IV	0 (0.0%)	42 (58.3%)	30 (41.7%)	0 (0.0%)	72
Primary biliary cholangitis	0 (0.0%)	12 (16.7%)	48 (66.7%)	12 (16.7%)	72
Adjuvant therapy	1 (1.4%)	32 (45.1%)	30 (42.3%)	8 (11.3%)	71
Scleroderma	10 (14.1%)	12 (16.9%)	44 (62.0%)	5 (7.0%)	71
Insulin-requiring type 2 diabetes mellitus	1 (1.4%)	1 (1.4%)	46 (64.8%)	23 (32.4%)	71
Blood uric acid increased	1 (1.4%)	9 (12.7%)	17 (23.9%)	44 (62.0%)	71
Hypertriglyceridaemia	10 (14.1%)	26 (36.6%)	33 (46.5%)	2 (2.8%)	71
Dyshidrotic eczema	5 (7.0%)	31 (43.7%)	34 (47.9%)	1 (1.4%)	71
Ulcer	6 (8.5%)	18 (25.4%)	28 (39.4%)	19 (26.8%)	71
Plasmacytoma	0 (0.0%)	13 (18.3%)	45 (63.4%)	13 (18.3%)	71
Toothache	24 (34.3%)	37 (52.9%)	7 (10.0%)	2 (2.9%)	70
Blood glucose abnormal	0 (0.0%)	12 (17.1%)	44 (62.9%)	14 (20.0%)	70
Carcinoid syndrome	0 (0.0%)	5 (7.1%)	50 (71.4%)	15 (21.4%)	70
Colon cancer stage IV	0 (0.0%)	9 (12.9%)	37 (52.9%)	24 (34.3%)	70
Vulvovaginal dryness	0 (0.0%)	3 (4.3%)	57 (81.4%)	10 (14.3%)	70
Acquired ATTR amyloidosis	0 (0.0%)	1 (1.4%)	21 (30.0%)	48 (68.6%)	70
Age-related macular degeneration	0 (0.0%)	0 (0.0%)	24 (34.3%)	46 (65.7%)	70
Chronic hepatitis B	1 (1.4%)	18 (25.7%)	48 (68.6%)	3 (4.3%)	70
Pelvic pain	13 (18.6%)	29 (41.4%)	26 (37.1%)	2 (2.9%)	70

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Depressed mood	12 (17.4%)	12 (17.4%)	38 (55.1%)	7 (10.1%)	69
Urinary incontinence	3 (4.3%)	5 (7.2%)	34 (49.3%)	27 (39.1%)	69
Gastrointestinal haemorrhage	10 (14.5%)	9 (13.0%)	28 (40.6%)	22 (31.9%)	69
Hepatic cirrhosis	3 (4.3%)	6 (8.7%)	47 (68.1%)	13 (18.8%)	69
Osteolysis	0 (0.0%)	3 (4.3%)	50 (72.5%)	16 (23.2%)	69
Hallucination, auditory	39 (56.5%)	20 (29.0%)	8 (11.6%)	2 (2.9%)	69
Chronic myelomonocytic leukaemia	0 (0.0%)	7 (10.3%)	39 (57.4%)	22 (32.4%)	68
Diagnostic procedure	9 (13.2%)	20 (29.4%)	37 (54.4%)	2 (2.9%)	68
Metastatic gastric cancer	0 (0.0%)	6 (8.8%)	32 (47.1%)	30 (44.1%)	68
Respiratory failure	5 (7.4%)	10 (14.7%)	42 (61.8%)	11 (16.2%)	68
Bronchiectasis	4 (5.9%)	4 (5.9%)	44 (64.7%)	16 (23.5%)	68
Hodgkin's disease stage IV	59 (86.8%)	1 (1.5%)	8 (11.8%)	0 (0.0%)	68
Squamous cell carcinoma of skin	0 (0.0%)	4 (5.9%)	44 (64.7%)	20 (29.4%)	68
Breast cancer stage II	0 (0.0%)	27 (39.7%)	36 (52.9%)	5 (7.4%)	68
Acute kidney injury	7 (10.4%)	9 (13.4%)	37 (55.2%)	14 (20.9%)	67
Pyelonephritis	5 (7.5%)	12 (17.9%)	43 (64.2%)	7 (10.4%)	67
Hyperemesis gravidarum	3 (4.5%)	64 (95.5%)	0 (0.0%)	0 (0.0%)	67
Arthropathy	0 (0.0%)	15 (22.4%)	45 (67.2%)	7 (10.4%)	67
Acquired immunodeficiency syndrome	5 (7.5%)	47 (70.1%)	15 (22.4%)	0 (0.0%)	67
Oesophagitis	9 (13.4%)	9 (13.4%)	44 (65.7%)	5 (7.5%)	67
Meningitis cryptococcal	0 (0.0%)	5 (7.5%)	59 (88.1%)	3 (4.5%)	67
Renal disorder	4 (6.0%)	12 (17.9%)	30 (44.8%)	21 (31.3%)	67
Drug hypersensitivity	4 (6.0%)	4 (6.0%)	40 (59.7%)	19 (28.4%)	67
Hyponatraemia	2 (3.0%)	13 (19.7%)	27 (40.9%)	24 (36.4%)	66
Post procedural infection	10 (15.2%)	1 (1.5%)	15 (22.7%)	40 (60.6%)	66
Hepatic function abnormal	0 (0.0%)	19 (28.8%)	35 (53.0%)	12 (18.2%)	66
Pneumonia pseudomonal	0 (0.0%)	29 (43.9%)	35 (53.0%)	2 (3.0%)	66

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Acute respiratory distress syndrome	11 (16.7%)	30 (45.5%)	22 (33.3%)	3 (4.5%)	66
Colorectal cancer stage IV	0 (0.0%)	6 (9.1%)	60 (90.9%)	0 (0.0%)	66
Plasma cell myeloma recurrent	0 (0.0%)	6 (9.1%)	45 (68.2%)	15 (22.7%)	66
Pollakiuria	0 (0.0%)	35 (53.0%)	18 (27.3%)	13 (19.7%)	66
Epidural anaesthesia	3 (4.5%)	63 (95.5%)	0 (0.0%)	0 (0.0%)	66
Enterobacter infection	18 (27.3%)	36 (54.5%)	9 (13.6%)	3 (4.5%)	66
Hyperphosphataemia	0 (0.0%)	8 (12.3%)	23 (35.4%)	34 (52.3%)	65
Colorectal adenocarcinoma	3 (4.6%)	17 (26.2%)	38 (58.5%)	7 (10.8%)	65
Prader-Willi syndrome	60 (92.3%)	5 (7.7%)	0 (0.0%)	0 (0.0%)	65
Bursitis	0 (0.0%)	38 (58.5%)	12 (18.5%)	15 (23.1%)	65
Idiopathic generalised epilepsy	19 (29.2%)	46 (70.8%)	0 (0.0%)	0 (0.0%)	65
Angioimmunoblastic T-cell lymphoma	0 (0.0%)	2 (3.1%)	51 (78.5%)	12 (18.5%)	65
Atrophic vulvovaginitis	0 (0.0%)	1 (1.6%)	44 (68.8%)	19 (29.7%)	64
Immune-mediated myositis	0 (0.0%)	32 (50.0%)	28 (43.8%)	4 (6.3%)	64
Cardiac arrest	41 (64.1%)	13 (20.3%)	8 (12.5%)	2 (3.1%)	64
Mucosal inflammation	1 (1.6%)	4 (6.3%)	24 (37.5%)	35 (54.7%)	64
Supraventricular tachycardia	17 (26.6%)	24 (37.5%)	15 (23.4%)	8 (12.5%)	64
Dysuria	2 (3.2%)	13 (20.6%)	26 (41.3%)	22 (34.9%)	63
Sarcoma	19 (30.2%)	11 (17.5%)	24 (38.1%)	9 (14.3%)	63
Platelet count decreased	4 (6.3%)	14 (22.2%)	38 (60.3%)	7 (11.1%)	63
Nerve block	22 (34.9%)	10 (15.9%)	30 (47.6%)	1 (1.6%)	63
Scan with contrast	6 (9.5%)	19 (30.2%)	31 (49.2%)	7 (11.1%)	63
Hypereosinophilic syndrome	1 (1.6%)	26 (41.3%)	29 (46.0%)	7 (11.1%)	63
Tooth infection	13 (21.0%)	15 (24.2%)	30 (48.4%)	4 (6.5%)	62
Prostatic specific antigen	0 (0.0%)	58 (93.5%)	4 (6.5%)	0 (0.0%)	62
Soft tissue sarcoma	11 (17.7%)	17 (27.4%)	30 (48.4%)	4 (6.5%)	62
Basal cell carcinoma	0 (0.0%)	5 (8.1%)	30 (48.4%)	27 (43.5%)	62

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Skin cosmetic procedure	2 (3.2%)	36 (58.1%)	20 (32.3%)	4 (6.5%)	62
High-grade B-cell lymphoma	0 (0.0%)	11 (17.7%)	51 (82.3%)	0 (0.0%)	62
Acquired haemophilia	0 (0.0%)	2 (3.2%)	27 (43.5%)	33 (53.2%)	62
Polycystic ovaries	3 (4.9%)	53 (86.9%)	5 (8.2%)	0 (0.0%)	61
Angiogram	1 (1.6%)	13 (21.3%)	35 (57.4%)	12 (19.7%)	61
Glomerulonephritis minimal lesion	57 (93.4%)	3 (4.9%)	1 (1.6%)	0 (0.0%)	61
Recurrent cancer	47 (77.0%)	14 (23.0%)	0 (0.0%)	0 (0.0%)	61
Androgenetic alopecia	11 (18.0%)	39 (63.9%)	11 (18.0%)	0 (0.0%)	61
Viral infection	15 (24.6%)	13 (21.3%)	26 (42.6%)	7 (11.5%)	61
Prostatic disorder	0 (0.0%)	1 (1.6%)	42 (68.9%)	18 (29.5%)	61
Endophthalmitis	0 (0.0%)	13 (21.3%)	37 (60.7%)	11 (18.0%)	61
Spinal osteoarthritis	4 (6.6%)	27 (44.3%)	26 (42.6%)	4 (6.6%)	61
Paronychia	2 (3.3%)	4 (6.6%)	49 (80.3%)	6 (9.8%)	61
Brain neoplasm malignant	20 (32.8%)	11 (18.0%)	25 (41.0%)	5 (8.2%)	61
Herpes simplex	12 (19.7%)	13 (21.3%)	15 (24.6%)	21 (34.4%)	61
Glomerulonephritis	10 (16.4%)	8 (13.1%)	25 (41.0%)	18 (29.5%)	61
Electrolyte substitution therapy	2 (3.3%)	10 (16.7%)	46 (76.7%)	2 (3.3%)	60
Von Willebrand's disease	20 (33.3%)	20 (33.3%)	13 (21.7%)	7 (11.7%)	60
Angiocardiogram	0 (0.0%)	15 (25.0%)	32 (53.3%)	13 (21.7%)	60
Gait disturbance	0 (0.0%)	20 (33.3%)	30 (50.0%)	10 (16.7%)	60
Uterine leiomyoma	0 (0.0%)	53 (88.3%)	7 (11.7%)	0 (0.0%)	60
Drug eruption	4 (6.7%)	8 (13.3%)	31 (51.7%)	17 (28.3%)	60
Medical device site joint infection	0 (0.0%)	0 (0.0%)	59 (98.3%)	1 (1.7%)	60
Anxiolytic therapy	0 (0.0%)	15 (25.4%)	38 (64.4%)	6 (10.2%)	59
Essential thrombocythaemia	0 (0.0%)	9 (15.3%)	25 (42.4%)	25 (42.4%)	59
Encephalitis	11 (18.6%)	16 (27.1%)	27 (45.8%)	5 (8.5%)	59
Steroid therapy	12 (20.3%)	11 (18.6%)	30 (50.8%)	6 (10.2%)	59

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Acute lymphocytic leukaemia recurrent	29 (49.2%)	6 (10.2%)	23 (39.0%)	1 (1.7%)	59
Pleural mesothelioma	0 (0.0%)	12 (20.3%)	35 (59.3%)	12 (20.3%)	59
Philadelphia positive chronic myeloid leukaemia	2 (3.4%)	21 (35.6%)	28 (47.5%)	8 (13.6%)	59
Polyarteritis nodosa	3 (5.1%)	19 (32.2%)	37 (62.7%)	0 (0.0%)	59
Prolactin-producing pituitary tumour	0 (0.0%)	48 (81.4%)	9 (15.3%)	2 (3.4%)	59
Overlap syndrome	2 (3.4%)	42 (71.2%)	10 (16.9%)	5 (8.5%)	59
Meningitis	8 (13.6%)	15 (25.4%)	35 (59.3%)	1 (1.7%)	59
Disease progression	0 (0.0%)	10 (16.9%)	46 (78.0%)	3 (5.1%)	59
Synovitis	5 (8.6%)	42 (72.4%)	10 (17.2%)	1 (1.7%)	58
Dysmenorrhoea	32 (55.2%)	25 (43.1%)	1 (1.7%)	0 (0.0%)	58
Rosacea	3 (5.2%)	20 (34.5%)	27 (46.6%)	8 (13.8%)	58
Localised infection	4 (6.9%)	2 (3.4%)	36 (62.1%)	16 (27.6%)	58
Cardiomyopathy	1 (1.7%)	3 (5.2%)	40 (69.0%)	14 (24.1%)	58
Diabetic ketoacidosis	13 (22.4%)	20 (34.5%)	23 (39.7%)	2 (3.4%)	58
Pre-eclampsia	7 (12.1%)	51 (87.9%)	0 (0.0%)	0 (0.0%)	58
Mood swings	37 (63.8%)	14 (24.1%)	7 (12.1%)	0 (0.0%)	58
Gastroenteritis	21 (36.2%)	12 (20.7%)	18 (31.0%)	7 (12.1%)	58
Oropharyngeal pain	13 (22.4%)	21 (36.2%)	19 (32.8%)	5 (8.6%)	58
Pneumonitis	1 (1.7%)	4 (6.9%)	38 (65.5%)	15 (25.9%)	58
Small cell lung cancer metastatic	0 (0.0%)	6 (10.5%)	42 (73.7%)	9 (15.8%)	57
White blood cell count decreased	1 (1.8%)	7 (12.3%)	39 (68.4%)	10 (17.5%)	57
Dilated cardiomyopathy	27 (47.4%)	17 (29.8%)	13 (22.8%)	0 (0.0%)	57
Infusion related reaction	6 (10.5%)	22 (38.6%)	16 (28.1%)	13 (22.8%)	57
Castleman's disease	12 (21.1%)	10 (17.5%)	26 (45.6%)	9 (15.8%)	57
Thyroidectomy	2 (3.5%)	14 (24.6%)	34 (59.6%)	7 (12.3%)	57
Dysphonia	0 (0.0%)	0 (0.0%)	4 (7.0%)	53 (93.0%)	57
Withdrawal syndrome	1 (1.8%)	54 (94.7%)	2 (3.5%)	0 (0.0%)	57

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Glycosylated haemoglobin increased	0 (0.0%)	23 (40.4%)	27 (47.4%)	7 (12.3%)	57
T-cell lymphoma	2 (3.5%)	15 (26.3%)	35 (61.4%)	5 (8.8%)	57
Rhinorrhoea	5 (8.9%)	7 (12.5%)	24 (42.9%)	20 (35.7%)	56
Iridocyclitis	13 (23.2%)	19 (33.9%)	24 (42.9%)	0 (0.0%)	56
Blood phosphorus increased	0 (0.0%)	1 (1.8%)	2 (3.6%)	53 (94.6%)	56
Therapeutic procedure	3 (5.4%)	23 (41.1%)	29 (51.8%)	1 (1.8%)	56
Stress echocardiogram	0 (0.0%)	9 (16.1%)	43 (76.8%)	4 (7.1%)	56
Gastrooesophageal reflux prophylaxis	0 (0.0%)	8 (14.3%)	37 (66.1%)	11 (19.6%)	56
Positron emission tomogram	0 (0.0%)	1 (1.8%)	32 (57.1%)	23 (41.1%)	56
Gastrointestinal disorder therapy	0 (0.0%)	9 (16.1%)	38 (67.9%)	9 (16.1%)	56
Immunoglobulin G4 related disease	0 (0.0%)	3 (5.4%)	45 (80.4%)	8 (14.3%)	56
Renal impairment	1 (1.8%)	5 (8.9%)	38 (67.9%)	12 (21.4%)	56
Haematopoietic stem cell mobilisation	13 (23.2%)	15 (26.8%)	28 (50.0%)	0 (0.0%)	56
Nocardiosis	0 (0.0%)	15 (26.8%)	37 (66.1%)	4 (7.1%)	56
Embolism	0 (0.0%)	5 (8.9%)	43 (76.8%)	8 (14.3%)	56
Transgender hormonal therapy	23 (41.8%)	24 (43.6%)	8 (14.5%)	0 (0.0%)	55
Oesophageal carcinoma recurrent	0 (0.0%)	0 (0.0%)	35 (63.6%)	20 (36.4%)	55
Systemic candida	25 (45.5%)	6 (10.9%)	14 (25.5%)	10 (18.2%)	55
Invasive lobular breast carcinoma	0 (0.0%)	8 (14.5%)	24 (43.6%)	23 (41.8%)	55
Philadelphia positive acute lymphocytic leukaemia	14 (25.5%)	15 (27.3%)	24 (43.6%)	2 (3.6%)	55
Blood growth hormone abnormal	49 (89.1%)	1 (1.8%)	4 (7.3%)	1 (1.8%)	55
Nephroblastoma	55 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	55
Angina unstable	0 (0.0%)	3 (5.5%)	14 (25.5%)	38 (69.1%)	55
Neutrophic keratopathy	1 (1.8%)	9 (16.4%)	27 (49.1%)	18 (32.7%)	55
Alopecia scarring	0 (0.0%)	44 (80.0%)	10 (18.2%)	1 (1.8%)	55
Morning sickness	17 (31.5%)	37 (68.5%)	0 (0.0%)	0 (0.0%)	54
Postoperative wound infection	1 (1.9%)	14 (25.9%)	25 (46.3%)	14 (25.9%)	54

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Analgesic intervention supportive therapy	3 (5.6%)	15 (27.8%)	21 (38.9%)	15 (27.8%)	54
Glioblastoma multiforme	10 (18.5%)	11 (20.4%)	33 (61.1%)	0 (0.0%)	54
Cognitive disorder	0 (0.0%)	1 (1.9%)	29 (53.7%)	24 (44.4%)	54
Musculoskeletal pain	0 (0.0%)	11 (20.4%)	20 (37.0%)	23 (42.6%)	54
Squamous cell carcinoma of the cervix	0 (0.0%)	8 (14.8%)	45 (83.3%)	1 (1.9%)	54
Temporal lobe epilepsy	21 (38.9%)	20 (37.0%)	2 (3.7%)	11 (20.4%)	54
Colitis microscopic	0 (0.0%)	15 (27.8%)	34 (63.0%)	5 (9.3%)	54
Klebsiella infection	8 (14.8%)	12 (22.2%)	26 (48.1%)	8 (14.8%)	54
Myoclonus	12 (22.6%)	19 (35.8%)	18 (34.0%)	4 (7.5%)	53
Hypoalbuminaemia	2 (3.8%)	6 (11.3%)	43 (81.1%)	2 (3.8%)	53
Chronic leukaemia	0 (0.0%)	0 (0.0%)	52 (98.1%)	1 (1.9%)	53
Onychomycosis	3 (5.7%)	7 (13.2%)	37 (69.8%)	6 (11.3%)	53
Focal dyscognitive seizures	40 (75.5%)	5 (9.4%)	7 (13.2%)	1 (1.9%)	53
Polymyositis	0 (0.0%)	7 (13.2%)	41 (77.4%)	5 (9.4%)	53
Neurofibromatosis	39 (73.6%)	11 (20.8%)	3 (5.7%)	0 (0.0%)	53
Palmar-plantar erythrodysesthesia syndrome	0 (0.0%)	6 (11.3%)	43 (81.1%)	4 (7.5%)	53
Rectal cancer metastatic	0 (0.0%)	20 (37.7%)	28 (52.8%)	5 (9.4%)	53
Oral contraception	11 (21.2%)	39 (75.0%)	2 (3.8%)	0 (0.0%)	52
Ear infection	17 (32.7%)	18 (34.6%)	15 (28.8%)	2 (3.8%)	52
Pituitary tumour	5 (9.6%)	6 (11.5%)	40 (76.9%)	1 (1.9%)	52
Panic attack	4 (7.7%)	16 (30.8%)	25 (48.1%)	7 (13.5%)	52
Choroidal neovascularisation	3 (5.8%)	11 (21.2%)	28 (53.8%)	10 (19.2%)	52
Osteonecrosis of jaw	0 (0.0%)	0 (0.0%)	13 (25.0%)	39 (75.0%)	52
Hyperhidrosis	16 (30.8%)	18 (34.6%)	18 (34.6%)	0 (0.0%)	52
Toxic epidermal necrolysis	16 (30.8%)	17 (32.7%)	16 (30.8%)	3 (5.8%)	52
Rhabdomyosarcoma	43 (82.7%)	7 (13.5%)	2 (3.8%)	0 (0.0%)	52
Chronic lymphocytic leukaemia refractory	0 (0.0%)	40 (78.4%)	5 (9.8%)	6 (11.8%)	51

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Routine health maintenance	0 (0.0%)	5 (9.8%)	25 (49.0%)	21 (41.2%)	51
Cutaneous T-cell lymphoma	3 (5.9%)	7 (13.7%)	26 (51.0%)	15 (29.4%)	51
Graft versus host disease in lung	0 (0.0%)	2 (3.9%)	49 (96.1%)	0 (0.0%)	51
Polycystic ovarian syndrome	7 (13.7%)	37 (72.5%)	7 (13.7%)	0 (0.0%)	51
Eosinophilic fasciitis	3 (5.9%)	15 (29.4%)	23 (45.1%)	10 (19.6%)	51
Immune effector cell-associated neurotoxicity syndro	1 (2.0%)	6 (11.8%)	41 (80.4%)	3 (5.9%)	51
Neuroendocrine carcinoma	0 (0.0%)	1 (2.0%)	28 (54.9%)	22 (43.1%)	51
Lichen planopilaris	0 (0.0%)	5 (10.0%)	34 (68.0%)	11 (22.0%)	50
Wrong patient	0 (0.0%)	6 (12.0%)	28 (56.0%)	16 (32.0%)	50
Child abuse	50 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	50
Malignant neoplasm of renal pelvis	0 (0.0%)	1 (2.0%)	34 (68.0%)	15 (30.0%)	50
Fallopian tube cancer	0 (0.0%)	10 (20.0%)	40 (80.0%)	0 (0.0%)	50
Cervix carcinoma recurrent	0 (0.0%)	41 (82.0%)	9 (18.0%)	0 (0.0%)	50
Iron overload	13 (26.0%)	4 (8.0%)	29 (58.0%)	4 (8.0%)	50
Ascites	1 (2.0%)	5 (10.0%)	36 (72.0%)	8 (16.0%)	50
Chronic graft versus host disease in skin	46 (92.0%)	2 (4.0%)	2 (4.0%)	0 (0.0%)	50
Postoperative care	3 (6.0%)	12 (24.0%)	26 (52.0%)	9 (18.0%)	50
Controlled ovarian stimulation	3 (6.0%)	47 (94.0%)	0 (0.0%)	0 (0.0%)	50
Metabolic surgery	0 (0.0%)	5 (10.2%)	44 (89.8%)	0 (0.0%)	49
Depressive symptom	16 (32.7%)	8 (16.3%)	7 (14.3%)	18 (36.7%)	49
Choriocarcinoma	8 (16.3%)	33 (67.3%)	8 (16.3%)	0 (0.0%)	49
Cytomegalovirus viraemia	17 (34.7%)	12 (24.5%)	15 (30.6%)	5 (10.2%)	49
Hypopharyngeal cancer	0 (0.0%)	1 (2.0%)	44 (89.8%)	4 (8.2%)	49
Metastases to meninges	14 (28.6%)	8 (16.3%)	27 (55.1%)	0 (0.0%)	49
Hypoxia	4 (8.2%)	12 (24.5%)	23 (46.9%)	10 (20.4%)	49
Dry age-related macular degeneration	0 (0.0%)	2 (4.1%)	11 (22.4%)	36 (73.5%)	49
Vertigo	1 (2.0%)	6 (12.2%)	39 (79.6%)	3 (6.1%)	49

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood potassium decreased	0 (0.0%)	9 (18.4%)	21 (42.9%)	19 (38.8%)	49
Breast cancer male	0 (0.0%)	3 (6.1%)	37 (75.5%)	9 (18.4%)	49
Hypervolaemia	3 (6.3%)	4 (8.3%)	26 (54.2%)	15 (31.3%)	48
Mood altered	21 (43.8%)	11 (22.9%)	13 (27.1%)	3 (6.3%)	48
Sinus polyp	2 (4.2%)	23 (47.9%)	22 (45.8%)	1 (2.1%)	48
Dermatitis acneiform	4 (8.3%)	11 (22.9%)	28 (58.3%)	5 (10.4%)	48
Stent placement	0 (0.0%)	1 (2.1%)	34 (70.8%)	13 (27.1%)	48
Papillary thyroid cancer	0 (0.0%)	7 (14.6%)	33 (68.8%)	8 (16.7%)	48
Hypertensive heart disease	0 (0.0%)	2 (4.2%)	20 (41.7%)	26 (54.2%)	48
Mycobacterium chelonae infection	12 (25.0%)	8 (16.7%)	23 (47.9%)	5 (10.4%)	48
Catatonía	20 (41.7%)	22 (45.8%)	5 (10.4%)	1 (2.1%)	48
Febrile bone marrow aplasia	23 (47.9%)	2 (4.2%)	2 (4.2%)	21 (43.8%)	48
Macular oedema	1 (2.1%)	7 (14.6%)	27 (56.3%)	13 (27.1%)	48
Cytomegalovirus infection reactivation	9 (18.8%)	17 (35.4%)	22 (45.8%)	0 (0.0%)	48
Intraocular pressure increased	6 (12.5%)	5 (10.4%)	26 (54.2%)	11 (22.9%)	48
Autoimmune disorder	4 (8.3%)	23 (47.9%)	18 (37.5%)	3 (6.3%)	48
Oral candidiasis	0 (0.0%)	6 (12.5%)	33 (68.8%)	9 (18.8%)	48
Adenocarcinoma metastatic	0 (0.0%)	7 (14.9%)	34 (72.3%)	6 (12.8%)	47
Guillain-Barre syndrome	2 (4.3%)	25 (53.2%)	10 (21.3%)	10 (21.3%)	47
Diabetic neuropathy	17 (36.2%)	5 (10.6%)	23 (48.9%)	2 (4.3%)	47
Arteriosclerosis coronary artery	0 (0.0%)	5 (10.6%)	27 (57.4%)	15 (31.9%)	47
Endometrial cancer metastatic	0 (0.0%)	1 (2.1%)	40 (85.1%)	6 (12.8%)	47
Stenotrophomonas infection	0 (0.0%)	24 (51.1%)	20 (42.6%)	3 (6.4%)	47
Sinus tachycardia	0 (0.0%)	18 (38.3%)	27 (57.4%)	2 (4.3%)	47
Restlessness	6 (12.8%)	12 (25.5%)	25 (53.2%)	4 (8.5%)	47
Intraductal proliferative breast lesion	1 (2.1%)	14 (29.8%)	21 (44.7%)	11 (23.4%)	47
Myeloid leukaemia	1 (2.1%)	16 (34.0%)	21 (44.7%)	9 (19.1%)	47

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tumour pain	2 (4.3%)	10 (21.7%)	23 (50.0%)	11 (23.9%)	46
Erysipelas	0 (0.0%)	9 (19.6%)	9 (19.6%)	28 (60.9%)	46
Chest discomfort	0 (0.0%)	6 (13.0%)	18 (39.1%)	22 (47.8%)	46
Folate deficiency	2 (4.3%)	12 (26.1%)	20 (43.5%)	12 (26.1%)	46
Peripheral swelling	0 (0.0%)	5 (10.9%)	21 (45.7%)	20 (43.5%)	46
Blood pressure decreased	1 (2.2%)	21 (45.7%)	21 (45.7%)	3 (6.5%)	46
Psychomotor hyperactivity	21 (45.7%)	1 (2.2%)	19 (41.3%)	5 (10.9%)	46
Intentional self-injury	14 (30.4%)	14 (30.4%)	18 (39.1%)	0 (0.0%)	46
Helicobacter gastritis	4 (8.7%)	21 (45.7%)	16 (34.8%)	5 (10.9%)	46
Dystonia	31 (67.4%)	7 (15.2%)	4 (8.7%)	4 (8.7%)	46
Tonsillitis	9 (19.6%)	14 (30.4%)	23 (50.0%)	0 (0.0%)	46
Testis cancer	3 (6.5%)	37 (80.4%)	6 (13.0%)	0 (0.0%)	46
Haemarthrosis	13 (28.9%)	30 (66.7%)	2 (4.4%)	0 (0.0%)	45
Neonatal seizure	45 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	45
Pancreatic neuroendocrine tumour metastatic	2 (4.4%)	22 (48.9%)	20 (44.4%)	1 (2.2%)	45
Retinal vein occlusion	1 (2.2%)	3 (6.7%)	26 (57.8%)	15 (33.3%)	45
Antiphospholipid syndrome	10 (22.2%)	24 (53.3%)	11 (24.4%)	0 (0.0%)	45
Irritability	39 (86.7%)	5 (11.1%)	1 (2.2%)	0 (0.0%)	45
Lung neoplasm	0 (0.0%)	4 (8.9%)	20 (44.4%)	21 (46.7%)	45
Advanced systemic mastocytosis	0 (0.0%)	5 (11.1%)	29 (64.4%)	11 (24.4%)	45
Fusarium infection	25 (55.6%)	6 (13.3%)	14 (31.1%)	0 (0.0%)	45
Disseminated mycobacterium avium complex infection	3 (6.7%)	42 (93.3%)	0 (0.0%)	0 (0.0%)	45
Anaplastic large cell lymphoma T- and null-cell type	3 (6.7%)	24 (53.3%)	14 (31.1%)	4 (8.9%)	45
Turner's syndrome	40 (88.9%)	5 (11.1%)	0 (0.0%)	0 (0.0%)	45
Leiomyosarcoma	0 (0.0%)	12 (27.3%)	28 (63.6%)	4 (9.1%)	44
Wrong patient received product	0 (0.0%)	0 (0.0%)	8 (18.2%)	36 (81.8%)	44
Metastatic bronchial carcinoma	0 (0.0%)	1 (2.3%)	43 (97.7%)	0 (0.0%)	44

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Reflux gastritis	4 (9.1%)	12 (27.3%)	26 (59.1%)	2 (4.5%)	44
Hereditary angioedema with normal C1 esterase inhibi	4 (9.1%)	28 (63.6%)	12 (27.3%)	0 (0.0%)	44
HIV test positive	0 (0.0%)	2 (4.5%)	42 (95.5%)	0 (0.0%)	44
Kawasaki's disease	42 (95.5%)	2 (4.5%)	0 (0.0%)	0 (0.0%)	44
Eye disorder	2 (4.5%)	5 (11.4%)	22 (50.0%)	15 (34.1%)	44
Lung squamous cell carcinoma stage III	0 (0.0%)	0 (0.0%)	40 (90.9%)	4 (9.1%)	44
Hypophosphataemia	10 (22.7%)	2 (4.5%)	20 (45.5%)	12 (27.3%)	44
Intra-uterine contraceptive device insertion	8 (18.2%)	32 (72.7%)	4 (9.1%)	0 (0.0%)	44
Vitamin D decreased	3 (6.8%)	11 (25.0%)	24 (54.5%)	6 (13.6%)	44
New onset refractory status epilepticus	6 (13.6%)	35 (79.5%)	3 (6.8%)	0 (0.0%)	44
Cholangitis	0 (0.0%)	2 (4.5%)	33 (75.0%)	9 (20.5%)	44
Brain neoplasm	12 (27.3%)	12 (27.3%)	15 (34.1%)	5 (11.4%)	44
Immunomodulatory therapy	3 (6.8%)	25 (56.8%)	15 (34.1%)	1 (2.3%)	44
Escherichia infection	12 (27.9%)	17 (39.5%)	7 (16.3%)	7 (16.3%)	43
Head titubation	0 (0.0%)	0 (0.0%)	13 (30.2%)	30 (69.8%)	43
Borderline personality disorder	20 (46.5%)	22 (51.2%)	1 (2.3%)	0 (0.0%)	43
Vulvovaginal pain	36 (83.7%)	2 (4.7%)	3 (7.0%)	2 (4.7%)	43
Hypomania	0 (0.0%)	12 (27.9%)	29 (67.4%)	2 (4.7%)	43
Malnutrition	7 (16.3%)	3 (7.0%)	30 (69.8%)	3 (7.0%)	43
Burkitt's lymphoma stage III	42 (97.7%)	0 (0.0%)	0 (0.0%)	1 (2.3%)	43
Ischaemic heart disease prophylaxis	0 (0.0%)	4 (9.3%)	31 (72.1%)	8 (18.6%)	43
Targeted cancer therapy	1 (2.3%)	6 (14.0%)	30 (69.8%)	6 (14.0%)	43
Tuberculosis of central nervous system	43 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	43
Nasopharyngeal cancer	1 (2.3%)	18 (41.9%)	21 (48.8%)	3 (7.0%)	43
Pneumonia klebsiella	3 (7.0%)	8 (18.6%)	21 (48.8%)	11 (25.6%)	43
Stevens-Johnson syndrome	15 (34.9%)	15 (34.9%)	8 (18.6%)	5 (11.6%)	43
Joint stiffness	1 (2.3%)	3 (7.0%)	4 (9.3%)	35 (81.4%)	43

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Venous thrombosis	2 (4.7%)	13 (30.2%)	22 (51.2%)	6 (14.0%)	43
Encephalopathy	16 (38.1%)	10 (23.8%)	10 (23.8%)	6 (14.3%)	42
Malaise	3 (7.1%)	12 (28.6%)	26 (61.9%)	1 (2.4%)	42
Electrolyte imbalance	6 (14.3%)	10 (23.8%)	23 (54.8%)	3 (7.1%)	42
Resting tremor	0 (0.0%)	0 (0.0%)	14 (33.3%)	28 (66.7%)	42
Mixed hepatocellular cholangiocarcinoma	2 (4.8%)	9 (21.4%)	23 (54.8%)	8 (19.0%)	42
Intervertebral disc protrusion	0 (0.0%)	10 (23.8%)	26 (61.9%)	6 (14.3%)	42
Breast cancer stage III	0 (0.0%)	18 (42.9%)	19 (45.2%)	5 (11.9%)	42
Gastric disorder	7 (16.7%)	8 (19.0%)	22 (52.4%)	5 (11.9%)	42
Leukopenia	7 (16.7%)	5 (11.9%)	29 (69.0%)	1 (2.4%)	42
Alcohol use disorder	0 (0.0%)	7 (16.7%)	35 (83.3%)	0 (0.0%)	42
Embolism venous	0 (0.0%)	10 (24.4%)	22 (53.7%)	9 (22.0%)	41
Minimal residual disease	1 (2.4%)	4 (9.8%)	36 (87.8%)	0 (0.0%)	41
Type V hyperlipidaemia	0 (0.0%)	1 (2.4%)	25 (61.0%)	15 (36.6%)	41
Memory impairment	0 (0.0%)	1 (2.4%)	18 (43.9%)	22 (53.7%)	41
Overdose	12 (29.3%)	13 (31.7%)	15 (36.6%)	1 (2.4%)	41
Congenital hypogammaglobulinaemia	7 (17.1%)	11 (26.8%)	18 (43.9%)	5 (12.2%)	41
Human epidermal growth factor receptor negative	0 (0.0%)	4 (9.8%)	35 (85.4%)	2 (4.9%)	41
Peyronie's disease	0 (0.0%)	8 (19.5%)	31 (75.6%)	2 (4.9%)	41
Injury	16 (39.0%)	7 (17.1%)	14 (34.1%)	4 (9.8%)	41
Endotracheal intubation	5 (12.2%)	11 (26.8%)	21 (51.2%)	4 (9.8%)	41
Diabetic retinopathy	3 (7.3%)	6 (14.6%)	28 (68.3%)	4 (9.8%)	41
Adult T-cell lymphoma/leukaemia	0 (0.0%)	14 (34.1%)	9 (22.0%)	18 (43.9%)	41
Urinary retention	1 (2.4%)	3 (7.3%)	23 (56.1%)	14 (34.1%)	41
Blood glucose	0 (0.0%)	11 (26.8%)	20 (48.8%)	10 (24.4%)	41
Gouty arthritis	2 (4.9%)	2 (4.9%)	28 (68.3%)	9 (22.0%)	41
Oppositional defiant disorder	41 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	41

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Computerised tomogram thorax	1 (2.5%)	10 (25.0%)	20 (50.0%)	9 (22.5%)	40
Wound infection	0 (0.0%)	16 (40.0%)	20 (50.0%)	4 (10.0%)	40
Paraesthesia	3 (7.5%)	8 (20.0%)	24 (60.0%)	5 (12.5%)	40
Peripheral T-cell lymphoma unspecified	0 (0.0%)	0 (0.0%)	30 (75.0%)	10 (25.0%)	40
Cholelithiasis	2 (5.0%)	13 (32.5%)	23 (57.5%)	2 (5.0%)	40
Rhabdomyolysis	7 (17.5%)	0 (0.0%)	33 (82.5%)	0 (0.0%)	40
Respiratory syncytial virus infection	30 (75.0%)	1 (2.5%)	3 (7.5%)	6 (15.0%)	40
Nephrolithiasis	3 (7.5%)	7 (17.5%)	29 (72.5%)	1 (2.5%)	40
Night sweats	0 (0.0%)	4 (10.0%)	24 (60.0%)	12 (30.0%)	40
Blood growth hormone	36 (92.3%)	0 (0.0%)	3 (7.7%)	0 (0.0%)	39
Anti-melanoma differentiation-associated protein 5 a	16 (41.0%)	9 (23.1%)	14 (35.9%)	0 (0.0%)	39
Muscular weakness	4 (10.3%)	11 (28.2%)	17 (43.6%)	7 (17.9%)	39
Lipids abnormal	0 (0.0%)	3 (7.7%)	29 (74.4%)	7 (17.9%)	39
Alveolar rhabdomyosarcoma	37 (94.9%)	0 (0.0%)	2 (5.1%)	0 (0.0%)	39
Skin cancer	1 (2.6%)	2 (5.1%)	29 (74.4%)	7 (17.9%)	39
Hepatitis	1 (2.6%)	13 (33.3%)	24 (61.5%)	1 (2.6%)	39
Sickle cell anaemia with crisis	20 (51.3%)	17 (43.6%)	2 (5.1%)	0 (0.0%)	39
Musculoskeletal stiffness	0 (0.0%)	6 (15.4%)	32 (82.1%)	1 (2.6%)	39
Hyperchlorhydria	3 (7.7%)	5 (12.8%)	23 (59.0%)	8 (20.5%)	39
Hypergammaglobulinaemia	7 (17.9%)	9 (23.1%)	22 (56.4%)	1 (2.6%)	39
Functional gastrointestinal disorder	6 (15.4%)	4 (10.3%)	26 (66.7%)	3 (7.7%)	39
Malignant fibrous histiocyoma	2 (5.1%)	28 (71.8%)	9 (23.1%)	0 (0.0%)	39
Parkinsonian rest tremor	0 (0.0%)	0 (0.0%)	9 (23.1%)	30 (76.9%)	39
Pleural effusion	4 (10.3%)	4 (10.3%)	16 (41.0%)	15 (38.5%)	39
Asthenia	2 (5.1%)	7 (17.9%)	20 (51.3%)	10 (25.6%)	39
Epstein-Barr virus infection	15 (38.5%)	13 (33.3%)	11 (28.2%)	0 (0.0%)	39
Psychiatric decompensation	18 (46.2%)	0 (0.0%)	21 (53.8%)	0 (0.0%)	39

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skin lesion	20 (51.3%)	5 (12.8%)	13 (33.3%)	1 (2.6%)	39
Anaemia prophylaxis	2 (5.3%)	13 (34.2%)	14 (36.8%)	9 (23.7%)	38
Blood triglycerides abnormal	0 (0.0%)	7 (18.4%)	24 (63.2%)	7 (18.4%)	38
Cardiac failure acute	2 (5.3%)	4 (10.5%)	13 (34.2%)	19 (50.0%)	38
Breakthrough pain	0 (0.0%)	15 (39.5%)	10 (26.3%)	13 (34.2%)	38
Salivary gland cancer	0 (0.0%)	5 (13.2%)	28 (73.7%)	5 (13.2%)	38
Pharyngitis	22 (57.9%)	8 (21.1%)	7 (18.4%)	1 (2.6%)	38
Musculoskeletal chest pain	0 (0.0%)	4 (10.5%)	25 (65.8%)	9 (23.7%)	38
Peptic ulcer	2 (5.3%)	6 (15.8%)	28 (73.7%)	2 (5.3%)	38
Medication error	1 (2.6%)	10 (26.3%)	10 (26.3%)	17 (44.7%)	38
Chronic graft versus host disease in lung	38 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	38
Somatic symptom disorder	0 (0.0%)	0 (0.0%)	37 (97.4%)	1 (2.6%)	38
Migraine with aura	1 (2.6%)	21 (55.3%)	16 (42.1%)	0 (0.0%)	38
Acute monocytic leukaemia	26 (68.4%)	7 (18.4%)	5 (13.2%)	0 (0.0%)	38
Pulmonary sarcoidosis	0 (0.0%)	13 (34.2%)	24 (63.2%)	1 (2.6%)	38
Lung adenocarcinoma stage III	0 (0.0%)	11 (28.9%)	26 (68.4%)	1 (2.6%)	38
Influenza immunisation	4 (10.5%)	6 (15.8%)	20 (52.6%)	8 (21.1%)	38
Angiosarcoma	7 (18.9%)	23 (62.2%)	5 (13.5%)	2 (5.4%)	37
Cystic fibrosis lung	10 (27.0%)	18 (48.6%)	8 (21.6%)	1 (2.7%)	37
Autoimmune hepatitis	11 (29.7%)	13 (35.1%)	13 (35.1%)	0 (0.0%)	37
Laxative supportive care	3 (8.1%)	4 (10.8%)	15 (40.5%)	15 (40.5%)	37
BRAF gene mutation	0 (0.0%)	6 (16.2%)	27 (73.0%)	4 (10.8%)	37
Mobility decreased	0 (0.0%)	0 (0.0%)	2 (5.4%)	35 (94.6%)	37
Mantle cell lymphoma stage IV	0 (0.0%)	7 (18.9%)	30 (81.1%)	0 (0.0%)	37
Bronchitis chronic	0 (0.0%)	2 (5.4%)	31 (83.8%)	4 (10.8%)	37
Chills	1 (2.7%)	5 (13.5%)	26 (70.3%)	5 (13.5%)	37
Micturition urgency	0 (0.0%)	2 (5.4%)	26 (70.3%)	9 (24.3%)	37

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Rectosigmoid cancer	0 (0.0%)	2 (5.4%)	34 (91.9%)	1 (2.7%)	37
Chorioretinitis	26 (70.3%)	1 (2.7%)	8 (21.6%)	2 (5.4%)	37
Perichondritis	2 (5.6%)	1 (2.8%)	31 (86.1%)	2 (5.6%)	36
Ventricular extrasystoles	8 (22.2%)	3 (8.3%)	13 (36.1%)	12 (33.3%)	36
Kidney transplant rejection	6 (16.7%)	2 (5.6%)	25 (69.4%)	3 (8.3%)	36
Brain abscess	0 (0.0%)	13 (36.1%)	15 (41.7%)	8 (22.2%)	36
Haemostasis	13 (36.1%)	5 (13.9%)	14 (38.9%)	4 (11.1%)	36
Shock	2 (5.6%)	20 (55.6%)	10 (27.8%)	4 (11.1%)	36
Diabetes mellitus management	0 (0.0%)	8 (22.2%)	25 (69.4%)	3 (8.3%)	36
Aortic dissection	0 (0.0%)	3 (8.3%)	20 (55.6%)	13 (36.1%)	36
Leukaemia recurrent	7 (19.4%)	0 (0.0%)	29 (80.6%)	0 (0.0%)	36
Raynaud's phenomenon	1 (2.8%)	18 (50.0%)	15 (41.7%)	2 (5.6%)	36
Diabetes prophylaxis	9 (25.0%)	19 (52.8%)	8 (22.2%)	0 (0.0%)	36
Pancreatitis	3 (8.3%)	8 (22.2%)	17 (47.2%)	8 (22.2%)	36
Papillary renal cell carcinoma	0 (0.0%)	4 (11.1%)	24 (66.7%)	8 (22.2%)	36
Infusion site pain	0 (0.0%)	16 (44.4%)	19 (52.8%)	1 (2.8%)	36
Coronavirus infection	1 (2.8%)	0 (0.0%)	22 (61.1%)	13 (36.1%)	36
Ovarian cancer stage IV	0 (0.0%)	16 (44.4%)	18 (50.0%)	2 (5.6%)	36
Bowel preparation	1 (2.8%)	7 (19.4%)	19 (52.8%)	9 (25.0%)	36
VEXAS syndrome	0 (0.0%)	0 (0.0%)	35 (97.2%)	1 (2.8%)	36
Post-traumatic headache	34 (94.4%)	0 (0.0%)	2 (5.6%)	0 (0.0%)	36
Imaging procedure	1 (2.8%)	11 (30.6%)	20 (55.6%)	4 (11.1%)	36
Psychotherapy	1 (2.8%)	14 (38.9%)	20 (55.6%)	1 (2.8%)	36
Herpes virus infection	3 (8.3%)	8 (22.2%)	22 (61.1%)	3 (8.3%)	36
Disruptive mood dysregulation disorder	35 (97.2%)	1 (2.8%)	0 (0.0%)	0 (0.0%)	36
Salivary hypersecretion	3 (8.6%)	10 (28.6%)	20 (57.1%)	2 (5.7%)	35
Abscess	14 (40.0%)	10 (28.6%)	7 (20.0%)	4 (11.4%)	35

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Nephropathy	0 (0.0%)	12 (34.3%)	22 (62.9%)	1 (2.9%)	35
Wrong drug	0 (0.0%)	0 (0.0%)	0 (0.0%)	35 (100.0%)	35
Electrolyte depletion	0 (0.0%)	0 (0.0%)	0 (0.0%)	35 (100.0%)	35
Aspartate aminotransferase increased	0 (0.0%)	8 (22.9%)	24 (68.6%)	3 (8.6%)	35
Anaesthesia procedure	4 (11.4%)	2 (5.7%)	19 (54.3%)	10 (28.6%)	35
Liver abscess	0 (0.0%)	3 (8.6%)	23 (65.7%)	9 (25.7%)	35
Pulmonary oedema	4 (11.4%)	22 (62.9%)	5 (14.3%)	4 (11.4%)	35
PIK3CA related overgrowth spectrum	21 (60.0%)	10 (28.6%)	4 (11.4%)	0 (0.0%)	35
Connective tissue disorder	0 (0.0%)	9 (25.7%)	23 (65.7%)	3 (8.6%)	35
Takayasu's arteritis	27 (77.1%)	8 (22.9%)	0 (0.0%)	0 (0.0%)	35
Myeloproliferative neoplasm	0 (0.0%)	3 (8.6%)	25 (71.4%)	7 (20.0%)	35
Oesophageal squamous cell carcinoma stage IV	0 (0.0%)	6 (17.1%)	15 (42.9%)	14 (40.0%)	35
Indolent systemic mastocytosis	1 (2.9%)	11 (31.4%)	18 (51.4%)	5 (14.3%)	35
Prophylaxis against diarrhoea	0 (0.0%)	1 (2.9%)	33 (94.3%)	1 (2.9%)	35
Anaplastic large-cell lymphoma	5 (14.3%)	1 (2.9%)	19 (54.3%)	10 (28.6%)	35
Uterine hypotonus	13 (37.1%)	22 (62.9%)	0 (0.0%)	0 (0.0%)	35
Anaplastic thyroid cancer	0 (0.0%)	9 (25.7%)	17 (48.6%)	9 (25.7%)	35
Follicular lymphoma stage III	0 (0.0%)	6 (17.1%)	21 (60.0%)	8 (22.9%)	35
Sickle cell anaemia	8 (22.9%)	6 (17.1%)	21 (60.0%)	0 (0.0%)	35
Oral pain	2 (5.9%)	13 (38.2%)	18 (52.9%)	1 (2.9%)	34
Actinic keratosis	0 (0.0%)	1 (2.9%)	27 (79.4%)	6 (17.6%)	34
Extrapyramidal disorder	2 (5.9%)	10 (29.4%)	19 (55.9%)	3 (8.8%)	34
Pulmonary nocardiosis	0 (0.0%)	0 (0.0%)	33 (97.1%)	1 (2.9%)	34
Oropharyngeal cancer	0 (0.0%)	1 (2.9%)	27 (79.4%)	6 (17.6%)	34
Alopecia universalis	10 (29.4%)	13 (38.2%)	11 (32.4%)	0 (0.0%)	34
Diabetes insipidus	14 (41.2%)	10 (29.4%)	6 (17.6%)	4 (11.8%)	34
Bile acid malabsorption	2 (5.9%)	23 (67.6%)	9 (26.5%)	0 (0.0%)	34

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chronic recurrent multifocal osteomyelitis	34 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	34
Latent tuberculosis	14 (41.2%)	4 (11.8%)	15 (44.1%)	1 (2.9%)	34
Lymphadenopathy	4 (11.8%)	13 (38.2%)	11 (32.4%)	6 (17.6%)	34
Blastic plasmacytoid dendritic cell neoplasia	3 (8.8%)	0 (0.0%)	25 (73.5%)	6 (17.6%)	34
Lymphocytic leukaemia	15 (44.1%)	6 (17.6%)	10 (29.4%)	3 (8.8%)	34
Scoliosis	1 (2.9%)	28 (82.4%)	1 (2.9%)	4 (11.8%)	34
Maternal therapy to enhance foetal lung maturity	8 (23.5%)	26 (76.5%)	0 (0.0%)	0 (0.0%)	34
Peritonitis bacterial	4 (11.8%)	4 (11.8%)	24 (70.6%)	2 (5.9%)	34
Eosinophilia	1 (2.9%)	10 (29.4%)	22 (64.7%)	1 (2.9%)	34
Neutropenic sepsis	14 (41.2%)	16 (47.1%)	4 (11.8%)	0 (0.0%)	34
Mesothelioma	0 (0.0%)	1 (3.0%)	18 (54.5%)	14 (42.4%)	33
Amyloidosis senile	0 (0.0%)	0 (0.0%)	7 (21.2%)	26 (78.8%)	33
EGFR gene mutation	0 (0.0%)	3 (9.1%)	17 (51.5%)	13 (39.4%)	33
Ejection fraction decreased	0 (0.0%)	9 (27.3%)	18 (54.5%)	6 (18.2%)	33
Middle insomnia	24 (72.7%)	2 (6.1%)	4 (12.1%)	3 (9.1%)	33
Respiratory disorder	5 (15.2%)	8 (24.2%)	11 (33.3%)	9 (27.3%)	33
Rheumatoid factor negative	0 (0.0%)	6 (18.2%)	21 (63.6%)	6 (18.2%)	33
Heart rate increased	0 (0.0%)	7 (21.2%)	24 (72.7%)	2 (6.1%)	33
Seborrhoeic dermatitis	11 (33.3%)	9 (27.3%)	12 (36.4%)	1 (3.0%)	33
Muscle building therapy	1 (3.0%)	32 (97.0%)	0 (0.0%)	0 (0.0%)	33
Acute psychosis	16 (48.5%)	14 (42.4%)	3 (9.1%)	0 (0.0%)	33
Retinoblastoma	33 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	33
Respiratory distress	6 (18.2%)	7 (21.2%)	18 (54.5%)	2 (6.1%)	33
Salvage therapy	20 (60.6%)	3 (9.1%)	9 (27.3%)	1 (3.0%)	33
Pneumonia mycoplasmal	15 (45.5%)	13 (39.4%)	3 (9.1%)	2 (6.1%)	33
Ectopic pregnancy	3 (9.1%)	30 (90.9%)	0 (0.0%)	0 (0.0%)	33
Gastrointestinal carcinoma	0 (0.0%)	1 (3.0%)	31 (93.9%)	1 (3.0%)	33

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ocular hyperaemia	2 (6.1%)	5 (15.2%)	22 (66.7%)	4 (12.1%)	33
Haemochromatosis	10 (30.3%)	7 (21.2%)	11 (33.3%)	5 (15.2%)	33
Cataract	0 (0.0%)	10 (30.3%)	16 (48.5%)	7 (21.2%)	33
Orthostatic hypotension	0 (0.0%)	4 (12.5%)	17 (53.1%)	11 (34.4%)	32
Haemoglobin decreased	2 (6.3%)	5 (15.6%)	19 (59.4%)	6 (18.8%)	32
Postoperative analgesia	3 (9.4%)	2 (6.3%)	26 (81.3%)	1 (3.1%)	32
Tonic convulsion	26 (81.3%)	6 (18.8%)	0 (0.0%)	0 (0.0%)	32
Optic neuritis	12 (37.5%)	7 (21.9%)	13 (40.6%)	0 (0.0%)	32
Arteritis	2 (6.3%)	3 (9.4%)	20 (62.5%)	7 (21.9%)	32
Sinus disorder	3 (9.4%)	3 (9.4%)	15 (46.9%)	11 (34.4%)	32
Cervix carcinoma stage III	0 (0.0%)	11 (34.4%)	20 (62.5%)	1 (3.1%)	32
Hypoproteinaemia	1 (3.1%)	4 (12.5%)	18 (56.3%)	9 (28.1%)	32
Neoadjuvant therapy	0 (0.0%)	11 (34.4%)	20 (62.5%)	1 (3.1%)	32
Mantle cell lymphoma recurrent	0 (0.0%)	10 (31.3%)	11 (34.4%)	11 (34.4%)	32
Nasal sinus cancer	0 (0.0%)	3 (9.7%)	25 (80.6%)	3 (9.7%)	31
Alpha haemolytic streptococcal infection	2 (6.5%)	0 (0.0%)	2 (6.5%)	27 (87.1%)	31
Pulmonary sepsis	0 (0.0%)	12 (38.7%)	19 (61.3%)	0 (0.0%)	31
Extranodal marginal zone B-cell lymphoma (MALT type)	2 (6.5%)	0 (0.0%)	25 (80.6%)	4 (12.9%)	31
Cholecystitis	0 (0.0%)	3 (9.7%)	12 (38.7%)	16 (51.6%)	31
Follicular lymphoma stage II	0 (0.0%)	0 (0.0%)	12 (38.7%)	19 (61.3%)	31
Dysphagia	3 (9.7%)	13 (41.9%)	12 (38.7%)	3 (9.7%)	31
Disease risk factor	1 (3.2%)	2 (6.5%)	22 (71.0%)	6 (19.4%)	31
Diabetic nephropathy	0 (0.0%)	0 (0.0%)	24 (77.4%)	7 (22.6%)	31
Syncope	4 (12.9%)	12 (38.7%)	10 (32.3%)	5 (16.1%)	31
C3 glomerulopathy	16 (51.6%)	12 (38.7%)	3 (9.7%)	0 (0.0%)	31
Alanine aminotransferase increased	1 (3.2%)	7 (22.6%)	17 (54.8%)	6 (19.4%)	31
Bronchopulmonary dysplasia	31 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	31

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypertransaminasaemia	22 (71.0%)	8 (25.8%)	1 (3.2%)	0 (0.0%)	31
Otitis media acute	30 (96.8%)	0 (0.0%)	0 (0.0%)	1 (3.2%)	31
Oestrogen therapy	17 (54.8%)	2 (6.5%)	9 (29.0%)	3 (9.7%)	31
Urticaria chronic	4 (12.9%)	20 (64.5%)	6 (19.4%)	1 (3.2%)	31
Colorectal cancer stage III	0 (0.0%)	4 (12.9%)	26 (83.9%)	1 (3.2%)	31
Hypercalcaemia of malignancy	1 (3.2%)	10 (32.3%)	18 (58.1%)	2 (6.5%)	31
Upper gastrointestinal haemorrhage	14 (45.2%)	0 (0.0%)	15 (48.4%)	2 (6.5%)	31
Autologous haematopoietic stem cell transplant	1 (3.2%)	14 (45.2%)	15 (48.4%)	1 (3.2%)	31
Glomerulonephritis rapidly progressive	1 (3.2%)	3 (9.7%)	26 (83.9%)	1 (3.2%)	31
Hysterectomy	0 (0.0%)	1 (3.2%)	25 (80.6%)	5 (16.1%)	31
Otitis media	11 (35.5%)	13 (41.9%)	6 (19.4%)	1 (3.2%)	31
Post procedural complication	1 (3.2%)	9 (29.0%)	21 (67.7%)	0 (0.0%)	31
Cerebral palsy	26 (83.9%)	3 (9.7%)	2 (6.5%)	0 (0.0%)	31
Pityriasis rubra pilaris	12 (38.7%)	3 (9.7%)	16 (51.6%)	0 (0.0%)	31
Familial haemophagocytic lymphohistiocytosis	12 (38.7%)	12 (38.7%)	7 (22.6%)	0 (0.0%)	31
Blood iron decreased	1 (3.2%)	6 (19.4%)	15 (48.4%)	9 (29.0%)	31
Ocular hypertension	0 (0.0%)	1 (3.3%)	25 (83.3%)	4 (13.3%)	30
Nocturia	0 (0.0%)	5 (16.7%)	15 (50.0%)	10 (33.3%)	30
Ileus paralytic	0 (0.0%)	0 (0.0%)	30 (100.0%)	0 (0.0%)	30
Right ventricular failure	0 (0.0%)	1 (3.3%)	27 (90.0%)	2 (6.7%)	30
Angiocentric lymphoma	0 (0.0%)	20 (66.7%)	10 (33.3%)	0 (0.0%)	30
Transplant dysfunction	26 (86.7%)	0 (0.0%)	4 (13.3%)	0 (0.0%)	30
Shock haemorrhagic	0 (0.0%)	0 (0.0%)	30 (100.0%)	0 (0.0%)	30
Juvenile myoclonic epilepsy	22 (73.3%)	8 (26.7%)	0 (0.0%)	0 (0.0%)	30
Colony stimulating factor therapy	0 (0.0%)	7 (23.3%)	17 (56.7%)	6 (20.0%)	30
Immune reconstitution inflammatory syndrome	3 (10.0%)	18 (60.0%)	9 (30.0%)	0 (0.0%)	30
Completed suicide	0 (0.0%)	8 (26.7%)	14 (46.7%)	8 (26.7%)	30

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Immune tolerance induction	12 (40.0%)	7 (23.3%)	9 (30.0%)	2 (6.7%)	30
Neuromuscular blockade reversal	6 (20.0%)	9 (30.0%)	12 (40.0%)	3 (10.0%)	30
Malignant melanoma stage IV	0 (0.0%)	4 (13.3%)	18 (60.0%)	8 (26.7%)	30
Brain oedema	6 (20.0%)	8 (26.7%)	14 (46.7%)	2 (6.7%)	30
Bradycardia	1 (3.3%)	6 (20.0%)	12 (40.0%)	11 (36.7%)	30
Anal squamous cell carcinoma	0 (0.0%)	11 (36.7%)	19 (63.3%)	0 (0.0%)	30
Isocitrate dehydrogenase gene mutation	3 (10.0%)	27 (90.0%)	0 (0.0%)	0 (0.0%)	30
Hypersensitivity pneumonitis	0 (0.0%)	3 (10.0%)	18 (60.0%)	9 (30.0%)	30
Abdominal distension	4 (13.3%)	5 (16.7%)	19 (63.3%)	2 (6.7%)	30
Ureteric cancer	0 (0.0%)	0 (0.0%)	15 (50.0%)	15 (50.0%)	30
Non-small cell lung cancer stage III	0 (0.0%)	0 (0.0%)	26 (89.7%)	3 (10.3%)	29
Nightmare	3 (10.3%)	5 (17.2%)	4 (13.8%)	17 (58.6%)	29
Mucormycosis	3 (10.3%)	8 (27.6%)	18 (62.1%)	0 (0.0%)	29
Monkeypox	1 (3.4%)	28 (96.6%)	0 (0.0%)	0 (0.0%)	29
Malignant melanoma stage III	0 (0.0%)	11 (37.9%)	15 (51.7%)	3 (10.3%)	29
Ovarian cancer metastatic	0 (0.0%)	5 (17.2%)	23 (79.3%)	1 (3.4%)	29
Magnesium deficiency	1 (3.4%)	9 (31.0%)	17 (58.6%)	2 (6.9%)	29
Kaposi's sarcoma	0 (0.0%)	12 (41.4%)	6 (20.7%)	11 (37.9%)	29
Biliary neoplasm	0 (0.0%)	5 (17.2%)	23 (79.3%)	1 (3.4%)	29
Appendicitis	4 (13.8%)	6 (20.7%)	16 (55.2%)	3 (10.3%)	29
Urinary tract disorder	0 (0.0%)	2 (6.9%)	19 (65.5%)	8 (27.6%)	29
Intracranial pressure increased	2 (6.9%)	10 (34.5%)	12 (41.4%)	5 (17.2%)	29
Gestational trophoblastic tumour	0 (0.0%)	24 (82.8%)	5 (17.2%)	0 (0.0%)	29
Preoperative care	0 (0.0%)	14 (48.3%)	10 (34.5%)	5 (17.2%)	29
Magnetic resonance imaging head	5 (17.2%)	16 (55.2%)	6 (20.7%)	2 (6.9%)	29
Haemophilia A without inhibitors	11 (37.9%)	7 (24.1%)	9 (31.0%)	2 (6.9%)	29
Impaired gastric emptying	5 (17.2%)	9 (31.0%)	14 (48.3%)	1 (3.4%)	29

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Osteoporotic fracture	0 (0.0%)	0 (0.0%)	17 (58.6%)	12 (41.4%)	29
On and off phenomenon	0 (0.0%)	0 (0.0%)	11 (37.9%)	18 (62.1%)	29
Grey zone lymphoma	0 (0.0%)	28 (100.0%)	0 (0.0%)	0 (0.0%)	28
Prophylaxis against dehydration	3 (10.7%)	5 (17.9%)	11 (39.3%)	9 (32.1%)	28
Mixed connective tissue disease	6 (21.4%)	6 (21.4%)	16 (57.1%)	0 (0.0%)	28
Drug withdrawal syndrome	1 (3.6%)	26 (92.9%)	1 (3.6%)	0 (0.0%)	28
Lipids increased	0 (0.0%)	3 (10.7%)	18 (64.3%)	7 (25.0%)	28
Malignant neoplasm progression	0 (0.0%)	4 (14.3%)	24 (85.7%)	0 (0.0%)	28
Prophylactic chemotherapy	4 (14.3%)	3 (10.7%)	10 (35.7%)	11 (39.3%)	28
Metabolic acidosis	8 (28.6%)	5 (17.9%)	14 (50.0%)	1 (3.6%)	28
Acute lymphocytic leukaemia refractory	19 (67.9%)	0 (0.0%)	5 (17.9%)	4 (14.3%)	28
Diabetes mellitus inadequate control	1 (3.6%)	3 (10.7%)	20 (71.4%)	4 (14.3%)	28
Influenza like illness	1 (3.6%)	5 (17.9%)	17 (60.7%)	5 (17.9%)	28
Myelin oligodendrocyte glycoprotein antibody-associa	15 (53.6%)	9 (32.1%)	4 (14.3%)	0 (0.0%)	28
Folliculitis	1 (3.6%)	13 (46.4%)	14 (50.0%)	0 (0.0%)	28
Intestinal transplant	27 (96.4%)	1 (3.6%)	0 (0.0%)	0 (0.0%)	28
Kidney infection	1 (3.6%)	18 (64.3%)	8 (28.6%)	1 (3.6%)	28
Philadelphia chromosome negative	4 (14.3%)	5 (17.9%)	19 (67.9%)	0 (0.0%)	28
Foetal growth restriction	27 (96.4%)	1 (3.6%)	0 (0.0%)	0 (0.0%)	28
Dwarfism	26 (92.9%)	0 (0.0%)	2 (7.1%)	0 (0.0%)	28
Subacute cutaneous lupus erythematosus	0 (0.0%)	9 (32.1%)	18 (64.3%)	1 (3.6%)	28
Hypertonia	2 (7.4%)	3 (11.1%)	18 (66.7%)	4 (14.8%)	27
Escherichia bacteraemia	1 (3.7%)	0 (0.0%)	21 (77.8%)	5 (18.5%)	27
Essential tremor	1 (3.7%)	0 (0.0%)	21 (77.8%)	5 (18.5%)	27
Epstein-Barr viraemia	9 (33.3%)	12 (44.4%)	6 (22.2%)	0 (0.0%)	27
Thymic carcinoma	2 (7.4%)	7 (25.9%)	17 (63.0%)	1 (3.7%)	27
Neuroendocrine carcinoma of the skin	0 (0.0%)	4 (14.8%)	12 (44.4%)	11 (40.7%)	27

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pyelonephritis acute	0 (0.0%)	0 (0.0%)	21 (77.8%)	6 (22.2%)	27
Organ transplant	5 (18.5%)	9 (33.3%)	11 (40.7%)	2 (7.4%)	27
Mycobacterium haemophilum infection	0 (0.0%)	0 (0.0%)	15 (55.6%)	12 (44.4%)	27
Metabolic disorder	6 (22.2%)	16 (59.3%)	4 (14.8%)	1 (3.7%)	27
Thrombocytopenic purpura	3 (11.1%)	1 (3.7%)	23 (85.2%)	0 (0.0%)	27
Seronegative arthritis	2 (7.4%)	7 (25.9%)	13 (48.1%)	5 (18.5%)	27
Demyelination	6 (22.2%)	18 (66.7%)	3 (11.1%)	0 (0.0%)	27
Henoch-Schonlein purpura	19 (70.4%)	5 (18.5%)	3 (11.1%)	0 (0.0%)	27
Antipyresis	8 (29.6%)	3 (11.1%)	10 (37.0%)	6 (22.2%)	27
Joint swelling	1 (3.7%)	2 (7.4%)	20 (74.1%)	4 (14.8%)	27
Thalassaemia beta	19 (70.4%)	5 (18.5%)	2 (7.4%)	1 (3.7%)	27
Haemolytic anaemia	5 (18.5%)	5 (18.5%)	17 (63.0%)	0 (0.0%)	27
Hepatoblastoma	27 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	27
Vitamin D	0 (0.0%)	1 (3.7%)	4 (14.8%)	22 (81.5%)	27
Visual impairment	0 (0.0%)	3 (11.1%)	9 (33.3%)	15 (55.6%)	27
Food allergy	8 (29.6%)	14 (51.9%)	3 (11.1%)	2 (7.4%)	27
Pregnancy	8 (29.6%)	19 (70.4%)	0 (0.0%)	0 (0.0%)	27
BRAF V600E mutation positive	0 (0.0%)	8 (29.6%)	19 (70.4%)	0 (0.0%)	27
HIV infection CDC Group III	0 (0.0%)	12 (44.4%)	15 (55.6%)	0 (0.0%)	27
Procoagulant therapy	1 (3.7%)	1 (3.7%)	15 (55.6%)	10 (37.0%)	27
Bacillus infection	27 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	27
Urosepsis	1 (3.7%)	6 (22.2%)	10 (37.0%)	10 (37.0%)	27
Antisynthetase syndrome	0 (0.0%)	8 (29.6%)	19 (70.4%)	0 (0.0%)	27
Epilepsy with myoclonic-atonic seizures	27 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	27
Precursor T-lymphoblastic lymphoma/leukaemia	23 (85.2%)	0 (0.0%)	4 (14.8%)	0 (0.0%)	27
Gigantism	0 (0.0%)	10 (37.0%)	14 (51.9%)	3 (11.1%)	27
Chloroma	12 (44.4%)	7 (25.9%)	6 (22.2%)	2 (7.4%)	27

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cryopyrin associated periodic syndrome	14 (53.8%)	6 (23.1%)	5 (19.2%)	1 (3.8%)	26
Goitre	8 (30.8%)	1 (3.8%)	8 (30.8%)	9 (34.6%)	26
HER2 low breast cancer	0 (0.0%)	4 (15.4%)	19 (73.1%)	3 (11.5%)	26
Blood disorder	0 (0.0%)	2 (7.7%)	13 (50.0%)	11 (42.3%)	26
Metabolic syndrome	0 (0.0%)	15 (57.7%)	5 (19.2%)	6 (23.1%)	26
Heart rate irregular	2 (7.7%)	0 (0.0%)	9 (34.6%)	15 (57.7%)	26
Laryngeal cancer	0 (0.0%)	1 (3.8%)	18 (69.2%)	7 (26.9%)	26
Cord blood transplant therapy	3 (11.5%)	6 (23.1%)	17 (65.4%)	0 (0.0%)	26
Sleep related hypermotor epilepsy	22 (84.6%)	4 (15.4%)	0 (0.0%)	0 (0.0%)	26
Encephalitis cytomegalovirus	0 (0.0%)	26 (100.0%)	0 (0.0%)	0 (0.0%)	26
Impulse-control disorder	24 (92.3%)	2 (7.7%)	0 (0.0%)	0 (0.0%)	26
Cold type haemolytic anaemia	0 (0.0%)	6 (23.1%)	13 (50.0%)	7 (26.9%)	26
Hypothalamo-pituitary disorder	10 (38.5%)	9 (34.6%)	7 (26.9%)	0 (0.0%)	26
Endocarditis bacterial	4 (15.4%)	0 (0.0%)	15 (57.7%)	7 (26.9%)	26
Peripheral sensory neuropathy	0 (0.0%)	1 (3.8%)	15 (57.7%)	10 (38.5%)	26
T-cell lymphoma stage IV	0 (0.0%)	0 (0.0%)	26 (100.0%)	0 (0.0%)	26
Vasopressive therapy	0 (0.0%)	10 (38.5%)	16 (61.5%)	0 (0.0%)	26
Blood glucose decreased	1 (3.8%)	4 (15.4%)	13 (50.0%)	8 (30.8%)	26
Acidosis	4 (15.4%)	11 (42.3%)	8 (30.8%)	3 (11.5%)	26
Necrotising fasciitis	1 (3.8%)	15 (57.7%)	10 (38.5%)	0 (0.0%)	26
Gastric cancer stage IV	0 (0.0%)	3 (11.5%)	19 (73.1%)	4 (15.4%)	26
Venous thrombosis limb	0 (0.0%)	1 (3.8%)	24 (92.3%)	1 (3.8%)	26
Neurogenic bladder	1 (3.8%)	7 (26.9%)	16 (61.5%)	2 (7.7%)	26
Epidural analgesia	4 (15.4%)	21 (80.8%)	1 (3.8%)	0 (0.0%)	26
Central hypothyroidism	16 (61.5%)	7 (26.9%)	3 (11.5%)	0 (0.0%)	26
Infective pulmonary exacerbation of cystic fibrosis	6 (23.1%)	18 (69.2%)	2 (7.7%)	0 (0.0%)	26
Flatulence	2 (7.7%)	7 (26.9%)	14 (53.8%)	3 (11.5%)	26

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Oxygen therapy	3 (11.5%)	6 (23.1%)	11 (42.3%)	6 (23.1%)	26
Metastatic carcinoma of the bladder	0 (0.0%)	2 (8.0%)	14 (56.0%)	9 (36.0%)	25
Neuromuscular blocking therapy	2 (8.0%)	3 (12.0%)	20 (80.0%)	0 (0.0%)	25
Endometrial cancer stage IV	0 (0.0%)	4 (16.0%)	19 (76.0%)	2 (8.0%)	25
Eye infection	6 (24.0%)	6 (24.0%)	11 (44.0%)	2 (8.0%)	25
Neoplasm prophylaxis	4 (16.0%)	3 (12.0%)	18 (72.0%)	0 (0.0%)	25
Acarodermatitis	4 (16.0%)	10 (40.0%)	7 (28.0%)	4 (16.0%)	25
Acinetobacter infection	9 (36.0%)	5 (20.0%)	11 (44.0%)	0 (0.0%)	25
Metastases to adrenals	0 (0.0%)	0 (0.0%)	24 (96.0%)	1 (4.0%)	25
Progressive multiple sclerosis	11 (44.0%)	5 (20.0%)	9 (36.0%)	0 (0.0%)	25
Chronic graft versus host disease in liver	25 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	25
HIV infection CDC category C	0 (0.0%)	25 (100.0%)	0 (0.0%)	0 (0.0%)	25
Diffuse large B-cell lymphoma stage I	0 (0.0%)	0 (0.0%)	19 (76.0%)	6 (24.0%)	25
Affect lability	5 (20.0%)	3 (12.0%)	9 (36.0%)	8 (32.0%)	25
Thrombolysis	0 (0.0%)	2 (8.0%)	19 (76.0%)	4 (16.0%)	25
Bone density abnormal	1 (4.0%)	1 (4.0%)	16 (64.0%)	7 (28.0%)	25
Breast cancer stage I	0 (0.0%)	11 (44.0%)	14 (56.0%)	0 (0.0%)	25
Abdominal pain lower	0 (0.0%)	19 (76.0%)	6 (24.0%)	0 (0.0%)	25
Decompensated hypothyroidism	0 (0.0%)	17 (68.0%)	8 (32.0%)	0 (0.0%)	25
Renovascular hypertension	24 (96.0%)	1 (4.0%)	0 (0.0%)	0 (0.0%)	25
Palpitations	0 (0.0%)	7 (28.0%)	13 (52.0%)	5 (20.0%)	25
Micturition disorder	2 (8.0%)	2 (8.0%)	15 (60.0%)	6 (24.0%)	25
Hypoaesthesia	0 (0.0%)	4 (16.0%)	16 (64.0%)	5 (20.0%)	25
Social anxiety disorder	5 (20.0%)	20 (80.0%)	0 (0.0%)	0 (0.0%)	25
Infarction	0 (0.0%)	0 (0.0%)	23 (92.0%)	2 (8.0%)	25
Palliative sedation	25 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	25
Infertility female	0 (0.0%)	25 (100.0%)	0 (0.0%)	0 (0.0%)	25

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Substance-induced psychotic disorder	6 (24.0%)	1 (4.0%)	18 (72.0%)	0 (0.0%)	25
Lymphoproliferative disorder	14 (56.0%)	0 (0.0%)	9 (36.0%)	2 (8.0%)	25
Ischaemia	7 (28.0%)	2 (8.0%)	14 (56.0%)	2 (8.0%)	25
Cryoglobulinaemia	0 (0.0%)	12 (48.0%)	12 (48.0%)	1 (4.0%)	25
Juvenile chronic myelomonocytic leukaemia	25 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	25
Adrenal gland cancer	12 (48.0%)	3 (12.0%)	6 (24.0%)	4 (16.0%)	25
Evans syndrome	13 (52.0%)	4 (16.0%)	8 (32.0%)	0 (0.0%)	25
Plasma cell disorder	0 (0.0%)	0 (0.0%)	25 (100.0%)	0 (0.0%)	25
Epstein-Barr virus associated lymphoma	0 (0.0%)	3 (12.0%)	5 (20.0%)	17 (68.0%)	25
Product use issue	1 (4.0%)	1 (4.0%)	5 (20.0%)	18 (72.0%)	25
FLT3 gene mutation	4 (16.0%)	6 (24.0%)	13 (52.0%)	2 (8.0%)	25
Ex-tobacco user	6 (25.0%)	4 (16.7%)	7 (29.2%)	7 (29.2%)	24
Endometrial cancer stage I	0 (0.0%)	4 (16.7%)	20 (83.3%)	0 (0.0%)	24
Dermatitis bullous	0 (0.0%)	2 (8.3%)	10 (41.7%)	12 (50.0%)	24
Drug toxicity prophylaxis	11 (45.8%)	1 (4.2%)	11 (45.8%)	1 (4.2%)	24
Maternal drugs affecting foetus	24 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	24
Facial pain	0 (0.0%)	10 (41.7%)	13 (54.2%)	1 (4.2%)	24
Haemorrhage intracranial	2 (8.3%)	13 (54.2%)	8 (33.3%)	1 (4.2%)	24
Pituitary tumour benign	2 (8.3%)	13 (54.2%)	9 (37.5%)	0 (0.0%)	24
SARS-CoV-2 test positive	0 (0.0%)	5 (20.8%)	16 (66.7%)	3 (12.5%)	24
Small cell carcinoma	0 (0.0%)	1 (4.2%)	15 (62.5%)	8 (33.3%)	24
Tumour invasion	0 (0.0%)	24 (100.0%)	0 (0.0%)	0 (0.0%)	24
Cystinuria	6 (25.0%)	8 (33.3%)	10 (41.7%)	0 (0.0%)	24
Superovulation	0 (0.0%)	24 (100.0%)	0 (0.0%)	0 (0.0%)	24
Peripheral spondyloarthritis	6 (25.0%)	10 (41.7%)	8 (33.3%)	0 (0.0%)	24
Spinal fracture	0 (0.0%)	0 (0.0%)	18 (75.0%)	6 (25.0%)	24
Hepatotoxicity	1 (4.2%)	2 (8.3%)	21 (87.5%)	0 (0.0%)	24

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ganglioneuroblastoma	15 (62.5%)	9 (37.5%)	0 (0.0%)	0 (0.0%)	24
Thyroid cancer metastatic	1 (4.2%)	4 (16.7%)	13 (54.2%)	6 (25.0%)	24
Disseminated aspergillosis	7 (29.2%)	1 (4.2%)	16 (66.7%)	0 (0.0%)	24
Hallucination, visual	1 (4.2%)	0 (0.0%)	8 (33.3%)	15 (62.5%)	24
Tongue neoplasm malignant stage unspecified	0 (0.0%)	4 (16.7%)	18 (75.0%)	2 (8.3%)	24
Palmoplantar pustulosis	0 (0.0%)	8 (33.3%)	15 (62.5%)	1 (4.2%)	24
Porphyria acute	23 (95.8%)	1 (4.2%)	0 (0.0%)	0 (0.0%)	24
Neuroblastoma recurrent	24 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	24
Anaplastic lymphoma kinase gene mutation	7 (29.2%)	13 (54.2%)	3 (12.5%)	1 (4.2%)	24
Mast cell activation syndrome	6 (25.0%)	12 (50.0%)	6 (25.0%)	0 (0.0%)	24
Torticollis	2 (8.3%)	6 (25.0%)	15 (62.5%)	1 (4.2%)	24
Labour induction	12 (50.0%)	12 (50.0%)	0 (0.0%)	0 (0.0%)	24
Drug resistance	0 (0.0%)	12 (50.0%)	11 (45.8%)	1 (4.2%)	24
Calcium deficiency	1 (4.2%)	8 (33.3%)	10 (41.7%)	5 (20.8%)	24
Vulvovaginal mycotic infection	3 (12.5%)	10 (41.7%)	9 (37.5%)	2 (8.3%)	24
Abdominal infection	3 (12.5%)	2 (8.3%)	18 (75.0%)	1 (4.2%)	24
Adenocarcinoma of the cervix	0 (0.0%)	7 (29.2%)	16 (66.7%)	1 (4.2%)	24
Arrhythmia prophylaxis	0 (0.0%)	4 (16.7%)	8 (33.3%)	12 (50.0%)	24
Normochromic normocytic anaemia	23 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	23
Cholangitis sclerosing	2 (8.7%)	4 (17.4%)	17 (73.9%)	0 (0.0%)	23
Pulmonary alveolar haemorrhage	0 (0.0%)	0 (0.0%)	21 (91.3%)	2 (8.7%)	23
Lichen myxoedematosus	0 (0.0%)	10 (43.5%)	13 (56.5%)	0 (0.0%)	23
Lichen planus	1 (4.3%)	5 (21.7%)	12 (52.2%)	5 (21.7%)	23
Ear pain	13 (56.5%)	4 (17.4%)	5 (21.7%)	1 (4.3%)	23
Metastases to pleura	0 (0.0%)	7 (30.4%)	15 (65.2%)	1 (4.3%)	23
Metastases to bone marrow	14 (60.9%)	7 (30.4%)	2 (8.7%)	0 (0.0%)	23
Alopecia totalis	7 (30.4%)	7 (30.4%)	9 (39.1%)	0 (0.0%)	23

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mediastinitis	0 (0.0%)	3 (13.0%)	6 (26.1%)	14 (60.9%)	23
Detoxification	10 (43.5%)	8 (34.8%)	4 (17.4%)	1 (4.3%)	23
Clostridium difficile colitis	0 (0.0%)	4 (17.4%)	14 (60.9%)	5 (21.7%)	23
Prostate cancer stage IV	0 (0.0%)	2 (8.7%)	16 (69.6%)	5 (21.7%)	23
Blood magnesium decreased	2 (8.7%)	5 (21.7%)	12 (52.2%)	4 (17.4%)	23
Hiccups	0 (0.0%)	11 (47.8%)	10 (43.5%)	2 (8.7%)	23
Catheter management	0 (0.0%)	15 (65.2%)	7 (30.4%)	1 (4.3%)	23
Platelet aggregation inhibition	1 (4.3%)	0 (0.0%)	16 (69.6%)	6 (26.1%)	23
Anger	17 (73.9%)	1 (4.3%)	5 (21.7%)	0 (0.0%)	23
Hepatic steatosis	4 (17.4%)	4 (17.4%)	9 (39.1%)	6 (26.1%)	23
Myoclonic epilepsy	14 (60.9%)	1 (4.3%)	8 (34.8%)	0 (0.0%)	23
Ischaemic cardiomyopathy	0 (0.0%)	2 (8.7%)	8 (34.8%)	13 (56.5%)	23
Hyperparathyroidism	2 (8.7%)	6 (26.1%)	14 (60.9%)	1 (4.3%)	23
Post-acute COVID-19 syndrome	2 (8.7%)	19 (82.6%)	0 (0.0%)	2 (8.7%)	23
Scedosporium infection	5 (21.7%)	2 (8.7%)	16 (69.6%)	0 (0.0%)	23
Malignant connective tissue neoplasm	7 (30.4%)	8 (34.8%)	6 (26.1%)	2 (8.7%)	23
Pneumonia staphylococcal	2 (8.7%)	0 (0.0%)	21 (91.3%)	0 (0.0%)	23
Double hit lymphoma	0 (0.0%)	0 (0.0%)	14 (60.9%)	9 (39.1%)	23
Coronary arterial stent insertion	0 (0.0%)	0 (0.0%)	14 (60.9%)	9 (39.1%)	23
Central pain syndrome	2 (8.7%)	1 (4.3%)	20 (87.0%)	0 (0.0%)	23
Scleritis	1 (4.3%)	3 (13.0%)	18 (78.3%)	1 (4.3%)	23
Central nervous system leukaemia	20 (87.0%)	3 (13.0%)	0 (0.0%)	0 (0.0%)	23
Vitamin B complex deficiency	2 (8.7%)	6 (26.1%)	14 (60.9%)	1 (4.3%)	23
Non-Hodgkin's lymphoma metastatic	14 (60.9%)	0 (0.0%)	6 (26.1%)	3 (13.0%)	23
Caesarean section	4 (18.2%)	18 (81.8%)	0 (0.0%)	0 (0.0%)	22
Neuroendocrine carcinoma metastatic	0 (0.0%)	5 (22.7%)	15 (68.2%)	2 (9.1%)	22
Nervous system disorder prophylaxis	3 (13.6%)	10 (45.5%)	8 (36.4%)	1 (4.5%)	22

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Reduction of increased intracranial pressure	4 (18.2%)	6 (27.3%)	8 (36.4%)	4 (18.2%)	22
Bacterial endophthalmitis	0 (0.0%)	0 (0.0%)	15 (68.2%)	7 (31.8%)	22
Metastatic squamous cell carcinoma	0 (0.0%)	2 (9.1%)	16 (72.7%)	4 (18.2%)	22
Lung squamous cell carcinoma metastatic	0 (0.0%)	1 (4.5%)	16 (72.7%)	5 (22.7%)	22
Libido decreased	0 (0.0%)	15 (68.2%)	7 (31.8%)	0 (0.0%)	22
Keratitis	10 (45.5%)	2 (9.1%)	7 (31.8%)	3 (13.6%)	22
Intestinal obstruction	0 (0.0%)	1 (4.5%)	17 (77.3%)	4 (18.2%)	22
Skin exfoliation	0 (0.0%)	2 (9.1%)	15 (68.2%)	5 (22.7%)	22
Corneal infection	22 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	22
Myasthenic syndrome	0 (0.0%)	3 (13.6%)	18 (81.8%)	1 (4.5%)	22
Computerised tomogram heart	0 (0.0%)	4 (18.2%)	16 (72.7%)	2 (9.1%)	22
Premenstrual syndrome	0 (0.0%)	8 (36.4%)	3 (13.6%)	11 (50.0%)	22
Hyperparathyroidism primary	4 (18.2%)	4 (18.2%)	10 (45.5%)	4 (18.2%)	22
Varicella zoster virus infection	2 (9.1%)	4 (18.2%)	16 (72.7%)	0 (0.0%)	22
Pleurisy	0 (0.0%)	2 (9.1%)	20 (90.9%)	0 (0.0%)	22
Necrotising myositis	0 (0.0%)	7 (31.8%)	13 (59.1%)	2 (9.1%)	22
Pneumonia fungal	1 (4.5%)	1 (4.5%)	15 (68.2%)	5 (22.7%)	22
Portal hypertension	4 (18.2%)	8 (36.4%)	8 (36.4%)	2 (9.1%)	22
Gastrointestinal bacterial overgrowth	9 (40.9%)	5 (22.7%)	5 (22.7%)	3 (13.6%)	22
Agranulocytosis	2 (9.1%)	2 (9.1%)	17 (77.3%)	1 (4.5%)	22
Cataract operation	0 (0.0%)	2 (9.1%)	18 (81.8%)	2 (9.1%)	22
Nicotine dependence	0 (0.0%)	4 (18.2%)	17 (77.3%)	1 (4.5%)	22
Palisaded neutrophilic granulomatous dermatitis	0 (0.0%)	0 (0.0%)	22 (100.0%)	0 (0.0%)	22
Barrett's oesophagus	0 (0.0%)	5 (22.7%)	12 (54.5%)	5 (22.7%)	22
Eye pruritus	0 (0.0%)	3 (13.6%)	18 (81.8%)	1 (4.5%)	22
Insulinoma	1 (4.5%)	0 (0.0%)	2 (9.1%)	19 (86.4%)	22
Mouth ulceration	6 (28.6%)	2 (9.5%)	12 (57.1%)	1 (4.8%)	21

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Coronary artery dilatation	0 (0.0%)	0 (0.0%)	0 (0.0%)	21 (100.0%)	21
Tuberous sclerosis complex	12 (57.1%)	9 (42.9%)	0 (0.0%)	0 (0.0%)	21
Artificial menopause	0 (0.0%)	9 (42.9%)	12 (57.1%)	0 (0.0%)	21
Empty sella syndrome	0 (0.0%)	0 (0.0%)	21 (100.0%)	0 (0.0%)	21
Morphoea	10 (47.6%)	6 (28.6%)	5 (23.8%)	0 (0.0%)	21
Rectosigmoid cancer stage IV	0 (0.0%)	3 (14.3%)	18 (85.7%)	0 (0.0%)	21
Metastases to spine	0 (0.0%)	3 (14.3%)	15 (71.4%)	3 (14.3%)	21
HIV test	1 (4.8%)	19 (90.5%)	1 (4.8%)	0 (0.0%)	21
Acute myelomonocytic leukaemia	2 (9.5%)	4 (19.0%)	10 (47.6%)	5 (23.8%)	21
Renal cancer stage IV	0 (0.0%)	5 (23.8%)	15 (71.4%)	1 (4.8%)	21
Dry mouth	0 (0.0%)	3 (14.3%)	16 (76.2%)	2 (9.5%)	21
Rectal cancer stage IV	0 (0.0%)	0 (0.0%)	11 (52.4%)	10 (47.6%)	21
Chronic graft versus host disease in eye	19 (90.5%)	0 (0.0%)	2 (9.5%)	0 (0.0%)	21
Malignant neoplasm of ampulla of Vater	0 (0.0%)	0 (0.0%)	21 (100.0%)	0 (0.0%)	21
Lymphoplasmacytoid lymphoma/immunocytoma	0 (0.0%)	0 (0.0%)	3 (14.3%)	18 (85.7%)	21
Lung carcinoma cell type unspecified recurrent	0 (0.0%)	5 (23.8%)	11 (52.4%)	5 (23.8%)	21
Ludwig angina	0 (0.0%)	21 (100.0%)	0 (0.0%)	0 (0.0%)	21
Blood testosterone decreased	2 (9.5%)	6 (28.6%)	13 (61.9%)	0 (0.0%)	21
Cystoid macular oedema	1 (4.8%)	5 (23.8%)	15 (71.4%)	0 (0.0%)	21
Skin papilloma	3 (14.3%)	12 (57.1%)	3 (14.3%)	3 (14.3%)	21
Flushing	2 (9.5%)	5 (23.8%)	12 (57.1%)	2 (9.5%)	21
Spinal stenosis	0 (0.0%)	0 (0.0%)	18 (85.7%)	3 (14.3%)	21
Histoplasmosis	0 (0.0%)	12 (57.1%)	8 (38.1%)	1 (4.8%)	21
Hormone level abnormal	4 (19.0%)	5 (23.8%)	11 (52.4%)	1 (4.8%)	21
Hyperbilirubinaemia	21 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	21
Hodgkin's disease nodular sclerosis stage IV	0 (0.0%)	21 (100.0%)	0 (0.0%)	0 (0.0%)	21
High grade B-cell lymphoma Burkitt-like lymphoma	21 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	21

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Aplasia pure red cell	0 (0.0%)	0 (0.0%)	14 (66.7%)	7 (33.3%)	21
Anaphylactic shock	4 (19.0%)	3 (14.3%)	14 (66.7%)	0 (0.0%)	21
Disseminated intravascular coagulation	2 (9.5%)	7 (33.3%)	9 (42.9%)	3 (14.3%)	21
Tourette's disorder	17 (81.0%)	4 (19.0%)	0 (0.0%)	0 (0.0%)	21
Tooth abscess	2 (9.5%)	6 (28.6%)	9 (42.9%)	4 (19.0%)	21
Cerebral haemorrhage	4 (19.0%)	1 (4.8%)	10 (47.6%)	6 (28.6%)	21
Tubulointerstitial nephritis	3 (14.3%)	8 (38.1%)	7 (33.3%)	3 (14.3%)	21
Undifferentiated sarcoma	3 (14.3%)	3 (14.3%)	15 (71.4%)	0 (0.0%)	21
Poor quality sleep	1 (4.8%)	9 (42.9%)	11 (52.4%)	0 (0.0%)	21
Post lumbar puncture syndrome	0 (0.0%)	20 (95.2%)	1 (4.8%)	0 (0.0%)	21
Drug intolerance	1 (4.8%)	1 (4.8%)	14 (66.7%)	5 (23.8%)	21
Cachexia	0 (0.0%)	2 (9.5%)	13 (61.9%)	6 (28.6%)	21
Gallbladder cancer	0 (0.0%)	1 (4.8%)	18 (85.7%)	2 (9.5%)	21
Blood cholesterol decreased	0 (0.0%)	3 (14.3%)	13 (61.9%)	5 (23.8%)	21
Asthmatic crisis	1 (4.8%)	15 (71.4%)	5 (23.8%)	0 (0.0%)	21
Mastocytosis	0 (0.0%)	8 (38.1%)	13 (61.9%)	0 (0.0%)	21
Wound treatment	6 (28.6%)	7 (33.3%)	0 (0.0%)	8 (38.1%)	21
White blood cell count increased	1 (4.8%)	4 (19.0%)	16 (76.2%)	0 (0.0%)	21
Prophylaxis urinary tract infection	3 (14.3%)	0 (0.0%)	8 (38.1%)	10 (47.6%)	21
5q minus syndrome	0 (0.0%)	0 (0.0%)	7 (33.3%)	14 (66.7%)	21
Carcinoid tumour of the small bowel	0 (0.0%)	1 (4.8%)	15 (71.4%)	5 (23.8%)	21
Prurigo	2 (10.0%)	3 (15.0%)	4 (20.0%)	11 (55.0%)	20
Epistaxis	3 (15.0%)	10 (50.0%)	4 (20.0%)	3 (15.0%)	20
Epilepsy congenital	20 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	20
Neuromuscular blockade	10 (50.0%)	0 (0.0%)	9 (45.0%)	1 (5.0%)	20
Pulmonary mass	0 (0.0%)	5 (25.0%)	13 (65.0%)	2 (10.0%)	20
Natural killer-cell leukaemia	0 (0.0%)	0 (0.0%)	10 (50.0%)	10 (50.0%)	20

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Enterocolitis	0 (0.0%)	3 (15.0%)	12 (60.0%)	5 (25.0%)	20
Transitional cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	15 (75.0%)	5 (25.0%)	20
Renal neoplasm	0 (0.0%)	0 (0.0%)	18 (90.0%)	2 (10.0%)	20
Bronchopulmonary aspergillosis allergic	0 (0.0%)	15 (75.0%)	5 (25.0%)	0 (0.0%)	20
Eczema nummular	3 (15.0%)	2 (10.0%)	13 (65.0%)	2 (10.0%)	20
Heart disease congenital	16 (80.0%)	0 (0.0%)	2 (10.0%)	2 (10.0%)	20
Chest scan	0 (0.0%)	1 (5.0%)	19 (95.0%)	0 (0.0%)	20
Dysbiosis	3 (15.0%)	7 (35.0%)	8 (40.0%)	2 (10.0%)	20
Dry skin prophylaxis	3 (15.0%)	4 (20.0%)	10 (50.0%)	3 (15.0%)	20
Maternal exposure timing unspecified	20 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	20
Mineral deficiency	6 (30.0%)	2 (10.0%)	11 (55.0%)	1 (5.0%)	20
Abnormal behaviour	13 (65.0%)	5 (25.0%)	1 (5.0%)	1 (5.0%)	20
Bone tuberculosis	0 (0.0%)	16 (80.0%)	4 (20.0%)	0 (0.0%)	20
Eye irritation	1 (5.0%)	4 (20.0%)	12 (60.0%)	3 (15.0%)	20
Bone giant cell tumour	10 (50.0%)	7 (35.0%)	3 (15.0%)	0 (0.0%)	20
Lip and/or oral cavity cancer	0 (0.0%)	0 (0.0%)	13 (65.0%)	7 (35.0%)	20
Legionella infection	0 (0.0%)	4 (20.0%)	4 (20.0%)	12 (60.0%)	20
Rash maculo-papular	0 (0.0%)	3 (15.0%)	16 (80.0%)	1 (5.0%)	20
Cytogenetic abnormality	20 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	20
Pancytopenia	1 (5.0%)	3 (15.0%)	15 (75.0%)	1 (5.0%)	20
Thoracic vertebral fracture	0 (0.0%)	11 (55.0%)	9 (45.0%)	0 (0.0%)	20
Hereditary haemorrhagic telangiectasia	0 (0.0%)	2 (10.0%)	18 (90.0%)	0 (0.0%)	20
Proctitis	1 (5.0%)	5 (25.0%)	14 (70.0%)	0 (0.0%)	20
Small for dates baby	20 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	20
Idiopathic interstitial pneumonia	0 (0.0%)	6 (30.0%)	9 (45.0%)	5 (25.0%)	20
Spinal disorder	0 (0.0%)	5 (25.0%)	13 (65.0%)	2 (10.0%)	20
Cystitis noninfective	0 (0.0%)	0 (0.0%)	20 (100.0%)	0 (0.0%)	20

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Autoinflammatory disease	19 (95.0%)	0 (0.0%)	0 (0.0%)	1 (5.0%)	20
Abortion induced	3 (15.0%)	17 (85.0%)	0 (0.0%)	0 (0.0%)	20
Respiratory syncytial virus immunisation	18 (90.0%)	0 (0.0%)	2 (10.0%)	0 (0.0%)	20
Tobacco user	0 (0.0%)	4 (20.0%)	14 (70.0%)	2 (10.0%)	20
Varices oesophageal	2 (10.0%)	5 (25.0%)	12 (60.0%)	1 (5.0%)	20
Nerve injury	0 (0.0%)	4 (20.0%)	14 (70.0%)	2 (10.0%)	20
Gingival cancer	0 (0.0%)	0 (0.0%)	18 (90.0%)	2 (10.0%)	20
Gastrointestinal motility disorder	6 (30.0%)	5 (25.0%)	9 (45.0%)	0 (0.0%)	20
Immune-mediated enterocolitis	2 (10.0%)	1 (5.0%)	13 (65.0%)	4 (20.0%)	20
Gastric pH decreased	2 (10.0%)	1 (5.0%)	16 (80.0%)	1 (5.0%)	20
Central nervous system infection	2 (10.0%)	6 (30.0%)	2 (10.0%)	10 (50.0%)	20
Oropharyngeal squamous cell carcinoma	0 (0.0%)	6 (30.0%)	8 (40.0%)	6 (30.0%)	20
Bacterial disease carrier	4 (20.0%)	6 (30.0%)	10 (50.0%)	0 (0.0%)	20
Organising pneumonia	1 (5.0%)	4 (20.0%)	13 (65.0%)	2 (10.0%)	20
Neuropsychiatric lupus	19 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19
Trisomy 21	19 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19
Rectal haemorrhage	2 (10.5%)	6 (31.6%)	9 (47.4%)	2 (10.5%)	19
Renal and pancreas transplant	0 (0.0%)	8 (42.1%)	11 (57.9%)	0 (0.0%)	19
Lipidosis	2 (10.5%)	7 (36.8%)	8 (42.1%)	2 (10.5%)	19
Discomfort	4 (21.1%)	0 (0.0%)	15 (78.9%)	0 (0.0%)	19
Dialysis	1 (5.3%)	1 (5.3%)	13 (68.4%)	4 (21.1%)	19
Low density lipoprotein abnormal	0 (0.0%)	1 (5.3%)	14 (73.7%)	4 (21.1%)	19
Transitional cell cancer of the renal pelvis and ure	0 (0.0%)	0 (0.0%)	11 (57.9%)	8 (42.1%)	19
Desmoid tumour	4 (21.1%)	12 (63.2%)	3 (15.8%)	0 (0.0%)	19
Rhabdoid tumour	19 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19
Lacunar infarction	0 (0.0%)	0 (0.0%)	16 (84.2%)	3 (15.8%)	19
Post procedural hypothyroidism	0 (0.0%)	3 (15.8%)	13 (68.4%)	3 (15.8%)	19

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Isodicentric chromosome 15 syndrome	16 (84.2%)	3 (15.8%)	0 (0.0%)	0 (0.0%)	19
Hepatic failure	1 (5.3%)	2 (10.5%)	12 (63.2%)	4 (21.1%)	19
Non-renal cell carcinoma of kidney	0 (0.0%)	19 (100.0%)	0 (0.0%)	0 (0.0%)	19
Vision blurred	0 (0.0%)	0 (0.0%)	17 (89.5%)	2 (10.5%)	19
Volvulus	0 (0.0%)	1 (5.3%)	18 (94.7%)	0 (0.0%)	19
Radiculopathy	4 (21.1%)	5 (26.3%)	10 (52.6%)	0 (0.0%)	19
Anal incontinence	0 (0.0%)	2 (10.5%)	2 (10.5%)	15 (78.9%)	19
Soft tissue infection	2 (10.5%)	4 (21.1%)	10 (52.6%)	3 (15.8%)	19
Spinal fusion surgery	1 (5.3%)	14 (73.7%)	4 (21.1%)	0 (0.0%)	19
Complement deficiency disease	2 (10.5%)	7 (36.8%)	10 (52.6%)	0 (0.0%)	19
Perinatal depression	8 (42.1%)	11 (57.9%)	0 (0.0%)	0 (0.0%)	19
Sleep deficit	10 (52.6%)	0 (0.0%)	3 (15.8%)	6 (31.6%)	19
Tic	19 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19
Autonomic neuropathy	2 (10.5%)	10 (52.6%)	6 (31.6%)	1 (5.3%)	19
Neoplasm prostate	0 (0.0%)	0 (0.0%)	12 (63.2%)	7 (36.8%)	19
Coronary artery bypass	0 (0.0%)	1 (5.3%)	16 (84.2%)	2 (10.5%)	19
Ileus	1 (5.3%)	2 (10.5%)	9 (47.4%)	7 (36.8%)	19
Cervix cancer metastatic	0 (0.0%)	8 (42.1%)	8 (42.1%)	3 (15.8%)	19
Graft infection	14 (73.7%)	0 (0.0%)	3 (15.8%)	2 (10.5%)	19
Pre-existing disease	0 (0.0%)	0 (0.0%)	9 (47.4%)	10 (52.6%)	19
Wisdom teeth removal	9 (47.4%)	9 (47.4%)	1 (5.3%)	0 (0.0%)	19
Appendix cancer	0 (0.0%)	3 (15.8%)	15 (78.9%)	1 (5.3%)	19
Neuroendocrine tumour of the rectum	0 (0.0%)	3 (15.8%)	16 (84.2%)	0 (0.0%)	19
Pneumocystis jirovecii infection	4 (21.1%)	7 (36.8%)	7 (36.8%)	1 (5.3%)	19
Ocular icterus	19 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19
Cryptococcosis	0 (0.0%)	1 (5.3%)	16 (84.2%)	2 (10.5%)	19
Fungaemia	3 (15.8%)	2 (10.5%)	11 (57.9%)	3 (15.8%)	19

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Primary hypothyroidism	0 (0.0%)	2 (10.5%)	15 (78.9%)	2 (10.5%)	19
Performance enhancing product use	0 (0.0%)	18 (94.7%)	1 (5.3%)	0 (0.0%)	19
Partial seizures with secondary generalisation	18 (94.7%)	0 (0.0%)	1 (5.3%)	0 (0.0%)	19
Paraganglion neoplasm	15 (78.9%)	3 (15.8%)	1 (5.3%)	0 (0.0%)	19
Renal cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	15 (78.9%)	4 (21.1%)	19
Factor VII deficiency	13 (68.4%)	4 (21.1%)	2 (10.5%)	0 (0.0%)	19
Blood thyroid stimulating hormone increased	4 (21.1%)	6 (31.6%)	6 (31.6%)	3 (15.8%)	19
Pancreatitis acute	0 (0.0%)	11 (57.9%)	6 (31.6%)	2 (10.5%)	19
Accidental exposure to product by child	19 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19
Dental care	3 (15.8%)	6 (31.6%)	10 (52.6%)	0 (0.0%)	19
Erythema multiforme	1 (5.3%)	1 (5.3%)	16 (84.2%)	1 (5.3%)	19
Tumour necrosis factor receptor-associated periodic	3 (16.7%)	9 (50.0%)	5 (27.8%)	1 (5.6%)	18
Obstructive airways disorder	0 (0.0%)	6 (33.3%)	12 (66.7%)	0 (0.0%)	18
Neuropsychological symptoms	16 (88.9%)	0 (0.0%)	2 (11.1%)	0 (0.0%)	18
Microalbuminuria	0 (0.0%)	0 (0.0%)	18 (100.0%)	0 (0.0%)	18
Pulmonary congestion	1 (5.6%)	3 (16.7%)	6 (33.3%)	8 (44.4%)	18
Neoplasm progression	4 (22.2%)	1 (5.6%)	7 (38.9%)	6 (33.3%)	18
Acute respiratory failure	4 (22.2%)	6 (33.3%)	7 (38.9%)	1 (5.6%)	18
Myopathy	0 (0.0%)	4 (22.2%)	8 (44.4%)	6 (33.3%)	18
Myelosuppression	1 (5.6%)	4 (22.2%)	9 (50.0%)	4 (22.2%)	18
Chordoma	0 (0.0%)	0 (0.0%)	18 (100.0%)	0 (0.0%)	18
Emotional disorder	9 (50.0%)	6 (33.3%)	2 (11.1%)	1 (5.6%)	18
Chronic actinic dermatitis	0 (0.0%)	0 (0.0%)	17 (94.4%)	1 (5.6%)	18
Arterial disorder	0 (0.0%)	3 (16.7%)	9 (50.0%)	6 (33.3%)	18
Metaplastic breast carcinoma	0 (0.0%)	0 (0.0%)	18 (100.0%)	0 (0.0%)	18
Meningococcal sepsis	18 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	18
Acinar cell carcinoma of pancreas	0 (0.0%)	18 (100.0%)	0 (0.0%)	0 (0.0%)	18

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Weight increased	3 (16.7%)	6 (33.3%)	7 (38.9%)	2 (11.1%)	18
Retroperitoneal fibrosis	0 (0.0%)	1 (5.6%)	15 (83.3%)	2 (11.1%)	18
Body mass index decreased	18 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	18
Heart rate	0 (0.0%)	2 (11.1%)	14 (77.8%)	2 (11.1%)	18
Immune-mediated lung disease	0 (0.0%)	12 (66.7%)	5 (27.8%)	1 (5.6%)	18
Pathogen resistance	0 (0.0%)	12 (66.7%)	3 (16.7%)	3 (16.7%)	18
Squamous cell carcinoma of the tongue	0 (0.0%)	1 (5.6%)	13 (72.2%)	4 (22.2%)	18
Percutaneous coronary intervention	0 (0.0%)	4 (22.2%)	5 (27.8%)	9 (50.0%)	18
Huntington's disease	0 (0.0%)	4 (22.2%)	12 (66.7%)	2 (11.1%)	18
Myopericarditis	4 (22.2%)	7 (38.9%)	7 (38.9%)	0 (0.0%)	18
Soft tissue neoplasm	2 (11.1%)	6 (33.3%)	9 (50.0%)	1 (5.6%)	18
Persistent depressive disorder	2 (11.1%)	2 (11.1%)	14 (77.8%)	0 (0.0%)	18
Burning sensation	3 (16.7%)	6 (33.3%)	8 (44.4%)	1 (5.6%)	18
Otitis externa	1 (5.6%)	7 (38.9%)	0 (0.0%)	10 (55.6%)	18
Postmenopause	1 (5.6%)	2 (11.1%)	14 (77.8%)	1 (5.6%)	18
Keratopathy	0 (0.0%)	0 (0.0%)	15 (83.3%)	3 (16.7%)	18
Gingivitis	5 (27.8%)	8 (44.4%)	5 (27.8%)	0 (0.0%)	18
Conjunctivitis allergic	3 (16.7%)	7 (38.9%)	6 (33.3%)	2 (11.1%)	18
Carpal tunnel syndrome	3 (16.7%)	1 (5.6%)	12 (66.7%)	2 (11.1%)	18
Cheilitis	18 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	18
Atypical pneumonia	0 (0.0%)	5 (27.8%)	13 (72.2%)	0 (0.0%)	18
Campylobacter infection	0 (0.0%)	11 (61.1%)	2 (11.1%)	5 (27.8%)	18
Hypovolaemia	0 (0.0%)	1 (5.6%)	12 (66.7%)	5 (27.8%)	18
Intermenstrual bleeding	5 (27.8%)	12 (66.7%)	1 (5.6%)	0 (0.0%)	18
Pseudomonal bacteraemia	0 (0.0%)	0 (0.0%)	7 (38.9%)	11 (61.1%)	18
Carcinoid tumour pulmonary	0 (0.0%)	0 (0.0%)	18 (100.0%)	0 (0.0%)	18
Asthma prophylaxis	3 (17.6%)	2 (11.8%)	5 (29.4%)	7 (41.2%)	17

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Euphoric mood	8 (47.1%)	9 (52.9%)	0 (0.0%)	0 (0.0%)	17
Addison's disease	2 (11.8%)	8 (47.1%)	7 (41.2%)	0 (0.0%)	17
Neuroendocrine tumour of the lung	0 (0.0%)	0 (0.0%)	14 (82.4%)	3 (17.6%)	17
Astrocytoma, low grade	11 (64.7%)	5 (29.4%)	1 (5.9%)	0 (0.0%)	17
Adjustment disorder with depressed mood	0 (0.0%)	10 (58.8%)	4 (23.5%)	3 (17.6%)	17
Trichophytosis	0 (0.0%)	17 (100.0%)	0 (0.0%)	0 (0.0%)	17
Menstrual disorder	9 (52.9%)	7 (41.2%)	1 (5.9%)	0 (0.0%)	17
Menstrual cycle management	9 (52.9%)	6 (35.3%)	2 (11.8%)	0 (0.0%)	17
Duodenitis	5 (29.4%)	6 (35.3%)	6 (35.3%)	0 (0.0%)	17
Dermo-hypodermatitis	0 (0.0%)	3 (17.6%)	12 (70.6%)	2 (11.8%)	17
Lymph node tuberculosis	0 (0.0%)	8 (47.1%)	5 (29.4%)	4 (23.5%)	17
Warm autoimmune haemolytic anaemia	6 (35.3%)	2 (11.8%)	4 (23.5%)	5 (29.4%)	17
Listeriosis	0 (0.0%)	0 (0.0%)	5 (29.4%)	12 (70.6%)	17
Allergic respiratory symptom	2 (11.8%)	1 (5.9%)	8 (47.1%)	6 (35.3%)	17
Blood triglycerides	0 (0.0%)	3 (17.6%)	13 (76.5%)	1 (5.9%)	17
Keratoconus	5 (29.4%)	10 (58.8%)	2 (11.8%)	0 (0.0%)	17
Sarcomatoid carcinoma of the lung	0 (0.0%)	0 (0.0%)	17 (100.0%)	0 (0.0%)	17
Self-medication	0 (0.0%)	0 (0.0%)	15 (88.2%)	2 (11.8%)	17
Akathisia	1 (5.9%)	11 (64.7%)	2 (11.8%)	3 (17.6%)	17
Paranoia	8 (47.1%)	3 (17.6%)	1 (5.9%)	5 (29.4%)	17
Incontinence	0 (0.0%)	1 (5.9%)	11 (64.7%)	5 (29.4%)	17
Confusional state	1 (5.9%)	0 (0.0%)	11 (64.7%)	5 (29.4%)	17
Colon cancer stage III	0 (0.0%)	9 (52.9%)	3 (17.6%)	5 (29.4%)	17
Computerised tomogram head	0 (0.0%)	6 (35.3%)	10 (58.8%)	1 (5.9%)	17
Spinal compression fracture	0 (0.0%)	0 (0.0%)	7 (41.2%)	10 (58.8%)	17
Bladder dysfunction	0 (0.0%)	3 (17.6%)	12 (70.6%)	2 (11.8%)	17
Thrombocytosis	2 (11.8%)	4 (23.5%)	6 (35.3%)	5 (29.4%)	17

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Infertility	1 (5.9%)	16 (94.1%)	0 (0.0%)	0 (0.0%)	17
Thalassaemia	10 (58.8%)	2 (11.8%)	5 (29.4%)	0 (0.0%)	17
Necrotising scleritis	0 (0.0%)	2 (11.8%)	0 (0.0%)	15 (88.2%)	17
Contusion	0 (0.0%)	7 (41.2%)	10 (58.8%)	0 (0.0%)	17
Product substitution	0 (0.0%)	1 (5.9%)	15 (88.2%)	1 (5.9%)	17
Poisoning	4 (23.5%)	1 (5.9%)	11 (64.7%)	1 (5.9%)	17
B-cell lymphoma recurrent	0 (0.0%)	0 (0.0%)	17 (100.0%)	0 (0.0%)	17
Primitive neuroectodermal tumour	3 (17.6%)	0 (0.0%)	14 (82.4%)	0 (0.0%)	17
B-cell lymphoma stage IV	0 (0.0%)	10 (58.8%)	7 (41.2%)	0 (0.0%)	17
B-cell lymphoma stage II	0 (0.0%)	17 (100.0%)	0 (0.0%)	0 (0.0%)	17
Gastrointestinal lymphoma	0 (0.0%)	13 (76.5%)	4 (23.5%)	0 (0.0%)	17
Gastric cancer recurrent	0 (0.0%)	2 (11.8%)	11 (64.7%)	4 (23.5%)	17
Lung adenocarcinoma stage II	0 (0.0%)	1 (5.9%)	16 (94.1%)	0 (0.0%)	17
Paroxysmal sympathetic hyperactivity	4 (23.5%)	5 (29.4%)	8 (47.1%)	0 (0.0%)	17
Flank pain	3 (17.6%)	5 (29.4%)	8 (47.1%)	1 (5.9%)	17
Progressive familial intrahepatic cholestasis	17 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	17
Neurosarcoidosis	3 (18.8%)	5 (31.3%)	8 (50.0%)	0 (0.0%)	16
Enthesopathy	9 (56.3%)	6 (37.5%)	1 (6.3%)	0 (0.0%)	16
Engraftment syndrome	2 (12.5%)	8 (50.0%)	6 (37.5%)	0 (0.0%)	16
Acinetobacter test positive	0 (0.0%)	0 (0.0%)	16 (100.0%)	0 (0.0%)	16
Metastases to skin	0 (0.0%)	9 (56.3%)	1 (6.3%)	6 (37.5%)	16
Metastases to breast	0 (0.0%)	8 (50.0%)	3 (18.8%)	5 (31.3%)	16
Transfusion	6 (37.5%)	3 (18.8%)	5 (31.3%)	2 (12.5%)	16
Menstruation irregular	6 (37.5%)	9 (56.3%)	1 (6.3%)	0 (0.0%)	16
Haemodynamic instability	7 (43.8%)	1 (6.3%)	7 (43.8%)	1 (6.3%)	16
Transcatheter arterial chemoembolisation	0 (0.0%)	0 (0.0%)	13 (81.3%)	3 (18.8%)	16
Lymphoedema	0 (0.0%)	3 (18.8%)	9 (56.3%)	4 (25.0%)	16

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lymphocytic lymphoma	0 (0.0%)	0 (0.0%)	12 (75.0%)	4 (25.0%)	16
Lung opacity	0 (0.0%)	5 (31.3%)	7 (43.8%)	4 (25.0%)	16
Lung adenocarcinoma recurrent	0 (0.0%)	0 (0.0%)	9 (56.3%)	7 (43.8%)	16
Low density lipoprotein	0 (0.0%)	0 (0.0%)	11 (68.8%)	5 (31.3%)	16
Liver transplant rejection	1 (6.3%)	5 (31.3%)	10 (62.5%)	0 (0.0%)	16
Lipid metabolism disorder	6 (37.5%)	0 (0.0%)	6 (37.5%)	4 (25.0%)	16
Linear IgA disease	5 (31.3%)	0 (0.0%)	11 (68.8%)	0 (0.0%)	16
Chronic myeloid leukaemia (in remission)	0 (0.0%)	1 (6.3%)	11 (68.8%)	4 (25.0%)	16
Dependence	1 (6.3%)	10 (62.5%)	5 (31.3%)	0 (0.0%)	16
Chronic lymphocytic leukaemia recurrent	0 (0.0%)	0 (0.0%)	10 (62.5%)	6 (37.5%)	16
Multifocal motor neuropathy	0 (0.0%)	6 (37.5%)	10 (62.5%)	0 (0.0%)	16
Serotonin syndrome	5 (31.3%)	9 (56.3%)	2 (12.5%)	0 (0.0%)	16
Thrombophlebitis	0 (0.0%)	2 (12.5%)	8 (50.0%)	6 (37.5%)	16
Germ cell neoplasm	6 (37.5%)	0 (0.0%)	10 (62.5%)	0 (0.0%)	16
Hepatobiliary disorder prophylaxis	2 (12.5%)	7 (43.8%)	5 (31.3%)	2 (12.5%)	16
Giant cell tumour of tendon sheath	5 (31.3%)	4 (25.0%)	5 (31.3%)	2 (12.5%)	16
Thalamus haemorrhage	0 (0.0%)	0 (0.0%)	10 (62.5%)	6 (37.5%)	16
Hypertensive crisis	0 (0.0%)	7 (43.8%)	9 (56.3%)	0 (0.0%)	16
Sleep apnoea syndrome	1 (6.3%)	3 (18.8%)	12 (75.0%)	0 (0.0%)	16
Arthritis enteropathic	0 (0.0%)	10 (62.5%)	6 (37.5%)	0 (0.0%)	16
Hyperprolactinaemia	3 (18.8%)	11 (68.8%)	2 (12.5%)	0 (0.0%)	16
Oligodendroglioma	0 (0.0%)	12 (75.0%)	4 (25.0%)	0 (0.0%)	16
Primary myelofibrosis	0 (0.0%)	3 (18.8%)	8 (50.0%)	5 (31.3%)	16
Humoral immune defect	3 (18.8%)	2 (12.5%)	11 (68.8%)	0 (0.0%)	16
Swelling face	0 (0.0%)	5 (31.3%)	10 (62.5%)	1 (6.3%)	16
Hyperaldosteronism	1 (6.3%)	1 (6.3%)	14 (87.5%)	0 (0.0%)	16
Substance abuse	0 (0.0%)	14 (87.5%)	2 (12.5%)	0 (0.0%)	16

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Subdural haematoma	1 (6.3%)	0 (0.0%)	1 (6.3%)	14 (87.5%)	16
Babesiosis	0 (0.0%)	9 (56.3%)	1 (6.3%)	6 (37.5%)	16
Streptococcal bacteraemia	1 (6.3%)	0 (0.0%)	11 (68.8%)	4 (25.0%)	16
Hyperphenylalaninaemia	11 (68.8%)	4 (25.0%)	1 (6.3%)	0 (0.0%)	16
Frontal lobe epilepsy	1 (6.3%)	6 (37.5%)	9 (56.3%)	0 (0.0%)	16
Hodgkin's disease refractory	0 (0.0%)	16 (100.0%)	0 (0.0%)	0 (0.0%)	16
Sneezing	1 (6.3%)	2 (12.5%)	11 (68.8%)	2 (12.5%)	16
Herpes zoster oticus	0 (0.0%)	16 (100.0%)	0 (0.0%)	0 (0.0%)	16
Animal bite	0 (0.0%)	13 (81.3%)	3 (18.8%)	0 (0.0%)	16
Groin pain	0 (0.0%)	0 (0.0%)	15 (93.8%)	1 (6.3%)	16
Chronic respiratory disease	14 (87.5%)	1 (6.3%)	1 (6.3%)	0 (0.0%)	16
Cholestasis	10 (62.5%)	0 (0.0%)	6 (37.5%)	0 (0.0%)	16
Acute sinusitis	0 (0.0%)	2 (12.5%)	14 (87.5%)	0 (0.0%)	16
Cerebrovascular disorder	1 (6.3%)	6 (37.5%)	4 (25.0%)	5 (31.3%)	16
Uveal melanoma	0 (0.0%)	1 (6.3%)	14 (87.5%)	1 (6.3%)	16
Primary adrenal insufficiency	2 (12.5%)	9 (56.3%)	5 (31.3%)	0 (0.0%)	16
Antitussive therapy	2 (12.5%)	8 (50.0%)	5 (31.3%)	1 (6.3%)	16
Inflammatory carcinoma of the breast	0 (0.0%)	2 (12.5%)	12 (75.0%)	2 (12.5%)	16
Muckle-Wells syndrome	9 (56.3%)	3 (18.8%)	4 (25.0%)	0 (0.0%)	16
Inhalation therapy	1 (6.3%)	0 (0.0%)	14 (87.5%)	1 (6.3%)	16
Glycosylated haemoglobin	0 (0.0%)	10 (62.5%)	5 (31.3%)	1 (6.3%)	16
Antidiarrhoeal supportive care	2 (12.5%)	2 (12.5%)	9 (56.3%)	3 (18.8%)	16
Weight loss diet	0 (0.0%)	11 (68.8%)	5 (31.3%)	0 (0.0%)	16
X-linked lymphoproliferative syndrome	16 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	16
Oesophageal squamous cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	12 (80.0%)	3 (20.0%)	15
Oesophageal pain	0 (0.0%)	8 (53.3%)	7 (46.7%)	0 (0.0%)	15
Vitiligo	2 (13.3%)	5 (33.3%)	8 (53.3%)	0 (0.0%)	15

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Oesophageal candidiasis	2 (13.3%)	2 (13.3%)	9 (60.0%)	2 (13.3%)	15
Enteritis	2 (13.3%)	8 (53.3%)	5 (33.3%)	0 (0.0%)	15
Guttate psoriasis	4 (26.7%)	4 (26.7%)	6 (40.0%)	1 (6.7%)	15
Multivisceral transplantation	15 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15
Multisystem inflammatory syndrome in children	15 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15
Prophylaxis of neural tube defect	14 (93.3%)	1 (6.7%)	0 (0.0%)	0 (0.0%)	15
Choroidal detachment	0 (0.0%)	0 (0.0%)	15 (100.0%)	0 (0.0%)	15
Tracheobronchitis	0 (0.0%)	6 (40.0%)	8 (53.3%)	1 (6.7%)	15
Wiskott-Aldrich syndrome	15 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15
Brain cancer metastatic	5 (33.3%)	6 (40.0%)	3 (20.0%)	1 (6.7%)	15
Malignant neoplasm of unknown primary site	0 (0.0%)	2 (13.3%)	5 (33.3%)	8 (53.3%)	15
Disseminated cryptococcosis	1 (6.7%)	5 (33.3%)	7 (46.7%)	2 (13.3%)	15
Osteosarcoma metastatic	10 (66.7%)	3 (20.0%)	2 (13.3%)	0 (0.0%)	15
Bone neoplasm	0 (0.0%)	0 (0.0%)	13 (86.7%)	2 (13.3%)	15
Bone loss	0 (0.0%)	4 (26.7%)	11 (73.3%)	0 (0.0%)	15
Faeces hard	0 (0.0%)	0 (0.0%)	10 (66.7%)	5 (33.3%)	15
Tonsil cancer	0 (0.0%)	0 (0.0%)	15 (100.0%)	0 (0.0%)	15
Eczema infantile	14 (93.3%)	0 (0.0%)	1 (6.7%)	0 (0.0%)	15
Bone density decreased	2 (13.3%)	7 (46.7%)	4 (26.7%)	2 (13.3%)	15
Heart rate decreased	0 (0.0%)	1 (6.7%)	7 (46.7%)	7 (46.7%)	15
Intestinal fistula	0 (0.0%)	1 (6.7%)	14 (93.3%)	0 (0.0%)	15
Vulval cancer	0 (0.0%)	5 (33.3%)	10 (66.7%)	0 (0.0%)	15
Anti-SRP antibody positive	0 (0.0%)	6 (40.0%)	9 (60.0%)	0 (0.0%)	15
Varicose vein	1 (6.7%)	4 (26.7%)	10 (66.7%)	0 (0.0%)	15
Carotid artery stenosis	0 (0.0%)	0 (0.0%)	13 (86.7%)	2 (13.3%)	15
Small intestine neuroendocrine tumour	0 (0.0%)	2 (13.3%)	12 (80.0%)	1 (6.7%)	15
Splenic marginal zone lymphoma	0 (0.0%)	0 (0.0%)	3 (20.0%)	12 (80.0%)	15

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Differentiation syndrome	0 (0.0%)	4 (26.7%)	0 (0.0%)	11 (73.3%)	15
Inflammatory myofibroblastic tumour	6 (40.0%)	9 (60.0%)	0 (0.0%)	0 (0.0%)	15
Bladder transitional cell carcinoma stage IV	0 (0.0%)	0 (0.0%)	6 (40.0%)	9 (60.0%)	15
Hypercoagulation	0 (0.0%)	10 (66.7%)	5 (33.3%)	0 (0.0%)	15
General physical health deterioration	1 (6.7%)	7 (46.7%)	5 (33.3%)	2 (13.3%)	15
Primary hypogonadism	0 (0.0%)	2 (13.3%)	13 (86.7%)	0 (0.0%)	15
Arthropod bite	1 (6.7%)	2 (13.3%)	11 (73.3%)	1 (6.7%)	15
Heritable pulmonary arterial hypertension	2 (13.3%)	2 (13.3%)	10 (66.7%)	1 (6.7%)	15
Cutibacterium acnes infection	6 (40.0%)	0 (0.0%)	9 (60.0%)	0 (0.0%)	15
Cytomegalovirus chorioretinitis	4 (26.7%)	9 (60.0%)	0 (0.0%)	2 (13.3%)	15
Fungal skin infection	2 (13.3%)	2 (13.3%)	11 (73.3%)	0 (0.0%)	15
Phlebitis	0 (0.0%)	1 (6.7%)	12 (80.0%)	2 (13.3%)	15
Thymoma	0 (0.0%)	5 (33.3%)	10 (66.7%)	0 (0.0%)	15
Rheumatoid vasculitis	0 (0.0%)	3 (20.0%)	5 (33.3%)	7 (46.7%)	15
Autonomic nervous system imbalance	1 (6.7%)	5 (33.3%)	5 (33.3%)	4 (26.7%)	15
Haemoptysis	0 (0.0%)	2 (13.3%)	12 (80.0%)	1 (6.7%)	15
Rectosigmoid cancer metastatic	0 (0.0%)	7 (46.7%)	8 (53.3%)	0 (0.0%)	15
Growth retardation	15 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15
Pustule	0 (0.0%)	4 (26.7%)	11 (73.3%)	0 (0.0%)	15
Tuberculosis of genitourinary system	0 (0.0%)	15 (100.0%)	0 (0.0%)	0 (0.0%)	15
Graft versus host disease in skin	9 (60.0%)	2 (13.3%)	4 (26.7%)	0 (0.0%)	15
Corneal epithelial downgrowth	0 (0.0%)	6 (40.0%)	2 (13.3%)	7 (46.7%)	15
Glossodynia	0 (0.0%)	4 (26.7%)	11 (73.3%)	0 (0.0%)	15
Portal vein thrombosis	2 (13.3%)	3 (20.0%)	9 (60.0%)	1 (6.7%)	15
Sacroiliitis	7 (46.7%)	7 (46.7%)	1 (6.7%)	0 (0.0%)	15
Gender dysphoria	6 (40.0%)	3 (20.0%)	6 (40.0%)	0 (0.0%)	15
Gaucher's disease type I	1 (6.7%)	4 (26.7%)	9 (60.0%)	1 (6.7%)	15

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pathological fracture	0 (0.0%)	5 (33.3%)	7 (46.7%)	3 (20.0%)	15
Meningococcal immunisation	1 (6.7%)	10 (66.7%)	0 (0.0%)	4 (26.7%)	15
Cardiac sarcoidosis	0 (0.0%)	2 (13.3%)	13 (86.7%)	0 (0.0%)	15
Wrong product administered	2 (13.3%)	1 (6.7%)	0 (0.0%)	12 (80.0%)	15
Eosinophilic pneumonia acute	0 (0.0%)	4 (28.6%)	10 (71.4%)	0 (0.0%)	14
Oesophageal spasm	0 (0.0%)	3 (21.4%)	10 (71.4%)	1 (7.1%)	14
Myelodysplastic syndrome with excess blasts	0 (0.0%)	1 (7.1%)	6 (42.9%)	7 (50.0%)	14
Musculoskeletal disorder	0 (0.0%)	4 (28.6%)	9 (64.3%)	1 (7.1%)	14
Rectal cancer recurrent	0 (0.0%)	0 (0.0%)	14 (100.0%)	0 (0.0%)	14
Cardiac dysfunction	8 (57.1%)	0 (0.0%)	5 (35.7%)	1 (7.1%)	14
Metastatic ocular melanoma	0 (0.0%)	12 (85.7%)	1 (7.1%)	1 (7.1%)	14
Streptococcal sepsis	0 (0.0%)	10 (71.4%)	4 (28.6%)	0 (0.0%)	14
Drug-induced liver injury	0 (0.0%)	1 (7.1%)	13 (92.9%)	0 (0.0%)	14
Ovarian neoplasm	0 (0.0%)	0 (0.0%)	13 (92.9%)	1 (7.1%)	14
Lyme disease	0 (0.0%)	5 (35.7%)	9 (64.3%)	0 (0.0%)	14
Head and neck cancer stage IV	0 (0.0%)	7 (50.0%)	5 (35.7%)	2 (14.3%)	14
Thyroid therapy	2 (14.3%)	5 (35.7%)	7 (50.0%)	0 (0.0%)	14
Lactic acidosis	3 (21.4%)	4 (28.6%)	0 (0.0%)	7 (50.0%)	14
Schizotypal personality disorder	0 (0.0%)	12 (85.7%)	0 (0.0%)	2 (14.3%)	14
Keratosis follicular	1 (7.1%)	12 (85.7%)	1 (7.1%)	0 (0.0%)	14
Intraocular pressure test abnormal	3 (21.4%)	1 (7.1%)	4 (28.6%)	6 (42.9%)	14
Intraocular pressure test	1 (7.1%)	3 (21.4%)	3 (21.4%)	7 (50.0%)	14
Cystocele	0 (0.0%)	0 (0.0%)	5 (35.7%)	9 (64.3%)	14
Adrenocortical insufficiency acute	5 (35.7%)	3 (21.4%)	6 (42.9%)	0 (0.0%)	14
Blood calcium decreased	1 (7.1%)	4 (28.6%)	5 (35.7%)	4 (28.6%)	14
Panniculitis	6 (42.9%)	2 (14.3%)	6 (42.9%)	0 (0.0%)	14
Ureaplasma infection	13 (92.9%)	1 (7.1%)	0 (0.0%)	0 (0.0%)	14

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vogt-Koyanagi-Harada disease	0 (0.0%)	6 (42.9%)	6 (42.9%)	2 (14.3%)	14
Sinus congestion	1 (7.1%)	1 (7.1%)	6 (42.9%)	6 (42.9%)	14
Paralysis	1 (7.1%)	11 (78.6%)	2 (14.3%)	0 (0.0%)	14
Blood immunoglobulin G decreased	5 (35.7%)	0 (0.0%)	8 (57.1%)	1 (7.1%)	14
HER2 positive colorectal cancer	0 (0.0%)	5 (35.7%)	9 (64.3%)	0 (0.0%)	14
Vitamin K deficiency	5 (35.7%)	5 (35.7%)	4 (28.6%)	0 (0.0%)	14
Tension headache	4 (28.6%)	7 (50.0%)	3 (21.4%)	0 (0.0%)	14
Somatic dysfunction	0 (0.0%)	0 (0.0%)	14 (100.0%)	0 (0.0%)	14
Torsade de pointes	8 (57.1%)	4 (28.6%)	2 (14.3%)	0 (0.0%)	14
Mycobacterium fortuitum infection	10 (71.4%)	0 (0.0%)	4 (28.6%)	0 (0.0%)	14
Autoimmune colitis	0 (0.0%)	0 (0.0%)	14 (100.0%)	0 (0.0%)	14
Mycoplasma infection	11 (78.6%)	1 (7.1%)	1 (7.1%)	1 (7.1%)	14
Hyperammonaemia	5 (35.7%)	5 (35.7%)	4 (28.6%)	0 (0.0%)	14
Substance use	3 (21.4%)	8 (57.1%)	3 (21.4%)	0 (0.0%)	14
Subarachnoid haemorrhage	0 (0.0%)	2 (14.3%)	3 (21.4%)	9 (64.3%)	14
Peripheral ischaemia	0 (0.0%)	0 (0.0%)	13 (92.9%)	1 (7.1%)	14
Fear	0 (0.0%)	0 (0.0%)	9 (64.3%)	5 (35.7%)	14
Peripheral venous disease	0 (0.0%)	0 (0.0%)	6 (42.9%)	8 (57.1%)	14
Colon cancer recurrent	0 (0.0%)	0 (0.0%)	8 (57.1%)	6 (42.9%)	14
Clear cell endometrial carcinoma	0 (0.0%)	0 (0.0%)	14 (100.0%)	0 (0.0%)	14
Sacral pain	0 (0.0%)	9 (64.3%)	5 (35.7%)	0 (0.0%)	14
Head injury	8 (57.1%)	3 (21.4%)	3 (21.4%)	0 (0.0%)	14
Respiratory tract congestion	1 (7.1%)	4 (28.6%)	5 (35.7%)	4 (28.6%)	14
Haemolytic uraemic syndrome	3 (21.4%)	2 (14.3%)	3 (21.4%)	6 (42.9%)	14
Pulmonary mucormycosis	4 (28.6%)	1 (7.1%)	9 (64.3%)	0 (0.0%)	14
Chondrosarcoma	0 (0.0%)	10 (71.4%)	4 (28.6%)	0 (0.0%)	14
Glomerulonephritis proliferative	0 (0.0%)	5 (35.7%)	0 (0.0%)	9 (64.3%)	14

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> (N=27299)	<i>Group2 (26-50)</i> (N=52972)	<i>Group3 (51-75)</i> (N=112199)	<i>Group4 (75+)</i> (N=39042)	<i>Total</i> (N=231512)
Urogram	1 (7.1%)	1 (7.1%)	11 (78.6%)	1 (7.1%)	14
Cerebral toxoplasmosis	0 (0.0%)	8 (57.1%)	6 (42.9%)	0 (0.0%)	14
Gastrointestinal stoma complication	2 (14.3%)	0 (0.0%)	4 (28.6%)	8 (57.1%)	14
Gastrointestinal inflammation	2 (14.3%)	0 (0.0%)	12 (85.7%)	0 (0.0%)	14
Blood culture positive	5 (35.7%)	0 (0.0%)	7 (50.0%)	2 (14.3%)	14
B-lymphocyte abnormalities	1 (7.1%)	5 (35.7%)	5 (35.7%)	3 (21.4%)	14
Pericardial effusion	2 (14.3%)	3 (21.4%)	7 (50.0%)	2 (14.3%)	14
Pancreatic disorder	6 (42.9%)	0 (0.0%)	7 (50.0%)	1 (7.1%)	14
Gestational hypertension	8 (57.1%)	6 (42.9%)	0 (0.0%)	0 (0.0%)	14
Pancreatic neoplasm	0 (0.0%)	2 (14.3%)	12 (85.7%)	0 (0.0%)	14
Vulvovaginal candidiasis	8 (57.1%)	5 (35.7%)	1 (7.1%)	0 (0.0%)	14
Oxygen saturation decreased	1 (7.1%)	0 (0.0%)	12 (85.7%)	1 (7.1%)	14
Nodular melanoma	0 (0.0%)	0 (0.0%)	13 (92.9%)	1 (7.1%)	14
Ovarian Sertoli-Leydig cell tumour	14 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	14
Yao syndrome	0 (0.0%)	14 (100.0%)	0 (0.0%)	0 (0.0%)	14
Non-small cell lung cancer stage IIIB	0 (0.0%)	2 (15.4%)	4 (30.8%)	7 (53.8%)	13
Ocular discomfort	0 (0.0%)	1 (7.7%)	5 (38.5%)	7 (53.8%)	13
Epstein-Barr virus associated lymphoproliferative di	4 (30.8%)	1 (7.7%)	8 (61.5%)	0 (0.0%)	13
Epithelioid mesothelioma	0 (0.0%)	1 (7.7%)	9 (69.2%)	3 (23.1%)	13
Neurotoxicity	6 (46.2%)	0 (0.0%)	2 (15.4%)	5 (38.5%)	13
Dyspnoea exertional	0 (0.0%)	1 (7.7%)	12 (92.3%)	0 (0.0%)	13
Rash pruritic	5 (38.5%)	0 (0.0%)	6 (46.2%)	2 (15.4%)	13
Muscle hypertrophy	0 (0.0%)	13 (100.0%)	0 (0.0%)	0 (0.0%)	13
HER2 mutant non-small cell lung cancer	0 (0.0%)	5 (38.5%)	8 (61.5%)	0 (0.0%)	13
Eye abscess	13 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13
Radiotherapy	0 (0.0%)	1 (7.7%)	9 (69.2%)	3 (23.1%)	13
Bronchial disorder	0 (0.0%)	0 (0.0%)	2 (15.4%)	11 (84.6%)	13

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Metastatic choriocarcinoma	0 (0.0%)	11 (84.6%)	2 (15.4%)	0 (0.0%)	13
Metastases to spleen	7 (53.8%)	3 (23.1%)	3 (23.1%)	0 (0.0%)	13
Dysgeusia	0 (0.0%)	0 (0.0%)	8 (61.5%)	5 (38.5%)	13
Acute myeloid leukaemia (in remission)	1 (7.7%)	6 (46.2%)	5 (38.5%)	1 (7.7%)	13
Brain sarcoma	12 (92.3%)	1 (7.7%)	0 (0.0%)	0 (0.0%)	13
Mechanical ventilation	0 (0.0%)	3 (23.1%)	10 (76.9%)	0 (0.0%)	13
Magnetic resonance imaging abdominal	1 (7.7%)	6 (46.2%)	5 (38.5%)	1 (7.7%)	13
Ovarian clear cell carcinoma	0 (0.0%)	5 (38.5%)	8 (61.5%)	0 (0.0%)	13
Rheumatoid arthritis-associated interstitial lung di	5 (38.5%)	0 (0.0%)	8 (61.5%)	0 (0.0%)	13
Bone cancer metastatic	0 (0.0%)	0 (0.0%)	9 (69.2%)	4 (30.8%)	13
Limb discomfort	2 (15.4%)	5 (38.5%)	5 (38.5%)	1 (7.7%)	13
Ligament pain	13 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13
Lichenoid keratosis	0 (0.0%)	0 (0.0%)	12 (92.3%)	1 (7.7%)	13
Leptospirosis	0 (0.0%)	13 (100.0%)	0 (0.0%)	0 (0.0%)	13
Cardiac stress test	0 (0.0%)	0 (0.0%)	10 (76.9%)	3 (23.1%)	13
Left ventricular dysfunction	2 (15.4%)	4 (30.8%)	7 (53.8%)	0 (0.0%)	13
Overgrowth bacterial	8 (61.5%)	0 (0.0%)	4 (30.8%)	1 (7.7%)	13
Scan myocardial perfusion	2 (15.4%)	4 (30.8%)	6 (46.2%)	1 (7.7%)	13
Klebsiella bacteraemia	0 (0.0%)	11 (84.6%)	2 (15.4%)	0 (0.0%)	13
Embolism arterial	0 (0.0%)	0 (0.0%)	9 (69.2%)	4 (30.8%)	13
Joint injection	0 (0.0%)	0 (0.0%)	4 (30.8%)	9 (69.2%)	13
Adjustment disorder	6 (46.2%)	3 (23.1%)	3 (23.1%)	1 (7.7%)	13
Thyroid mass	0 (0.0%)	4 (30.8%)	9 (69.2%)	0 (0.0%)	13
Hepatic pain	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Hepatitis viral	0 (0.0%)	4 (30.8%)	8 (61.5%)	1 (7.7%)	13
Proctitis ulcerative	0 (0.0%)	6 (46.2%)	7 (53.8%)	0 (0.0%)	13
Injection site pain	2 (15.4%)	7 (53.8%)	4 (30.8%)	0 (0.0%)	13

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Intervertebral disc disorder	2 (15.4%)	4 (30.8%)	3 (23.1%)	4 (30.8%)	13
Coccidioidomycosis	3 (23.1%)	4 (30.8%)	6 (46.2%)	0 (0.0%)	13
Intestinal adenocarcinoma	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Smith-Lemli-Opitz syndrome	10 (76.9%)	3 (23.1%)	0 (0.0%)	0 (0.0%)	13
Anogenital warts	11 (84.6%)	1 (7.7%)	1 (7.7%)	0 (0.0%)	13
T-cell prolymphocytic leukaemia	0 (0.0%)	0 (0.0%)	10 (76.9%)	3 (23.1%)	13
Staphylococcal sepsis	2 (15.4%)	4 (30.8%)	1 (7.7%)	6 (46.2%)	13
Streptococcal infection	7 (53.8%)	4 (30.8%)	1 (7.7%)	1 (7.7%)	13
Cervix carcinoma stage I	0 (0.0%)	4 (30.8%)	9 (69.2%)	0 (0.0%)	13
Hormone suppression therapy	2 (15.4%)	6 (46.2%)	5 (38.5%)	0 (0.0%)	13
Blepharitis	0 (0.0%)	1 (7.7%)	10 (76.9%)	2 (15.4%)	13
Adrenocortical steroid therapy	0 (0.0%)	4 (30.8%)	8 (61.5%)	1 (7.7%)	13
Clostridial infection	0 (0.0%)	0 (0.0%)	11 (84.6%)	2 (15.4%)	13
Aplasia	6 (46.2%)	0 (0.0%)	1 (7.7%)	6 (46.2%)	13
Heart transplant rejection	4 (30.8%)	0 (0.0%)	9 (69.2%)	0 (0.0%)	13
Hairy cell leukaemia	0 (0.0%)	2 (15.4%)	7 (53.8%)	4 (30.8%)	13
Induction and maintenance of anaesthesia	2 (15.4%)	5 (38.5%)	4 (30.8%)	2 (15.4%)	13
Toxic skin eruption	0 (0.0%)	0 (0.0%)	10 (76.9%)	3 (23.1%)	13
Gastroenteritis Escherichia coli	0 (0.0%)	0 (0.0%)	5 (38.5%)	8 (61.5%)	13
Radicular pain	0 (0.0%)	4 (30.8%)	9 (69.2%)	0 (0.0%)	13
Triple positive breast cancer	0 (0.0%)	6 (46.2%)	6 (46.2%)	1 (7.7%)	13
Pituitary tumour removal	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Polychondritis	2 (15.4%)	0 (0.0%)	10 (76.9%)	1 (7.7%)	13
Psychomotor retardation	2 (15.4%)	0 (0.0%)	11 (84.6%)	0 (0.0%)	13
Prostate infection	0 (0.0%)	0 (0.0%)	12 (92.3%)	1 (7.7%)	13
Gastroenteritis radiation	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (100.0%)	13
Progressive multifocal leukoencephalopathy	0 (0.0%)	1 (7.7%)	12 (92.3%)	0 (0.0%)	13

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastrointestinal infection	0 (0.0%)	4 (30.8%)	5 (38.5%)	4 (30.8%)	13
Gender reassignment therapy	8 (61.5%)	5 (38.5%)	0 (0.0%)	0 (0.0%)	13
Toxoplasmosis	0 (0.0%)	10 (76.9%)	3 (23.1%)	0 (0.0%)	13
Impulsive behaviour	7 (53.8%)	2 (15.4%)	4 (30.8%)	0 (0.0%)	13
Corynebacterium infection	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Gastrointestinal cancer metastatic	2 (15.4%)	0 (0.0%)	11 (84.6%)	0 (0.0%)	13
Craniocerebral injury	9 (69.2%)	1 (7.7%)	3 (23.1%)	0 (0.0%)	13
Postural orthostatic tachycardia syndrome	4 (30.8%)	3 (23.1%)	6 (46.2%)	0 (0.0%)	13
Periarthritis	0 (0.0%)	1 (7.7%)	10 (76.9%)	2 (15.4%)	13
Fluid imbalance	0 (0.0%)	7 (53.8%)	3 (23.1%)	3 (23.1%)	13
Injection site reaction	0 (0.0%)	1 (7.7%)	11 (84.6%)	1 (7.7%)	13
Osteitis deformans	0 (0.0%)	1 (7.7%)	5 (38.5%)	7 (53.8%)	13
Onycholysis	0 (0.0%)	0 (0.0%)	13 (100.0%)	0 (0.0%)	13
Non-Hodgkin's lymphoma unspecified histology indolen	0 (0.0%)	2 (16.7%)	8 (66.7%)	2 (16.7%)	12
Neurofibroma	10 (83.3%)	2 (16.7%)	0 (0.0%)	0 (0.0%)	12
Neuralgic amyotrophy	0 (0.0%)	10 (83.3%)	2 (16.7%)	0 (0.0%)	12
Nephropathy toxic	0 (0.0%)	3 (25.0%)	9 (75.0%)	0 (0.0%)	12
Cholecystectomy	1 (8.3%)	6 (50.0%)	0 (0.0%)	5 (41.7%)	12
Blood HIV RNA below assay limit	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Myelitis transverse	3 (25.0%)	5 (41.7%)	4 (33.3%)	0 (0.0%)	12
Endocrine ophthalmopathy	0 (0.0%)	0 (0.0%)	6 (50.0%)	6 (50.0%)	12
Endocrine disorder	5 (41.7%)	1 (8.3%)	5 (41.7%)	1 (8.3%)	12
Muscle strain	1 (8.3%)	6 (50.0%)	5 (41.7%)	0 (0.0%)	12
Hysteroscopy	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Xanthoma	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Embolic stroke	0 (0.0%)	1 (8.3%)	6 (50.0%)	5 (41.7%)	12
Mixed dementia	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (100.0%)	12

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Eye inflammation	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Middle cerebral artery stroke	0 (0.0%)	2 (16.7%)	10 (83.3%)	0 (0.0%)	12
Metastatic lymphoma	3 (25.0%)	5 (41.7%)	2 (16.7%)	2 (16.7%)	12
Metastatic carcinoid tumour	1 (8.3%)	0 (0.0%)	11 (91.7%)	0 (0.0%)	12
Breast mass	0 (0.0%)	1 (8.3%)	11 (91.7%)	0 (0.0%)	12
Glomerulonephritis chronic	0 (0.0%)	2 (16.7%)	10 (83.3%)	0 (0.0%)	12
Wound	3 (25.0%)	5 (41.7%)	4 (33.3%)	0 (0.0%)	12
Meningococcal infection	8 (66.7%)	1 (8.3%)	0 (0.0%)	3 (25.0%)	12
Hypotony maculopathy	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Malignant central nervous system neoplasm	12 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12
Disease recurrence	0 (0.0%)	5 (41.7%)	5 (41.7%)	2 (16.7%)	12
Connective tissue neoplasm	1 (8.3%)	6 (50.0%)	5 (41.7%)	0 (0.0%)	12
Lysosomal acid lipase deficiency	11 (91.7%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	12
Bone marrow failure	1 (8.3%)	3 (25.0%)	8 (66.7%)	0 (0.0%)	12
Insulin-like growth factor increased	0 (0.0%)	10 (83.3%)	1 (8.3%)	1 (8.3%)	12
Device related thrombosis	1 (8.3%)	0 (0.0%)	10 (83.3%)	1 (8.3%)	12
Bronchiolitis obliterans syndrome	6 (50.0%)	3 (25.0%)	3 (25.0%)	0 (0.0%)	12
Aortic stenosis	0 (0.0%)	2 (16.7%)	8 (66.7%)	2 (16.7%)	12
Lip disorder	0 (0.0%)	10 (83.3%)	1 (8.3%)	1 (8.3%)	12
Lichen sclerosus	0 (0.0%)	6 (50.0%)	1 (8.3%)	5 (41.7%)	12
Thyroid hormone replacement therapy	0 (0.0%)	7 (58.3%)	2 (16.7%)	3 (25.0%)	12
Laryngitis	3 (25.0%)	6 (50.0%)	3 (25.0%)	0 (0.0%)	12
Chronic respiratory failure	2 (16.7%)	1 (8.3%)	4 (33.3%)	5 (41.7%)	12
Blood test	0 (0.0%)	1 (8.3%)	9 (75.0%)	2 (16.7%)	12
Knee arthroplasty	0 (0.0%)	0 (0.0%)	11 (91.7%)	1 (8.3%)	12
Mucopolysaccharidosis	9 (75.0%)	1 (8.3%)	2 (16.7%)	0 (0.0%)	12
Accidental exposure to product	8 (66.7%)	1 (8.3%)	2 (16.7%)	1 (8.3%)	12

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Alcohol abuse	1 (8.3%)	3 (25.0%)	8 (66.7%)	0 (0.0%)	12
Cytopenia	8 (66.7%)	0 (0.0%)	3 (25.0%)	1 (8.3%)	12
Investigation	6 (50.0%)	1 (8.3%)	5 (41.7%)	0 (0.0%)	12
Cytomegalovirus colitis	0 (0.0%)	5 (41.7%)	7 (58.3%)	0 (0.0%)	12
Hepatic neoplasm	2 (16.7%)	1 (8.3%)	8 (66.7%)	1 (8.3%)	12
Intervertebral disc operation	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Initial insomnia	3 (25.0%)	2 (16.7%)	5 (41.7%)	2 (16.7%)	12
Sinus polyp degeneration	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Small intestine adenocarcinoma	2 (16.7%)	0 (0.0%)	8 (66.7%)	2 (16.7%)	12
Back disorder	0 (0.0%)	2 (16.7%)	8 (66.7%)	2 (16.7%)	12
Blood folate decreased	0 (0.0%)	1 (8.3%)	4 (33.3%)	7 (58.3%)	12
Small intestine carcinoma metastatic	0 (0.0%)	0 (0.0%)	10 (83.3%)	2 (16.7%)	12
Transient acantholytic dermatosis	0 (0.0%)	1 (8.3%)	7 (58.3%)	4 (33.3%)	12
Acute febrile neutrophilic dermatosis	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Congenital cytomegalovirus infection	12 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12
Superinfection bacterial	0 (0.0%)	9 (75.0%)	2 (16.7%)	1 (8.3%)	12
Bladder spasm	1 (8.3%)	2 (16.7%)	8 (66.7%)	1 (8.3%)	12
Steroid diabetes	1 (8.3%)	0 (0.0%)	9 (75.0%)	2 (16.7%)	12
Histoplasmosis disseminated	2 (16.7%)	2 (16.7%)	3 (25.0%)	5 (41.7%)	12
Presenile dementia	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (100.0%)	12
Cold urticaria	3 (25.0%)	3 (25.0%)	3 (25.0%)	3 (25.0%)	12
Selective IgA immunodeficiency	1 (8.3%)	4 (33.3%)	7 (58.3%)	0 (0.0%)	12
Gamma-glutamyltransferase increased	0 (0.0%)	7 (58.3%)	5 (41.7%)	0 (0.0%)	12
Heart valve replacement	0 (0.0%)	3 (25.0%)	8 (66.7%)	1 (8.3%)	12
Angiopathy	1 (8.3%)	2 (16.7%)	9 (75.0%)	0 (0.0%)	12
Plasmablastic lymphoma	0 (0.0%)	2 (16.7%)	10 (83.3%)	0 (0.0%)	12
Renal vasculitis	0 (0.0%)	0 (0.0%)	9 (75.0%)	3 (25.0%)	12

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Crying	6 (50.0%)	1 (8.3%)	3 (25.0%)	2 (16.7%)	12
Haematotoxicity	0 (0.0%)	1 (8.3%)	11 (91.7%)	0 (0.0%)	12
Hypouricaemia	0 (0.0%)	0 (0.0%)	8 (66.7%)	4 (33.3%)	12
Chorioretinal folds	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Rash erythematous	0 (0.0%)	2 (16.7%)	7 (58.3%)	3 (25.0%)	12
Rapid eye movement sleep behaviour disorder	0 (0.0%)	0 (0.0%)	3 (25.0%)	9 (75.0%)	12
Tracheitis	0 (0.0%)	8 (66.7%)	3 (25.0%)	1 (8.3%)	12
Granuloma annulare	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Contraceptive implant	6 (50.0%)	6 (50.0%)	0 (0.0%)	0 (0.0%)	12
Coronary artery occlusion	0 (0.0%)	2 (16.7%)	10 (83.3%)	0 (0.0%)	12
Immunotherapy	0 (0.0%)	1 (8.3%)	11 (91.7%)	0 (0.0%)	12
Pouchitis	0 (0.0%)	2 (16.7%)	10 (83.3%)	0 (0.0%)	12
Post procedural hypoparathyroidism	0 (0.0%)	10 (83.3%)	1 (8.3%)	1 (8.3%)	12
Post coital contraception	3 (25.0%)	9 (75.0%)	0 (0.0%)	0 (0.0%)	12
Gallbladder cancer stage IV	0 (0.0%)	0 (0.0%)	11 (91.7%)	1 (8.3%)	12
Follicular lymphoma stage I	0 (0.0%)	0 (0.0%)	10 (83.3%)	2 (16.7%)	12
Autoimmune heparin-induced thrombocytopenia	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Paracoccidioides infection	2 (16.7%)	9 (75.0%)	1 (8.3%)	0 (0.0%)	12
Cardiac neoplasm malignant	0 (0.0%)	6 (50.0%)	6 (50.0%)	0 (0.0%)	12
Orchitis	4 (33.3%)	6 (50.0%)	2 (16.7%)	0 (0.0%)	12
Adenocarcinoma of appendix	0 (0.0%)	0 (0.0%)	12 (100.0%)	0 (0.0%)	12
Ocular lymphoma	0 (0.0%)	8 (72.7%)	3 (27.3%)	0 (0.0%)	11
Non-small cell lung cancer stage IIIA	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Niemann-Pick disease	9 (81.8%)	2 (18.2%)	0 (0.0%)	0 (0.0%)	11
Ewing's sarcoma metastatic	8 (72.7%)	0 (0.0%)	3 (27.3%)	0 (0.0%)	11
Nephritic syndrome	4 (36.4%)	3 (27.3%)	4 (36.4%)	0 (0.0%)	11
Balance disorder	1 (9.1%)	1 (9.1%)	5 (45.5%)	4 (36.4%)	11

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Neoplasm recurrence	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Oesophageal adenocarcinoma recurrent	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11
Enterococcal bacteraemia	0 (0.0%)	2 (18.2%)	7 (63.6%)	2 (18.2%)	11
Burkitt's leukaemia	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Myocardial injury	0 (0.0%)	0 (0.0%)	6 (54.5%)	5 (45.5%)	11
Endometrial neoplasm	0 (0.0%)	1 (9.1%)	10 (90.9%)	0 (0.0%)	11
Embryonal rhabdomyosarcoma	5 (45.5%)	6 (54.5%)	0 (0.0%)	0 (0.0%)	11
Mitral valve incompetence	6 (54.5%)	0 (0.0%)	2 (18.2%)	3 (27.3%)	11
Bronchial hyperreactivity	5 (45.5%)	2 (18.2%)	3 (27.3%)	1 (9.1%)	11
Haemangioma	10 (90.9%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	11
Dermatitis papillaris capillitii	0 (0.0%)	10 (90.9%)	1 (9.1%)	0 (0.0%)	11
Renal colic	0 (0.0%)	3 (27.3%)	8 (72.7%)	0 (0.0%)	11
Atrial tachycardia	1 (9.1%)	0 (0.0%)	1 (9.1%)	9 (81.8%)	11
Disturbance in social behaviour	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Malignant glioma	3 (27.3%)	4 (36.4%)	4 (36.4%)	0 (0.0%)	11
Anaesthetic premedication	7 (63.6%)	1 (9.1%)	3 (27.3%)	0 (0.0%)	11
Magnetic resonance imaging pelvic	1 (9.1%)	7 (63.6%)	3 (27.3%)	0 (0.0%)	11
Haemorrhagic diathesis	6 (54.5%)	3 (27.3%)	1 (9.1%)	1 (9.1%)	11
Retinopathy of prematurity	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Low birth weight baby	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Device related sepsis	3 (27.3%)	6 (54.5%)	2 (18.2%)	0 (0.0%)	11
Fall	2 (18.2%)	6 (54.5%)	3 (27.3%)	0 (0.0%)	11
Chronic myeloid leukaemia recurrent	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Blood uric acid	0 (0.0%)	3 (27.3%)	4 (36.4%)	4 (36.4%)	11
Large granular lymphocytosis	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Schizophreniform disorder	4 (36.4%)	4 (36.4%)	3 (27.3%)	0 (0.0%)	11
Angiosarcoma metastatic	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hepatic cancer metastatic	0 (0.0%)	3 (27.3%)	8 (72.7%)	0 (0.0%)	11
Decubitus ulcer	0 (0.0%)	1 (9.1%)	4 (36.4%)	6 (54.5%)	11
Juvenile psoriatic arthritis	6 (54.5%)	1 (9.1%)	4 (36.4%)	0 (0.0%)	11
Mucositis management	1 (9.1%)	0 (0.0%)	10 (90.9%)	0 (0.0%)	11
Intermittent explosive disorder	9 (81.8%)	2 (18.2%)	0 (0.0%)	0 (0.0%)	11
Intestinal metastasis	0 (0.0%)	0 (0.0%)	7 (63.6%)	4 (36.4%)	11
Cystinosis	5 (45.5%)	6 (54.5%)	0 (0.0%)	0 (0.0%)	11
Intervertebral disc degeneration	2 (18.2%)	5 (45.5%)	4 (36.4%)	0 (0.0%)	11
Acquired epileptic aphasia	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Septic arthritis staphylococcal	10 (90.9%)	0 (0.0%)	0 (0.0%)	1 (9.1%)	11
Clostridium bacteraemia	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Pancreatitis chronic	0 (0.0%)	5 (45.5%)	4 (36.4%)	2 (18.2%)	11
Cutaneous lupus erythematosus	1 (9.1%)	4 (36.4%)	4 (36.4%)	2 (18.2%)	11
Hepatobiliary cancer	0 (0.0%)	2 (18.2%)	9 (81.8%)	0 (0.0%)	11
Simple partial seizures	0 (0.0%)	3 (27.3%)	8 (72.7%)	0 (0.0%)	11
Hereditary ataxia	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Skin bacterial infection	1 (9.1%)	1 (9.1%)	8 (72.7%)	1 (9.1%)	11
Hereditary neuropathic amyloidosis	0 (0.0%)	0 (0.0%)	6 (54.5%)	5 (45.5%)	11
Skin fissures	0 (0.0%)	0 (0.0%)	10 (90.9%)	1 (9.1%)	11
Skin laceration	0 (0.0%)	1 (9.1%)	9 (81.8%)	1 (9.1%)	11
Taste disorder	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11
HLA-B*1502 assay negative	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Toxic shock syndrome streptococcal	3 (27.3%)	0 (0.0%)	8 (72.7%)	0 (0.0%)	11
Hormone receptor negative HER2 positive breast cance	0 (0.0%)	10 (90.9%)	1 (9.1%)	0 (0.0%)	11
Hypogonadism	1 (9.1%)	3 (27.3%)	7 (63.6%)	0 (0.0%)	11
Hyperthermia	6 (54.5%)	2 (18.2%)	3 (27.3%)	0 (0.0%)	11
Superficial vein thrombosis	0 (0.0%)	1 (9.1%)	6 (54.5%)	4 (36.4%)	11

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypergammaglobulinaemia benign monoclonal	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11
Q fever	0 (0.0%)	4 (36.4%)	3 (27.3%)	4 (36.4%)	11
Substance dependence	5 (45.5%)	1 (9.1%)	5 (45.5%)	0 (0.0%)	11
Hydronephrosis	0 (0.0%)	0 (0.0%)	5 (45.5%)	6 (54.5%)	11
Fracture pain	2 (18.2%)	0 (0.0%)	3 (27.3%)	6 (54.5%)	11
Squamous cell carcinoma of the hypopharynx	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Holmes tremor	0 (0.0%)	1 (9.1%)	10 (90.9%)	0 (0.0%)	11
Genital herpes	0 (0.0%)	2 (18.2%)	8 (72.7%)	1 (9.1%)	11
Hodgkin's disease mixed cellularity stage unspecifie	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Snake bite	1 (9.1%)	7 (63.6%)	2 (18.2%)	1 (9.1%)	11
Gallbladder adenocarcinoma	0 (0.0%)	6 (54.5%)	5 (45.5%)	0 (0.0%)	11
Generalised oedema	0 (0.0%)	3 (27.3%)	6 (54.5%)	2 (18.2%)	11
Postpartum haemorrhage	2 (18.2%)	9 (81.8%)	0 (0.0%)	0 (0.0%)	11
Road traffic accident	9 (81.8%)	2 (18.2%)	0 (0.0%)	0 (0.0%)	11
Hypopharyngeal cancer stage IV	0 (0.0%)	0 (0.0%)	6 (54.5%)	5 (45.5%)	11
Retroperitoneal cancer	3 (27.3%)	2 (18.2%)	6 (54.5%)	0 (0.0%)	11
Hypophysitis	0 (0.0%)	2 (18.2%)	5 (45.5%)	4 (36.4%)	11
Retinal haemorrhage	0 (0.0%)	1 (9.1%)	8 (72.7%)	2 (18.2%)	11
Plasmodium vivax infection	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Renal disorder prophylaxis	0 (0.0%)	3 (27.3%)	7 (63.6%)	1 (9.1%)	11
Haematological malignancy	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11
Vaginal disorder	0 (0.0%)	1 (9.1%)	5 (45.5%)	5 (45.5%)	11
Pneumonia cytomegaloviral	4 (36.4%)	3 (27.3%)	4 (36.4%)	0 (0.0%)	11
HIV infection CDC Group IV subgroup C2	0 (0.0%)	8 (72.7%)	3 (27.3%)	0 (0.0%)	11
Bacterial vaginosis	3 (27.3%)	5 (45.5%)	3 (27.3%)	0 (0.0%)	11
Prostatic adenoma	0 (0.0%)	0 (0.0%)	7 (63.6%)	4 (36.4%)	11
Uraemic pruritus	0 (0.0%)	0 (0.0%)	8 (72.7%)	3 (27.3%)	11

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Coronary artery thrombosis	0 (0.0%)	9 (81.8%)	2 (18.2%)	0 (0.0%)	11
Chalazion	0 (0.0%)	6 (54.5%)	4 (36.4%)	1 (9.1%)	11
Germ cell cancer	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Cerebrohepatorenal syndrome	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Thyroiditis	1 (9.1%)	1 (9.1%)	9 (81.8%)	0 (0.0%)	11
Portopulmonary hypertension	7 (63.6%)	0 (0.0%)	4 (36.4%)	0 (0.0%)	11
Maternal exposure during pregnancy	11 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11
Cerebral haematoma	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Gastroenteritis astroviral	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Vascular dementia	0 (0.0%)	0 (0.0%)	7 (63.6%)	4 (36.4%)	11
Mastoiditis	10 (90.9%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	11
Phaeochromocytoma	1 (9.1%)	2 (18.2%)	8 (72.7%)	0 (0.0%)	11
Vena cava thrombosis	0 (0.0%)	4 (36.4%)	7 (63.6%)	0 (0.0%)	11
Catheterisation cardiac	0 (0.0%)	2 (18.2%)	9 (81.8%)	0 (0.0%)	11
Perinatal HIV infection	0 (0.0%)	11 (100.0%)	0 (0.0%)	0 (0.0%)	11
Viral hepatitis carrier	1 (9.1%)	0 (0.0%)	5 (45.5%)	5 (45.5%)	11
Inflammatory pain	0 (0.0%)	0 (0.0%)	11 (100.0%)	0 (0.0%)	11
Glomerulonephritis membranoproliferative	2 (18.2%)	4 (36.4%)	1 (9.1%)	4 (36.4%)	11
Osteomyelitis chronic	8 (72.7%)	0 (0.0%)	3 (27.3%)	0 (0.0%)	11
Cardiac fibrillation	0 (0.0%)	0 (0.0%)	7 (63.6%)	4 (36.4%)	11
Eye pain	0 (0.0%)	2 (18.2%)	9 (81.8%)	0 (0.0%)	11
Oestrogen replacement therapy	0 (0.0%)	0 (0.0%)	10 (90.9%)	1 (9.1%)	11
Oesophageal squamous cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	7 (70.0%)	3 (30.0%)	10
Exposure to communicable disease	2 (20.0%)	8 (80.0%)	0 (0.0%)	0 (0.0%)	10
Noonan syndrome	9 (90.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	10
Asthma-chronic obstructive pulmonary disease overlap	0 (0.0%)	1 (10.0%)	7 (70.0%)	2 (20.0%)	10
Erythrodermic psoriasis	0 (0.0%)	4 (40.0%)	5 (50.0%)	1 (10.0%)	10

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Non-compactation cardiomyopathy	1 (10.0%)	9 (90.0%)	0 (0.0%)	0 (0.0%)	10
Epithelioid sarcoma	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Neuropathy vitamin B12 deficiency	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Epididymitis	0 (0.0%)	9 (90.0%)	1 (10.0%)	0 (0.0%)	10
Nervousness	3 (30.0%)	1 (10.0%)	3 (30.0%)	3 (30.0%)	10
Eosinophilic cellulitis	0 (0.0%)	0 (0.0%)	1 (10.0%)	9 (90.0%)	10
Nephritis	2 (20.0%)	5 (50.0%)	2 (20.0%)	1 (10.0%)	10
Necrotising colitis	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Necrobiosis lipoidica diabetorum	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Ammonia increased	6 (60.0%)	0 (0.0%)	4 (40.0%)	0 (0.0%)	10
Burkholderia cepacia complex infection	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Idiopathic intracranial hypertension	0 (0.0%)	6 (60.0%)	4 (40.0%)	0 (0.0%)	10
Brucellosis	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Motion sickness	0 (0.0%)	3 (30.0%)	6 (60.0%)	1 (10.0%)	10
Arterial thrombosis	2 (20.0%)	4 (40.0%)	4 (40.0%)	0 (0.0%)	10
Mevalonate kinase deficiency	10 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10
Metastases to the mediastinum	0 (0.0%)	7 (70.0%)	3 (30.0%)	0 (0.0%)	10
Red blood cell transfusion	4 (40.0%)	4 (40.0%)	2 (20.0%)	0 (0.0%)	10
Metastases to gastrointestinal tract	0 (0.0%)	2 (20.0%)	3 (30.0%)	5 (50.0%)	10
Meningitis bacterial	2 (20.0%)	5 (50.0%)	3 (30.0%)	0 (0.0%)	10
Medullary thyroid cancer	1 (10.0%)	1 (10.0%)	5 (50.0%)	3 (30.0%)	10
Medical diet	1 (10.0%)	4 (40.0%)	5 (50.0%)	0 (0.0%)	10
Angiogram cerebral	1 (10.0%)	3 (30.0%)	4 (40.0%)	2 (20.0%)	10
Medical device site abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (100.0%)	10
Dopamine agonist withdrawal syndrome	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Brain contusion	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Haemolytic transfusion reaction	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Disturbance in attention	6 (60.0%)	2 (20.0%)	1 (10.0%)	1 (10.0%)	10
Malaria prophylaxis	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Aphthous ulcer	5 (50.0%)	0 (0.0%)	4 (40.0%)	1 (10.0%)	10
Hair disorder	0 (0.0%)	5 (50.0%)	3 (30.0%)	2 (20.0%)	10
Lumbar spinal stenosis	0 (0.0%)	0 (0.0%)	5 (50.0%)	5 (50.0%)	10
Lower urinary tract symptoms	0 (0.0%)	0 (0.0%)	4 (40.0%)	6 (60.0%)	10
Body temperature increased	2 (20.0%)	4 (40.0%)	4 (40.0%)	0 (0.0%)	10
Dermatophytosis of nail	0 (0.0%)	3 (30.0%)	6 (60.0%)	1 (10.0%)	10
Limb injury	1 (10.0%)	3 (30.0%)	4 (40.0%)	2 (20.0%)	10
Leiomyosarcoma metastatic	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Latent autoimmune diabetes in adults	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Hemiplegic migraine	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Defaecation disorder	0 (0.0%)	1 (10.0%)	8 (80.0%)	1 (10.0%)	10
Cytomegalovirus enterocolitis	0 (0.0%)	3 (30.0%)	3 (30.0%)	4 (40.0%)	10
Xerosis	1 (10.0%)	0 (0.0%)	6 (60.0%)	3 (30.0%)	10
Hepatitis E	1 (10.0%)	2 (20.0%)	7 (70.0%)	0 (0.0%)	10
Urticaria pressure	0 (0.0%)	9 (90.0%)	1 (10.0%)	0 (0.0%)	10
Cutaneous T-cell lymphoma stage IV	0 (0.0%)	0 (0.0%)	9 (90.0%)	1 (10.0%)	10
Tubular breast carcinoma	0 (0.0%)	8 (80.0%)	1 (10.0%)	1 (10.0%)	10
Skin reaction	1 (10.0%)	7 (70.0%)	1 (10.0%)	1 (10.0%)	10
Tachypnoea	1 (10.0%)	1 (10.0%)	7 (70.0%)	1 (10.0%)	10
Tooth extraction	1 (10.0%)	1 (10.0%)	5 (50.0%)	3 (30.0%)	10
Anti-glomerular basement membrane disease	0 (0.0%)	2 (20.0%)	6 (60.0%)	2 (20.0%)	10
Thromboangiitis obliterans	0 (0.0%)	9 (90.0%)	1 (10.0%)	0 (0.0%)	10
Testicular germ cell tumour mixed	10 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10
Subclavian vein thrombosis	2 (20.0%)	5 (50.0%)	3 (30.0%)	0 (0.0%)	10
Substance use disorder	0 (0.0%)	6 (60.0%)	1 (10.0%)	3 (30.0%)	10

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Squamous cell carcinoma of pharynx	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Genital neoplasm malignant female	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Hordeolum	1 (10.0%)	1 (10.0%)	8 (80.0%)	0 (0.0%)	10
Myelodysplastic syndrome with ringed sideroblasts	0 (0.0%)	0 (0.0%)	2 (20.0%)	8 (80.0%)	10
Acute generalised exanthematous pustulosis	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Phantom limb syndrome	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Scar	1 (10.0%)	2 (20.0%)	7 (70.0%)	0 (0.0%)	10
Sarcoma metastatic	4 (40.0%)	1 (10.0%)	3 (30.0%)	2 (20.0%)	10
Cor pulmonale	3 (30.0%)	0 (0.0%)	7 (70.0%)	0 (0.0%)	10
Antiandrogen therapy	0 (0.0%)	3 (30.0%)	1 (10.0%)	6 (60.0%)	10
Pulmonary pain	0 (0.0%)	5 (50.0%)	5 (50.0%)	0 (0.0%)	10
Prostatic specific antigen increased	0 (0.0%)	0 (0.0%)	6 (60.0%)	4 (40.0%)	10
Coronary angioplasty	0 (0.0%)	0 (0.0%)	4 (40.0%)	6 (60.0%)	10
Product administration error	5 (50.0%)	1 (10.0%)	3 (30.0%)	1 (10.0%)	10
Procedural haemorrhage	0 (0.0%)	8 (80.0%)	2 (20.0%)	0 (0.0%)	10
Gastrointestinal adenocarcinoma	0 (0.0%)	0 (0.0%)	7 (70.0%)	3 (30.0%)	10
Anaplastic astrocytoma	5 (50.0%)	4 (40.0%)	1 (10.0%)	0 (0.0%)	10
Anaphylaxis prophylaxis	0 (0.0%)	2 (20.0%)	8 (80.0%)	0 (0.0%)	10
Central nervous system vasculitis	0 (0.0%)	2 (20.0%)	3 (30.0%)	5 (50.0%)	10
Peritoneal carcinoma metastatic	10 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	10
Peripheral vascular disorder	0 (0.0%)	1 (10.0%)	4 (40.0%)	5 (50.0%)	10
Fracture	4 (40.0%)	2 (20.0%)	3 (30.0%)	1 (10.0%)	10
Peripheral T-cell lymphoma unspecified recurrent	0 (0.0%)	0 (0.0%)	10 (100.0%)	0 (0.0%)	10
Autoimmune hypothyroidism	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Pericarditis constrictive	4 (40.0%)	5 (50.0%)	0 (0.0%)	1 (10.0%)	10
Pelvic neoplasm	0 (0.0%)	6 (60.0%)	4 (40.0%)	0 (0.0%)	10
Procedural headache	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cutaneous calcification	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Paraneoplastic pemphigus	0 (0.0%)	6 (60.0%)	4 (40.0%)	0 (0.0%)	10
Upper respiratory tract inflammation	0 (0.0%)	0 (0.0%)	5 (50.0%)	5 (50.0%)	10
Renal cell carcinoma stage III	0 (0.0%)	0 (0.0%)	8 (80.0%)	2 (20.0%)	10
Cutaneous vasculitis	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10
Eructation	0 (0.0%)	9 (90.0%)	0 (0.0%)	1 (10.0%)	10
Familial amyloidosis	3 (30.0%)	0 (0.0%)	5 (50.0%)	2 (20.0%)	10
Ovarian germ cell endodermal sinus tumour	0 (0.0%)	10 (100.0%)	0 (0.0%)	0 (0.0%)	10
Weight abnormal	0 (0.0%)	3 (30.0%)	7 (70.0%)	0 (0.0%)	10
Anaesthesia eye	0 (0.0%)	4 (40.0%)	6 (60.0%)	0 (0.0%)	10
Ophthalmic herpes zoster	0 (0.0%)	0 (0.0%)	8 (80.0%)	2 (20.0%)	10
Interventional procedure	0 (0.0%)	1 (10.0%)	8 (80.0%)	1 (10.0%)	10
Odynophagia	4 (44.4%)	3 (33.3%)	2 (22.2%)	0 (0.0%)	9
Obsessive thoughts	4 (44.4%)	3 (33.3%)	2 (22.2%)	0 (0.0%)	9
Non-Hodgkin's lymphoma refractory	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Neutrophilia	1 (11.1%)	0 (0.0%)	8 (88.9%)	0 (0.0%)	9
Prosthetic valve endocarditis	0 (0.0%)	0 (0.0%)	6 (66.7%)	3 (33.3%)	9
Acne cystic	7 (77.8%)	2 (22.2%)	0 (0.0%)	0 (0.0%)	9
C-reactive protein increased	0 (0.0%)	1 (11.1%)	3 (33.3%)	5 (55.6%)	9
Nasal septum deviation	1 (11.1%)	5 (55.6%)	3 (33.3%)	0 (0.0%)	9
NSAID exacerbated respiratory disease	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Myelopathy	2 (22.2%)	2 (22.2%)	5 (55.6%)	0 (0.0%)	9
Gynaecomastia	8 (88.9%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	9
Transitional cell carcinoma urethra	0 (0.0%)	0 (0.0%)	2 (22.2%)	7 (77.8%)	9
Multiple organ dysfunction syndrome	2 (22.2%)	0 (0.0%)	4 (44.4%)	3 (33.3%)	9
Rash macular	2 (22.2%)	1 (11.1%)	4 (44.4%)	2 (22.2%)	9
Mucous membrane pemphigoid	0 (0.0%)	0 (0.0%)	7 (77.8%)	2 (22.2%)	9

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mucopolysaccharidosis I	7 (77.8%)	2 (22.2%)	0 (0.0%)	0 (0.0%)	9
Mucoepidermoid carcinoma	0 (0.0%)	8 (88.9%)	1 (11.1%)	0 (0.0%)	9
Ehlers-Danlos syndrome	1 (11.1%)	6 (66.7%)	2 (22.2%)	0 (0.0%)	9
Oral fungal infection	0 (0.0%)	4 (44.4%)	1 (11.1%)	4 (44.4%)	9
Ectopic ACTH syndrome	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Eating disorder	2 (22.2%)	5 (55.6%)	2 (22.2%)	0 (0.0%)	9
Brief psychotic disorder, with postpartum onset	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Adrenal disorder	3 (33.3%)	0 (0.0%)	6 (66.7%)	0 (0.0%)	9
Ear, nose and throat infection	4 (44.4%)	2 (22.2%)	3 (33.3%)	0 (0.0%)	9
Metastases to retroperitoneum	0 (0.0%)	4 (44.4%)	2 (22.2%)	3 (33.3%)	9
Metastases to muscle	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Metastases to abdominal cavity	2 (22.2%)	0 (0.0%)	7 (77.8%)	0 (0.0%)	9
Arrhythmic storm	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Meningioma	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Appetite disorder	4 (44.4%)	0 (0.0%)	2 (22.2%)	3 (33.3%)	9
Brain injury	3 (33.3%)	1 (11.1%)	2 (22.2%)	3 (33.3%)	9
Respiration abnormal	1 (11.1%)	0 (0.0%)	5 (55.6%)	3 (33.3%)	9
Body mass index increased	1 (11.1%)	4 (44.4%)	2 (22.2%)	2 (22.2%)	9
Malignant melanoma of sites other than skin	0 (0.0%)	0 (0.0%)	4 (44.4%)	5 (55.6%)	9
Malignant catatonia	4 (44.4%)	3 (33.3%)	2 (22.2%)	0 (0.0%)	9
Diffuse alveolar damage	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Hair growth abnormal	1 (11.1%)	2 (22.2%)	6 (66.7%)	0 (0.0%)	9
Lung transplant rejection	0 (0.0%)	5 (55.6%)	4 (44.4%)	0 (0.0%)	9
Diabetic foot	0 (0.0%)	3 (33.3%)	5 (55.6%)	1 (11.1%)	9
Aortic valve replacement	0 (0.0%)	0 (0.0%)	6 (66.7%)	3 (33.3%)	9
Aortic valve incompetence	1 (11.1%)	2 (22.2%)	4 (44.4%)	2 (22.2%)	9
Dermatitis psoriasiform	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dermatitis diaper	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Heart rate abnormal	0 (0.0%)	0 (0.0%)	5 (55.6%)	4 (44.4%)	9
Dental disorder prophylaxis	0 (0.0%)	4 (44.4%)	4 (44.4%)	1 (11.1%)	9
Progressive relapsing multiple sclerosis	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Keloid scar	8 (88.9%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	9
Hepatic enzyme increased	2 (22.2%)	1 (11.1%)	6 (66.7%)	0 (0.0%)	9
Chronic active Epstein-Barr virus infection	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Abdominal tenderness	8 (88.9%)	0 (0.0%)	1 (11.1%)	0 (0.0%)	9
Thymic cancer metastatic	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Sinus node dysfunction	0 (0.0%)	0 (0.0%)	7 (77.8%)	2 (22.2%)	9
Blepharokeratoconjunctivitis	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Agoraphobia	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Adrenogenital syndrome	5 (55.6%)	4 (44.4%)	0 (0.0%)	0 (0.0%)	9
Urticaria cholinergic	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Teratoma	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Upper-airway cough syndrome	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Acute graft versus host disease in skin	3 (33.3%)	0 (0.0%)	6 (66.7%)	0 (0.0%)	9
Spinal cord injury	1 (11.1%)	3 (33.3%)	5 (55.6%)	0 (0.0%)	9
Bladder cancer stage II	0 (0.0%)	0 (0.0%)	7 (77.8%)	2 (22.2%)	9
Hypotonia	1 (11.1%)	2 (22.2%)	5 (55.6%)	1 (11.1%)	9
Tonsillectomy	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Synovial sarcoma	3 (33.3%)	4 (44.4%)	2 (22.2%)	0 (0.0%)	9
Thalassaemia sickle cell	3 (33.3%)	2 (22.2%)	4 (44.4%)	0 (0.0%)	9
Hyperpituitarism	6 (66.7%)	2 (22.2%)	1 (11.1%)	0 (0.0%)	9
Tachyarrhythmia	2 (22.2%)	0 (0.0%)	6 (66.7%)	1 (11.1%)	9
Immunoglobulin therapy	1 (11.1%)	7 (77.8%)	0 (0.0%)	1 (11.1%)	9
Hypercalciuria	3 (33.3%)	1 (11.1%)	5 (55.6%)	0 (0.0%)	9

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Primary cardiac lymphoma	0 (0.0%)	0 (0.0%)	4 (44.4%)	5 (55.6%)	9
Hodgkin's disease recurrent	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9
Pernicious anaemia	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Tendonitis	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Herpes simplex encephalitis	2 (22.2%)	0 (0.0%)	6 (66.7%)	1 (11.1%)	9
Skin abrasion	4 (44.4%)	1 (11.1%)	3 (33.3%)	1 (11.1%)	9
Abscess limb	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Silver-Russell syndrome	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Blepharospasm	0 (0.0%)	0 (0.0%)	7 (77.8%)	2 (22.2%)	9
Carcinoid tumour of the liver	0 (0.0%)	2 (22.2%)	7 (77.8%)	0 (0.0%)	9
Blister	0 (0.0%)	1 (11.1%)	7 (77.8%)	1 (11.1%)	9
Hypocholesterolaemia	0 (0.0%)	0 (0.0%)	7 (77.8%)	2 (22.2%)	9
Rosai-Dorfman syndrome	3 (33.3%)	2 (22.2%)	4 (44.4%)	0 (0.0%)	9
Beta haemolytic streptococcal infection	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Haemosiderosis	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Retinal vasculitis	0 (0.0%)	6 (66.7%)	3 (33.3%)	0 (0.0%)	9
Gaucher's disease type III	8 (88.9%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	9
Tracheal cancer	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Benign familial pemphigus	0 (0.0%)	1 (11.1%)	8 (88.9%)	0 (0.0%)	9
Haematochezia	0 (0.0%)	2 (22.2%)	6 (66.7%)	1 (11.1%)	9
Rectal cancer stage III	0 (0.0%)	2 (22.2%)	5 (55.6%)	2 (22.2%)	9
Graft versus host disease in liver	7 (77.8%)	0 (0.0%)	2 (22.2%)	0 (0.0%)	9
Immune enhancement therapy	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Glucocorticoid deficiency	5 (55.6%)	2 (22.2%)	2 (22.2%)	0 (0.0%)	9
Immune-mediated hepatitis	0 (0.0%)	1 (11.1%)	4 (44.4%)	4 (44.4%)	9
Procedural nausea	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Urinary tract infection bacterial	0 (0.0%)	3 (33.3%)	2 (22.2%)	4 (44.4%)	9

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastrooesophageal cancer	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Cerebral venous thrombosis	4 (44.4%)	5 (55.6%)	0 (0.0%)	0 (0.0%)	9
Gastrointestinal pain	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Gastrointestinal neoplasm	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Poor peripheral circulation	1 (11.1%)	0 (0.0%)	7 (77.8%)	1 (11.1%)	9
Urine alkalinisation therapy	1 (11.1%)	2 (22.2%)	5 (55.6%)	1 (11.1%)	9
Subcutaneous abscess	0 (0.0%)	5 (55.6%)	4 (44.4%)	0 (0.0%)	9
Gastric bypass	0 (0.0%)	3 (33.3%)	6 (66.7%)	0 (0.0%)	9
Vascular disorder prophylaxis	0 (0.0%)	1 (11.1%)	6 (66.7%)	2 (22.2%)	9
Adenosine deaminase 2 deficiency	9 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9
Pharyngitis streptococcal	4 (44.4%)	4 (44.4%)	0 (0.0%)	1 (11.1%)	9
Infected fistula	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Fusobacterium infection	2 (22.2%)	6 (66.7%)	0 (0.0%)	1 (11.1%)	9
Peritoneal mesothelioma malignant	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Vasogenic cerebral oedema	1 (11.1%)	0 (0.0%)	6 (66.7%)	2 (22.2%)	9
Follicular dendritic cell sarcoma	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9
Impetigo	1 (11.1%)	7 (77.8%)	1 (11.1%)	0 (0.0%)	9
Infusion	1 (11.1%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	9
Papilloedema	0 (0.0%)	8 (88.9%)	1 (11.1%)	0 (0.0%)	9
Neutrophilic dermatosis	5 (55.6%)	0 (0.0%)	4 (44.4%)	0 (0.0%)	9
Pain in jaw	0 (0.0%)	3 (33.3%)	4 (44.4%)	2 (22.2%)	9
Pachymeningitis	0 (0.0%)	0 (0.0%)	5 (55.6%)	4 (44.4%)	9
Probiotic therapy	2 (22.2%)	2 (22.2%)	4 (44.4%)	1 (11.1%)	9
Faeces soft	1 (11.1%)	2 (22.2%)	4 (44.4%)	2 (22.2%)	9
Chemotherapy cytokine prophylaxis	6 (66.7%)	3 (33.3%)	0 (0.0%)	0 (0.0%)	9
Factor V Leiden mutation	1 (11.1%)	5 (55.6%)	1 (11.1%)	2 (22.2%)	9
Eye infection toxoplasmal	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	9

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Zinc deficiency	1 (11.1%)	1 (11.1%)	3 (33.3%)	4 (44.4%)	9
Extraskelatal myxoid chondrosarcoma	0 (0.0%)	4 (44.4%)	5 (55.6%)	0 (0.0%)	9
Nonspecific reaction	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Ocular ischaemic syndrome	6 (75.0%)	1 (12.5%)	1 (12.5%)	0 (0.0%)	8
Erythromelalgia	1 (12.5%)	0 (0.0%)	7 (87.5%)	0 (0.0%)	8
Nongerminomatous germ cell tumour of the CNS	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Nijmegen breakage syndrome	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
New onset diabetes after transplantation	7 (87.5%)	0 (0.0%)	1 (12.5%)	0 (0.0%)	8
Assisted fertilisation	3 (37.5%)	5 (62.5%)	0 (0.0%)	0 (0.0%)	8
Psychotic disorder due to a general medical conditio	0 (0.0%)	0 (0.0%)	4 (50.0%)	4 (50.0%)	8
Eosinophilic pneumonia chronic	4 (50.0%)	2 (25.0%)	2 (25.0%)	0 (0.0%)	8
Obstructive sleep apnoea syndrome	1 (12.5%)	0 (0.0%)	5 (62.5%)	2 (25.0%)	8
Oesophageal adenocarcinoma stage IV	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Neonatal respiratory distress syndrome	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Granuloma	2 (25.0%)	5 (62.5%)	1 (12.5%)	0 (0.0%)	8
Cholecystitis acute	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Pulmonary veno-occlusive disease	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Endoscopy upper gastrointestinal tract	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Myosclerosis	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Endometritis	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	8
Burkholderia gladioli infection	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Endometrial cancer stage III	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Arthritis reactive	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Corneal abscess	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Quadripareisis	3 (37.5%)	1 (12.5%)	4 (50.0%)	0 (0.0%)	8
Radiation necrosis	6 (75.0%)	0 (0.0%)	2 (25.0%)	0 (0.0%)	8
Endocarditis staphylococcal	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Muscle disorder	1 (12.5%)	4 (50.0%)	2 (25.0%)	1 (12.5%)	8
Yolk sac tumour site unspecified	3 (37.5%)	5 (62.5%)	0 (0.0%)	0 (0.0%)	8
Encephalitis brain stem	5 (62.5%)	3 (37.5%)	0 (0.0%)	0 (0.0%)	8
Empyema	1 (12.5%)	2 (25.0%)	5 (62.5%)	0 (0.0%)	8
Multimorbidity	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Eye allergy	0 (0.0%)	3 (37.5%)	3 (37.5%)	2 (25.0%)	8
Amenorrhoea	3 (37.5%)	5 (62.5%)	0 (0.0%)	0 (0.0%)	8
Abnormal faeces	0 (0.0%)	4 (50.0%)	2 (25.0%)	2 (25.0%)	8
Arteriovenous fistula	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Mouth haemorrhage	5 (62.5%)	0 (0.0%)	0 (0.0%)	3 (37.5%)	8
Arteriospasm coronary	0 (0.0%)	1 (12.5%)	4 (50.0%)	3 (37.5%)	8
Bronchiolitis	5 (62.5%)	0 (0.0%)	3 (37.5%)	0 (0.0%)	8
Ectopic pregnancy termination	1 (12.5%)	7 (87.5%)	0 (0.0%)	0 (0.0%)	8
Echinococciasis	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Metastatic cutaneous Crohn's disease	3 (37.5%)	1 (12.5%)	4 (50.0%)	0 (0.0%)	8
Dyspareunia	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Breast cancer in situ	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Blood bilirubin increased	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Haematoma	2 (25.0%)	0 (0.0%)	4 (50.0%)	2 (25.0%)	8
Meningitis aseptic	1 (12.5%)	7 (87.5%)	0 (0.0%)	0 (0.0%)	8
Drug withdrawal maintenance therapy	1 (12.5%)	5 (62.5%)	2 (25.0%)	0 (0.0%)	8
Medulloblastoma recurrent	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Brain stem glioma	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Haemoglobin abnormal	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Chronic fatigue syndrome	1 (12.5%)	5 (62.5%)	1 (12.5%)	1 (12.5%)	8
Appendectomy	3 (37.5%)	1 (12.5%)	1 (12.5%)	3 (37.5%)	8
Malignant neoplasm of thymus	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Allogenic bone marrow transplantation therapy	2 (25.0%)	1 (12.5%)	5 (62.5%)	0 (0.0%)	8
Disorientation	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Magnetic resonance imaging spinal	1 (12.5%)	5 (62.5%)	1 (12.5%)	1 (12.5%)	8
Allergy to animal	1 (12.5%)	6 (75.0%)	1 (12.5%)	0 (0.0%)	8
Lung abscess	1 (12.5%)	4 (50.0%)	3 (37.5%)	0 (0.0%)	8
Lumbar vertebral fracture	1 (12.5%)	2 (25.0%)	1 (12.5%)	4 (50.0%)	8
Low density lipoprotein decreased	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Long QT syndrome	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Liver function test increased	1 (12.5%)	0 (0.0%)	4 (50.0%)	3 (37.5%)	8
Liposarcoma	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Aortic aneurysm	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Leukoencephalopathy	4 (50.0%)	2 (25.0%)	1 (12.5%)	1 (12.5%)	8
Delusional disorder, unspecified type	0 (0.0%)	5 (62.5%)	2 (25.0%)	1 (12.5%)	8
Lacrimation increased	1 (12.5%)	2 (25.0%)	5 (62.5%)	0 (0.0%)	8
Labour pain	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Klebsiella sepsis	0 (0.0%)	0 (0.0%)	2 (25.0%)	6 (75.0%)	8
Jugular vein thrombosis	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Dandy-Walker syndrome	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Biliary cancer metastatic	0 (0.0%)	0 (0.0%)	3 (37.5%)	5 (62.5%)	8
Cytomegalovirus test positive	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Antioxidant therapy	3 (37.5%)	2 (25.0%)	3 (37.5%)	0 (0.0%)	8
Intraoperative care	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Vitrectomy	5 (62.5%)	0 (0.0%)	3 (37.5%)	0 (0.0%)	8
Sexual dysfunction	0 (0.0%)	6 (75.0%)	0 (0.0%)	2 (25.0%)	8
Vulvovaginal disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (100.0%)	8
Blood growth hormone decreased	7 (87.5%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	8
Oocyte harvest	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vaginal cancer	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Skin test	2 (25.0%)	1 (12.5%)	4 (50.0%)	1 (12.5%)	8
Type IV hypersensitivity reaction	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Tuberculoma of central nervous system	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (100.0%)	8
Hodgkin's disease lymphocyte depletion type stage II	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Transcatheter aortic valve implantation	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Primary hypercholesterolaemia	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Acute graft versus host disease in intestine	1 (12.5%)	6 (75.0%)	1 (12.5%)	0 (0.0%)	8
Human T-cell lymphotropic virus type I infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (100.0%)	8
Anal fissure	3 (37.5%)	2 (25.0%)	3 (37.5%)	0 (0.0%)	8
Congenital megacolon	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Hyperadrenocorticism	1 (12.5%)	3 (37.5%)	2 (25.0%)	2 (25.0%)	8
Anti IFN gamma autoantibody syndrome	0 (0.0%)	6 (75.0%)	2 (25.0%)	0 (0.0%)	8
Hyperammonaemic encephalopathy	0 (0.0%)	7 (87.5%)	0 (0.0%)	1 (12.5%)	8
Systemic sclerosis pulmonary	0 (0.0%)	1 (12.5%)	4 (50.0%)	3 (37.5%)	8
Superior vena cava occlusion	2 (25.0%)	6 (75.0%)	0 (0.0%)	0 (0.0%)	8
Syphilis	3 (37.5%)	4 (50.0%)	1 (12.5%)	0 (0.0%)	8
Traumatic intracranial haemorrhage	0 (0.0%)	1 (12.5%)	1 (12.5%)	6 (75.0%)	8
Bladder pain	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Infective myositis	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Colon cancer stage II	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Amnesia	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Blau syndrome	4 (50.0%)	4 (50.0%)	0 (0.0%)	0 (0.0%)	8
Small fibre neuropathy	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Tendon disorder	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Coeliac disease	2 (25.0%)	0 (0.0%)	6 (75.0%)	0 (0.0%)	8
Anti-NMDA antibody	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Testicular seminoma (pure)	0 (0.0%)	0 (0.0%)	2 (25.0%)	6 (75.0%)	8
Skin mass	1 (12.5%)	1 (12.5%)	5 (62.5%)	1 (12.5%)	8
Hernia	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Tension	0 (0.0%)	2 (25.0%)	4 (50.0%)	2 (25.0%)	8
Thinking abnormal	1 (12.5%)	0 (0.0%)	7 (87.5%)	0 (0.0%)	8
Hepatic sarcoma	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Secondary hypogonadism	0 (0.0%)	3 (37.5%)	5 (62.5%)	0 (0.0%)	8
Idiopathic pneumonia syndrome	7 (87.5%)	0 (0.0%)	1 (12.5%)	0 (0.0%)	8
Heparin-induced thrombocytopenia	1 (12.5%)	1 (12.5%)	5 (62.5%)	1 (12.5%)	8
Sarcomatoid carcinoma	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Retinal detachment	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Chronic graft versus host disease in intestine	5 (62.5%)	0 (0.0%)	3 (37.5%)	0 (0.0%)	8
Haemolysis	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Gastric haemorrhage	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Chronic eosinophilic rhinosinusitis	0 (0.0%)	6 (75.0%)	2 (25.0%)	0 (0.0%)	8
Chronic disease	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Haematopoietic neoplasm	0 (0.0%)	2 (25.0%)	5 (62.5%)	1 (12.5%)	8
Renal cell carcinoma stage I	0 (0.0%)	2 (25.0%)	0 (0.0%)	6 (75.0%)	8
Vaginal infection	0 (0.0%)	5 (62.5%)	2 (25.0%)	1 (12.5%)	8
Vaginal cancer metastatic	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Pneumococcal infection	1 (12.5%)	1 (12.5%)	4 (50.0%)	2 (25.0%)	8
Bell's palsy	1 (12.5%)	1 (12.5%)	6 (75.0%)	0 (0.0%)	8
Chromophobe renal cell carcinoma	0 (0.0%)	0 (0.0%)	4 (50.0%)	4 (50.0%)	8
Choroidal effusion	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Choroid melanoma	0 (0.0%)	4 (50.0%)	2 (25.0%)	2 (25.0%)	8
Blood calcium abnormal	1 (12.5%)	1 (12.5%)	6 (75.0%)	0 (0.0%)	8
Growth hormone-producing pituitary tumour	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	8

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tuberculin test	4 (50.0%)	4 (50.0%)	0 (0.0%)	0 (0.0%)	8
Bacteriuria	0 (0.0%)	6 (75.0%)	2 (25.0%)	0 (0.0%)	8
Immune disorder prophylaxis	1 (12.5%)	0 (0.0%)	6 (75.0%)	1 (12.5%)	8
Proteus test positive	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Polyomavirus-associated nephropathy	2 (25.0%)	0 (0.0%)	6 (75.0%)	0 (0.0%)	8
Inappropriate antidiuretic hormone secretion	1 (12.5%)	0 (0.0%)	5 (62.5%)	2 (25.0%)	8
Chemical poisoning	0 (0.0%)	5 (62.5%)	3 (37.5%)	0 (0.0%)	8
Chelation therapy	3 (37.5%)	1 (12.5%)	4 (50.0%)	0 (0.0%)	8
Giant cell myocarditis	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Urethral cancer	0 (0.0%)	5 (62.5%)	2 (25.0%)	1 (12.5%)	8
Prenatal care	7 (87.5%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	8
Immunoglobulins decreased	0 (0.0%)	5 (62.5%)	2 (25.0%)	1 (12.5%)	8
Cerebral disorder	1 (12.5%)	1 (12.5%)	3 (37.5%)	3 (37.5%)	8
Costochondritis	1 (12.5%)	7 (87.5%)	0 (0.0%)	0 (0.0%)	8
Cerebral thrombosis	0 (0.0%)	3 (37.5%)	0 (0.0%)	5 (62.5%)	8
Post inflammatory pigmentation change	2 (25.0%)	2 (25.0%)	3 (37.5%)	1 (12.5%)	8
Polypoidal choroidal vasculopathy	0 (0.0%)	0 (0.0%)	5 (62.5%)	3 (37.5%)	8
Pneumonia viral	0 (0.0%)	2 (25.0%)	4 (50.0%)	2 (25.0%)	8
Pneumonia streptococcal	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Pneumonia legionella	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Gastrointestinal ulcer	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Epiglottic cancer	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Increased appetite	2 (25.0%)	3 (37.5%)	3 (37.5%)	0 (0.0%)	8
Vasculitic rash	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Premenstrual dysphoric disorder	1 (12.5%)	7 (87.5%)	0 (0.0%)	0 (0.0%)	8
Vasodilatation	0 (0.0%)	4 (50.0%)	4 (50.0%)	0 (0.0%)	8
Peripheral artery occlusion	0 (0.0%)	0 (0.0%)	2 (25.0%)	6 (75.0%)	8

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ventricular arrhythmia	0 (0.0%)	5 (62.5%)	1 (12.5%)	2 (25.0%)	8
Penile vascular disorder	8 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	8
Vestibular migraine	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Vitamin B12 decreased	0 (0.0%)	3 (37.5%)	4 (50.0%)	1 (12.5%)	8
Parasitic infection prophylaxis	0 (0.0%)	1 (12.5%)	7 (87.5%)	0 (0.0%)	8
Coronary artery stenosis	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Paraneoplastic dermatomyositis	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Adenoid cystic carcinoma	0 (0.0%)	2 (25.0%)	6 (75.0%)	0 (0.0%)	8
Pancreatic fistula	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Cardiorenal syndrome	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Cutaneous tuberculosis	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Vulvovaginal discomfort	0 (0.0%)	1 (12.5%)	6 (75.0%)	1 (12.5%)	8
Familial partial lipodystrophy	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	8
Atrioventricular block	1 (12.5%)	1 (12.5%)	4 (50.0%)	2 (25.0%)	8
Cardiac operation	0 (0.0%)	0 (0.0%)	1 (12.5%)	7 (87.5%)	8
Cardiac flutter	0 (0.0%)	0 (0.0%)	7 (87.5%)	1 (12.5%)	8
Atrial septal defect	5 (62.5%)	0 (0.0%)	3 (37.5%)	0 (0.0%)	8
Oropharyngeal cancer stage IV	0 (0.0%)	0 (0.0%)	6 (75.0%)	2 (25.0%)	8
Oral submucosal fibrosis	0 (0.0%)	8 (100.0%)	0 (0.0%)	0 (0.0%)	8
Oral neoplasm	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Cardiac aneurysm	0 (0.0%)	0 (0.0%)	8 (100.0%)	0 (0.0%)	8
Abdominal abscess	1 (12.5%)	1 (12.5%)	5 (62.5%)	1 (12.5%)	8
Oligoastrocytoma	1 (12.5%)	0 (0.0%)	7 (87.5%)	0 (0.0%)	8
Asymptomatic HIV infection	0 (0.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)	8
Capnocytophaga infection	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Occipital neuralgia	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Normal tension glaucoma	0 (0.0%)	3 (42.9%)	2 (28.6%)	2 (28.6%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anaemia of chronic disease	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Calcinosis	1 (14.3%)	6 (85.7%)	0 (0.0%)	0 (0.0%)	7
Neuroendocrine carcinoma of the cervix	0 (0.0%)	0 (0.0%)	3 (42.9%)	4 (57.1%)	7
Tumour associated fever	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Epidermolysis bullosa	5 (71.4%)	2 (28.6%)	0 (0.0%)	0 (0.0%)	7
Eosinophilic pneumonia	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Eosinophilic myocarditis	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Enzyme supplementation	5 (71.4%)	1 (14.3%)	1 (14.3%)	0 (0.0%)	7
Enuresis	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Nasal disorder	0 (0.0%)	2 (28.6%)	2 (28.6%)	3 (42.9%)	7
Myelitis	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Bundle branch block left	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Musculoskeletal discomfort	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Muscle mass	1 (14.3%)	6 (85.7%)	0 (0.0%)	0 (0.0%)	7
Muscle haemorrhage	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Multicentric reticulohistiocytosis	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Movement disorder	1 (14.3%)	0 (0.0%)	5 (71.4%)	1 (14.3%)	7
Mononeuropathy	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Metastatic uterine cancer	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Breast pain	0 (0.0%)	5 (71.4%)	1 (14.3%)	1 (14.3%)	7
Metastases to pancreas	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Dust allergy	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Meningitis meningococcal	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Arnold-Chiari malformation	4 (57.1%)	0 (0.0%)	2 (28.6%)	1 (14.3%)	7
Diverticulum	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Malignant nipple neoplasm female	0 (0.0%)	1 (14.3%)	2 (28.6%)	4 (57.1%)	7
Malignant melanoma stage II	0 (0.0%)	0 (0.0%)	2 (28.6%)	5 (71.4%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Malaria	1 (14.3%)	2 (28.6%)	4 (57.1%)	0 (0.0%)	7
Magnetic resonance imaging heart	3 (42.9%)	1 (14.3%)	2 (28.6%)	1 (14.3%)	7
Magnetic resonance imaging breast	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Haemophilus infection	1 (14.3%)	1 (14.3%)	5 (71.4%)	0 (0.0%)	7
Haemorrhoidal haemorrhage	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Lung carcinoma cell type unspecified stage III	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Localised oedema	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Liver injury	0 (0.0%)	4 (57.1%)	1 (14.3%)	2 (28.6%)	7
Acute lymphocytic leukaemia (in remission)	2 (28.6%)	1 (14.3%)	3 (42.9%)	1 (14.3%)	7
Listeria encephalitis	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Limb immobilisation	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Body fat disorder	2 (28.6%)	4 (57.1%)	1 (14.3%)	0 (0.0%)	7
Tinea pedis	2 (28.6%)	1 (14.3%)	3 (42.9%)	1 (14.3%)	7
Acute leukaemia in remission	0 (0.0%)	3 (42.9%)	3 (42.9%)	1 (14.3%)	7
Large intestine infection	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Familial tremor	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Dedifferentiated liposarcoma	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Alcohol rehabilitation	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Alcohol poisoning	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Blood pressure fluctuation	1 (14.3%)	1 (14.3%)	4 (57.1%)	1 (14.3%)	7
Joint prosthesis user	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Dandruff	1 (14.3%)	2 (28.6%)	3 (42.9%)	1 (14.3%)	7
Angle closure glaucoma	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Thyroid cyst	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Citrobacter infection	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Blood potassium abnormal	0 (0.0%)	1 (14.3%)	3 (42.9%)	3 (42.9%)	7
Intracranial infection	1 (14.3%)	2 (28.6%)	4 (57.1%)	0 (0.0%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Selective eating disorder	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Seizure cluster	4 (57.1%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	7
Antineutrophil cytoplasmic antibody	0 (0.0%)	1 (14.3%)	2 (28.6%)	4 (57.1%)	7
Wrong dose	0 (0.0%)	0 (0.0%)	1 (14.3%)	6 (85.7%)	7
Wound infection staphylococcal	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Anhedonia	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Serpiginous choroiditis	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Serum ferritin decreased	1 (14.3%)	5 (71.4%)	0 (0.0%)	1 (14.3%)	7
Fibrinous bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Hepatorenal syndrome	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Ventricular dysfunction	4 (57.1%)	0 (0.0%)	3 (42.9%)	0 (0.0%)	7
Paraproteinaemia	3 (42.9%)	4 (57.1%)	0 (0.0%)	0 (0.0%)	7
Herpes zoster immunisation	1 (14.3%)	1 (14.3%)	2 (28.6%)	3 (42.9%)	7
Urea cycle disorder	2 (28.6%)	5 (71.4%)	0 (0.0%)	0 (0.0%)	7
Tumour thrombosis	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Tonic clonic movements	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Stenosis	0 (0.0%)	4 (57.1%)	2 (28.6%)	1 (14.3%)	7
Hyperinsulinism	6 (85.7%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	7
Tenosynovitis	0 (0.0%)	6 (85.7%)	0 (0.0%)	1 (14.3%)	7
Perioperative analgesia	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Bladder transitional cell carcinoma metastatic	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Surgical preconditioning	1 (14.3%)	0 (0.0%)	6 (85.7%)	0 (0.0%)	7
Stupor	0 (0.0%)	4 (57.1%)	1 (14.3%)	2 (28.6%)	7
Stress urinary incontinence	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Complement factor abnormal	2 (28.6%)	4 (57.1%)	1 (14.3%)	0 (0.0%)	7
Hyper IgM syndrome	2 (28.6%)	3 (42.9%)	2 (28.6%)	0 (0.0%)	7
Streptococcal endocarditis	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Androgen deficiency	0 (0.0%)	2 (28.6%)	4 (57.1%)	1 (14.3%)	7
Squamous cell carcinoma of the oral cavity	0 (0.0%)	4 (57.1%)	2 (28.6%)	1 (14.3%)	7
Spontaneous bacterial peritonitis	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Spondylolisthesis	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Peritoneal tuberculosis	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Autoimmune neutropenia	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Congenital anomaly	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Herpes zoster reactivation	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Testicular germ cell cancer metastatic	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Hepatomegaly	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Sexually inappropriate behaviour	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Secondary adrenocortical insufficiency	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Seborrhoeic keratosis	0 (0.0%)	1 (14.3%)	2 (28.6%)	4 (57.1%)	7
Cervical radiculopathy	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Seasonal affective disorder	2 (28.6%)	0 (0.0%)	5 (71.4%)	0 (0.0%)	7
Chylothorax	6 (85.7%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	7
Sarcoma uterus	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Salmonellosis	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Sympathetic ophthalmia	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Adrenal neoplasm	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Blood albumin decreased	1 (14.3%)	1 (14.3%)	3 (42.9%)	2 (28.6%)	7
Heart and lung transplant	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Eczema herpeticum	1 (14.3%)	5 (71.4%)	1 (14.3%)	0 (0.0%)	7
Angioplasty	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Rib fracture	0 (0.0%)	3 (42.9%)	2 (28.6%)	2 (28.6%)	7
Hand dermatitis	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Chronic left ventricular failure	0 (0.0%)	3 (42.9%)	2 (28.6%)	2 (28.6%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Benign rolandic epilepsy	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Chronic kidney disease-mineral and bone disorder	0 (0.0%)	5 (71.4%)	1 (14.3%)	1 (14.3%)	7
Retinal artery occlusion	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Adrenal gland cancer metastatic	6 (85.7%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	7
Respiratory disorder prophylaxis	5 (71.4%)	0 (0.0%)	1 (14.3%)	1 (14.3%)	7
Pituitary-dependent Cushing's syndrome	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Vaginal haemorrhage	0 (0.0%)	6 (85.7%)	0 (0.0%)	1 (14.3%)	7
Renal amyloidosis	0 (0.0%)	1 (14.3%)	3 (42.9%)	3 (42.9%)	7
Reflux laryngitis	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Radiation skin injury	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Pyruvate kinase deficiency anaemia	2 (28.6%)	2 (28.6%)	3 (42.9%)	0 (0.0%)	7
Putamen haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Pulmonary vasculitis	0 (0.0%)	2 (28.6%)	5 (71.4%)	0 (0.0%)	7
Pulmonary thrombosis	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Pulmonary haemorrhage	1 (14.3%)	6 (85.7%)	0 (0.0%)	0 (0.0%)	7
Pulmonary capillary haemangiomatosis	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Illusion	5 (71.4%)	2 (28.6%)	0 (0.0%)	0 (0.0%)	7
Type III immune complex mediated reaction	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Prostatism	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Prostatic pain	0 (0.0%)	6 (85.7%)	1 (14.3%)	0 (0.0%)	7
Aneurysm	0 (0.0%)	1 (14.3%)	2 (28.6%)	4 (57.1%)	7
Immune-mediated myocarditis	0 (0.0%)	3 (42.9%)	1 (14.3%)	3 (42.9%)	7
Prophylaxis against Rh isoimmunisation	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Primary hyperthyroidism	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Primary hyperaldosteronism	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
General symptom	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (100.0%)	7
Gastrostomy	6 (85.7%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Urinary tract pain	3 (42.9%)	2 (28.6%)	2 (28.6%)	0 (0.0%)	7
Polyp	0 (0.0%)	2 (28.6%)	3 (42.9%)	2 (28.6%)	7
Azotaemia	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Gastritis erosive	0 (0.0%)	1 (14.3%)	4 (57.1%)	2 (28.6%)	7
Pneumococcal immunisation	0 (0.0%)	3 (42.9%)	0 (0.0%)	4 (57.1%)	7
Central venous catheterisation	1 (14.3%)	4 (57.1%)	2 (28.6%)	0 (0.0%)	7
Central nervous system neoplasm	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Vascular stent thrombosis	0 (0.0%)	0 (0.0%)	3 (42.9%)	4 (57.1%)	7
Vascular stent insertion	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Infective exacerbation of bronchiectasis	0 (0.0%)	0 (0.0%)	1 (14.3%)	6 (85.7%)	7
Periodontitis	0 (0.0%)	0 (0.0%)	5 (71.4%)	2 (28.6%)	7
Ventricular septal defect	7 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	7
Pericardial effusion malignant	0 (0.0%)	5 (71.4%)	2 (28.6%)	0 (0.0%)	7
Follicular lymphoma recurrent	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Follicle centre lymphoma, follicular grade I, II, III	0 (0.0%)	3 (42.9%)	4 (57.1%)	0 (0.0%)	7
Vipoma	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Abdominal neoplasm	0 (0.0%)	1 (14.3%)	5 (71.4%)	1 (14.3%)	7
Vitamin D abnormal	0 (0.0%)	0 (0.0%)	3 (42.9%)	4 (57.1%)	7
Paradoxical drug reaction	0 (0.0%)	0 (0.0%)	1 (14.3%)	6 (85.7%)	7
Acute hepatic failure	0 (0.0%)	1 (14.3%)	6 (85.7%)	0 (0.0%)	7
Pancreatic carcinoma recurrent	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Familial periodic paralysis	3 (42.9%)	3 (42.9%)	1 (14.3%)	0 (0.0%)	7
Insulin autoimmune syndrome	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Visceral pain	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)	7
Ovarian granulosa cell tumour	3 (42.9%)	4 (57.1%)	0 (0.0%)	0 (0.0%)	7
Faecal management	0 (0.0%)	0 (0.0%)	4 (57.1%)	3 (42.9%)	7
Ovarian cancer stage I	0 (0.0%)	2 (28.6%)	1 (14.3%)	4 (57.1%)	7

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Face oedema	0 (0.0%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	7
Face lift	0 (0.0%)	0 (0.0%)	6 (85.7%)	1 (14.3%)	7
Eye injury	6 (85.7%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	7
Extraskelatal osteosarcoma	2 (28.6%)	0 (0.0%)	5 (71.4%)	0 (0.0%)	7
Intertrigo	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	7
Ulcerative keratitis	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Asthma late onset	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Ocular pemphigoid	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Anaemia of pregnancy	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Candida sepsis	2 (33.3%)	3 (50.0%)	1 (16.7%)	0 (0.0%)	6
Non-alcoholic fatty liver	0 (0.0%)	5 (83.3%)	0 (0.0%)	1 (16.7%)	6
Non-Hodgkin's lymphoma stage IV	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Non-Hodgkin's lymphoma recurrent	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
New daily persistent headache	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Abnormal uterine bleeding	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Calciphylaxis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Epileptic encephalopathy	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Neuroleptic malignant syndrome	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Epigastric discomfort	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Neurofibrosarcoma	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
Gouty tophus	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Amniotic cavity infection	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Exposure during pregnancy	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Arthropod sting	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Endoscopy gastrointestinal	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Endoscopy	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Myelodysplastic syndrome with multilineage dysplasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bulimia nervosa	5 (83.3%)	1 (16.7%)	0 (0.0%)	0 (0.0%)	6
Muscle tightness	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Muscle rupture	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Encephalomyelitis	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Mitochondrial cytopathy	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Microvillous inclusion disease	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Microsporidia infection	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Bronchial anastomosis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Ear discomfort	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Arterial occlusive disease	0 (0.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	6
Metastases to pelvis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Metastases to ovary	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Meningoencephalitis bacterial	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Mechanical urticaria	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Angiogram retina	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Mean arterial pressure	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Thyroiditis subacute	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Maternal use of illicit drugs	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Drug abuser	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Mass	0 (0.0%)	0 (0.0%)	1 (16.7%)	5 (83.3%)	6
Mantle cell lymphoma refractory	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Malignant mast cell neoplasm	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Bordetella infection	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Malformation venous	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Maculopathy	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Bone marrow transplant rejection	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Lung squamous cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Haemophilia A with anti factor VIII	1 (16.7%)	3 (50.0%)	1 (16.7%)	1 (16.7%)	6
Lung adenocarcinoma stage I	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Rheumatoid factor	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Liposarcoma metastatic	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Developmental delay	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Lipids decreased	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Lip swelling	2 (33.3%)	1 (16.7%)	3 (50.0%)	0 (0.0%)	6
Lip cosmetic procedure	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Body height decreased	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Dermatitis exfoliative generalised	0 (0.0%)	4 (66.7%)	1 (16.7%)	1 (16.7%)	6
Left ventricle outflow tract obstruction	0 (0.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	6
Learning disability	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Laurence-Moon-Bardet-Biedl syndrome	4 (66.7%)	2 (33.3%)	0 (0.0%)	0 (0.0%)	6
Laryngeal cancer recurrent	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Demodex blepharitis	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Blood test abnormal	1 (16.7%)	3 (50.0%)	2 (33.3%)	0 (0.0%)	6
Labyrinthitis	0 (0.0%)	4 (66.7%)	1 (16.7%)	1 (16.7%)	6
Delivery	3 (50.0%)	3 (50.0%)	0 (0.0%)	0 (0.0%)	6
Laboratory test abnormal	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Thyroid stimulating hormone-producing pituitary tumo	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Blood sodium decreased	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Deafness	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Jaundice cholestatic	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Irrigation therapy	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Cytomegalovirus gastroenteritis	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Antioestrogen therapy	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Scrotal infection	0 (0.0%)	4 (66.7%)	0 (0.0%)	2 (33.3%)	6

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Intracardiac thrombus	0 (0.0%)	1 (16.7%)	2 (33.3%)	3 (50.0%)	6
Intestinal resection	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Cystitis escherichia	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Intestinal ischaemia	2 (33.3%)	1 (16.7%)	3 (50.0%)	0 (0.0%)	6
Selenium deficiency	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Wound complication	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Vitamin E deficiency	2 (33.3%)	0 (0.0%)	1 (16.7%)	3 (50.0%)	6
Ventricle rupture	0 (0.0%)	1 (16.7%)	3 (50.0%)	2 (33.3%)	6
Cotard's syndrome	4 (66.7%)	0 (0.0%)	2 (33.3%)	0 (0.0%)	6
Cortical dysplasia	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Immune-mediated pericarditis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Solid organ transplant rejection	4 (66.7%)	0 (0.0%)	2 (33.3%)	0 (0.0%)	6
Tuberculous pleurisy	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Histiocytosis	2 (33.3%)	1 (16.7%)	3 (50.0%)	0 (0.0%)	6
Trigger finger	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Tooth disorder	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Thyroid hormones decreased	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Throat irritation	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Stress ulcer	1 (16.7%)	2 (33.3%)	3 (50.0%)	0 (0.0%)	6
Temporomandibular joint syndrome	1 (16.7%)	4 (66.7%)	1 (16.7%)	0 (0.0%)	6
Computerised tomogram neck	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Hyperkeratosis	3 (50.0%)	1 (16.7%)	2 (33.3%)	0 (0.0%)	6
Superior vena cava syndrome	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Complications of transplanted lung	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Acute erythroid leukaemia	0 (0.0%)	0 (0.0%)	1 (16.7%)	5 (83.3%)	6
Cryptosporidiosis infection	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Human herpesvirus 7 infection	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hormonal contraception	2 (33.3%)	4 (66.7%)	0 (0.0%)	0 (0.0%)	6
Bladder cancer stage III	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Spinal decompression	0 (0.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	6
Bladder cancer recurrent	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Computerised tomogram pelvis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Adenomyosis	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Bladder ablation	0 (0.0%)	0 (0.0%)	1 (16.7%)	5 (83.3%)	6
Anti-HLA antibody test positive	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Testicular cancer metastatic	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Aesthesioneuroblastoma	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Sleep terror	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Skin irritation	0 (0.0%)	3 (50.0%)	2 (33.3%)	1 (16.7%)	6
Central nervous system immune reconstitution inflamm	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Therapeutic skin care topical	2 (33.3%)	1 (16.7%)	3 (50.0%)	0 (0.0%)	6
Sinus headache	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Signet-ring cell carcinoma	0 (0.0%)	2 (33.3%)	0 (0.0%)	4 (66.7%)	6
Congenital hypoparathyroidism	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Serum sickness	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Hepatitis B reactivation	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Clear cell sarcoma of soft tissue	2 (33.3%)	3 (50.0%)	1 (16.7%)	0 (0.0%)	6
Secondary amyloidosis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Hepatic cancer stage III	0 (0.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	6
Scleroderma associated digital ulcer	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Scan	1 (16.7%)	1 (16.7%)	4 (66.7%)	0 (0.0%)	6
Round cell liposarcoma	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Hypolipidaemia	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Rhabdomyosarcoma recurrent	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypoplastic left heart syndrome	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Respiratory syncytial virus bronchiolitis	2 (33.3%)	0 (0.0%)	4 (66.7%)	0 (0.0%)	6
Resorption bone increased	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Reproductive hormone	0 (0.0%)	6 (100.0%)	0 (0.0%)	0 (0.0%)	6
Renal pain	3 (50.0%)	2 (33.3%)	1 (16.7%)	0 (0.0%)	6
Platelet disorder	2 (33.3%)	0 (0.0%)	4 (66.7%)	0 (0.0%)	6
Pneumococcal sepsis	2 (33.3%)	0 (0.0%)	0 (0.0%)	4 (66.7%)	6
Relaxation therapy	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Haemangioma-thrombocytopenia syndrome	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Haemangioblastoma	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
HLA-B*27 positive	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
HER2 protein overexpression	0 (0.0%)	3 (50.0%)	0 (0.0%)	3 (50.0%)	6
Traumatic haemorrhage	2 (33.3%)	4 (66.7%)	0 (0.0%)	0 (0.0%)	6
Trichodysplasia spinulosa	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Trichosporon infection	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Pyelonephritis chronic	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Purpura	1 (16.7%)	0 (0.0%)	5 (83.3%)	0 (0.0%)	6
Pupil dilation procedure	0 (0.0%)	2 (33.3%)	4 (66.7%)	0 (0.0%)	6
Pudendal canal syndrome	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Bacterial prostatitis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Prostate cancer recurrent	0 (0.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	6
Chemotherapy toxicity attenuation	3 (50.0%)	0 (0.0%)	0 (0.0%)	3 (50.0%)	6
Gingivitis ulcerative	3 (50.0%)	1 (16.7%)	2 (33.3%)	0 (0.0%)	6
Posterior reversible encephalopathy syndrome	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Urge incontinence	0 (0.0%)	0 (0.0%)	2 (33.3%)	4 (66.7%)	6
Uterine leiomyosarcoma	0 (0.0%)	3 (50.0%)	3 (50.0%)	0 (0.0%)	6
Polyserositis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Inborn error of metabolism	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Pneumonia acinetobacter	5 (83.3%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	6
Pneumomediastinum	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Pneumatoxis	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Gastric pH increased	1 (16.7%)	1 (16.7%)	3 (50.0%)	1 (16.7%)	6
Cerebellar infarction	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Vaginal prolapse	0 (0.0%)	0 (0.0%)	4 (66.7%)	2 (33.3%)	6
Gastric cancer stage III	0 (0.0%)	0 (0.0%)	3 (50.0%)	3 (50.0%)	6
Incorrect route of product administration	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Vascular malformation	4 (66.7%)	0 (0.0%)	2 (33.3%)	0 (0.0%)	6
Phimosis	3 (50.0%)	0 (0.0%)	3 (50.0%)	0 (0.0%)	6
Infective exacerbation of chronic obstructive airway	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Catheter site erythema	3 (50.0%)	0 (0.0%)	3 (50.0%)	0 (0.0%)	6
Pericoronitis	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Vertebral artery occlusion	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Autoimmune enteropathy	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Abortion	1 (16.7%)	5 (83.3%)	0 (0.0%)	0 (0.0%)	6
Acquired factor VIII deficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Vitamin A	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Fistula of small intestine	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Carotid artery occlusion	0 (0.0%)	2 (33.3%)	3 (50.0%)	1 (16.7%)	6
Cutaneous sarcoidosis	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Anal fistula	0 (0.0%)	5 (83.3%)	1 (16.7%)	0 (0.0%)	6
Felty's syndrome	0 (0.0%)	1 (16.7%)	4 (66.7%)	1 (16.7%)	6
Feeling of relaxation	2 (33.3%)	0 (0.0%)	4 (66.7%)	0 (0.0%)	6
Pancreatic cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Pancreas transplant	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Alagille syndrome	6 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6
Ovarian cyst	2 (33.3%)	4 (66.7%)	0 (0.0%)	0 (0.0%)	6
Cardiac pacemaker insertion	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (100.0%)	6
Factor V deficiency	4 (66.7%)	1 (16.7%)	1 (16.7%)	0 (0.0%)	6
Meningoencephalitis herpetic	0 (0.0%)	4 (66.7%)	2 (33.3%)	0 (0.0%)	6
Eyelid ptosis	2 (33.3%)	0 (0.0%)	3 (50.0%)	1 (16.7%)	6
X-ray with contrast	0 (0.0%)	0 (0.0%)	5 (83.3%)	1 (16.7%)	6
Oral dysaesthesia	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Oral discomfort	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Optic disc disorder	5 (83.3%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	6
Ophthalmoplegia	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Ophthalmic migraine	0 (0.0%)	1 (16.7%)	2 (33.3%)	3 (50.0%)	6
Facial paralysis	0 (0.0%)	1 (16.7%)	5 (83.3%)	0 (0.0%)	6
Extrapulmonary tuberculosis	4 (66.7%)	2 (33.3%)	0 (0.0%)	0 (0.0%)	6
Extragonadal primary seminoma (pure)	0 (0.0%)	0 (0.0%)	6 (100.0%)	0 (0.0%)	6
Carcinoid tumour of the ovary	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Astrocytoma malignant	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Ocular rosacea	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Ewing's sarcoma recurrent	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Cannabinoid hyperemesis syndrome	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Anaemia of malignant disease	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Noninfective chorioretinitis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Non-small cell lung cancer stage II	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Acoustic neuroma	2 (40.0%)	0 (0.0%)	2 (40.0%)	1 (20.0%)	5
Non-cardiac chest pain	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Non-alcoholic steatohepatitis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Nodule	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Erdheim-Chester disease	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5
Neurological symptom	1 (20.0%)	1 (20.0%)	2 (40.0%)	1 (20.0%)	5
Neurodegenerative disorder	1 (20.0%)	0 (0.0%)	1 (20.0%)	3 (60.0%)	5
Nasopharyngeal cancer recurrent	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Enteritis infectious	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Myocardial bridging	0 (0.0%)	3 (60.0%)	0 (0.0%)	2 (40.0%)	5
Endometrial hyperplasia	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Mydriasis	2 (40.0%)	0 (0.0%)	1 (20.0%)	2 (40.0%)	5
Chondrocalcinosis	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Mycobacterium kansasii infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Endocrine disorder prophylaxis	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Bruxism	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Bruton's agammaglobulinaemia	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Mitral valve replacement	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Eczema eyelids	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Behavioural therapy	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Microcytic anaemia	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Metastatic bone disease prophylaxis	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Dysplasia	1 (20.0%)	2 (40.0%)	1 (20.0%)	1 (20.0%)	5
Metastases to biliary tract	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Arrhythmia supraventricular	3 (60.0%)	0 (0.0%)	1 (20.0%)	1 (20.0%)	5
Mesenteric panniculitis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Duodenal ulcer haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Dumping syndrome	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Meningitis listeria	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Melaena	3 (60.0%)	0 (0.0%)	0 (0.0%)	2 (40.0%)	5
Meibomian gland dysfunction	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mastocytic leukaemia	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Malignant urinary tract neoplasm	2 (40.0%)	0 (0.0%)	2 (40.0%)	1 (20.0%)	5
Malignant oligodendroglioma	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Malignant neoplasm of islets of Langerhans	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Malignant mediastinal neoplasm	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Disseminated Bacillus Calmette-Guerin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Disinhibited social engagement disorder of childhood	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Acute megakaryocytic leukaemia	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Acid fast bacilli infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Respiratory symptom	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Lymphopenia	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Lymphocytic infiltration	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Lymphangiosis carcinomatosa	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Allergy test	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Lymph node pain	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Lupus-like syndrome	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Aortic valve stenosis	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Diabetic gastroparesis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Diabetic foot infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Acid base balance	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Diabetic complication	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Loss of libido	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Loss of consciousness	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Tobacco abuse	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Tinnitus	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Lipoprotein (a) increased	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Rhodococcus infection	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Aortic bypass	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Linitis plastica	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Lice infestation	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Libido disorder	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Depression suicidal	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Leprosy	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
Dental caries	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Delusion of parasitosis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Delirium tremens	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Keratinising squamous cell carcinoma of nasopharynx	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Debridement	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Cytoreductive surgery	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Cytomegalovirus gastrointestinal infection	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Blood phosphorus	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Intradialytic parenteral nutrition	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Intestinal tuberculosis	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Cystitis haemorrhagic	3 (60.0%)	1 (20.0%)	0 (0.0%)	1 (20.0%)	5
Intestinal perforation	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Weight	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Cutaneous sporotrichosis	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Hepatitis C virus test positive	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Vitamin B1 deficiency	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Vitamin A deficiency	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Visceral leishmaniasis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Ventricular remodelling	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Cryptococcal meningoencephalitis	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Skin discolouration	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Vaginal discharge	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Therapeutic embolisation	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Skin disorder prophylaxis	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Urticarial vasculitis	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Urticaria papular	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Immunosuppressant drug level increased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Immunology test abnormal	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Ureteral stent insertion	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Tumefactive multiple sclerosis	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Blood catecholamines increased	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Tricuspid valve incompetence	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Transversus abdominis plane block	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Blood alkalinisation therapy	0 (0.0%)	2 (40.0%)	3 (60.0%)	0 (0.0%)	5
Tocolysis	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Hypertensive encephalopathy	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Synovial cyst	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Supraventricular extrasystoles	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Supplementary motor area syndrome	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Crystal arthropathy	0 (0.0%)	1 (20.0%)	2 (40.0%)	2 (40.0%)	5
Susac's syndrome	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Humerus fracture	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Colostomy	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Status migrainosus	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Systemic inflammatory response syndrome	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Anorexia nervosa	2 (40.0%)	3 (60.0%)	0 (0.0%)	0 (0.0%)	5
Sputum increased	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Sputum abnormal	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Splenomegaly	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Bladder cancer stage IV	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Splenic vein thrombosis	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Spindle cell sarcoma	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Spinal cord neoplasm	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Somatostatinoma	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Soft tissue haemorrhage	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
High density lipoprotein increased	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Colectomy	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Herpes simplex reactivation	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Skin toxicity	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Coccydynia	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Herpes gestationis	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Ankle operation	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Skeletal injury	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Coagulation factor VIII level decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Silicon granuloma	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Binge eating	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Congenital generalised lipodystrophy	2 (40.0%)	2 (40.0%)	1 (20.0%)	0 (0.0%)	5
Hepato-lenticular degeneration	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Shoulder arthroplasty	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Blindness	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Septo-optic dysplasia	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Thermal burn	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Secondary hypertension	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Hepatic cyst	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Circulatory collapse	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Apathy	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Bile duct adenocarcinoma	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Schizoaffective disorder depressive type	0 (0.0%)	4 (80.0%)	1 (20.0%)	0 (0.0%)	5
Hemiparesis	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Bile acid synthesis disorder	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5
Chronic myeloid leukaemia transformation	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
SAPHO syndrome	1 (20.0%)	2 (40.0%)	2 (40.0%)	0 (0.0%)	5
Head and neck cancer metastatic	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Rheumatoid meningitis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Chronic lymphocytic leukaemia (in remission)	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Retinopathy	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Retinitis viral	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Retinal neovascularisation	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Chronic granulomatous disease	3 (60.0%)	0 (0.0%)	0 (0.0%)	2 (40.0%)	5
Tracheostomy	1 (20.0%)	3 (60.0%)	1 (20.0%)	0 (0.0%)	5
Renal cancer recurrent	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Rectosigmoid cancer recurrent	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Choroid plexus carcinoma	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
HIV carrier	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Transpupillary thermotherapy	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Idiopathic orbital inflammation	1 (20.0%)	1 (20.0%)	3 (60.0%)	0 (0.0%)	5
Growth failure	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Abortion spontaneous	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Psychiatric disorder prophylaxis	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Psychiatric care	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Psoas abscess	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Bacterial pyelonephritis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Underweight	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Prophylaxis against solar radiation	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Ileostomy	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Product dispensing error	1 (20.0%)	0 (0.0%)	0 (0.0%)	4 (80.0%)	5
Blood corticotrophin increased	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)	5
Geotrichum infection	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
BRCA1 gene mutation	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Presbyopia	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Cervicobrachial syndrome	0 (0.0%)	3 (60.0%)	1 (20.0%)	1 (20.0%)	5
Precursor T-lymphoblastic lymphoma/leukaemia refract	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Anastomotic stenosis	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Postpartum hypopituitarism	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Poorly differentiated thyroid carcinoma	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Polyomavirus viraemia	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Adenosquamous cell lung cancer stage IV	0 (0.0%)	2 (40.0%)	0 (0.0%)	3 (60.0%)	5
B-cell depletion therapy	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Polymenorrhoea	1 (20.0%)	4 (80.0%)	0 (0.0%)	0 (0.0%)	5
Polycythaemia	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Gastrointestinal angiodysplasia	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Gastroenteritis proteus	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pneumonia necrotising	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Axillary vein thrombosis	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Pneumonia influenzal	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Cerebral artery occlusion	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Platelet count increased	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Varicella	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Platelet aggregation abnormal	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pigmentation disorder	1 (20.0%)	0 (0.0%)	3 (60.0%)	1 (20.0%)	5
Gallbladder disorder	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Vascular graft	0 (0.0%)	0 (0.0%)	3 (60.0%)	2 (40.0%)	5
Cryptitis	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Central nervous system lesion	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Pharyngotonsillitis	4 (80.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	5
Pharyngitis bacterial	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Autoimmune pancreatitis	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Fungal endocarditis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (100.0%)	5
Cellulitis orbital	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Peritonsillar abscess	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
Full blood count decreased	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Anastomotic ulcer	2 (40.0%)	1 (20.0%)	2 (40.0%)	0 (0.0%)	5
Presyncope	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Full blood count abnormal	2 (40.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	5
Cataract operation complication	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Cat scratch disease	3 (60.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	5
Cough variant asthma	0 (0.0%)	1 (20.0%)	3 (60.0%)	1 (20.0%)	5
Infusion site erythema	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Infusion site swelling	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Carotid artery disease	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Paranasal sinus hypersecretion	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Parainfluenzae virus infection	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Vitreous degeneration	0 (0.0%)	4 (80.0%)	0 (0.0%)	1 (20.0%)	5
Cardioversion	0 (0.0%)	1 (20.0%)	1 (20.0%)	3 (60.0%)	5
Cardiovascular insufficiency	1 (20.0%)	0 (0.0%)	4 (80.0%)	0 (0.0%)	5
Cardiotoxicity	3 (60.0%)	1 (20.0%)	1 (20.0%)	0 (0.0%)	5

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pancreatic calcification	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Pancreas transplant rejection	4 (80.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	5
Fanconi syndrome	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
PIK3CA-activated mutation	0 (0.0%)	1 (20.0%)	4 (80.0%)	0 (0.0%)	5
Cardiac valve prosthesis user	0 (0.0%)	0 (0.0%)	2 (40.0%)	3 (60.0%)	5
Cardiac valve disease	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Back injury	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Whipple's disease	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Osteomyelitis fungal	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Osteomalacia	0 (0.0%)	3 (60.0%)	2 (40.0%)	0 (0.0%)	5
Blood iron abnormal	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
X-ray gastrointestinal tract	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Xanthogranuloma	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Eye lubrication therapy	1 (20.0%)	0 (0.0%)	2 (40.0%)	2 (40.0%)	5
Oral infection	1 (20.0%)	2 (40.0%)	0 (0.0%)	2 (40.0%)	5
Optic glioma	5 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5
Opportunistic infection	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Cardiac ablation	0 (0.0%)	2 (40.0%)	2 (40.0%)	1 (20.0%)	5
Extrasystoles	0 (0.0%)	0 (0.0%)	1 (20.0%)	4 (80.0%)	5
Onychomadesis	0 (0.0%)	0 (0.0%)	4 (80.0%)	1 (20.0%)	5
Oestrogen deficiency	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Extra-osseous Ewing's sarcoma	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	5
Carcinoid tumour of the pancreas	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Oesophageal haemorrhage	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Ultrasound scan	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Exfoliative rash	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Oedema due to cardiac disease	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Carbuncle	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Astroblastoma	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Ocular surface squamous neoplasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Euthanasia	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Eustachian tube operation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Normocytic anaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Candida pneumonia	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Non-small cell lung cancer stage I	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Anaemia macrocytic	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cancer hormonal therapy	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Erosive oesophagitis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Nodal arrhythmia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Campylobacter gastroenteritis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Asteatosis	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Neutrophil count increased	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Neuropathic pruritus	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
CREST syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Epidermal naevus	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Neuritis	2 (50.0%)	1 (25.0%)	0 (0.0%)	1 (25.0%)	4
Aspergillus test	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Nerve compression	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Eosinophilic gastritis	2 (50.0%)	1 (25.0%)	0 (0.0%)	1 (25.0%)	4
CDKL5 deficiency disorder	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Neoplasm of appendix	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Natural killer-cell lymphoblastic lymphoma	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Enterococcal sepsis	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Nasal decongestion therapy	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Nasal cavity cancer	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Nail psoriasis	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Nail disorder	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Energy increased	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
NPM1 gene mutation	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Burkitt's lymphoma refractory	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Acute pulmonary oedema	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Mycotic allergy	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Ammonia abnormal	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Muscle necrosis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Murine typhus	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Acinetobacter sepsis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Bronchitis pneumococcal	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Monogenic diabetes	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Mitochondrial toxicity	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Arteriogram carotid	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Ecthyma	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Microsatellite instability cancer	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Methylobacterium infection	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Methaemoglobinaemia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Ear disorder	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Breast scan	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Acinetobacter bacteraemia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Mesothelioma malignant	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Mesenteric vein thrombosis	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Dysarthria	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Dysaesthesia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Menopausal disorder	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Menometrorrhagia	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Meniscus injury	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Breakthrough COVID-19	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Medication overuse headache	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Drug specific antibody present	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Mediastinum neoplasm	0 (0.0%)	2 (50.0%)	0 (0.0%)	2 (50.0%)	4
Drug ineffective	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Mastitis postpartum	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Drooling	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Mastectomy	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Marginal zone lymphoma recurrent	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Brain empyema	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Appendicitis perforated	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4
Marasmus	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Malignant sweat gland neoplasm	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Malignant pituitary tumour	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Malignant palate neoplasm	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Malignant nipple neoplasm	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Brachioradial pruritus	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Dissociation	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Brachial plexopathy	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Apnoea	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Malignant melanoma of eyelid	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4
Botulism	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Malignant lymphoid neoplasm	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Malignant genitourinary tract neoplasm	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Borderline leprosy	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Bone sarcoma	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Allergy to arthropod sting	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Diphtheria	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Lymphocyte count decreased	0 (0.0%)	2 (50.0%)	0 (0.0%)	2 (50.0%)	4
Lymphocyte adoptive therapy	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Lymphatic mapping	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lymphangioma	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Lymphangioliomyomatosis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Lymphangiectasia	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Bone lesion	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lupus endocarditis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Allergic sinusitis	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Device therapy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Device occlusion	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Allergic respiratory disease	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lithiasis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Chronic lymphocytic leukaemia stage 3	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Body temperature	1 (25.0%)	0 (0.0%)	1 (25.0%)	2 (50.0%)	4
Body mass index abnormal	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Lipids	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Body mass index	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Dermatosis	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Limbic encephalitis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Aortic arteriosclerosis	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Blood volume expansion	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Blood uric acid decreased	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Leptomeningeal myelomatosis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Lepromatous leprosy	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Leg amputation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Left ventricular hypertrophy	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Dental operation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Large cell lung cancer	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Lactation stimulation therapy	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Blood testosterone abnormal	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Lactation inhibition therapy	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Chronic villitis of unknown etiology	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Delftia acidovorans infection	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Knee operation	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Blood pressure systolic increased	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Joint stabilisation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Joint range of motion decreased	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Joint injury	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Joint dislocation	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
DNMT3A gene mutation	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Cytotoxic lesions of corpus callosum	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Blood potassium	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cytokine storm	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Antinuclear antibody positive	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Intracranial mass	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Intracranial aneurysm	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Abdominal hernia obstructive	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Blood oestrogen decreased	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Intestinal anastomosis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
International normalised ratio increased	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Hepatic neuroendocrine tumour	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Internal fixation of fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Intentional product use issue	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Withdrawal catatonia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cyst	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Cyanosis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Waldenstrom's macroglobulinaemia recurrent	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Vulvovaginal pruritus	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4
Vitamin C deficiency	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Vestibular disorder	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Culture urine positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Venous hypertension	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Infective aneurysm	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Vasospasm	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Vasculitis necrotising	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Infant sedation	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Urine abnormality	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Urinary tract inflammation	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Coronavirus pneumonia	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Ureteric cancer metastatic	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Unevaluable event	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Tympanic membrane perforation	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Corneal transplant	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Solvent sensitivity	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Tropical spastic paresis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Corneal abrasion	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood calcium increased	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Transurethral bladder resection	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Transfusion reaction	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Contrast media allergy	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Blood beta-D-glucan positive	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Tonsillitis bacterial	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Stasis syndrome	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Throat cancer	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hypertensive nephropathy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Tetanus	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Congenital aplastic anaemia	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Hyperreflexia	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Tachycardia paroxysmal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Synovial sarcoma metastatic	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Adverse reaction	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hyperinsulinaemia	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Superinfection	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Superinfection fungal	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Superficial spreading melanoma stage unspecified	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Hyperferritinaemia	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Complications of transplanted liver	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Suicidal behaviour	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Bladder neoplasm	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Complement factor	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hungry bone syndrome	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Steroid dependence	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Blast crisis in myelogenous leukaemia	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Staphylococcal osteomyelitis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Acute disseminated encephalomyelitis	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Adult T-cell lymphoma/leukaemia stage III	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hodgkin's disease stage III	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Spinal cord injury cervical	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Histiocytic necrotising lymphadenitis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Solitary fibrous tumour	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Collagen disorder	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Hip arthroplasty	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Small intestinal obstruction	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Small cell lung cancer limited stage	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hypersexuality	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Coeliac artery stenosis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Herpes simplex hepatitis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Skin hyperpigmentation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hereditary non-polyposis colorectal cancer syndrome	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Hereditary hypophosphataemic rickets	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Coagulation factor increased	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Coagulation factor VIII level	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Coagulation factor	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Shigella infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Hypoaesthesia eye	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Selective polysaccharide antibody deficiency	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Angular cheilitis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Biliary colic	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Hepatic fibrosis	1 (25.0%)	0 (0.0%)	2 (50.0%)	1 (25.0%)	4
Hepatic enzyme abnormal	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Scrub typhus	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Scrotal pain	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Abscess bacterial	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Congenital syphilitic osteochondritis	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Congenital retinoblastoma	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Rotator cuff syndrome	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Chronic lymphocytic leukaemia stage 4	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Rhupus syndrome	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Rhinocerebral mucormycosis	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Rheumatoid lung	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Hypophagia	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Tonsillar inflammation	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Retroperitoneal abscess	2 (50.0%)	0 (0.0%)	2 (50.0%)	0 (0.0%)	4
Haemorrhagic disorder	3 (75.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	4
Retinal disorder	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Renal tubular acidosis	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Renal hypertension	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Renal cell carcinoma stage II	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Haematemesis	2 (50.0%)	0 (0.0%)	0 (0.0%)	2 (50.0%)	4
HIV wasting syndrome	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
HIV infection CDC category A	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Rash pustular	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Ictal bradycardia syndrome	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Radiochemotherapy	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
H1N1 influenza	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Gynaecological disorder prophylaxis	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Corneal dystrophy	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Punctate keratitis	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Grief reaction	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Tuberculosis gastrointestinal	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Pulmonary function test decreased	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Graft complication	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Psychotic behaviour	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Psychogenic seizure	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Glycosylated haemoglobin abnormal	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Pseudomonas test positive	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Pseudomonas aeruginosa meningitis	3 (75.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	4
Chloasma	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Protothecosis	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Tyrosine kinase mutation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Glossopharyngeal neuralgia	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Protein S deficiency	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Unknown immunisation status	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Chemotherapy multiple agents systemic	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Progressive supranuclear palsy	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Progesterone receptor assay negative	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Product substitution issue	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Product prescribing issue	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Androgen therapy	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Adhesion	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cervix carcinoma stage II	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Presumed ocular histoplasmosis syndrome	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Prescription drug used without a prescription	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Cervicogenic headache	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Urethritis	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Premature rupture of membranes	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
General physical condition abnormal	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Precursor B-lymphoblastic lymphoma	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Postprandial hypoglycaemia	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Urinary tract infection fungal	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Posterior fossa syndrome	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Post-traumatic epilepsy	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Blood creatinine increased	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cerebral venous sinus thrombosis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Post procedural inflammation	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Gastrointestinal scan	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Ileal stenosis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Corynebacterium bacteraemia	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Cerebral nocardiosis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Gastrointestinal hypomotility	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Polymenorrhagia	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Gastroenteritis salmonella	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Pneumonia pneumococcal	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Gastroduodenal ulcer	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Incorrect dose administered	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Axillary pain	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Pleurodesis	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Pleural mesothelioma malignant recurrent	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Cerebrovascular insufficiency	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Plasmodium falciparum infection	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Placental disorder	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastrectomy	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Gangrene	0 (0.0%)	1 (25.0%)	0 (0.0%)	3 (75.0%)	4
Pituitary cancer metastatic	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Physical examination	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Photophobia	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Furuncle	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Fungal oesophagitis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Fungal foot infection	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Persecutory delusion	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Peroneal nerve palsy	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Fundoscopy	2 (50.0%)	2 (50.0%)	0 (0.0%)	0 (0.0%)	4
Analgesic drug level	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Autoimmune myositis	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Frequent bowel movements	1 (25.0%)	1 (25.0%)	1 (25.0%)	1 (25.0%)	4
Peripheral sensorimotor neuropathy	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Infectious pleural effusion	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Cauda equina syndrome	0 (0.0%)	3 (75.0%)	0 (0.0%)	1 (25.0%)	4
Peripheral artery bypass	0 (0.0%)	1 (25.0%)	2 (50.0%)	1 (25.0%)	4
Fournier's gangrene	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Peripheral T-cell lymphoma unspecified stage IV	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (100.0%)	4
Foot operation	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Periorbital oedema	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Perioral dermatitis	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Catheter placement	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Follicular thyroid cancer	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Pericarditis tuberculous	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Adenoma benign	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pelvic mass	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Pelvic inflammatory disease	1 (25.0%)	2 (50.0%)	1 (25.0%)	0 (0.0%)	4
Pathological fracture prophylaxis	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Autoimmune encephalopathy	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Procedural complication	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Parasomnia	0 (0.0%)	2 (50.0%)	1 (25.0%)	1 (25.0%)	4
Carotid artery aneurysm	0 (0.0%)	0 (0.0%)	2 (50.0%)	2 (50.0%)	4
Carotid arteriosclerosis	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Fibrodysplasia ossificans progressiva	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Feminisation acquired	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Feeling cold	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Pancreatic enzymes	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Atypical mycobacterial lower respiratory tract infec	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Pancreatic carcinoma stage I	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Pancreatectomy	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Fatty acid oxidation disorder	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Palindromic rheumatism	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Cardiomegaly	0 (0.0%)	1 (25.0%)	1 (25.0%)	2 (50.0%)	4
Oxygen saturation	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Anal abscess	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Failure to thrive	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Cyclic vomiting syndrome	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Ovarian epithelial cancer recurrent	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Insulin therapy	0 (0.0%)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4
Atrioventricular septal defect	4 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4
Otorrhoea	1 (25.0%)	0 (0.0%)	3 (75.0%)	0 (0.0%)	4
Factor I deficiency	1 (25.0%)	2 (50.0%)	0 (0.0%)	1 (25.0%)	4

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Facial spasm	2 (50.0%)	0 (0.0%)	0 (0.0%)	2 (50.0%)	4
Osteopathic treatment	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Cardiac monitoring	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Osteogenesis imperfecta	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Oropharyngeal discomfort	1 (25.0%)	3 (75.0%)	0 (0.0%)	0 (0.0%)	4
Anaesthesia reversal	0 (0.0%)	3 (75.0%)	1 (25.0%)	0 (0.0%)	4
Eye operation	0 (0.0%)	0 (0.0%)	1 (25.0%)	3 (75.0%)	4
Atopy	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Eye irrigation	0 (0.0%)	0 (0.0%)	3 (75.0%)	1 (25.0%)	4
Opsoclonus myoclonus	3 (75.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	4
Exudative retinopathy	2 (50.0%)	1 (25.0%)	1 (25.0%)	0 (0.0%)	4
Oligoarthritis	1 (25.0%)	1 (25.0%)	2 (50.0%)	0 (0.0%)	4
Carcinoid tumour of the stomach	0 (0.0%)	2 (50.0%)	2 (50.0%)	0 (0.0%)	4
Oestrogen receptor assay positive	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Extracorporeal circulation	0 (0.0%)	0 (0.0%)	4 (100.0%)	0 (0.0%)	4
Anaemia vitamin B12 deficiency	0 (0.0%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	4
Oesophageal disorder	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Oedema mucosal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ocular vasculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Ocular myasthenia	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Capillary leak syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Capillary disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Nutritional condition abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Escherichia urinary tract infection	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Escherichia sepsis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Asthma exercise induced	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Non-Hodgkin's lymphoma stage III	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cancer screening	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Campylobacter test	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Epstein-Barr virus test positive	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Neutrophil count abnormal	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Neutropenic infection	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Episcleritis	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Epiphyseal disorder	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Epileptic psychosis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Neuromyopathy	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Neurogenic bowel	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Neuroendocrine tumour of the lung metastatic	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Epididymal cancer	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Neurectomy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
CHARGE syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Amputation stump pain	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Eosinophilic angiocentric fibrosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Nephrocalcinosis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Aspergilloma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
CANDLE syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Enzyme abnormality	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Necrosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Arthroscopy	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Nail infection	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Enema administration	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
NTRK gene fusion cancer	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Myxoedema coma	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Myometritis	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Myokymia	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Myeloid leukaemia in remission	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Myelodysplastic syndrome with single lineage dysplas	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Myelodysplastic syndrome transformation	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Bullous impetigo	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Mutism	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Endocarditis candida	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Muscle twitching	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Radioisotope scan	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Multisystem inflammatory syndrome in adults	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Multiple congenital abnormalities	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Mucosal disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Embolic cerebral infarction	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Amaurosis fugax	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Bronchitis bacterial	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Electroencephalogram abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Electrocardiogram ST segment elevation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Electrocardiogram QT prolonged	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Electrocardiogram QRS complex prolonged	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Mite allergy	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Arteriogram	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Milk-alkali syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Bronchial artery embolisation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Early onset familial Alzheimer's disease	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Metastatic salivary gland cancer	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Metastases to spinal cord	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Arterial graft	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Breast cyst	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Breast cellulitis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Abnormal dreams	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Metastases to abdominal wall	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Abdomen scan	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Metabolic abnormality management	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Dyschezia	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Mental fatigue	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Menstrual discomfort	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Breast adenoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Meniere's disease	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Melanoma recurrent	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Aptyalism	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Megacolon	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Drug provocation test	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Mediastinal fibrosis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Mediastinal abscess	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Meckel's cave tumour	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Measles	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Drainage	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Donor specific antibody present	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Diverticulum intestinal	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Diverticulum gastric	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Malignant respiratory tract neoplasm	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Bradykinesia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Dissociative disorder	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Apocrine breast carcinoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Malignant neoplasm of spinal cord	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Malignant melanoma in situ	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Malignant histiocytosis	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Malignant anorectal neoplasm	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Magnetic resonance imaging joint	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Apheresis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Aphasia	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Bone marrow disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Lymphatic malformation	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Dientamoeba infection	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Diastolic dysfunction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lymphadenopathy mediastinal	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Lymphadenitis	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Lupus enteritis	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Diabetic ketosis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Allergic transfusion reaction	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Lung carcinoma cell type unspecified stage I	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Diabetic dyslipidaemia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Bone density increased	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Lower limb fracture	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
DiGeorge's syndrome	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Aortic stent insertion	1 (33.3%)	0 (0.0%)	0 (0.0%)	2 (66.7%)	3
Liver sarcoidosis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Device physical property issue	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lithotripsy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lipoprotein metabolism disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Lipoprotein (a) abnormal	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Lipodystrophy acquired	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Accidental overdose	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Ligament sprain	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Blood zinc decreased	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Dermatillomania	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Lemierre syndrome	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Alcoholic liver disease	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Blood triglycerides decreased	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Laryngeal cancer stage III	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Large intestine polyp	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Large cell lung cancer stage IV	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Lactation insufficiency	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Antithrombin III deficiency	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Blood stem cell harvest	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Klebsiella urinary tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Kernicterus	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Kaposiform haemangioendothelioma	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Decreased interest	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Kaposi sarcoma inflammatory cytokine syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
KMT2A gene mutation	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Juvenile spondyloarthritis	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Dacryocystitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Alcohol detoxification	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Blood potassium increased	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Janus kinase 2 mutation	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Isosporiasis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Iron metabolism disorder	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Involuntary commitment	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Blood phosphorus abnormal	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Albuminuria	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Intraocular lens implant	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Antineutrophil cytoplasmic antibody positive	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Intestinal congestion	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Cystic fibrosis related diabetes	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Xanthomatosis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Blood loss anaemia	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Alanine aminotransferase	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Wolff-Parkinson-White syndrome	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
White coat hypertension	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cyclothymic disorder	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Blood insulin increased	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Blood insulin abnormal	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Injection site rash	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Vitreous haemorrhage	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Injection	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vitamin B6 deficiency	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vitamin B12	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Visual snow syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Visual field defect	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Cutaneous T-cell lymphoma stage II	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Visual acuity reduced	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Very long-chain acyl-coenzyme A dehydrogenase defi	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Vertigo positional	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ventricular tachyarrhythmia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood glucose fluctuation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Infectious mononucleosis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Infection reactivation	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vasodilation procedure	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Infected cyst	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Vascular stenosis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Vascular access complication	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Vanishing bile duct syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Craniopharyngioma	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Uveitic glaucoma	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Uterine haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Urine flow decreased	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Ureteral disorder	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ultrasound urinary system	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Ultrasound kidney	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Immune-mediated encephalitis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Soft tissue swelling	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Type 2 lepra reaction	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Corneal disorder	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Trichomoniasis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Treatment noncompliance	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Transplantation complication	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
IRVAN syndrome	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Conversion disorder	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Ageusia	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Transitional cell cancer of renal pelvis and ureter	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Trace element deficiency	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Topical steroid withdrawal reaction	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Tonsillitis streptococcal	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Tonsillar hypertrophy	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Conjunctival hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Tinea versicolour	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Tilt table test	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Thyroid operation	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Hypoglobulinaemia	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Thymoma malignant	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Congenital multiplex arthrogryposis	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Thrombosis with thrombocytopenia syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Congenital hypothyroidism	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Hydrotherapy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Testicular pain	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Testicular failure	0 (0.0%)	1 (33.3%)	0 (0.0%)	2 (66.7%)	3
Bleeding time prolonged	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Tendon pain	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Hyperpyrexia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Computerised tomogram aorta	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Hyperinsulinaemic hypoglycaemia	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Suspected COVID-19	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Bladder transitional cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Composite lymphoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Subdural abscess	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Subcutaneous emphysema	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Hyperaesthesia	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Stoma site reaction	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Stem cell donor	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Human epidermal growth factor receptor positive	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Stasis dermatitis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Stargardt's disease	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Hypernatraemia	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Hospitalisation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Squamous cell breast carcinoma	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Sputum retention	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Sputum purulent	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Systemic mycosis	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Anorectal stenosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Spinal operation	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hodgkin's disease mixed cellularity refractory	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Spinal column injury	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Spina bifida	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Histiocytic sarcoma	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Speech disorder	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hip surgery	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Adrenoleukodystrophy	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Skin wound	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Skin erosion	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Biopsy skin	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Sinusitis fungal	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Coagulation factor deficiency	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Hereditary alpha tryptasaemia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Therapy change	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Adrenocorticotrophic hormone deficiency	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Sialoadenitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Shoulder operation	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Shoulder injury related to vaccine administration	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Biliary tract infection	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Clostridium colitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Serratia infection	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hepatitis A immunisation	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Separation anxiety disorder	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Clinical trial participant	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Selective IgM immunodeficiency	1 (33.3%)	1 (33.3%)	0 (0.0%)	1 (33.3%)	3
Hepatic cancer stage IV	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Hepatic cancer recurrent	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Congenital nephrotic syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Hepatic amoebiasis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Schnitzler's syndrome	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Hemiplegia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Scan thyroid gland	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Hemianopia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Helminthic infection	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Saliva altered	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Activated PI3 kinase delta syndrome	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Hypokinesia	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Right ventricular dysfunction	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Rhinovirus infection	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Rheumatoid nodule	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Rheumatic fever	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Blood aldosterone decreased	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tongue neoplasm	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Retinoschisis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Chronic infantile neurological cutaneous and articul	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Retinal vascular occlusion	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Retinal oedema	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Retinal degeneration	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Retching	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Resuscitation	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Toxic shock syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Respiratory tract infection viral	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Angioimmunoblastic T-cell lymphoma stage III	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Respiratory therapy	1 (33.3%)	0 (0.0%)	0 (0.0%)	2 (66.7%)	3
Blood bicarbonate decreased	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Benign lung neoplasm	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Haemoglobin C disease	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Benign hydatidiform mole	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Renal artery stenosis	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3
Transaminases increased	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Refeeding syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Red blood cell count	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Rectal cancer stage II	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Actinomyces test positive	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
HIV infection CDC Group IV subgroup E	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Rasmussen encephalitis	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Rash papular	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
HER2 positive bladder cancer	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Rabies	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Quadriplegia	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Cholinergic syndrome	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pyoderma	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Growth of eyelashes	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Pulpitis dental	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Greater trochanteric pain syndrome	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Barium swallow	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Pulmonary toxicity	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Balance test	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Tuberculosis immunisation	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Graft versus host disease oral	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Pulmonary eosinophilia	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Pulmonary artery stenosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Puberty	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Goodpasture's syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Pseudomembranous colitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Tumour haemorrhage	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Proteus infection	1 (33.3%)	0 (0.0%)	0 (0.0%)	2 (66.7%)	3
Ultrasound liver	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Prostatic obstruction	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Unknown schedule of product administration	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Propionic acidaemia	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Prophylaxis against bronchospasm	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Glaucoma surgery	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Bacterascites	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Prolymphocytic leukaemia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Acute haemolytic transfusion reaction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chemotherapeutic drug level above therapeutic	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Gingival bleeding	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Procedural hypertension	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Procedural anxiety	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Genitourinary symptom	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Primary insulin like growth factor-1 deficiency	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Urethral disorder	0 (0.0%)	1 (33.3%)	1 (33.3%)	1 (33.3%)	3
Priapism	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Ureterolithiasis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Premature labour	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Cervical spinal stenosis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Gene mutation	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Gastrointestinal vascular malformation haemorrhagic	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
B-cell prolymphocytic leukaemia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Urine output decreased	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Gastrointestinal procedural complication	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Immune-mediated pancreatitis	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Cerebral oedema management	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Polyneuropathy alcoholic	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Inclusion body myositis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pneumonitis aspiration	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Azoospermia	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Blood electrolytes abnormal	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cerebral aspergillosis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Cerebral artery stenosis	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Gastric ulcer haemorrhage	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Increased upper airway secretion	1 (33.3%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	3

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Axillary nerve injury	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Anaphylaxis treatment	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Gastric neuroendocrine carcinoma	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Pleomorphic adenoma	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Gastric mucosal lesion	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Cerebellar haemorrhage	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Plasmapheresis	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Cerebellar ataxia	1 (33.3%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	3
Central serous chorioretinopathy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Cryofibrinogenaemia	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Pituitary apoplexy	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Infantile genetic agranulocytosis	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Automatic bladder	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Acquired generalised lipodystrophy	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Pharyngeal swelling	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Personality change	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Frustration tolerance decreased	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Frontotemporal dementia	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Anticoagulation drug level therapeutic	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Fragile X syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Peripheral blood stem cell apheresis	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Autoimmune lymphoproliferative syndrome	2 (66.7%)	1 (33.3%)	0 (0.0%)	0 (0.0%)	3
Peripheral artery stenosis	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Peripheral artery angioplasty	1 (33.3%)	0 (0.0%)	0 (0.0%)	2 (66.7%)	3
Catheter site pain	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Anal sphincter hypertonia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Periodic limb movement disorder	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vibrio vulnificus infection	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Pelvic fracture	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Viral myelitis	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Cutaneous T-cell lymphoma stage I	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Floating-Harbor syndrome	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Parathyroid tumour malignant	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Fibrosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Fibrosarcoma	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Paranasal sinus discomfort	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Injection site erythema	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Paradoxical pain	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Injection site pruritus	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Papilloma viral infection	1 (33.3%)	2 (66.7%)	0 (0.0%)	0 (0.0%)	3
Cutaneous symptom	0 (0.0%)	0 (0.0%)	1 (33.3%)	2 (66.7%)	3
Femur fracture	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)	3
Panniculitis lobular	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Panic reaction	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Pancreatitis necrotising	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Feeling of despair	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Febrile convulsion	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Cardiopulmonary failure	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Cardiopulmonary bypass	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Fasciitis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Cardio-respiratory arrest	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
POEMS syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Atrophy	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Fallot's tetralogy	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cardiac tamponade	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Ovarian hyperstimulation syndrome	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Ovarian germ cell teratoma	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Wernicke's encephalopathy	1 (33.3%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	3
Faecaloma	2 (66.7%)	0 (0.0%)	1 (33.3%)	0 (0.0%)	3
Factor VIII inhibition	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Osteonecrosis	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Eyelid infection	2 (66.7%)	0 (0.0%)	0 (0.0%)	1 (33.3%)	3
Oropharyngeal candidiasis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Oropharyngeal cancer recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3
Organ donor	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Oral disorder	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Cystic fibrosis gastrointestinal disease	3 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3
Eye drop instillation	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Optic ischaemic neuropathy	0 (0.0%)	0 (0.0%)	2 (66.7%)	1 (33.3%)	3
Atherosclerosis prophylaxis	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Ophthalmological examination	0 (0.0%)	2 (66.7%)	1 (33.3%)	0 (0.0%)	3
Oophorectomy bilateral	0 (0.0%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3
Onychoclasia	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Oestradiol increased	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3
Oesophagogastrroduodenoscopy	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	3
Exposure to toxic agent	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oesophageal perforation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Exposure keratitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Oesophageal obstruction	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Oesophageal neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Exfoliation glaucoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Oedema due to renal disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Excessive cerumen production	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Ocular sarcoidosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Occipital lobe stroke	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Obsessive-compulsive symptom	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Obliterative bronchiolitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Candida test positive	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Nosocomial infection	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Norovirus infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Erythrodermic atopic dermatitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cancer surgery	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Erythema nodosum	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Non-Hodgkin's lymphoma unspecified histology aggress	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Erythema dyschromicum perstans	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Non-Hodgkin's lymphoma stage I	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Nodal marginal zone B-cell lymphoma stage IV	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Newborn persistent pulmonary hypertension	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Calculus urinary	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Calcium metabolism disorder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Neurosyphilis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neurosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Neuropsychiatric syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neuropathic arthropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neuronal ceroid lipofuscinosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Calcification metastatic	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Neuromyotonia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Epilepsia partialis continua	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Aspiration pleural cavity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neurological examination abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
CSF pressure	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Epidural injection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Acute stress disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Neuroendocrine carcinoma of the bladder	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Neuroendocrine carcinoma of prostate	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neuroendocrine cancer of the prostate metastatic	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neuroectodermal neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neurodegeneration with brain iron accumulation disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Aspergillus test positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
COPD assessment test	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Nephroprotective therapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Nephrogenic diabetes insipidus	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
CHA2DS2-VASc annual stroke risk high	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Eosinophil count increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Neoplasm skin	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Amputation	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Aspartate aminotransferase	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Neonatal pulmonary hypertension	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Nematodiasis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neisseria infection	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Enterocutaneous fistula	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neck plastic surgery	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Neck injury	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bursitis infective	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Enterocolitis bacterial	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Artificial heart implant	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Nasal septal operation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Burns third degree	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Nasal obstruction	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Nasal irrigation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Enterobiasis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Nasal dryness	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Nasal discharge discolouration	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Burnout syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Burning mouth syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Enteral nutrition	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Nail discolouration	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Burn oesophageal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Myxofibrosarcoma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Myxoedema	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Endoscopy small intestine	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Myotonia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Endometrial sarcoma metastatic	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Burkholderia pseudomallei infection	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Endometrial sarcoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endometrial disorder	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Endometrial cancer stage II	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Mycotic endophthalmitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mycobacterium tuberculosis complex test	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Endodontic procedure	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bullous haemorrhagic dermatosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Endocrine neoplasm malignant	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bulbar palsy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Endocarditis noninfective	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endocarditis histoplasma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Muscle strength abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Endarterectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Muscle rigidity	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Amino acid metabolism disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Brugada syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Encephalitis viral	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Brow ptosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mumps immunisation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Bronchostenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Encapsulating peritoneal sclerosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Multiple-drug resistance	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Amino acid level increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Artery dissection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Bronchoscopy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Emphysematous pyelonephritis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Multi-vitamin deficiency	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Mueller's mixed tumour	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mucosal infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Arteriovenous fistula operation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bronchopneumopathy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Mucocutaneous disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mucocutaneous candidiasis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Mucinous adenocarcinoma of appendix	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Monoplegia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Monoclonal B-cell lymphocytosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Molluscum contagiosum	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Elbow operation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Ejection fraction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mitral valve stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Mitral valve prolapse	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Altered state of consciousness	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Bronchial obstruction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mismatched donor bone marrow transplantation therapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mismatch repair cancer syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Bronchial neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Eczema asteatotic	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Miosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Alport's syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Microscopic enteritis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Early onset primary dystonia	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Alpha-mannosidosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Ear pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Ear neoplasm malignant	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Brief psychotic disorder with marked stressors	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Breath sounds abnormal	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Ear congestion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Metastases to urinary tract	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Metastases to thorax	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Arterial haemorrhage	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Metastases to stomach	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Metastases to soft tissue	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dyssomnia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Alpha-1 anti-trypsin	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Breast hyperplasia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Metastases to kidney	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Metastases to heart	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Metabolic encephalopathy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Metabolic disorder prophylaxis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Meralgia paraesthetica	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Mental status changes	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Menstruation delayed	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Dupuytren's contracture	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Menopausal depression	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Meningoradiculitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Meningoencephalitis amoebic	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Meningitis candida	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Application site reaction	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Medical procedure	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Application site discolouration	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Brain radiation necrosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Drug level increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mechanical ileus	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Brain neoplasm benign	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Maternal distress during labour	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Brain malformation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Mastitis bacterial	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Mastitis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Brain fog	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Manic symptom	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mammoplasty	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diverticulitis intestinal perforated	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Mammogram	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Malignant pleural effusion	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Distributive shock	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Malignant neoplasm papilla of Vater	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Malignant neoplasm of uterine adnexa	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Allergy to plants	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Disseminated mucormycosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Malignant hydatidiform mole	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Disorder of orbit	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Malignant atrophic papulosis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Disease susceptibility	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Magnetic resonance imaging renal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Disease complication	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Magnetic resonance imaging prostate	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bone scan	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Apical granuloma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Magnetic resonance imaging hepatobiliary	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Madarosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Macroprolactinaemia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Acute macular neuroretinopathy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Diffuse idiopathic skeletal hyperostosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diarrhoea haemorrhagic	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lupus cystitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Aortitis salmonella	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Bone graft	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bone giant cell tumour malignant	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Lung squamous cell carcinoma stage II	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Diabetic eye disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lower respiratory tract congestion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Aortic thrombosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Body temperature abnormal	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Device dislocation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lipoprotein increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Lipoprotein deficiency	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Lipoprotein abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lipoedema	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Alkalosis hypochloraemic	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Dermatophytosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lip blister	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Light anaesthesia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Lichenification	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood urine present	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Dermal filler injection	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Dermal cyst	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acute lung injury	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Leiomyoma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Dental plaque	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anuria	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Leber's congenital amaurosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Laryngopharyngitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Laryngeal squamous cell carcinoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Large intestinal ulcer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood thyroid stimulating hormone	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Language disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Antiviral drug level	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Delusional disorder, somatic type	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lactobacillus bacteraemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Delusion of replacement	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Lactation disorder	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Lacrimation decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Labile hypertension	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Alcohol use	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Delayed puberty	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Kleefstra syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Blood sodium	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Deficiency anaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Keratitis fungal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Junctional ectopic tachycardia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Dactylitis	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Blood pressure ambulatory	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Dacryoadenitis acquired	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
DNA antibody negative	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Jejunostomy	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Acute interstitial pneumonitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Iritis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Invasive papillary breast carcinoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
ALK gene rearrangement positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Intrauterine infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Antinuclear antibody negative	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood osmolarity decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Blood osmolarity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cystitis klebsiella	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Albright's disease	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Intestinal transit time	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Intestinal pseudo-obstruction	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Intestinal haemorrhage	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Antineutrophil cytoplasmic antibody negative	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Blood oestrogen abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cystic lung disease	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Yellow fever immunisation	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Interstitial lung abnormality	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cystic fibrosis carrier	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
X-ray	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Wrong schedule	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Blood iron increased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Acute hepatitis B	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
White blood cell disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
White blood cell count	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Insulin-like growth factor abnormal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Insulin resistant diabetes	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Walking disability	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vulvovaginal injury	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Blood insulin	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vulvitis	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Injection site irritation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Volume blood decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vocal cord dysfunction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood immunoglobulin E increased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Cutaneous lymphoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vitreous floaters	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Vitamin B12 abnormal	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Cutaneous T-cell lymphoma stage III	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Influenza A virus test positive	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Viral labyrinthitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Viraemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Airway secretion clearance therapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vertebrobasilar insufficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Culture stool positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Inferior vena caval occlusion	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Venous occlusion	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Venous angioplasty	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Vein disorder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Infection parasitic	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infected skin ulcer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Vasoactive intestinal polypeptide test abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infected bite	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Vascular occlusion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Induction of cervix ripening	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Anticoagulation drug level abnormal	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Varicella immunisation	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Vaginal douching	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anticoagulation drug level	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Incision site cellulitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Blood disorder prophylaxis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Uterine neoplasm	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Acute haemorrhagic conjunctivitis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Uterine contractions abnormal	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Urine odour abnormal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Urine analysis abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Urinary tract infection enterococcal	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Urinary tract disorder prophylaxis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood creatine phosphokinase increased	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Cortisol decreased	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Blood corticotrophin decreased	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Upper respiratory tract congestion	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Unwanted pregnancy	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Immune-mediated neurological disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Coronary artery insufficiency	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Umbilical hernia repair	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ultrafiltration failure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Immune-mediated adverse reaction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tumour of ampulla of Vater	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Antibiotic level	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tuberculin test positive	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Truncus coeliacus thrombosis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Troponin increased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Trisomy 8	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Trismus	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Traumatic haematoma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ichthyosis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
IVth nerve paralysis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Transitional cell carcinoma recurrent	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Transient hypogammaglobulinaemia of infancy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blood calcium	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Transfusion-related acute lung injury	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tracheal dilatation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypotonic urinary bladder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Blood bicarbonate	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Toxic encephalopathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hyposmia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Tooth restoration	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Tooth impacted	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Tonsillar disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Tongue cancer recurrent	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Tissue adhesion prophylaxis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Tinea infection	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Tinea cruris	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypogonadism male	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Thyroid stimulating hormone deficiency	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Thyroid neoplasm	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bloch-Sulzberger syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hypoferritinaemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anti-cyclic citrullinated peptide antibody positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Thymectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypoaesthesia oral	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hypnotherapy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Hypnic headache	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Thermohyperaesthesia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Therapy cessation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Therapeutic ovarian suppression	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Therapeutic gargle	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tetanus immunisation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Congenital coronary artery malformation	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Testicular disorder	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Terminal state	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Tenosynovitis stenosans	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Tattoo	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Hyperplasia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Blastocystis infection	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
T-cell lymphoma refractory	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anti-GAD antibody	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Computerised tomogram limb	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypermobility syndrome	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Hyperleukocytosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Swollen tongue	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hyperhomocysteinaemia	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Hyperglycaemic hyperosmolar nonketotic syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Superior mesenteric artery syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anterior chamber inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Hypercholia	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Subperiosteal abscess	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Subdural hygroma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Complication associated with device	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bladder operation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Subacute hepatic failure	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anovulatory cycle	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Strongyloidiasis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Stress management	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Stress cardiomyopathy	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Streptococcus test positive	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Stoma site pain	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Hydrocephalus	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Stoma site abscess	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Bladder irritation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Anosmia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Stoma care	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Coma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Stenotrophomonas test positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Symptom recurrence	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Human herpesvirus 8 infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Stenotrophomonas bacteraemia	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Anorgasmia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Human herpes virus 8 test positive	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Status dystonicus	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Staphylococcus test positive	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Staphylococcal skin infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bladder discomfort	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Colorectal cancer recurrent	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Sputum discoloured	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sputum culture positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bladder catheterisation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Spondylolysis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Homicide	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Anorectal disorder	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Spinal myelogram	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Spinal cord infarction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bladder cancer stage 0, with cancer in situ	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Speech disorder developmental	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Collateral circulation	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Hip fracture	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
High-resolution computerised tomogram of lung	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Solar lentigo	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Soft tissue disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hyperparathyroidism tertiary	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Sodium retention	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Social problem	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Colitis ischaemic	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Birdshot chorioretinopathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
High density lipoprotein decreased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Sleeve gastrectomy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Sleep study	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Coarctation of the aorta	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Herpes ophthalmic	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Skin haemorrhage	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Coagulation time prolonged	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Skin depigmentation	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Hereditary leiomyomatosis renal cell carcinoma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Skin candida	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Skin burning sensation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Ankle fracture	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Biopsy breast	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Sinusitis aspergillus	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Biopsy bone marrow	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Sinus pain	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Acute chest syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Sinus bradycardia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Sideroblastic anaemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hepatitis D	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Sexually active	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Serum serotonin decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Animal attack	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Biliary tract disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Serum ferritin increased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Serositis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Biliary sepsis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Septic embolus	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Septic cardiomyopathy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Septal myectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sensory processing disorder	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Senile dementia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Self-destructive behaviour	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Hepatic hydrothorax	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Sedation complication	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Hypofibrinogenaemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Biliary cirrhosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hepatic encephalopathy prophylaxis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Citrobacter bacteraemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cirrhosis alcoholic	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Angiosarcoma recurrent	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hepatic angiogram	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sciatic nerve neuropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Heparin neutralisation therapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bile acids	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Sarcomatoid mesothelioma	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Sarcoidosis of lymph node	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Heavy chain disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Heat illness	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
AIDS related complex	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Sacroiliac joint dysfunction	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Congestive hepatopathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Head discomfort	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Rheumatoid scleritis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hashimoto's encephalopathy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Rheumatic heart disease	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
African trypanosomiasis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Chronic lymphocytic inflammation with pontine periva	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Conjunctival irritation	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hypometabolism	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Conjunctival scar	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Hair transplant	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Restrictive pulmonary disease	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Chronic graft versus host disease oral	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Haemophilic arthropathy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Haemophilia carrier	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Respiratory papilloma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Respiratory fume inhalation disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Respiratory depression	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Reocclusion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Benign lymph node neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Contrast echocardiogram	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Renal vein thrombosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Renal tubular necrosis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Haemoglobin	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Renal stone removal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Haemodynamic rebound	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Renal lithiasis prophylaxis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Renal injury	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Haemodialysis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Renal infarct	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Renal cyst	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Trans-sexualism	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Hypovolaemic shock	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Haematological infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Renal cancer stage III	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Haematocrit abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Renal aneurysm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Haemangioma of liver	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Refraction disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Haemangioma congenital	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Red blood cell count decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Red blood cell count abnormal	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Hysterosalpingogram	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Red blood cell abnormality	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
HIV-2 infection	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
HIV test negative	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Rectal neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Rectal abscess	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Adrenal adenoma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Rash morbilliform	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Chorea	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Radiotherapy to prostate	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Basal ganglion degeneration	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Chondrosarcoma metastatic	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Radioimmunotherapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
HELLP syndrome	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Radiation pneumonitis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
RPE65 gene mutation	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Basal ganglia infarction	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pyogenic sterile arthritis pyoderma gangrenosum and	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Angiodysplasia	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pupillary reflex impaired	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cholera	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cholecystitis chronic	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Granulomatous dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Gram stain positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pulmonary dysmaturity syndrome	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Bacteroides infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cholangitis infective	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pulmonary artery aneurysm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Bacteroides bacteraemia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cholangiosarcoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pterygium	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Tumour excision	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gorham's disease	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Psychophysiologic insomnia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Glycosylated haemoglobin decreased	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Choanal atresia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pseudocyst	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pseudoaldosteronism	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Bacterial test	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pruritus genital	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Glomerulonephropathy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Protein C deficiency	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Prosthetic cardiac valve calcification	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Prostatitis Escherichia coli	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Undifferentiated connective tissue disease	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Glomerular vascular disorder	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Glomerular filtration rate decreased	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Prostate cancer stage 0	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Prophylaxis of abortion	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gleason grading score	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Glaucomatous optic neuropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Glaucoma drug therapy	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Acral lentiginous melanoma stage III	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Chemotherapy cardiotoxicity attenuation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gingival swelling	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Product dispensing issue	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Chapped lips	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Procedural vomiting	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Androgen replacement therapy	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Germ cell cancer metastatic	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Primary pulmonary melanoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Genitourinary tract neoplasm	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Primary mediastinal large B-cell lymphoma stage IV	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Antibody test abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Genitourinary melanoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Primary ciliary dyskinesia	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Urethral stenosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Genital infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Immunoglobulins	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Genital candidiasis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Urethral meatus stenosis	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Premature menopause	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Precursor T-lymphoblastic lymphoma/leukaemia stage I	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Postural tremor	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Urinary tract infection pseudomonal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Postpericardiotomy syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Postpartum anxiety	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anastomotic complication	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Postinfarction angina	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Post-traumatic pain	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Implant site infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Anticipatory anxiety	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Post procedural sepsis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Post procedural hypotension	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Abdominal cavity drainage	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Anaplastic meningioma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gastrointestinal neuroendocrine carcinoma	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Positron emission tomogram prostate	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Gastrointestinal necrosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Cerebral microinfarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Polyradiculoneuropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cerebral ischaemia	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2
Polypectomy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Uterine polyp	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Gastrointestinal disorder congenital	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Cranial nerve neoplasm benign	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Gastrointestinal carcinoma in situ	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pneumoperitoneum	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pneumonia respiratory syncytial viral	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pneumonia haemophilus	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Uterine prolapse	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pneumonia cryptococcal	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Gastrin secretion disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gastric varices haemorrhage	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cerebral arteriosclerosis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Gastric neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Increased viscosity of bronchial secretion	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Adenosquamous cell carcinoma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Plasma protein metabolism disorder	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Plasma cell leukaemia in remission	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pityriasis lichenoides et varioliformis acuta	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gastric antral vascular ectasia	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Autonomic dysreflexia	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Ganglioglioma	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pituitary cyst	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Vascular headache	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Gallbladder squamous cell carcinoma	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Phytotherapy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Gallbladder neoplasm	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Photodynamic diagnostic procedure	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Central nervous system lupus	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Galactosialidosis	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Gait inability	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Central nervous system inflammation	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Fusobacterium test positive	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pharyngeal cancer recurrent	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pharyngeal cancer	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Phakomatosis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Perthes disease	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Peroneal nerve injury	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Peritumoural oedema	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Fulminant type 1 diabetes mellitus	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cellulite	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Autoimmune neuropathy	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Peritoneal neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Peritoneal mesothelioma malignant recurrent	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Cryptogenic cirrhosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cell-mediated cytotoxicity	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Peritoneal dialysis complication	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Perirectal abscess	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Friedreich's ataxia	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Autoimmune myocarditis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Peripheral motor neuropathy	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Adenomatous polyposis coli	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Peripheral artery thrombosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Peripheral artery stent insertion	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Catheter site warmth	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Catheter site rash	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Foreign body sensation in eyes	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Autoimmune lung disease	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Catheter site infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Food craving	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pericardial disease	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anal pruritus	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Catarrh	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Penile pain	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Follicular disorder	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Penile erosion	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Anal injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Pelvic infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Foetal exposure timing unspecified	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Patent ductus arteriosus repair	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Parvimonas micra infection	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Parkinsonian crisis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Infusion site pruritus	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Autoimmune demyelinating disease	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Parathyroid disorder	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Fistula	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Parasitic gastroenteritis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fibrous histiocytoma	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Fibrous dysplasia of jaw	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Paraparesis	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Paraneoplastic syndrome	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Fibroma	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anal fungal infection	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Fibrin D dimer increased	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Fibrillary glomerulonephritis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Femoral neck fracture	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Female reproductive tract disorder	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Female reproductive neoplasm	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pancreaticoduodenectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Feeling hot	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Pancreatic enzymes increased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Feeling abnormal	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Pancreatic enzyme replacement therapy	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Vulvovaginal burning sensation	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pancreatic carcinoma stage IV	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Febrile infection	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fatty acid deficiency	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Fat tissue increased	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Fasting	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Pain of skin	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Paget's disease of nipple	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiac ventricular thrombosis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Familial hypocalciuric hypercalcaemia	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Oxygen consumption	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Familial hypertriglyceridaemia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Ovulation pain	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Aborted pregnancy	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Familial cold autoinflammatory syndrome	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Acquired epidermolysis bullosa	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Cardiac stress test abnormal	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Factor XIII deficiency	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Ovarian cancer stage II	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Anaesthetic ophthalmic procedure	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Cardiac murmur	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Facet joint syndrome	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Orthopaedic procedure	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Orchidopexy	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
International normalised ratio abnormal	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Eye movement disorder	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Oral surgery	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
Optic neuropathy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Atopic keratoconjunctivitis	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Optic nerve neoplasm	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Eye disorder prophylaxis	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Eye discharge	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	2
Ophthalmic herpes simplex	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2
Atelectasis	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
17-hydroxyprogesterone increased	2 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2
Extraskkeletal ossification	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Ataxia	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	2
Oliguria	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Extramedullary haemopoiesis	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Olfacto genital dysplasia	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	2
Asymptomatic gene carrier	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Extradural abscess	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Abdominal mass	1 (50.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	2
External ear pain	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	2
Oesophagoscopy	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Carcinoid tumour of the prostate	0 (0.0%)	0 (0.0%)	2 (100.0%)	0 (0.0%)	2
Oesophageal varices haemorrhage	0 (0.0%)	2 (100.0%)	0 (0.0%)	0 (0.0%)	2
Oesophageal ulcer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exposure via breast milk	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oesophageal stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Exposure to radiation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exostosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carcinoid tumour in the large intestine	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Exophthalmos	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exocrine pancreatic function test abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Oesophageal atresia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Exfoliation syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Exercise tolerance decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Excessive granulation tissue	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anaemia postoperative	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Carbohydrate antigen 125 increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Excessive gingival display	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular toxicity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Astigmatism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Capsular contracture associated with breast implant	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ocular melanoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Occipital lobe epilepsy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Euthyroid sick syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Obstructive pancreatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Capillary fragility	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Obstruction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Euglycaemic diabetic ketoacidosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nutritional supplement allergy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Normochromic anaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Escherichia test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Noninfective encephalitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Escherichia pyelonephritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cancer with a high tumour mutational burden	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Non-cirrhotic portal hypertension	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cancer staging	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erythema migrans	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Erythema annulare	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Asthenopia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Nodular lymphocyte predominant Hodgkin lymphoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nodal marginal zone B-cell lymphoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Erosive duodenitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Nipple resection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nipple disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anaemia folate deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Campylobacter colitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Epstein-Barr virus antigen positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acne fulminans	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acute undifferentiated leukaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Assisted suicide	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Neutrophil function disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Epstein Barr virus positive mucocutaneous ulcer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Epiglottitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Neuroma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aspiration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neurofibrosarcoma recurrent	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Neurofibrosarcoma metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Epididymal disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Asphyxia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Epidermal naevus syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ependymoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Neuroborreliosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neuritic plaques	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Eosinophilic otitis media	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nervous system neoplasm	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
CNS ventriculitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nephrosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nephroptosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eosinophilic cystitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
CHA2DS2-VASc annual stroke risk moderate	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Eosinophilic colitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nephritis bacterial	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nephrectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enzyme level abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
CD4 lymphocytes decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Enzyme inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Enzyme activity decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Neonatal respiratory distress syndrome prophylaxis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Enterovirus infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enterovesical fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enteropathy-associated T-cell lymphoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
C-reactive protein abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enteropathic spondylitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Amoebiasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Butterfly rash	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enterocolitis infectious	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Neck mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enterocolitis haemorrhagic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nasopharyngeal cancer metastatic	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nasal turbinate hypertrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bursa disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nasal pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Enteroclysis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enterobacter bacteraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nasal abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nail ridging	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Arthropod-borne disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enteric neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Nail operation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Nail hypertrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal lymphadenopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Abnormal loss of weight	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Amniorrhoea	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Nail atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
NTRK gene fusion positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Myxoid liposarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endothelial dysfunction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myotonic dystrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Burkitt's lymphoma stage I	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Myopic traction maculopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myopia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Myopathy toxic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Myofascitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Arthrogram	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Endometrial thickening	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myocarditis bacterial	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Arthrodesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Burkholderia mallei infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Myelomalacia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Myelodysplastic syndrome unclassifiable	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bundle branch block right	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ammonia decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Endometrial atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mycobacterium ulcerans infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Endocrine neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mycobacterial peritonitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arthritis fungal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Endocrine hypertension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mycetoma mycotic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Myasthenia gravis crisis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Musculoskeletal disorder prophylaxis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Budd-Chiari syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Muscle injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Muscle contracture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Muscle atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Muscle abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Enanthema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Multiple sclerosis relapse prophylaxis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Enamel anomaly	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Multiple fractures	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Multiple endocrine neoplasia Type 1	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Emphysematous cystitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Muir-Torre syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchopulmonary disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Emotional distress	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arteriovenous malformation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Emergency care	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mucosal haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mucopolysaccharidosis IV	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mucopolysaccharidosis III	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mucopolipidosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute phase reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Elliptocytosis hereditary	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Moyamoya disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mosaicism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mononeuropathy multiplex	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Monolid eyes	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Elderly	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mole excision	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mixed delusion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bronchial ulceration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Effusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bronchial secretion retention	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mitral valve disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mitochondrial DNA mutation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Miller Fisher syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Miliaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bronchial dysplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ectopic posterior pituitary gland	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Migrainous infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arterial tortuosity syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Middle ear inflammation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eclampsia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Middle ear disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eccrine carcinoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bronchial artery hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Micrococcus infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arterial therapeutic procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Methylenetetrahydrofolate reductase gene mutation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Arterial stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ear inflammation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Breath sounds	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Metastases to vagina	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eagle Barrett syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Metastases to the respiratory system	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Dystonic tremor	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metastases to reproductive organ	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dyspraxia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Metastases to rectum	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dyspnoea paroxysmal nocturnal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Arterial fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Breast feeding	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dysphoria	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dysphemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal injury	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Metal poisoning	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Metachromatic leukodystrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dyslexia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dysgraphia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Mesotherapy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Duodenogastric reflux	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aromatase inhibition therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Meningoencephalitis viral	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meningococcal bacteraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Meningitis pneumococcal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Meningitis leptospiral	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Breast abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Meningitis fungal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dry gangrene	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Argininosuccinate synthetase deficiency	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Membrane stabilising effect	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Melanosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Brain stem syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Meigs' syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Brain stem infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Brain stem haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Medical device pain	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Mediastinal mass	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mediastinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Drug level therapeutic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Mediastinal haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Drug level	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Application site anaesthesia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Measles immunisation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
May-Thurner syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Maternally inherited diabetes and deafness	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Drug detoxification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alloimmunisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Maternal exposure during breast feeding	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Drug clearance decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Massage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Marrow hyperplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Marginal zone lymphoma refractory	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Acute monocytic leukaemia (in remission)	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alloimmune hepatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dizziness postural	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Marfan's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Mantle cell lymphoma stage III	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Management of reproduction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Mammogram abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bradypnoea	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diverticular perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Apoptosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Disturbance in sexual arousal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Dissociative identity disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant neoplasm of thorax	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant neoplasm of spermatic cord	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Malignant neoplasm of pleura	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Disseminated neonatal herpes simplex	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Malignant neoplasm of conjunctiva	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Disinhibition	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Allergy to chemicals	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Borderline glaucoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Male sexual dysfunction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Discouragement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Magnetic resonance imaging pancreas	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Magnetic resonance imaging neck	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Discharge	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Disability	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diplopia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diplegia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Magnetic resonance cholangiopancreatography	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone non-union	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Maffucci syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Macular telangiectasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dihydropyrimidine dehydrogenase deficiency	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diffuse vasculitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Macrophage activation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bone marrow tumour cell infiltration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
MELAS syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lysozyme	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lymphoma AIDS related	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lymphocytosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone marrow infiltration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lymphocytic oesophagitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diffuse cutaneous mastocytosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aortogram	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lymphangiectasia intestinal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diarrhoea infectious	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Luteal phase deficiency	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Aortoenteric fistula	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Dialysis hypotension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lupus vulgaris	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bone growth stimulation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Diagnostic aspiration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lupus anticoagulant hypoprothrombinaemia syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Diabetic vascular disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aortitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bone giant cell tumour benign	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lung infiltration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic metabolic decompensation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lung diffusion disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lung cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bone fissure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lung carcinoma cell type unspecified stage II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lung assist device therapy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bone development abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal wall wound	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diabetic diet	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Diabetic dermopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lumbar spinal drainage complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Diabetic complication neurological	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lumbar radiculopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lumbar puncture	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Diabetes with hyperosmolarity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aortic valve calcification	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Bone densitometry	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Low density lipoprotein normal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bone demineralisation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Low cardiac output syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Local anaesthetic systemic toxicity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lobular breast carcinoma in situ	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Liver scan	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Body tinea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Device related bacteraemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Device issue	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Device infusion issue	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Liposuction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Device dependence	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Developmental hip dysplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lipoprotein (a) decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lipogranuloma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aortic dilatation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dermoid cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lip neoplasm malignant stage unspecified	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Body height	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Limb mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alkalosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dermatitis infected	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Limb asymmetry	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Body dysmorphic disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Aortic aneurysm repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ligament injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ligament disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Dermatitis artefacta	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood viscosity abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Libido increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lewis-Sumner syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Leukoplakia oral	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Leukocyturia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Leukocytosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Leukapheresis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Leukaemoid reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Alcoholic psychosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Lethargy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Leriche syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood uric acid abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Depressed level of consciousness	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Lentigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Dependence on respirator	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Leishmaniasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood urea increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dependence on oxygen therapy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dental necrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dental implantation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Latent syphilis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Dental discomfort	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laryngomalacia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Dental cleaning	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Laryngo-onycho-cutaneous syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal wall abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Laryngeal mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Dengue fever	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood thyroid stimulating hormone abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Large intestine perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Demyelinating polyneuropathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Large intestinal polypectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Large intestinal obstruction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Antiviral drug level above therapeutic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Blood thromboplastin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Large cell lung cancer stage III	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Lactose tolerance test	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lactose intolerance	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Delusional disorder, persecutory type	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood testosterone	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Lacrimal disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Laboratory test normal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Laboratory test	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Labile blood pressure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Kounis syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Knee deformity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Degenerative bone disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Kerion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood pressure systolic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Decreased ventricular preload	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Decreased ventricular afterload	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Kaposi's sarcoma AIDS related	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Decreased immune responsiveness	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Death	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Juvenile absence epilepsy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Deafness neurosensory	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood pressure diastolic increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Joint noise	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Joint irrigation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Joint destruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint contracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint arthroplasty	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Joint ankylosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Job change	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antiphospholipid antibodies	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Jaundice	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cytomegalovirus gastritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood phosphorus decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
ACTH stimulation test	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Intraventricular haemorrhage neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intrathecal pump insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cytokine abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Accident	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute hepatitis C	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood pH	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood oestrogen increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cystitis bacterial	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intestinal mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intestinal fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood oestrogen	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cystic fibrosis respiratory infection suppression	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intervertebral disc displacement	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cystic fibrosis pancreatic	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Intervertebral disc compression	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Interventricular septum rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
pH body fluid abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood luteinising hormone abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cystic fibrosis hepatic disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Zoonotic bacterial infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Xerophthalmia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
International normalised ratio fluctuation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Internal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cystatin C	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intermittent claudication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Wrist fracture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Wound haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cyst removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Intercapillary glomerulosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Wound drainage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cyst drainage	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
White blood cell count abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
West Nile virus test positive	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood iron	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cycloplegia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Werner's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Insulin-like growth factor	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Weight gain poor	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Weight fluctuation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cyclic neutropenia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vulvovaginitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Injury of conjunctiva	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vulvovaginal swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Injury associated with device	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site warmth	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site urticaria	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Injection site swelling	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vulval cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vulval cancer metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood immunoglobulin M decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Von Willebrand's factor antigen increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Von Willebrand's factor antibody positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Von Hippel-Lindau disease	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site induration	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Accelerated hypertension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vitritis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cutaneous mucormycosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Injection site abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vitreous opacities	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Injection related reaction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Inguinal hernia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ingrown hair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood growth hormone normal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cutaneous amyloidosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Antidepressant drug level	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Blood growth hormone increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Virilism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cutaneous T-cell lymphoma refractory	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Viral haemorrhagic cystitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vibration syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anticonvulsant drug level therapeutic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vestibular paroxysmia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Inflammatory marker increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vestibular neuronitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infertility tests	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ventriculo-peritoneal shunt	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anticonvulsant drug level	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cubital tunnel syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Crystalluria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acute haemorrhagic leukoencephalitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Venomous bite	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Venogram	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Venipuncture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cryptorchism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vena cava embolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vasoplegia syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vasectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anticoagulation drug level below therapeutic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular operation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Vascular insufficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Infantile apnoea	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Vascular graft infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Infant	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vascular device user	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood fibrinogen decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Induced labour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vaginal stricture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cronkhite-Canada syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaginal pessary insertion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Blood electrolytes decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Increased bronchial secretion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Vaginal abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vaccination site pain	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vaccination site mass	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Vlth nerve paralysis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Incision site pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Uterovaginal prolapse	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Uterine pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal symptom	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cranial nerve disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Inappropriate schedule of product administration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Uterine infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Agonal respiration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Inappropriate affect	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Uterine contractions during pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
In vivo gene therapy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Implantation complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine uric acid abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Implantable defibrillator insertion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urine osmolarity decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urine osmolarity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Impaired healing	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary tract spasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Impaired fasting glucose	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood creatinine decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cortisol increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urinary tract infection staphylococcal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anticholinergic syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cortisol free urine increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urinary hesitation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Immunoglobulins abnormal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cortisol abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Urethral pain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood creatine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urethral haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urethral cancer metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immunodeficiency congenital	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urethral atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ureteric obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ureteric cancer recurrent	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Immune-mediated thyroiditis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Upper respiratory tract infection bacterial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Upper limb fracture	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Agitated depression	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Immune-mediated neuropathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Upper airway obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood corticotrophin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Unevaluable therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Undifferentiated spondyloarthritis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Coronary artery dissection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Undifferentiated nasopharyngeal carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood cholesterol normal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune-mediated hepatic disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune-mediated gastritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune-mediated encephalopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ulcer haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Typical aura without headache	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Immune-mediated cholangitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Typhoid fever immunisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Immune-mediated arthritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Antibiotic level above therapeutic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cornelia de Lange syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tumour pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tumour marker abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Corneal opacity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tumour inflammation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tumour flare	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Corneal oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Imaging procedure abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Corneal lesion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood chloride increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tuberculosis of intrathoracic lymph nodes	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tuberculosis liver	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acariasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood chloride abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Corneal erosion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Iliac artery occlusion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aggregatibacter infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Antiangiogenic therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Troponin I increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tricuspid valve disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Trichotillomania	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Idiopathic neutropenia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Idiopathic inflammatory myopathy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Treatment boosted antibody positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cor pulmonale acute	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Idiopathic CD4 lymphocytopenia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Traumatic fracture	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cooling therapy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Illrd nerve paralysis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hysterosalpingo-oophorectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Transgender operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypozaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood calcitonin increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Contrast media reaction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Transaminases decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Transaminases	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tractional retinal detachment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Trachoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Anti-platelet factor 4 antibody positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypoventilation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tracheomalacia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tracheo-oesophageal fistula	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypotrichosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tracheal stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Trabeculectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypothermia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Toxic optic neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Toxic nodular goitre	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Toxic neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypothalamic pituitary adrenal axis suppression	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Toxic goitre	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypoprothrombinaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypopnoea	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypophosphataemic osteomalacia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Blood alkaline phosphatase increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypopharyngeal neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tongue tie operation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tongue movement disturbance	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hypopharyngeal cancer recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tongue disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anti-interferon antibody positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tongue carcinoma stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tongue cancer metastatic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Tolosa-Hunt syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Conjunctival abrasion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Tissue irritation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blood albumin increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tissue injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tick-borne fever	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Thyroxine increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Congenital subglottic stenosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypokalaemic syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroxine free decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroxine decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Thyroxine abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital pulmonary airway malformation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypogonadism female	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thyroiditis chronic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abdominal rigidity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abstains from alcohol	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital osteodystrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypoglycaemia neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Congenital neuropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid hormones increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thyroid dysfunction in pregnancy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Thyroid cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypocitraturia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital musculoskeletal disorder of limbs	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thymus disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Thymoma malignant recurrent	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypoaldosteronism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Thrombotic cerebral infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Thrombopoietin level abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thrombophlebitis septic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypo HDL cholesterolaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Thrombophlebitis migrans	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anti-aquaporin-4 antibody	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital hepatitis B infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperventilation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thrombin time prolonged	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hypertrophic scar	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Thoracic radiculopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital fibrosarcoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Therapy responder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Therapy partial responder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Congenital dysfibrinogenaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Therapeutic product effect increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Congenital dyserythropoietic anaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperthermia malignant	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Therapeutic drug monitoring	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Testicular germ cell tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypertelorism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Congenital chylothorax	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hypersplenism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Teratogenicity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypersensitivity vasculitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tendon injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Telangiectasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blastomycosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Teething	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Tearfulness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Tachyphrenia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperphagia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aerophagia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
T-cell lymphoma recurrent	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Computerised tomogram liver	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Systolic hypertension	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Systolic dysfunction	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hyperoxaluria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Systemic lupus erythematosus rash	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Computerised tomogram kidney	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Systemic infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Systemic bacterial infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blast cell crisis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Computerised tomogram intestine	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypermagnesaemia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperlactacidaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hyperkinesia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Symblepharon	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Suture rupture	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Abscess of eyelid	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anterograde amnesia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Computerised tomogram abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Suspected suicide attempt	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Supraventricular tachyarrhythmia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hyperglycinaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Compression fracture	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Supine hypertension	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hyperglobulinaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypergastrinaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Superficial siderosis of central nervous system	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Superficial inflammatory dermatosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sudden visual loss	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Complications of transplanted kidney	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sudden hearing loss	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Complication of pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Substance abuser	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hyperchloraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hypercapnia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Subcorneal pustular dermatosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Complicated malaria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Subconjunctival injection procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Subacute endocarditis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stridor	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Stress fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bladder metaplasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hydrotubation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stomach mass	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Community acquired infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Stoma site erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stoma site discharge	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Combined pulmonary fibrosis and emphysema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hydrocele	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Stoma complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bladder irrigation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stent removal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Colour vision tests abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Human rhinovirus test positive	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hypermetropia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stem cell therapy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bladder hypertrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Human herpesvirus 6 infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Steatohepatitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Human ehrlichiosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Colorectal cancer stage II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Huerthle cell carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Colorectal cancer stage I	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Staphylococcal abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Stag horn calculus	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sports injury	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spontaneous heparin-induced thrombocytopenia syndrom	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spondylitic myelopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abscess neck	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Splenic infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Colon operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Splenectomy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Spinal synovial cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Spinal stroke	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anorectal discomfort	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spinal cord disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Spinal cord compression	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Spinal cord abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sperm concentration decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hirsutism	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Spasmodic dysphonia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anomalous pulmonary venous connection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hippocampal sclerosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Somnambulism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Solar urticaria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
High risk sexual behaviour	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Soft tissue injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
High risk pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
High risk infant	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Social avoidant behaviour	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Social (pragmatic) communication disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
High density lipoprotein abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
High density lipoprotein	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bipolar disorder relapse prophylaxis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Small intestinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Anogenital lichen planus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sluggishness	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Herpes zoster infection neurological	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Slipping rib syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sleep-related eating disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cogan's syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Herpes zoster cutaneous disseminated	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Herpes simplex viraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Herpes simplex pneumonia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Skin swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Skin plaque	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biphasic mesothelioma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Skin neoplasm excision	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Skin necrosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Herpes dermatitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Skin implant removal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hernia pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Skin hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Biopsy stomach	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coagulation time shortened	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Skin fibrosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hereditary spastic paraplegia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Coagulation test abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Coagulation factor inhibitor assay	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Skin adhesion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sinusitis bacterial	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sinus rhythm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coagulation factor VIII level increased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sinus operation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hepatopulmonary syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Animal scratch	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biopsy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sinus cancer metastatic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Sinonasal obstruction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blepharoplasty	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Coagulation factor V level	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Simple mastectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Coagulation factor IX level	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Sickle cell trait	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis toxoplasmal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Shunt malfunction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Biliary tract infection bacterial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hepatitis toxic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Shoulder fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis neonatal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis cholestatic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Sexually transmitted disease	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis C antibody	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sexual activity decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Severe asthma with fungal sensitisation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis B virus test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hepatitis B surface antigen	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis B immunisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis B core antibody positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Seroma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Closed fracture manipulation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatitis B DNA decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Clonic convulsion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Septic coagulopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Blister infected	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Biliary dilatation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cleft palate	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Acute biphenotypic leukaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Hepatic mass	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hepatic lesion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Seizure like phenomena	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Secretion gastric absent	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Secondary syphilis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Claustrophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Secondary hyperthyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Sebaceous gland disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Screaming	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Scratch	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bile duct stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Sclerotherapy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Scleral disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scan brain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Scan adrenal gland	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salpingitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salpingectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salmonella bacteraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Salivary gland neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Heart valve incompetence	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
STING-associated vasculopathy with onset in infancy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
SMN2 status assay	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
SARS-CoV-2 antibody test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bicytopenia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Rubella immunisation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rotavirus infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Bickerstaff's encephalitis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Right ventricular dilatation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hearing therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rickets	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Bezoar	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rhinophyma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rhinitis prophylaxis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Head and neck cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haploinsufficiency of A20	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rheumatoid bursitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Bentall procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Halo vision	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rhesus incompatibility	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Tongue injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Rhabdomyoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Angiomyolipoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Benign uterine neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Hairy cell leukaemia recurrent	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rhabdoid tumour of the kidney	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Reversal of sedation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Reversal of opiate activity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Retroperitoneum cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Retroperitoneal neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Hair texture abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retroperitoneal lymphadenopathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Hair growth rate abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Actinomycotic pulmonary infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Adrenal haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Angiolipoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign renal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retinitis pigmentosa	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Retinal vein thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retinal vascular disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Retinal tear	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign recurrent intrahepatic cholestasis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haemorrhagic ovarian cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Retinal operation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemorrhagic fever with renal syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retinal neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Retinal ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Retinal injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Angiokeratoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chronic hepatitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Haemorrhage urinary tract	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chronic hepatic failure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign ovarian tumour	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Respiratory tract neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Haemophilus influenzae type b immunisation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Respiratory tract malformation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign neoplasm of islets of Langerhans	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Respiratory tract infection bacterial	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Benign neoplasm of adrenal gland	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Respiratory arrest	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Renin-angiotensin system inhibition	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Haemoglobinuria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renin decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Actinomycosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Haemoglobin increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal-limited thrombotic microangiopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal vein embolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal tuberculosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal transplant failure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Contrast media deposition	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Renal hamartoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Renal cyst ruptured	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Chronic coronary syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Angiogram pulmonary	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Benign breast neoplasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Chronic allograft nephropathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Haematocolpos	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Benign bone neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Remission not achieved	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Chromosomal deletion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Regurgitation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Angiogram peripheral	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Regressive behaviour	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Haemangioma of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Refsum's disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Chromaturia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Red blood cell sedimentation rate abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rectosigmoid cancer stage II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Rebound effect	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Becker's muscular dystrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rathke's cleft cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Rash vesicular	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rash papulosquamous	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chorioretinal disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
HIV antigen	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Basilar artery occlusion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
HER2 positive salivary gland cancer	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rapid eye movements sleep abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Rapid correction of hyponatraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radius fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Angiofibroma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Radiosensitisation therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radiologically isolated syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Basal ganglia stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Radical hysterectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chondropathy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Radiation retinopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Radiation proctitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Adolescence	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gynaecological examination normal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Radiation injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chondroma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gynaecological examination	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Quality of life decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pyomyositis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Cholesterosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pyelonephritis fungal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bartholin's abscess	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cholestasis of pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Purpura fulminans	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pure white cell aplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Puncture site inflammation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Adnexa uteri pain	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cholelithiasis obstructive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary vascular disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Granulomatous rosacea	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary renal syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary infarction	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary imaging procedure abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary imaging procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Granulocyte count decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary haemosiderosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary haematoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary contusion	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pulmonary blastomycosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary artery thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pulmonary artery therapeutic procedure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pubertal failure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Immobile	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cholangiogram	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Psychomotor skills impaired	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Choking	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Glycosuria	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudostrabismus	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudophakia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Glucose urine present	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bacterial translocation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Glucose tolerance test	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pseudomonal skin infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Glucose tolerance impaired in pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chlamydial infection	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pseudofolliculitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adjustment disorder with mixed disturbance of emotio	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Glucocorticoids normal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pseudo Cushing's syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chimerism	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Glucocorticoids abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Providencia urinary tract infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Glucagonoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Glottis carcinoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Bacterial sepsis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Childhood depression	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Protein total decreased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Protein total abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Protein total	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Protein deficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Aneurysmal bone cyst	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Childhood asthma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Glomerulosclerosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Protein albumin ratio	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Prosthesis implantation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Aneurysm repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Chest injury	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prostatic mass	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prostatic hypoplasia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Prostate cancer stage II	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Glomerular filtration rate	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Chemotherapy urothelial toxicity attenuation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gliososis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prostate ablation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gliosarcoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gliomatosis cerebri	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Immune-mediated optic neuritis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Abortion of ectopic pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prophylaxis against alcoholic withdrawal syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Promotion of peripheral circulation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Prolonged pregnancy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Glanzmann's disease	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Prolapse repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Progesterone increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gingival hypertrophy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Progesterone	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Gingival blister	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Product prescribing error	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Giardiasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Change of bowel habit	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Procedural hypotension	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gestational alloimmune liver disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cervix neoplasm	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Procalcitonin increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Primary stabbing headache	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Genitourinary operation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Primary hypoparathyroidism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Genitourinary chlamydia infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Genitalia external ambiguous	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Genital rash	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Preterm premature rupture of membranes	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Prescribed overdose	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Acral lentiginous melanoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adenovirus infection	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Genital abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Generalised resistance to thyroid hormone	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
BK virus infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Precursor T-lymphoblastic leukaemia acute	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Precerebral artery embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cerumen removal	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Prealbumin	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerumen impaction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Postpartum state	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Postpartum disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adenoviral encephalitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Postoperative delirium	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Postoperative abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Urinary tract toxicity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Posterior capsule opacification	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal ulcer management	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cerebral ventricular rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal tube insertion	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post vaccination syndrome	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastrointestinal tract mucosal discolouration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post thrombotic syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post stroke seizure	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gastrointestinal tract irritation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Post stroke epilepsy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post procedural swelling	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrointestinal stenosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Post procedural haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Post procedural diarrhoea	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gastrointestinal polyp haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abdominal operation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Abortion missed	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adenotonsillectomy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gastrointestinal perforation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebral small vessel ischaemic disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Post breast therapy pain syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Post abortion complication	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Portal vein phlebitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Portal shunt procedure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Porphyria non-acute	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1

Indication Summary Table
Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Porphyria	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Poor venous access	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Polyneuropathy in malignant disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Polyneuropathy chronic	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cerebral hypoperfusion	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Polyglandular disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cerebral fungal infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cerebral endovascular aneurysm repair	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastroenteritis viral	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebral cyst	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebral cavernous malformation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pneumonia lipoid	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adenosquamous cell lung cancer stage III	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebral artery thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastrinoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Craniosynostosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pneumoconiosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastric residual assessment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pneumococcal bacteraemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cerebral artery embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gastric polyps	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cerebellar stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Platelet count abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Platelet aggregation test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gastric mucosa erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Platelet aggregation normal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Avoidant personality disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Gastric infection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Platelet aggregation increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cerebellar atrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Gastric dilatation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Plaque shift	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Central sleep apnoea syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pityriasis alba	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pituitary scan	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pituitary hyperplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pinealoblastoma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Phytosterolaemia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Physical assault	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Photosensitivity reaction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Photosensitive seizure	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Gallbladder cancer metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Photodynamic therapy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Phonophobia	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Phobic postural vertigo	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Phlebotomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Gadolinium deposition disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
GM2 gangliosidosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal ulceration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal oedema	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Pharyngeal erythema	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pharyngeal disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Phaeohyphomycosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cellulitis staphylococcal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Personal hygiene	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Peritoneal permeability decreased	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Full blood count	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Cell death	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peristalsis visible	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cavernous sinus thrombosis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Freezing phenomenon	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Peripheral primitive neuroectodermal tumour of soft	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Peripheral embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Acquired foramen magnum stenosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral circulatory failure	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Fractional exhaled nitric oxide increased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fractional exhaled nitric oxide abnormal	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral artery aneurysm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peripheral arteriogram	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Foraminotomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Periorbital swelling	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Periorbital haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Foot fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Periorbital discomfort	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Foot deformity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Periorbital cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Autoimmune inner ear disease	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Foot amputation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Periodontal disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perineal injury	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perineal disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Pericardial haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Follicular lymphoma refractory	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Perfume sensitivity	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cataract subcapsular	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Peptic ulcer haemorrhage	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Penile erythema	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Penile cancer	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Inflammatory marker test	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Follicle centre lymphoma diffuse small cell lymphoma	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic venous thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic organ prolapse	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Foetal therapeutic procedure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Foetal heart rate abnormal	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pelvic floor dysfunction	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Pelvic discomfort	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pelvic abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Patent ductus arteriosus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Patellofemoral pain syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Patella fracture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Adenoidal hypertrophy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Anal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Passive smoking	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cartilage-hair hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Partner stress	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Parotitis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fluid balance assessment	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Parosmia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Carotid intima-media thickness increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Parkinsonism hyperpyrexia syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carotid bruit	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fixed eruption	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Parietal lobe stroke	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Carotid artery stent insertion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Fistula repair	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Parathyroid tumour benign	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paraspinal abscess	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Finger deformity	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Parapsoriasis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Paraplegia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paraphilia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Fibrous dysplasia of bone	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Adenoidal disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anal haemorrhage	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Autoimmune cerebellar ataxia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paraneoplastic retinopathy	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Paraneoplastic hypoglycaemia	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paranasal sinus neoplasm	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paranasal sinus inflammation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carotid angioplasty	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Fibroadenoma of breast	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Paradoxical psoriasis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carnitine deficiency	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Fibrinolysis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Paradoxical embolism	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Fibrinogen degradation products increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Paracentesis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Aura	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Carnitine abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Papule	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Auditory nerve disorder	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Carney complex	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pancreatogenous diabetes	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cardiovascular symptom	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Pancreatitis relapsing	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Vulval ulceration	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Feeding disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pancreatic enzyme abnormality	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pancreatic atrophy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Pallor	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Anal cancer metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atypical migraine	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Fat necrosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Painful erection	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Family stress	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
PD-L1 protein expression	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
PCDH19 gene-related epilepsy	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
PASH syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac valve vegetation	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
PACS1 neurodevelopmental disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ovulation disorder	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Overchelation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Ovarian low malignant potential tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian granulosa-theca cell tumour	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian germ cell cancer	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Failed back surgery syndrome	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian failure postoperative	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian failure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Ovarian epithelial cancer stage IV	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Ovarian epithelial cancer metastatic	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac septal defect	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ovarian disorder	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atrioventricular block complete	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Factor X deficiency	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac output decreased	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Otospondylomegapiphyseal dysplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Adenocarcinoma of salivary gland	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atrial thrombosis	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Factor II mutation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac imaging procedure	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Osteo-meningeal breaches	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac function test abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Osmotic demyelination syndrome	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Anaesthetic complication	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Orthostatic tremor	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eyelid ptosis congenital	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Orthopoxvirus test positive	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oropharyngeal plaque	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cyst rupture	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1

Indication Summary Table

Derived Age Group

	Group1 (0-25) (N=27299)	Group2 (26-50) (N=52972)	Group3 (51-75) (N=112199)	Group4 (75+) (N=39042)	Total (N=231512)
Eyelid myoclonus	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oropharyngeal oedema	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oropharyngeal fistula	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Cardiac failure high output	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eyelid haemangioma	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Acquired Von Willebrand's disease	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Eye swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Orofacial granulomatosis	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ornithine transcarbamoylase deficiency	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Eye naevus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Orbital myositis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Orbital decompression	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Atrial appendage closure	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oral mucosal scar	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oral mucosal blistering	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac discomfort	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Eye infection bacterial	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Optic perineuritis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Cardiac assistance device user	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Optic nerve hypoplasia	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Ophthalmologic treatment	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Extubation	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oophorectomy	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
pH urine increased	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
ACTH-producing pituitary tumour	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Carcinoma in situ	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
Oncologic complication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1

Indication Summary Table
Derived Age Group

	<i>Group1 (0-25)</i> <i>(N=27299)</i>	<i>Group2 (26-50)</i> <i>(N=52972)</i>	<i>Group3 (51-75)</i> <i>(N=112199)</i>	<i>Group4 (75+)</i> <i>(N=39042)</i>	<i>Total</i> <i>(N=231512)</i>
Omphalitis	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Carcinoma ex-pleomorphic adenoma	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Oligohydramnios	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1
Abnormal weight gain	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	1
Oil acne	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1
Oestrogen receptor assay	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1
External ear inflammation	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1